{"id": "1_1", "text": "Tremor, muscle stiffness, and slowness of movement are symptoms of Parkinson's disease.", "tags": [{"end": 6, "start": 0, "tag": "SignOrSymptom"}, {"end": 24, "start": 8, "tag": "SignOrSymptom"}, {"end": 63, "start": 55, "tag": "SignOrSymptom"}, {"end": 86, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 30, "tag": "SignOrSymptom"}]}{"id": "1_7", "text": "Our results can be used to mathematically study the mechanisms behind these diseases.", "tags": [{"end": 47, "start": 42, "tag": "ResearchActivity"}]}{"id": "2_2", "text": "This process preserves mitochondrial health.", "tags": [{"end": 36, "start": 23, "tag": "CellComponent"}, {"end": 43, "start": 37, "tag": "HealthCareActivity"}]}{"id": "2_3", "text": "However, defective mitophagy triggers the accumulation of damaged mitochondria, causing major neurodegenerative disorders.", "tags": [{"end": 121, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 66, "tag": "CellComponent"}, {"end": 78, "start": 58, "tag": "CellOrMolecularDysfunction"}, {"end": 28, "start": 9, "tag": "CellOrMolecularDysfunction"}]}{"id": "2_4", "text": "This review introduces molecular mechanisms and signaling pathways behind mitophagy regulation.", "tags": [{"end": 94, "start": 74, "tag": "CellFunction"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 66, "start": 48, "tag": "CellFunction"}, {"end": 43, "start": 23, "tag": "CellFunction"}]}{"id": "4_6", "text": "Olfactory dysfunction is present in both premanifest and manifest patients with HD, showing a progressive decline over time with more severe deficits at advanced stages.", "tags": [{"end": 21, "start": 0, "tag": "PathologicFunction"}, {"end": 65, "start": 57, "tag": "SignOrSymptom"}, {"end": 168, "start": 153, "tag": "TemporalConcept"}, {"end": 82, "start": 66, "tag": "PatientOrDisabledGroup"}, {"end": 123, "start": 119, "tag": "TemporalConcept"}, {"end": 149, "start": 134, "tag": "Finding"}, {"end": 21, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 94, "tag": "Finding"}]}{"id": "9_2", "text": "Also emerging are the roles of other polyglutamine disease proteins in DNA damage repair mechanisms.", "tags": [{"end": 50, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 71, "tag": "CellFunction"}]}{"id": "10_0", "text": "There has been substantial progress in the development of regenerative medicine strategies for CNS disorders over the last decade, with progression to early clinical studies for some conditions.", "tags": [{"end": 108, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 157, "tag": "ResearchActivity"}, {"end": 129, "start": 118, "tag": "TemporalConcept"}, {"end": 98, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 27, "tag": "TemporalConcept"}, {"end": 147, "start": 136, "tag": "PathologicFunction"}, {"end": 147, "start": 136, "tag": "TemporalConcept"}, {"end": 79, "start": 58, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 156, "start": 151, "tag": "TemporalConcept"}]}{"id": "10_3", "text": "Furthermore, clinical trials that incorporate principles of efficient design and disease-specific outcomes are urgently needed (particularly for those undertaken in rare diseases, where relatively small cohorts are an additional limiting factor), and all processes must be adaptable in a dynamic regulatory environment.", "tags": [{"end": 28, "start": 13, "tag": "ResearchActivity"}, {"end": 76, "start": 70, "tag": "HealthCareActivity"}, {"end": 178, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 203, "tag": "PopulationGroup"}, {"end": 106, "start": 81, "tag": "HealthCareActivity"}]}{"id": "11_5", "text": "Spectral-domain Optical Coherence Tomography (SD-OCT) was used to evaluate the macular thickness and peripapillary retinal nerve fiber layer (pRNFL).", "tags": [{"end": 147, "start": 142, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 79, "tag": "ClinicalAttribute"}, {"end": 140, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 46, "tag": "HealthCareActivity"}, {"end": 44, "start": 0, "tag": "HealthCareActivity"}]}{"id": "11_11", "text": "Age and disease duration were negatively correlated with macular thickness in HD patients.", "tags": [{"end": 24, "start": 8, "tag": "TemporalConcept"}, {"end": 74, "start": 57, "tag": "SignOrSymptom"}, {"end": 89, "start": 78, "tag": "PatientOrDisabledGroup"}, {"end": 3, "start": 0, "tag": "OrganismAttribute"}]}{"id": "11_14", "text": "It can support the hypothesis that the retina may be a potential biomarker for monitoring the neurodegenerative process in HD.", "tags": [{"end": 45, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 39, "tag": "Cell"}, {"end": 74, "start": 55, "tag": "ClinicalAttribute"}, {"end": 119, "start": 94, "tag": "CellOrMolecularDysfunction"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 79, "tag": "HealthCareActivity"}]}{"id": "12_0", "text": "Neurodegenerative diseases are the second most common cause of death and characterized by progressive impairments in movement or mental functioning in the central or peripheral nervous system.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 129, "tag": "BiologicFunction"}, {"end": 191, "start": 166, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 63, "tag": "BiologicFunction"}, {"end": 68, "start": 63, "tag": "PathologicFunction"}, {"end": 125, "start": 90, "tag": "ClinicalAttribute"}]}{"id": "12_3", "text": "Cumulative evidence indicates that melatonin has a wide range of neuroprotective roles by regulating pathophysiological mechanisms and signaling pathways.", "tags": [{"end": 19, "start": 0, "tag": "Finding"}, {"end": 130, "start": 90, "tag": "BiologicFunction"}, {"end": 119, "start": 101, "tag": "PathologicFunction"}, {"end": 153, "start": 135, "tag": "CellFunction"}, {"end": 86, "start": 65, "tag": "CellFunction"}, {"end": 44, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 35, "tag": "PharmacologicSubstance"}, {"end": 44, "start": 35, "tag": "Chemical"}]}{"id": "13_3", "text": "There are currently still no treatments available for HD, but approaches targeting the HTT levels offer systematic, mechanism-driven routes towards curing HD and other neurodegenerative diseases.", "tags": [{"end": 39, "start": 26, "tag": "Finding"}, {"end": 19, "start": 10, "tag": "TemporalConcept"}, {"end": 39, "start": 29, "tag": "HealthCareActivity"}, {"end": 39, "start": 29, "tag": "ResearchActivity"}, {"end": 90, "start": 87, "tag": "GeneOrGenome"}, {"end": 90, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 194, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 155, "tag": "DiseaseOrSyndrome"}]}{"id": "14_9", "text": "Conclusions Provision of primary palliative care for HD in an interdisciplinary clinic is feasible.", "tags": [{"end": 21, "start": 12, "tag": "HealthCareActivity"}, {"end": 48, "start": 25, "tag": "HealthCareActivity"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 62, "tag": "HealthCareRelatedOrganization"}]}{"id": "27_8", "text": "As an ideal biorecognition element for neurodegenerative disease detection, the chapter summarizes recent advances on aptamers and their application in the detection of neurodegenerative diseases.", "tags": [{"end": 126, "start": 118, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 74, "start": 65, "tag": "HealthCareActivity"}, {"end": 165, "start": 156, "tag": "HealthCareActivity"}, {"end": 114, "start": 106, "tag": "Finding"}, {"end": 105, "start": 99, "tag": "TemporalConcept"}, {"end": 195, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 39, "tag": "DiseaseOrSyndrome"}]}{"id": "28_1", "text": "The disease is inherited in an autosomal dominant fashion by an increased number of CAG repeats on the short arm of chromosome 4p16.3 in the Huntingtin gene.", "tags": [{"end": 95, "start": 84, "tag": "MolecularSequence"}, {"end": 49, "start": 31, "tag": "CellFunction"}, {"end": 49, "start": 41, "tag": "CellFunction"}, {"end": 24, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 141, "tag": "GeneOrGenome"}, {"end": 133, "start": 103, "tag": "CellComponent"}]}{"id": "28_5", "text": "There is no cure for the disease, and there is a high rate of neuropsychiatric symptoms including depression, and aggressive behavior.", "tags": [{"end": 133, "start": 114, "tag": "IndividualBehavior"}, {"end": 16, "start": 9, "tag": "Finding"}, {"end": 87, "start": 62, "tag": "SignOrSymptom"}, {"end": 108, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 54, "tag": "TemporalConcept"}]}{"id": "36_0", "text": "Substantial evidence indicates that oxidative/nitrosative stress contributes to the neurodegenerative diseases.", "tags": [{"end": 64, "start": 36, "tag": "NaturalPhenomenonOrProcess"}, {"end": 20, "start": 12, "tag": "Finding"}, {"end": 110, "start": 84, "tag": "DiseaseOrSyndrome"}]}{"id": "45_0", "text": "There is a growing body of evidence that prionoid protein behaviors are a core element of neurodegenerative diseases (NDs) that afflict humans.", "tags": [{"end": 121, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 27, "tag": "Finding"}, {"end": 142, "start": 136, "tag": "Eukaryote"}, {"end": 116, "start": 90, "tag": "DiseaseOrSyndrome"}]}{"id": "47_1", "text": "The neuronal damage caused by these diseases may be associated with abnormal alterations of connexins in glia.", "tags": [{"end": 88, "start": 68, "tag": "Finding"}, {"end": 76, "start": 68, "tag": "Cell"}, {"end": 101, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 105, "tag": "Cell"}, {"end": 12, "start": 4, "tag": "Cell"}, {"end": 19, "start": 13, "tag": "InjuryOrPoisoning"}]}{"id": "76_6", "text": "In Huntington's disease male mice, we revealed an inefficiency of FMT engraftment, which is potentially due to the more pronounced changes in the structure, composition and instability of the gut microbial community, and the imbalance in acetate and gut immune profiles found in these mice.", "tags": [{"end": 62, "start": 50, "tag": "Finding"}, {"end": 69, "start": 66, "tag": "HealthCareActivity"}, {"end": 184, "start": 173, "tag": "CellOrMolecularDysfunction"}, {"end": 195, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 215, "start": 196, "tag": "Organism"}, {"end": 245, "start": 238, "tag": "Chemical"}, {"end": 269, "start": 238, "tag": "ResearchActivity"}, {"end": 234, "start": 225, "tag": "CellOrMolecularDysfunction"}, {"end": 28, "start": 24, "tag": "OrganismAttribute"}, {"end": 81, "start": 70, "tag": "ResearchActivity"}, {"end": 81, "start": 70, "tag": "HealthCareActivity"}, {"end": 33, "start": 29, "tag": "Eukaryote"}, {"end": 289, "start": 285, "tag": "Eukaryote"}, {"end": 23, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 131, "tag": "Finding"}]}{"id": "78_6", "text": "We put special emphasis on intricate We not only describe aberrant changes in p53 level/activity observed in CNS regions affected by particular diseases but, most importantly, put special attention to the complicated reciprocal tuning connections prevailing between p53 and molecules considered in pathological hallmarks of these disorders.", "tags": [{"end": 81, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 109, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 269, "start": 266, "tag": "AminoAcidPeptideOrProtein"}, {"end": 269, "start": 266, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 58, "tag": "PathologicFunction"}, {"end": 320, "start": 311, "tag": "Finding"}, {"end": 283, "start": 274, "tag": "Substance"}, {"end": 112, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 197, "start": 188, "tag": "BiologicFunction"}, {"end": 74, "start": 67, "tag": "Finding"}]}{"id": "86_5", "text": "Based on our systematic review, treatment with stem cells significantly improves neurological and behavioral outcomes in animal models of HD.", "tags": [{"end": 30, "start": 13, "tag": "ResearchActivity"}, {"end": 30, "start": 13, "tag": "HealthCareActivity"}, {"end": 57, "start": 47, "tag": "Cell"}, {"end": 41, "start": 32, "tag": "HealthCareActivity"}, {"end": 41, "start": 32, "tag": "ResearchActivity"}, {"end": 134, "start": 121, "tag": "ResearchActivity"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 81, "tag": "Finding"}, {"end": 140, "start": 121, "tag": "ExperimentalModelOfDisease"}]}{"id": "102_2", "text": "We introduce the first case of a HD patient with CVT, iron-deficiency anemia and neutropenia.", "tags": [{"end": 27, "start": 23, "tag": "ManufacturedObject"}, {"end": 52, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 49, "tag": "PathologicFunction"}, {"end": 69, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 33, "tag": "PatientOrDisabledGroup"}, {"end": 92, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 81, "tag": "AnatomicalAbnormality"}]}{"id": "271_4", "text": "This work investigates the potential of classifying patient disease severity based on individual footstep pressure data using deep learning techniques.", "tags": [{"end": 105, "start": 86, "tag": "OrganismAttribute"}, {"end": 76, "start": 60, "tag": "ClinicalAttribute"}, {"end": 76, "start": 60, "tag": "Finding"}, {"end": 119, "start": 115, "tag": "ResearchActivity"}, {"end": 59, "start": 52, "tag": "PatientOrDisabledGroup"}, {"end": 114, "start": 97, "tag": "ClinicalAttribute"}, {"end": 150, "start": 126, "tag": "MachineActivity"}]}{"id": "342_3", "text": "Since the retina is an extension of the brain and shares a common embryological origin with the central nervous system, there has also been intense interest in leveraging the expanding armamentarium of retinal imaging technology to understand, diagnose and monitor neurological diseases.", "tags": [{"end": 86, "start": 66, "tag": "EmbryonicStructure"}, {"end": 228, "start": 202, "tag": "HealthCareActivity"}, {"end": 264, "start": 257, "tag": "HealthCareActivity"}, {"end": 264, "start": 257, "tag": "ManufacturedObject"}, {"end": 16, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 10, "tag": "Cell"}, {"end": 45, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 286, "start": 265, "tag": "DiseaseOrSyndrome"}]}{"id": "629_2", "text": "We used mutant Huntingtin (mHTT) expressing bacterial artificial chromosome Huntington's disease mice to determine if they exhibit electrocardiogram (ECG) abnormalities involving cardiac conduction that are known to increase risk of sudden arrhythmic death in humans.", "tags": [{"end": 25, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 44, "tag": "Bacterium"}, {"end": 197, "start": 179, "tag": "BiologicFunction"}, {"end": 31, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 27, "tag": "CellOrMolecularDysfunction"}, {"end": 25, "start": 8, "tag": "CellOrMolecularDysfunction"}, {"end": 43, "start": 33, "tag": "CellFunction"}, {"end": 256, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 266, "start": 260, "tag": "Eukaryote"}, {"end": 101, "start": 97, "tag": "Eukaryote"}, {"end": 148, "start": 131, "tag": "HealthCareActivity"}, {"end": 148, "start": 131, "tag": "ManufacturedObject"}, {"end": 153, "start": 150, "tag": "HealthCareActivity"}, {"end": 153, "start": 150, "tag": "ManufacturedObject"}, {"end": 229, "start": 225, "tag": "Finding"}, {"end": 96, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 44, "tag": "ManufacturedObject"}, {"end": 101, "start": 44, "tag": "ExperimentalModelOfDisease"}, {"end": 168, "start": 155, "tag": "Finding"}]}{"id": "1066_1", "text": "Previous literature has focused on the direct effects of the air pollution components on neuronal and glial cells, as well as on involvement of oxidative stress and neuroinflammation on microglia and astrocyte reactivity.", "tags": [{"end": 56, "start": 46, "tag": "PathologicFunction"}, {"end": 74, "start": 61, "tag": "EnvironmentalEffectOfHumans"}, {"end": 19, "start": 9, "tag": "ResearchActivity"}, {"end": 113, "start": 102, "tag": "Cell"}, {"end": 97, "start": 89, "tag": "Cell"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 160, "start": 144, "tag": "CellOrMolecularDysfunction"}, {"end": 209, "start": 200, "tag": "Cell"}, {"end": 85, "start": 75, "tag": "CellComponent"}, {"end": 140, "start": 129, "tag": "Finding"}, {"end": 182, "start": 165, "tag": "PathologicFunction"}, {"end": 195, "start": 186, "tag": "Cell"}, {"end": 220, "start": 200, "tag": "CellFunction"}, {"end": 220, "start": 210, "tag": "CellFunction"}, {"end": 195, "start": 186, "tag": "CellFunction"}]}{"id": "1084_0", "text": "People living with HIV (PLH) have significantly higher rates of cognitive impairment (CI) and major depressive disorder (MDD) versus the general population.", "tags": [{"end": 119, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 137, "tag": "PopulationGroup"}, {"end": 6, "start": 0, "tag": "PopulationGroup"}, {"end": 22, "start": 19, "tag": "Virus"}, {"end": 155, "start": 145, "tag": "PopulationGroup"}, {"end": 84, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 7, "tag": "Finding"}, {"end": 27, "start": 24, "tag": "PatientOrDisabledGroup"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}]}{"id": "1422_9", "text": "However, parameters reflecting gait variability were substantially altered in HD patients (+ 17% stride length CV up to + 41% stride time CV with largest effect size) and showed strong correlations to TMS and TFC (0.416 <= r(Sp) <= 0.690).", "tags": [{"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 133, "tag": "TemporalConcept"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 35, "start": 31, "tag": "OrganismAttribute"}, {"end": 197, "start": 185, "tag": "ResearchActivity"}, {"end": 165, "start": 161, "tag": "OrganismAttribute"}, {"end": 110, "start": 97, "tag": "OrganismAttribute"}, {"end": 204, "start": 201, "tag": "HealthCareActivity"}, {"end": 212, "start": 209, "tag": "HealthCareActivity"}, {"end": 47, "start": 31, "tag": "ClinicalAttribute"}]}{"id": "1422_10", "text": "Objective gait variability parameters correlated with disease stage based upon TFC.", "tags": [{"end": 67, "start": 54, "tag": "ClinicalAttribute"}, {"end": 67, "start": 54, "tag": "TemporalConcept"}, {"end": 14, "start": 10, "tag": "OrganismAttribute"}, {"end": 82, "start": 79, "tag": "HealthCareActivity"}, {"end": 26, "start": 10, "tag": "ClinicalAttribute"}]}{"id": "1422_11", "text": "Conclusions Sensor-based gait variability parameters were identified as clinically most relevant digital biomarker for gait impairment in HD.", "tags": [{"end": 134, "start": 119, "tag": "Finding"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 25, "tag": "OrganismAttribute"}, {"end": 123, "start": 119, "tag": "OrganismAttribute"}, {"end": 114, "start": 97, "tag": "ClinicalAttribute"}, {"end": 41, "start": 25, "tag": "ClinicalAttribute"}]}{"id": "1422_12", "text": "Altered gait variability represents characteristic irregularity of gait in HD and reflects disease severity.", "tags": [{"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 91, "tag": "ClinicalAttribute"}, {"end": 12, "start": 8, "tag": "OrganismAttribute"}, {"end": 71, "start": 67, "tag": "OrganismAttribute"}, {"end": 71, "start": 51, "tag": "Finding"}, {"end": 24, "start": 8, "tag": "ClinicalAttribute"}]}{"id": "1423_0", "text": "Background: Fatigue is the major cause of disability in MS.", "tags": [{"end": 19, "start": 12, "tag": "SignOrSymptom"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 42, "tag": "Finding"}]}{"id": "1423_1", "text": "Fatigue has been suggested to be primary, part of the neurological disease; it can also be secondary to other diseases outside the CNS or exist as a separate comorbidity.", "tags": [{"end": 7, "start": 0, "tag": "SignOrSymptom"}, {"end": 169, "start": 158, "tag": "Finding"}, {"end": 74, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1423_2", "text": "The only forms of measurement currently available are through subjective standardized questionnaires, which are not able to identify primary MS-related fatigue.", "tags": [{"end": 100, "start": 62, "tag": "HealthCareActivity"}, {"end": 159, "start": 152, "tag": "SignOrSymptom"}, {"end": 143, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 18, "tag": "ResearchActivity"}, {"end": 29, "start": 18, "tag": "HealthCareActivity"}, {"end": 39, "start": 30, "tag": "TemporalConcept"}]}{"id": "1423_3", "text": "Therefore, there is a need for objective biomarkers of fatigue in MS.", "tags": [{"end": 62, "start": 55, "tag": "SignOrSymptom"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 41, "tag": "ClinicalAttribute"}]}{"id": "1423_4", "text": "This study explored the viability of 17 possible biomarkers of primary fatigue in MS.", "tags": [{"end": 33, "start": 24, "tag": "CellFunction"}, {"end": 78, "start": 63, "tag": "SignOrSymptom"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 49, "tag": "ClinicalAttribute"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}]}{"id": "1423_5", "text": "Our chosen biomarker panel represents the function and health of different parts of the CNS.", "tags": [{"end": 50, "start": 42, "tag": "BiologicFunction"}, {"end": 50, "start": 42, "tag": "CellFunction"}, {"end": 91, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 11, "tag": "ClinicalAttribute"}, {"end": 61, "start": 55, "tag": "HealthCareActivity"}, {"end": 26, "start": 11, "tag": "ResearchActivity"}]}{"id": "1423_6", "text": "Methods: We evaluated 31 MS patients and 17 healthy controls using the Fatigue Severity Scale (FSS) and Insomnia Severity Index (ISI).", "tags": [{"end": 127, "start": 104, "tag": "HealthCareActivity"}, {"end": 132, "start": 129, "tag": "HealthCareActivity"}, {"end": 27, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 28, "tag": "PatientOrDisabledGroup"}, {"end": 51, "start": 44, "tag": "OrganismAttribute"}, {"end": 60, "start": 52, "tag": "PopulationGroup"}, {"end": 93, "start": 71, "tag": "HealthCareActivity"}, {"end": 98, "start": 95, "tag": "HealthCareActivity"}]}{"id": "1423_7", "text": "We assessed clinical parameters and collected CSF from all participants to analyze 17 biomarkers, some of which in multiple targeted sequences, reflecting structural and functional changes in the brain.", "tags": [{"end": 49, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 196, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 59, "tag": "PopulationGroup"}, {"end": 96, "start": 86, "tag": "ClinicalAttribute"}, {"end": 31, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1423_8", "text": "Based on FSS scores, MS was divided into MS-Fatigue (MS-F, FSS >= 4) and MS-NoFatigue (MS-NoF, FSS < 4).", "tags": [{"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 13, "tag": "Finding"}, {"end": 12, "start": 9, "tag": "HealthCareActivity"}, {"end": 62, "start": 59, "tag": "HealthCareActivity"}]}{"id": "1423_9", "text": "Results: MS-F had significantly lower levels of amyloid precursor protein (APP) peptides than MS-NoF (p = 0.005, p = 0.011).", "tags": [{"end": 88, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 75, "tag": "GeneOrGenome"}, {"end": 78, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}{"id": "1423_10", "text": "The only biomarker correlating with FSS in any group was APP in MS (r = -0.47, -0.52; p = 0.007, 0.002).", "tags": [{"end": 66, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 57, "tag": "GeneOrGenome"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 9, "tag": "ClinicalAttribute"}, {"end": 52, "start": 47, "tag": "PopulationGroup"}, {"end": 39, "start": 36, "tag": "HealthCareActivity"}]}{"id": "1423_11", "text": "APP did not correlate with any clinical parameter in MS but correlated with multiple markers.", "tags": [{"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 85, "tag": "ClinicalAttribute"}, {"end": 49, "start": 31, "tag": "ClinicalAttribute"}]}{"id": "1423_12", "text": "In MS, FSS correlated with the ISI and months since diagnosis.", "tags": [{"end": 34, "start": 31, "tag": "HealthCareActivity"}, {"end": 5, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 52, "tag": "HealthCareActivity"}, {"end": 45, "start": 39, "tag": "TemporalConcept"}, {"end": 10, "start": 7, "tag": "HealthCareActivity"}]}{"id": "1423_13", "text": "Conclusion: Although the mechanisms remain unknown, altered APP metabolism in MS seems to be associated with fatigue.", "tags": [{"end": 116, "start": 109, "tag": "SignOrSymptom"}, {"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 60, "tag": "GeneOrGenome"}, {"end": 63, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 64, "tag": "BiologicFunction"}, {"end": 74, "start": 64, "tag": "CellFunction"}]}{"id": "1423_14", "text": "APP should be evaluated as a biomarker of the role of structural MS pathology in the development of fatigue in individual MS patients.", "tags": [{"end": 107, "start": 100, "tag": "SignOrSymptom"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 29, "tag": "ClinicalAttribute"}, {"end": 133, "start": 125, "tag": "PatientOrDisabledGroup"}, {"end": 96, "start": 85, "tag": "BiologicFunction"}, {"end": 96, "start": 85, "tag": "CellFunction"}, {"end": 77, "start": 68, "tag": "PathologicFunction"}, {"end": 77, "start": 68, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 121, "start": 111, "tag": "PopulationGroup"}]}{"id": "1424_0", "text": "Alzheimer's disease (AD) is the most common fatal neurodegenerative disease of the elderly worldwide.", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 83, "tag": "PopulationGroup"}]}{"id": "1424_1", "text": "The identification of AD biomarkers will allow for earlier diagnosis and thus earlier intervention.", "tags": [{"end": 68, "start": 59, "tag": "HealthCareActivity"}, {"end": 35, "start": 25, "tag": "ClinicalAttribute"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 51, "tag": "TemporalConcept"}, {"end": 85, "start": 78, "tag": "TemporalConcept"}]}{"id": "1424_2", "text": "The aim of this study was to find such biomarkers.", "tags": [{"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 49, "start": 39, "tag": "ClinicalAttribute"}]}{"id": "1424_3", "text": "It was observed that the expression of Alix was significantly decreased in brain tissues and serum samples from AD patients compared to the controls.", "tags": [{"end": 43, "start": 39, "tag": "GeneOrGenome"}, {"end": 88, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 140, "tag": "PopulationGroup"}, {"end": 123, "start": 115, "tag": "PatientOrDisabledGroup"}, {"end": 98, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 39, "tag": "BiologicallyActiveSubstance"}]}{"id": "1424_4", "text": "A significant correlation between Alix levels and cognitive decline was observed (r = 0.80; p < 0.001) as well as a significant negative correlation between Alix and A beta(40) in serum levels (r =-0.60, p < 0.001).", "tags": [{"end": 38, "start": 34, "tag": "GeneOrGenome"}, {"end": 161, "start": 157, "tag": "GeneOrGenome"}, {"end": 172, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 180, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 157, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1424_5", "text": "The receiver operating characteristic curve (ROC) analysis showed the area under the curve (AUC) of Alix was 0.80, and the optimal cut-off point of 199.5 pg/ml was selected with the highest sum of sensitivity and specificity.", "tags": [{"end": 104, "start": 100, "tag": "GeneOrGenome"}, {"end": 208, "start": 197, "tag": "Finding"}, {"end": 224, "start": 213, "tag": "Finding"}, {"end": 58, "start": 50, "tag": "ResearchActivity"}, {"end": 43, "start": 4, "tag": "ResearchActivity"}, {"end": 90, "start": 70, "tag": "ResearchActivity"}, {"end": 95, "start": 92, "tag": "ResearchActivity"}, {"end": 104, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 100, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1424_6", "text": "The diagnostic accuracy for serum Alix was 74%, with 76% sensitivity and 71% specificity respectively, which could differentiate AD from controls.", "tags": [{"end": 33, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 34, "tag": "GeneOrGenome"}, {"end": 68, "start": 57, "tag": "Finding"}, {"end": 88, "start": 77, "tag": "Finding"}, {"end": 131, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 137, "tag": "PopulationGroup"}, {"end": 38, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 34, "tag": "BiologicallyActiveSubstance"}]}{"id": "1424_7", "text": "In addition, the expression of Alix was found to be significantly decreased in AD compared to vascular dementia (VaD).", "tags": [{"end": 35, "start": 31, "tag": "GeneOrGenome"}, {"end": 116, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 31, "tag": "BiologicallyActiveSubstance"}]}{"id": "1424_8", "text": "ROC analysis between AD and VaD showed that the AUC was 0.777, which could be indicative of the role of serum Alix as a biomarker in the differential diagnosis between AD and VaD.", "tags": [{"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 110, "tag": "GeneOrGenome"}, {"end": 159, "start": 150, "tag": "HealthCareActivity"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 51, "start": 48, "tag": "ResearchActivity"}, {"end": 159, "start": 137, "tag": "HealthCareActivity"}, {"end": 129, "start": 120, "tag": "ClinicalAttribute"}, {"end": 114, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 175, "tag": "DiseaseOrSyndrome"}]}{"id": "1424_9", "text": "Most surprisingly, the decreased expression of Alix was attenuated after the treatment of Memantine in different AD animal models.", "tags": [{"end": 51, "start": 47, "tag": "GeneOrGenome"}, {"end": 99, "start": 90, "tag": "Chemical"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 77, "tag": "HealthCareActivity"}, {"end": 86, "start": 77, "tag": "ResearchActivity"}, {"end": 129, "start": 116, "tag": "ResearchActivity"}, {"end": 51, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 90, "tag": "PharmacologicSubstance"}]}{"id": "1424_10", "text": "In conclusion, our results indicate the possibility of serum Alix as a novel and non-invasive biomarker for AD for the first time.", "tags": [{"end": 60, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 61, "tag": "GeneOrGenome"}, {"end": 129, "start": 125, "tag": "TemporalConcept"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 119, "tag": "TemporalConcept"}, {"end": 103, "start": 81, "tag": "ClinicalAttribute"}, {"end": 65, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 94, "tag": "ClinicalAttribute"}, {"end": 76, "start": 71, "tag": "ClinicalAttribute"}]}{"id": "1425_0", "text": "Alzheimer's disease (AD) neuropathology is extremely heterogeneous, and the evolution from preclinical to mild cognitive impairment until dementia is driven by interacting genetic/biological mechanisms not fully captured by current clinical/research criteria.", "tags": [{"end": 85, "start": 76, "tag": "BiologicFunction"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 224, "tag": "TemporalConcept"}, {"end": 131, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 241, "tag": "ResearchActivity"}, {"end": 39, "start": 25, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 39, "start": 25, "tag": "PathologicFunction"}]}{"id": "1425_1", "text": "We characterized the heterogeneous construct of AD through a cerebrospinal fluid biomarker-guided stratification approach.", "tags": [{"end": 80, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 81, "tag": "ClinicalAttribute"}, {"end": 121, "start": 98, "tag": "ResearchActivity"}]}{"id": "1425_2", "text": "We analyzed 5 validated pathophysiological cerebrospinal fluid biomarkers (A beta(1-42), t-tau, -p-tau(181), NFL, YKL-40) in 113 participants (healthy controls [N = 20], subjective memory complainers [N = 36], mild cognitive impairment [N = 20], and AD dementia [N = 37], age: 66.7 +/- 10.4, 70.4 +/- 7.7, 71.7 +/- 8.4, 76.2 +/- 3.5 years [mean +/- SD], respectively) using Density-Based Spatial Clustering of Applications with Noise, which does not require a priori determination of the number of clusters.", "tags": [{"end": 112, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 275, "start": 272, "tag": "OrganismAttribute"}, {"end": 94, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 63, "tag": "ClinicalAttribute"}, {"end": 338, "start": 333, "tag": "TemporalConcept"}, {"end": 81, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 252, "start": 250, "tag": "DiseaseOrSyndrome"}, {"end": 261, "start": 253, "tag": "DiseaseOrSyndrome"}, {"end": 235, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 143, "tag": "OrganismAttribute"}, {"end": 141, "start": 129, "tag": "PopulationGroup"}, {"end": 235, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 24, "tag": "PathologicFunction"}, {"end": 159, "start": 143, "tag": "PopulationGroup"}, {"end": 94, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 433, "start": 374, "tag": "MachineActivity"}]}{"id": "1425_3", "text": "We found 5 distinct clusters (sizes: N = 38, 16, 24, 14, and 21) whose composition was independent of phenotypical groups.", "tags": []}{"id": "1425_4", "text": "Two clusters showed biomarker profiles linked to neurodegenerative processes not associated with classical AD-related pathophysiology.", "tags": [{"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 118, "tag": "PathologicFunction"}, {"end": 133, "start": 118, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 29, "start": 20, "tag": "ClinicalAttribute"}]}{"id": "1425_5", "text": "One cluster was characterized by the neuroinflammation biomarker YKL-40.", "tags": [{"end": 71, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 37, "tag": "PathologicFunction"}, {"end": 64, "start": 55, "tag": "ClinicalAttribute"}]}{"id": "1425_6", "text": "Combining nonlinear data aggregation with informative biomarkers can generate novel patient strata which are representative of cellular/molecular pathophysiology and may aid in predicting disease evolution and mechanistic drug response.", "tags": [{"end": 205, "start": 196, "tag": "BiologicFunction"}, {"end": 36, "start": 10, "tag": "ResearchActivity"}, {"end": 91, "start": 84, "tag": "PatientOrDisabledGroup"}, {"end": 64, "start": 54, "tag": "ClinicalAttribute"}, {"end": 161, "start": 146, "tag": "PathologicFunction"}, {"end": 226, "start": 222, "tag": "PharmacologicSubstance"}, {"end": 161, "start": 146, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 205, "start": 188, "tag": "Finding"}, {"end": 235, "start": 222, "tag": "BiologicFunction"}]}{"id": "1425_7", "text": "(C) 2019 The Authors.", "tags": []}{"id": "1425_8", "text": "Published by Elsevier Inc.", "tags": []}{"id": "1426_0", "text": "Johansson et al.", "tags": []}{"id": "1426_1", "text": "describe plasma biomarkers in a longitudinal Swedish cohort of patients with monogenic Alzheimer's disease.", "tags": [{"end": 106, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 16, "tag": "ClinicalAttribute"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 63, "tag": "PatientOrDisabledGroup"}, {"end": 59, "start": 53, "tag": "PopulationGroup"}]}{"id": "1426_2", "text": "Plasma GFAP began to increase 10 years before symptom onset, prior to P-tau181 and NfL, suggesting that GFAP is mirroring Alzheimer's disease pathology upstream of tau phosphorylation and neurodegeneration.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 39, "tag": "TemporalConcept"}, {"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 108, "start": 104, "tag": "GeneOrGenome"}, {"end": 183, "start": 168, "tag": "CellFunction"}, {"end": 167, "start": 164, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 33, "tag": "TemporalConcept"}, {"end": 205, "start": 188, "tag": "CellOrMolecularDysfunction"}, {"end": 141, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 134, "tag": "PathologicFunction"}, {"end": 59, "start": 46, "tag": "TemporalConcept"}, {"end": 53, "start": 46, "tag": "SignOrSymptom"}, {"end": 167, "start": 164, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 70, "tag": "BiologicallyActiveSubstance"}]}{"id": "1426_3", "text": "Emerging plasma biomarkers of Alzheimer's disease might be non-invasive tools to trace early Alzheimer's disease-related abnormalities such as the accumulation of amyloid-beta peptides, neurofibrillary tau tangles, glial activation and neurodegeneration.", "tags": [{"end": 213, "start": 186, "tag": "CellOrMolecularDysfunction"}, {"end": 201, "start": 186, "tag": "CellComponent"}, {"end": 231, "start": 215, "tag": "CellFunction"}, {"end": 71, "start": 59, "tag": "ClinicalAttribute"}, {"end": 220, "start": 215, "tag": "Cell"}, {"end": 71, "start": 63, "tag": "Finding"}, {"end": 184, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 205, "start": 202, "tag": "AminoAcidPeptideOrProtein"}, {"end": 253, "start": 236, "tag": "CellOrMolecularDysfunction"}, {"end": 49, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 16, "tag": "ClinicalAttribute"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 175, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 202, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 147, "tag": "CellOrMolecularDysfunction"}]}{"id": "1426_4", "text": "It is, however, unclear which pathological processes in the CNS can be adequately detected by peripheral measurements and whether plasma biomarkers are equally applicable in both clinical and preclinical phases.", "tags": [{"end": 63, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 30, "tag": "PathologicFunction"}, {"end": 147, "start": 137, "tag": "ClinicalAttribute"}, {"end": 136, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1426_5", "text": "Here we aimed to explore the timing and performance of plasma biomarkers in mutation carriers compared to non-carriers in autosomal dominant Alzheimer's disease.", "tags": [{"end": 35, "start": 29, "tag": "TemporalConcept"}, {"end": 93, "start": 85, "tag": "PopulationGroup"}, {"end": 140, "start": 132, "tag": "CellFunction"}, {"end": 51, "start": 40, "tag": "Finding"}, {"end": 152, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 62, "tag": "ClinicalAttribute"}, {"end": 61, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 76, "tag": "CellOrMolecularDysfunction"}, {"end": 118, "start": 106, "tag": "PopulationGroup"}]}{"id": "1426_6", "text": "Samples (n = 164) from mutation carriers (n = 33) and non-carriers (n = 42) in a Swedish cohort of autosomal dominant Alzheimer's disease (APP p.KM670/671NL, APP p.E693G and PSEN1 p.H163Y) were included in explorative longitudinal analyses.", "tags": [{"end": 40, "start": 32, "tag": "PopulationGroup"}, {"end": 88, "start": 81, "tag": "PopulationGroup"}, {"end": 117, "start": 99, "tag": "CellFunction"}, {"end": 142, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 139, "tag": "GeneOrGenome"}, {"end": 161, "start": 158, "tag": "GeneOrGenome"}, {"end": 142, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 109, "tag": "CellFunction"}, {"end": 179, "start": 174, "tag": "GeneOrGenome"}, {"end": 179, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 89, "tag": "PopulationGroup"}, {"end": 239, "start": 206, "tag": "ResearchActivity"}, {"end": 31, "start": 23, "tag": "CellOrMolecularDysfunction"}, {"end": 66, "start": 54, "tag": "PopulationGroup"}]}{"id": "1426_7", "text": "Plasma phosphorylated tau (P-tau181), total tau (T-tau), neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) concentrations were measured with a single-molecule array method as previously described.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 196, "start": 168, "tag": "ResearchActivity"}, {"end": 21, "start": 7, "tag": "CellFunction"}, {"end": 124, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 93, "tag": "GeneOrGenome"}, {"end": 130, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "GeneOrGenome"}, {"end": 196, "start": 190, "tag": "ResearchActivity"}, {"end": 98, "start": 93, "tag": "Cell"}, {"end": 196, "start": 190, "tag": "HealthCareActivity"}, {"end": 25, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 27, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1426_8", "text": "Plasma biomarkers were additionally correlated to Alzheimer's disease core biomarkers in the CSF.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 7, "tag": "ClinicalAttribute"}, {"end": 85, "start": 75, "tag": "ClinicalAttribute"}, {"end": 96, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1426_9", "text": "Results from the longitudinal analyses confirmed that plasma P-tau181, NfL and GFAP concentrations were higher in mutation carriers compared to non-carriers.", "tags": [{"end": 131, "start": 123, "tag": "PopulationGroup"}, {"end": 83, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 79, "tag": "GeneOrGenome"}, {"end": 60, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 38, "start": 17, "tag": "ResearchActivity"}, {"end": 122, "start": 114, "tag": "CellOrMolecularDysfunction"}, {"end": 69, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 144, "tag": "PopulationGroup"}]}{"id": "1426_10", "text": "This change was observed in the presymptomatic phase and detectable first as an increase in GFAP approximately 10 years before estimated symptom onset, followed by increased levels of P-tau181 and NfL closer to expected onset.", "tags": [{"end": 96, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 92, "tag": "GeneOrGenome"}, {"end": 180, "start": 164, "tag": "Finding"}, {"end": 119, "start": 114, "tag": "TemporalConcept"}, {"end": 200, "start": 197, "tag": "BiologicallyActiveSubstance"}, {"end": 200, "start": 197, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 220, "tag": "TemporalConcept"}, {"end": 52, "start": 47, "tag": "TemporalConcept"}, {"end": 150, "start": 137, "tag": "TemporalConcept"}, {"end": 144, "start": 137, "tag": "SignOrSymptom"}, {"end": 192, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 184, "tag": "BiologicallyActiveSubstance"}]}{"id": "1426_11", "text": "Plasma P-tau181 levels were correlated to levels of P-tau181 and T-tau in the CSF.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 52, "tag": "BiologicallyActiveSubstance"}]}{"id": "1426_12", "text": "Altogether, plasma P-tau181, GFAP and NfL seem to be feasible biomarkers to detect different Alzheimer's disease-related pathologies already in presymptomatic individuals.", "tags": [{"end": 33, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 29, "tag": "GeneOrGenome"}, {"end": 132, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 62, "tag": "ClinicalAttribute"}, {"end": 18, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 144, "tag": "PopulationGroup"}, {"end": 27, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 19, "tag": "BiologicallyActiveSubstance"}]}{"id": "1426_13", "text": "Interestingly, changes in plasma GFAP concentrations were detected prior to P-tau181 and NfL.", "tags": [{"end": 37, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 33, "tag": "GeneOrGenome"}, {"end": 32, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 76, "tag": "BiologicallyActiveSubstance"}]}{"id": "1426_14", "text": "Our results suggest that plasma GFAP might reflect Alzheimer's disease pathology upstream to accumulation of tangles and neurodegeneration.", "tags": [{"end": 36, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 32, "tag": "GeneOrGenome"}, {"end": 116, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 138, "start": 121, "tag": "CellOrMolecularDysfunction"}, {"end": 70, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 63, "tag": "PathologicFunction"}]}{"id": "1426_15", "text": "The implications of these findings need additional validation, in particular because of the limited sample size.", "tags": [{"end": 61, "start": 51, "tag": "ResearchActivity"}, {"end": 111, "start": 107, "tag": "OrganismAttribute"}]}{"id": "1427_0", "text": "Introduction: We developed the Alzheimer's Biomarker Survey to assess willingness to enroll in biomarker studies that disclose results and anticipated reactions to an elevated biomarker result.", "tags": [{"end": 192, "start": 186, "tag": "Finding"}, {"end": 112, "start": 105, "tag": "ResearchActivity"}, {"end": 104, "start": 95, "tag": "ClinicalAttribute"}, {"end": 185, "start": 176, "tag": "ClinicalAttribute"}, {"end": 59, "start": 31, "tag": "HealthCareActivity"}]}{"id": "1427_1", "text": "Methods: Participants included cognitively unimpaired adults enrolled in longitudinal AD studies (n = 334, mean age = 64.8 +/- 7.7, 44% non-Hispanic Black or African American).", "tags": [{"end": 174, "start": 136, "tag": "PopulationGroup"}, {"end": 115, "start": 112, "tag": "OrganismAttribute"}, {"end": 96, "start": 89, "tag": "ResearchActivity"}, {"end": 85, "start": 73, "tag": "ResearchActivity"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 54, "tag": "PopulationGroup"}, {"end": 21, "start": 9, "tag": "PopulationGroup"}]}{"id": "1427_2", "text": "Exploratory and confirmatory factor analyses determined the latent structure comprising anticipated reactions to learning AD biomarker results.", "tags": [{"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 125, "tag": "ClinicalAttribute"}, {"end": 121, "start": 113, "tag": "BiologicFunction"}]}{"id": "1427_3", "text": "Measurement invariance was tested across racial groups.", "tags": [{"end": 54, "start": 41, "tag": "PopulationGroup"}]}{"id": "1427_4", "text": "Results: Two models comprising behavior change and psychological impact fit well for the total sample and the two racial groups.", "tags": [{"end": 46, "start": 31, "tag": "Finding"}, {"end": 71, "start": 51, "tag": "Finding"}, {"end": 39, "start": 31, "tag": "BiologicFunction"}, {"end": 39, "start": 31, "tag": "IndividualBehavior"}, {"end": 39, "start": 31, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 19, "start": 13, "tag": "ResearchActivity"}, {"end": 127, "start": 114, "tag": "PopulationGroup"}, {"end": 101, "start": 95, "tag": "Substance"}, {"end": 101, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1427_5", "text": "The 2-factor behavior change model assessed constructs of planning and dementia risk-reduction.", "tags": [{"end": 66, "start": 58, "tag": "BiologicFunction"}, {"end": 21, "start": 13, "tag": "BiologicFunction"}, {"end": 21, "start": 13, "tag": "IndividualBehavior"}, {"end": 21, "start": 13, "tag": "ResearchActivity"}, {"end": 94, "start": 71, "tag": "Finding"}, {"end": 79, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 4, "tag": "ResearchActivity"}]}{"id": "1427_6", "text": "The 3-factor psychological impact model assessed constructs of distress, cognitive symptoms, and stigma.", "tags": [{"end": 71, "start": 63, "tag": "BiologicFunction"}, {"end": 103, "start": 97, "tag": "Finding"}, {"end": 91, "start": 73, "tag": "SignOrSymptom"}, {"end": 39, "start": 4, "tag": "ResearchActivity"}, {"end": 103, "start": 97, "tag": "CellComponent"}]}{"id": "1427_7", "text": "Both models exhibited measurement invariance across racial groups.", "tags": [{"end": 33, "start": 22, "tag": "ResearchActivity"}, {"end": 33, "start": 22, "tag": "HealthCareActivity"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 65, "start": 52, "tag": "PopulationGroup"}]}{"id": "1427_8", "text": "Discussion: The 28-item Anticipated Reactions to AD Biomarker Disclosure scale is a reliable and valid measure of anticipated reactions when communicating AD biomarker results to research participants.", "tags": [{"end": 61, "start": 52, "tag": "ClinicalAttribute"}, {"end": 187, "start": 179, "tag": "ResearchActivity"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 158, "tag": "ClinicalAttribute"}, {"end": 200, "start": 188, "tag": "PopulationGroup"}, {"end": 78, "start": 49, "tag": "HealthCareActivity"}]}{"id": "1428_0", "text": "Background Alzheimer disease (AD) is the most common cause of dementia.", "tags": [{"end": 28, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 62, "tag": "DiseaseOrSyndrome"}]}{"id": "1428_1", "text": "Preclinical AD is the period during which early AD brain changes are present but cognitive symptoms have not yet manifest.", "tags": [{"end": 99, "start": 81, "tag": "SignOrSymptom"}, {"end": 28, "start": 22, "tag": "TemporalConcept"}, {"end": 14, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 51, "tag": "Finding"}]}{"id": "1428_2", "text": "The presence of AD brain changes can be ascertained by molecular biomarkers obtained via imaging and lumbar puncture.", "tags": [{"end": 75, "start": 55, "tag": "ClinicalAttribute"}, {"end": 75, "start": 65, "tag": "ClinicalAttribute"}, {"end": 18, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 101, "tag": "HealthCareActivity"}, {"end": 96, "start": 89, "tag": "HealthCareActivity"}, {"end": 32, "start": 19, "tag": "Finding"}]}{"id": "1428_3", "text": "However, the use of these methods is limited by cost, acceptability, and availability.", "tags": []}{"id": "1428_4", "text": "The preclinical stage of AD may have a subtle functional signature, which can impact complex behaviours such as driving.", "tags": [{"end": 103, "start": 93, "tag": "IndividualBehavior"}, {"end": 66, "start": 57, "tag": "ResearchActivity"}, {"end": 27, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 4, "tag": "TemporalConcept"}, {"end": 119, "start": 112, "tag": "IndividualBehavior"}]}{"id": "1428_5", "text": "The objective of the present study was to evaluate the ability of in-vehicle GPS data loggers to distinguish cognitively normal older drivers with preclinical AD from those without preclinical AD using machine learning methods.", "tags": [{"end": 141, "start": 134, "tag": "PopulationGroup"}, {"end": 127, "start": 121, "tag": "Finding"}, {"end": 218, "start": 202, "tag": "MachineActivity"}, {"end": 34, "start": 29, "tag": "ResearchActivity"}, {"end": 161, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 66, "tag": "ManufacturedObject"}, {"end": 133, "start": 128, "tag": "TemporalConcept"}, {"end": 62, "start": 55, "tag": "OrganismAttribute"}, {"end": 218, "start": 210, "tag": "BiologicFunction"}]}{"id": "1428_6", "text": "Methods We followed naturalistic driving in cognitively normal older drivers for 1 year with a commercial in-vehicle GPS data logger.", "tags": [{"end": 62, "start": 56, "tag": "Finding"}, {"end": 68, "start": 63, "tag": "TemporalConcept"}, {"end": 87, "start": 83, "tag": "TemporalConcept"}, {"end": 76, "start": 69, "tag": "PopulationGroup"}, {"end": 132, "start": 106, "tag": "ManufacturedObject"}, {"end": 40, "start": 33, "tag": "IndividualBehavior"}]}{"id": "1428_7", "text": "The cohort included n = 64 individuals with and n = 75 without preclinical AD, as determined by cerebrospinal fluid biomarkers.", "tags": [{"end": 126, "start": 116, "tag": "ClinicalAttribute"}, {"end": 77, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 4, "tag": "PopulationGroup"}, {"end": 115, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 27, "tag": "PopulationGroup"}]}{"id": "1428_8", "text": "Four Random Forest (RF) models were trained to detect preclinical AD.", "tags": [{"end": 68, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 5, "tag": "ResearchActivity"}]}{"id": "1428_9", "text": "RF Gini index was used to identify the strongest predictors of preclinical AD.", "tags": [{"end": 77, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 49, "tag": "Finding"}, {"end": 13, "start": 0, "tag": "ResearchActivity"}]}{"id": "1428_10", "text": "Results The F1 score of the RF models for identifying preclinical AD was 0.85 using APOE epsilon 4 status and age only, 0.82 using GPS-based driving indicators only, 0.88 using age and driving indicators, and 0.91 using age, APOE epsilon 4 status, and driving.", "tags": [{"end": 98, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 99, "tag": "Finding"}, {"end": 239, "start": 225, "tag": "AminoAcidPeptideOrProtein"}, {"end": 246, "start": 240, "tag": "Finding"}, {"end": 113, "start": 110, "tag": "OrganismAttribute"}, {"end": 180, "start": 177, "tag": "OrganismAttribute"}, {"end": 223, "start": 220, "tag": "OrganismAttribute"}, {"end": 68, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 37, "start": 28, "tag": "ResearchActivity"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 259, "start": 252, "tag": "IndividualBehavior"}, {"end": 159, "start": 131, "tag": "ResearchActivity"}, {"end": 203, "start": 185, "tag": "ResearchActivity"}, {"end": 192, "start": 185, "tag": "IndividualBehavior"}, {"end": 148, "start": 141, "tag": "IndividualBehavior"}]}{"id": "1428_11", "text": "The area under the receiver operating curve for the final model was 0.96.", "tags": [{"end": 63, "start": 58, "tag": "ResearchActivity"}, {"end": 43, "start": 4, "tag": "ResearchActivity"}]}{"id": "1428_12", "text": "Conclusion The findings suggest that GPS driving may serve as an effective and accurate digital biomarker for identifying preclinical AD among older adults.", "tags": [{"end": 136, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 96, "tag": "ClinicalAttribute"}, {"end": 148, "start": 143, "tag": "TemporalConcept"}, {"end": 155, "start": 149, "tag": "PopulationGroup"}, {"end": 105, "start": 88, "tag": "ClinicalAttribute"}, {"end": 40, "start": 37, "tag": "ManufacturedObject"}, {"end": 48, "start": 41, "tag": "IndividualBehavior"}]}{"id": "1429_0", "text": "BackgroundCognitive decline has been reported in premanifest and manifest Huntington's disease but reliable biomarkers are lacking.", "tags": [{"end": 94, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 65, "tag": "SignOrSymptom"}, {"end": 118, "start": 108, "tag": "ClinicalAttribute"}, {"end": 27, "start": 10, "tag": "DiseaseOrSyndrome"}]}{"id": "1429_1", "text": "Inner retinal layer thickness seems to be a good biomarker of cognition in other neurodegenerative diseases.ObjectiveTo explore the relationship between optical coherence tomography-derived metrics and global cognition in Huntington's Disease.MethodsThirty-six patients with Huntington's disease (16 premanifest and 20 manifest) and 36 controls matched by age, sex, smoking status, and hypertension status underwent macular volumetric and peripapillary optical coherence tomography scans.", "tags": [{"end": 398, "start": 386, "tag": "DiseaseOrSyndrome"}, {"end": 487, "start": 453, "tag": "HealthCareActivity"}, {"end": 242, "start": 222, "tag": "DiseaseOrSyndrome"}, {"end": 295, "start": 275, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 153, "tag": "HealthCareActivity"}, {"end": 481, "start": 453, "tag": "HealthCareActivity"}, {"end": 19, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 364, "start": 361, "tag": "OrganismAttribute"}, {"end": 107, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 327, "start": 319, "tag": "SignOrSymptom"}, {"end": 58, "start": 49, "tag": "ClinicalAttribute"}, {"end": 344, "start": 336, "tag": "PopulationGroup"}, {"end": 269, "start": 261, "tag": "PatientOrDisabledGroup"}, {"end": 487, "start": 482, "tag": "HealthCareActivity"}, {"end": 359, "start": 356, "tag": "OrganismAttribute"}, {"end": 71, "start": 62, "tag": "BiologicFunction"}, {"end": 218, "start": 209, "tag": "BiologicFunction"}, {"end": 144, "start": 132, "tag": "Finding"}, {"end": 380, "start": 374, "tag": "Finding"}, {"end": 405, "start": 399, "tag": "Finding"}, {"end": 434, "start": 424, "tag": "HealthCareActivity"}, {"end": 29, "start": 0, "tag": "ClinicalAttribute"}, {"end": 373, "start": 366, "tag": "IndividualBehavior"}, {"end": 423, "start": 416, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 452, "start": 439, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1429_2", "text": "Disease duration, motor status, global cognition and CAG repeats were recorded in patients.", "tags": [{"end": 16, "start": 0, "tag": "TemporalConcept"}, {"end": 64, "start": 53, "tag": "MolecularSequence"}, {"end": 90, "start": 82, "tag": "PatientOrDisabledGroup"}, {"end": 48, "start": 39, "tag": "BiologicFunction"}, {"end": 30, "start": 24, "tag": "Finding"}]}{"id": "1429_3", "text": "Group differences in imaging parameters and their association with clinical outcomes were analyzed using linear mixed-effect models.ResultsPremanifest and manifest Huntington's disease patients presented thinner retinal external limiting membrane-Bruch's membrane complex, and manifest patients had thinner temporal peripapillary retinal nerve fiber layer compared to controls.", "tags": [{"end": 5, "start": 0, "tag": "PopulationGroup"}, {"end": 84, "start": 67, "tag": "ClinicalAttribute"}, {"end": 184, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 355, "start": 307, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 21, "tag": "HealthCareActivity"}, {"end": 246, "start": 212, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 376, "start": 368, "tag": "PopulationGroup"}, {"end": 193, "start": 185, "tag": "PatientOrDisabledGroup"}, {"end": 163, "start": 155, "tag": "PatientOrDisabledGroup"}, {"end": 17, "start": 6, "tag": "Finding"}, {"end": 131, "start": 105, "tag": "ResearchActivity"}, {"end": 98, "start": 90, "tag": "ResearchActivity"}, {"end": 271, "start": 247, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 294, "start": 277, "tag": "PatientOrDisabledGroup"}]}{"id": "1429_4", "text": "In manifest Huntington's disease, macular thickness was significantly associated with MoCA scores, inner nuclear layer showing the largest regression coefficients.", "tags": [{"end": 118, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 86, "tag": "HealthCareActivity"}, {"end": 32, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 34, "tag": "ClinicalAttribute"}, {"end": 51, "start": 34, "tag": "SignOrSymptom"}, {"end": 51, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 3, "tag": "SignOrSymptom"}, {"end": 97, "start": 91, "tag": "Finding"}, {"end": 162, "start": 139, "tag": "ResearchActivity"}]}{"id": "1429_5", "text": "This relationship was consistent after adjusting for age, sex, and education and p-value correction with False Discovery Rate.", "tags": [{"end": 125, "start": 105, "tag": "Finding"}, {"end": 61, "start": 58, "tag": "OrganismAttribute"}, {"end": 56, "start": 53, "tag": "OrganismAttribute"}, {"end": 17, "start": 5, "tag": "Finding"}, {"end": 76, "start": 67, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 99, "start": 81, "tag": "ResearchActivity"}]}{"id": "1429_6", "text": "None of the retinal variables were related to Unified Huntington's Disease Rating Scale score, disease duration, or disease burden.", "tags": [{"end": 130, "start": 116, "tag": "ResearchActivity"}, {"end": 111, "start": 95, "tag": "HealthCareActivity"}, {"end": 111, "start": 95, "tag": "TemporalConcept"}, {"end": 87, "start": 46, "tag": "HealthCareActivity"}, {"end": 19, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 88, "tag": "Finding"}]}{"id": "1429_7", "text": "Premanifest patients did not show a significant association between OCT-derived parameters and clinical outcomes in corrected models.ConclusionsIn line with other neurodegenerative diseases, OCT is a potential biomarker of cognitive status in manifest HD.", "tags": [{"end": 59, "start": 36, "tag": "Finding"}, {"end": 112, "start": 95, "tag": "ClinicalAttribute"}, {"end": 71, "start": 68, "tag": "HealthCareActivity"}, {"end": 194, "start": 191, "tag": "HealthCareActivity"}, {"end": 239, "start": 223, "tag": "BiologicFunction"}, {"end": 189, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 254, "start": 252, "tag": "DiseaseOrSyndrome"}, {"end": 251, "start": 243, "tag": "SignOrSymptom"}, {"end": 20, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 132, "start": 126, "tag": "ResearchActivity"}, {"end": 219, "start": 200, "tag": "ClinicalAttribute"}]}{"id": "1429_8", "text": "Future prospective studies are needed to evaluate OCT as a potential surrogate marker of cognitive decline in HD.", "tags": [{"end": 26, "start": 7, "tag": "ResearchActivity"}, {"end": 53, "start": 50, "tag": "HealthCareActivity"}, {"end": 85, "start": 69, "tag": "ClinicalAttribute"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 89, "tag": "DiseaseOrSyndrome"}]}{"id": "1430_0", "text": "Multiple sclerosis (MS) and glioblastoma (GBM) are two distinct diseases that affect the central nervous system (CNS).", "tags": [{"end": 40, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1430_1", "text": "However, perturbation in CNS vasculature are hallmarks of both diseases.", "tags": [{"end": 40, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 45, "tag": "Finding"}]}{"id": "1430_2", "text": "ELTD1 (epidermal growth factor, latrophilin, and 7 transmembrane domain containing protein 1 on chromosome 1) is associated with vascular development, and has been linked with tumor angiogenesis.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 30, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 32, "tag": "GeneOrGenome"}, {"end": 71, "start": 51, "tag": "MolecularSequence"}, {"end": 194, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 129, "tag": "BiologicFunction"}, {"end": 149, "start": 138, "tag": "BiologicFunction"}, {"end": 149, "start": 138, "tag": "CellFunction"}, {"end": 137, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 7, "tag": "PharmacologicSubstance"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 7, "tag": "GeneOrGenome"}]}{"id": "1430_3", "text": "In glioblastomas, we detected overexpression of ELTD1, and found that an antibody targeting ELTD1 could increase animal survival and decrease tumor volumes in a xenograft GBM model.", "tags": [{"end": 16, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 30, "tag": "CellFunction"}, {"end": 44, "start": 30, "tag": "Finding"}, {"end": 44, "start": 30, "tag": "CellOrMolecularDysfunction"}, {"end": 53, "start": 48, "tag": "GeneOrGenome"}, {"end": 81, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 73, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 92, "tag": "GeneOrGenome"}, {"end": 147, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 161, "tag": "HealthCareActivity"}, {"end": 174, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 120, "tag": "CellFunction"}, {"end": 180, "start": 175, "tag": "ResearchActivity"}, {"end": 119, "start": 113, "tag": "Eukaryote"}, {"end": 53, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 142, "tag": "ClinicalAttribute"}]}{"id": "1430_4", "text": "RNA-seq analysis of the preclinical data in the model for GBM identified that some of the molecular pathways affected by the anti-ELTD1 antibody therapy are also found to be associated with MS.", "tags": [{"end": 61, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 24, "tag": "ResearchActivity"}, {"end": 108, "start": 90, "tag": "CellFunction"}, {"end": 108, "start": 100, "tag": "CellFunction"}, {"end": 3, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 40, "start": 36, "tag": "ResearchActivity"}, {"end": 16, "start": 0, "tag": "ResearchActivity"}, {"end": 53, "start": 48, "tag": "ResearchActivity"}, {"end": 192, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 145, "tag": "HealthCareActivity"}, {"end": 144, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 125, "tag": "BiologicallyActiveSubstance"}]}{"id": "1430_5", "text": "In this study, we used molecular-targeted (mt) MR imaging and immunohistochemistry to assess ELTD1 levels in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS.", "tags": [{"end": 98, "start": 93, "tag": "GeneOrGenome"}, {"end": 82, "start": 62, "tag": "ResearchActivity"}, {"end": 150, "start": 109, "tag": "ExperimentalModelOfDisease"}, {"end": 155, "start": 152, "tag": "ExperimentalModelOfDisease"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 171, "start": 166, "tag": "ResearchActivity"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 50, "tag": "HealthCareActivity"}, {"end": 177, "start": 160, "tag": "ExperimentalModelOfDisease"}, {"end": 57, "start": 23, "tag": "ResearchActivity"}, {"end": 98, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 93, "tag": "BiologicallyActiveSubstance"}]}{"id": "1430_6", "text": "Specifically, we found that ELTD1 is readily detected in the brains of mice with EAE and is predominantly found in the corpus callosum.", "tags": [{"end": 33, "start": 28, "tag": "GeneOrGenome"}, {"end": 134, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 81, "tag": "ExperimentalModelOfDisease"}, {"end": 75, "start": 71, "tag": "Eukaryote"}, {"end": 67, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 71, "tag": "ExperimentalModelOfDisease"}]}{"id": "1430_7", "text": "In addition, we found that the blood-brain barrier (BBB) was compromised in the brains of EAE mice using contrast-enhanced MRI (CE-MRI), as well as altered relative cerebral blood flow (rCBF) in the brains and cervical spinal cords of these mice using perfusion imaging, compared to controls.", "tags": [{"end": 126, "start": 105, "tag": "HealthCareActivity"}, {"end": 134, "start": 128, "tag": "HealthCareActivity"}, {"end": 184, "start": 165, "tag": "BiologicFunction"}, {"end": 190, "start": 186, "tag": "HealthCareActivity"}, {"end": 231, "start": 210, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 269, "start": 252, "tag": "HealthCareActivity"}, {"end": 93, "start": 90, "tag": "ExperimentalModelOfDisease"}, {"end": 98, "start": 90, "tag": "ExperimentalModelOfDisease"}, {"end": 231, "start": 219, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 94, "tag": "Eukaryote"}, {"end": 245, "start": 241, "tag": "Eukaryote"}, {"end": 291, "start": 283, "tag": "PopulationGroup"}, {"end": 126, "start": 123, "tag": "HealthCareActivity"}, {"end": 134, "start": 131, "tag": "HealthCareActivity"}, {"end": 269, "start": 262, "tag": "HealthCareActivity"}, {"end": 86, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 205, "start": 199, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 156, "tag": "HealthCareActivity"}]}{"id": "1430_8", "text": "These findings indicate that ELTD1 may be a promising biomarker for CNS-inflammation in MS.", "tags": [{"end": 34, "start": 29, "tag": "GeneOrGenome"}, {"end": 71, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 54, "tag": "ClinicalAttribute"}, {"end": 90, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 72, "tag": "PathologicFunction"}, {"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}]}{"id": "1431_0", "text": "Background Juvenile-onset Huntington's disease (JOHD) is a rare and particularly devastating form of Huntington's disease (HD) for which clinical diagnosis is challenging and robust outcome measures are lacking.", "tags": [{"end": 46, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 182, "tag": "Finding"}, {"end": 46, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 20, "tag": "TemporalConcept"}, {"end": 155, "start": 137, "tag": "HealthCareActivity"}, {"end": 63, "start": 59, "tag": "TemporalConcept"}]}{"id": "1431_1", "text": "Neurofilament light protein (NfL) in plasma has emerged as a prognostic biomarker for adult-onset HD.", "tags": [{"end": 27, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 86, "tag": "Finding"}, {"end": 91, "start": 86, "tag": "PopulationGroup"}, {"end": 81, "start": 61, "tag": "ClinicalAttribute"}, {"end": 19, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 92, "tag": "TemporalConcept"}]}{"id": "1431_2", "text": "Methods We performed a retrospective analysis of samples and data collected between 2009 and 2020 from the Kids-HD and Kids-JHD studies.", "tags": [{"end": 127, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 61, "tag": "ResearchActivity"}, {"end": 135, "start": 128, "tag": "ResearchActivity"}, {"end": 114, "start": 107, "tag": "ResearchActivity"}, {"end": 45, "start": 23, "tag": "ResearchActivity"}, {"end": 56, "start": 49, "tag": "Substance"}, {"end": 56, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 119, "tag": "ResearchActivity"}]}{"id": "1431_3", "text": "Plasma samples from children and young adults with JOHD, premanifest HD (preHD) mutation carriers, and age-matched controls were used to quantify plasma NfL concentrations using ultrasensitive immunoassay.", "tags": [{"end": 28, "start": 20, "tag": "PopulationGroup"}, {"end": 45, "start": 33, "tag": "PopulationGroup"}, {"end": 55, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 204, "start": 178, "tag": "ResearchActivity"}, {"end": 71, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 80, "tag": "CellOrMolecularDysfunction"}, {"end": 156, "start": 153, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 115, "tag": "PopulationGroup"}, {"end": 152, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 103, "tag": "OrganismAttribute"}, {"end": 97, "start": 89, "tag": "PopulationGroup"}, {"end": 14, "start": 7, "tag": "Substance"}, {"end": 14, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 171, "start": 146, "tag": "ClinicalAttribute"}, {"end": 78, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 80, "tag": "PopulationGroup"}]}{"id": "1431_4", "text": "Results We report elevated plasma NfL concentrations in JOHD and premanifest HD mutation-carrying children.", "tags": [{"end": 60, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 98, "tag": "PopulationGroup"}, {"end": 79, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 80, "tag": "CellOrMolecularDysfunction"}, {"end": 37, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "HealthCareActivity"}, {"end": 17, "start": 11, "tag": "ResearchActivity"}, {"end": 52, "start": 34, "tag": "ClinicalAttribute"}]}{"id": "1431_5", "text": "In pediatric HD mutation carriers who were within 20 years of their predicted onset and patients with JOHD, plasma NfL level was associated with caudate and putamen volumes.", "tags": [{"end": 106, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 16, "tag": "CellOrMolecularDysfunction"}, {"end": 118, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 88, "tag": "PatientOrDisabledGroup"}, {"end": 114, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 53, "tag": "TemporalConcept"}, {"end": 83, "start": 78, "tag": "TemporalConcept"}, {"end": 33, "start": 25, "tag": "PopulationGroup"}, {"end": 33, "start": 16, "tag": "PopulationGroup"}, {"end": 124, "start": 108, "tag": "ClinicalAttribute"}, {"end": 172, "start": 157, "tag": "ClinicalAttribute"}, {"end": 172, "start": 165, "tag": "ClinicalAttribute"}, {"end": 152, "start": 145, "tag": "ClinicalAttribute"}]}{"id": "1431_6", "text": "Conclusions Quantifying plasma NfL concentration may assist clinical diagnosis and therapeutic trial design in the pediatric population.", "tags": [{"end": 135, "start": 115, "tag": "PopulationGroup"}, {"end": 34, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 83, "tag": "ResearchActivity"}, {"end": 78, "start": 60, "tag": "HealthCareActivity"}, {"end": 48, "start": 24, "tag": "ClinicalAttribute"}]}{"id": "1431_7", "text": "(c) 2022 The Authors.", "tags": []}{"id": "1431_8", "text": "Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.", "tags": [{"end": 90, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 67, "tag": "HealthCareRelatedOrganization"}]}{"id": "1432_0", "text": "Study Objectives: To determine the effect of self-reported clinical diagnosis of obstructive sleep apnea (OSA) on longitudinal changes in brain amyloid PET and CSF biomarkers (A beta 42, T-tau, and P-tau) in cognitively normal (NL), mild cognitive impairment (MCI), and Alzheimer's disease (AD) elderly.", "tags": [{"end": 5, "start": 0, "tag": "ResearchActivity"}, {"end": 77, "start": 45, "tag": "ResearchActivity"}, {"end": 106, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 228, "tag": "Finding"}, {"end": 192, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 114, "tag": "Finding"}, {"end": 226, "start": 220, "tag": "Finding"}, {"end": 185, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 176, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 198, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 189, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 289, "start": 270, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 189, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 200, "tag": "BiologicallyActiveSubstance"}, {"end": 293, "start": 291, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 68, "tag": "HealthCareActivity"}, {"end": 174, "start": 164, "tag": "ClinicalAttribute"}, {"end": 263, "start": 260, "tag": "DiseaseOrSyndrome"}, {"end": 226, "start": 208, "tag": "Finding"}, {"end": 302, "start": 295, "tag": "PopulationGroup"}, {"end": 155, "start": 152, "tag": "HealthCareActivity"}, {"end": 258, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 59, "tag": "HealthCareActivity"}]}{"id": "1432_1", "text": "Methods: Longitudinal study with mean follow-up time of 2.52 +/- 0.51 years.", "tags": [{"end": 27, "start": 9, "tag": "ResearchActivity"}, {"end": 52, "start": 48, "tag": "TemporalConcept"}, {"end": 47, "start": 38, "tag": "HealthCareActivity"}, {"end": 47, "start": 38, "tag": "TemporalConcept"}, {"end": 75, "start": 70, "tag": "TemporalConcept"}]}{"id": "1432_2", "text": "Data were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.", "tags": [{"end": 87, "start": 79, "tag": "ResearchActivity"}, {"end": 71, "start": 28, "tag": "ResearchActivity"}, {"end": 71, "start": 28, "tag": "HealthCareRelatedOrganization"}, {"end": 77, "start": 73, "tag": "HealthCareRelatedOrganization"}, {"end": 77, "start": 73, "tag": "ResearchActivity"}, {"end": 47, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 4, "start": 0, "tag": "ResearchActivity"}]}{"id": "1432_3", "text": "Participants included 516 NL, 798 MCI, and 325 AD elderly.", "tags": [{"end": 28, "start": 26, "tag": "Finding"}, {"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 57, "start": 50, "tag": "PopulationGroup"}]}{"id": "1432_4", "text": "Main outcomes were annual rate of change in brain amyloid burden (i.e.", "tags": [{"end": 30, "start": 26, "tag": "TemporalConcept"}, {"end": 49, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 19, "tag": "TemporalConcept"}, {"end": 13, "start": 5, "tag": "Finding"}, {"end": 64, "start": 58, "tag": "ResearchActivity"}]}{"id": "1432_5", "text": "longitudinal increases in florbetapir PET uptake or decreases in CSF A beta 42 levels); and tau protein aggregation (i.e.", "tags": [{"end": 37, "start": 26, "tag": "Chemical"}, {"end": 61, "start": 52, "tag": "Finding"}, {"end": 78, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 38, "tag": "HealthCareActivity"}, {"end": 75, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 48, "start": 42, "tag": "BiologicFunction"}, {"end": 48, "start": 42, "tag": "CellFunction"}, {"end": 85, "start": 65, "tag": "ClinicalAttribute"}, {"end": 115, "start": 92, "tag": "CellOrMolecularDysfunction"}]}{"id": "1432_6", "text": "longitudinal increases in CSF total tau [T-tau] and phosphorylated tau [P-tau]).", "tags": [{"end": 46, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 52, "tag": "CellFunction"}, {"end": 77, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 26, "tag": "ClinicalAttribute"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}]}{"id": "1432_7", "text": "Adjusted multilevel mixed effects linear regression models with randomly varying intercepts and slopes was used to test whether the rate of biomarker change differed between participants with and without OSA.", "tags": [{"end": 207, "start": 204, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 132, "tag": "TemporalConcept"}, {"end": 58, "start": 0, "tag": "ResearchActivity"}, {"end": 149, "start": 140, "tag": "ClinicalAttribute"}, {"end": 186, "start": 174, "tag": "PopulationGroup"}, {"end": 119, "start": 115, "tag": "ResearchActivity"}, {"end": 119, "start": 115, "tag": "HealthCareActivity"}, {"end": 156, "start": 150, "tag": "Finding"}]}{"id": "1432_8", "text": "Results: In NL and MCI groups, OSA+ subjects experienced faster annual increase in florbetapir uptake (B =.06, 95% CI =.02,.11 and B =.08, 95% CI =.05, .12, respectively) and decrease in CSF A beta 42 levels (B = -2.71, 95% CI = -3.11, -2.35 and B = -2.62, 95% CI = -3.23, -2.03, respectively); as well as increases in CSF T-tau (B = 3.68, 95% CI = 3.31, 4.07 and B = 2.21, 95% CI = 1.58, 2.86, respectively) and P-tau (B = 1.221, 95% CI = 1.02, 1.42 and B = 1.74, 95% CI = 1.22, 2.27, respectively); compared with OSA- participants.", "tags": [{"end": 14, "start": 12, "tag": "Finding"}, {"end": 94, "start": 83, "tag": "Chemical"}, {"end": 183, "start": 175, "tag": "Finding"}, {"end": 328, "start": 323, "tag": "AminoAcidPeptideOrProtein"}, {"end": 328, "start": 323, "tag": "BiologicallyActiveSubstance"}, {"end": 200, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 200, "start": 191, "tag": "BiologicallyActiveSubstance"}, {"end": 418, "start": 413, "tag": "AminoAcidPeptideOrProtein"}, {"end": 418, "start": 413, "tag": "BiologicallyActiveSubstance"}, {"end": 328, "start": 325, "tag": "AminoAcidPeptideOrProtein"}, {"end": 418, "start": 415, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 322, "start": 319, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 328, "start": 325, "tag": "BiologicallyActiveSubstance"}, {"end": 418, "start": 415, "tag": "BiologicallyActiveSubstance"}, {"end": 532, "start": 520, "tag": "PopulationGroup"}, {"end": 22, "start": 19, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 64, "tag": "TemporalConcept"}, {"end": 117, "start": 115, "tag": "ResearchActivity"}, {"end": 226, "start": 224, "tag": "ResearchActivity"}, {"end": 263, "start": 261, "tag": "ResearchActivity"}, {"end": 346, "start": 344, "tag": "ResearchActivity"}, {"end": 380, "start": 378, "tag": "ResearchActivity"}, {"end": 437, "start": 435, "tag": "ResearchActivity"}, {"end": 471, "start": 469, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 29, "start": 23, "tag": "PopulationGroup"}, {"end": 44, "start": 36, "tag": "PopulationGroup"}, {"end": 197, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 95, "tag": "BiologicFunction"}, {"end": 101, "start": 95, "tag": "CellFunction"}, {"end": 207, "start": 187, "tag": "ClinicalAttribute"}, {"end": 328, "start": 319, "tag": "ClinicalAttribute"}]}{"id": "1432_9", "text": "No significant variations in the biomarker changes over time were seen in the AD group.", "tags": [{"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 33, "tag": "ClinicalAttribute"}, {"end": 60, "start": 56, "tag": "TemporalConcept"}, {"end": 86, "start": 81, "tag": "PopulationGroup"}, {"end": 50, "start": 43, "tag": "Finding"}, {"end": 25, "start": 0, "tag": "Finding"}]}{"id": "1432_10", "text": "Conclusions: In both NL and MCI, elderly, clinical interventions aimed to treat OSA are needed to test if OSA treatment may affect the progression of cognitive impairment due to AD.", "tags": [{"end": 23, "start": 21, "tag": "Finding"}, {"end": 83, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 42, "tag": "HealthCareActivity"}, {"end": 180, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 110, "tag": "HealthCareActivity"}, {"end": 119, "start": 110, "tag": "ResearchActivity"}, {"end": 170, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 135, "tag": "PathologicFunction"}, {"end": 146, "start": 135, "tag": "TemporalConcept"}, {"end": 40, "start": 33, "tag": "PopulationGroup"}, {"end": 102, "start": 98, "tag": "ResearchActivity"}, {"end": 102, "start": 98, "tag": "HealthCareActivity"}]}{"id": "1433_0", "text": "Oxidative stress has long been implicated in the pathophysiology and progression of Huntington's disease (HD).", "tags": [{"end": 16, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 104, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 49, "tag": "PathologicFunction"}, {"end": 64, "start": 49, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 80, "start": 69, "tag": "PathologicFunction"}, {"end": 80, "start": 69, "tag": "TemporalConcept"}]}{"id": "1433_1", "text": "Uric acid (UA) is a naturally occurring antioxidant that is present in the brain and periphery.", "tags": [{"end": 9, "start": 0, "tag": "Chemical"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 11, "tag": "Chemical"}, {"end": 13, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 40, "tag": "PharmacologicSubstance"}, {"end": 51, "start": 40, "tag": "CellFunction"}, {"end": 80, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1433_2", "text": "Growing evidence has implicated UA as a molecular biomarker for several neurodegenerative diseases, most notably Parkinson's disease (PD).", "tags": [{"end": 34, "start": 32, "tag": "Chemical"}, {"end": 34, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 40, "tag": "ClinicalAttribute"}, {"end": 98, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 0, "tag": "Finding"}]}{"id": "1433_3", "text": "In this study, we investigated UA levels in clinical samples from HD patients and normal controls (NCs) and assessed potential relationships between UA levels and disease and clinical data.", "tags": [{"end": 33, "start": 31, "tag": "Chemical"}, {"end": 33, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 149, "tag": "Chemical"}, {"end": 151, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 82, "tag": "Finding"}, {"end": 188, "start": 175, "tag": "ResearchActivity"}, {"end": 77, "start": 66, "tag": "PatientOrDisabledGroup"}, {"end": 97, "start": 82, "tag": "PopulationGroup"}, {"end": 140, "start": 127, "tag": "Finding"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 60, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 44, "tag": "Substance"}]}{"id": "1433_4", "text": "UA levels were measured in plasma (n = 107) and saliva (n = 178) samples from premanifest (pre-HD) and manifest HD patients and control subjects.", "tags": [{"end": 2, "start": 0, "tag": "Chemical"}, {"end": 2, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 103, "tag": "PatientOrDisabledGroup"}, {"end": 144, "start": 128, "tag": "PopulationGroup"}, {"end": 54, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 128, "tag": "PopulationGroup"}, {"end": 144, "start": 136, "tag": "PopulationGroup"}, {"end": 72, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 65, "tag": "Substance"}, {"end": 123, "start": 112, "tag": "PatientOrDisabledGroup"}, {"end": 89, "start": 78, "tag": "PatientOrDisabledGroup"}]}{"id": "1433_5", "text": "Gender effects of UA levels were observed in both biofluids, with male patients showing higher UA levels compared to female patients.", "tags": [{"end": 6, "start": 0, "tag": "OrganismAttribute"}, {"end": 20, "start": 18, "tag": "Chemical"}, {"end": 20, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 95, "tag": "Chemical"}, {"end": 97, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 117, "tag": "OrganismAttribute"}, {"end": 70, "start": 66, "tag": "OrganismAttribute"}, {"end": 79, "start": 71, "tag": "PatientOrDisabledGroup"}, {"end": 132, "start": 124, "tag": "PatientOrDisabledGroup"}, {"end": 59, "start": 50, "tag": "Substance"}, {"end": 14, "start": 7, "tag": "Finding"}]}{"id": "1433_6", "text": "Comparisons of UA levels across diagnostic groups, separated by gender, revealed that both plasma and salivary UA levels were significantly lower in female pre-HD and manifest HD patients compared to NCs.", "tags": [{"end": 17, "start": 15, "tag": "Chemical"}, {"end": 17, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 111, "tag": "Chemical"}, {"end": 113, "start": 111, "tag": "ResearchActivity"}, {"end": 162, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 149, "tag": "OrganismAttribute"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 167, "tag": "PatientOrDisabledGroup"}, {"end": 110, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 97, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 43, "tag": "PopulationGroup"}, {"end": 70, "start": 64, "tag": "OrganismAttribute"}, {"end": 120, "start": 102, "tag": "ClinicalAttribute"}, {"end": 120, "start": 111, "tag": "ClinicalAttribute"}, {"end": 97, "start": 91, "tag": "ClinicalAttribute"}]}{"id": "1433_7", "text": "Salivary levels of UA were also significantly lower in male manifest HD patients versus controls, but not in plasma.", "tags": [{"end": 21, "start": 19, "tag": "Chemical"}, {"end": 21, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 60, "tag": "PatientOrDisabledGroup"}, {"end": 68, "start": 60, "tag": "SignOrSymptom"}, {"end": 59, "start": 55, "tag": "OrganismAttribute"}, {"end": 96, "start": 88, "tag": "PopulationGroup"}, {"end": 115, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1433_8", "text": "Correlations of peripheral UA levels to clinical data also showed differences according to gender.", "tags": [{"end": 29, "start": 27, "tag": "Chemical"}, {"end": 29, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 40, "tag": "ResearchActivity"}, {"end": 77, "start": 66, "tag": "Finding"}, {"end": 97, "start": 91, "tag": "OrganismAttribute"}, {"end": 26, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 16, "tag": "ClinicalAttribute"}]}{"id": "1433_9", "text": "In male HD patients, both plasma and salivary UA levels were significantly negatively correlated with total functional capacity (TFC), while positive correlations were observed with total motor score (TMS).", "tags": [{"end": 48, "start": 46, "tag": "Chemical"}, {"end": 48, "start": 46, "tag": "ResearchActivity"}, {"end": 127, "start": 108, "tag": "Finding"}, {"end": 199, "start": 182, "tag": "HealthCareActivity"}, {"end": 127, "start": 102, "tag": "HealthCareActivity"}, {"end": 204, "start": 201, "tag": "HealthCareActivity"}, {"end": 132, "start": 129, "tag": "HealthCareActivity"}, {"end": 19, "start": 8, "tag": "PatientOrDisabledGroup"}, {"end": 45, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 3, "tag": "OrganismAttribute"}, {"end": 32, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 150, "tag": "ResearchActivity"}, {"end": 55, "start": 37, "tag": "ClinicalAttribute"}, {"end": 55, "start": 46, "tag": "ClinicalAttribute"}, {"end": 32, "start": 26, "tag": "ClinicalAttribute"}]}{"id": "1433_10", "text": "Female HD patients showed a significant positive correlation between plasma UA levels and TMS, while salivary UA levels from female patients were significantly correlated to disease burden.", "tags": [{"end": 6, "start": 0, "tag": "PopulationGroup"}, {"end": 6, "start": 0, "tag": "OrganismAttribute"}, {"end": 78, "start": 76, "tag": "Chemical"}, {"end": 78, "start": 76, "tag": "ResearchActivity"}, {"end": 188, "start": 174, "tag": "ResearchActivity"}, {"end": 93, "start": 90, "tag": "HealthCareActivity"}, {"end": 131, "start": 125, "tag": "OrganismAttribute"}, {"end": 18, "start": 7, "tag": "PatientOrDisabledGroup"}, {"end": 140, "start": 132, "tag": "PatientOrDisabledGroup"}, {"end": 75, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 28, "tag": "ResearchActivity"}, {"end": 85, "start": 69, "tag": "ClinicalAttribute"}, {"end": 119, "start": 101, "tag": "ClinicalAttribute"}]}{"id": "1433_11", "text": "Finally, in a separate cohort, we show that UA levels are decreased in postmortem prefrontal cortical samples (n = 20) from HD subjects compared to matched controls.", "tags": [{"end": 46, "start": 44, "tag": "Chemical"}, {"end": 46, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 58, "tag": "Finding"}, {"end": 101, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 124, "tag": "PatientOrDisabledGroup"}, {"end": 164, "start": 156, "tag": "PopulationGroup"}, {"end": 135, "start": 127, "tag": "PopulationGroup"}, {"end": 81, "start": 71, "tag": "TemporalConcept"}, {"end": 29, "start": 23, "tag": "PopulationGroup"}, {"end": 109, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 102, "tag": "Substance"}]}{"id": "1433_12", "text": "These findings suggest that decreased levels of UA in the brains of HD patients can be reflected in peripheral fluids, with salivary measures of UA particularly offering significant promise as a potentially relevant, non-invasive biomarker of disease symptoms and burden.", "tags": [{"end": 50, "start": 48, "tag": "Chemical"}, {"end": 50, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 145, "tag": "Chemical"}, {"end": 147, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 28, "tag": "Finding"}, {"end": 259, "start": 243, "tag": "SignOrSymptom"}, {"end": 239, "start": 217, "tag": "ClinicalAttribute"}, {"end": 79, "start": 68, "tag": "PatientOrDisabledGroup"}, {"end": 132, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 239, "start": 230, "tag": "ClinicalAttribute"}, {"end": 270, "start": 264, "tag": "ResearchActivity"}, {"end": 110, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 111, "tag": "Substance"}]}{"id": "1433_13", "text": "Our findings further highlight the impact of sexual dimorphism in HD pathophysiology.", "tags": [{"end": 62, "start": 45, "tag": "BiologicFunction"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 69, "tag": "PathologicFunction"}]}{"id": "1434_0", "text": "Background Brain-derived neurotrophic factor (BDNF) is secreted by immune cells in response to neuroimmune and inflammatory cascades as an act to prevent axonal and neuronal damage after various pathological insults.", "tags": [{"end": 106, "start": 95, "tag": "BiologicFunction"}, {"end": 132, "start": 124, "tag": "BiologicFunction"}, {"end": 44, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 165, "tag": "Cell"}, {"end": 79, "start": 67, "tag": "Cell"}, {"end": 160, "start": 154, "tag": "CellComponent"}, {"end": 132, "start": 111, "tag": "BiologicFunction"}, {"end": 180, "start": 174, "tag": "InjuryOrPoisoning"}]}{"id": "1434_1", "text": "The serum level of BDNF is altered in a diversity of neurological diseases.", "tags": [{"end": 74, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 4, "tag": "ClinicalAttribute"}]}{"id": "1434_2", "text": "The aim of this work was to investigate the serum level of BDNF in patients with relapsing-remitting multiple sclerosis and the relation between BDNF and disease activity and severity.", "tags": [{"end": 170, "start": 154, "tag": "HealthCareActivity"}, {"end": 183, "start": 175, "tag": "ClinicalAttribute"}, {"end": 183, "start": 175, "tag": "Finding"}, {"end": 49, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 67, "tag": "PatientOrDisabledGroup"}, {"end": 63, "start": 44, "tag": "ClinicalAttribute"}]}{"id": "1434_3", "text": "Methods A case-control study was conducted on 90 subjects: 60 patients with relapsing-remitting multiple sclerosis (30 in relapse and 30 in remission) on different lines of medical treatment and 30 healthy volunteers as a control.", "tags": [{"end": 28, "start": 10, "tag": "ResearchActivity"}, {"end": 149, "start": 140, "tag": "Finding"}, {"end": 190, "start": 173, "tag": "HealthCareActivity"}, {"end": 129, "start": 122, "tag": "TemporalConcept"}, {"end": 129, "start": 122, "tag": "Finding"}, {"end": 216, "start": 206, "tag": "PopulationGroup"}, {"end": 114, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 62, "tag": "PatientOrDisabledGroup"}, {"end": 205, "start": 198, "tag": "OrganismAttribute"}, {"end": 14, "start": 10, "tag": "ManufacturedObject"}, {"end": 22, "start": 15, "tag": "PopulationGroup"}, {"end": 229, "start": 222, "tag": "PopulationGroup"}, {"end": 57, "start": 49, "tag": "PopulationGroup"}]}{"id": "1434_4", "text": "Clinical, functional, and radiological evaluation was done for the patients, and all the patients and controls were subjected to assessment of the serum level of BDNF by sandwich-ELISA technique.", "tags": [{"end": 49, "start": 39, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "HealthCareActivity"}, {"end": 194, "start": 170, "tag": "ResearchActivity"}, {"end": 194, "start": 185, "tag": "ResearchActivity"}, {"end": 152, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 162, "tag": "AminoAcidPeptideOrProtein"}, {"end": 166, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 102, "tag": "PopulationGroup"}, {"end": 75, "start": 67, "tag": "PatientOrDisabledGroup"}, {"end": 97, "start": 89, "tag": "PatientOrDisabledGroup"}, {"end": 139, "start": 129, "tag": "HealthCareActivity"}, {"end": 139, "start": 129, "tag": "ResearchActivity"}, {"end": 49, "start": 26, "tag": "HealthCareActivity"}, {"end": 166, "start": 147, "tag": "ClinicalAttribute"}]}{"id": "1434_5", "text": "Results The BDNF level was significantly higher in MS patients in relapse than in patients in remission (P value = 0.006).", "tags": [{"end": 103, "start": 94, "tag": "Finding"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 66, "tag": "TemporalConcept"}, {"end": 73, "start": 66, "tag": "Finding"}, {"end": 16, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 54, "tag": "PatientOrDisabledGroup"}, {"end": 90, "start": 82, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 112, "start": 105, "tag": "ResearchActivity"}, {"end": 22, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1434_6", "text": "In the remission group, there was no significant linear correlation between different MS patients' characteristics and BDNF level, while in the relapse group, a positive linear correlation was found between the number of T2 infratentorial lesions and BDNF level (r = 0.402, P = 0.028).", "tags": [{"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 238, "start": 224, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 144, "tag": "TemporalConcept"}, {"end": 151, "start": 144, "tag": "Finding"}, {"end": 246, "start": 239, "tag": "InjuryOrPoisoning"}, {"end": 123, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 255, "start": 251, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 255, "start": 251, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 99, "tag": "OrganismAttribute"}, {"end": 97, "start": 89, "tag": "PatientOrDisabledGroup"}, {"end": 22, "start": 17, "tag": "PopulationGroup"}, {"end": 157, "start": 152, "tag": "PopulationGroup"}, {"end": 16, "start": 7, "tag": "Finding"}, {"end": 67, "start": 49, "tag": "ResearchActivity"}, {"end": 188, "start": 170, "tag": "ResearchActivity"}, {"end": 246, "start": 221, "tag": "ClinicalAttribute"}, {"end": 129, "start": 119, "tag": "ClinicalAttribute"}, {"end": 261, "start": 251, "tag": "ClinicalAttribute"}]}{"id": "1434_7", "text": "There was no statistically significant difference between the BDNF level in patients administered different drugs for MS in both remission and relapse groups (P value > 0.05).", "tags": [{"end": 138, "start": 129, "tag": "Finding"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 143, "tag": "TemporalConcept"}, {"end": 150, "start": 143, "tag": "Finding"}, {"end": 66, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 76, "tag": "PatientOrDisabledGroup"}, {"end": 113, "start": 108, "tag": "PharmacologicSubstance"}, {"end": 157, "start": 151, "tag": "PopulationGroup"}, {"end": 49, "start": 10, "tag": "Finding"}, {"end": 166, "start": 159, "tag": "ResearchActivity"}, {"end": 72, "start": 62, "tag": "ClinicalAttribute"}]}{"id": "1434_8", "text": "Conclusion BDNF was significantly higher in relapsing-remitting multiple sclerosis patients in the relapse phase.", "tags": [{"end": 106, "start": 99, "tag": "TemporalConcept"}, {"end": 106, "start": 99, "tag": "Finding"}, {"end": 15, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 83, "tag": "PatientOrDisabledGroup"}, {"end": 112, "start": 107, "tag": "TemporalConcept"}]}{"id": "1434_9", "text": "Attention should be paid to the link between serum BDNF level as a neuroprotective factor and multiple sclerosis; it can be a biomarker for MS activity in the near future.", "tags": [{"end": 9, "start": 0, "tag": "BiologicFunction"}, {"end": 89, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 126, "tag": "ClinicalAttribute"}, {"end": 170, "start": 164, "tag": "TemporalConcept"}, {"end": 61, "start": 45, "tag": "ClinicalAttribute"}]}{"id": "1435_0", "text": "Huntington's disease is a dominantly inherited, fatal neurodegenerative disorder caused by a CAG expansion in the huntingtin (HTT) gene, coding for pathological mutant HTT protein (mHTT).", "tags": [{"end": 179, "start": 148, "tag": "CellOrMolecularDysfunction"}, {"end": 96, "start": 93, "tag": "MolecularSequence"}, {"end": 135, "start": 131, "tag": "GeneOrGenome"}, {"end": 124, "start": 114, "tag": "GeneOrGenome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 129, "start": 126, "tag": "GeneOrGenome"}, {"end": 129, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 185, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 181, "tag": "CellOrMolecularDysfunction"}]}{"id": "1435_1", "text": "Because of its gain-of-function mechanism and monogenic aetiology, strategies to lower HTT are being actively investigated as disease-modifying therapies.", "tags": [{"end": 90, "start": 87, "tag": "GeneOrGenome"}, {"end": 90, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 126, "tag": "HealthCareActivity"}, {"end": 65, "start": 46, "tag": "Finding"}, {"end": 90, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 15, "tag": "CellFunction"}]}{"id": "1435_2", "text": "Most approaches are currently targeted at the manifest stage, where clinical outcomes are used to evaluate the effectiveness of therapy.", "tags": [{"end": 85, "start": 68, "tag": "ClinicalAttribute"}, {"end": 124, "start": 111, "tag": "Finding"}, {"end": 29, "start": 20, "tag": "TemporalConcept"}, {"end": 135, "start": 128, "tag": "HealthCareActivity"}, {"end": 60, "start": 46, "tag": "TemporalConcept"}]}{"id": "1435_3", "text": "However, as almost 50% of striatal volume has been lost at the time of onset of clinical manifest, it would be preferable to begin therapy in the premanifest period.", "tags": [{"end": 34, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 26, "tag": "ClinicalAttribute"}, {"end": 97, "start": 80, "tag": "SignOrSymptom"}, {"end": 164, "start": 146, "tag": "TemporalConcept"}, {"end": 67, "start": 63, "tag": "TemporalConcept"}, {"end": 138, "start": 131, "tag": "HealthCareActivity"}, {"end": 76, "start": 71, "tag": "TemporalConcept"}]}{"id": "1435_4", "text": "An unmet challenge is how to evaluate therapeutic efficacy before the presence of clinical symptoms as outcome measures.", "tags": [{"end": 18, "start": 9, "tag": "HealthCareActivity"}, {"end": 99, "start": 82, "tag": "SignOrSymptom"}, {"end": 78, "start": 70, "tag": "Finding"}, {"end": 65, "start": 59, "tag": "TemporalConcept"}, {"end": 58, "start": 38, "tag": "Finding"}, {"end": 110, "start": 103, "tag": "Finding"}]}{"id": "1435_5", "text": "To address this, we aim to develop non-invasive sensitive biomarkers that provide insight into therapeutic efficacy in the premanifest stage of Huntington's disease.", "tags": [{"end": 164, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 58, "tag": "ClinicalAttribute"}, {"end": 47, "start": 35, "tag": "ClinicalAttribute"}, {"end": 115, "start": 95, "tag": "Finding"}, {"end": 140, "start": 123, "tag": "TemporalConcept"}]}{"id": "1435_6", "text": "In this study, we mapped the temporal trajectories of arteriolar cerebral blood volumes (CBVa) using inflow-based vascular-space-occupancy (iVASO) MRI in the heterozygous zQ175 mice, a full-length mHTT expressing and slowly progressing model with a premanifest period as in human Huntington's disease.", "tags": [{"end": 212, "start": 202, "tag": "CellFunction"}, {"end": 300, "start": 280, "tag": "DiseaseOrSyndrome"}, {"end": 267, "start": 261, "tag": "TemporalConcept"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 150, "start": 147, "tag": "HealthCareActivity"}, {"end": 138, "start": 101, "tag": "HealthCareActivity"}, {"end": 24, "start": 18, "tag": "ResearchActivity"}, {"end": 241, "start": 217, "tag": "ResearchActivity"}, {"end": 37, "start": 29, "tag": "TemporalConcept"}, {"end": 279, "start": 274, "tag": "Eukaryote"}, {"end": 87, "start": 54, "tag": "ClinicalAttribute"}, {"end": 87, "start": 74, "tag": "ClinicalAttribute"}, {"end": 145, "start": 140, "tag": "HealthCareActivity"}, {"end": 181, "start": 158, "tag": "ExperimentalModelOfDisease"}, {"end": 201, "start": 197, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 197, "tag": "CellOrMolecularDysfunction"}, {"end": 93, "start": 89, "tag": "ClinicalAttribute"}]}{"id": "1435_7", "text": "Significantly elevated CBVa was evident in premanifest zQ175 mice prior to motor deficits and striatal atrophy, recapitulating altered CBVa in human premanifest Huntington's disease.", "tags": [{"end": 110, "start": 94, "tag": "Finding"}, {"end": 102, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 75, "tag": "PathologicFunction"}, {"end": 181, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "Finding"}, {"end": 148, "start": 143, "tag": "Eukaryote"}, {"end": 65, "start": 43, "tag": "ExperimentalModelOfDisease"}, {"end": 27, "start": 23, "tag": "ClinicalAttribute"}, {"end": 139, "start": 135, "tag": "ClinicalAttribute"}]}{"id": "1435_8", "text": "CRISPR/Cas9-mediated non-allele-specific HTT silencing in striatal neurons restored altered CBVa in premanifest zQ175 mice, delayed onset of striatal atrophy, and slowed the progression of motor phenotype and brain pathology.", "tags": [{"end": 137, "start": 124, "tag": "TemporalConcept"}, {"end": 157, "start": 141, "tag": "Finding"}, {"end": 149, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 58, "tag": "Cell"}, {"end": 44, "start": 41, "tag": "GeneOrGenome"}, {"end": 44, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 0, "tag": "ResearchActivity"}, {"end": 11, "start": 0, "tag": "BiologicFunction"}, {"end": 6, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 204, "start": 195, "tag": "OrganismAttribute"}, {"end": 185, "start": 174, "tag": "PathologicFunction"}, {"end": 185, "start": 174, "tag": "TemporalConcept"}, {"end": 31, "start": 25, "tag": "GeneOrGenome"}, {"end": 224, "start": 209, "tag": "PathologicFunction"}, {"end": 44, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 0, "tag": "ResearchActivity"}, {"end": 122, "start": 100, "tag": "ExperimentalModelOfDisease"}, {"end": 96, "start": 92, "tag": "ClinicalAttribute"}]}{"id": "1435_9", "text": "This study-for the first time-shows that a non-invasive functional MRI measure detects therapeutic efficacy in the premanifest stage and demonstrates long-term benefits of a non-allele-selective HTT silencing treatment introduced in the premanifest Huntington's disease.", "tags": [{"end": 269, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 150, "tag": "TemporalConcept"}, {"end": 24, "start": 19, "tag": "TemporalConcept"}, {"end": 218, "start": 174, "tag": "HealthCareActivity"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 29, "start": 25, "tag": "TemporalConcept"}, {"end": 107, "start": 87, "tag": "Finding"}, {"end": 70, "start": 43, "tag": "HealthCareActivity"}, {"end": 132, "start": 115, "tag": "TemporalConcept"}, {"end": 168, "start": 160, "tag": "Finding"}]}{"id": "1436_0", "text": "The authors used PET imaging to stage individuals according to the Braak neuropathological system for Alzheimer's disease.", "tags": [{"end": 37, "start": 32, "tag": "TemporalConcept"}, {"end": 37, "start": 32, "tag": "ClinicalAttribute"}, {"end": 20, "start": 17, "tag": "HealthCareActivity"}, {"end": 28, "start": 17, "tag": "HealthCareActivity"}, {"end": 121, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 21, "tag": "HealthCareActivity"}, {"end": 49, "start": 38, "tag": "PopulationGroup"}, {"end": 97, "start": 67, "tag": "HealthCareActivity"}]}{"id": "1436_1", "text": "PET stage was associated with biomarker and cognitive changes, highlighting the potential to stage Alzheimer's disease in living people.", "tags": [{"end": 9, "start": 4, "tag": "TemporalConcept"}, {"end": 9, "start": 4, "tag": "ClinicalAttribute"}, {"end": 61, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 93, "tag": "TemporalConcept"}, {"end": 98, "start": 93, "tag": "ClinicalAttribute"}, {"end": 3, "start": 0, "tag": "HealthCareActivity"}, {"end": 118, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 30, "tag": "ClinicalAttribute"}, {"end": 135, "start": 122, "tag": "PopulationGroup"}]}{"id": "1436_2", "text": "Gold-standard diagnosis of Alzheimer's disease (AD) relies on histopathological staging systems.", "tags": [{"end": 23, "start": 14, "tag": "HealthCareActivity"}, {"end": 46, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 62, "tag": "HealthCareActivity"}]}{"id": "1436_3", "text": "Using the topographical information from [F-18]MK6240 tau positron-emission tomography (PET), we applied the Braak tau staging system to 324 living individuals.", "tags": [{"end": 86, "start": 54, "tag": "HealthCareActivity"}, {"end": 91, "start": 88, "tag": "HealthCareActivity"}, {"end": 57, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 141, "tag": "PopulationGroup"}, {"end": 126, "start": 119, "tag": "TemporalConcept"}, {"end": 57, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 109, "tag": "HealthCareActivity"}]}{"id": "1436_4", "text": "We used PET-based Braak stage to model the trajectories of amyloid-beta, phosphorylated tau (pTau) in cerebrospinal fluid (pTau(181), pTau(217), pTau(231) and pTau(235)) and plasma (pTau(181) and pTau(231)), neurodegeneration and cognitive symptoms.", "tags": [{"end": 97, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 248, "start": 230, "tag": "SignOrSymptom"}, {"end": 11, "start": 8, "tag": "HealthCareActivity"}, {"end": 91, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 208, "tag": "CellOrMolecularDysfunction"}, {"end": 180, "start": 174, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 33, "tag": "ResearchActivity"}, {"end": 121, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 8, "tag": "HealthCareActivity"}, {"end": 97, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 143, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 191, "start": 182, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 196, "tag": "AminoAcidPeptideOrProtein"}, {"end": 205, "start": 196, "tag": "BiologicallyActiveSubstance"}]}{"id": "1436_5", "text": "We identified nonlinear AD biomarker trajectories corresponding to the spatial extent of tau-PET, with modest biomarker changes detectable by Braak stage II and significant changes occurring at stages III-IV, followed by plateaus.", "tags": [{"end": 200, "start": 194, "tag": "TemporalConcept"}, {"end": 96, "start": 93, "tag": "HealthCareActivity"}, {"end": 92, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 27, "tag": "ClinicalAttribute"}, {"end": 119, "start": 110, "tag": "ClinicalAttribute"}, {"end": 92, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 142, "tag": "HealthCareActivity"}]}{"id": "1436_6", "text": "Early Braak stages were associated with isolated memory impairment, whereas Braak stages V-VI were incompatible with normal cognition.", "tags": [{"end": 18, "start": 12, "tag": "TemporalConcept"}, {"end": 88, "start": 82, "tag": "TemporalConcept"}, {"end": 133, "start": 117, "tag": "Finding"}, {"end": 123, "start": 117, "tag": "Finding"}, {"end": 133, "start": 124, "tag": "BiologicFunction"}, {"end": 5, "start": 0, "tag": "TemporalConcept"}, {"end": 66, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 6, "tag": "HealthCareActivity"}, {"end": 93, "start": 76, "tag": "HealthCareActivity"}]}{"id": "1436_7", "text": "In 159 individuals with follow-up tau-PET, progression beyond stage III took place uniquely in the presence of amyloid-beta positivity.", "tags": [{"end": 41, "start": 38, "tag": "HealthCareActivity"}, {"end": 54, "start": 43, "tag": "PathologicFunction"}, {"end": 54, "start": 43, "tag": "TemporalConcept"}, {"end": 37, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 24, "tag": "HealthCareActivity"}, {"end": 33, "start": 24, "tag": "TemporalConcept"}, {"end": 18, "start": 7, "tag": "PopulationGroup"}, {"end": 118, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 34, "tag": "BiologicallyActiveSubstance"}]}{"id": "1436_8", "text": "Our findings support PET-based Braak staging as a framework to model the natural history of AD and monitor AD severity in living humans.", "tags": [{"end": 106, "start": 99, "tag": "HealthCareActivity"}, {"end": 106, "start": 99, "tag": "ManufacturedObject"}, {"end": 118, "start": 110, "tag": "ClinicalAttribute"}, {"end": 118, "start": 110, "tag": "Finding"}, {"end": 135, "start": 129, "tag": "Eukaryote"}, {"end": 24, "start": 21, "tag": "HealthCareActivity"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 63, "tag": "ResearchActivity"}, {"end": 88, "start": 81, "tag": "Finding"}, {"end": 44, "start": 37, "tag": "TemporalConcept"}, {"end": 44, "start": 21, "tag": "HealthCareActivity"}]}{"id": "1437_0", "text": "Introduction Synaptic dysfunction and degeneration is one of the earliest events in Alzheimer's disease (AD) and the best correlate of cognitive decline.", "tags": [{"end": 33, "start": 13, "tag": "CellOrMolecularDysfunction"}, {"end": 33, "start": 22, "tag": "PathologicFunction"}, {"end": 73, "start": 65, "tag": "TemporalConcept"}, {"end": 50, "start": 38, "tag": "PathologicFunction"}, {"end": 103, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 135, "tag": "DiseaseOrSyndrome"}]}{"id": "1437_1", "text": "Thus, identification and validation of biomarkers reflecting synaptic degeneration to be used as prognostic biomarkers are greatly needed.", "tags": [{"end": 35, "start": 25, "tag": "ResearchActivity"}, {"end": 82, "start": 70, "tag": "PathologicFunction"}, {"end": 49, "start": 39, "tag": "ClinicalAttribute"}, {"end": 118, "start": 97, "tag": "ClinicalAttribute"}, {"end": 82, "start": 61, "tag": "CellOrMolecularDysfunction"}]}{"id": "1437_2", "text": "Method Solid-phase extraction and parallel reaction monitoring mass spectrometry were used to quantify 17 synaptic proteins in CSF, in two cross-sectional studies including AD (n = 52) and controls (n = 37).", "tags": [{"end": 162, "start": 139, "tag": "ResearchActivity"}, {"end": 123, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 175, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 197, "start": 189, "tag": "PopulationGroup"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 18, "start": 13, "tag": "TemporalConcept"}, {"end": 80, "start": 34, "tag": "HealthCareActivity"}, {"end": 29, "start": 7, "tag": "ResearchActivity"}]}{"id": "1437_3", "text": "Results Increased concentrations of beta-synuclein, gamma-synuclein, neurogranin, phosphatidylethanolamine-binding protein 1, and 14-3-3 proteins were observed in AD patients compared to controls, while neuronal pentraxin-2 and neuronal pentraxin receptor were decreased.", "tags": [{"end": 32, "start": 18, "tag": "BiologicFunction"}, {"end": 50, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 82, "tag": "GeneOrGenome"}, {"end": 124, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 255, "start": 228, "tag": "AminoAcidPeptideOrProtein"}, {"end": 255, "start": 228, "tag": "GeneOrGenome"}, {"end": 255, "start": 228, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 166, "tag": "PatientOrDisabledGroup"}, {"end": 195, "start": 187, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 223, "start": 203, "tag": "AminoAcidPeptideOrProtein"}, {"end": 223, "start": 203, "tag": "BiologicallyActiveSubstance"}, {"end": 223, "start": 203, "tag": "GeneOrGenome"}, {"end": 145, "start": 130, "tag": "BiologicallyActiveSubstance"}]}{"id": "1437_4", "text": "Discussion We have established a method with a novel panel of synaptic proteins as biomarkers of synaptic dysfunction.", "tags": [{"end": 117, "start": 97, "tag": "CellOrMolecularDysfunction"}, {"end": 117, "start": 106, "tag": "PathologicFunction"}, {"end": 39, "start": 33, "tag": "ResearchActivity"}, {"end": 39, "start": 33, "tag": "HealthCareActivity"}, {"end": 79, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 83, "tag": "ClinicalAttribute"}]}{"id": "1437_5", "text": "The results indicate that several of the proteins included in the panel may serve as synaptic biomarkers for AD.", "tags": [{"end": 49, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 94, "tag": "ClinicalAttribute"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}]}{"id": "1438_0", "text": "Introduction: The retina is a potential source of noninvasive vascular biomarkers for Alzheimer's disease (AD).", "tags": [{"end": 61, "start": 50, "tag": "Finding"}, {"end": 24, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 18, "tag": "Cell"}, {"end": 105, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 71, "tag": "ClinicalAttribute"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1438_1", "text": "We assessed retinal microvasculature in well-characterized AD cases, taking ophthalmological confounders into account.", "tags": [{"end": 36, "start": 20, "tag": "BiologicFunction"}, {"end": 36, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 76, "tag": "Finding"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1438_2", "text": "Methods: We included 48 amyloid-positive AD patients and 38 amyloid-negative cognitively normal control subjects.", "tags": [{"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 24, "tag": "PatientOrDisabledGroup"}, {"end": 112, "start": 96, "tag": "PopulationGroup"}, {"end": 76, "start": 60, "tag": "PopulationGroup"}, {"end": 31, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 77, "tag": "Finding"}]}{"id": "1438_3", "text": "All participants underwent ophthalmological screening to exclude interfering ocular disease.", "tags": [{"end": 16, "start": 4, "tag": "PopulationGroup"}, {"end": 91, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 27, "tag": "HealthCareActivity"}]}{"id": "1438_4", "text": "Using a multimodal approach, we measured retinal vascular parameters, choroidal thickness, macular vascular density, and foveal avascular zone size.", "tags": [{"end": 127, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 41, "tag": "ClinicalAttribute"}, {"end": 27, "start": 8, "tag": "ResearchActivity"}, {"end": 89, "start": 70, "tag": "ClinicalAttribute"}, {"end": 115, "start": 91, "tag": "ClinicalAttribute"}, {"end": 147, "start": 121, "tag": "ClinicalAttribute"}]}{"id": "1438_5", "text": "Results: We found no disease effects on retinal vascular measures (all beta's, vertical bar 0.15 vertical bar, all P..2), adjusted for confounders.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 47, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 40, "tag": "ClinicalAttribute"}, {"end": 146, "start": 135, "tag": "Finding"}]}{"id": "1438_6", "text": "Venular tortuosity was inversely associated with Fazekas score in control subjects (beta -0.56, P < .01), while vessel density in the outer ring of the macula was inversely associated with Fazekas score in AD cases (beta -0.64, P < .01).", "tags": [{"end": 18, "start": 8, "tag": "Finding"}, {"end": 118, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 112, "tag": "ClinicalAttribute"}, {"end": 82, "start": 66, "tag": "PopulationGroup"}, {"end": 82, "start": 74, "tag": "PopulationGroup"}, {"end": 62, "start": 49, "tag": "HealthCareActivity"}, {"end": 18, "start": 0, "tag": "ClinicalAttribute"}, {"end": 158, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 202, "start": 189, "tag": "HealthCareActivity"}]}{"id": "1438_7", "text": "Discussion: In conclusion, retinal vasculature did not discriminate patients with AD from control subjects, despite evident changes on clinical, neuroimaging, and cerebrospinal fluid biomarkers, challenging the use of retinal vasculature measurements as AD biomarker.", "tags": [{"end": 46, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 237, "start": 226, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 250, "start": 218, "tag": "HealthCareActivity"}, {"end": 193, "start": 183, "tag": "ClinicalAttribute"}, {"end": 143, "start": 135, "tag": "ClinicalAttribute"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 254, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 68, "tag": "PatientOrDisabledGroup"}, {"end": 266, "start": 257, "tag": "ClinicalAttribute"}, {"end": 182, "start": 163, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 90, "tag": "PopulationGroup"}, {"end": 34, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 225, "start": 218, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 98, "tag": "PopulationGroup"}, {"end": 157, "start": 145, "tag": "HealthCareActivity"}]}{"id": "1438_8", "text": "(C) 2019 The Authors.", "tags": []}{"id": "1438_9", "text": "Published by Elsevier Inc.", "tags": []}{"id": "1438_10", "text": "on behalf of the Alzheimer's Association.", "tags": [{"end": 40, "start": 17, "tag": "HealthCareRelatedOrganization"}]}{"id": "1439_0", "text": "Background: African American/Black adults have a disproportionate incidence of Alzheimer's disease (AD) and are underrepresented in biomarker discovery efforts.", "tags": [{"end": 19, "start": 12, "tag": "PopulationGroup"}, {"end": 75, "start": 66, "tag": "Finding"}, {"end": 151, "start": 142, "tag": "ResearchActivity"}, {"end": 98, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 132, "tag": "ClinicalAttribute"}, {"end": 41, "start": 12, "tag": "PopulationGroup"}]}{"id": "1439_1", "text": "Objective: This study aimed to identify potential diagnostic biomarkers for AD using a combination of proteomics and machine learning approaches in a cohort that included African American/Black adults.", "tags": [{"end": 112, "start": 102, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 178, "start": 171, "tag": "PopulationGroup"}, {"end": 133, "start": 117, "tag": "MachineActivity"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 71, "start": 50, "tag": "ClinicalAttribute"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 150, "tag": "PopulationGroup"}, {"end": 200, "start": 171, "tag": "PopulationGroup"}, {"end": 133, "start": 125, "tag": "BiologicFunction"}, {"end": 112, "start": 102, "tag": "ResearchActivity"}]}{"id": "1439_2", "text": "Methods: We conducted a discovery-based plasma proteomics study on plasma samples (N = 113) obtained from clinically diagnosed AD and cognitively normal adults that were self-reported African American/Black or non-Hispanic White.", "tags": [{"end": 152, "start": 134, "tag": "Finding"}, {"end": 126, "start": 117, "tag": "HealthCareActivity"}, {"end": 63, "start": 47, "tag": "ResearchActivity"}, {"end": 33, "start": 24, "tag": "ResearchActivity"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 153, "tag": "PopulationGroup"}, {"end": 228, "start": 210, "tag": "PopulationGroup"}, {"end": 206, "start": 184, "tag": "PopulationGroup"}]}{"id": "1439_3", "text": "Sets of differentially-expressed proteins were then classified using a support vector machine (SVM) to identify biomarker candidates.", "tags": [{"end": 41, "start": 8, "tag": "Finding"}, {"end": 41, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 112, "tag": "ClinicalAttribute"}, {"end": 93, "start": 71, "tag": "MachineActivity"}, {"end": 98, "start": 95, "tag": "MachineActivity"}]}{"id": "1439_4", "text": "Results: In total, 740 proteins were identified of which, 25 differentially-expressed proteins in AD came from comparisons within a single racial and ethnic background group.", "tags": [{"end": 94, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 150, "tag": "PopulationGroup"}, {"end": 31, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 76, "tag": "CellFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 173, "start": 168, "tag": "PopulationGroup"}]}{"id": "1439_5", "text": "Six proteins were differentially-expressed in AD regardless of racial and ethnic background.", "tags": [{"end": 91, "start": 74, "tag": "PopulationGroup"}, {"end": 12, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 46, "tag": "DiseaseOrSyndrome"}]}{"id": "1439_6", "text": "Supervised classification by SVM yielded an area under the curve (AUC) of 0.91 and accuracy of 86% for differentiating AD in samples from non-Hispanic White adults when trained with differentially-expressed proteins unique to that group.", "tags": [{"end": 215, "start": 182, "tag": "Finding"}, {"end": 215, "start": 207, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 66, "tag": "ResearchActivity"}, {"end": 206, "start": 197, "tag": "CellFunction"}, {"end": 163, "start": 138, "tag": "PopulationGroup"}, {"end": 236, "start": 231, "tag": "PopulationGroup"}, {"end": 64, "start": 44, "tag": "ResearchActivity"}, {"end": 91, "start": 83, "tag": "Finding"}]}{"id": "1439_7", "text": "However, the same model yielded an AUC of 0.49 and accuracy of 47% for differentiating AD in samples from African American/Black adults.", "tags": [{"end": 135, "start": 106, "tag": "PopulationGroup"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 18, "tag": "ResearchActivity"}, {"end": 38, "start": 35, "tag": "ResearchActivity"}, {"end": 135, "start": 129, "tag": "PopulationGroup"}, {"end": 59, "start": 51, "tag": "Finding"}]}{"id": "1439_8", "text": "Other covariates such as age, APOE4 status, sex, and years of education were found to improve the model mostly in the samples from non-Hispanic White adults for classifying AD.", "tags": [{"end": 35, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "ResearchActivity"}, {"end": 42, "start": 36, "tag": "Finding"}, {"end": 71, "start": 62, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 28, "start": 25, "tag": "OrganismAttribute"}, {"end": 58, "start": 53, "tag": "TemporalConcept"}, {"end": 175, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 98, "tag": "ResearchActivity"}, {"end": 156, "start": 131, "tag": "PopulationGroup"}, {"end": 47, "start": 44, "tag": "OrganismAttribute"}]}{"id": "1439_9", "text": "Conclusion: These results demonstrate the importance of study designs in AD biomarker discovery, which must include diverse racial and ethnic groups such as African American/Black adults to develop effective biomarkers.", "tags": [{"end": 148, "start": 135, "tag": "PopulationGroup"}, {"end": 186, "start": 157, "tag": "PopulationGroup"}, {"end": 61, "start": 56, "tag": "ResearchActivity"}, {"end": 95, "start": 86, "tag": "ResearchActivity"}, {"end": 218, "start": 208, "tag": "ClinicalAttribute"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 76, "tag": "ClinicalAttribute"}, {"end": 186, "start": 180, "tag": "PopulationGroup"}]}{"id": "1440_0", "text": "Alzheimer's disease (AD) is now conceptualized as a biological entity defined by amyloid and tau deposition and neurodegeneration, with heterogeneous clinical presentations.", "tags": [{"end": 172, "start": 159, "tag": "SignOrSymptom"}, {"end": 149, "start": 136, "tag": "OrganismAttribute"}, {"end": 96, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 112, "tag": "CellOrMolecularDysfunction"}, {"end": 107, "start": 93, "tag": "PathologicFunction"}]}{"id": "1440_1", "text": "With the aid of in vivo biomarkers, clinicians are better poised to examine clinical syndromic variability arising from a common pathology.", "tags": [{"end": 46, "start": 36, "tag": "HealthCareActivity"}, {"end": 34, "start": 24, "tag": "ClinicalAttribute"}, {"end": 138, "start": 129, "tag": "PathologicFunction"}, {"end": 138, "start": 129, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 106, "start": 76, "tag": "Finding"}, {"end": 23, "start": 16, "tag": "ResearchActivity"}]}{"id": "1440_2", "text": "Word retrieval deficits, measured using verbal fluency and confrontation naming tests, are hallmark features of the early clinical stages of the amnestic presentations of AD, specifically in category fluency and naming with relatively spared letter fluency.", "tags": [{"end": 218, "start": 212, "tag": "BiologicFunction"}, {"end": 23, "start": 15, "tag": "Finding"}, {"end": 99, "start": 91, "tag": "Finding"}, {"end": 137, "start": 122, "tag": "TemporalConcept"}, {"end": 173, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 116, "tag": "TemporalConcept"}, {"end": 85, "start": 80, "tag": "ResearchActivity"}, {"end": 85, "start": 59, "tag": "HealthCareActivity"}, {"end": 14, "start": 0, "tag": "BiologicFunction"}, {"end": 54, "start": 40, "tag": "OrganismAttribute"}, {"end": 85, "start": 80, "tag": "HealthCareActivity"}, {"end": 54, "start": 40, "tag": "HealthCareActivity"}]}{"id": "1440_3", "text": "As yet, there is no consensus regarding performance on these tests in atypical clinical phenotypes of AD, including posterior cortical atrophy (PCA) and logopenic primary progressive aphasia (lvPPA), in individuals who are amyloid-positive (A beta+) but present with different clinical profiles and patterns of neurodegeneration compared to amnestic AD.", "tags": [{"end": 142, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 144, "tag": "ResearchActivity"}, {"end": 98, "start": 79, "tag": "ClinicalAttribute"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 352, "start": 341, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 203, "tag": "PopulationGroup"}, {"end": 190, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 230, "start": 223, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 70, "tag": "Finding"}, {"end": 51, "start": 40, "tag": "Finding"}, {"end": 66, "start": 61, "tag": "ResearchActivity"}, {"end": 66, "start": 61, "tag": "HealthCareActivity"}, {"end": 247, "start": 241, "tag": "AminoAcidPeptideOrProtein"}, {"end": 328, "start": 311, "tag": "CellOrMolecularDysfunction"}, {"end": 307, "start": 299, "tag": "ResearchActivity"}, {"end": 197, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 294, "start": 277, "tag": "ClinicalAttribute"}]}{"id": "1440_4", "text": "The goal of the current study is to determine how A beta+ individuals across the syndromic spectrum of AD perform on three different word retrieval tasks.", "tags": [{"end": 105, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 16, "tag": "TemporalConcept"}, {"end": 69, "start": 58, "tag": "PopulationGroup"}, {"end": 29, "start": 24, "tag": "ResearchActivity"}, {"end": 56, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 133, "tag": "HealthCareActivity"}]}{"id": "1440_5", "text": "A secondary goal is to determine the neuroanatomical substrates underlying word retrieval performance in these A beta+ individuals.", "tags": [{"end": 130, "start": 119, "tag": "PopulationGroup"}, {"end": 101, "start": 90, "tag": "Finding"}, {"end": 117, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 37, "tag": "Finding"}, {"end": 89, "start": 75, "tag": "BiologicFunction"}]}{"id": "1440_6", "text": "Thirty-two A beta+ participants with the amnestic presentation, 16 with A beta+ PCA, 22 with A beta+ lvPPA, and 99 amyloid-negative (A beta-) control participants were evaluated with verbal fluency and visual confrontation naming tests as well as high-resolution MRI.", "tags": [{"end": 83, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 80, "tag": "ResearchActivity"}, {"end": 31, "start": 19, "tag": "PopulationGroup"}, {"end": 162, "start": 150, "tag": "PopulationGroup"}, {"end": 122, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 142, "tag": "PopulationGroup"}, {"end": 266, "start": 247, "tag": "HealthCareActivity"}, {"end": 235, "start": 202, "tag": "HealthCareActivity"}, {"end": 17, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 251, "start": 247, "tag": "Finding"}, {"end": 106, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 183, "tag": "OrganismAttribute"}]}{"id": "1440_7", "text": "The A beta+ patient groups were rated at very mild or mild levels of severity (CDR 0.5 or 1) and had comparable levels of global cognitive impairment (average MMSE = 23.7 + 3.9).", "tags": [{"end": 149, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 12, "tag": "PatientOrDisabledGroup"}, {"end": 163, "start": 159, "tag": "HealthCareActivity"}, {"end": 77, "start": 69, "tag": "ClinicalAttribute"}, {"end": 77, "start": 69, "tag": "Finding"}, {"end": 149, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 20, "tag": "PopulationGroup"}, {"end": 82, "start": 79, "tag": "HealthCareActivity"}, {"end": 10, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 46, "tag": "Finding"}, {"end": 58, "start": 54, "tag": "Finding"}]}{"id": "1440_8", "text": "Behaviorally, we found that the word retrieval profile of PCA patients is comparable to that of amnestic patients, characterized by intact letter fluency but impaired category fluency and visual confrontation naming, while lvPPA patients demonstrated impairment across all tests of word retrieval.", "tags": [{"end": 215, "start": 188, "tag": "BiologicFunction"}, {"end": 261, "start": 251, "tag": "Finding"}, {"end": 138, "start": 132, "tag": "Finding"}, {"end": 61, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 58, "tag": "ResearchActivity"}, {"end": 70, "start": 62, "tag": "PatientOrDisabledGroup"}, {"end": 113, "start": 96, "tag": "PatientOrDisabledGroup"}, {"end": 237, "start": 229, "tag": "PatientOrDisabledGroup"}, {"end": 278, "start": 273, "tag": "ResearchActivity"}, {"end": 278, "start": 273, "tag": "HealthCareActivity"}, {"end": 46, "start": 32, "tag": "BiologicFunction"}, {"end": 153, "start": 139, "tag": "OrganismAttribute"}, {"end": 228, "start": 223, "tag": "DiseaseOrSyndrome"}, {"end": 296, "start": 282, "tag": "BiologicFunction"}, {"end": 183, "start": 167, "tag": "OrganismAttribute"}]}{"id": "1440_9", "text": "Across all AD variants, we observed that letter fluency was associated with cortical thickness in prefrontal, central precuneus, lateral parietal and temporal cortex, while category fluency and naming were associated with cortical thickness in left middle frontal gyrus, posterior middle temporal gyrus, and lateral parietal cortex.", "tags": [{"end": 108, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 165, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 200, "start": 194, "tag": "BiologicFunction"}, {"end": 269, "start": 244, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 302, "start": 271, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 331, "start": 308, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 230, "start": 222, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 76, "tag": "ClinicalAttribute"}, {"end": 240, "start": 222, "tag": "ClinicalAttribute"}, {"end": 13, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 41, "tag": "OrganismAttribute"}, {"end": 165, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 189, "start": 173, "tag": "OrganismAttribute"}]}{"id": "1440_10", "text": "Visual confrontation naming was uniquely associated with atrophy in inferior temporal and visual association cortex.", "tags": [{"end": 85, "start": 77, "tag": "TemporalConcept"}, {"end": 64, "start": 57, "tag": "PathologicFunction"}, {"end": 64, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 0, "tag": "BiologicFunction"}, {"end": 115, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1440_11", "text": "We conclude that a better understanding of the word retrieval profiles and underlying neurodegeneration across the AD syndromic spectrum will help improve interpretation of neuropsychological profiles with regard to the localization of neurodegeneration, particularly in the atypical AD variants.", "tags": [{"end": 154, "start": 147, "tag": "Finding"}, {"end": 136, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 286, "start": 284, "tag": "DiseaseOrSyndrome"}, {"end": 283, "start": 275, "tag": "Finding"}, {"end": 39, "start": 26, "tag": "BiologicFunction"}, {"end": 103, "start": 86, "tag": "CellOrMolecularDysfunction"}, {"end": 253, "start": 236, "tag": "CellOrMolecularDysfunction"}, {"end": 191, "start": 173, "tag": "HealthCareActivity"}, {"end": 70, "start": 62, "tag": "ResearchActivity"}, {"end": 200, "start": 192, "tag": "ResearchActivity"}, {"end": 61, "start": 47, "tag": "BiologicFunction"}]}{"id": "1441_0", "text": "Introduction: Biomarkers of Alzheimer's disease (AD) that can easily be measured in routine health checkups are desirable.", "tags": [{"end": 107, "start": 92, "tag": "HealthCareActivity"}, {"end": 91, "start": 84, "tag": "TemporalConcept"}, {"end": 24, "start": 14, "tag": "ClinicalAttribute"}, {"end": 47, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}]}{"id": "1441_1", "text": "Urine is a source of biomarkers that can be collected easily and noninvasively.", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 21, "tag": "ClinicalAttribute"}]}{"id": "1441_2", "text": "We previously reported on the comprehensive profile of the urinary proteome of AD patients and identified proteins estimated to be significantly increased or decreased in AD patients by a label-free quantification method.", "tags": [{"end": 198, "start": 188, "tag": "ResearchActivity"}, {"end": 167, "start": 158, "tag": "Finding"}, {"end": 75, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 82, "tag": "PatientOrDisabledGroup"}, {"end": 182, "start": 174, "tag": "PatientOrDisabledGroup"}, {"end": 154, "start": 131, "tag": "Finding"}, {"end": 220, "start": 214, "tag": "ResearchActivity"}, {"end": 220, "start": 214, "tag": "HealthCareActivity"}, {"end": 114, "start": 106, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1441_3", "text": "The present study aimed to validate urinary levels of proteins that significantly differed between AD and control samples from our proteomics study (i.e., apolipoprotein C3 [ApoC3], insulin-like growth factor-binding protein 3 [Igfbp3], and apolipoprotein D [ApoD]).", "tags": [{"end": 172, "start": 155, "tag": "GeneOrGenome"}, {"end": 172, "start": 155, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 174, "tag": "GeneOrGenome"}, {"end": 179, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 179, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 226, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 226, "start": 182, "tag": "AminoAcidPeptideOrProtein"}, {"end": 234, "start": 228, "tag": "AminoAcidPeptideOrProtein"}, {"end": 234, "start": 228, "tag": "BiologicallyActiveSubstance"}, {"end": 234, "start": 228, "tag": "GeneOrGenome"}, {"end": 257, "start": 241, "tag": "AminoAcidPeptideOrProtein"}, {"end": 257, "start": 241, "tag": "GeneOrGenome"}, {"end": 257, "start": 241, "tag": "BiologicallyActiveSubstance"}, {"end": 263, "start": 259, "tag": "GeneOrGenome"}, {"end": 141, "start": 131, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 147, "start": 131, "tag": "ResearchActivity"}, {"end": 141, "start": 131, "tag": "ResearchActivity"}, {"end": 43, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 62, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 106, "tag": "PopulationGroup"}, {"end": 189, "start": 182, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 182, "tag": "PharmacologicSubstance"}, {"end": 121, "start": 114, "tag": "Substance"}, {"end": 121, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 263, "start": 259, "tag": "BiologicallyActiveSubstance"}, {"end": 263, "start": 259, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1441_4", "text": "Methods: Enzyme-linked immunosorbent assays (ELISAs) were performed using urine samples from the same patient and control groups analyzed in the previous proteomics study (18 AD and 18 controls, set 1) and urine samples from an independent group of AD patients and controls (13 AD, 5 mild cognitive impairment [MCI], and 32 controls) from the National Center for Geriatrics and Gerontology Biobank (set 2).", "tags": [{"end": 43, "start": 9, "tag": "ResearchActivity"}, {"end": 51, "start": 45, "tag": "ResearchActivity"}, {"end": 239, "start": 228, "tag": "Finding"}, {"end": 164, "start": 154, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 170, "start": 154, "tag": "ResearchActivity"}, {"end": 164, "start": 154, "tag": "ResearchActivity"}, {"end": 109, "start": 102, "tag": "PatientOrDisabledGroup"}, {"end": 128, "start": 114, "tag": "PopulationGroup"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 251, "start": 249, "tag": "DiseaseOrSyndrome"}, {"end": 280, "start": 278, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 185, "tag": "PopulationGroup"}, {"end": 273, "start": 265, "tag": "PopulationGroup"}, {"end": 332, "start": 324, "tag": "PopulationGroup"}, {"end": 260, "start": 252, "tag": "PatientOrDisabledGroup"}, {"end": 314, "start": 311, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 114, "tag": "PopulationGroup"}, {"end": 128, "start": 122, "tag": "PopulationGroup"}, {"end": 309, "start": 284, "tag": "DiseaseOrSyndrome"}, {"end": 245, "start": 240, "tag": "PopulationGroup"}, {"end": 137, "start": 129, "tag": "ResearchActivity"}, {"end": 87, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 219, "start": 206, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 397, "start": 343, "tag": "HealthCareRelatedOrganization"}]}{"id": "1441_5", "text": "Results: In set 1, the crude urinary levels of ApoD, Igfbp3, and creatinine-adjusted ApoD were significantly higher in the AD group relative to the control group (p = 0.003, p = 0.002, and p = 0.019, respectively), consistent with our previous proteomics results.", "tags": [{"end": 51, "start": 47, "tag": "GeneOrGenome"}, {"end": 59, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 53, "tag": "GeneOrGenome"}, {"end": 89, "start": 85, "tag": "GeneOrGenome"}, {"end": 254, "start": 244, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 254, "start": 244, "tag": "ResearchActivity"}, {"end": 36, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 148, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 131, "start": 126, "tag": "PopulationGroup"}, {"end": 161, "start": 156, "tag": "PopulationGroup"}, {"end": 161, "start": 148, "tag": "PopulationGroup"}, {"end": 51, "start": 29, "tag": "ClinicalAttribute"}, {"end": 89, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 65, "tag": "Chemical"}, {"end": 75, "start": 65, "tag": "BiologicallyActiveSubstance"}]}{"id": "1441_6", "text": "In set 2, however, the crude urinary levels of Igfbp3 were significantly lower in the AD+MCI group than in the control group (p = 0.028), and the levels of ApoD and ApoC3 did not differ significantly compared to the control group.", "tags": [{"end": 53, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 47, "tag": "GeneOrGenome"}, {"end": 160, "start": 156, "tag": "GeneOrGenome"}, {"end": 170, "start": 165, "tag": "GeneOrGenome"}, {"end": 170, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 111, "tag": "PopulationGroup"}, {"end": 223, "start": 216, "tag": "PopulationGroup"}, {"end": 98, "start": 93, "tag": "PopulationGroup"}, {"end": 124, "start": 119, "tag": "PopulationGroup"}, {"end": 229, "start": 224, "tag": "PopulationGroup"}, {"end": 124, "start": 111, "tag": "PopulationGroup"}, {"end": 229, "start": 216, "tag": "PopulationGroup"}, {"end": 53, "start": 29, "tag": "ClinicalAttribute"}]}{"id": "1441_7", "text": "Combined analysis of all samples revealed creatinine-adjusted ApoC3 levels to be significantly higher in the AD+MCI group ( p = 0.015) and the AD-only group (p = 0.011) relative to the control group.", "tags": [{"end": 67, "start": 62, "tag": "GeneOrGenome"}, {"end": 67, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 185, "tag": "PopulationGroup"}, {"end": 17, "start": 0, "tag": "ResearchActivity"}, {"end": 121, "start": 116, "tag": "PopulationGroup"}, {"end": 156, "start": 151, "tag": "PopulationGroup"}, {"end": 198, "start": 193, "tag": "PopulationGroup"}, {"end": 198, "start": 185, "tag": "PopulationGroup"}, {"end": 32, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 25, "tag": "Substance"}, {"end": 52, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 52, "start": 42, "tag": "Chemical"}]}{"id": "1441_8", "text": "Conclusion: ApoC3 may be a potential biomarker for AD, as validated by ELISA.", "tags": [{"end": 17, "start": 12, "tag": "GeneOrGenome"}, {"end": 17, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 71, "tag": "ResearchActivity"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 27, "tag": "ClinicalAttribute"}]}{"id": "1441_9", "text": "Further analysis of ApoC3 as a urinary biomarker for AD is warranted.", "tags": [{"end": 25, "start": 20, "tag": "GeneOrGenome"}, {"end": 25, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 39, "tag": "ClinicalAttribute"}, {"end": 16, "start": 8, "tag": "ResearchActivity"}]}{"id": "1441_10", "text": "(c) 2020 The Author(s) Published by S.", "tags": []}{"id": "1441_11", "text": "Karger AG, Basel", "tags": []}{"id": "1442_0", "text": "Objective: We aim to explain why salivary lactoferrin (Lf) levels are reduced in patients suffering mild cognitive impairment (MCI) and sporadic Alzheimer's disease (sAD).", "tags": [{"end": 57, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 59, "tag": "ClinicalAttribute"}, {"end": 53, "start": 33, "tag": "ClinicalAttribute"}, {"end": 169, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 136, "tag": "TemporalConcept"}, {"end": 156, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 125, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 55, "tag": "BiologicallyActiveSubstance"}]}{"id": "1442_1", "text": "(1)We also will discuss if such Lf decrease could be due to a downregulation of the sAD associated systemic immunity.", "tags": [{"end": 34, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 99, "tag": "BiologicFunction"}, {"end": 76, "start": 62, "tag": "CellFunction"}, {"end": 34, "start": 32, "tag": "BiologicallyActiveSubstance"}]}{"id": "1442_2", "text": "Background: Several non-neurological alterations have been described in sAD, mainly in skin, blood cell, and immunological capacities.", "tags": [{"end": 75, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 109, "tag": "ClinicalAttribute"}, {"end": 103, "start": 93, "tag": "Cell"}]}{"id": "1442_3", "text": "We reviewed briefly the main pathophysiological theories of sAD (amyloid cascade, tau, unfolder protein tau, and amyloid deposits) emphasizing the most brain based hypotheses such as the updated tau-related neuron skeletal hypothesis; we also comment on the systemic theories that emphasize the fetal origin of the complex disorders that include the low inflammatory and immunity theories of sAD.", "tags": [{"end": 63, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 113, "tag": "AnatomicalAbnormality"}, {"end": 222, "start": 214, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 379, "start": 371, "tag": "BiologicFunction"}, {"end": 395, "start": 392, "tag": "DiseaseOrSyndrome"}, {"end": 213, "start": 207, "tag": "Cell"}, {"end": 11, "start": 3, "tag": "HealthCareActivity"}, {"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 307, "start": 301, "tag": "TemporalConcept"}, {"end": 19, "start": 12, "tag": "TemporalConcept"}, {"end": 85, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 198, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 198, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 29, "tag": "PathologicFunction"}, {"end": 275, "start": 258, "tag": "ResearchActivity"}, {"end": 366, "start": 350, "tag": "Finding"}]}{"id": "1442_4", "text": "New/updated hypothesis: Lf has important anti-infectious and immunomodulatory roles in health and disease.", "tags": [{"end": 26, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 41, "tag": "PharmacologicSubstance"}, {"end": 93, "start": 87, "tag": "HealthCareActivity"}, {"end": 83, "start": 61, "tag": "Finding"}]}{"id": "1442_5", "text": "We present the hypothesis that the reduced levels of saliva Lf could be an effect of immunological disturbances associated to sAD.", "tags": [{"end": 62, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 85, "tag": "PathologicFunction"}]}{"id": "1442_6", "text": "Under this scenario, two alternative pathways are possible: first, whether sAD could be a systemic disorder (or disorders) related to early immunological and low inflammatory alterations; second, if systemic immunity alterations of sAD manifestations could be downstream of early sAD brain affectations.", "tags": [{"end": 78, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 175, "tag": "Finding"}, {"end": 153, "start": 140, "tag": "Finding"}, {"end": 186, "start": 158, "tag": "Finding"}, {"end": 216, "start": 208, "tag": "BiologicFunction"}, {"end": 235, "start": 232, "tag": "DiseaseOrSyndrome"}, {"end": 283, "start": 280, "tag": "DiseaseOrSyndrome"}, {"end": 250, "start": 236, "tag": "SignOrSymptom"}, {"end": 289, "start": 284, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 37, "tag": "CellFunction"}, {"end": 65, "start": 60, "tag": "TemporalConcept"}]}{"id": "1442_7", "text": "Major challenges for the hypothesis: The major challenge of the Lf as early sAD biomarker would be its validation in other clinical and population-based studies.", "tags": [{"end": 66, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 103, "tag": "ResearchActivity"}, {"end": 16, "start": 6, "tag": "HealthCareActivity"}, {"end": 146, "start": 136, "tag": "PopulationGroup"}, {"end": 160, "start": 153, "tag": "ResearchActivity"}, {"end": 131, "start": 123, "tag": "ResearchActivity"}, {"end": 89, "start": 80, "tag": "ClinicalAttribute"}, {"end": 56, "start": 47, "tag": "HealthCareActivity"}]}{"id": "1442_8", "text": "It is possible the decreased salivary Lf in early sAD could be related to immunological modulation actions, but other different unknown mechanisms could be the origin of such reduction.", "tags": [{"end": 40, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 160, "tag": "TemporalConcept"}, {"end": 37, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 175, "tag": "Finding"}, {"end": 184, "start": 175, "tag": "NaturalPhenomenonOrProcess"}, {"end": 106, "start": 74, "tag": "Finding"}, {"end": 40, "start": 29, "tag": "ClinicalAttribute"}]}{"id": "1442_9", "text": "Linkage to other major theories: This hypothesis is in agreement with two physiopathological explanations of the sAD as a downstream process determined by the early lesions of the hypothalamus and autonomic vegetative system (neurodegeneration), or as a consequence of low neuroinflammation and dysimmunity since the early life aggravated in the elderly (immunosenescence).", "tags": [{"end": 116, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 272, "start": 269, "tag": "Finding"}, {"end": 371, "start": 355, "tag": "BiologicFunction"}, {"end": 192, "start": 180, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 243, "start": 226, "tag": "CellOrMolecularDysfunction"}, {"end": 290, "start": 273, "tag": "PathologicFunction"}, {"end": 172, "start": 165, "tag": "InjuryOrPoisoning"}, {"end": 327, "start": 323, "tag": "TemporalConcept"}, {"end": 353, "start": 346, "tag": "PopulationGroup"}, {"end": 306, "start": 295, "tag": "PathologicFunction"}, {"end": 224, "start": 197, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1443_0", "text": "Introduction: Multiple immunity biomarkers have been suggested as tracers of neuroinflammation in neurodegeneration.", "tags": [{"end": 31, "start": 23, "tag": "BiologicFunction"}, {"end": 73, "start": 66, "tag": "Chemical"}, {"end": 115, "start": 98, "tag": "CellOrMolecularDysfunction"}, {"end": 42, "start": 32, "tag": "ClinicalAttribute"}, {"end": 94, "start": 77, "tag": "PathologicFunction"}]}{"id": "1443_1", "text": "This study aimed to verify findings in cerebrospinal fluid (CSF) samples of Alzheimer's disease (AD) and Parkinson's disease (PD) subjects from the network of the European, Innovative Medicines Initiative-funded project AETIONOMY.", "tags": [{"end": 171, "start": 163, "tag": "PopulationGroup"}, {"end": 229, "start": 212, "tag": "ResearchActivity"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 124, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 130, "tag": "PopulationGroup"}, {"end": 204, "start": 163, "tag": "HealthCareRelatedOrganization"}]}{"id": "1443_2", "text": "Methods: A total of 227 samples from the studies/centres AETIONOMY, ICEBERG, and IDIBAPS were used to analyse 21 selected immunity biomarkers in CSF.", "tags": [{"end": 75, "start": 68, "tag": "NaturalPhenomenonOrProcess"}, {"end": 130, "start": 122, "tag": "BiologicFunction"}, {"end": 48, "start": 41, "tag": "ResearchActivity"}, {"end": 141, "start": 131, "tag": "ClinicalAttribute"}, {"end": 148, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 57, "tag": "ResearchActivity"}, {"end": 75, "start": 68, "tag": "ResearchActivity"}, {"end": 88, "start": 81, "tag": "ResearchActivity"}]}{"id": "1443_3", "text": "Results were compared to data of an independent cohort of 399 subjects previously published.", "tags": [{"end": 29, "start": 25, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 54, "start": 48, "tag": "PopulationGroup"}, {"end": 70, "start": 62, "tag": "PopulationGroup"}]}{"id": "1443_4", "text": "Results: Immunity markers were predominantly and reproducibly associated with pathological levels of tau isoforms, but also with amyloid levels, aging, sex, APOE genotype, and center-specific factors.", "tags": [{"end": 17, "start": 9, "tag": "BiologicFunction"}, {"end": 161, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 162, "tag": "OrganismAttribute"}, {"end": 113, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 145, "tag": "BiologicFunction"}, {"end": 150, "start": 145, "tag": "CellFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 155, "start": 152, "tag": "OrganismAttribute"}, {"end": 136, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 9, "tag": "ClinicalAttribute"}, {"end": 143, "start": 129, "tag": "ClinicalAttribute"}, {"end": 113, "start": 78, "tag": "ClinicalAttribute"}]}{"id": "1443_5", "text": "Discussion: Immunity biomarker levels in CSF reflect molecular and cellular pathology rather than diagnosis in neurodegenerative disorders.", "tags": [{"end": 20, "start": 12, "tag": "BiologicFunction"}, {"end": 62, "start": 53, "tag": "CellFunction"}, {"end": 85, "start": 67, "tag": "CellOrMolecularDysfunction"}, {"end": 138, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 98, "tag": "HealthCareActivity"}, {"end": 30, "start": 21, "tag": "ClinicalAttribute"}, {"end": 44, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1443_6", "text": "Assay standardization and stratification for age and other covariates could improve the power of such markers in clinical applications or intervention studies targeting immune responses in neurodegeneration.", "tags": [{"end": 5, "start": 0, "tag": "ResearchActivity"}, {"end": 21, "start": 6, "tag": "ResearchActivity"}, {"end": 185, "start": 169, "tag": "BiologicFunction"}, {"end": 134, "start": 113, "tag": "HealthCareActivity"}, {"end": 40, "start": 26, "tag": "ResearchActivity"}, {"end": 48, "start": 45, "tag": "OrganismAttribute"}, {"end": 206, "start": 189, "tag": "CellOrMolecularDysfunction"}, {"end": 158, "start": 138, "tag": "ResearchActivity"}]}{"id": "1444_0", "text": "Background An association has been found between the presence of lipid-specific oligoclonal IgM bands (LS-OCMB) in cerebrospinal fluid and a more severe clinical multiple sclerosis course.", "tags": [{"end": 70, "start": 65, "tag": "Chemical"}, {"end": 152, "start": 146, "tag": "Finding"}, {"end": 180, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 129, "tag": "Substance"}, {"end": 134, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 187, "start": 181, "tag": "TemporalConcept"}, {"end": 101, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 103, "tag": "BiologicallyActiveSubstance"}]}{"id": "1444_1", "text": "Objective To investigate lipid-specific oligoclonal IgM bands as a prognostic biomarker of cognitive impairment in the early stages of multiple sclerosis.", "tags": [{"end": 131, "start": 119, "tag": "TemporalConcept"}, {"end": 131, "start": 125, "tag": "TemporalConcept"}, {"end": 30, "start": 25, "tag": "Chemical"}, {"end": 87, "start": 78, "tag": "ClinicalAttribute"}, {"end": 87, "start": 67, "tag": "ClinicalAttribute"}, {"end": 153, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 25, "tag": "BiologicallyActiveSubstance"}]}{"id": "1444_2", "text": "Methods Forty-four patients underwent neuropsychological assessment at baseline and 4 years.", "tags": [{"end": 67, "start": 38, "tag": "HealthCareActivity"}, {"end": 91, "start": 86, "tag": "TemporalConcept"}, {"end": 27, "start": 19, "tag": "PatientOrDisabledGroup"}]}{"id": "1444_3", "text": "Cognitive performance at follow-up was compared adjusting by age, education, anxiety-depression, and baseline performance.", "tags": [{"end": 75, "start": 66, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 21, "start": 0, "tag": "ClinicalAttribute"}, {"end": 121, "start": 101, "tag": "ClinicalAttribute"}, {"end": 95, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 61, "tag": "OrganismAttribute"}, {"end": 84, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 25, "tag": "HealthCareActivity"}, {"end": 34, "start": 25, "tag": "TemporalConcept"}]}{"id": "1444_4", "text": "Results LS-OCMB+ patients only performed worse for Long-Term Storage in the Selective Reminding Test (p = .018).", "tags": [{"end": 60, "start": 51, "tag": "TemporalConcept"}, {"end": 60, "start": 51, "tag": "HealthCareActivity"}, {"end": 68, "start": 61, "tag": "CellComponent"}, {"end": 68, "start": 61, "tag": "BiologicFunction"}, {"end": 25, "start": 17, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 15, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 76, "tag": "HealthCareActivity"}]}{"id": "1444_5", "text": "Conclusion There are no remarkable cognitive differences between LS-OCMB- and LS-OCMB+ patients in the early stages of MS.", "tags": [{"end": 115, "start": 103, "tag": "TemporalConcept"}, {"end": 115, "start": 109, "tag": "TemporalConcept"}, {"end": 95, "start": 87, "tag": "PatientOrDisabledGroup"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 78, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1445_0", "text": "Background We aimed to investigate the tau biomarker discrepancies of Alzheimer's disease (AD) using plasma tau phosphorylated at threonine 181 (p-tau181), cerebrospinal fluid (CSF) p-tau181, and AV1451 positron emission tomography (PET).", "tags": [{"end": 66, "start": 53, "tag": "Finding"}, {"end": 202, "start": 196, "tag": "Chemical"}, {"end": 126, "start": 112, "tag": "CellFunction"}, {"end": 42, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 180, "start": 177, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 43, "tag": "ClinicalAttribute"}, {"end": 175, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 236, "start": 233, "tag": "HealthCareActivity"}, {"end": 175, "start": 170, "tag": "Substance"}, {"end": 231, "start": 203, "tag": "HealthCareActivity"}, {"end": 231, "start": 203, "tag": "ManufacturedObject"}, {"end": 143, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 182, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 196, "tag": "PharmacologicSubstance"}]}{"id": "1445_1", "text": "Methods In the Alzheimer's Disease Neuroimaging Initiative, 724 non-demented participants were categorized into plasma/CSF and plasma/PET groups.", "tags": [{"end": 118, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 77, "tag": "PopulationGroup"}, {"end": 137, "start": 134, "tag": "HealthCareActivity"}, {"end": 34, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 138, "tag": "PopulationGroup"}, {"end": 58, "start": 15, "tag": "ResearchActivity"}, {"end": 76, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 15, "tag": "HealthCareRelatedOrganization"}]}{"id": "1445_2", "text": "Demographic and clinical variables, amyloid-beta (A beta) burden, flortaucipir-PET binding in Braak regions of interest (ROIs), longitudinal changes in clinical outcomes, and conversion risk were compared.", "tags": [{"end": 185, "start": 175, "tag": "CellFunction"}, {"end": 64, "start": 58, "tag": "ResearchActivity"}, {"end": 148, "start": 128, "tag": "ResearchActivity"}, {"end": 48, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 79, "tag": "HealthCareActivity"}, {"end": 169, "start": 161, "tag": "Finding"}, {"end": 56, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 121, "tag": "ResearchActivity"}, {"end": 190, "start": 175, "tag": "ClinicalAttribute"}, {"end": 169, "start": 152, "tag": "ClinicalAttribute"}, {"end": 78, "start": 66, "tag": "Chemical"}, {"end": 119, "start": 94, "tag": "ResearchActivity"}]}{"id": "1445_3", "text": "Results Across different tau biomarker groups, the proportion of participants with a discordant profile varied (plasma+/CSF- 15.6%, plasma-/CSF+ 15.3%, plasma+/PET- 22.4%, and plasma-/PET+ 6.1%).", "tags": [{"end": 28, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 176, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 28, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 29, "tag": "ClinicalAttribute"}, {"end": 77, "start": 65, "tag": "PopulationGroup"}, {"end": 163, "start": 160, "tag": "HealthCareActivity"}, {"end": 187, "start": 184, "tag": "HealthCareActivity"}, {"end": 45, "start": 39, "tag": "PopulationGroup"}]}{"id": "1445_4", "text": "Within the plasma/CSF categories, we found an increase from concordant-negative to discordant to concordant-positive in the frequency of A beta pathology or cognitive impairment, rates of cognitive decline, and risk of cognitive conversion.", "tags": [{"end": 17, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 144, "tag": "PathologicFunction"}, {"end": 153, "start": 144, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 205, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 124, "tag": "TemporalConcept"}, {"end": 239, "start": 211, "tag": "Finding"}]}{"id": "1445_5", "text": "However, the two discordant categories (plasma+/CSF- and plasma-/CSF+) showed comparable performances, resulting in similarly reduced cognitive capacities.", "tags": [{"end": 46, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 89, "tag": "IndividualBehavior"}, {"end": 154, "start": 126, "tag": "Finding"}]}{"id": "1445_6", "text": "Regarding plasma/PET categories, as expected, PET-positive individuals had increased A beta burden, elevated flortaucipir retention in Braak ROIs, and accelerated cognitive deterioration than concordant-negative persons.", "tags": [{"end": 131, "start": 122, "tag": "BiologicFunction"}, {"end": 131, "start": 122, "tag": "ClinicalAttribute"}, {"end": 131, "start": 122, "tag": "CellFunction"}, {"end": 186, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 212, "tag": "PopulationGroup"}, {"end": 98, "start": 92, "tag": "ResearchActivity"}, {"end": 16, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 59, "tag": "PopulationGroup"}, {"end": 20, "start": 17, "tag": "HealthCareActivity"}, {"end": 49, "start": 46, "tag": "HealthCareActivity"}, {"end": 91, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 135, "tag": "ResearchActivity"}, {"end": 121, "start": 109, "tag": "Chemical"}]}{"id": "1445_7", "text": "Noteworthy, discordant participants with normal PET exhibited reduced flortaucipir uptake in Braak stage ROIs and slower rates of cognitive decline, relative to those PET-positive.", "tags": [{"end": 89, "start": 83, "tag": "BiologicFunction"}, {"end": 89, "start": 83, "tag": "CellFunction"}, {"end": 35, "start": 23, "tag": "PopulationGroup"}, {"end": 47, "start": 41, "tag": "Finding"}, {"end": 51, "start": 48, "tag": "HealthCareActivity"}, {"end": 170, "start": 167, "tag": "HealthCareActivity"}, {"end": 147, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 93, "tag": "ResearchActivity"}, {"end": 82, "start": 70, "tag": "Chemical"}]}{"id": "1445_8", "text": "Therefore, individuals with PET abnormality appeared to have advanced tau pathological changes and poorer cognitive function, regardless of the plasma status.", "tags": [{"end": 124, "start": 106, "tag": "BiologicFunction"}, {"end": 73, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 151, "tag": "Finding"}, {"end": 22, "start": 11, "tag": "PopulationGroup"}, {"end": 31, "start": 28, "tag": "HealthCareActivity"}, {"end": 43, "start": 28, "tag": "ClinicalAttribute"}, {"end": 94, "start": 61, "tag": "Finding"}]}{"id": "1445_9", "text": "Furthermore, these results were found only in individuals with A beta pathology.", "tags": [{"end": 79, "start": 70, "tag": "PathologicFunction"}, {"end": 79, "start": 70, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 57, "start": 46, "tag": "PopulationGroup"}, {"end": 69, "start": 63, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1445_10", "text": "Conclusions Our results indicate that plasma and CSF p-tau181 abnormalities associated with amyloidosis occur simultaneously in the progression of AD pathogenesis and related cognitive decline, before tau-PET turns positive.", "tags": [{"end": 103, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 150, "tag": "PathologicFunction"}, {"end": 200, "start": 194, "tag": "TemporalConcept"}, {"end": 204, "start": 201, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 204, "start": 201, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 205, "tag": "HealthCareActivity"}, {"end": 143, "start": 132, "tag": "PathologicFunction"}, {"end": 143, "start": 132, "tag": "TemporalConcept"}, {"end": 192, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 110, "tag": "TemporalConcept"}, {"end": 61, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 53, "tag": "CellOrMolecularDysfunction"}]}{"id": "1446_0", "text": "Vascular dementia (VD) and Alzheimer's disease (AD) are common types of dementia for which no curative therapies are known.", "tags": [{"end": 17, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 19, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 103, "tag": "HealthCareActivity"}, {"end": 46, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 72, "tag": "DiseaseOrSyndrome"}]}{"id": "1446_1", "text": "In this study, we identified hub genes associated with AD and VD in order to explore new potential therapeutic targets.", "tags": [{"end": 118, "start": 89, "tag": "ResearchActivity"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 29, "tag": "GeneOrGenome"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}]}{"id": "1446_2", "text": "Genes differentially expressed in VD and AD in all three datasets (GSE122063, GSE132903, and GSE5281) were identified and used to construct a protein-protein interaction network.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 177, "start": 142, "tag": "CellFunction"}, {"end": 36, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 21, "tag": "CellFunction"}, {"end": 117, "start": 107, "tag": "Finding"}, {"end": 30, "start": 6, "tag": "Finding"}, {"end": 65, "start": 57, "tag": "ResearchActivity"}, {"end": 76, "start": 67, "tag": "ResearchActivity"}, {"end": 87, "start": 78, "tag": "ResearchActivity"}, {"end": 100, "start": 93, "tag": "ResearchActivity"}]}{"id": "1446_3", "text": "We identified 10 modules containing 427 module genes in AD and VD.", "tags": [{"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 40, "tag": "GeneOrGenome"}]}{"id": "1446_4", "text": "Module genes showing an area under the diagnostic curve > 0.60 for AD or VD were used to construct a least absolute shrinkage and selection operator model and were entered into a support vector machine-recursive feature elimination algorithm, which identified REPS1 as a hub gene in AD and VD.", "tags": [{"end": 265, "start": 260, "tag": "GeneOrGenome"}, {"end": 125, "start": 116, "tag": "Finding"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 292, "start": 290, "tag": "HealthCareActivity"}, {"end": 241, "start": 202, "tag": "MachineActivity"}, {"end": 201, "start": 179, "tag": "MachineActivity"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 285, "start": 283, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 0, "tag": "GeneOrGenome"}, {"end": 154, "start": 149, "tag": "ResearchActivity"}, {"end": 55, "start": 24, "tag": "ResearchActivity"}, {"end": 279, "start": 271, "tag": "GeneOrGenome"}, {"end": 265, "start": 260, "tag": "AminoAcidPeptideOrProtein"}, {"end": 265, "start": 260, "tag": "BiologicallyActiveSubstance"}]}{"id": "1446_5", "text": "Furthermore, REPS1 was associated with activation of pyruvate metabolism and inhibition of Ras signaling pathway.", "tags": [{"end": 18, "start": 13, "tag": "GeneOrGenome"}, {"end": 72, "start": 53, "tag": "CellFunction"}, {"end": 112, "start": 91, "tag": "CellFunction"}, {"end": 87, "start": 77, "tag": "CellFunction"}, {"end": 72, "start": 62, "tag": "BiologicFunction"}, {"end": 72, "start": 62, "tag": "CellFunction"}, {"end": 18, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 13, "tag": "BiologicallyActiveSubstance"}]}{"id": "1446_6", "text": "Module genes, together with differentially expressed microRNAs from the dataset GSE46579, were used to construct a regulatory network.", "tags": [{"end": 133, "start": 115, "tag": "CellFunction"}, {"end": 62, "start": 53, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 62, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 80, "tag": "ResearchActivity"}, {"end": 12, "start": 0, "tag": "GeneOrGenome"}, {"end": 79, "start": 72, "tag": "ResearchActivity"}, {"end": 52, "start": 28, "tag": "Finding"}]}{"id": "1446_7", "text": "REPS1 was predicted to bind to the microRNA hsa_miR_5701.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 27, "start": 23, "tag": "CellFunction"}, {"end": 56, "start": 35, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 56, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1446_8", "text": "Single-sample gene set enrichment analysis was used to explore immune cell infiltration, which suggested a negative correlation between REPS1 expression and infiltration by plasmacytoid dendritic cells in AD and VD.", "tags": [{"end": 74, "start": 63, "tag": "Cell"}, {"end": 185, "start": 173, "tag": "Cell"}, {"end": 201, "start": 186, "tag": "Cell"}, {"end": 214, "start": 212, "tag": "HealthCareActivity"}, {"end": 42, "start": 14, "tag": "ResearchActivity"}, {"end": 207, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 7, "tag": "Substance"}, {"end": 13, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 63, "tag": "CellFunction"}, {"end": 127, "start": 107, "tag": "ResearchActivity"}, {"end": 152, "start": 136, "tag": "CellFunction"}]}{"id": "1446_9", "text": "In conclusion, our results suggest core pathways involved in both AD and VD, and they identify REPS1 as a potential biomarker of both diseases.", "tags": [{"end": 48, "start": 35, "tag": "CellFunction"}, {"end": 100, "start": 95, "tag": "GeneOrGenome"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 40, "tag": "CellFunction"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 106, "tag": "ClinicalAttribute"}, {"end": 100, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 95, "tag": "BiologicallyActiveSubstance"}]}{"id": "1446_10", "text": "This protein may aid in early diagnosis, monitoring of treatment response, and even efforts to prevent these debilitating disorders.", "tags": [{"end": 73, "start": 55, "tag": "ClinicalAttribute"}, {"end": 131, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 41, "tag": "HealthCareActivity"}, {"end": 64, "start": 55, "tag": "HealthCareActivity"}, {"end": 64, "start": 55, "tag": "ResearchActivity"}, {"end": 39, "start": 30, "tag": "HealthCareActivity"}, {"end": 29, "start": 24, "tag": "TemporalConcept"}, {"end": 73, "start": 65, "tag": "OrganismAttribute"}, {"end": 39, "start": 24, "tag": "HealthCareActivity"}]}{"id": "1447_0", "text": "IMPORTANCE There is currently no consensus as to which biomarkers best predict longitudinal tau accumulation at different clinical stages of Alzheimer disease (AD).", "tags": [{"end": 137, "start": 122, "tag": "TemporalConcept"}, {"end": 29, "start": 20, "tag": "TemporalConcept"}, {"end": 10, "start": 0, "tag": "Finding"}, {"end": 158, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 55, "tag": "ClinicalAttribute"}, {"end": 108, "start": 96, "tag": "Finding"}, {"end": 91, "start": 79, "tag": "ResearchActivity"}]}{"id": "1447_1", "text": "OBJECTIVE To describe longitudinal [F-18]RO948 tau positron emission tomography (PET) findings across the clinical continuum of AD and determine which biomarker combinations showed the strongest associations with longitudinal tau PET and best optimized clinical trial enrichment.", "tags": [{"end": 278, "start": 268, "tag": "ResearchActivity"}, {"end": 267, "start": 253, "tag": "ResearchActivity"}, {"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 229, "start": 226, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 229, "start": 226, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 151, "tag": "ClinicalAttribute"}, {"end": 84, "start": 81, "tag": "HealthCareActivity"}, {"end": 233, "start": 230, "tag": "HealthCareActivity"}, {"end": 79, "start": 51, "tag": "HealthCareActivity"}, {"end": 46, "start": 35, "tag": "Chemical"}, {"end": 124, "start": 115, "tag": "TemporalConcept"}]}{"id": "1447_2", "text": "DESIGN, SETTING, AND PARTICIPANTS This longitudinal cohort study consecutively enrolled amyloid-beta (A beta)-negative cognitively unimpaired (CU) participants, A beta-positive CU individuals, A beta-positive individuals with mild cognitive impairment (MCI), and individuals with AD dementia between September 2017 and November 2020 from the Swedish BioFINDER-2 (discovery cohort) and BioFINDER-1 (validation cohort) studies.", "tags": [{"end": 64, "start": 39, "tag": "ResearchActivity"}, {"end": 349, "start": 342, "tag": "PopulationGroup"}, {"end": 141, "start": 119, "tag": "Finding"}, {"end": 408, "start": 398, "tag": "ResearchActivity"}, {"end": 15, "start": 8, "tag": "BiologicFunction"}, {"end": 282, "start": 280, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 147, "tag": "PopulationGroup"}, {"end": 191, "start": 180, "tag": "PopulationGroup"}, {"end": 220, "start": 209, "tag": "PopulationGroup"}, {"end": 274, "start": 263, "tag": "PopulationGroup"}, {"end": 424, "start": 417, "tag": "ResearchActivity"}, {"end": 95, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 291, "start": 283, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 253, "tag": "DiseaseOrSyndrome"}, {"end": 372, "start": 363, "tag": "ResearchActivity"}, {"end": 100, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 251, "start": 226, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 167, "start": 161, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 193, "tag": "AminoAcidPeptideOrProtein"}, {"end": 379, "start": 373, "tag": "PopulationGroup"}, {"end": 415, "start": 409, "tag": "PopulationGroup"}, {"end": 361, "start": 350, "tag": "ResearchActivity"}, {"end": 396, "start": 385, "tag": "ResearchActivity"}, {"end": 33, "start": 21, "tag": "PopulationGroup"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}]}{"id": "1447_3", "text": "EXPOSURES Baseline plasma and cerebrospinal fluid A beta 42/A beta 40, tau phosphorylated at threonine-217 (p-tau217), p-tau181 and neurofilament light, magnetic resonance imaging, amyloid PET ([F-18]flutemetamol), and tau PET ([F-18]RO948 in the BioFINDER-2 study; [F-18]flortaucipir in the BioFINDER-1 study).", "tags": [{"end": 151, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 75, "tag": "CellFunction"}, {"end": 284, "start": 266, "tag": "Chemical"}, {"end": 74, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 219, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 222, "start": 219, "tag": "BiologicallyActiveSubstance"}, {"end": 188, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 181, "tag": "BiologicallyActiveSubstance"}, {"end": 264, "start": 247, "tag": "ResearchActivity"}, {"end": 309, "start": 292, "tag": "ResearchActivity"}, {"end": 25, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 189, "tag": "HealthCareActivity"}, {"end": 226, "start": 223, "tag": "HealthCareActivity"}, {"end": 179, "start": 153, "tag": "HealthCareActivity"}, {"end": 69, "start": 30, "tag": "ClinicalAttribute"}, {"end": 106, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 239, "start": 228, "tag": "Chemical"}, {"end": 212, "start": 194, "tag": "Chemical"}]}{"id": "1447_4", "text": "MAIN OUTCOMES AND MEASURES Baseline tau PET standardized uptake value ratio (SUVR) and annual percent change in tau PET SUVR across regions of interest derived using a data-driven approach combining clustering and event-based modeling.", "tags": [{"end": 234, "start": 214, "tag": "ResearchActivity"}, {"end": 151, "start": 132, "tag": "ResearchActivity"}, {"end": 39, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 209, "start": 168, "tag": "ResearchActivity"}, {"end": 93, "start": 87, "tag": "TemporalConcept"}, {"end": 43, "start": 40, "tag": "HealthCareActivity"}, {"end": 119, "start": 116, "tag": "HealthCareActivity"}, {"end": 75, "start": 44, "tag": "ResearchActivity"}, {"end": 81, "start": 77, "tag": "ResearchActivity"}, {"end": 124, "start": 120, "tag": "ResearchActivity"}]}{"id": "1447_5", "text": "Regression models were used to examine associations between individual biomarkers and longitudinal tau PET and to identify which combinations best predicted longitudinal tau PET.", "tags": [{"end": 17, "start": 0, "tag": "ResearchActivity"}, {"end": 102, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 71, "tag": "ClinicalAttribute"}, {"end": 70, "start": 60, "tag": "PopulationGroup"}, {"end": 70, "start": 60, "tag": "OrganismAttribute"}, {"end": 106, "start": 103, "tag": "HealthCareActivity"}, {"end": 177, "start": 157, "tag": "HealthCareActivity"}]}{"id": "1447_6", "text": "These combinations were then entered in a power analysis to examine how their use as an enrichment strategy would affect sample size in a simulated clinical trial.", "tags": [{"end": 162, "start": 148, "tag": "ResearchActivity"}, {"end": 132, "start": 128, "tag": "OrganismAttribute"}, {"end": 56, "start": 42, "tag": "ResearchActivity"}, {"end": 127, "start": 121, "tag": "Substance"}, {"end": 127, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1447_7", "text": "RESULTS Of 343 participants, the mean (SD) age was 72.56 (7.24) years, and 157 (51.1%) were female.", "tags": [{"end": 98, "start": 92, "tag": "OrganismAttribute"}, {"end": 27, "start": 15, "tag": "PopulationGroup"}, {"end": 46, "start": 43, "tag": "OrganismAttribute"}, {"end": 69, "start": 64, "tag": "TemporalConcept"}, {"end": 41, "start": 39, "tag": "ResearchActivity"}]}{"id": "1447_8", "text": "The clustering/event-based modeling-based approach identified 5 regions of interest (stages).", "tags": [{"end": 50, "start": 4, "tag": "ResearchActivity"}, {"end": 91, "start": 85, "tag": "TemporalConcept"}, {"end": 83, "start": 64, "tag": "ResearchActivity"}]}{"id": "1447_9", "text": "In A beta-positive CU individuals, the largest annual increase in tau PET SUVR was seen in stage I (entorhinal cortex, hippocampus, and amygdala; 4.04% [95% CI, 2.67%-5.32%]).", "tags": [{"end": 117, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 22, "tag": "PopulationGroup"}, {"end": 53, "start": 47, "tag": "TemporalConcept"}, {"end": 159, "start": 157, "tag": "ResearchActivity"}, {"end": 73, "start": 70, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 91, "tag": "TemporalConcept"}, {"end": 96, "start": 91, "tag": "ClinicalAttribute"}, {"end": 78, "start": 74, "tag": "ResearchActivity"}]}{"id": "1447_10", "text": "In A beta-positive individuals with MCI and with AD dementia, the greatest increases were seen in stages II (temporal cortical regions; 4.45% [95% CI, 3.41%-5.49%]) and IV (certain frontal regions; 5.22% [95% CI, 3.95%-6.49%]), respectively.", "tags": [{"end": 134, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 98, "tag": "TemporalConcept"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 19, "tag": "PopulationGroup"}, {"end": 60, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 147, "tag": "ResearchActivity"}, {"end": 211, "start": 209, "tag": "ResearchActivity"}, {"end": 196, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 3, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1447_11", "text": "In A beta-negative CU individuals and those with MCI, modest change was seen in stage I (1.38% [95% CI, 0.78%-1.99%] and 1.80% [95% CI, 0.76%-2.84%], respectively).", "tags": [{"end": 33, "start": 22, "tag": "PopulationGroup"}, {"end": 52, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 100, "tag": "ResearchActivity"}, {"end": 134, "start": 132, "tag": "ResearchActivity"}, {"end": 9, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 80, "tag": "TemporalConcept"}, {"end": 85, "start": 80, "tag": "ClinicalAttribute"}, {"end": 67, "start": 54, "tag": "Finding"}]}{"id": "1447_12", "text": "When looking at individual predictors and longitudinal tau PET in the stages that showed most change, plasma p-tau217 (R-2 = 0.27, P < .005), tau PET (stage I baseline SUVR; R-2 = 0.13, P < .05) and amyloid PET (R-2 = 0.10, P < .05) were significantly associated with longitudinal tau PET in stage I in A beta-positive CU individuals.", "tags": [{"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 37, "start": 27, "tag": "Finding"}, {"end": 58, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 284, "start": 281, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 284, "start": 281, "tag": "BiologicallyActiveSubstance"}, {"end": 333, "start": 322, "tag": "PopulationGroup"}, {"end": 206, "start": 199, "tag": "AminoAcidPeptideOrProtein"}, {"end": 206, "start": 199, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 16, "tag": "PopulationGroup"}, {"end": 26, "start": 16, "tag": "OrganismAttribute"}, {"end": 62, "start": 59, "tag": "HealthCareActivity"}, {"end": 149, "start": 146, "tag": "HealthCareActivity"}, {"end": 210, "start": 207, "tag": "HealthCareActivity"}, {"end": 288, "start": 285, "tag": "HealthCareActivity"}, {"end": 309, "start": 303, "tag": "AminoAcidPeptideOrProtein"}, {"end": 280, "start": 268, "tag": "ResearchActivity"}, {"end": 156, "start": 151, "tag": "TemporalConcept"}, {"end": 297, "start": 292, "tag": "TemporalConcept"}, {"end": 156, "start": 151, "tag": "ClinicalAttribute"}, {"end": 297, "start": 292, "tag": "ClinicalAttribute"}, {"end": 117, "start": 102, "tag": "ClinicalAttribute"}, {"end": 172, "start": 168, "tag": "ResearchActivity"}]}{"id": "1447_13", "text": "In A beta-positive individuals with MCI, plasma p-tau217 (R-2 = 0.24, P < .005) and tau PET (stage II baseline SUVR; R-2 = 0.44, P < .001) were significantly associated with longitudinal tau PET in stage II.", "tags": [{"end": 87, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 19, "tag": "PopulationGroup"}, {"end": 39, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 88, "tag": "HealthCareActivity"}, {"end": 194, "start": 174, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 93, "tag": "TemporalConcept"}, {"end": 203, "start": 198, "tag": "TemporalConcept"}, {"end": 98, "start": 93, "tag": "ClinicalAttribute"}, {"end": 203, "start": 198, "tag": "ClinicalAttribute"}, {"end": 56, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 111, "tag": "ResearchActivity"}]}{"id": "1447_14", "text": "Findings were replicated in BioFINDER-1 using longitudinal [F-18]flortaucipir.", "tags": [{"end": 77, "start": 59, "tag": "Chemical"}, {"end": 39, "start": 28, "tag": "ResearchActivity"}]}{"id": "1447_15", "text": "For the power analysis component, plasma p-tau217 with tau PET resulted in sample size reductions of 43% (95% CI, 34%-46%; P < .005) in A beta-positive CU individuals and of 68% (95% CI, 61%-73%; P < .001) in A beta-positive individuals with MCI.", "tags": [{"end": 97, "start": 87, "tag": "NaturalPhenomenonOrProcess"}, {"end": 97, "start": 87, "tag": "HealthCareActivity"}, {"end": 58, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 155, "tag": "PopulationGroup"}, {"end": 236, "start": 225, "tag": "PopulationGroup"}, {"end": 245, "start": 242, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 82, "tag": "OrganismAttribute"}, {"end": 112, "start": 110, "tag": "ResearchActivity"}, {"end": 185, "start": 183, "tag": "ResearchActivity"}, {"end": 22, "start": 8, "tag": "ResearchActivity"}, {"end": 62, "start": 59, "tag": "HealthCareActivity"}, {"end": 142, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 215, "start": 209, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 75, "tag": "Substance"}, {"end": 81, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 34, "tag": "ClinicalAttribute"}]}{"id": "1447_16", "text": "CONCLUSIONS AND RELEVANCE In trials using tau PET as the outcome, plasma p-tau217 with tau PET may prove optimal for enrichment in preclinical and prodromal AD.", "tags": [{"end": 64, "start": 57, "tag": "Finding"}, {"end": 127, "start": 117, "tag": "ResearchActivity"}, {"end": 159, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 46, "tag": "HealthCareActivity"}, {"end": 94, "start": 91, "tag": "HealthCareActivity"}, {"end": 81, "start": 66, "tag": "ClinicalAttribute"}]}{"id": "1447_17", "text": "However, plasma p-tau217 was most important in preclinical AD, while tau PET was more important in prodromal AD.", "tags": [{"end": 111, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 73, "tag": "HealthCareActivity"}, {"end": 24, "start": 9, "tag": "ClinicalAttribute"}, {"end": 76, "start": 69, "tag": "ClinicalAttribute"}]}{"id": "1448_0", "text": "Introduction: Amyloid beta (A beta) deposition was identified to precede tau pathology and neurodegeneration in familial Alzheimer's disease (AD).", "tags": [{"end": 120, "start": 112, "tag": "PopulationGroup"}, {"end": 140, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 73, "tag": "PathologicFunction"}, {"end": 34, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 91, "tag": "CellOrMolecularDysfunction"}, {"end": 61, "start": 51, "tag": "Finding"}, {"end": 26, "start": 14, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1448_1", "text": "But the divergence between sporadic and familial AD limits the extension of these findings to sporadic AD.", "tags": [{"end": 48, "start": 40, "tag": "PopulationGroup"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 27, "tag": "TemporalConcept"}, {"end": 102, "start": 94, "tag": "TemporalConcept"}]}{"id": "1448_2", "text": "Methods: Longitudinal changes of biomarkers among different stages were assessed using linear mixed-effects models.", "tags": [{"end": 21, "start": 9, "tag": "ResearchActivity"}, {"end": 114, "start": 87, "tag": "ResearchActivity"}, {"end": 66, "start": 60, "tag": "TemporalConcept"}, {"end": 43, "start": 33, "tag": "ClinicalAttribute"}, {"end": 107, "start": 100, "tag": "Finding"}, {"end": 107, "start": 100, "tag": "PathologicFunction"}]}{"id": "1448_3", "text": "The slopes of the models were used to estimate rates of change to calculate the biomarker trajectories in sporadic AD.", "tags": [{"end": 117, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 80, "tag": "ClinicalAttribute"}, {"end": 24, "start": 18, "tag": "ResearchActivity"}, {"end": 114, "start": 106, "tag": "TemporalConcept"}]}{"id": "1448_4", "text": "Results: Cerebrospinal fluid (CSF) A beta was estimated to decline 45.2 years (abnormal: 27.8 years) before dementia, and A beta deposition seemed to increase 31.7 years (abnormal: 26.7 years) before dementia.", "tags": [{"end": 99, "start": 92, "tag": "TemporalConcept"}, {"end": 28, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 79, "tag": "Finding"}, {"end": 179, "start": 171, "tag": "Finding"}, {"end": 33, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 101, "tag": "TemporalConcept"}, {"end": 199, "start": 193, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "TemporalConcept"}, {"end": 99, "start": 94, "tag": "TemporalConcept"}, {"end": 169, "start": 164, "tag": "TemporalConcept"}, {"end": 191, "start": 186, "tag": "TemporalConcept"}, {"end": 41, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 122, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1448_5", "text": "It was estimated to take 29.0 years (CSF t-tau), 12.2 years (memory), 11.6 years (hippocampus), 9.3 years (hypometabolism), and 6.1 years (cognition) to move from normal to dementia.", "tags": [{"end": 121, "start": 107, "tag": "Finding"}, {"end": 80, "start": 73, "tag": "TemporalConcept"}, {"end": 169, "start": 163, "tag": "Finding"}, {"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "TemporalConcept"}, {"end": 59, "start": 54, "tag": "TemporalConcept"}, {"end": 80, "start": 75, "tag": "TemporalConcept"}, {"end": 105, "start": 100, "tag": "TemporalConcept"}, {"end": 137, "start": 132, "tag": "TemporalConcept"}, {"end": 148, "start": 139, "tag": "BiologicFunction"}, {"end": 93, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 61, "tag": "BiologicFunction"}]}{"id": "1448_6", "text": "Discussion: The trajectory in sporadic AD is led by A beta accumulation, followed by CSF t-tau increase, memory deficits, brain atrophy, hypometabolism, and cognitive decline.", "tags": [{"end": 120, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 137, "tag": "Finding"}, {"end": 135, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 91, "tag": "Finding"}, {"end": 120, "start": 112, "tag": "Finding"}, {"end": 94, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 30, "tag": "TemporalConcept"}, {"end": 58, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 59, "tag": "Finding"}, {"end": 111, "start": 105, "tag": "BiologicFunction"}]}{"id": "1449_0", "text": "Posterior cortical atrophy (PCA) and logopenic progressive aphasia (LPA) are clinical syndromes that commonly have underlying Alzheimer's disease (AD), although non-AD pathologies have also been reported.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "ResearchActivity"}, {"end": 179, "start": 168, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 18, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 37, "tag": "DiseaseOrSyndrome"}]}{"id": "1449_1", "text": "PET imaging allows for identification of beta-amyloid (A beta) and tau in AD, so we aimed to assess these in a large cohort to identify patients that do not have evidence for biomarker-defined AD.", "tags": [{"end": 11, "start": 0, "tag": "HealthCareActivity"}, {"end": 53, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 4, "tag": "HealthCareActivity"}, {"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 175, "tag": "ClinicalAttribute"}, {"end": 144, "start": 136, "tag": "PatientOrDisabledGroup"}, {"end": 53, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 162, "tag": "Finding"}, {"end": 3, "start": 0, "tag": "HealthCareActivity"}, {"end": 61, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 117, "tag": "PopulationGroup"}]}{"id": "1449_2", "text": "Eight-one patients, 47 PCA and 34 LPA, underwent extensive neurological and neuropsychological testing, [C-11] Pittsburgh compound B, [F-18] flortaucipir and [F-18] fluorodeoxyglucose PETs.", "tags": [{"end": 37, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 134, "tag": "Chemical"}, {"end": 26, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 23, "tag": "ResearchActivity"}, {"end": 102, "start": 76, "tag": "HealthCareActivity"}, {"end": 18, "start": 10, "tag": "PatientOrDisabledGroup"}, {"end": 102, "start": 95, "tag": "HealthCareActivity"}, {"end": 94, "start": 76, "tag": "HealthCareActivity"}, {"end": 132, "start": 104, "tag": "Chemical"}, {"end": 183, "start": 158, "tag": "Chemical"}, {"end": 188, "start": 184, "tag": "HealthCareActivity"}]}{"id": "1449_3", "text": "Global A beta and tau-PET standardized uptake value ratios (SUVRs) were plotted for all patients and outliers, and patients with abnormally low SUVRs compared to the biomarker-classic cohort were identified.", "tags": [{"end": 143, "start": 140, "tag": "Finding"}, {"end": 21, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 175, "start": 166, "tag": "ClinicalAttribute"}, {"end": 96, "start": 88, "tag": "PatientOrDisabledGroup"}, {"end": 123, "start": 115, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 22, "tag": "HealthCareActivity"}, {"end": 13, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 184, "tag": "PopulationGroup"}, {"end": 58, "start": 26, "tag": "ResearchActivity"}, {"end": 65, "start": 60, "tag": "ResearchActivity"}, {"end": 149, "start": 144, "tag": "ResearchActivity"}]}{"id": "1449_4", "text": "Six (7.4%) biomarker-outlier cases were identified, and three patterns were observed: (i) negative/borderline A beta-PET and striking widespread tau-PET uptake (two LPA); (ii) negative/borderline A beta-PET and low tau-PET uptake (three PCA) and (iii) elevated A beta-PET uptake but mild focal tau-PET uptake (one LPA).", "tags": [{"end": 168, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 317, "start": 314, "tag": "DiseaseOrSyndrome"}, {"end": 240, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 240, "start": 237, "tag": "ResearchActivity"}, {"end": 214, "start": 211, "tag": "Finding"}, {"end": 148, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 215, "tag": "AminoAcidPeptideOrProtein"}, {"end": 297, "start": 294, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 218, "start": 215, "tag": "BiologicallyActiveSubstance"}, {"end": 297, "start": 294, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 11, "tag": "ClinicalAttribute"}, {"end": 120, "start": 117, "tag": "HealthCareActivity"}, {"end": 152, "start": 149, "tag": "HealthCareActivity"}, {"end": 206, "start": 203, "tag": "HealthCareActivity"}, {"end": 222, "start": 219, "tag": "HealthCareActivity"}, {"end": 271, "start": 268, "tag": "HealthCareActivity"}, {"end": 301, "start": 298, "tag": "HealthCareActivity"}, {"end": 116, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 196, "tag": "AminoAcidPeptideOrProtein"}, {"end": 267, "start": 261, "tag": "AminoAcidPeptideOrProtein"}, {"end": 287, "start": 283, "tag": "Finding"}, {"end": 70, "start": 62, "tag": "ResearchActivity"}, {"end": 159, "start": 153, "tag": "BiologicFunction"}, {"end": 229, "start": 223, "tag": "BiologicFunction"}, {"end": 278, "start": 272, "tag": "BiologicFunction"}, {"end": 308, "start": 302, "tag": "BiologicFunction"}, {"end": 159, "start": 153, "tag": "CellFunction"}, {"end": 229, "start": 223, "tag": "CellFunction"}, {"end": 278, "start": 272, "tag": "CellFunction"}, {"end": 308, "start": 302, "tag": "CellFunction"}]}{"id": "1449_5", "text": "Among the unusual patients in group ii, two patients showed no abnormal tau uptake suggesting non-AD pathology, with one developing features of cortico-basal syndrome and the other dementia with Lewy bodies.", "tags": [{"end": 71, "start": 63, "tag": "Finding"}, {"end": 206, "start": 195, "tag": "CellComponent"}, {"end": 206, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 18, "tag": "PatientOrDisabledGroup"}, {"end": 52, "start": 44, "tag": "PatientOrDisabledGroup"}, {"end": 189, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 101, "tag": "PathologicFunction"}, {"end": 110, "start": 101, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 35, "start": 30, "tag": "PopulationGroup"}, {"end": 82, "start": 76, "tag": "BiologicFunction"}, {"end": 82, "start": 76, "tag": "CellFunction"}]}{"id": "1449_6", "text": "The remaining patient showed very mild focal tau uptake.", "tags": [{"end": 21, "start": 14, "tag": "PatientOrDisabledGroup"}, {"end": 48, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 34, "tag": "Finding"}, {"end": 55, "start": 49, "tag": "BiologicFunction"}, {"end": 55, "start": 49, "tag": "CellFunction"}]}{"id": "1449_7", "text": "This study demonstrates that a small minority (similar to 8%) of PCA and LPA patients do not show the typical striking patterns of A beta and tau PET uptake, with only 2% showing absence of both proteins.", "tags": [{"end": 45, "start": 37, "tag": "PopulationGroup"}, {"end": 76, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 65, "tag": "ResearchActivity"}, {"end": 145, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 77, "tag": "PatientOrDisabledGroup"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 203, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 146, "tag": "HealthCareActivity"}, {"end": 137, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 119, "tag": "ResearchActivity"}, {"end": 156, "start": 150, "tag": "BiologicFunction"}, {"end": 156, "start": 150, "tag": "CellFunction"}]}{"id": "1449_8", "text": "These findings will help inform the use of molecular PET in clinical treatment trials that include patients with atypical phenotypes of AD.", "tags": [{"end": 52, "start": 43, "tag": "CellFunction"}, {"end": 138, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "PatientOrDisabledGroup"}, {"end": 85, "start": 60, "tag": "ResearchActivity"}, {"end": 132, "start": 122, "tag": "OrganismAttribute"}, {"end": 121, "start": 113, "tag": "Finding"}, {"end": 56, "start": 53, "tag": "HealthCareActivity"}, {"end": 78, "start": 60, "tag": "HealthCareActivity"}]}{"id": "1450_0", "text": "INTRODUCTIONSecernin-1 (SCRN1) is a neuronal protein that co-localizes with neurofibrillary tangles in Alzheimer's disease (AD), but not with tau inclusions in corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), or Pick's disease.", "tags": [{"end": 52, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 76, "tag": "CellComponent"}, {"end": 145, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 36, "tag": "Cell"}, {"end": 99, "start": 76, "tag": "CellOrMolecularDysfunction"}, {"end": 22, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 24, "tag": "GeneOrGenome"}, {"end": 156, "start": 142, "tag": "CellOrMolecularDysfunction"}]}{"id": "1450_1", "text": "METHODSWe measured SCRN1 concentration in cerebrospinal fluid (CSF) using a novel mass spectrometric parallel reaction monitoring method in three clinical cohorts comprising patients with neurochemically characterized AD (n = 25) and controls (n = 28), clinically diagnosed Parkinson's disease (PD; n = 38), multiple system atrophy (MSA; n = 31), PSP (n = 20), CBD (n = 8), healthy controls (n = 37), and neuropathology-confirmed AD (n = 47).", "tags": [{"end": 38, "start": 25, "tag": "BiologicFunction"}, {"end": 331, "start": 308, "tag": "PathologicFunction"}, {"end": 336, "start": 333, "tag": "PathologicFunction"}, {"end": 350, "start": 347, "tag": "DiseaseOrSyndrome"}, {"end": 364, "start": 361, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 220, "start": 218, "tag": "DiseaseOrSyndrome"}, {"end": 432, "start": 430, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 242, "start": 234, "tag": "PopulationGroup"}, {"end": 182, "start": 174, "tag": "PatientOrDisabledGroup"}, {"end": 419, "start": 405, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 419, "start": 405, "tag": "PathologicFunction"}, {"end": 381, "start": 374, "tag": "OrganismAttribute"}, {"end": 273, "start": 264, "tag": "HealthCareActivity"}, {"end": 293, "start": 274, "tag": "DiseaseOrSyndrome"}, {"end": 297, "start": 295, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 155, "tag": "PopulationGroup"}, {"end": 390, "start": 374, "tag": "PopulationGroup"}, {"end": 136, "start": 82, "tag": "ResearchActivity"}, {"end": 136, "start": 82, "tag": "HealthCareActivity"}, {"end": 24, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 19, "tag": "GeneOrGenome"}, {"end": 24, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 19, "tag": "ClinicalAttribute"}]}{"id": "1450_2", "text": "RESULTSCSF SCRN1 was significantly increased in AD (P < 0.01, fold change = 1.4) compared to controls (receiver operating characteristic area under the curve = 0.78) but not in CBD, PSP, PD, or MSA.", "tags": [{"end": 180, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 194, "tag": "PathologicFunction"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 93, "tag": "PopulationGroup"}, {"end": 44, "start": 21, "tag": "Finding"}, {"end": 157, "start": 137, "tag": "ResearchActivity"}, {"end": 189, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 7, "tag": "ClinicalAttribute"}]}{"id": "1450_3", "text": "CSF SCRN1 positively correlated with CSF total tau (R = 0.78, P = 1.1 x 10(-13)), phosphorylated tau(181) (R = 0.64, P = 3.2 x 10(-8)), and Braak stage and negatively correlated with Mini-Mental State Examination score.", "tags": [{"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 212, "start": 183, "tag": "HealthCareActivity"}, {"end": 151, "start": 140, "tag": "HealthCareActivity"}, {"end": 50, "start": 37, "tag": "ClinicalAttribute"}, {"end": 218, "start": 213, "tag": "Finding"}, {"end": 9, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1450_4", "text": "DISCUSSIONCSF SCRN1 is a candidate biomarker of AD, reflecting tau pathology.", "tags": [{"end": 66, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 35, "tag": "ClinicalAttribute"}, {"end": 76, "start": 63, "tag": "PathologicFunction"}, {"end": 19, "start": 10, "tag": "ClinicalAttribute"}]}{"id": "1450_5", "text": "HIGHLIGHTSWe developed a parallel reaction monitoring assay to measure secernin-1 (SCRN1) in cerebrospinal fluid (CSF).CSF SCRN1 was increased in Alzheimer's disease compared to healthy controls.CSF SCRN1 remained unchanged in Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, or corticobasal degeneration compared to controls.CSF SCRN1 correlated strongly with CSF phosphorylated tau and total tau.CSF SCRN1 increased across Braak stages and negatively correlated with Mini-Mental State Examination score.", "tags": [{"end": 223, "start": 214, "tag": "Finding"}, {"end": 271, "start": 248, "tag": "PathologicFunction"}, {"end": 303, "start": 285, "tag": "DiseaseOrSyndrome"}, {"end": 466, "start": 454, "tag": "HealthCareActivity"}, {"end": 165, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 198, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 358, "start": 355, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 393, "start": 390, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 354, "start": 346, "tag": "PopulationGroup"}, {"end": 284, "start": 273, "tag": "TemporalConcept"}, {"end": 426, "start": 417, "tag": "AminoAcidPeptideOrProtein"}, {"end": 426, "start": 417, "tag": "BiologicallyActiveSubstance"}, {"end": 412, "start": 394, "tag": "AminoAcidPeptideOrProtein"}, {"end": 412, "start": 394, "tag": "BiologicallyActiveSubstance"}, {"end": 527, "start": 498, "tag": "HealthCareActivity"}, {"end": 185, "start": 178, "tag": "OrganismAttribute"}, {"end": 246, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 178, "tag": "PopulationGroup"}, {"end": 59, "start": 25, "tag": "HealthCareActivity"}, {"end": 533, "start": 528, "tag": "Finding"}, {"end": 81, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 83, "tag": "GeneOrGenome"}, {"end": 128, "start": 119, "tag": "ClinicalAttribute"}, {"end": 204, "start": 195, "tag": "ClinicalAttribute"}, {"end": 333, "start": 308, "tag": "DiseaseOrSyndrome"}, {"end": 364, "start": 355, "tag": "ClinicalAttribute"}, {"end": 436, "start": 427, "tag": "ClinicalAttribute"}]}{"id": "1451_0", "text": "While heart disease remains a common cause of mortality, cerebrovascular disease also increases with age, and has been implicated in Alzheimer's disease and related dementias (ADRD).", "tags": [{"end": 19, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 46, "tag": "Finding"}, {"end": 152, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 101, "tag": "OrganismAttribute"}, {"end": 174, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 176, "tag": "DiseaseOrSyndrome"}]}{"id": "1451_1", "text": "We have described hydrogen sulfide (H2S), a signaling molecule important in vascular homeostasis, as a biomarker of cardiovascular disease.", "tags": [{"end": 34, "start": 18, "tag": "Chemical"}, {"end": 62, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 44, "tag": "CellFunction"}, {"end": 138, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 18, "tag": "Chemical"}, {"end": 96, "start": 85, "tag": "BiologicFunction"}, {"end": 112, "start": 103, "tag": "ClinicalAttribute"}, {"end": 84, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 36, "tag": "InjuryOrPoisoning"}, {"end": 34, "start": 18, "tag": "InjuryOrPoisoning"}, {"end": 39, "start": 36, "tag": "Chemical"}]}{"id": "1451_2", "text": "We hypothesize that plasma H2S and its metabolites also relate to vascular and cognitive dysfunction in ADRD.", "tags": [{"end": 100, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 27, "tag": "Chemical"}, {"end": 30, "start": 27, "tag": "InjuryOrPoisoning"}, {"end": 108, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 20, "tag": "ClinicalAttribute"}]}{"id": "1451_3", "text": "We used analytical biochemical methods to measure plasma H2S metabolites and MRI to evaluate indicators of microvascular disease in ADRD.", "tags": [{"end": 103, "start": 93, "tag": "Chemical"}, {"end": 128, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 77, "tag": "HealthCareActivity"}, {"end": 136, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 8, "tag": "ResearchActivity"}, {"end": 60, "start": 57, "tag": "Chemical"}, {"end": 60, "start": 57, "tag": "InjuryOrPoisoning"}, {"end": 60, "start": 50, "tag": "ClinicalAttribute"}]}{"id": "1451_4", "text": "Levels of total H2S and specific metabolites were increased in ADRD versus controls.", "tags": [{"end": 44, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 75, "tag": "PopulationGroup"}, {"end": 67, "start": 63, "tag": "DiseaseOrSyndrome"}]}{"id": "1451_5", "text": "Cognition and microvascular disease indices were correlated with H2S levels.", "tags": [{"end": 9, "start": 0, "tag": "BiologicFunction"}, {"end": 35, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 65, "tag": "ClinicalAttribute"}]}{"id": "1451_6", "text": "Total plasma sulfide was the strongest indicator of ADRD, and partially drove the relationship between cognitive dysfunction and white matter lesion volume, an indicator of microvascular disease.", "tags": [{"end": 20, "start": 13, "tag": "Chemical"}, {"end": 48, "start": 39, "tag": "Chemical"}, {"end": 169, "start": 160, "tag": "Chemical"}, {"end": 194, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 142, "tag": "InjuryOrPoisoning"}, {"end": 94, "start": 82, "tag": "Finding"}, {"end": 56, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 129, "tag": "ClinicalAttribute"}, {"end": 148, "start": 129, "tag": "Finding"}]}{"id": "1451_7", "text": "Our findings show that H2S is dysregulated in dementia, providing a potential biomarker for diagnosis and intervention.", "tags": [{"end": 42, "start": 30, "tag": "PathologicFunction"}, {"end": 87, "start": 68, "tag": "ClinicalAttribute"}, {"end": 54, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 92, "tag": "HealthCareActivity"}, {"end": 26, "start": 23, "tag": "Chemical"}, {"end": 26, "start": 23, "tag": "InjuryOrPoisoning"}]}{"id": "1452_0", "text": "The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or plasma, has shown great promise in detecting Alzheimer's disease (AD) pathophysiology.", "tags": [{"end": 36, "start": 22, "tag": "CellFunction"}, {"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 44, "tag": "Substance"}, {"end": 176, "start": 161, "tag": "PathologicFunction"}, {"end": 176, "start": 161, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 97, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1452_1", "text": "Tau phosphorylated at threonine 231 (p-tau231) is one such biomarker in CSF but its usefulness as a blood biomarker is currently unknown.", "tags": [{"end": 18, "start": 4, "tag": "CellFunction"}, {"end": 128, "start": 119, "tag": "TemporalConcept"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 84, "tag": "Finding"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 59, "tag": "ClinicalAttribute"}, {"end": 115, "start": 106, "tag": "ClinicalAttribute"}, {"end": 105, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 37, "tag": "BiologicallyActiveSubstance"}]}{"id": "1452_2", "text": "Here, we developed an ultrasensitive Single molecule array (Simoa) for the quantification of plasma p-tau231 which was validated in four independent cohorts (n = 588) in different settings, including the full AD continuum and non-AD neurodegenerative disorders.", "tags": [{"end": 148, "start": 137, "tag": "Finding"}, {"end": 221, "start": 212, "tag": "TemporalConcept"}, {"end": 260, "start": 226, "tag": "DiseaseOrSyndrome"}, {"end": 260, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 232, "start": 230, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 149, "tag": "PopulationGroup"}, {"end": 99, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 22, "tag": "ResearchActivity"}, {"end": 65, "start": 60, "tag": "ResearchActivity"}, {"end": 108, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 100, "tag": "BiologicallyActiveSubstance"}]}{"id": "1452_3", "text": "Plasma p-tau231 was able to identify patients with AD and differentiate them from amyloid-beta negative cognitively unimpaired (CU) older adults with high accuracy (AUC = 0.92-0.94).", "tags": [{"end": 71, "start": 58, "tag": "CellFunction"}, {"end": 126, "start": 104, "tag": "Finding"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 132, "tag": "TemporalConcept"}, {"end": 144, "start": 132, "tag": "PopulationGroup"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 37, "tag": "PatientOrDisabledGroup"}, {"end": 89, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 155, "tag": "Finding"}, {"end": 94, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 165, "tag": "ResearchActivity"}, {"end": 144, "start": 138, "tag": "PopulationGroup"}, {"end": 154, "start": 150, "tag": "Finding"}, {"end": 15, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1452_4", "text": "Plasma p-tau231 also distinguished AD patients from patients with non-AD neurodegenerative disorders (AUC = 0.93), as well as from amyloid-beta negative MCI patients (AUC = 0.89).", "tags": [{"end": 100, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 38, "tag": "PatientOrDisabledGroup"}, {"end": 60, "start": 52, "tag": "PatientOrDisabledGroup"}, {"end": 165, "start": 157, "tag": "PatientOrDisabledGroup"}, {"end": 138, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 102, "tag": "ResearchActivity"}, {"end": 170, "start": 167, "tag": "ResearchActivity"}, {"end": 15, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1452_5", "text": "In a neuropathology cohort, plasma p-tau231 in samples taken on avergae 4.2 years prior to post-mortem very accurately identified AD neuropathology in comparison to non-AD neurodegenerative disorders (AUC = 0.99), this is despite all patients being given an AD dementia diagnosis during life.", "tags": [{"end": 199, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 291, "start": 287, "tag": "TemporalConcept"}, {"end": 199, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 151, "tag": "ResearchActivity"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 260, "start": 258, "tag": "DiseaseOrSyndrome"}, {"end": 242, "start": 234, "tag": "PatientOrDisabledGroup"}, {"end": 19, "start": 5, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 147, "start": 133, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 19, "start": 5, "tag": "PathologicFunction"}, {"end": 147, "start": 133, "tag": "PathologicFunction"}, {"end": 269, "start": 261, "tag": "DiseaseOrSyndrome"}, {"end": 279, "start": 270, "tag": "HealthCareActivity"}, {"end": 34, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 76, "tag": "TemporalConcept"}, {"end": 26, "start": 20, "tag": "PopulationGroup"}, {"end": 204, "start": 201, "tag": "ResearchActivity"}, {"end": 95, "start": 91, "tag": "TemporalConcept"}, {"end": 102, "start": 91, "tag": "TemporalConcept"}, {"end": 43, "start": 28, "tag": "ClinicalAttribute"}, {"end": 54, "start": 47, "tag": "Substance"}, {"end": 54, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1452_6", "text": "Plasma p-tau231 was highly correlated with CSF p-tau231, tau pathology as assessed by [F-18]MK-6240 positron emission tomography (PET), and brain amyloidosis by [F-18]AZD469 PET.", "tags": [{"end": 157, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 57, "tag": "PathologicFunction"}, {"end": 157, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 130, "tag": "HealthCareActivity"}, {"end": 177, "start": 174, "tag": "HealthCareActivity"}, {"end": 128, "start": 100, "tag": "HealthCareActivity"}, {"end": 15, "start": 0, "tag": "ClinicalAttribute"}, {"end": 55, "start": 43, "tag": "ClinicalAttribute"}, {"end": 99, "start": 86, "tag": "Chemical"}, {"end": 173, "start": 161, "tag": "Chemical"}]}{"id": "1452_7", "text": "Remarkably, the inflection point of plasma p-tau231, increasing as a function of continuous [F-18]AZD469 amyloid-beta PET standardized uptake value ratio, was shown to be earlier than standard thresholds of amyloid-beta PET positivity and the increase of plasma p-tau181.", "tags": [{"end": 77, "start": 69, "tag": "BiologicFunction"}, {"end": 77, "start": 69, "tag": "OrganismAttribute"}, {"end": 77, "start": 69, "tag": "CellFunction"}, {"end": 192, "start": 184, "tag": "HealthCareActivity"}, {"end": 234, "start": 224, "tag": "ResearchActivity"}, {"end": 178, "start": 171, "tag": "TemporalConcept"}, {"end": 63, "start": 53, "tag": "Finding"}, {"end": 91, "start": 81, "tag": "TemporalConcept"}, {"end": 112, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 214, "start": 207, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 214, "start": 207, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 261, "start": 255, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 219, "start": 207, "tag": "AminoAcidPeptideOrProtein"}, {"end": 270, "start": 262, "tag": "AminoAcidPeptideOrProtein"}, {"end": 270, "start": 262, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 118, "tag": "HealthCareActivity"}, {"end": 223, "start": 220, "tag": "HealthCareActivity"}, {"end": 203, "start": 193, "tag": "Finding"}, {"end": 141, "start": 135, "tag": "BiologicFunction"}, {"end": 141, "start": 135, "tag": "CellFunction"}, {"end": 270, "start": 255, "tag": "ClinicalAttribute"}, {"end": 51, "start": 36, "tag": "ClinicalAttribute"}]}{"id": "1452_8", "text": "Furthermore, plasma p-tau231 was significantly increased in amyloid-beta PET quartiles 2-4, whereas CSF p-tau217 and plasma p-tau181 increased only at quartiles 3-4 and 4, respectively.", "tags": [{"end": 103, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 33, "tag": "Finding"}, {"end": 67, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 73, "tag": "HealthCareActivity"}, {"end": 28, "start": 13, "tag": "ClinicalAttribute"}, {"end": 112, "start": 100, "tag": "ClinicalAttribute"}, {"end": 132, "start": 117, "tag": "ClinicalAttribute"}]}{"id": "1452_9", "text": "Finally, plasma p-tau231 differentiated individuals across the entire Braak stage spectrum, including Braak staging from Braak 0 through Braak I-II, which was not observed for plasma p-tau181.", "tags": [{"end": 115, "start": 108, "tag": "TemporalConcept"}, {"end": 90, "start": 70, "tag": "HealthCareActivity"}, {"end": 51, "start": 40, "tag": "PopulationGroup"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 176, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 191, "start": 183, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 183, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 9, "tag": "ClinicalAttribute"}, {"end": 115, "start": 102, "tag": "HealthCareActivity"}, {"end": 128, "start": 121, "tag": "HealthCareActivity"}, {"end": 147, "start": 137, "tag": "HealthCareActivity"}, {"end": 191, "start": 176, "tag": "ClinicalAttribute"}]}{"id": "1452_10", "text": "To conclude, this novel plasma p-tau231 assay identifies the clinical stages of AD and neuropathology equally well as plasma p-tau181, but increases earlier, already with subtle amyloid-beta deposition, prior to the threshold for amyloid-beta PET positivity has been attained, and also in response to early brain tau deposition.", "tags": [{"end": 225, "start": 216, "tag": "Finding"}, {"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 82, "start": 70, "tag": "ClinicalAttribute"}, {"end": 257, "start": 247, "tag": "ResearchActivity"}, {"end": 76, "start": 61, "tag": "TemporalConcept"}, {"end": 156, "start": 149, "tag": "TemporalConcept"}, {"end": 316, "start": 313, "tag": "AminoAcidPeptideOrProtein"}, {"end": 316, "start": 313, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 87, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 101, "start": 87, "tag": "PathologicFunction"}, {"end": 312, "start": 307, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 237, "start": 230, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 178, "tag": "BiologicallyActiveSubstance"}, {"end": 237, "start": 230, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 242, "start": 230, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 306, "start": 301, "tag": "TemporalConcept"}, {"end": 246, "start": 243, "tag": "HealthCareActivity"}, {"end": 297, "start": 289, "tag": "OrganismAttribute"}, {"end": 201, "start": 178, "tag": "PathologicFunction"}, {"end": 327, "start": 313, "tag": "PathologicFunction"}, {"end": 39, "start": 24, "tag": "ClinicalAttribute"}, {"end": 133, "start": 118, "tag": "ClinicalAttribute"}]}{"id": "1452_11", "text": "Thus, plasma p-tau231 is a promising novel biomarker of emerging AD pathology with the potential to facilitate clinical trials to identify vulnerable populations below PET threshold of amyloid-beta positivity or apparent entorhinal tau deposition.", "tags": [{"end": 181, "start": 172, "tag": "Finding"}, {"end": 52, "start": 37, "tag": "ClinicalAttribute"}, {"end": 208, "start": 198, "tag": "ResearchActivity"}, {"end": 161, "start": 150, "tag": "PopulationGroup"}, {"end": 126, "start": 111, "tag": "ResearchActivity"}, {"end": 231, "start": 221, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 235, "start": 232, "tag": "AminoAcidPeptideOrProtein"}, {"end": 235, "start": 232, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 43, "tag": "ClinicalAttribute"}, {"end": 192, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 185, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 197, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 68, "tag": "PathologicFunction"}, {"end": 77, "start": 68, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 171, "start": 168, "tag": "HealthCareActivity"}, {"end": 246, "start": 232, "tag": "PathologicFunction"}, {"end": 21, "start": 6, "tag": "ClinicalAttribute"}]}{"id": "1453_0", "text": "Alterations in Alzheimer's disease (AD) biomarkers have been observed decades before the onset of dementia.", "tags": [{"end": 77, "start": 70, "tag": "TemporalConcept"}, {"end": 34, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 40, "tag": "ClinicalAttribute"}, {"end": 84, "start": 78, "tag": "TemporalConcept"}, {"end": 94, "start": 89, "tag": "TemporalConcept"}]}{"id": "1453_1", "text": "Cognitive dysfunction, while central to the clinical diagnosis of AD, has long been considered as a late-stage phenomenon.", "tags": [{"end": 21, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 100, "tag": "TemporalConcept"}, {"end": 21, "start": 10, "tag": "PathologicFunction"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 53, "tag": "HealthCareActivity"}, {"end": 62, "start": 44, "tag": "HealthCareActivity"}, {"end": 110, "start": 105, "tag": "TemporalConcept"}, {"end": 110, "start": 105, "tag": "ClinicalAttribute"}]}{"id": "1453_2", "text": "This assumption is currently challenged and signals on some cognitive tests are now being observed within the preclinical stage.", "tags": [{"end": 28, "start": 19, "tag": "TemporalConcept"}, {"end": 75, "start": 60, "tag": "HealthCareActivity"}, {"end": 75, "start": 60, "tag": "ResearchActivity"}, {"end": 75, "start": 70, "tag": "ResearchActivity"}, {"end": 75, "start": 70, "tag": "HealthCareActivity"}, {"end": 127, "start": 122, "tag": "TemporalConcept"}, {"end": 127, "start": 122, "tag": "ClinicalAttribute"}, {"end": 127, "start": 110, "tag": "TemporalConcept"}, {"end": 51, "start": 44, "tag": "CellFunction"}]}{"id": "1453_3", "text": "As part of the European Prevention of Alzheimer's Dementia (EPAD) project, a battery of cognitive tests has been proposed (the EPAD Neuropsychological Examination, ENE) which is designed to detect cognitive changes in persons without clinical signs of AD but who are at high risk.", "tags": [{"end": 58, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 77, "tag": "ManufacturedObject"}, {"end": 279, "start": 270, "tag": "Finding"}, {"end": 248, "start": 234, "tag": "SignOrSymptom"}, {"end": 225, "start": 218, "tag": "PopulationGroup"}, {"end": 214, "start": 197, "tag": "Finding"}, {"end": 73, "start": 66, "tag": "ResearchActivity"}, {"end": 58, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 254, "start": 252, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 88, "tag": "HealthCareActivity"}, {"end": 103, "start": 88, "tag": "ResearchActivity"}, {"end": 103, "start": 98, "tag": "ResearchActivity"}, {"end": 103, "start": 98, "tag": "HealthCareActivity"}, {"end": 23, "start": 15, "tag": "PopulationGroup"}, {"end": 274, "start": 270, "tag": "Finding"}, {"end": 58, "start": 15, "tag": "ResearchActivity"}, {"end": 64, "start": 60, "tag": "ResearchActivity"}, {"end": 162, "start": 127, "tag": "ResearchActivity"}, {"end": 167, "start": 164, "tag": "ResearchActivity"}]}{"id": "1453_4", "text": "Analysis of results from the 361 participants with complete measures and without dementia recruited into the EPAD Longitudinal Cohort Study showed that the majority have elevated biomarker levels, with significant associations between an episodic verbal memory task and tau, while amyloid-beta (A beta) was associated with a central executive task.", "tags": [{"end": 246, "start": 238, "tag": "TemporalConcept"}, {"end": 260, "start": 247, "tag": "BiologicFunction"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 273, "start": 270, "tag": "AminoAcidPeptideOrProtein"}, {"end": 273, "start": 270, "tag": "BiologicallyActiveSubstance"}, {"end": 188, "start": 179, "tag": "ClinicalAttribute"}, {"end": 45, "start": 33, "tag": "PopulationGroup"}, {"end": 288, "start": 281, "tag": "AminoAcidPeptideOrProtein"}, {"end": 288, "start": 281, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 293, "start": 281, "tag": "AminoAcidPeptideOrProtein"}, {"end": 301, "start": 295, "tag": "AminoAcidPeptideOrProtein"}, {"end": 260, "start": 254, "tag": "BiologicFunction"}, {"end": 139, "start": 109, "tag": "ResearchActivity"}, {"end": 265, "start": 238, "tag": "ResearchActivity"}, {"end": 347, "start": 325, "tag": "ResearchActivity"}]}{"id": "1453_5", "text": "These preliminary findings suggest that profiles of cognitive performance may be specific to a given biomarker, with a primarily hippocampal task being associated with higher levels of tau and a frontal executive task being associated with higher levels of A beta.", "tags": [{"end": 17, "start": 6, "tag": "TemporalConcept"}, {"end": 188, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 185, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 101, "tag": "ClinicalAttribute"}, {"end": 73, "start": 62, "tag": "Finding"}, {"end": 73, "start": 52, "tag": "Finding"}, {"end": 263, "start": 257, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 145, "start": 129, "tag": "ResearchActivity"}, {"end": 217, "start": 195, "tag": "ResearchActivity"}, {"end": 188, "start": 175, "tag": "ClinicalAttribute"}, {"end": 263, "start": 247, "tag": "ClinicalAttribute"}]}{"id": "1453_6", "text": "While previous research has focused on the relationship between cognition and levels of A beta, our findings suggest that p-tau may potentially be a more significant correlate.", "tags": [{"end": 127, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 15, "tag": "ResearchActivity"}, {"end": 73, "start": 64, "tag": "BiologicFunction"}, {"end": 55, "start": 43, "tag": "Finding"}, {"end": 127, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 78, "tag": "ClinicalAttribute"}]}{"id": "1454_0", "text": "Huntington disease (HD) is a neurodegenerative disease caused by a trinucleotide repeat expansion in the HTT gene encoding an elongated polyglutamine tract in the huntingtin (HTT) protein.", "tags": [{"end": 87, "start": 67, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 135, "start": 126, "tag": "Finding"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 114, "tag": "BiologicFunction"}, {"end": 113, "start": 105, "tag": "GeneOrGenome"}, {"end": 155, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 105, "tag": "GeneOrGenome"}, {"end": 178, "start": 175, "tag": "GeneOrGenome"}, {"end": 108, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 187, "start": 180, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 67, "tag": "CellOrMolecularDysfunction"}]}{"id": "1454_1", "text": "Expanded mutant HTT (mHTT) is toxic and leads to regional atrophy and neuronal cell loss in the brain, which occurs earliest in the striatum.", "tags": [{"end": 19, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 140, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "InjuryOrPoisoning"}, {"end": 124, "start": 116, "tag": "TemporalConcept"}, {"end": 83, "start": 70, "tag": "Cell"}, {"end": 101, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 58, "tag": "PathologicFunction"}, {"end": 65, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 21, "tag": "CellOrMolecularDysfunction"}, {"end": 88, "start": 70, "tag": "CellOrMolecularDysfunction"}]}{"id": "1454_2", "text": "Therapeutic lowering of mHTT in the central nervous system (CNS) has shown promise in preclinical studies, with multiple approaches currently in clinical development for HD.", "tags": [{"end": 28, "start": 0, "tag": "HealthCareActivity"}, {"end": 63, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 86, "tag": "ResearchActivity"}, {"end": 172, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 132, "tag": "TemporalConcept"}, {"end": 165, "start": 154, "tag": "BiologicFunction"}, {"end": 165, "start": 154, "tag": "CellFunction"}]}{"id": "1454_3", "text": "Quantitation of mHTT in the cerebrospinal fluid (CSF) is being used as a clinical pharmacodynamic biomarker of target engagement in the CNS.", "tags": [{"end": 97, "start": 82, "tag": "BiologicFunction"}, {"end": 97, "start": 82, "tag": "ResearchActivity"}, {"end": 139, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 111, "tag": "Finding"}, {"end": 128, "start": 118, "tag": "Finding"}, {"end": 52, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 98, "tag": "ClinicalAttribute"}, {"end": 47, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 0, "tag": "HealthCareActivity"}]}{"id": "1454_4", "text": "We have previously shown that the CNS is a major source of mHTT in the CSF.", "tags": [{"end": 37, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 59, "tag": "CellOrMolecularDysfunction"}]}{"id": "1454_5", "text": "However, little is known about the specific brain regions and cell types that contribute to CSF mHTT.", "tags": [{"end": 72, "start": 62, "tag": "Cell"}, {"end": 57, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 92, "tag": "ClinicalAttribute"}]}{"id": "1454_6", "text": "Therefore, a better understanding of the origins of CSF mHTT and whether therapies targeting mHTT in the striatum would be expected to be associated with significant lowering of mHTT in the CSF is needed.", "tags": [{"end": 113, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 73, "tag": "HealthCareActivity"}, {"end": 48, "start": 41, "tag": "TemporalConcept"}, {"end": 55, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 190, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 20, "tag": "BiologicFunction"}, {"end": 60, "start": 52, "tag": "ClinicalAttribute"}, {"end": 97, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 182, "start": 178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 182, "start": 178, "tag": "CellOrMolecularDysfunction"}]}{"id": "1454_7", "text": "Here, we use complementary pharmacological and genetic-based approaches to either restrict expression of mHTT to the striatum or selectively deplete mHTT in the striatum to evaluate the contribution of this brain region to mHTT in the CSF.", "tags": [{"end": 125, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 169, "start": 161, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 219, "start": 207, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 235, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 27, "tag": "ResearchActivity"}, {"end": 109, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 105, "tag": "CellOrMolecularDysfunction"}, {"end": 153, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 149, "tag": "CellOrMolecularDysfunction"}, {"end": 227, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 227, "start": 223, "tag": "CellOrMolecularDysfunction"}]}{"id": "1454_8", "text": "We show that viral expression of a mHTT fragment restricted to the striatum leads to detectable mHTT in the CSF.", "tags": [{"end": 29, "start": 13, "tag": "CellFunction"}, {"end": 75, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 85, "tag": "ClinicalAttribute"}, {"end": 48, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 96, "tag": "CellOrMolecularDysfunction"}]}{"id": "1454_9", "text": "We demonstrate that targeted lowering of mHTT selectively in the striatum using an antisense oligonucleotide leads to a significant reduction of mHTT in the CSF of HD mice.", "tags": [{"end": 73, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 83, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 108, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 83, "tag": "Chemical"}, {"end": 141, "start": 120, "tag": "Finding"}, {"end": 171, "start": 164, "tag": "ExperimentalModelOfDisease"}, {"end": 141, "start": 132, "tag": "Finding"}, {"end": 141, "start": 132, "tag": "NaturalPhenomenonOrProcess"}, {"end": 160, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 171, "start": 167, "tag": "Eukaryote"}, {"end": 45, "start": 20, "tag": "HealthCareActivity"}, {"end": 149, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 145, "tag": "CellOrMolecularDysfunction"}]}{"id": "1454_10", "text": "Furthermore, using a transgenic mouse model of HD that expresses full length human mHTT and wild type HTT, we show that genetic inactivation of mHTT selectively in the striatum results in a significant reduction of mHTT in the CSF.", "tags": [{"end": 101, "start": 92, "tag": "GeneOrGenome"}, {"end": 101, "start": 92, "tag": "ResearchActivity"}, {"end": 127, "start": 120, "tag": "HealthCareActivity"}, {"end": 140, "start": 128, "tag": "CellFunction"}, {"end": 176, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 102, "tag": "GeneOrGenome"}, {"end": 105, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 190, "tag": "Finding"}, {"end": 49, "start": 21, "tag": "ExperimentalModelOfDisease"}, {"end": 76, "start": 70, "tag": "ResearchActivity"}, {"end": 211, "start": 202, "tag": "Finding"}, {"end": 211, "start": 202, "tag": "NaturalPhenomenonOrProcess"}, {"end": 230, "start": 227, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 77, "tag": "Eukaryote"}, {"end": 87, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 83, "tag": "CellOrMolecularDysfunction"}, {"end": 148, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 144, "tag": "CellOrMolecularDysfunction"}, {"end": 219, "start": 215, "tag": "AminoAcidPeptideOrProtein"}, {"end": 219, "start": 215, "tag": "CellOrMolecularDysfunction"}]}{"id": "1454_11", "text": "Taken together, our data supports the conclusion that the striatum contributes sufficiently to the pool of mHTT in the CSF that therapeutic levels of mHTT lowering in the striatum can be detected by this measure in HD mice.", "tags": [{"end": 103, "start": 99, "tag": "ClinicalAttribute"}, {"end": 66, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 222, "start": 215, "tag": "ExperimentalModelOfDisease"}, {"end": 122, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 20, "tag": "ResearchActivity"}, {"end": 222, "start": 218, "tag": "Eukaryote"}, {"end": 111, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 107, "tag": "CellOrMolecularDysfunction"}, {"end": 154, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 150, "tag": "CellOrMolecularDysfunction"}]}{"id": "1454_12", "text": "This suggests that CSF mHTT may represent a pharmacodynamic biomarker for therapies that lower mHTT in the striatum.", "tags": [{"end": 59, "start": 44, "tag": "BiologicFunction"}, {"end": 59, "start": 44, "tag": "ResearchActivity"}, {"end": 115, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 74, "tag": "HealthCareActivity"}, {"end": 22, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 60, "tag": "ClinicalAttribute"}, {"end": 27, "start": 19, "tag": "ClinicalAttribute"}, {"end": 99, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 95, "tag": "CellOrMolecularDysfunction"}]}{"id": "1455_0", "text": "Background: The hippocampus, entorhinal cortex (EC), and basal forebrain (BF) are among the earliest regions affected by Alzheimer's disease (AD) pathology.", "tags": [{"end": 72, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 92, "tag": "TemporalConcept"}, {"end": 140, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 146, "tag": "PathologicFunction"}, {"end": 155, "start": 146, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 27, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1455_1", "text": "They play an essential role in spatial pattern separation, a process critical for accurate discrimination between similar locations.", "tags": [{"end": 57, "start": 31, "tag": "BiologicFunction"}, {"end": 131, "start": 91, "tag": "BiologicFunction"}]}{"id": "1455_2", "text": "Objective: We examined differences in spatial pattern separation performance between older adults with amnestic mild cognitive impairment (aMCI) with AD versus those with non-Alzheimer's pathologic change (non-AD) and interrelations between volumes of the hippocampal, EC subregions and BF nuclei projecting to these subregions (medial septal nuclei and vertical limb of the diagonal band of Broca - Ch1-2 nuclei) with respect to performance.", "tags": [{"end": 296, "start": 287, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 349, "start": 329, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 296, "start": 290, "tag": "CellComponent"}, {"end": 282, "start": 269, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 271, "start": 269, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 85, "tag": "TemporalConcept"}, {"end": 97, "start": 85, "tag": "PopulationGroup"}, {"end": 143, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 23, "tag": "Finding"}, {"end": 76, "start": 65, "tag": "Finding"}, {"end": 441, "start": 430, "tag": "Finding"}, {"end": 137, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 112, "tag": "Finding"}, {"end": 97, "start": 91, "tag": "PopulationGroup"}, {"end": 267, "start": 256, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 38, "tag": "BiologicFunction"}, {"end": 204, "start": 187, "tag": "PathologicFunction"}, {"end": 327, "start": 317, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 412, "start": 354, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1455_3", "text": "Methods: Hundred and eighteen older adults were recruited from the Czech Brain Aging Study.", "tags": [{"end": 78, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 30, "tag": "TemporalConcept"}, {"end": 42, "start": 30, "tag": "PopulationGroup"}, {"end": 42, "start": 36, "tag": "PopulationGroup"}, {"end": 90, "start": 67, "tag": "ResearchActivity"}]}{"id": "1455_4", "text": "Participants with AD aMCI (n = 37), non-AD aMCI (n = 26), mild AD dementia (n = 26), and cognitively normal older adults (CN; n = 29) underwent spatial pattern separation testing, cognitive assessment and brain magnetic resonance imaging.", "tags": [{"end": 25, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 101, "tag": "Finding"}, {"end": 124, "start": 122, "tag": "Finding"}, {"end": 113, "start": 108, "tag": "TemporalConcept"}, {"end": 120, "start": 108, "tag": "PopulationGroup"}, {"end": 25, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 171, "tag": "HealthCareActivity"}, {"end": 74, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 180, "tag": "HealthCareActivity"}, {"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 107, "start": 89, "tag": "Finding"}, {"end": 62, "start": 58, "tag": "Finding"}, {"end": 120, "start": 114, "tag": "PopulationGroup"}, {"end": 237, "start": 211, "tag": "HealthCareActivity"}, {"end": 170, "start": 144, "tag": "BiologicFunction"}]}{"id": "1455_5", "text": "Results: The AD aMCI group had less accurate spatial pattern separation performance than the non-AD aMCI (p = 0.039) and CN (p < 0.001) groups.", "tags": [{"end": 20, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 121, "tag": "Finding"}, {"end": 20, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 72, "tag": "Finding"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 142, "start": 136, "tag": "PopulationGroup"}, {"end": 26, "start": 21, "tag": "PopulationGroup"}, {"end": 71, "start": 45, "tag": "BiologicFunction"}]}{"id": "1455_6", "text": "The AD aMCI and non-AD groups did not differ in other cognitive tests.", "tags": [{"end": 11, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 7, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 23, "tag": "PopulationGroup"}, {"end": 69, "start": 54, "tag": "HealthCareActivity"}, {"end": 69, "start": 54, "tag": "ResearchActivity"}]}{"id": "1455_7", "text": "Decreased BF Ch1-2 volume was indirectly associated with worse performance through reduced hippocampal tail volume and reduced posteromedial EC and hippocampal tail or body volumes operating in serial.", "tags": [{"end": 9, "start": 0, "tag": "Finding"}, {"end": 12, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 200, "start": 194, "tag": "TemporalConcept"}, {"end": 143, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 57, "tag": "Finding"}, {"end": 172, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 63, "tag": "Finding"}, {"end": 164, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 10, "tag": "ClinicalAttribute"}, {"end": 114, "start": 91, "tag": "ClinicalAttribute"}, {"end": 180, "start": 168, "tag": "ClinicalAttribute"}, {"end": 159, "start": 148, "tag": "ClinicalAttribute"}, {"end": 180, "start": 173, "tag": "ClinicalAttribute"}, {"end": 164, "start": 148, "tag": "ClinicalAttribute"}]}{"id": "1455_8", "text": "Conclusion: The study demonstrates that spatial pattern separation testing differentiates AD biomarker positive and negative older adults with aMCI and provides evidence that BF Ch1-2 nuclei influence spatial pattern separation through the posteromedial EC and the posterior hippocampus.", "tags": [{"end": 256, "start": 254, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 256, "start": 240, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 125, "tag": "TemporalConcept"}, {"end": 137, "start": 125, "tag": "PopulationGroup"}, {"end": 147, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 93, "tag": "ClinicalAttribute"}, {"end": 74, "start": 67, "tag": "HealthCareActivity"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 169, "start": 161, "tag": "Finding"}, {"end": 286, "start": 265, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 131, "tag": "PopulationGroup"}, {"end": 190, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 227, "start": 201, "tag": "BiologicFunction"}, {"end": 66, "start": 40, "tag": "BiologicFunction"}]}{"id": "1456_0", "text": "Multiple biomarkers can capture different facets of Alzheimer's disease.", "tags": [{"end": 71, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 9, "tag": "ClinicalAttribute"}]}{"id": "1456_1", "text": "However, statistical models of biomarkers to predict outcomes in Alzheimer's rarely model nonlinear interactions between these measures.", "tags": [{"end": 61, "start": 45, "tag": "HealthCareActivity"}, {"end": 76, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 90, "tag": "Finding"}, {"end": 41, "start": 31, "tag": "ClinicalAttribute"}, {"end": 61, "start": 53, "tag": "Finding"}, {"end": 89, "start": 84, "tag": "ResearchActivity"}, {"end": 27, "start": 9, "tag": "ResearchActivity"}]}{"id": "1456_2", "text": "Here, we used Gaussian Processes to address this, modelling nonlinear interactions to predict progression from mild cognitive impairment (MCI) to Alzheimer's over 3 years, using Alzheimer's Disease Neuroimaging Initiative (ADNI) data.", "tags": [{"end": 59, "start": 50, "tag": "ResearchActivity"}, {"end": 157, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 178, "tag": "ResearchActivity"}, {"end": 221, "start": 178, "tag": "HealthCareRelatedOrganization"}, {"end": 82, "start": 60, "tag": "Finding"}, {"end": 227, "start": 223, "tag": "HealthCareRelatedOrganization"}, {"end": 227, "start": 223, "tag": "ResearchActivity"}, {"end": 233, "start": 229, "tag": "ResearchActivity"}, {"end": 136, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 94, "tag": "PathologicFunction"}, {"end": 105, "start": 94, "tag": "TemporalConcept"}, {"end": 170, "start": 165, "tag": "TemporalConcept"}, {"end": 136, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 111, "tag": "Finding"}, {"end": 32, "start": 14, "tag": "ResearchActivity"}]}{"id": "1456_3", "text": "Measures included: demographics, APOE4 genotype, CSF (amyloid-beta 42, total tau, phosphorylated tau), [18(F)]florbetapir, hippocampal volume and brain-age.", "tags": [{"end": 96, "start": 82, "tag": "CellFunction"}, {"end": 80, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 152, "tag": "OrganismAttribute"}, {"end": 47, "start": 39, "tag": "OrganismAttribute"}, {"end": 38, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 123, "tag": "ClinicalAttribute"}, {"end": 121, "start": 104, "tag": "Chemical"}]}{"id": "1456_4", "text": "We examined: (a) the independent value of each biomarker; and (b) whether modelling nonlinear interactions between biomarkers improved predictions.", "tags": [{"end": 83, "start": 74, "tag": "ResearchActivity"}, {"end": 134, "start": 126, "tag": "Finding"}, {"end": 106, "start": 84, "tag": "Finding"}, {"end": 56, "start": 47, "tag": "ClinicalAttribute"}, {"end": 125, "start": 115, "tag": "ClinicalAttribute"}]}{"id": "1456_5", "text": "Each measured added complementary information when predicting conversion to Alzheimer's.", "tags": [{"end": 87, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 62, "tag": "Finding"}]}{"id": "1456_6", "text": "A linear model classifying stable from progressive MCI explained over half the variance (R-2= 0.51,p < .001); the strongest independently contributing biomarker was hippocampal volume (R-2= 0.13).", "tags": [{"end": 14, "start": 2, "tag": "ResearchActivity"}, {"end": 160, "start": 151, "tag": "ClinicalAttribute"}, {"end": 50, "start": 39, "tag": "TemporalConcept"}, {"end": 54, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 165, "tag": "ClinicalAttribute"}, {"end": 87, "start": 79, "tag": "ResearchActivity"}]}{"id": "1456_7", "text": "When comparing sensitivity of different models to progressive MCI (independent biomarker models, additive models, nonlinear interaction models), we observed a significant improvement (p < .001) for various two-way interaction models.", "tags": [{"end": 88, "start": 79, "tag": "ClinicalAttribute"}, {"end": 61, "start": 50, "tag": "TemporalConcept"}, {"end": 65, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 15, "tag": "Finding"}, {"end": 46, "start": 40, "tag": "ResearchActivity"}, {"end": 95, "start": 89, "tag": "ResearchActivity"}, {"end": 112, "start": 106, "tag": "ResearchActivity"}, {"end": 142, "start": 114, "tag": "ResearchActivity"}, {"end": 232, "start": 206, "tag": "ResearchActivity"}]}{"id": "1456_8", "text": "The best performing model included an interaction between amyloid-beta-PET and P-tau, while accounting for hippocampal volume (sensitivity = 0.77, AUC = 0.826).", "tags": [{"end": 84, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 127, "tag": "Finding"}, {"end": 70, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 20, "tag": "ResearchActivity"}, {"end": 74, "start": 71, "tag": "HealthCareActivity"}, {"end": 150, "start": 147, "tag": "ResearchActivity"}, {"end": 125, "start": 107, "tag": "ClinicalAttribute"}]}{"id": "1456_9", "text": "Closely related biomarkers contributed uniquely to predict conversion to Alzheimer's.", "tags": [{"end": 84, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 16, "tag": "ClinicalAttribute"}, {"end": 69, "start": 59, "tag": "Finding"}]}{"id": "1456_10", "text": "Nonlinear biomarker interactions were also implicated, and results showed that although for some patients adding additional biomarkers may add little value (i.e., when hippocampal volume is high), for others (i.e., with low hippocampal volume) further invasive and expensive examination may be warranted.", "tags": [{"end": 286, "start": 275, "tag": "HealthCareActivity"}, {"end": 274, "start": 265, "tag": "Finding"}, {"end": 260, "start": 252, "tag": "Finding"}, {"end": 32, "start": 20, "tag": "Finding"}, {"end": 9, "start": 0, "tag": "Finding"}, {"end": 223, "start": 220, "tag": "Finding"}, {"end": 19, "start": 10, "tag": "ClinicalAttribute"}, {"end": 105, "start": 97, "tag": "PatientOrDisabledGroup"}, {"end": 134, "start": 124, "tag": "ClinicalAttribute"}, {"end": 186, "start": 168, "tag": "ClinicalAttribute"}, {"end": 242, "start": 224, "tag": "ClinicalAttribute"}, {"end": 194, "start": 190, "tag": "Finding"}]}{"id": "1456_11", "text": "Our framework enables visualisation of these interactions, in individual patient biomarker 'space', providing information for personalised or stratified healthcare or clinical trial design.", "tags": [{"end": 181, "start": 167, "tag": "ResearchActivity"}, {"end": 80, "start": 73, "tag": "PatientOrDisabledGroup"}, {"end": 57, "start": 45, "tag": "Finding"}, {"end": 90, "start": 81, "tag": "ClinicalAttribute"}, {"end": 72, "start": 62, "tag": "PopulationGroup"}, {"end": 72, "start": 62, "tag": "OrganismAttribute"}, {"end": 188, "start": 182, "tag": "ResearchActivity"}, {"end": 188, "start": 182, "tag": "HealthCareActivity"}, {"end": 163, "start": 126, "tag": "HealthCareActivity"}]}{"id": "1457_0", "text": "Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer's disease (AD) patients.", "tags": [{"end": 10, "start": 0, "tag": "Cell"}, {"end": 39, "start": 30, "tag": "CellFunction"}, {"end": 86, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 92, "tag": "PatientOrDisabledGroup"}, {"end": 63, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 40, "tag": "OrganismAttribute"}]}{"id": "1457_1", "text": "Here, we studied the associations of cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) and chitinase-3-like protein 1 (YKL-40) levels with brain amyloid-beta (A beta) and tau pathologies.", "tags": [{"end": 94, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 96, "tag": "GeneOrGenome"}, {"end": 132, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 189, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 167, "start": 160, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 186, "tag": "DiseaseOrSyndrome"}]}{"id": "1457_2", "text": "We assessed 121 individuals across the aging and AD clinical spectrum with positron emission tomography (PET) brain imaging for A beta ([F-18]AZD4694) and tau ([F-18]MK-6240), as well as CSF GFAP and YKL-40 measures.", "tags": [{"end": 123, "start": 110, "tag": "HealthCareActivity"}, {"end": 195, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 195, "start": 191, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 191, "tag": "GeneOrGenome"}, {"end": 206, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 206, "start": 200, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 39, "tag": "BiologicFunction"}, {"end": 44, "start": 39, "tag": "CellFunction"}, {"end": 158, "start": 155, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 16, "tag": "PopulationGroup"}, {"end": 108, "start": 105, "tag": "HealthCareActivity"}, {"end": 134, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 75, "tag": "HealthCareActivity"}, {"end": 69, "start": 52, "tag": "ClinicalAttribute"}, {"end": 149, "start": 136, "tag": "Chemical"}, {"end": 174, "start": 160, "tag": "Chemical"}, {"end": 195, "start": 187, "tag": "ClinicalAttribute"}, {"end": 206, "start": 200, "tag": "ClinicalAttribute"}, {"end": 190, "start": 187, "tag": "ClinicalAttribute"}]}{"id": "1457_3", "text": "We observed that higher CSF GFAP levels were associated with elevated A beta-PET but not tau-PET load.", "tags": [{"end": 32, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 28, "tag": "GeneOrGenome"}, {"end": 92, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 77, "tag": "HealthCareActivity"}, {"end": 96, "start": 93, "tag": "HealthCareActivity"}, {"end": 76, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 24, "tag": "ClinicalAttribute"}]}{"id": "1457_4", "text": "By contrast, higher CSF YKL-40 levels were associated with elevated tau-PET but not A beta-PET burden.", "tags": [{"end": 30, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 72, "tag": "HealthCareActivity"}, {"end": 94, "start": 91, "tag": "HealthCareActivity"}, {"end": 90, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 95, "tag": "ResearchActivity"}, {"end": 37, "start": 20, "tag": "ClinicalAttribute"}]}{"id": "1457_5", "text": "Structural equation modeling revealed that CSF GFAP and YKL-40 mediate the effects of A beta and tau, respectively, on hippocampal atrophy, which was further associated with cognitive impairment.", "tags": [{"end": 28, "start": 0, "tag": "ResearchActivity"}, {"end": 51, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 47, "tag": "GeneOrGenome"}, {"end": 62, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 194, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 75, "tag": "Finding"}, {"end": 92, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 119, "tag": "PathologicFunction"}, {"end": 138, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 43, "tag": "ClinicalAttribute"}, {"end": 62, "start": 56, "tag": "ClinicalAttribute"}, {"end": 46, "start": 43, "tag": "ClinicalAttribute"}]}{"id": "1457_6", "text": "Our results suggest the existence of distinct astrocyte biomarker signatures in response to brain A beta and tau accumulation, which may contribute to our understanding of the complex link between reactive astrogliosis heterogeneity and AD progression.", "tags": [{"end": 218, "start": 197, "tag": "PathologicFunction"}, {"end": 55, "start": 46, "tag": "Cell"}, {"end": 232, "start": 219, "tag": "Finding"}, {"end": 112, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 239, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 56, "tag": "ClinicalAttribute"}, {"end": 97, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 251, "start": 240, "tag": "PathologicFunction"}, {"end": 251, "start": 240, "tag": "TemporalConcept"}, {"end": 168, "start": 155, "tag": "BiologicFunction"}, {"end": 104, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 113, "tag": "Finding"}]}{"id": "1458_0", "text": "Alzheimer's disease (AD) is a neurodegenerative disease characterized by a progressive loss of memory and cognitive decline.", "tags": [{"end": 55, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 75, "tag": "TemporalConcept"}, {"end": 123, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 87, "tag": "SignOrSymptom"}, {"end": 101, "start": 95, "tag": "BiologicFunction"}]}{"id": "1458_1", "text": "Over the last decade, it has been found that defects in sensory systems could be highly associated with AD.", "tags": [{"end": 71, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 9, "tag": "TemporalConcept"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}]}{"id": "1458_2", "text": "Hearing is an important neural sense.", "tags": [{"end": 7, "start": 0, "tag": "BiologicFunction"}, {"end": 36, "start": 24, "tag": "BiologicFunction"}]}{"id": "1458_3", "text": "However, little is known about hearing functional changes in AD.", "tags": [{"end": 38, "start": 31, "tag": "BiologicFunction"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 39, "tag": "Finding"}]}{"id": "1458_4", "text": "In this study, APP/PS1 AD mice (Jackson Lab: Stack No.", "tags": [{"end": 43, "start": 32, "tag": "HealthCareRelatedOrganization"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 30, "start": 15, "tag": "ExperimentalModelOfDisease"}]}{"id": "1458_5", "text": "004462) were used.", "tags": []}{"id": "1458_6", "text": "Hearing function was assessed by auditory brainstem response (ABR), distortion product otoacoustic emission (DPOAE), and cochlear microphonics (CM) recordings.", "tags": [{"end": 16, "start": 0, "tag": "BiologicFunction"}, {"end": 60, "start": 33, "tag": "ClinicalAttribute"}, {"end": 65, "start": 62, "tag": "ClinicalAttribute"}, {"end": 158, "start": 148, "tag": "HealthCareActivity"}, {"end": 107, "start": 68, "tag": "HealthCareActivity"}, {"end": 158, "start": 148, "tag": "HealthCareActivity"}, {"end": 142, "start": 121, "tag": "HealthCareActivity"}, {"end": 114, "start": 109, "tag": "HealthCareActivity"}]}{"id": "1458_7", "text": "Wild-type (WT) littermates served as control.", "tags": [{"end": 13, "start": 11, "tag": "ResearchActivity"}, {"end": 44, "start": 37, "tag": "PopulationGroup"}, {"end": 26, "start": 15, "tag": "ResearchActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}]}{"id": "1458_8", "text": "We found that APP/PS1 AD mice measured as ABR threshold had hearing loss.", "tags": [{"end": 45, "start": 42, "tag": "ClinicalAttribute"}, {"end": 72, "start": 60, "tag": "Finding"}, {"end": 55, "start": 46, "tag": "Finding"}, {"end": 38, "start": 30, "tag": "HealthCareActivity"}, {"end": 29, "start": 14, "tag": "ExperimentalModelOfDisease"}]}{"id": "1458_9", "text": "The hearing loss appeared at high frequency as early as 2 months old, prior to the reported occurrence of spatial learning deficit at 6-7 months of age in this AD mouse model.", "tags": [{"end": 16, "start": 4, "tag": "Finding"}, {"end": 122, "start": 106, "tag": "BiologicFunction"}, {"end": 102, "start": 92, "tag": "TemporalConcept"}, {"end": 43, "start": 34, "tag": "TemporalConcept"}, {"end": 151, "start": 148, "tag": "OrganismAttribute"}, {"end": 52, "start": 47, "tag": "TemporalConcept"}, {"end": 64, "start": 58, "tag": "TemporalConcept"}, {"end": 144, "start": 138, "tag": "TemporalConcept"}, {"end": 33, "start": 29, "tag": "Finding"}, {"end": 174, "start": 160, "tag": "ExperimentalModelOfDisease"}]}{"id": "1458_10", "text": "The hearing loss was progressive and extended from high frequency to low frequency.", "tags": [{"end": 16, "start": 4, "tag": "Finding"}, {"end": 72, "start": 69, "tag": "Finding"}, {"end": 32, "start": 21, "tag": "TemporalConcept"}, {"end": 65, "start": 56, "tag": "TemporalConcept"}, {"end": 82, "start": 73, "tag": "TemporalConcept"}, {"end": 55, "start": 51, "tag": "Finding"}]}{"id": "1458_11", "text": "At 3-4 months old, the hearing loss appeared in the whole-frequency range.", "tags": [{"end": 35, "start": 23, "tag": "Finding"}, {"end": 67, "start": 58, "tag": "TemporalConcept"}, {"end": 13, "start": 7, "tag": "TemporalConcept"}]}{"id": "1458_12", "text": "Moreover, the wave IV and V in the super-threshold ABR were eliminated, indicating substantial impairment in inferior colliculus, nuclei of lateral lemniscus, and medial geniculate body in the upper brainstem.", "tags": [{"end": 54, "start": 51, "tag": "ClinicalAttribute"}, {"end": 105, "start": 95, "tag": "Finding"}, {"end": 128, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 157, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 163, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 193, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 41, "tag": "Finding"}]}{"id": "1458_13", "text": "DPOAE in APP/PS1 AD mice was also reduced.", "tags": [{"end": 5, "start": 0, "tag": "HealthCareActivity"}, {"end": 24, "start": 9, "tag": "ExperimentalModelOfDisease"}]}{"id": "1458_14", "text": "However, there was no reduction in CM in APP/PS1 mice.", "tags": [{"end": 31, "start": 22, "tag": "Finding"}, {"end": 31, "start": 22, "tag": "NaturalPhenomenonOrProcess"}, {"end": 53, "start": 41, "tag": "ExperimentalModelOfDisease"}]}{"id": "1458_15", "text": "These data demonstrate that unlike age-related hearing loss APP/PS1 AD mice have early onset of hearing loss.", "tags": [{"end": 59, "start": 35, "tag": "PathologicFunction"}, {"end": 108, "start": 96, "tag": "Finding"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 86, "start": 81, "tag": "TemporalConcept"}, {"end": 92, "start": 87, "tag": "TemporalConcept"}, {"end": 75, "start": 60, "tag": "ExperimentalModelOfDisease"}]}{"id": "1458_16", "text": "These data also suggest that hearing function testing could provide a simple, sensitive, non-invasive screen-tool for early detecting AD and localizing lesion.", "tags": [{"end": 158, "start": 152, "tag": "InjuryOrPoisoning"}, {"end": 87, "start": 78, "tag": "PathologicFunction"}, {"end": 136, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 53, "start": 46, "tag": "HealthCareActivity"}, {"end": 123, "start": 118, "tag": "TemporalConcept"}, {"end": 113, "start": 89, "tag": "HealthCareActivity"}, {"end": 113, "start": 89, "tag": "ResearchActivity"}, {"end": 45, "start": 29, "tag": "BiologicFunction"}]}{"id": "1459_0", "text": "Disclosure of Alzheimer's disease (AD) biomarkers to cognitively unimpaired adults are currently conducted only in research settings.", "tags": [{"end": 75, "start": 53, "tag": "Finding"}, {"end": 96, "start": 87, "tag": "TemporalConcept"}, {"end": 10, "start": 0, "tag": "IndividualBehavior"}, {"end": 33, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 115, "tag": "ResearchActivity"}, {"end": 49, "start": 39, "tag": "ClinicalAttribute"}, {"end": 82, "start": 76, "tag": "PopulationGroup"}]}{"id": "1459_1", "text": "Yet, US Food and Drug Administration approval of a disease-modifying treatment for symptomatic individuals, improved understanding of the preclinical phase of disease, and advancements toward more accessible biomarker tests suggest such disclosure will increase in frequency, eventually becoming routine in clinical practice.", "tags": [{"end": 36, "start": 8, "tag": "HealthCareRelatedOrganization"}, {"end": 45, "start": 37, "tag": "ResearchActivity"}, {"end": 78, "start": 51, "tag": "HealthCareActivity"}, {"end": 303, "start": 296, "tag": "TemporalConcept"}, {"end": 247, "start": 237, "tag": "IndividualBehavior"}, {"end": 324, "start": 307, "tag": "HealthCareActivity"}, {"end": 155, "start": 138, "tag": "TemporalConcept"}, {"end": 217, "start": 208, "tag": "ClinicalAttribute"}, {"end": 106, "start": 83, "tag": "PopulationGroup"}, {"end": 274, "start": 265, "tag": "TemporalConcept"}, {"end": 130, "start": 117, "tag": "BiologicFunction"}, {"end": 223, "start": 218, "tag": "ResearchActivity"}, {"end": 223, "start": 218, "tag": "HealthCareActivity"}]}{"id": "1459_2", "text": "The changing landscape in AD research to focus on biomarkers has generated debate on the validity and clinical utility of disclosure to cognitively unimpaired adults.", "tags": [{"end": 132, "start": 122, "tag": "IndividualBehavior"}, {"end": 158, "start": 136, "tag": "Finding"}, {"end": 28, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 29, "tag": "ResearchActivity"}, {"end": 97, "start": 89, "tag": "Finding"}, {"end": 60, "start": 50, "tag": "ClinicalAttribute"}, {"end": 165, "start": 159, "tag": "PopulationGroup"}, {"end": 118, "start": 102, "tag": "Finding"}, {"end": 22, "start": 4, "tag": "Finding"}]}{"id": "1459_3", "text": "This article explores the broader social implications of more widespread AD biomarker disclosure-that is, of individuals learning their risk for developing dementia caused by AD.", "tags": [{"end": 96, "start": 86, "tag": "IndividualBehavior"}, {"end": 155, "start": 136, "tag": "Finding"}, {"end": 129, "start": 121, "tag": "BiologicFunction"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 76, "tag": "ClinicalAttribute"}, {"end": 120, "start": 109, "tag": "PopulationGroup"}, {"end": 164, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 5, "tag": "ResearchActivity"}, {"end": 53, "start": 34, "tag": "Finding"}]}{"id": "1459_4", "text": "We identify 10 challenges and offer preliminary solutions.", "tags": [{"end": 57, "start": 48, "tag": "Substance"}, {"end": 25, "start": 15, "tag": "HealthCareActivity"}, {"end": 47, "start": 36, "tag": "TemporalConcept"}]}{"id": "1459_5", "text": "As the field continues to evolve, it is essential to anticipate and address these broader ethical, legal, and social implications of disclosure.", "tags": [{"end": 143, "start": 133, "tag": "IndividualBehavior"}, {"end": 129, "start": 110, "tag": "Finding"}, {"end": 129, "start": 117, "tag": "Finding"}, {"end": 97, "start": 90, "tag": "Finding"}, {"end": 129, "start": 117, "tag": "Finding"}, {"end": 104, "start": 99, "tag": "Finding"}]}{"id": "1460_0", "text": "The NIH-funded Alzheimer's Biomarker Consortium Down Syndrome (ABC-DS) and the European Horizon 21 Consortium are collecting critical new information on the natural history of Alzheimer's Disease (AD) biomarkers in adults with Down syndrome (DS), a population genetically predisposed to developing AD.", "tags": [{"end": 240, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 244, "start": 242, "tag": "DiseaseOrSyndrome"}, {"end": 259, "start": 249, "tag": "PopulationGroup"}, {"end": 195, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 201, "tag": "ClinicalAttribute"}, {"end": 199, "start": 197, "tag": "DiseaseOrSyndrome"}, {"end": 300, "start": 298, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 165, "tag": "Finding"}, {"end": 221, "start": 215, "tag": "PopulationGroup"}, {"end": 7, "start": 4, "tag": "HealthCareRelatedOrganization"}, {"end": 61, "start": 15, "tag": "HealthCareRelatedOrganization"}, {"end": 109, "start": 79, "tag": "HealthCareRelatedOrganization"}, {"end": 69, "start": 63, "tag": "HealthCareRelatedOrganization"}]}{"id": "1460_1", "text": "These studies are also providing key insights into which biomarkers best represent clinically meaningful outcomes that are most feasible in clinical trials.", "tags": [{"end": 113, "start": 105, "tag": "Finding"}, {"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 67, "start": 57, "tag": "ClinicalAttribute"}, {"end": 155, "start": 140, "tag": "ResearchActivity"}]}{"id": "1460_2", "text": "This paper considers how these data can be integrated in clinical trials for individuals with DS.", "tags": [{"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 35, "start": 31, "tag": "ResearchActivity"}, {"end": 72, "start": 57, "tag": "ResearchActivity"}, {"end": 88, "start": 77, "tag": "PopulationGroup"}]}{"id": "1460_3", "text": "The Alzheimer's Clinical Trial Consortium - Down syndrome (ACTC-DS) is a platform that brings expert researchers from both networks together to conduct clinical trials for AD in DS across international sites while building on their expertise and experience.", "tags": [{"end": 57, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 246, "tag": "BiologicFunction"}, {"end": 112, "start": 101, "tag": "ResearchActivity"}, {"end": 174, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 152, "tag": "ResearchActivity"}, {"end": 57, "start": 4, "tag": "ResearchActivity"}, {"end": 66, "start": 59, "tag": "ResearchActivity"}]}{"id": "1461_0", "text": "Objective There is still an urgent need for supportive minimally invasive and cost-effective biomarkers for early diagnosis of Alzheimer's disease (AD).", "tags": [{"end": 73, "start": 55, "tag": "Finding"}, {"end": 146, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 93, "tag": "ClinicalAttribute"}, {"end": 123, "start": 108, "tag": "HealthCareActivity"}]}{"id": "1461_1", "text": "Previous work in our lab has identified Kallikrein-8 (KLK8) as a potential candidate since it shows an excessive increase in human brain in preclinical disease stages.", "tags": [{"end": 24, "start": 21, "tag": "HealthCareRelatedOrganization"}, {"end": 166, "start": 152, "tag": "ClinicalAttribute"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 136, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 125, "tag": "Eukaryote"}, {"end": 52, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 54, "tag": "GeneOrGenome"}]}{"id": "1461_2", "text": "The aim of this study was to evaluate the diagnostic performance of cerebrospinal fluid (CSF) and blood KLK8 for AD and mild cognitive impairment (MCI) due to AD.", "tags": [{"end": 92, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 150, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 42, "tag": "Finding"}, {"end": 145, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 98, "tag": "ClinicalAttribute"}]}{"id": "1461_3", "text": "Methods In this multi-centre trans-sectional study, clinical and laboratory data as well as CSF and/or blood serum samples of 237 participants, including 98 patients with mild AD, 21 with MCI due to AD and 118 controls were collected.", "tags": [{"end": 122, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 199, "tag": "DiseaseOrSyndrome"}, {"end": 218, "start": 210, "tag": "PopulationGroup"}, {"end": 165, "start": 157, "tag": "PatientOrDisabledGroup"}, {"end": 80, "start": 52, "tag": "ResearchActivity"}, {"end": 142, "start": 130, "tag": "PopulationGroup"}, {"end": 50, "start": 16, "tag": "ResearchActivity"}, {"end": 191, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 171, "tag": "Finding"}]}{"id": "1461_4", "text": "CSF and/or serum KLK8 levels were analysed by ELISA.", "tags": [{"end": 51, "start": 46, "tag": "ResearchActivity"}, {"end": 16, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 11, "tag": "ClinicalAttribute"}, {"end": 28, "start": 17, "tag": "ClinicalAttribute"}, {"end": 3, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1461_5", "text": "The diagnostic accuracy of KLK8 in CSF and blood was determined using receiver operating characteristic (ROC) analyses and compared with that of CSF core biomarkers A beta 42, P-tau and T-tau.", "tags": [{"end": 191, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 4, "tag": "Finding"}, {"end": 108, "start": 105, "tag": "ResearchActivity"}, {"end": 181, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 176, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 154, "tag": "ClinicalAttribute"}, {"end": 23, "start": 15, "tag": "Finding"}, {"end": 48, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 110, "tag": "ResearchActivity"}, {"end": 103, "start": 70, "tag": "ResearchActivity"}, {"end": 14, "start": 4, "tag": "HealthCareActivity"}]}{"id": "1461_6", "text": "Results The diagnostic accuracy of CSF KLK8 was as good as that of core CSF biomarkers for AD (area under the curve (AUC)=0.89) and in case of MCI (AUC=0.97) even superior to CSF A beta 42.", "tags": [{"end": 188, "start": 179, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 179, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 12, "tag": "Finding"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 95, "tag": "ResearchActivity"}, {"end": 86, "start": 76, "tag": "ClinicalAttribute"}, {"end": 146, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 135, "tag": "ManufacturedObject"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 120, "start": 117, "tag": "ResearchActivity"}, {"end": 151, "start": 148, "tag": "ResearchActivity"}, {"end": 43, "start": 35, "tag": "ClinicalAttribute"}, {"end": 188, "start": 175, "tag": "ClinicalAttribute"}]}{"id": "1461_7", "text": "Blood KLK8 was a similarly strong discriminator for MCI (AUC=0.94) but slightly weaker for AD (AUC=0.83).", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 57, "tag": "ResearchActivity"}, {"end": 98, "start": 95, "tag": "ResearchActivity"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1461_8", "text": "Conclusions This is the first study to demonstrate the potential clinical utility of blood and CSF KLK8 as a biomarker for incipient AD.", "tags": [{"end": 132, "start": 123, "tag": "TemporalConcept"}, {"end": 29, "start": 24, "tag": "TemporalConcept"}, {"end": 98, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 109, "tag": "ClinicalAttribute"}, {"end": 35, "start": 30, "tag": "ResearchActivity"}, {"end": 90, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 95, "tag": "ClinicalAttribute"}]}{"id": "1461_9", "text": "Future prospective validation studies are warranted.", "tags": [{"end": 18, "start": 7, "tag": "BiologicFunction"}, {"end": 29, "start": 19, "tag": "ResearchActivity"}, {"end": 37, "start": 30, "tag": "ResearchActivity"}]}{"id": "1462_0", "text": "Alzheimer's disease (AD) begins with an asymptomatic preclinical phase, in which abnormal biomarkers indicate risk for developing cognitive impairment.", "tags": [{"end": 52, "start": 40, "tag": "Finding"}, {"end": 89, "start": 81, "tag": "Finding"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 90, "tag": "ClinicalAttribute"}, {"end": 70, "start": 53, "tag": "TemporalConcept"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 110, "tag": "Finding"}]}{"id": "1462_1", "text": "Biomarker information is increasingly being disclosed in research settings, and is moving toward clinical settings with the development of cheaper and non-invasive testing.", "tags": [{"end": 89, "start": 83, "tag": "BiologicFunction"}, {"end": 171, "start": 151, "tag": "HealthCareActivity"}, {"end": 114, "start": 97, "tag": "ResearchActivity"}, {"end": 9, "start": 0, "tag": "ClinicalAttribute"}, {"end": 65, "start": 57, "tag": "ResearchActivity"}, {"end": 135, "start": 124, "tag": "BiologicFunction"}, {"end": 135, "start": 124, "tag": "CellFunction"}]}{"id": "1462_2", "text": "Limited research has focused on the safety and psychological effects of disclosing biomarker results to cognitively unimpaired adults.", "tags": [{"end": 42, "start": 36, "tag": "HealthCareActivity"}, {"end": 16, "start": 8, "tag": "ResearchActivity"}, {"end": 92, "start": 83, "tag": "ClinicalAttribute"}, {"end": 133, "start": 127, "tag": "PopulationGroup"}, {"end": 68, "start": 47, "tag": "Finding"}, {"end": 126, "start": 104, "tag": "Finding"}]}{"id": "1462_3", "text": "However, less is known about how to ensure equitable access and robust counseling for decision-making before testing, and how to effectively provide long-term follow-up and risk management after testing.", "tags": [{"end": 81, "start": 71, "tag": "HealthCareActivity"}, {"end": 188, "start": 173, "tag": "HealthCareActivity"}, {"end": 116, "start": 109, "tag": "HealthCareActivity"}, {"end": 202, "start": 195, "tag": "HealthCareActivity"}, {"end": 158, "start": 149, "tag": "TemporalConcept"}, {"end": 101, "start": 86, "tag": "BiologicFunction"}, {"end": 108, "start": 102, "tag": "TemporalConcept"}, {"end": 168, "start": 159, "tag": "HealthCareActivity"}, {"end": 168, "start": 159, "tag": "TemporalConcept"}]}{"id": "1462_4", "text": "Using the framework of Huntington's disease, which is based on extensive experience with disclosing and managing risk for a progressive neurodegenerative condition, this article proposes a conceptual model of pre-disclosure, disclosure, and post-disclosure phases for AD biomarker testing.", "tags": [{"end": 235, "start": 225, "tag": "IndividualBehavior"}, {"end": 177, "start": 170, "tag": "ResearchActivity"}, {"end": 288, "start": 281, "tag": "HealthCareActivity"}, {"end": 43, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 136, "tag": "CellOrMolecularDysfunction"}, {"end": 153, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 124, "tag": "TemporalConcept"}, {"end": 270, "start": 268, "tag": "DiseaseOrSyndrome"}, {"end": 280, "start": 271, "tag": "ClinicalAttribute"}, {"end": 205, "start": 200, "tag": "ResearchActivity"}, {"end": 83, "start": 73, "tag": "BiologicFunction"}, {"end": 245, "start": 241, "tag": "TemporalConcept"}, {"end": 117, "start": 104, "tag": "HealthCareActivity"}]}{"id": "1462_5", "text": "Addressing research questions in each phase will facilitate the transition of biomarker testing into clinical practice.", "tags": [{"end": 74, "start": 64, "tag": "Finding"}, {"end": 95, "start": 88, "tag": "HealthCareActivity"}, {"end": 118, "start": 101, "tag": "HealthCareActivity"}, {"end": 43, "start": 38, "tag": "TemporalConcept"}, {"end": 19, "start": 11, "tag": "ResearchActivity"}, {"end": 87, "start": 78, "tag": "ClinicalAttribute"}]}{"id": "1463_0", "text": "Background: The typical approach to identify blood-derived gene expression signatures as a biomarker for Alzheimer's disease (AD) have relied on training classification models using AD and healthy controls only.", "tags": [{"end": 85, "start": 64, "tag": "ResearchActivity"}, {"end": 74, "start": 59, "tag": "CellFunction"}, {"end": 124, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 91, "tag": "ClinicalAttribute"}, {"end": 196, "start": 189, "tag": "OrganismAttribute"}, {"end": 205, "start": 197, "tag": "PopulationGroup"}, {"end": 50, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 175, "start": 145, "tag": "MachineActivity"}]}{"id": "1463_1", "text": "This may inadvertently result in the identification of markers for general illness rather than being disease-specific.", "tags": [{"end": 62, "start": 55, "tag": "ClinicalAttribute"}, {"end": 82, "start": 75, "tag": "SignOrSymptom"}]}{"id": "1463_2", "text": "Objective: Investigate whether incorporating additional related disorders in the classification model development process can lead to the discovery of an AD-specific gene expression signature.", "tags": [{"end": 181, "start": 166, "tag": "CellFunction"}, {"end": 191, "start": 182, "tag": "ResearchActivity"}, {"end": 73, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 102, "tag": "BiologicFunction"}, {"end": 113, "start": 102, "tag": "CellFunction"}, {"end": 147, "start": 138, "tag": "ResearchActivity"}, {"end": 101, "start": 81, "tag": "ResearchActivity"}]}{"id": "1463_3", "text": "Methods: Two types of XGBoost classification models were developed.", "tags": [{"end": 51, "start": 22, "tag": "MachineActivity"}]}{"id": "1463_4", "text": "The first used 160 AD and 127 healthy controls and the second used the same 160 AD with 6,318 upsampled mixed controls consisting of Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, bipolar disorder, schizophrenia, coronary artery disease, rheumatoid arthritis, chronic obstructive pulmonary disease, and cognitively healthy subjects.", "tags": [{"end": 221, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 261, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 322, "start": 285, "tag": "DiseaseOrSyndrome"}, {"end": 283, "start": 263, "tag": "DiseaseOrSyndrome"}, {"end": 236, "start": 223, "tag": "DiseaseOrSyndrome"}, {"end": 203, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "TemporalConcept"}, {"end": 21, "start": 19, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 110, "tag": "PopulationGroup"}, {"end": 37, "start": 30, "tag": "OrganismAttribute"}, {"end": 152, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 38, "tag": "PopulationGroup"}, {"end": 356, "start": 348, "tag": "PopulationGroup"}, {"end": 347, "start": 328, "tag": "OrganismAttribute"}]}{"id": "1463_5", "text": "Both classification models were evaluated in an independent cohort consisting of 127 AD and 687 mixed controls.", "tags": [{"end": 59, "start": 48, "tag": "Finding"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 102, "tag": "PopulationGroup"}, {"end": 66, "start": 60, "tag": "PopulationGroup"}, {"end": 26, "start": 5, "tag": "ResearchActivity"}]}{"id": "1463_6", "text": "Results: The AD versus healthy control models resulted in an average 48.7% sensitivity (95% CI = 34.7-64.6), 41.9% specificity (95% CI = 26.8-54.3), 13.6% PPV (95% CI = 9.9-18.5), and 81.1% NPV (95% CI = 73.3-87.7).", "tags": [{"end": 15, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 23, "tag": "OrganismAttribute"}, {"end": 86, "start": 75, "tag": "Finding"}, {"end": 126, "start": 115, "tag": "Finding"}, {"end": 38, "start": 31, "tag": "PopulationGroup"}, {"end": 94, "start": 92, "tag": "ResearchActivity"}, {"end": 134, "start": 132, "tag": "ResearchActivity"}, {"end": 166, "start": 164, "tag": "ResearchActivity"}, {"end": 201, "start": 199, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 45, "start": 39, "tag": "ResearchActivity"}]}{"id": "1463_7", "text": "In contrast, the mixed control models resulted in an average of 40.8% sensitivity (95% CI = 27.5-52.0), 95.3% specificity (95% CI = 93.3-97.1), 61.4% PPV (95% CI = 53.8-69.6), and 89.7% NPV (95% CI = 87.8-91.4).", "tags": [{"end": 81, "start": 70, "tag": "Finding"}, {"end": 121, "start": 110, "tag": "Finding"}, {"end": 89, "start": 87, "tag": "ResearchActivity"}, {"end": 129, "start": 127, "tag": "ResearchActivity"}, {"end": 161, "start": 159, "tag": "ResearchActivity"}, {"end": 197, "start": 195, "tag": "ResearchActivity"}, {"end": 37, "start": 17, "tag": "ResearchActivity"}]}{"id": "1463_8", "text": "Conclusions: This early work demonstrates the value of incorporating additional related disorders into the classification model developmental process, which can result in models with improved ability to distinguish AD from a heterogeneous aging population.", "tags": [{"end": 141, "start": 128, "tag": "BiologicFunction"}, {"end": 141, "start": 128, "tag": "TemporalConcept"}, {"end": 191, "start": 183, "tag": "Finding"}, {"end": 238, "start": 225, "tag": "OrganismAttribute"}, {"end": 97, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 255, "start": 245, "tag": "PopulationGroup"}, {"end": 244, "start": 239, "tag": "BiologicFunction"}, {"end": 244, "start": 239, "tag": "CellFunction"}, {"end": 199, "start": 192, "tag": "OrganismAttribute"}, {"end": 217, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 161, "tag": "Finding"}, {"end": 23, "start": 18, "tag": "TemporalConcept"}, {"end": 127, "start": 107, "tag": "ResearchActivity"}, {"end": 177, "start": 171, "tag": "ResearchActivity"}]}{"id": "1463_9", "text": "However, further improvement to the sensitivity of the test is still required.", "tags": [{"end": 47, "start": 36, "tag": "Finding"}, {"end": 59, "start": 55, "tag": "ResearchActivity"}, {"end": 59, "start": 55, "tag": "HealthCareActivity"}]}{"id": "1464_0", "text": "IntroductionWe examined longitudinal cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarker changes among cognitively normal individuals with 10.7 years follow-up, on average.", "tags": [{"end": 82, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 88, "tag": "ClinicalAttribute"}, {"end": 56, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 131, "tag": "PopulationGroup"}, {"end": 168, "start": 159, "tag": "HealthCareActivity"}, {"end": 168, "start": 159, "tag": "TemporalConcept"}, {"end": 158, "start": 153, "tag": "TemporalConcept"}, {"end": 130, "start": 112, "tag": "Finding"}, {"end": 36, "start": 24, "tag": "ResearchActivity"}, {"end": 105, "start": 98, "tag": "Finding"}]}{"id": "1464_1", "text": "MethodsAnalyses included 278 participants (M age = 57.5 years); 94 have progressed from normal cognition to mild cognitive impairment (MCI).", "tags": [{"end": 44, "start": 43, "tag": "TemporalConcept"}, {"end": 94, "start": 88, "tag": "Finding"}, {"end": 104, "start": 88, "tag": "Finding"}, {"end": 41, "start": 29, "tag": "PopulationGroup"}, {"end": 138, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 45, "tag": "OrganismAttribute"}, {"end": 61, "start": 56, "tag": "TemporalConcept"}, {"end": 104, "start": 95, "tag": "BiologicFunction"}, {"end": 133, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 7, "tag": "ResearchActivity"}]}{"id": "1464_2", "text": "Amyloid beta (A beta)(42)/A beta(40), phosphorylated tau(181) (p-tau(181)), and total tau (t-tau) were measured using automated electrochemiluminescence assays.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 13, "tag": "ClinicalAttribute"}, {"end": 61, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 118, "tag": "ResearchActivity"}]}{"id": "1464_3", "text": "ResultsApolipoprotein E (APOE) epsilon 4 carriers had lower baseline A beta(42)/A beta(40), but longitudinal A beta(42)/A beta(40) decreases did not differ by APOE epsilon 4 after accounting for A beta(42)/A beta(40) positivity.", "tags": [{"end": 227, "start": 217, "tag": "ResearchActivity"}, {"end": 29, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 41, "tag": "PopulationGroup"}, {"end": 173, "start": 159, "tag": "GeneOrGenome"}, {"end": 40, "start": 31, "tag": "GeneOrGenome"}, {"end": 23, "start": 7, "tag": "GeneOrGenome"}, {"end": 90, "start": 69, "tag": "ClinicalAttribute"}, {"end": 130, "start": 109, "tag": "ClinicalAttribute"}, {"end": 216, "start": 195, "tag": "ClinicalAttribute"}]}{"id": "1464_4", "text": "Lower baseline A beta(42)/A beta(40) was associated with greater increases in tau (more strongly in males), and APOE epsilon 4 genotype was associated with greater tau increases after reaching A beta(42)/A beta(40) positivity.", "tags": [{"end": 105, "start": 100, "tag": "OrganismAttribute"}, {"end": 225, "start": 215, "tag": "ResearchActivity"}, {"end": 81, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 167, "start": 164, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 167, "start": 164, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 127, "tag": "OrganismAttribute"}, {"end": 126, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 15, "tag": "ClinicalAttribute"}, {"end": 214, "start": 193, "tag": "ClinicalAttribute"}]}{"id": "1464_5", "text": "Participants who progressed to MCI had more abnormal biomarker levels and greater tau increases prior to MCI symptom onset.", "tags": [{"end": 52, "start": 44, "tag": "Finding"}, {"end": 85, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 53, "tag": "ClinicalAttribute"}, {"end": 34, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 122, "start": 109, "tag": "TemporalConcept"}, {"end": 116, "start": 109, "tag": "SignOrSymptom"}]}{"id": "1464_6", "text": "Biomarkers were more abnormal among older adults, but unrelated to sex or education.", "tags": [{"end": 29, "start": 21, "tag": "Finding"}, {"end": 70, "start": 67, "tag": "OrganismAttribute"}, {"end": 41, "start": 36, "tag": "TemporalConcept"}, {"end": 48, "start": 36, "tag": "PopulationGroup"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 83, "start": 74, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 48, "start": 42, "tag": "PopulationGroup"}]}{"id": "1464_7", "text": "DiscussionOur results confirm accelerated biomarker changes during preclinical AD and highlight the important role of amyloid levels in tau accelerations.", "tags": [{"end": 132, "start": 118, "tag": "ClinicalAttribute"}, {"end": 139, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 42, "tag": "ClinicalAttribute"}, {"end": 125, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 52, "tag": "Finding"}]}{"id": "1465_0", "text": "We aimed to evaluate the specificity of neurogranin (Ng) for Alzheimer's disease (AD) in a dementia cohort.", "tags": [{"end": 55, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 25, "tag": "Finding"}, {"end": 106, "start": 100, "tag": "PopulationGroup"}]}{"id": "1465_1", "text": "Cerebrospinal fluid (CSF) Ng was measured (ELISA) in two independent cohorts: (1) clinical (n = 116; age 72 +/- 11 years): AD, non-AD (+ high T-tau), and controls; and (2) autopsy-confirmed (n = 97; age 71 +/- 11 years): AD and non-AD, and 50 controls (age 60 +/- 6 years).", "tags": [{"end": 28, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 43, "tag": "ResearchActivity"}, {"end": 147, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 221, "tag": "DiseaseOrSyndrome"}, {"end": 234, "start": 232, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 154, "tag": "PopulationGroup"}, {"end": 251, "start": 243, "tag": "PopulationGroup"}, {"end": 76, "start": 69, "tag": "PopulationGroup"}, {"end": 104, "start": 101, "tag": "OrganismAttribute"}, {"end": 202, "start": 199, "tag": "OrganismAttribute"}, {"end": 256, "start": 253, "tag": "OrganismAttribute"}, {"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 218, "start": 213, "tag": "TemporalConcept"}, {"end": 271, "start": 266, "tag": "TemporalConcept"}, {"end": 141, "start": 137, "tag": "Finding"}, {"end": 28, "start": 26, "tag": "ClinicalAttribute"}, {"end": 19, "start": 0, "tag": "ClinicalAttribute"}, {"end": 179, "start": 172, "tag": "HealthCareActivity"}]}{"id": "1465_2", "text": "In 16 autopsy-confirmed AD and 8 control subjects, Ng was measured in tissue (BA6 + BA22).", "tags": [{"end": 81, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 33, "tag": "PopulationGroup"}, {"end": 26, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 6, "tag": "HealthCareActivity"}]}{"id": "1465_3", "text": "Ng was compared across diagnostic groups or neu-ropathological staging using multilinear regression models.", "tags": [{"end": 2, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 63, "tag": "TemporalConcept"}, {"end": 106, "start": 77, "tag": "ResearchActivity"}, {"end": 40, "start": 34, "tag": "PopulationGroup"}, {"end": 33, "start": 23, "tag": "HealthCareActivity"}]}{"id": "1465_4", "text": "Median[IQR] Ng concentrations were elevated in AD (414[315-499]pg/mL) and non-AD (464[319- 699]pg/mL) compared to controls (260[193-306]pg/mL), but highest in AD-high-T-tau (874[716, 1148] pg/mL) and Creutzfeldt-Jakob disease (CJD; 828[703-1373]pg/mL) in cohort 1 ( p < 0.01), but not in co-hort 2: AD: 358[249-470]pg/mL; non-AD:245[137-416]pg/mL; controls: 259[193-370]pg/mL.", "tags": [{"end": 225, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 301, "start": 299, "tag": "DiseaseOrSyndrome"}, {"end": 328, "start": 326, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 114, "tag": "PopulationGroup"}, {"end": 356, "start": 348, "tag": "PopulationGroup"}, {"end": 261, "start": 255, "tag": "PopulationGroup"}, {"end": 166, "start": 162, "tag": "Finding"}, {"end": 29, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1465_5", "text": "Ng and tau biomarkers strongly correlated (r = 0.4-0.9, p < 0.05), except in CJD.", "tags": [{"end": 80, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 2, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 11, "tag": "ClinicalAttribute"}]}{"id": "1465_6", "text": "CSF Ng concentrations were not associated with neuropathological AD hallmarks, nor with tissue Ng concentrations.", "tags": [{"end": 6, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 68, "tag": "Finding"}, {"end": 64, "start": 47, "tag": "Finding"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 0, "tag": "ClinicalAttribute"}, {"end": 112, "start": 88, "tag": "ClinicalAttribute"}]}{"id": "1465_7", "text": "CSF Ng is a general biomarker for synaptic degeneration, strongly correlating with CSF tau, but with-out added value for AD differential diagnosis.", "tags": [{"end": 55, "start": 34, "tag": "CellOrMolecularDysfunction"}, {"end": 6, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 124, "tag": "HealthCareActivity"}, {"end": 90, "start": 83, "tag": "ClinicalAttribute"}, {"end": 90, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 20, "tag": "ClinicalAttribute"}, {"end": 146, "start": 137, "tag": "HealthCareActivity"}, {"end": 6, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1465_8", "text": "(C) 2021 The Authors.", "tags": []}{"id": "1465_9", "text": "Published by Elsevier Inc.", "tags": []}{"id": "1466_0", "text": "Background: Although numerous microRNAs (miRNAs) have been discovered to participate in the progression of Alzheimer's disease (AD), they are still difficult to apply in clinical work.", "tags": [{"end": 39, "start": 30, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 39, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 41, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 47, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 92, "tag": "PathologicFunction"}, {"end": 103, "start": 92, "tag": "TemporalConcept"}]}{"id": "1466_1", "text": "Thus, the identification of novel miRNAs and clarification of their clinical significance are importing for improving the diagnosis and treatment of AD.", "tags": [{"end": 89, "start": 68, "tag": "Finding"}, {"end": 40, "start": 34, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 40, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 136, "tag": "HealthCareActivity"}, {"end": 145, "start": 136, "tag": "ResearchActivity"}, {"end": 131, "start": 122, "tag": "HealthCareActivity"}]}{"id": "1466_2", "text": "The purpose of this study was to analyze the expression of miR-128 and its diagnostic value in patients with AD.", "tags": [{"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 95, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 20, "tag": "ResearchActivity"}, {"end": 66, "start": 59, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 66, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 75, "tag": "Finding"}]}{"id": "1466_3", "text": "Patients and Methods: In this study, 117 AD patients and 106 controls were enrolled, and the demographic data, biochemical parameters and serum miR-128 levels were collected.", "tags": [{"end": 109, "start": 93, "tag": "ResearchActivity"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 61, "tag": "PopulationGroup"}, {"end": 52, "start": 44, "tag": "PatientOrDisabledGroup"}, {"end": 35, "start": 30, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 158, "start": 138, "tag": "ClinicalAttribute"}]}{"id": "1466_4", "text": "These data were then used to build a logistic regression model, and receiver operating characteristic (ROC) curves were drawn to evaluate the diagnostic value of miR-128.", "tags": [{"end": 62, "start": 37, "tag": "ResearchActivity"}, {"end": 106, "start": 103, "tag": "ResearchActivity"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 169, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 162, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 114, "start": 108, "tag": "ResearchActivity"}, {"end": 101, "start": 68, "tag": "ResearchActivity"}, {"end": 158, "start": 142, "tag": "Finding"}]}{"id": "1466_5", "text": "The relationships between miR-128 and inflammatory factors (IL-113/TNF-alpha) were also analyzed from clinical serum data.", "tags": [{"end": 116, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 117, "tag": "ResearchActivity"}, {"end": 17, "start": 4, "tag": "Finding"}, {"end": 33, "start": 26, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 33, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 38, "tag": "BiologicallyActiveSubstance"}]}{"id": "1466_6", "text": "Results: Our study found that miR-128 was significantly upregulated in the serum samples of AD patients compared with controls, and that this upregulation was negatively correlated with Mini-Mental State Examination (MMSE) scores (r = -0.687, P< 0.01).", "tags": [{"end": 154, "start": 142, "tag": "CellFunction"}, {"end": 221, "start": 217, "tag": "HealthCareActivity"}, {"end": 80, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 229, "start": 223, "tag": "Finding"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 118, "tag": "PopulationGroup"}, {"end": 103, "start": 95, "tag": "PatientOrDisabledGroup"}, {"end": 215, "start": 186, "tag": "HealthCareActivity"}, {"end": 18, "start": 13, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 88, "start": 81, "tag": "Substance"}, {"end": 88, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 30, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1466_7", "text": "ROC curve showed that the area under the curve of miR-128 was 0.831.", "tags": [{"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 46, "start": 26, "tag": "ResearchActivity"}, {"end": 57, "start": 50, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 57, "start": 50, "tag": "BiologicallyActiveSubstance"}]}{"id": "1466_8", "text": "Logistic regression analyses showed that glycosylated hemoglobin (HbA1c) levels, low-density lipoprotein (LDL) levels, MMSE scores and serum miR-128 levels were statistically significant (P< 0.01), and the ROC curve of the combined detection of these variables was 0.906.", "tags": [{"end": 64, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 119, "tag": "HealthCareActivity"}, {"end": 130, "start": 124, "tag": "Finding"}, {"end": 28, "start": 0, "tag": "ResearchActivity"}, {"end": 241, "start": 232, "tag": "HealthCareActivity"}, {"end": 155, "start": 135, "tag": "ClinicalAttribute"}, {"end": 104, "start": 81, "tag": "Chemical"}, {"end": 104, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 215, "start": 206, "tag": "ResearchActivity"}]}{"id": "1466_9", "text": "The serum miR-128 levels in AD patients were positively correlated with the serum IL-113 (r=0.798, P<0.01) and serum TNF-alpha levels (r=0.733, P<0.01).", "tags": [{"end": 81, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 117, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 31, "tag": "PatientOrDisabledGroup"}, {"end": 133, "start": 111, "tag": "ClinicalAttribute"}, {"end": 24, "start": 4, "tag": "ClinicalAttribute"}, {"end": 88, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 76, "tag": "ClinicalAttribute"}]}{"id": "1466_10", "text": "Conclusion: Serum miR-128 is a candidate diagnostic biomarker in AD patients who achieved good diagnostic performance when used alone or in combination with other factors and may have the potential to be a novel therapeutic target for neuroinflammation.", "tags": [{"end": 230, "start": 206, "tag": "Finding"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 41, "tag": "ClinicalAttribute"}, {"end": 76, "start": 68, "tag": "PatientOrDisabledGroup"}, {"end": 252, "start": 235, "tag": "PathologicFunction"}, {"end": 117, "start": 95, "tag": "Finding"}, {"end": 25, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1467_0", "text": "IntroductionDespite increasing evidence of a role of rare genetic variation in the risk of Alzheimer's disease (AD), limited attention has been paid to its contribution to AD-related biomarker traits indicative of AD-relevant pathophysiological processes.", "tags": [{"end": 75, "start": 58, "tag": "NaturalPhenomenonOrProcess"}, {"end": 199, "start": 193, "tag": "OrganismAttribute"}, {"end": 254, "start": 226, "tag": "BiologicFunction"}, {"end": 39, "start": 20, "tag": "Finding"}, {"end": 134, "start": 125, "tag": "BiologicFunction"}, {"end": 30, "start": 20, "tag": "Finding"}, {"end": 110, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 214, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 183, "tag": "ClinicalAttribute"}, {"end": 39, "start": 31, "tag": "Finding"}, {"end": 57, "start": 53, "tag": "TemporalConcept"}, {"end": 87, "start": 83, "tag": "Finding"}]}{"id": "1467_1", "text": "MethodsWe performed whole-exome gene-based rare-variant association studies (RVASs) of 17 AD-related traits on whole-exome sequencing (WES) data generated in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study (n = 450) and whole-genome sequencing (WGS) data from ADNI (n = 808).", "tags": [{"end": 107, "start": 101, "tag": "OrganismAttribute"}, {"end": 133, "start": 111, "tag": "ResearchActivity"}, {"end": 138, "start": 135, "tag": "ResearchActivity"}, {"end": 334, "start": 330, "tag": "HealthCareRelatedOrganization"}, {"end": 334, "start": 330, "tag": "ResearchActivity"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 140, "tag": "ResearchActivity"}, {"end": 324, "start": 320, "tag": "ResearchActivity"}, {"end": 75, "start": 20, "tag": "ResearchActivity"}, {"end": 275, "start": 270, "tag": "ResearchActivity"}, {"end": 200, "start": 162, "tag": "HealthCareRelatedOrganization"}, {"end": 255, "start": 205, "tag": "ResearchActivity"}, {"end": 268, "start": 257, "tag": "ResearchActivity"}, {"end": 313, "start": 290, "tag": "ResearchActivity"}, {"end": 82, "start": 77, "tag": "ResearchActivity"}]}{"id": "1467_2", "text": "ResultsMutation screening revealed a novel probably pathogenic mutation (PSEN1 p.Leu232Phe).", "tags": [{"end": 78, "start": 73, "tag": "GeneOrGenome"}, {"end": 78, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 63, "tag": "CellOrMolecularDysfunction"}, {"end": 62, "start": 52, "tag": "PathologicFunction"}, {"end": 25, "start": 7, "tag": "ResearchActivity"}, {"end": 90, "start": 79, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1467_3", "text": "Gene-based RVAS revealed the exome-wide significant contribution of rare coding variation in RBKS and OR7A10 to cognitive performance and protection against left hippocampal atrophy, respectively.", "tags": [{"end": 97, "start": 93, "tag": "GeneOrGenome"}, {"end": 108, "start": 102, "tag": "GeneOrGenome"}, {"end": 181, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 112, "tag": "Finding"}, {"end": 72, "start": 68, "tag": "TemporalConcept"}, {"end": 15, "start": 11, "tag": "ResearchActivity"}]}{"id": "1467_4", "text": "DiscussionThe identification of these novel gene-trait associations offers new perspectives into the role of rare coding variation in the distinct pathophysiological processes culminating in AD, which may lead to identification of novel therapeutic and diagnostic targets.", "tags": [{"end": 175, "start": 147, "tag": "BiologicFunction"}, {"end": 193, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 263, "start": 253, "tag": "HealthCareActivity"}, {"end": 113, "start": 109, "tag": "TemporalConcept"}, {"end": 54, "start": 49, "tag": "OrganismAttribute"}, {"end": 48, "start": 44, "tag": "GeneOrGenome"}, {"end": 271, "start": 231, "tag": "Finding"}]}{"id": "1468_0", "text": "Introduction: Biomarkers that reflect pathologic processes affecting neuronal function during preclinical and early stages of Alzheimer's disease (AD) are needed to aid drug development.", "tags": [{"end": 58, "start": 38, "tag": "PathologicFunction"}, {"end": 122, "start": 110, "tag": "TemporalConcept"}, {"end": 122, "start": 116, "tag": "TemporalConcept"}, {"end": 86, "start": 69, "tag": "CellFunction"}, {"end": 185, "start": 169, "tag": "ResearchActivity"}, {"end": 145, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 174, "tag": "BiologicFunction"}, {"end": 185, "start": 174, "tag": "CellFunction"}, {"end": 24, "start": 14, "tag": "ClinicalAttribute"}, {"end": 173, "start": 169, "tag": "PharmacologicSubstance"}]}{"id": "1468_1", "text": "Methods: A targeted, stable isotope, quantitative mass spectrometry-based investigation of longitudinal changes in concentrations of previously identified candidate biomarkers was performed in cerebrospinal fluid (CSF) of Alzheimer's Disease Neuroimaging Initiative participants who were classified as cognitively normal (CN; n = 76) or with mild cognitive impairment (MCI; n = 111) at baseline.", "tags": [{"end": 35, "start": 21, "tag": "Chemical"}, {"end": 372, "start": 369, "tag": "DiseaseOrSyndrome"}, {"end": 324, "start": 322, "tag": "Finding"}, {"end": 320, "start": 302, "tag": "Finding"}, {"end": 241, "start": 222, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 165, "tag": "ClinicalAttribute"}, {"end": 217, "start": 214, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 207, "tag": "Substance"}, {"end": 87, "start": 74, "tag": "ResearchActivity"}, {"end": 278, "start": 266, "tag": "PopulationGroup"}, {"end": 212, "start": 193, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 367, "start": 347, "tag": "DiseaseOrSyndrome"}, {"end": 367, "start": 342, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 37, "tag": "ResearchActivity"}, {"end": 265, "start": 222, "tag": "ResearchActivity"}]}{"id": "1468_2", "text": "Results: Of the candidate biomarkers, the CSF concentration of neuronal pentraxin 2 (NPTX2), a protein involved in synaptic function, exhibited rates of change that were significantly different between three comparison groups (i.e., CN vs.", "tags": [{"end": 83, "start": 63, "tag": "GeneOrGenome"}, {"end": 83, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 85, "tag": "GeneOrGenome"}, {"end": 90, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 219, "tag": "PopulationGroup"}, {"end": 235, "start": 233, "tag": "Finding"}, {"end": 36, "start": 26, "tag": "ClinicalAttribute"}, {"end": 45, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 218, "start": 208, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 90, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 115, "tag": "CellFunction"}, {"end": 83, "start": 42, "tag": "ClinicalAttribute"}]}{"id": "1468_3", "text": "MCI participants; AD pathology positive vs.", "tags": [{"end": 3, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 21, "tag": "PathologicFunction"}, {"end": 30, "start": 21, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 16, "start": 4, "tag": "PopulationGroup"}]}{"id": "1468_4", "text": "negative defined by phosphorylated tau181/amyloid beta1-42 ratio; and clinical progressors vs.", "tags": [{"end": 58, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 70, "tag": "PopulationGroup"}]}{"id": "1468_5", "text": "non-progressors).", "tags": [{"end": 15, "start": 0, "tag": "PopulationGroup"}]}{"id": "1468_6", "text": "The rate of change of NPTX2 also significantly correlated with declining cognition.", "tags": [{"end": 27, "start": 22, "tag": "GeneOrGenome"}, {"end": 27, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 4, "tag": "TemporalConcept"}, {"end": 82, "start": 73, "tag": "BiologicFunction"}]}{"id": "1468_7", "text": "Discussion: CSF NPTX2 concentration is a strong prognostic biomarker candidate of accelerated cognitive decline with potential use as a therapeutic target.", "tags": [{"end": 21, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 59, "tag": "ClinicalAttribute"}, {"end": 15, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 48, "tag": "ClinicalAttribute"}, {"end": 111, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 136, "tag": "Finding"}, {"end": 35, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1469_0", "text": "Introduction: Brain cells secrete extracellular microvesicles (EVs) that cross the blood-brain barrier.", "tags": [{"end": 25, "start": 14, "tag": "Cell"}, {"end": 61, "start": 34, "tag": "CellComponent"}, {"end": 94, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 63, "tag": "CellComponent"}, {"end": 102, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1469_1", "text": "Involved in cell-to-cell communication, EVs contain surface markers and a biologically active cargo of molecules specific to their tissue (and cell) of origin, reflecting the tissue or cell's physiological state.", "tags": [{"end": 147, "start": 143, "tag": "Cell"}, {"end": 112, "start": 103, "tag": "Substance"}, {"end": 158, "start": 152, "tag": "TemporalConcept"}, {"end": 43, "start": 40, "tag": "CellComponent"}, {"end": 99, "start": 74, "tag": "CellFunction"}, {"end": 137, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 181, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 12, "tag": "CellFunction"}]}{"id": "1469_2", "text": "Isolation of brain-secreted EVs (BEVs) from blood provides a minimally invasive way to sample components of brain tissue in Alzheimer's disease (AD), and is considered a form of liquid biopsy.", "tags": [{"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 83, "start": 61, "tag": "Finding"}, {"end": 191, "start": 178, "tag": "HealthCareActivity"}, {"end": 104, "start": 94, "tag": "CellComponent"}, {"end": 120, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "CellComponent"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 33, "tag": "CellComponent"}, {"end": 31, "start": 13, "tag": "CellComponent"}]}{"id": "1469_3", "text": "Methods: We performed a comprehensive review of the PubMed literature to assess the biomarker and therapeutic potential of blood-isolated BEVs in AD.", "tags": [{"end": 69, "start": 59, "tag": "ResearchActivity"}, {"end": 119, "start": 98, "tag": "HealthCareActivity"}, {"end": 58, "start": 52, "tag": "HealthCareRelatedOrganization"}, {"end": 44, "start": 38, "tag": "ResearchActivity"}, {"end": 44, "start": 38, "tag": "HealthCareActivity"}, {"end": 148, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 84, "tag": "ClinicalAttribute"}, {"end": 142, "start": 138, "tag": "CellComponent"}]}{"id": "1469_4", "text": "Results: We summarize methods used for BEV isolation, validation, and novel biomarker discovery, as well as provide insights from 26 studies in humans on the biomarker potential in AD of four cell-specific BEVs isolated from blood: neuron-, neural precursor-, astrocyte-, and brain vasculature-derived BEVs.", "tags": [{"end": 52, "start": 43, "tag": "ResearchActivity"}, {"end": 64, "start": 54, "tag": "ResearchActivity"}, {"end": 238, "start": 232, "tag": "Cell"}, {"end": 269, "start": 260, "tag": "Cell"}, {"end": 150, "start": 144, "tag": "Eukaryote"}, {"end": 281, "start": 276, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 86, "tag": "ResearchActivity"}, {"end": 140, "start": 133, "tag": "ResearchActivity"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 225, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 76, "tag": "ClinicalAttribute"}, {"end": 167, "start": 158, "tag": "ClinicalAttribute"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 85, "start": 70, "tag": "ClinicalAttribute"}, {"end": 52, "start": 43, "tag": "HealthCareActivity"}, {"end": 210, "start": 206, "tag": "CellComponent"}, {"end": 293, "start": 282, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 306, "start": 302, "tag": "CellComponent"}, {"end": 257, "start": 241, "tag": "Cell"}]}{"id": "1469_5", "text": "Of these, neuron-derived BEVs has been investigated on several fronts, and these include levels of amyloid-beta and tau proteins, as well as synaptic proteins.", "tags": [{"end": 128, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 10, "tag": "Cell"}, {"end": 119, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 10, "tag": "CellComponent"}, {"end": 111, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 116, "tag": "BiologicallyActiveSubstance"}]}{"id": "1469_6", "text": "In addition, we provide a synopsis of the current landscape of BEV-based evaluation/monitoring of AD therapeutics based on two published trials and a review of registered clinical trials.", "tags": [{"end": 83, "start": 73, "tag": "HealthCareActivity"}, {"end": 83, "start": 73, "tag": "ResearchActivity"}, {"end": 113, "start": 101, "tag": "HealthCareActivity"}, {"end": 156, "start": 150, "tag": "ResearchActivity"}, {"end": 156, "start": 150, "tag": "HealthCareActivity"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 171, "tag": "ResearchActivity"}, {"end": 94, "start": 84, "tag": "HealthCareActivity"}, {"end": 49, "start": 42, "tag": "TemporalConcept"}, {"end": 66, "start": 63, "tag": "CellComponent"}, {"end": 143, "start": 127, "tag": "ResearchActivity"}]}{"id": "1469_7", "text": "Discussion: Blood-isolated BEVs have emerged as a novel player in the study of AD, with enormous potential as a diagnostic, evaluation of therapeutics, and treatment tool.", "tags": [{"end": 122, "start": 112, "tag": "HealthCareActivity"}, {"end": 134, "start": 124, "tag": "HealthCareActivity"}, {"end": 134, "start": 124, "tag": "ResearchActivity"}, {"end": 150, "start": 138, "tag": "HealthCareActivity"}, {"end": 75, "start": 70, "tag": "ResearchActivity"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 156, "tag": "HealthCareActivity"}, {"end": 165, "start": 156, "tag": "ResearchActivity"}, {"end": 17, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 12, "tag": "CellComponent"}]}{"id": "1469_8", "text": "The literature has largely concentrated on neuron-derived BEVs in the blood in AD.", "tags": [{"end": 49, "start": 43, "tag": "Cell"}, {"end": 14, "start": 4, "tag": "ResearchActivity"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 43, "tag": "CellComponent"}]}{"id": "1469_9", "text": "Given the multifactorial pathophysiology of AD, additional studies, in neuron-derived and other brain cell-specific BEVs are warranted to establish BEVs as a robust blood-based biomarker of AD.", "tags": [{"end": 24, "start": 10, "tag": "Finding"}, {"end": 77, "start": 71, "tag": "Cell"}, {"end": 106, "start": 96, "tag": "Cell"}, {"end": 66, "start": 59, "tag": "ResearchActivity"}, {"end": 46, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 177, "tag": "ClinicalAttribute"}, {"end": 40, "start": 25, "tag": "PathologicFunction"}, {"end": 40, "start": 25, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 120, "start": 116, "tag": "CellComponent"}, {"end": 152, "start": 148, "tag": "CellComponent"}]}{"id": "1470_0", "text": "Exosomes are small extracellular vesicles (EVs) present in human biofluids that can transport specific disease-associated molecules.", "tags": [{"end": 93, "start": 84, "tag": "CellFunction"}, {"end": 131, "start": 122, "tag": "Substance"}, {"end": 8, "start": 0, "tag": "CellComponent"}, {"end": 41, "start": 19, "tag": "CellComponent"}, {"end": 46, "start": 43, "tag": "CellComponent"}, {"end": 41, "start": 13, "tag": "CellComponent"}, {"end": 64, "start": 59, "tag": "Eukaryote"}, {"end": 74, "start": 65, "tag": "Substance"}]}{"id": "1470_1", "text": "Consequently blood-derived exosomes have emerged as important peripheral biomarker sources for a wide range of diseases, among them Alzheimer's disease (AD).", "tags": [{"end": 90, "start": 83, "tag": "Finding"}, {"end": 35, "start": 27, "tag": "CellComponent"}, {"end": 151, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 73, "tag": "ClinicalAttribute"}, {"end": 72, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1470_2", "text": "Although there is no effective cure for AD, an accurate diagnosis, relying on easily accessible peripheral biofluids, is still necessary to discriminate this disease from other dementias, test potential therapies and even monitor rate of disease progression.", "tags": [{"end": 186, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 222, "tag": "HealthCareActivity"}, {"end": 229, "start": 222, "tag": "ManufacturedObject"}, {"end": 35, "start": 31, "tag": "Finding"}, {"end": 35, "start": 31, "tag": "ResearchActivity"}, {"end": 234, "start": 230, "tag": "TemporalConcept"}, {"end": 257, "start": 246, "tag": "PathologicFunction"}, {"end": 257, "start": 246, "tag": "TemporalConcept"}, {"end": 65, "start": 56, "tag": "HealthCareActivity"}, {"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 203, "tag": "HealthCareActivity"}, {"end": 106, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 257, "start": 238, "tag": "PathologicFunction"}]}{"id": "1470_3", "text": "The ultimate goal is to produce a cost-effective and widely available alternative, which can also be employed as a first clinical screen.", "tags": [{"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 136, "start": 121, "tag": "HealthCareActivity"}]}{"id": "1470_4", "text": "In this study, EVs with exosome-like characteristics were isolated from serum of Controls and AD cases through precipitation- and column-based methods, followed by mass spectrometry analysis.", "tags": [{"end": 181, "start": 164, "tag": "ResearchActivity"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 18, "start": 15, "tag": "CellComponent"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 182, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 24, "tag": "CellComponent"}, {"end": 102, "start": 94, "tag": "PatientOrDisabledGroup"}, {"end": 89, "start": 81, "tag": "PopulationGroup"}, {"end": 150, "start": 130, "tag": "ResearchActivity"}, {"end": 150, "start": 137, "tag": "ResearchActivity"}, {"end": 125, "start": 111, "tag": "ResearchActivity"}]}{"id": "1470_5", "text": "The resulting proteomes were characterized by Gene Ontology (GO) and multivariate analyses.", "tags": [{"end": 23, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 46, "tag": "ResearchActivity"}, {"end": 63, "start": 61, "tag": "ResearchActivity"}, {"end": 90, "start": 69, "tag": "ResearchActivity"}]}{"id": "1470_6", "text": "Although GO terms were similar for exosomes' proteomes of Controls and ADs, using both methodologies, a clear segregation of disease cases was obtained when using the precipitation-based method.", "tags": [{"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 54, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 167, "tag": "ResearchActivity"}, {"end": 43, "start": 35, "tag": "CellComponent"}, {"end": 66, "start": 58, "tag": "PopulationGroup"}]}{"id": "1470_7", "text": "Nine significantly different abundant proteins were identified between Controls and AD cases, representing putative biomarker candidate targets.", "tags": [{"end": 46, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 116, "tag": "ClinicalAttribute"}]}{"id": "1470_8", "text": "Among them are AACT and C4BP alpha, two A beta-binding proteins, whose exosome levels were further validated in individuals from independent cohorts using antibody-based approaches.", "tags": [{"end": 19, "start": 15, "tag": "GeneOrGenome"}, {"end": 78, "start": 71, "tag": "CellComponent"}, {"end": 54, "start": 47, "tag": "CellFunction"}, {"end": 63, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 141, "tag": "PopulationGroup"}, {"end": 123, "start": 112, "tag": "PopulationGroup"}, {"end": 46, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 24, "tag": "GeneOrGenome"}, {"end": 19, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 155, "tag": "ResearchActivity"}]}{"id": "1470_9", "text": "The findings discussed represent an important contribution to the identification of novel exosomal biomarker candidates useful as potential blood-based tools for AD diagnosis.", "tags": [{"end": 174, "start": 165, "tag": "HealthCareActivity"}, {"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 90, "tag": "ClinicalAttribute"}]}{"id": "1471_0", "text": "Random Forest (RF) is a bagging ensemble model and has many important advantages, such as robustness to noise, an effective structure for complex multimodal data and parallel computing, and also provides important features that help investigate biomarkers.", "tags": [{"end": 255, "start": 245, "tag": "ClinicalAttribute"}, {"end": 161, "start": 146, "tag": "ResearchActivity"}, {"end": 46, "start": 41, "tag": "ResearchActivity"}, {"end": 13, "start": 0, "tag": "MachineActivity"}, {"end": 17, "start": 15, "tag": "MachineActivity"}]}{"id": "1471_1", "text": "Despite these benefits, RF is not used actively to predict Alzheimer's disease (AD) with brain MRIs.", "tags": [{"end": 94, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 95, "tag": "ManufacturedObject"}, {"end": 99, "start": 95, "tag": "HealthCareActivity"}, {"end": 26, "start": 24, "tag": "MachineActivity"}]}{"id": "1471_2", "text": "Recent studies have reported RF's effectiveness in predicting AD, but the test sample sizes were too small to draw any solid conclusions.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 47, "start": 34, "tag": "Finding"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 29, "tag": "MachineActivity"}, {"end": 85, "start": 79, "tag": "Substance"}, {"end": 85, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 86, "tag": "OrganismAttribute"}]}{"id": "1471_3", "text": "Thus, it is timely to compare RF with other learning model methods, including deep learning, particularly with large amounts of data.", "tags": [{"end": 91, "start": 78, "tag": "MachineActivity"}, {"end": 132, "start": 128, "tag": "ResearchActivity"}, {"end": 66, "start": 53, "tag": "ResearchActivity"}, {"end": 52, "start": 44, "tag": "BiologicFunction"}, {"end": 91, "start": 83, "tag": "BiologicFunction"}, {"end": 32, "start": 30, "tag": "MachineActivity"}]}{"id": "1471_4", "text": "In this study, we tested RF and various machine learning models with regional volumes from 2250 brain MRIs: 687 normal controls (NC), 1094 mild cognitive impairment (MCI), and 469 AD that ADNI (Alzheimer's Disease Neuroimaging Initiative database) provided.", "tags": [{"end": 169, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 246, "start": 194, "tag": "ResearchActivity"}, {"end": 118, "start": 112, "tag": "Finding"}, {"end": 213, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 40, "tag": "MachineActivity"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 101, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 119, "tag": "PopulationGroup"}, {"end": 164, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 48, "tag": "BiologicFunction"}, {"end": 63, "start": 57, "tag": "ResearchActivity"}, {"end": 164, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 25, "tag": "MachineActivity"}, {"end": 106, "start": 102, "tag": "ManufacturedObject"}, {"end": 106, "start": 102, "tag": "HealthCareActivity"}]}{"id": "1471_5", "text": "Three types of features sets (63, 29, and 22 features) were selected, and classification accuracies were computed with RF, Support vector machine (SVM), Multi-layer perceptron (MLP), and Convolutional neural network (CNN).", "tags": [{"end": 121, "start": 119, "tag": "MachineActivity"}, {"end": 145, "start": 123, "tag": "MachineActivity"}, {"end": 150, "start": 147, "tag": "MachineActivity"}, {"end": 175, "start": 153, "tag": "MachineActivity"}, {"end": 180, "start": 177, "tag": "MachineActivity"}, {"end": 215, "start": 187, "tag": "MachineActivity"}, {"end": 220, "start": 217, "tag": "MachineActivity"}]}{"id": "1471_6", "text": "As a result, RF, MLP, and CNN showed high performances of 90.2%, 89.6%, and 90.5% with 63 features.", "tags": [{"end": 11, "start": 5, "tag": "Finding"}, {"end": 54, "start": 42, "tag": "IndividualBehavior"}, {"end": 15, "start": 13, "tag": "MachineActivity"}, {"end": 20, "start": 17, "tag": "MachineActivity"}, {"end": 29, "start": 26, "tag": "MachineActivity"}]}{"id": "1471_7", "text": "Interestingly, when 22 features were used, RF showed the smallest decrease in accuracy, -3.8%, and the standard deviation did not change significantly, while MLP and CNN yielded decreases in accuracy of -6.8% and -4.5% with changes in the standard deviation from 3.3% to 4.0% for MLP and 2.1% to 7.0% for CNN, indicating that RF predicts AD more reliably with fewer features.", "tags": [{"end": 340, "start": 338, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 43, "tag": "MachineActivity"}, {"end": 328, "start": 326, "tag": "MachineActivity"}, {"end": 283, "start": 280, "tag": "MachineActivity"}, {"end": 308, "start": 305, "tag": "MachineActivity"}, {"end": 86, "start": 78, "tag": "Finding"}, {"end": 121, "start": 103, "tag": "ResearchActivity"}, {"end": 161, "start": 158, "tag": "MachineActivity"}, {"end": 169, "start": 166, "tag": "MachineActivity"}, {"end": 199, "start": 191, "tag": "Finding"}, {"end": 257, "start": 239, "tag": "ResearchActivity"}]}{"id": "1471_8", "text": "In addition, we investigated the importance of the features that RF provides, and identified the hippocampus, amygdala, and inferior lateral ventricle as the major contributors in classifying NC, MCI, and AD.", "tags": [{"end": 118, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 199, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 65, "tag": "MachineActivity"}, {"end": 150, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 194, "start": 192, "tag": "PopulationGroup"}]}{"id": "1471_9", "text": "On average, AD showed smaller hippocampus and amygdala volumes and a larger volume of inferior lateral ventricle than those of MCI and NC.", "tags": [{"end": 54, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 135, "tag": "PopulationGroup"}, {"end": 61, "start": 46, "tag": "ClinicalAttribute"}, {"end": 61, "start": 55, "tag": "ClinicalAttribute"}, {"end": 41, "start": 30, "tag": "ClinicalAttribute"}, {"end": 112, "start": 76, "tag": "ClinicalAttribute"}]}{"id": "1472_0", "text": "IntroductionAlthough many lesion-based MRI biomarkers in multiple sclerosis (MS) patients were investigated, none of the previous studies dealt with the signal intensity variations (SIVs) of MS lesions.", "tags": [{"end": 137, "start": 130, "tag": "ResearchActivity"}, {"end": 53, "start": 43, "tag": "ClinicalAttribute"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 39, "tag": "HealthCareActivity"}, {"end": 201, "start": 194, "tag": "InjuryOrPoisoning"}, {"end": 32, "start": 26, "tag": "InjuryOrPoisoning"}, {"end": 180, "start": 153, "tag": "ResearchActivity"}, {"end": 186, "start": 182, "tag": "ResearchActivity"}]}{"id": "1472_1", "text": "In this study, the SIVs of MS lesions on direct myelin imaging and standard clinical sequences as possible MRI biomarkers for disability in MS patients were assessed.", "tags": [{"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 121, "start": 111, "tag": "ClinicalAttribute"}, {"end": 151, "start": 143, "tag": "PatientOrDisabledGroup"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 107, "tag": "HealthCareActivity"}, {"end": 37, "start": 30, "tag": "InjuryOrPoisoning"}, {"end": 62, "start": 55, "tag": "HealthCareActivity"}, {"end": 54, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 48, "tag": "CellComponent"}, {"end": 136, "start": 126, "tag": "Finding"}, {"end": 23, "start": 19, "tag": "ResearchActivity"}]}{"id": "1472_2", "text": "MethodsTwenty seven MS patients were included in this prospective study.", "tags": [{"end": 71, "start": 54, "tag": "ResearchActivity"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}]}{"id": "1472_3", "text": "IR-UTE, FLAIR, and MPRAGE sequences were employed on a 3T scanner.", "tags": [{"end": 13, "start": 8, "tag": "Chemical"}, {"end": 13, "start": 8, "tag": "HealthCareActivity"}, {"end": 6, "start": 0, "tag": "HealthCareActivity"}, {"end": 35, "start": 19, "tag": "HealthCareActivity"}, {"end": 65, "start": 55, "tag": "HealthCareActivity"}, {"end": 65, "start": 55, "tag": "ManufacturedObject"}]}{"id": "1472_4", "text": "Regions of interest (ROIs) were manually drawn within the MS lesions, and the cerebrospinal fluid (CSF) and signal intensity ratios (SIR) were calculated from the derived values.", "tags": [{"end": 102, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 92, "tag": "Substance"}, {"end": 68, "start": 61, "tag": "InjuryOrPoisoning"}, {"end": 97, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 0, "tag": "ResearchActivity"}, {"end": 131, "start": 108, "tag": "ResearchActivity"}, {"end": 25, "start": 21, "tag": "ResearchActivity"}]}{"id": "1472_5", "text": "Variations coefficients were determined from the standard deviations (Coeff 1) and the absolute differences (Coeff 2) of the SIRs.", "tags": [{"end": 129, "start": 125, "tag": "ResearchActivity"}, {"end": 23, "start": 0, "tag": "ResearchActivity"}, {"end": 68, "start": 49, "tag": "ResearchActivity"}, {"end": 107, "start": 87, "tag": "ResearchActivity"}]}{"id": "1472_6", "text": "Disability grade was assessed by the expanded disability status scale (EDSS).", "tags": [{"end": 56, "start": 46, "tag": "Finding"}, {"end": 69, "start": 37, "tag": "HealthCareActivity"}, {"end": 75, "start": 71, "tag": "HealthCareActivity"}, {"end": 16, "start": 0, "tag": "Finding"}]}{"id": "1472_7", "text": "Cortical/gray matter, subcortical, infratentorial, and spinal lesions were excluded.", "tags": [{"end": 49, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 62, "tag": "InjuryOrPoisoning"}, {"end": 8, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1472_8", "text": "ResultsThe mean diameter of the lesions was 7.8 +/- 1.97 mm, while the mean EDSS score was 4.5 +/- 1.73.", "tags": [{"end": 39, "start": 32, "tag": "InjuryOrPoisoning"}, {"end": 80, "start": 76, "tag": "HealthCareActivity"}, {"end": 86, "start": 76, "tag": "HealthCareActivity"}]}{"id": "1472_9", "text": "We found moderate correlations between the EDSS and Coeff 1 and 2 on IR-UTE and MPRAGE images.", "tags": [{"end": 93, "start": 80, "tag": "HealthCareActivity"}, {"end": 17, "start": 9, "tag": "Finding"}, {"end": 30, "start": 18, "tag": "ResearchActivity"}, {"end": 47, "start": 43, "tag": "HealthCareActivity"}, {"end": 75, "start": 69, "tag": "HealthCareActivity"}]}{"id": "1472_10", "text": "Accordingly, Pearson's correlations on IR-UTE were R = 0.51 (p = 0.007) and R = 0.49 (p = 0.01) for Coeff 1 and 2, respectively.", "tags": [{"end": 35, "start": 13, "tag": "ResearchActivity"}, {"end": 45, "start": 39, "tag": "HealthCareActivity"}]}{"id": "1472_11", "text": "For MPRAGE, Pearson's correlations were R = 0.5 (p = 0.008) and R = 0.48 (p = 0.012) for Coeff 1 and 2, respectively.", "tags": [{"end": 10, "start": 4, "tag": "HealthCareActivity"}, {"end": 34, "start": 12, "tag": "ResearchActivity"}]}{"id": "1472_12", "text": "For FLAIR, only poor correlations could be found.", "tags": [{"end": 9, "start": 4, "tag": "Chemical"}, {"end": 9, "start": 4, "tag": "HealthCareActivity"}, {"end": 33, "start": 21, "tag": "ResearchActivity"}]}{"id": "1472_13", "text": "ConclusionThe SIVs of MS lesions on IR-UTE and MPRAGE images, assessed by Coeff 1 and 2, could be used as novel potential MRI biomarkers for patients' disability.", "tags": [{"end": 60, "start": 47, "tag": "HealthCareActivity"}, {"end": 136, "start": 126, "tag": "ClinicalAttribute"}, {"end": 149, "start": 141, "tag": "PatientOrDisabledGroup"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 122, "tag": "HealthCareActivity"}, {"end": 32, "start": 25, "tag": "InjuryOrPoisoning"}, {"end": 161, "start": 151, "tag": "Finding"}, {"end": 18, "start": 14, "tag": "ResearchActivity"}, {"end": 42, "start": 36, "tag": "HealthCareActivity"}]}{"id": "1473_0", "text": "BackgroundSpatial navigation impairment is a promising cognitive marker of Alzheimer's disease (AD) that can reflect the underlying pathology.", "tags": [{"end": 94, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 132, "tag": "PathologicFunction"}, {"end": 141, "start": 132, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 71, "start": 65, "tag": "ClinicalAttribute"}, {"end": 39, "start": 10, "tag": "SignOrSymptom"}, {"end": 28, "start": 10, "tag": "BiologicFunction"}]}{"id": "1473_1", "text": "ObjectivesWe assessed spatial navigation performance in AD biomarker positive older adults with amnestic mild cognitive impairment (AD aMCI) vs.", "tags": [{"end": 90, "start": 78, "tag": "PopulationGroup"}, {"end": 52, "start": 22, "tag": "ClinicalAttribute"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 59, "tag": "ClinicalAttribute"}, {"end": 83, "start": 78, "tag": "TemporalConcept"}, {"end": 90, "start": 84, "tag": "PopulationGroup"}, {"end": 130, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 22, "tag": "BiologicFunction"}]}{"id": "1473_2", "text": "those AD biomarker negative (non-AD aMCI), and examined associations between navigation performance, MRI measures of brain atrophy, and cerebrospinal fluid (CSF) biomarkers.", "tags": [{"end": 99, "start": 77, "tag": "ClinicalAttribute"}, {"end": 130, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 162, "tag": "ClinicalAttribute"}, {"end": 8, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 9, "tag": "ClinicalAttribute"}, {"end": 160, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 150, "tag": "Substance"}, {"end": 104, "start": 101, "tag": "HealthCareActivity"}, {"end": 155, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1473_3", "text": "MethodsA total of 122 participants with AD aMCI (n = 33), non-AD aMCI (n = 31), mild AD dementia (n = 28), and 30 cognitively normal older adults (CN) underwent cognitive assessment, brain MRI (n = 100 had high-quality images for volumetric analysis) and three virtual navigation tasks focused on route learning (body-centered navigation), wayfinding (world-centered navigation) and perspective taking/wayfinding.", "tags": [{"end": 84, "start": 80, "tag": "Finding"}, {"end": 181, "start": 161, "tag": "HealthCareActivity"}, {"end": 192, "start": 183, "tag": "HealthCareActivity"}, {"end": 249, "start": 230, "tag": "ResearchActivity"}, {"end": 285, "start": 261, "tag": "HealthCareActivity"}, {"end": 401, "start": 383, "tag": "BiologicFunction"}, {"end": 145, "start": 133, "tag": "PopulationGroup"}, {"end": 149, "start": 147, "tag": "Finding"}, {"end": 132, "start": 126, "tag": "Finding"}, {"end": 317, "start": 313, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 206, "tag": "ResearchActivity"}, {"end": 192, "start": 189, "tag": "HealthCareActivity"}, {"end": 138, "start": 133, "tag": "TemporalConcept"}, {"end": 34, "start": 22, "tag": "PopulationGroup"}, {"end": 145, "start": 139, "tag": "PopulationGroup"}, {"end": 311, "start": 297, "tag": "BiologicFunction"}, {"end": 337, "start": 313, "tag": "BiologicFunction"}, {"end": 350, "start": 340, "tag": "BiologicFunction"}, {"end": 377, "start": 352, "tag": "BiologicFunction"}, {"end": 412, "start": 402, "tag": "BiologicFunction"}]}{"id": "1473_4", "text": "Cognitively impaired participants underwent CSF biomarker assessment [amyloid-beta(1-42), total tau, and phosphorylated tau(181) (p-tau(181))] and amyloid PET imaging (n = 47 and n = 45, respectively), with a subset having both (n = 19).", "tags": [{"end": 158, "start": 155, "tag": "HealthCareActivity"}, {"end": 166, "start": 155, "tag": "HealthCareActivity"}, {"end": 99, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 48, "tag": "ClinicalAttribute"}, {"end": 88, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 159, "tag": "HealthCareActivity"}, {"end": 33, "start": 21, "tag": "PopulationGroup"}, {"end": 154, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 130, "tag": "BiologicallyActiveSubstance"}]}{"id": "1473_5", "text": "ResultsIn route learning, AD aMCI performed worse than non-AD aMCI (p < 0.001), who performed similarly to CN.", "tags": [{"end": 33, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 10, "tag": "BiologicFunction"}]}{"id": "1473_6", "text": "In wayfinding, aMCI participants performed worse than CN (both p <= 0.009) and AD aMCI performed worse than non-AD aMCI in the second task session (p = 0.032).", "tags": [{"end": 86, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 20, "tag": "PopulationGroup"}, {"end": 13, "start": 3, "tag": "BiologicFunction"}, {"end": 19, "start": 15, "tag": "DiseaseOrSyndrome"}]}{"id": "1473_7", "text": "In perspective taking/wayfinding, aMCI participants performed worse than CN (both p <= 0.001).", "tags": [{"end": 21, "start": 3, "tag": "BiologicFunction"}, {"end": 51, "start": 39, "tag": "PopulationGroup"}, {"end": 32, "start": 22, "tag": "BiologicFunction"}, {"end": 38, "start": 34, "tag": "DiseaseOrSyndrome"}]}{"id": "1473_8", "text": "AD aMCI and non-AD aMCI did not differ in conventional cognitive tests.", "tags": [{"end": 70, "start": 42, "tag": "HealthCareActivity"}, {"end": 70, "start": 42, "tag": "ResearchActivity"}, {"end": 70, "start": 65, "tag": "ResearchActivity"}, {"end": 70, "start": 65, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 16, "tag": "DiseaseOrSyndrome"}]}{"id": "1473_9", "text": "Route learning was associated with parietal thickness and amyloid-beta(1-42), wayfinding was associated with posterior medial temporal lobe (MTL) volume and p-tau(181) and perspective taking/wayfinding was correlated with MRI measures of several brain regions and all CSF biomarkers.", "tags": [{"end": 144, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 172, "tag": "BiologicFunction"}, {"end": 53, "start": 35, "tag": "ClinicalAttribute"}, {"end": 259, "start": 246, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 282, "start": 272, "tag": "ClinicalAttribute"}, {"end": 76, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 271, "start": 268, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 225, "start": 222, "tag": "HealthCareActivity"}, {"end": 76, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 167, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 0, "tag": "BiologicFunction"}, {"end": 88, "start": 78, "tag": "BiologicFunction"}, {"end": 139, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 191, "tag": "BiologicFunction"}, {"end": 152, "start": 146, "tag": "ClinicalAttribute"}, {"end": 139, "start": 109, "tag": "ClinicalAttribute"}]}{"id": "1473_10", "text": "ConclusionAD biomarker positive and negative older adults with aMCI had different profiles of spatial navigation deficits that were associated with posterior MTL and parietal atrophy and reflected AD pathology.", "tags": [{"end": 161, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 166, "tag": "AnatomicalAbnormality"}, {"end": 57, "start": 45, "tag": "PopulationGroup"}, {"end": 90, "start": 82, "tag": "ResearchActivity"}, {"end": 199, "start": 197, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 13, "tag": "ClinicalAttribute"}, {"end": 209, "start": 200, "tag": "PathologicFunction"}, {"end": 209, "start": 200, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 50, "start": 45, "tag": "TemporalConcept"}, {"end": 57, "start": 51, "tag": "PopulationGroup"}, {"end": 67, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 94, "tag": "BiologicFunction"}, {"end": 121, "start": 94, "tag": "SignOrSymptom"}]}{"id": "1474_0", "text": "Background: Retinal thickness can be measured non-invasively with optical coherence tomography (OCT) and may offer compelling potential as a biomarker for Alzheimer's disease (AD).", "tags": [{"end": 19, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 12, "tag": "ClinicalAttribute"}, {"end": 94, "start": 66, "tag": "HealthCareActivity"}, {"end": 99, "start": 96, "tag": "HealthCareActivity"}, {"end": 174, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 141, "tag": "ClinicalAttribute"}]}{"id": "1474_1", "text": "Retinal thinning is hypothesized to be a result of retrograde atrophy and/or parallel neurodegenerative processes.", "tags": [{"end": 7, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 41, "tag": "Finding"}, {"end": 69, "start": 52, "tag": "PathologicFunction"}, {"end": 16, "start": 0, "tag": "Finding"}]}{"id": "1474_2", "text": "Changes in the visual pathway are of particular interest in posterior cortical atrophy (PCA), the most common atypical AD phenotype predominantly affecting the parietal-occipital cortices.", "tags": [{"end": 29, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 110, "tag": "Finding"}, {"end": 131, "start": 122, "tag": "OrganismAttribute"}, {"end": 91, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 0, "tag": "Finding"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 187, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 88, "tag": "ResearchActivity"}]}{"id": "1474_3", "text": "We therefore evaluated retinal thickness as non-invasive biomarker of neurodegeneration in well-characterized participants with posterior cortical atrophy (PCA) and typical Alzheimer's disease (tAD).", "tags": [{"end": 154, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 156, "tag": "ResearchActivity"}, {"end": 87, "start": 70, "tag": "CellOrMolecularDysfunction"}, {"end": 192, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 57, "tag": "ClinicalAttribute"}, {"end": 122, "start": 110, "tag": "PopulationGroup"}, {"end": 30, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 44, "tag": "ClinicalAttribute"}, {"end": 159, "start": 156, "tag": "DiseaseOrSyndrome"}]}{"id": "1474_4", "text": "Methods: Retinal thickness measures were acquired from 48 patient participants (N = 25 PCA; N = 23 tAD) fulfilling consensus diagnostic criteria and 70 age-matched controls.", "tags": [{"end": 16, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 87, "tag": "ResearchActivity"}, {"end": 155, "start": 152, "tag": "OrganismAttribute"}, {"end": 172, "start": 164, "tag": "PopulationGroup"}, {"end": 144, "start": 125, "tag": "HealthCareActivity"}, {"end": 78, "start": 58, "tag": "PatientOrDisabledGroup"}, {"end": 35, "start": 9, "tag": "ClinicalAttribute"}, {"end": 90, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 99, "tag": "DiseaseOrSyndrome"}]}{"id": "1474_5", "text": "Participants were recruited between 2014 and 2016.", "tags": [{"end": 12, "start": 0, "tag": "PopulationGroup"}]}{"id": "1474_6", "text": "All participants underwent optical coherence tomography (OCT) imaging, including measurement of peripapillary retinal nerve fiber layer (pRNFL) thickness and total macular thickness (mRT).", "tags": [{"end": 142, "start": 137, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 181, "start": 164, "tag": "ClinicalAttribute"}, {"end": 181, "start": 164, "tag": "SignOrSymptom"}, {"end": 135, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 181, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 27, "tag": "HealthCareActivity"}, {"end": 60, "start": 57, "tag": "HealthCareActivity"}, {"end": 92, "start": 81, "tag": "ResearchActivity"}, {"end": 92, "start": 81, "tag": "HealthCareActivity"}, {"end": 16, "start": 4, "tag": "PopulationGroup"}, {"end": 69, "start": 62, "tag": "HealthCareActivity"}, {"end": 117, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1474_7", "text": "Participants did not show evidence of any significant ophthalmological conditions.", "tags": [{"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 34, "start": 26, "tag": "Finding"}, {"end": 81, "start": 54, "tag": "DiseaseOrSyndrome"}]}{"id": "1474_8", "text": "Subgroup analyses were performed in participants with available MRI and CSF measures, providing evidence of neurodegeneration and underlying AD pathology respectively.", "tags": [{"end": 125, "start": 108, "tag": "CellOrMolecularDysfunction"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 144, "tag": "PathologicFunction"}, {"end": 153, "start": 144, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 36, "tag": "PopulationGroup"}, {"end": 67, "start": 64, "tag": "HealthCareActivity"}, {"end": 104, "start": 96, "tag": "Finding"}, {"end": 17, "start": 0, "tag": "ResearchActivity"}]}{"id": "1474_9", "text": "Results: There was no evidence of overall between-group differences in pRNFL thickness (mean PCA 98.7 +/- 12.2; tAD 99.9 +/- 8.7; controls 99.6 +/- 10.0 mu m, one-way analysis of variance (ANOVA) p = 0.92) or total mRT (mean PCA 266.9 +/- 16.3; tAD 267.8 +/- 13.6; controls 269.3 +/- 13.6 mu m, one-way ANOVA p = 0.75).", "tags": [{"end": 76, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 93, "tag": "ResearchActivity"}, {"end": 228, "start": 225, "tag": "ResearchActivity"}, {"end": 67, "start": 50, "tag": "Finding"}, {"end": 67, "start": 56, "tag": "Finding"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 138, "start": 130, "tag": "PopulationGroup"}, {"end": 273, "start": 265, "tag": "PopulationGroup"}, {"end": 55, "start": 50, "tag": "PopulationGroup"}, {"end": 187, "start": 159, "tag": "ResearchActivity"}, {"end": 30, "start": 22, "tag": "Finding"}, {"end": 86, "start": 71, "tag": "ClinicalAttribute"}, {"end": 96, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 189, "tag": "ResearchActivity"}, {"end": 228, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 245, "tag": "DiseaseOrSyndrome"}, {"end": 308, "start": 295, "tag": "ResearchActivity"}]}{"id": "1474_10", "text": "Similarly, subgroup analysis with MRI biomarkers (PCA = 18, tAD = 17, controls = 31) showing neurodegeneration, and CSF biomarkers (PCA = 18, tAD = 14, controls = 13) supporting underlying AD pathology did not provide evidence of overall between-group differences in pRNFL or mRT measures (all p > 0.3).", "tags": [{"end": 63, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 272, "start": 267, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 50, "tag": "ResearchActivity"}, {"end": 135, "start": 132, "tag": "ResearchActivity"}, {"end": 263, "start": 246, "tag": "Finding"}, {"end": 263, "start": 252, "tag": "Finding"}, {"end": 110, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 48, "start": 38, "tag": "ClinicalAttribute"}, {"end": 130, "start": 120, "tag": "ClinicalAttribute"}, {"end": 119, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 192, "tag": "PathologicFunction"}, {"end": 201, "start": 192, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 191, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 70, "tag": "PopulationGroup"}, {"end": 160, "start": 152, "tag": "PopulationGroup"}, {"end": 37, "start": 34, "tag": "HealthCareActivity"}, {"end": 251, "start": 246, "tag": "PopulationGroup"}, {"end": 28, "start": 11, "tag": "ResearchActivity"}, {"end": 226, "start": 218, "tag": "Finding"}]}{"id": "1474_11", "text": "Conclusions: Retinal thickness did not discriminate tAD and PCA from controls or from one another despite unequivocal differences on standard clinical, neuro-imaging and CSF measures.", "tags": [{"end": 20, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 60, "tag": "ResearchActivity"}, {"end": 129, "start": 118, "tag": "Finding"}, {"end": 173, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 174, "tag": "HealthCareActivity"}, {"end": 165, "start": 152, "tag": "HealthCareActivity"}, {"end": 77, "start": 69, "tag": "PopulationGroup"}, {"end": 30, "start": 13, "tag": "ClinicalAttribute"}, {"end": 63, "start": 60, "tag": "DiseaseOrSyndrome"}]}{"id": "1474_12", "text": "Findings from this well-characterized sample, including cases with PCA, do not support the hypothesis that retinal neurodegeneration, measured using conventional OCT, is a useful biomarker for AD or PCA.", "tags": [{"end": 44, "start": 38, "tag": "Substance"}, {"end": 44, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "ResearchActivity"}, {"end": 202, "start": 199, "tag": "ResearchActivity"}, {"end": 165, "start": 149, "tag": "HealthCareActivity"}, {"end": 132, "start": 115, "tag": "CellOrMolecularDysfunction"}, {"end": 195, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 179, "tag": "ClinicalAttribute"}, {"end": 114, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 199, "tag": "DiseaseOrSyndrome"}]}{"id": "1475_0", "text": "The search for new, robust, and reproducible biomarkers for Alzheimer's disease (AD) diagnosis is a challenge.", "tags": [{"end": 10, "start": 4, "tag": "ResearchActivity"}, {"end": 109, "start": 100, "tag": "HealthCareActivity"}, {"end": 79, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 85, "tag": "HealthCareActivity"}, {"end": 55, "start": 45, "tag": "ClinicalAttribute"}]}{"id": "1475_1", "text": "We recently reported that salivary lactoferrin (Lf) could be presented as new biomarker candidate for AD, being both non-invasive and cost-effective, as well as having appropriate diagnostic performance for the clinical detection of AD subjects.", "tags": [{"end": 50, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 235, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 78, "tag": "ClinicalAttribute"}, {"end": 202, "start": 191, "tag": "Finding"}, {"end": 244, "start": 236, "tag": "PopulationGroup"}, {"end": 229, "start": 211, "tag": "HealthCareActivity"}, {"end": 11, "start": 3, "tag": "TemporalConcept"}, {"end": 190, "start": 180, "tag": "HealthCareActivity"}, {"end": 46, "start": 26, "tag": "ClinicalAttribute"}]}{"id": "1475_2", "text": "Saliva is an attractive sample type for biomarker-based testing approaches for several other diseases; however, its composition may change under certain circumstances.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 40, "tag": "ClinicalAttribute"}, {"end": 74, "start": 56, "tag": "HealthCareActivity"}, {"end": 30, "start": 24, "tag": "Substance"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1475_3", "text": "It is therefore critical to maintain a consistent salivary handling protocol, considering possible extrinsic factors that may influence salivary Lf concentration.", "tags": [{"end": 147, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 50, "tag": "HealthCareActivity"}, {"end": 161, "start": 136, "tag": "ClinicalAttribute"}]}{"id": "1475_4", "text": "In this work, we analyzed salivary Lf concentration under different handling conditions and donor-dependent factors including age, inter-diurnal variations, physical activity, and pharmacological treatments.", "tags": [{"end": 97, "start": 92, "tag": "PopulationGroup"}, {"end": 206, "start": 180, "tag": "HealthCareActivity"}, {"end": 206, "start": 180, "tag": "ResearchActivity"}, {"end": 37, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 98, "tag": "Finding"}, {"end": 174, "start": 157, "tag": "BiologicFunction"}, {"end": 129, "start": 126, "tag": "OrganismAttribute"}, {"end": 25, "start": 17, "tag": "ResearchActivity"}, {"end": 51, "start": 26, "tag": "ClinicalAttribute"}, {"end": 87, "start": 68, "tag": "HealthCareActivity"}]}{"id": "1475_5", "text": "Our aim was to evaluate the influence of such conditions on salivary Lf concentration.", "tags": [{"end": 71, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 60, "tag": "ClinicalAttribute"}]}{"id": "1475_6", "text": "In conclusion, we found that most of these extrinsic factors should be considered in the future when using Lf as a predictive biomarker for AD.", "tags": [{"end": 135, "start": 115, "tag": "ClinicalAttribute"}, {"end": 109, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 126, "tag": "ClinicalAttribute"}, {"end": 95, "start": 89, "tag": "TemporalConcept"}]}{"id": "1476_0", "text": "Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in the amyloid/tau/neurodegeneration [A/T/(N)] framework for Alzheimer's disease.", "tags": [{"end": 58, "start": 44, "tag": "CellFunction"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 143, "tag": "HealthCareActivity"}, {"end": 62, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 182, "tag": "AminoAcidPeptideOrProtein"}, {"end": 247, "start": 228, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 185, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 12, "tag": "ClinicalAttribute"}, {"end": 166, "start": 156, "tag": "ClinicalAttribute"}, {"end": 203, "start": 186, "tag": "CellOrMolecularDysfunction"}, {"end": 39, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 223, "start": 204, "tag": "ClinicalAttribute"}, {"end": 94, "start": 73, "tag": "Finding"}]}{"id": "1476_1", "text": "However, the blood-based neurodegeneration marker neurofilament light is not specific to Alzheimer's disease while total-tau shows lack of correlation with CSF total-tau.", "tags": [{"end": 69, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 43, "tag": "ClinicalAttribute"}, {"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 160, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 25, "tag": "CellOrMolecularDysfunction"}, {"end": 169, "start": 156, "tag": "ClinicalAttribute"}]}{"id": "1476_2", "text": "Recent studies suggest that blood total-tau originates principally from peripheral, non-brain sources.", "tags": [{"end": 101, "start": 94, "tag": "Finding"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 33, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 28, "tag": "ClinicalAttribute"}]}{"id": "1476_3", "text": "We sought to address this challenge by generating an anti-tau antibody that selectively binds brain-derived tau and avoids the peripherally expressed 'big tau' isoform.", "tags": [{"end": 167, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 88, "tag": "CellFunction"}, {"end": 70, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 53, "tag": "PharmacologicSubstance"}, {"end": 70, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 26, "tag": "HealthCareActivity"}, {"end": 111, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 155, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 140, "tag": "CellFunction"}, {"end": 99, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1476_4", "text": "We applied this antibody to develop an ultrasensitive blood-based assay for brain-derived tau, and validated it in five independent cohorts (n = 609) including a blood-to-autopsy cohort, CSF biomarker-classified cohorts and memory clinic cohorts.", "tags": [{"end": 24, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 24, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 200, "start": 191, "tag": "ClinicalAttribute"}, {"end": 139, "start": 132, "tag": "PopulationGroup"}, {"end": 219, "start": 212, "tag": "PopulationGroup"}, {"end": 245, "start": 238, "tag": "PopulationGroup"}, {"end": 81, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 162, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 179, "tag": "PopulationGroup"}, {"end": 230, "start": 224, "tag": "BiologicFunction"}, {"end": 71, "start": 54, "tag": "ResearchActivity"}, {"end": 178, "start": 171, "tag": "HealthCareActivity"}, {"end": 237, "start": 224, "tag": "HealthCareRelatedOrganization"}]}{"id": "1476_5", "text": "In paired samples, serum and CSF brain-derived tau were significantly correlated (rho = 0.85, P < 0.0001), while serum and CSF total-tau were not (rho = 0.23, P = 0.3364).", "tags": [{"end": 24, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 10, "tag": "Substance"}, {"end": 17, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 123, "tag": "ClinicalAttribute"}, {"end": 136, "start": 127, "tag": "ClinicalAttribute"}, {"end": 118, "start": 113, "tag": "ClinicalAttribute"}, {"end": 50, "start": 29, "tag": "ClinicalAttribute"}]}{"id": "1476_6", "text": "Blood-based brain-derived tau showed equivalent diagnostic performance as CSF total-tau and CSF brain-derived tau to separate biomarker-positive Alzheimer's disease participants from biomarker-negative controls.", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 126, "tag": "ClinicalAttribute"}, {"end": 192, "start": 183, "tag": "ClinicalAttribute"}, {"end": 210, "start": 202, "tag": "PopulationGroup"}, {"end": 17, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 177, "start": 165, "tag": "PopulationGroup"}, {"end": 70, "start": 48, "tag": "Finding"}, {"end": 87, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 74, "tag": "ClinicalAttribute"}, {"end": 113, "start": 92, "tag": "ClinicalAttribute"}]}{"id": "1476_7", "text": "Furthermore, plasma brain-derived tau accurately distinguished autopsy-confirmed Alzheimer's disease from other neurodegenerative diseases (area under the curve = 86.4%) while neurofilament light did not (area under the curve = 54.3%).", "tags": [{"end": 195, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 195, "start": 176, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 140, "tag": "ResearchActivity"}, {"end": 225, "start": 205, "tag": "ResearchActivity"}, {"end": 25, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 13, "tag": "ClinicalAttribute"}, {"end": 70, "start": 63, "tag": "HealthCareActivity"}]}{"id": "1476_8", "text": "These performances were independent of the presence of concomitant pathologies.", "tags": [{"end": 35, "start": 24, "tag": "Finding"}, {"end": 66, "start": 55, "tag": "TemporalConcept"}, {"end": 18, "start": 6, "tag": "IndividualBehavior"}, {"end": 78, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 43, "tag": "Finding"}]}{"id": "1476_9", "text": "Plasma brain-derived tau (rho = 0.52-0.67, P = 0.003), but not neurofilament light (rho = -0.14-0.17, P = 0.501), was associated with global and regional amyloid plaque and neurofibrillary tangle counts.", "tags": [{"end": 82, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 154, "tag": "AnatomicalAbnormality"}, {"end": 188, "start": 173, "tag": "CellComponent"}, {"end": 24, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 0, "tag": "ClinicalAttribute"}, {"end": 195, "start": 173, "tag": "CellOrMolecularDysfunction"}]}{"id": "1476_10", "text": "These results were further verified in two memory clinic cohorts where serum brain-derived tau differentiated Alzheimer's disease from a range of other neurodegenerative disorders, including frontotemporal lobar degeneration and atypical parkinsonian disorders (area under the curve up to 99.6%).", "tags": [{"end": 205, "start": 191, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 260, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 224, "start": 212, "tag": "PathologicFunction"}, {"end": 179, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 282, "start": 262, "tag": "ResearchActivity"}, {"end": 64, "start": 57, "tag": "PopulationGroup"}, {"end": 82, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 237, "start": 229, "tag": "Finding"}, {"end": 49, "start": 43, "tag": "BiologicFunction"}, {"end": 94, "start": 71, "tag": "ClinicalAttribute"}]}{"id": "1476_11", "text": "Notably, plasma/serum brain-derived tau correlated with neurofilament light only in Alzheimer's disease but not in the other neurodegenerative diseases.", "tags": [{"end": 75, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1476_12", "text": "Across cohorts, plasma/serum brain-derived tau was associated with CSF and plasma AT(N) biomarkers and cognitive function.", "tags": [{"end": 28, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 7, "tag": "PopulationGroup"}, {"end": 34, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 82, "tag": "ClinicalAttribute"}, {"end": 22, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 103, "tag": "BiologicFunction"}]}{"id": "1476_13", "text": "Brain-derived tau is a new blood-based biomarker that outperforms plasma total-tau and, unlike neurofilament light, shows specificity to Alzheimer's disease-type neurodegeneration.", "tags": [{"end": 114, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 39, "tag": "ClinicalAttribute"}, {"end": 133, "start": 122, "tag": "Finding"}, {"end": 72, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 179, "start": 162, "tag": "CellOrMolecularDysfunction"}, {"end": 82, "start": 66, "tag": "ClinicalAttribute"}]}{"id": "1476_14", "text": "Thus, brain-derived tau demonstrates potential to complete the AT(N) scheme in blood, and will be useful to evaluate Alzheimer's disease-dependent neurodegenerative processes for clinical and research purposes.", "tags": [{"end": 174, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 200, "start": 192, "tag": "ResearchActivity"}, {"end": 84, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1476_15", "text": "A blood-based biomarker that tracks neurodegeneration in Alzheimer's disease and differentiates it from other dementias is lacking.", "tags": [{"end": 35, "start": 29, "tag": "ManufacturedObject"}, {"end": 119, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 14, "tag": "ClinicalAttribute"}, {"end": 7, "start": 2, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 36, "tag": "CellOrMolecularDysfunction"}]}{"id": "1476_16", "text": "Gonzalez et al.", "tags": []}{"id": "1476_17", "text": "report the discovery and clinical validation of plasma brain-derived tau, an improved total-tau assay that specifically targets CNS tau in blood.", "tags": [{"end": 131, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 25, "tag": "ResearchActivity"}, {"end": 72, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 11, "tag": "ResearchActivity"}, {"end": 54, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 6, "start": 0, "tag": "HealthCareActivity"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 95, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 48, "tag": "ClinicalAttribute"}]}{"id": "1477_0", "text": "Amyloid-beta (A beta) deposition in the brain parenchyma is one of the pathological hallmarks of Alzheimer disease (AD).", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 84, "tag": "Finding"}, {"end": 20, "start": 14, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1477_1", "text": "We have previously identified amyloid precursor protein (APP)669-711 (a.k.a.", "tags": [{"end": 68, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 57, "tag": "GeneOrGenome"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 30, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1477_2", "text": "A beta(-3)-40) in human plasma using immunoprecipitation combined with matrix-assisted laser desorption ionization time-of-flight mass spectrometry (IP-MALDI-MS).", "tags": [{"end": 56, "start": 37, "tag": "ResearchActivity"}, {"end": 147, "start": 71, "tag": "ResearchActivity"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 18, "tag": "Eukaryote"}, {"end": 119, "start": 115, "tag": "TemporalConcept"}, {"end": 13, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 149, "tag": "ResearchActivity"}, {"end": 13, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1477_3", "text": "Furthermore, we found that the level of a composite biomarker, i.e., a combination of APP669-711/A beta 1-42 ratio and A beta 1-40/A beta 1-42 ratio in human plasma, correlates with the amyloid PET status of AD patients.", "tags": [{"end": 204, "start": 198, "tag": "Finding"}, {"end": 197, "start": 194, "tag": "HealthCareActivity"}, {"end": 210, "start": 208, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 219, "start": 211, "tag": "PatientOrDisabledGroup"}, {"end": 61, "start": 52, "tag": "ClinicalAttribute"}, {"end": 157, "start": 152, "tag": "Eukaryote"}, {"end": 193, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 131, "tag": "BiologicallyActiveSubstance"}]}{"id": "1477_4", "text": "However, the production mechanism of APP669-711 has remained unclear.", "tags": [{"end": 47, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 37, "tag": "BiologicallyActiveSubstance"}]}{"id": "1477_5", "text": "Using in vitro and in vivo assays, we identified A Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, type 4 (ADAMTS4) as a responsible enzyme for APP669-711 production.", "tags": [{"end": 62, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 67, "tag": "GeneOrGenome"}, {"end": 136, "start": 129, "tag": "GeneOrGenome"}, {"end": 136, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 155, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 6, "tag": "ResearchActivity"}, {"end": 33, "start": 19, "tag": "ResearchActivity"}, {"end": 127, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 92, "tag": "GeneOrGenome"}, {"end": 161, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 129, "tag": "BiologicallyActiveSubstance"}]}{"id": "1477_6", "text": "ADAMTS4 cleaves APP directly to generate the C-terminal stub c102, which is subsequently proteolyzed by gamma-secretase to release APP669-711.", "tags": [{"end": 7, "start": 0, "tag": "GeneOrGenome"}, {"end": 7, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 16, "tag": "GeneOrGenome"}, {"end": 19, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 131, "tag": "BiologicallyActiveSubstance"}]}{"id": "1477_7", "text": "Genetic knockout of ADAMTS4 reduced the production of endogenous APP669-711 by 30% to 40% in cultured cells as well as mouse plasma, irrespectively of A beta levels.", "tags": [{"end": 27, "start": 20, "tag": "GeneOrGenome"}, {"end": 27, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 93, "tag": "Cell"}, {"end": 107, "start": 93, "tag": "ResearchActivity"}, {"end": 131, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 119, "tag": "Eukaryote"}, {"end": 157, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 0, "tag": "ResearchActivity"}, {"end": 75, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 65, "tag": "BiologicallyActiveSubstance"}]}{"id": "1477_8", "text": "Finally, we found that the endogenous murine APP669-711/A beta 1-42 ratio was increased in aged AD model mice, which shows A beta deposition as observed in human patients.", "tags": [{"end": 95, "start": 91, "tag": "TemporalConcept"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 162, "tag": "PatientOrDisabledGroup"}, {"end": 161, "start": 156, "tag": "Eukaryote"}, {"end": 67, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 38, "tag": "Eukaryote"}, {"end": 55, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 91, "tag": "ExperimentalModelOfDisease"}]}{"id": "1477_9", "text": "These data suggest that ADAMTS4 is involved in the production of APP669-711, and a plasma biomarker determined by IP-MALDI-MS can be used to estimate the level of A beta deposition in the brain of mouse models.", "tags": [{"end": 31, "start": 24, "tag": "GeneOrGenome"}, {"end": 31, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 188, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 90, "tag": "ClinicalAttribute"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 202, "start": 197, "tag": "Eukaryote"}, {"end": 169, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 209, "start": 203, "tag": "ResearchActivity"}, {"end": 31, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 114, "tag": "ResearchActivity"}]}{"id": "1478_0", "text": "Aim: Identify a global resting-state functional connectivity (gFC) signature in mutation carriers (MC) from the Dominantly Inherited Alzheimer Network (DIAN).", "tags": [{"end": 97, "start": 80, "tag": "PopulationGroup"}, {"end": 101, "start": 99, "tag": "PopulationGroup"}, {"end": 60, "start": 37, "tag": "BiologicFunction"}, {"end": 88, "start": 80, "tag": "CellOrMolecularDysfunction"}, {"end": 142, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 112, "tag": "HealthCareRelatedOrganization"}, {"end": 156, "start": 152, "tag": "HealthCareRelatedOrganization"}, {"end": 76, "start": 67, "tag": "ClinicalAttribute"}, {"end": 60, "start": 16, "tag": "ClinicalAttribute"}, {"end": 65, "start": 62, "tag": "ClinicalAttribute"}]}{"id": "1478_1", "text": "Assess the gFC with regard to amyloid (A), tau (T), and neurodegeneration (N) biomarkers, and estimated years to symptom onset (EYO).", "tags": [{"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 56, "tag": "CellOrMolecularDysfunction"}, {"end": 88, "start": 78, "tag": "ClinicalAttribute"}, {"end": 126, "start": 94, "tag": "TemporalConcept"}, {"end": 37, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 11, "tag": "ClinicalAttribute"}, {"end": 131, "start": 128, "tag": "TemporalConcept"}]}{"id": "1478_2", "text": "Introduction: Cross-sectional measures were assessed in MC (n = 171) and mutation noncarrier (NC) (n = 70) participants.", "tags": [{"end": 58, "start": 56, "tag": "PopulationGroup"}, {"end": 119, "start": 107, "tag": "PopulationGroup"}, {"end": 81, "start": 73, "tag": "CellOrMolecularDysfunction"}]}{"id": "1478_3", "text": "A functional connectivity (FC) matrix that encompassed multiple resting-state networks was computed for each participant.", "tags": [{"end": 120, "start": 109, "tag": "PopulationGroup"}, {"end": 25, "start": 2, "tag": "BiologicFunction"}, {"end": 86, "start": 64, "tag": "BiologicFunction"}]}{"id": "1478_4", "text": "Methods: A global FC was compiled as a single index indicating FC strength.", "tags": [{"end": 20, "start": 11, "tag": "ClinicalAttribute"}]}{"id": "1478_5", "text": "The gFC signature was modeled as a nonlinear function of EYO.", "tags": [{"end": 17, "start": 4, "tag": "ClinicalAttribute"}, {"end": 60, "start": 57, "tag": "TemporalConcept"}]}{"id": "1478_6", "text": "The gFC was linearly associated with other biomarkers used for assessing the AT(N) framework, including cerebrospinal fluid (CSF), positron emission tomography (PET) molecular biomarkers, and structural magnetic resonance imaging.", "tags": [{"end": 186, "start": 166, "tag": "ClinicalAttribute"}, {"end": 159, "start": 131, "tag": "HealthCareActivity"}, {"end": 229, "start": 192, "tag": "HealthCareActivity"}, {"end": 229, "start": 192, "tag": "ManufacturedObject"}, {"end": 159, "start": 131, "tag": "ManufacturedObject"}, {"end": 164, "start": 161, "tag": "HealthCareActivity"}, {"end": 53, "start": 43, "tag": "ClinicalAttribute"}, {"end": 186, "start": 176, "tag": "ClinicalAttribute"}, {"end": 128, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 118, "tag": "Substance"}, {"end": 229, "start": 203, "tag": "HealthCareActivity"}, {"end": 229, "start": 222, "tag": "HealthCareActivity"}, {"end": 229, "start": 203, "tag": "ManufacturedObject"}, {"end": 123, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 4, "tag": "ClinicalAttribute"}]}{"id": "1478_7", "text": "Results: The gFC was reduced in MC compared with NC participants.", "tags": [{"end": 34, "start": 32, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 64, "start": 52, "tag": "PopulationGroup"}, {"end": 16, "start": 13, "tag": "ClinicalAttribute"}]}{"id": "1478_8", "text": "When MC participants were differentiated by clinical dementia rating (CDR), the gFC was significantly decreased in MC CDR >0 (demented) compared with either MC CDR 0 (cognitively normal) or NC participants.", "tags": [{"end": 7, "start": 5, "tag": "PopulationGroup"}, {"end": 117, "start": 115, "tag": "PopulationGroup"}, {"end": 134, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 157, "tag": "PopulationGroup"}, {"end": 185, "start": 179, "tag": "Finding"}, {"end": 61, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 8, "tag": "PopulationGroup"}, {"end": 205, "start": 193, "tag": "PopulationGroup"}, {"end": 68, "start": 44, "tag": "HealthCareActivity"}, {"end": 73, "start": 70, "tag": "HealthCareActivity"}, {"end": 83, "start": 80, "tag": "ClinicalAttribute"}, {"end": 121, "start": 118, "tag": "HealthCareActivity"}, {"end": 163, "start": 160, "tag": "HealthCareActivity"}]}{"id": "1478_9", "text": "The gFC varied nonlinearly with EYO and initially decreased at EYO = -24 years, followed by a stable period followed by a further decline near EYO = 0 years.", "tags": [{"end": 107, "start": 101, "tag": "TemporalConcept"}, {"end": 78, "start": 73, "tag": "TemporalConcept"}, {"end": 156, "start": 151, "tag": "TemporalConcept"}, {"end": 7, "start": 4, "tag": "ClinicalAttribute"}, {"end": 35, "start": 32, "tag": "TemporalConcept"}, {"end": 66, "start": 63, "tag": "TemporalConcept"}, {"end": 146, "start": 143, "tag": "TemporalConcept"}]}{"id": "1478_10", "text": "Irrespective of EYO, a lower gFC associated with values of amyloid PET, CSF A beta(1-42), CSF p-tau, CSF t-tau, 18F-fluorodeoxyglucose, and hippocampal volume.", "tags": [{"end": 151, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 140, "tag": "Cell"}, {"end": 70, "start": 67, "tag": "HealthCareActivity"}, {"end": 99, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 112, "tag": "Chemical"}, {"end": 158, "start": 140, "tag": "ClinicalAttribute"}, {"end": 19, "start": 16, "tag": "TemporalConcept"}, {"end": 32, "start": 29, "tag": "ClinicalAttribute"}, {"end": 88, "start": 76, "tag": "BiologicallyActiveSubstance"}]}{"id": "1478_11", "text": "Conclusions: The gFC correlated with biomarkers used for defining the AT(N) framework.", "tags": [{"end": 47, "start": 37, "tag": "ClinicalAttribute"}, {"end": 20, "start": 17, "tag": "ClinicalAttribute"}]}{"id": "1478_12", "text": "A biphasic change in the gFC suggested early changes associated with CSF amyloid and later changes associated with hippocampal volume.", "tags": [{"end": 126, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 115, "tag": "Cell"}, {"end": 72, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 115, "tag": "ClinicalAttribute"}, {"end": 28, "start": 25, "tag": "ClinicalAttribute"}]}{"id": "1479_0", "text": "Objective To determine the ordering of changes in Alzheimer disease (AD) biomarkers among cognitively normal individuals.", "tags": [{"end": 108, "start": 102, "tag": "Finding"}, {"end": 67, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 73, "tag": "ClinicalAttribute"}, {"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 109, "tag": "PopulationGroup"}]}{"id": "1479_1", "text": "Methods Cross-sectional data, including CSF analytes, molecular imaging of cerebral fibrillar beta-amyloid (A beta) with PET using the [C-11] benzothiazole tracer Pittsburgh compound B (PiB), MRI-based brain structures, and clinical/cognitive outcomes harmonized from 8 studies, collectively involving 3,284 cognitively normal individuals 18 to 101 years of age, were analyzed.", "tags": [{"end": 52, "start": 44, "tag": "Substance"}, {"end": 71, "start": 54, "tag": "HealthCareActivity"}, {"end": 189, "start": 186, "tag": "Chemical"}, {"end": 218, "start": 202, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 135, "tag": "Chemical"}, {"end": 326, "start": 320, "tag": "Finding"}, {"end": 124, "start": 121, "tag": "HealthCareActivity"}, {"end": 361, "start": 358, "tag": "OrganismAttribute"}, {"end": 354, "start": 349, "tag": "TemporalConcept"}, {"end": 277, "start": 270, "tag": "ResearchActivity"}, {"end": 28, "start": 8, "tag": "ResearchActivity"}, {"end": 43, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 195, "start": 192, "tag": "HealthCareActivity"}, {"end": 71, "start": 64, "tag": "HealthCareActivity"}, {"end": 338, "start": 327, "tag": "PopulationGroup"}, {"end": 114, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 75, "tag": "CellOrMolecularDysfunction"}]}{"id": "1479_2", "text": "The age at which each marker exhibited an accelerated change (called the change point) was estimated and compared across the markers.", "tags": [{"end": 7, "start": 4, "tag": "OrganismAttribute"}, {"end": 28, "start": 22, "tag": "ClinicalAttribute"}]}{"id": "1479_3", "text": "Results Accelerated changes in CSF A beta(1-42) (A beta(42)) occurred at 48.28 years of age and in A beta(42)/A beta(40) ratio at 46.02 years, followed by PiB mean cortical standardized uptake value ratio (SUVR) with a change point at 54.47 years.", "tags": [{"end": 158, "start": 155, "tag": "Chemical"}, {"end": 172, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 88, "tag": "OrganismAttribute"}, {"end": 84, "start": 79, "tag": "TemporalConcept"}, {"end": 141, "start": 136, "tag": "TemporalConcept"}, {"end": 246, "start": 241, "tag": "TemporalConcept"}, {"end": 34, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 41, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 204, "start": 155, "tag": "ResearchActivity"}]}{"id": "1479_4", "text": "CSF total tau (Tau) and tau phosphorylated at threonine 181 (Ptau) had a change point at approximate to 60 years, similar to those for MRI hippocampal volume and cortical thickness.", "tags": [{"end": 18, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 162, "tag": "ClinicalAttribute"}, {"end": 13, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 107, "tag": "TemporalConcept"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 135, "tag": "HealthCareActivity"}, {"end": 13, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 135, "tag": "ClinicalAttribute"}]}{"id": "1479_5", "text": "The change point for a cognitive composite occurred at 62.41 years.", "tags": [{"end": 66, "start": 61, "tag": "TemporalConcept"}]}{"id": "1479_6", "text": "The change points for CSF A beta(42) and A beta(42)/A beta(40) ratio, albeit not significantly different from that for PiB SUVR, occurred significantly earlier than that for CSF Tau, Ptau, MRI markers, and the cognitive composite.", "tags": [{"end": 122, "start": 119, "tag": "Chemical"}, {"end": 181, "start": 178, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 177, "start": 174, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 189, "tag": "HealthCareActivity"}, {"end": 36, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 152, "tag": "TemporalConcept"}, {"end": 36, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 183, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 183, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1479_7", "text": "Adjusted analyses confirmed that accelerated changes in CSF Tau, Ptau, MRI markers, and the cognitive composite occurred at ages not significantly different from each other.", "tags": [{"end": 63, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 124, "tag": "TemporalConcept"}, {"end": 59, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 71, "tag": "HealthCareActivity"}, {"end": 69, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 65, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1479_8", "text": "Conclusions Our findings support the hypothesized early changes of amyloid in preclinical AD and suggest that changes in neuronal injury and neurodegeneration markers occur close in time to cognitive decline.", "tags": [{"end": 129, "start": 121, "tag": "Cell"}, {"end": 158, "start": 141, "tag": "CellOrMolecularDysfunction"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 182, "tag": "TemporalConcept"}, {"end": 136, "start": 130, "tag": "InjuryOrPoisoning"}, {"end": 74, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 207, "start": 190, "tag": "DiseaseOrSyndrome"}]}{"id": "1480_0", "text": "An efficient method to identify whether mild cognitive impairment (MCI) has progressed to Alzheimer's disease (AD) will be beneficial to patient care.", "tags": [{"end": 149, "start": 137, "tag": "HealthCareActivity"}, {"end": 70, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 13, "tag": "ResearchActivity"}, {"end": 19, "start": 13, "tag": "HealthCareActivity"}, {"end": 149, "start": 145, "tag": "HealthCareActivity"}, {"end": 109, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 137, "tag": "PatientOrDisabledGroup"}, {"end": 65, "start": 40, "tag": "DiseaseOrSyndrome"}]}{"id": "1480_1", "text": "Previous studies have shown that magnetic resonance imaging (MRI) has enabled the assessment of AD progression based on imaging findings.", "tags": [{"end": 92, "start": 82, "tag": "HealthCareActivity"}, {"end": 92, "start": 82, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 110, "start": 99, "tag": "PathologicFunction"}, {"end": 110, "start": 99, "tag": "TemporalConcept"}, {"end": 16, "start": 9, "tag": "ResearchActivity"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 61, "tag": "HealthCareActivity"}, {"end": 59, "start": 33, "tag": "HealthCareActivity"}, {"end": 59, "start": 52, "tag": "HealthCareActivity"}, {"end": 127, "start": 120, "tag": "HealthCareActivity"}, {"end": 59, "start": 33, "tag": "ManufacturedObject"}]}{"id": "1480_2", "text": "The present work aimed to establish an algorithm based on three features, namely, volume, surface area, and surface curvature within the hippocampal subfields, to model variations, including atrophy and structural changes to the cortical surface.", "tags": [{"end": 102, "start": 90, "tag": "OrganismAttribute"}, {"end": 158, "start": 137, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 237, "start": 229, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 163, "tag": "ResearchActivity"}, {"end": 198, "start": 191, "tag": "PathologicFunction"}, {"end": 198, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 39, "tag": "MachineActivity"}, {"end": 158, "start": 108, "tag": "ClinicalAttribute"}]}{"id": "1480_3", "text": "In this study, a new biomarker, the ratio of principal curvatures (RPC), was proposed to characterize the folding patterns of the cortical gyrus and sulcus.", "tags": [{"end": 155, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 30, "start": 21, "tag": "ClinicalAttribute"}, {"end": 65, "start": 36, "tag": "ClinicalAttribute"}, {"end": 70, "start": 67, "tag": "ClinicalAttribute"}, {"end": 144, "start": 106, "tag": "BiologicFunction"}]}{"id": "1480_4", "text": "Along with volumes and surface areas, these morphological features associated with the hippocampal subfields were assessed in terms of their sensitivity to the changes in cognitive capacity by two different feature selection methods.", "tags": [{"end": 36, "start": 23, "tag": "OrganismAttribute"}, {"end": 108, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 141, "tag": "Finding"}, {"end": 232, "start": 207, "tag": "ResearchActivity"}]}{"id": "1480_5", "text": "Either the extracted features were statistically significantly different, or the features were selected through a random forest model.", "tags": [{"end": 133, "start": 114, "tag": "MachineActivity"}]}{"id": "1480_6", "text": "The identified subfields and their structural indices that are sensitive to the changes characteristic of the progression from MCI to AD were further assessed with a multilayer perceptron classifier to help facilitate the diagnosis.", "tags": [{"end": 130, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 110, "tag": "PathologicFunction"}, {"end": 121, "start": 110, "tag": "TemporalConcept"}, {"end": 231, "start": 222, "tag": "HealthCareActivity"}, {"end": 136, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 166, "tag": "MachineActivity"}]}{"id": "1480_7", "text": "The accuracy of the classification based on the proposed method to distinguish whether a MCI patient enters the AD stage amounted to 79.95%, solely using the information from the features selected by a logical feature selection method.", "tags": [{"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 120, "start": 115, "tag": "ClinicalAttribute"}, {"end": 92, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 57, "tag": "ResearchActivity"}, {"end": 234, "start": 202, "tag": "ResearchActivity"}, {"end": 63, "start": 57, "tag": "HealthCareActivity"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 93, "tag": "PatientOrDisabledGroup"}, {"end": 12, "start": 4, "tag": "Finding"}]}{"id": "1481_0", "text": "BackgroundMacrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine.", "tags": [{"end": 53, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 50, "tag": "GeneOrGenome"}, {"end": 85, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 21, "tag": "CellFunction"}, {"end": 76, "start": 60, "tag": "PathologicFunction"}, {"end": 20, "start": 10, "tag": "Cell"}, {"end": 48, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 50, "tag": "BiologicallyActiveSubstance"}]}{"id": "1481_1", "text": "Chronic inflammation induced by amyloid proteins (A) is one prominent neuropathological feature in Alzheimer's disease (AD) brain.MethodsElisa, Western blot, and immunohistochemical staining analysis were performed to examine the level of MIF protein in CSF and brain tissues.", "tags": [{"end": 20, "start": 0, "tag": "PathologicFunction"}, {"end": 48, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 144, "tag": "ResearchActivity"}, {"end": 275, "start": 262, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 257, "start": 254, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 8, "tag": "PathologicFunction"}, {"end": 48, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 162, "tag": "ResearchActivity"}, {"end": 142, "start": 137, "tag": "ResearchActivity"}, {"end": 257, "start": 230, "tag": "ClinicalAttribute"}]}{"id": "1481_2", "text": "MTT and LDH assays were used to examine the neurotoxicity, and the Morris Water Maze test was performed to examine the cognitive function in the MIF+/-/APP23 transgenic mice.ResultsMIF expression was upregulated in the brain of AD patients and AD model mice.", "tags": [{"end": 3, "start": 0, "tag": "Chemical"}, {"end": 57, "start": 44, "tag": "InjuryOrPoisoning"}, {"end": 89, "start": 67, "tag": "ResearchActivity"}, {"end": 137, "start": 119, "tag": "BiologicFunction"}, {"end": 173, "start": 158, "tag": "Eukaryote"}, {"end": 173, "start": 158, "tag": "ResearchActivity"}, {"end": 239, "start": 231, "tag": "PatientOrDisabledGroup"}, {"end": 230, "start": 228, "tag": "DiseaseOrSyndrome"}, {"end": 246, "start": 244, "tag": "DiseaseOrSyndrome"}, {"end": 224, "start": 219, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 252, "start": 247, "tag": "ResearchActivity"}, {"end": 173, "start": 169, "tag": "Eukaryote"}, {"end": 257, "start": 253, "tag": "Eukaryote"}, {"end": 18, "start": 8, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 3, "start": 0, "tag": "ResearchActivity"}, {"end": 173, "start": 145, "tag": "ExperimentalModelOfDisease"}, {"end": 184, "start": 181, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1481_3", "text": "Elevated MIF concentration was detected in the cerebrospinal fluid of AD patients but not in that of the patients suffering from mild cognitive impairment and vascular dementia.", "tags": [{"end": 12, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 9, "tag": "GeneOrGenome"}, {"end": 123, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 73, "tag": "PatientOrDisabledGroup"}, {"end": 113, "start": 105, "tag": "PatientOrDisabledGroup"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 176, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 61, "tag": "Substance"}, {"end": 176, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 0, "tag": "Finding"}, {"end": 12, "start": 9, "tag": "BiologicallyActiveSubstance"}]}{"id": "1481_4", "text": "Reduced MIF expression impaired learning and memory in the AD model mice.", "tags": [{"end": 11, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 8, "tag": "GeneOrGenome"}, {"end": 51, "start": 32, "tag": "BiologicFunction"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 32, "tag": "BiologicFunction"}, {"end": 67, "start": 62, "tag": "ResearchActivity"}, {"end": 72, "start": 68, "tag": "Eukaryote"}, {"end": 51, "start": 45, "tag": "BiologicFunction"}, {"end": 11, "start": 8, "tag": "BiologicallyActiveSubstance"}]}{"id": "1481_5", "text": "MIF expression largely associates with A deposits and microglia.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 63, "start": 54, "tag": "Cell"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1481_6", "text": "The binding assay revealed a direct association between MIF and A oligomers.", "tags": [{"end": 59, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 56, "tag": "GeneOrGenome"}, {"end": 17, "start": 4, "tag": "ResearchActivity"}, {"end": 59, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 66, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1481_7", "text": "Neurons instead of glial cells were responsible for the secretion of MIF upon stimulation by A oligomers.", "tags": [{"end": 7, "start": 0, "tag": "Cell"}, {"end": 65, "start": 56, "tag": "CellFunction"}, {"end": 72, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 69, "tag": "GeneOrGenome"}, {"end": 89, "start": 78, "tag": "HealthCareActivity"}, {"end": 89, "start": 78, "tag": "NaturalPhenomenonOrProcess"}, {"end": 30, "start": 19, "tag": "Cell"}, {"end": 24, "start": 19, "tag": "Cell"}, {"end": 104, "start": 95, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1481_8", "text": "In addition, overexpression of MIF significantly protected neuronal cells from A-induced cytotoxicity.ConclusionOur study suggests that neuronal secretion of MIF may serve as a defense mechanism to compensate for declined cognitive function in AD, and increased MIF level could be a potential AD biomarker.", "tags": [{"end": 34, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 31, "tag": "GeneOrGenome"}, {"end": 161, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 158, "tag": "GeneOrGenome"}, {"end": 240, "start": 222, "tag": "BiologicFunction"}, {"end": 265, "start": 262, "tag": "AminoAcidPeptideOrProtein"}, {"end": 265, "start": 262, "tag": "GeneOrGenome"}, {"end": 73, "start": 59, "tag": "Cell"}, {"end": 194, "start": 177, "tag": "BiologicFunction"}, {"end": 246, "start": 244, "tag": "DiseaseOrSyndrome"}, {"end": 295, "start": 293, "tag": "DiseaseOrSyndrome"}, {"end": 305, "start": 296, "tag": "ClinicalAttribute"}, {"end": 121, "start": 116, "tag": "ResearchActivity"}, {"end": 34, "start": 13, "tag": "Finding"}, {"end": 67, "start": 59, "tag": "Cell"}, {"end": 154, "start": 136, "tag": "CellFunction"}, {"end": 101, "start": 89, "tag": "InjuryOrPoisoning"}, {"end": 161, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 265, "start": 262, "tag": "BiologicallyActiveSubstance"}, {"end": 271, "start": 262, "tag": "ClinicalAttribute"}, {"end": 34, "start": 31, "tag": "BiologicallyActiveSubstance"}]}{"id": "1482_0", "text": "Introduction Neurofilament light (NfL), chitinase-3-like protein 1 (YKL-40), and neurogranin (Ng) are biomarkers for Alzheimer's disease (AD) to monitor axonal damage, astroglial activation, and synaptic degeneration, respectively.", "tags": [{"end": 32, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 168, "tag": "Cell"}, {"end": 216, "start": 195, "tag": "CellOrMolecularDysfunction"}, {"end": 136, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 102, "tag": "ClinicalAttribute"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 168, "tag": "CellFunction"}, {"end": 166, "start": 153, "tag": "CellOrMolecularDysfunction"}]}{"id": "1482_1", "text": "Methods We performed genome-wide association studies (GWAS) using DNA and cerebrospinal fluid (CSF) samples from the EMIF-AD Multimodal Biomarker Discovery study for discovery, and the Alzheimer's Disease Neuroimaging Initiative study for validation analyses.", "tags": [{"end": 52, "start": 21, "tag": "ResearchActivity"}, {"end": 258, "start": 239, "tag": "ResearchActivity"}, {"end": 58, "start": 54, "tag": "ResearchActivity"}, {"end": 69, "start": 66, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 27, "start": 21, "tag": "GeneOrGenome"}, {"end": 204, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 117, "tag": "ResearchActivity"}, {"end": 234, "start": 185, "tag": "ResearchActivity"}, {"end": 175, "start": 166, "tag": "ResearchActivity"}, {"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 88, "tag": "Substance"}, {"end": 93, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1482_2", "text": "GWAS were performed for all three CSF biomarkers using linear regression models adjusting for relevant covariates.", "tags": [{"end": 4, "start": 0, "tag": "ResearchActivity"}, {"end": 48, "start": 38, "tag": "ClinicalAttribute"}, {"end": 37, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 55, "tag": "ResearchActivity"}]}{"id": "1482_3", "text": "Results We identify novel genome-wide significant associations between DNA variants in TMEM106B and CSF levels of NfL, and between CPOX and YKL-40.", "tags": [{"end": 95, "start": 87, "tag": "GeneOrGenome"}, {"end": 135, "start": 131, "tag": "GeneOrGenome"}, {"end": 74, "start": 71, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 32, "start": 26, "tag": "GeneOrGenome"}, {"end": 103, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 146, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 131, "tag": "BiologicallyActiveSubstance"}]}{"id": "1482_4", "text": "We confirm previous work suggesting that YKL-40 levels are associated with DNA variants in CHI3L1.", "tags": [{"end": 97, "start": 91, "tag": "GeneOrGenome"}, {"end": 97, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 75, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 47, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 41, "tag": "BiologicallyActiveSubstance"}]}{"id": "1482_5", "text": "Discussion Our study provides important new insights into the genetic architecture underlying interindividual variation in three AD-related CSF biomarkers.", "tags": [{"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 154, "start": 144, "tag": "ClinicalAttribute"}, {"end": 131, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1482_6", "text": "In particular, our data shed light on the sequence of events regarding the initiation and progression of neuropathological processes relevant in AD.", "tags": [{"end": 101, "start": 90, "tag": "PathologicFunction"}, {"end": 101, "start": 90, "tag": "TemporalConcept"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 19, "tag": "ResearchActivity"}, {"end": 85, "start": 75, "tag": "TemporalConcept"}, {"end": 132, "start": 105, "tag": "PathologicFunction"}]}{"id": "1483_0", "text": "Salivary A beta 40, A beta 42, t-tau, and p-tau 181 are commonly employed in Alzheimer's disease (AD) investigations.", "tags": [{"end": 116, "start": 102, "tag": "ResearchActivity"}, {"end": 18, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 0, "tag": "ClinicalAttribute"}, {"end": 8, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 20, "tag": "ClinicalAttribute"}, {"end": 8, "start": 0, "tag": "ClinicalAttribute"}, {"end": 36, "start": 31, "tag": "ClinicalAttribute"}, {"end": 8, "start": 0, "tag": "ClinicalAttribute"}, {"end": 51, "start": 42, "tag": "ClinicalAttribute"}, {"end": 8, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1483_1", "text": "However, the collection method of these biomarkers can affect their levels.", "tags": [{"end": 30, "start": 13, "tag": "ResearchActivity"}, {"end": 50, "start": 40, "tag": "ClinicalAttribute"}]}{"id": "1483_2", "text": "To assess the impact of saliva collection methods on biomarkers in this study, 15 healthy people were employed in the morning with six saliva collection methods.", "tags": [{"end": 125, "start": 118, "tag": "TemporalConcept"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 141, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 82, "tag": "OrganismAttribute"}, {"end": 63, "start": 53, "tag": "ClinicalAttribute"}, {"end": 77, "start": 72, "tag": "ResearchActivity"}, {"end": 96, "start": 90, "tag": "PopulationGroup"}, {"end": 49, "start": 31, "tag": "ResearchActivity"}, {"end": 160, "start": 142, "tag": "ResearchActivity"}]}{"id": "1483_3", "text": "The chosen methods were then applied in 30 AD patients and 30 non-AD controls.", "tags": [{"end": 45, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 69, "tag": "PopulationGroup"}, {"end": 54, "start": 46, "tag": "PatientOrDisabledGroup"}]}{"id": "1483_4", "text": "The levels of salivary biomarkers were calculated by a specific enzyme-linked immunosorbent assay.", "tags": [{"end": 97, "start": 64, "tag": "ResearchActivity"}, {"end": 70, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 23, "tag": "ClinicalAttribute"}]}{"id": "1483_5", "text": "The receiver operating characteristic was utilized to assess salivary biomarkers in AD patients.", "tags": [{"end": 69, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 87, "tag": "PatientOrDisabledGroup"}, {"end": 80, "start": 70, "tag": "ClinicalAttribute"}, {"end": 37, "start": 4, "tag": "ResearchActivity"}]}{"id": "1483_6", "text": "The results demonstrated that the highest levels of salivary A beta 40, A beta 42, t-tau, and p-tau were in different saliva collection methods.", "tags": [{"end": 70, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 52, "tag": "ClinicalAttribute"}, {"end": 143, "start": 125, "tag": "ResearchActivity"}]}{"id": "1483_7", "text": "The correlations between different saliva biomarkers in the same collection method were different.", "tags": [{"end": 41, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 65, "tag": "ResearchActivity"}, {"end": 52, "start": 42, "tag": "ClinicalAttribute"}, {"end": 16, "start": 4, "tag": "ResearchActivity"}]}{"id": "1483_8", "text": "Salivary A beta 40, A beta 42, t-tau, and p-tau had no significant association.", "tags": [{"end": 78, "start": 52, "tag": "Finding"}, {"end": 18, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1483_9", "text": "Salivary A beta 42 was higher in AD than in non-AD controls.", "tags": [{"end": 18, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 51, "tag": "PopulationGroup"}, {"end": 18, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1483_10", "text": "However, p-tau/t-tau and A beta 42/A beta 40 had some relevance.", "tags": [{"end": 20, "start": 9, "tag": "ClinicalAttribute"}, {"end": 44, "start": 25, "tag": "ClinicalAttribute"}]}{"id": "1483_11", "text": "The area under the curve for four biomarkers combined in AD diagnosis was 92.11%.", "tags": [{"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 4, "tag": "ResearchActivity"}, {"end": 69, "start": 60, "tag": "HealthCareActivity"}, {"end": 44, "start": 34, "tag": "ClinicalAttribute"}]}{"id": "1483_12", "text": "An alternate saliva collection method (e.g., USS in A beta 40, UPS in A beta 42, t-tau, SSS in p-tau 181) was demonstrated in this study.", "tags": [{"end": 61, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 20, "tag": "ResearchActivity"}, {"end": 136, "start": 131, "tag": "ResearchActivity"}, {"end": 86, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 45, "tag": "ResearchActivity"}, {"end": 66, "start": 63, "tag": "ResearchActivity"}, {"end": 91, "start": 88, "tag": "ResearchActivity"}]}{"id": "1483_13", "text": "Moreover, combining numerous biomarkers improves AD diagnosis.", "tags": [{"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 52, "tag": "HealthCareActivity"}, {"end": 39, "start": 29, "tag": "ClinicalAttribute"}]}{"id": "1484_0", "text": "BackgroundReduced F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) brain metabolism was recognized as a biomarker of neurodegeneration in the recently proposed ATN framework for Alzheimer's disease (AD) biological definition.", "tags": [{"end": 97, "start": 81, "tag": "BiologicFunction"}, {"end": 211, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 118, "tag": "ClinicalAttribute"}, {"end": 79, "start": 72, "tag": "HealthCareActivity"}, {"end": 79, "start": 76, "tag": "HealthCareActivity"}, {"end": 41, "start": 18, "tag": "Chemical"}, {"end": 148, "start": 131, "tag": "CellOrMolecularDysfunction"}, {"end": 164, "start": 156, "tag": "TemporalConcept"}, {"end": 70, "start": 42, "tag": "HealthCareActivity"}, {"end": 187, "start": 174, "tag": "HealthCareActivity"}]}{"id": "1484_1", "text": "However, accumulating evidence suggested it is an independent biomarker, which is denoted as F in the very study.MethodsA total of 551 A+T+ individuals from the Alzheimer's Disease Neuroimaging Initiative database were recruited and then further divided into four groups based on the biomarker positivity as 132 A+T+N-F-, 102 A+T+N-F+, 113 A+T+N+F-, and 204 A+T+N+F+.", "tags": [{"end": 61, "start": 50, "tag": "Finding"}, {"end": 213, "start": 205, "tag": "ResearchActivity"}, {"end": 30, "start": 9, "tag": "Finding"}, {"end": 204, "start": 161, "tag": "ResearchActivity"}, {"end": 204, "start": 161, "tag": "HealthCareRelatedOrganization"}, {"end": 304, "start": 294, "tag": "ResearchActivity"}, {"end": 71, "start": 62, "tag": "ClinicalAttribute"}, {"end": 293, "start": 284, "tag": "ClinicalAttribute"}, {"end": 151, "start": 140, "tag": "PopulationGroup"}, {"end": 112, "start": 107, "tag": "ResearchActivity"}, {"end": 270, "start": 264, "tag": "PopulationGroup"}]}{"id": "1484_2", "text": "Frequency distributions of the groups were compared, as well as the clinical progression [measured by the longitudinal changes in cognition and brain structure, and mild cognitive impairment (MCI) to AD dementia conversion] between every pair of F+ and F- groups.ResultsThe prevalence of A+T+N+F+ profile was 66.24% in clinically diagnosed AD dementia patients; similarly, the majority of individuals with reduced FDG-PET were AD dementia subjects.", "tags": [{"end": 9, "start": 0, "tag": "TemporalConcept"}, {"end": 23, "start": 10, "tag": "BiologicFunction"}, {"end": 159, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 68, "tag": "TemporalConcept"}, {"end": 126, "start": 106, "tag": "ResearchActivity"}, {"end": 202, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 342, "start": 340, "tag": "DiseaseOrSyndrome"}, {"end": 429, "start": 427, "tag": "DiseaseOrSyndrome"}, {"end": 360, "start": 352, "tag": "PatientOrDisabledGroup"}, {"end": 339, "start": 330, "tag": "HealthCareActivity"}, {"end": 400, "start": 389, "tag": "PopulationGroup"}, {"end": 421, "start": 414, "tag": "HealthCareActivity"}, {"end": 211, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 351, "start": 343, "tag": "DiseaseOrSyndrome"}, {"end": 438, "start": 430, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 31, "tag": "PopulationGroup"}, {"end": 262, "start": 256, "tag": "PopulationGroup"}, {"end": 139, "start": 130, "tag": "BiologicFunction"}, {"end": 421, "start": 418, "tag": "HealthCareActivity"}, {"end": 190, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 447, "start": 439, "tag": "PopulationGroup"}, {"end": 222, "start": 212, "tag": "Finding"}]}{"id": "1484_3", "text": "Among the 551 individuals that included, 537 had at least one follow-up (varied from 1 to 8years).", "tags": [{"end": 25, "start": 14, "tag": "PopulationGroup"}, {"end": 71, "start": 62, "tag": "HealthCareActivity"}, {"end": 71, "start": 62, "tag": "TemporalConcept"}]}{"id": "1484_4", "text": "Individuals in F+ groups performed worse and dropped faster in Mini-Mental State Examination scale and had faster shrinking middle temporal lobe than those in F- groups (all p<0.05).", "tags": [{"end": 98, "start": 63, "tag": "HealthCareActivity"}, {"end": 40, "start": 35, "tag": "Finding"}, {"end": 11, "start": 0, "tag": "PopulationGroup"}, {"end": 92, "start": 63, "tag": "HealthCareActivity"}, {"end": 24, "start": 18, "tag": "PopulationGroup"}, {"end": 168, "start": 162, "tag": "PopulationGroup"}, {"end": 144, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1484_5", "text": "Moreover, in MCI patients, reduced FDG-PET exerted 2.47 to 4.08-fold risk of AD dementia progression compared with those without significantly impaired FDG-PET (both p<0.001).ConclusionsBased on the analyses, separating FDG-PET from N biomarker to build the ATN(F) system is necessary and well-founded.", "tags": [{"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 244, "start": 235, "tag": "ClinicalAttribute"}, {"end": 25, "start": 17, "tag": "PatientOrDisabledGroup"}, {"end": 42, "start": 35, "tag": "HealthCareActivity"}, {"end": 159, "start": 152, "tag": "HealthCareActivity"}, {"end": 227, "start": 220, "tag": "HealthCareActivity"}, {"end": 88, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 89, "tag": "PathologicFunction"}, {"end": 100, "start": 89, "tag": "TemporalConcept"}, {"end": 207, "start": 199, "tag": "ResearchActivity"}, {"end": 42, "start": 39, "tag": "HealthCareActivity"}, {"end": 159, "start": 156, "tag": "HealthCareActivity"}, {"end": 227, "start": 224, "tag": "HealthCareActivity"}, {"end": 73, "start": 69, "tag": "Finding"}, {"end": 271, "start": 258, "tag": "HealthCareActivity"}]}{"id": "1484_6", "text": "The analysis from this study could be a complement to the original ATN framework for AD's biological definition.", "tags": [{"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 23, "tag": "ResearchActivity"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 80, "start": 67, "tag": "HealthCareActivity"}]}{"id": "1485_0", "text": "BackgroundGrowing evidence has demonstrated that DNA methylation (DNAm) plays an important role in Alzheimer's disease (AD) and that DNAm differences can be detected in the blood of AD subjects.", "tags": [{"end": 70, "start": 66, "tag": "CellFunction"}, {"end": 137, "start": 133, "tag": "CellFunction"}, {"end": 64, "start": 49, "tag": "CellFunction"}, {"end": 149, "start": 138, "tag": "Finding"}, {"end": 118, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 185, "tag": "PopulationGroup"}, {"end": 52, "start": 49, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 26, "start": 18, "tag": "Finding"}]}{"id": "1485_1", "text": "Most studies have correlated blood DNAm with the clinical diagnosis of AD in living individuals.", "tags": [{"end": 39, "start": 35, "tag": "CellFunction"}, {"end": 12, "start": 5, "tag": "ResearchActivity"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 77, "tag": "PopulationGroup"}, {"end": 67, "start": 49, "tag": "HealthCareActivity"}]}{"id": "1485_2", "text": "However, as the pathophysiological process of AD can begin many years before the onset of clinical symptoms, there is often disagreement between neuropathology in the brain and clinical phenotypes.", "tags": [{"end": 107, "start": 90, "tag": "SignOrSymptom"}, {"end": 159, "start": 145, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 159, "start": 145, "tag": "PathologicFunction"}, {"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 69, "start": 64, "tag": "TemporalConcept"}, {"end": 86, "start": 81, "tag": "TemporalConcept"}, {"end": 48, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 167, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 16, "tag": "PathologicFunction"}, {"end": 196, "start": 177, "tag": "ClinicalAttribute"}]}{"id": "1485_3", "text": "Therefore, blood DNAm associated with AD neuropathology, rather than with clinical data, would provide more relevant information on AD pathogenesis.MethodsWe performed a comprehensive analysis to identify blood DNAm associated with cerebrospinal fluid (CSF) pathological biomarkers for AD.", "tags": [{"end": 21, "start": 17, "tag": "CellFunction"}, {"end": 215, "start": 211, "tag": "CellFunction"}, {"end": 147, "start": 135, "tag": "PathologicFunction"}, {"end": 55, "start": 41, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 55, "start": 41, "tag": "PathologicFunction"}, {"end": 281, "start": 271, "tag": "ClinicalAttribute"}, {"end": 256, "start": 253, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 288, "start": 286, "tag": "DiseaseOrSyndrome"}, {"end": 251, "start": 232, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 210, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 74, "tag": "ResearchActivity"}, {"end": 192, "start": 184, "tag": "ResearchActivity"}]}{"id": "1485_4", "text": "Our study included matched samples of whole blood DNA methylation, CSF A beta(42), phosphorylated tau(181) (pTau(181)), and total tau (tTau) biomarkers data, measured on the same subjects and at the same clinical visits from a total of 202 subjects (123 CN or cognitively normal, 79 AD) in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.", "tags": [{"end": 49, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 50, "tag": "CellFunction"}, {"end": 151, "start": 141, "tag": "ClinicalAttribute"}, {"end": 70, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 351, "start": 345, "tag": "PopulationGroup"}, {"end": 285, "start": 283, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 156, "start": 152, "tag": "ResearchActivity"}, {"end": 117, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 179, "tag": "PopulationGroup"}, {"end": 248, "start": 240, "tag": "PopulationGroup"}, {"end": 278, "start": 260, "tag": "Finding"}, {"end": 313, "start": 294, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 254, "tag": "Finding"}, {"end": 337, "start": 294, "tag": "ResearchActivity"}, {"end": 81, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 50, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 337, "start": 294, "tag": "HealthCareRelatedOrganization"}, {"end": 81, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 135, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1485_5", "text": "To validate our findings, we also examined the association between premortem blood DNAm and postmortem brain neuropathology measured on a group of 69 subjects in the London dataset.ResultsWe identified a number of novel associations between blood DNAm and CSF biomarkers, demonstrating that changes in pathological processes in the CSF are reflected in the blood epigenome.", "tags": [{"end": 87, "start": 83, "tag": "CellFunction"}, {"end": 123, "start": 103, "tag": "PathologicFunction"}, {"end": 251, "start": 247, "tag": "CellFunction"}, {"end": 372, "start": 363, "tag": "GeneOrGenome"}, {"end": 102, "start": 92, "tag": "TemporalConcept"}, {"end": 324, "start": 302, "tag": "PathologicFunction"}, {"end": 270, "start": 260, "tag": "ClinicalAttribute"}, {"end": 259, "start": 256, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 335, "start": 332, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 246, "start": 241, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 362, "start": 357, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 150, "tag": "PopulationGroup"}, {"end": 143, "start": 138, "tag": "PopulationGroup"}, {"end": 76, "start": 67, "tag": "TemporalConcept"}, {"end": 180, "start": 173, "tag": "ResearchActivity"}]}{"id": "1485_6", "text": "Overall, the CSF biomarker-associated DNAm is relatively distinct in CN and AD subjects, highlighting the importance of analyzing omics data measured on cognitively normal subjects (which includes preclinical AD subjects) to identify diagnostic biomarkers, and considering disease stages in the development and testing of AD treatment strategies.", "tags": [{"end": 42, "start": 38, "tag": "CellFunction"}, {"end": 287, "start": 273, "tag": "ClinicalAttribute"}, {"end": 345, "start": 325, "tag": "HealthCareActivity"}, {"end": 318, "start": 311, "tag": "HealthCareActivity"}, {"end": 135, "start": 130, "tag": "ResearchActivity"}, {"end": 345, "start": 325, "tag": "ResearchActivity"}, {"end": 255, "start": 245, "tag": "ClinicalAttribute"}, {"end": 16, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 324, "start": 322, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 17, "tag": "ClinicalAttribute"}, {"end": 211, "start": 197, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 136, "tag": "ResearchActivity"}, {"end": 306, "start": 295, "tag": "BiologicFunction"}, {"end": 306, "start": 295, "tag": "CellFunction"}, {"end": 287, "start": 281, "tag": "TemporalConcept"}, {"end": 87, "start": 79, "tag": "PopulationGroup"}, {"end": 180, "start": 172, "tag": "PopulationGroup"}, {"end": 220, "start": 212, "tag": "PopulationGroup"}, {"end": 171, "start": 153, "tag": "Finding"}, {"end": 255, "start": 234, "tag": "ClinicalAttribute"}, {"end": 71, "start": 69, "tag": "Finding"}]}{"id": "1485_7", "text": "Moreover, our analysis revealed biological processes associated with early brain impairment relevant to AD are marked by DNAm in the blood, and blood DNAm at several CpGs in the DMR on HOXA5 gene are associated with pTau(181) in the CSF, as well as tau-pathology and DNAm in the brain, nominating DNAm at this locus as a promising candidate AD biomarker.ConclusionsOur study provides a valuable resource for future mechanistic and biomarker studies of DNAm in AD.", "tags": [{"end": 125, "start": 121, "tag": "CellFunction"}, {"end": 154, "start": 150, "tag": "CellFunction"}, {"end": 195, "start": 185, "tag": "GeneOrGenome"}, {"end": 271, "start": 267, "tag": "CellFunction"}, {"end": 301, "start": 297, "tag": "CellFunction"}, {"end": 456, "start": 452, "tag": "CellFunction"}, {"end": 52, "start": 32, "tag": "BiologicFunction"}, {"end": 414, "start": 408, "tag": "TemporalConcept"}, {"end": 236, "start": 233, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 262, "start": 249, "tag": "PathologicFunction"}, {"end": 448, "start": 441, "tag": "ResearchActivity"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 343, "start": 341, "tag": "DiseaseOrSyndrome"}, {"end": 462, "start": 460, "tag": "DiseaseOrSyndrome"}, {"end": 353, "start": 344, "tag": "ClinicalAttribute"}, {"end": 440, "start": 431, "tag": "ClinicalAttribute"}, {"end": 374, "start": 369, "tag": "ResearchActivity"}, {"end": 80, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 284, "start": 279, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 225, "start": 216, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 216, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 14, "tag": "ResearchActivity"}, {"end": 170, "start": 166, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1486_0", "text": "BACKGROUND: Amyloid-beta (A beta) likely plays a primary role in Alzheimer's disease pathogenesis, but longitudinal A beta, tau, and neurodegeneration (A/T/N) measurements in the same individuals have rarely been examined to verify the temporal dynamics of these biomarkers.", "tags": [{"end": 244, "start": 236, "tag": "TemporalConcept"}, {"end": 97, "start": 85, "tag": "PathologicFunction"}, {"end": 253, "start": 245, "tag": "NaturalPhenomenonOrProcess"}, {"end": 115, "start": 103, "tag": "ResearchActivity"}, {"end": 127, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 133, "tag": "CellOrMolecularDysfunction"}, {"end": 84, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 273, "start": 263, "tag": "ClinicalAttribute"}, {"end": 127, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 184, "tag": "PopulationGroup"}, {"end": 32, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 159, "tag": "HealthCareActivity"}]}{"id": "1486_1", "text": "METHODS: In this study, we investigated the temporal ordering of A beta, tau, and neurodegeneration using longitudinal biomarkers in nondemented elderly individuals.", "tags": [{"end": 52, "start": 44, "tag": "TemporalConcept"}, {"end": 118, "start": 106, "tag": "ResearchActivity"}, {"end": 76, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 82, "tag": "CellOrMolecularDysfunction"}, {"end": 129, "start": 119, "tag": "ClinicalAttribute"}, {"end": 76, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}, {"end": 164, "start": 153, "tag": "PopulationGroup"}, {"end": 144, "start": 133, "tag": "PopulationGroup"}, {"end": 152, "start": 145, "tag": "PopulationGroup"}, {"end": 71, "start": 65, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1486_2", "text": "A total of 395 cognitively unimpaired individuals and 204 individuals with mild cognitive impairment (320 [53%] were female) were classified into 8 A +/-/T +/-/N +/- categories according to the abnormal (+)/normal (-) status of A beta (F-18-flor betapir or F-18-florbeta ben) positron emission tomography (PET), F-18-flortaucipir PET, and adjusted hippocampal volume (aHCV).", "tags": [{"end": 202, "start": 194, "tag": "Finding"}, {"end": 123, "start": 117, "tag": "OrganismAttribute"}, {"end": 224, "start": 218, "tag": "Finding"}, {"end": 213, "start": 207, "tag": "Finding"}, {"end": 49, "start": 15, "tag": "PopulationGroup"}, {"end": 69, "start": 58, "tag": "PopulationGroup"}, {"end": 309, "start": 306, "tag": "HealthCareActivity"}, {"end": 333, "start": 330, "tag": "HealthCareActivity"}, {"end": 100, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 234, "start": 228, "tag": "AminoAcidPeptideOrProtein"}, {"end": 304, "start": 276, "tag": "HealthCareActivity"}, {"end": 359, "start": 348, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 359, "start": 348, "tag": "Cell"}, {"end": 304, "start": 276, "tag": "ManufacturedObject"}, {"end": 366, "start": 339, "tag": "ClinicalAttribute"}, {"end": 253, "start": 236, "tag": "Chemical"}, {"end": 274, "start": 257, "tag": "Chemical"}, {"end": 329, "start": 312, "tag": "Chemical"}, {"end": 372, "start": 368, "tag": "ClinicalAttribute"}]}{"id": "1486_3", "text": "Follow-up A beta PET, tau PET, and aHCV measurements at 0.6 to 4.1 years were available for 35% to 63% of the sample.", "tags": [{"end": 116, "start": 110, "tag": "Substance"}, {"end": 116, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "TemporalConcept"}, {"end": 25, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 67, "tag": "TemporalConcept"}, {"end": 25, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 17, "tag": "HealthCareActivity"}, {"end": 29, "start": 26, "tag": "HealthCareActivity"}, {"end": 16, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 40, "tag": "HealthCareActivity"}, {"end": 39, "start": 35, "tag": "ClinicalAttribute"}]}{"id": "1486_4", "text": "Baseline A beta, tau, and aHCV were compared between different A/T/N profiles.", "tags": [{"end": 20, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 69, "tag": "ResearchActivity"}, {"end": 30, "start": 26, "tag": "ClinicalAttribute"}]}{"id": "1486_5", "text": "We investigated the associations of baseline and longitudinal A beta, tau, and neurodegeneration in relation to one another conti nuously.", "tags": [{"end": 61, "start": 49, "tag": "ResearchActivity"}, {"end": 73, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 79, "tag": "CellOrMolecularDysfunction"}, {"end": 73, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 62, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1486_6", "text": "RESULTS: Among T- participants, tau was higher for A+/T-/N- individuals compared with the A-/T-/N- group (p = .02).", "tags": [{"end": 35, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 18, "tag": "PopulationGroup"}, {"end": 71, "start": 60, "tag": "PopulationGroup"}, {"end": 104, "start": 99, "tag": "PopulationGroup"}]}{"id": "1486_7", "text": "Among N- participants, neurodegeneration was worse among A+/T+/N- individuals compared with the A-/T-/N- group (p = .001).", "tags": [{"end": 40, "start": 23, "tag": "CellOrMolecularDysfunction"}, {"end": 21, "start": 9, "tag": "PopulationGroup"}, {"end": 77, "start": 66, "tag": "PopulationGroup"}, {"end": 110, "start": 105, "tag": "PopulationGroup"}]}{"id": "1486_8", "text": "High baseline A beta was associated (p , .001) with subsequent tau increase and high baseline tau was associated (p = .002) with subsequent aHCV decrease, whereas high tau and low aHCV at baseline were not associated with subsequent A beta increase.", "tags": [{"end": 153, "start": 140, "tag": "Finding"}, {"end": 66, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 168, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 168, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 176, "tag": "Finding"}, {"end": 20, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 239, "start": 233, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 140, "tag": "ClinicalAttribute"}, {"end": 75, "start": 63, "tag": "Finding"}]}{"id": "1486_9", "text": "CONCLUSIONS: These findings define a sequence of pathological events in Alzheimer's disease that support a current model of Alzheimer's disease pathogenesis in which A beta appears early, followed by deposition of abnormal tau aggregates and subsequent neurodegeneration.", "tags": [{"end": 237, "start": 227, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 144, "tag": "PathologicFunction"}, {"end": 226, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 270, "start": 253, "tag": "CellOrMolecularDysfunction"}, {"end": 91, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 226, "start": 223, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 115, "tag": "ResearchActivity"}, {"end": 114, "start": 107, "tag": "TemporalConcept"}, {"end": 172, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 49, "tag": "PathologicFunction"}, {"end": 186, "start": 181, "tag": "TemporalConcept"}, {"end": 237, "start": 200, "tag": "CellOrMolecularDysfunction"}]}{"id": "1487_0", "text": "Background and purpose We investigated plasma neurofilament light chain concentration (pNfL) as a biomarker for neuroaxonal damage and disease activity using data from Phase 3 trials of ozanimod in relapsing multiple sclerosis (RMS).", "tags": [{"end": 182, "start": 168, "tag": "ResearchActivity"}, {"end": 175, "start": 168, "tag": "TemporalConcept"}, {"end": 194, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 231, "start": 228, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 98, "tag": "ClinicalAttribute"}, {"end": 162, "start": 158, "tag": "ResearchActivity"}, {"end": 65, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 135, "tag": "HealthCareActivity"}, {"end": 226, "start": 198, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 112, "tag": "InjuryOrPoisoning"}, {"end": 71, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 194, "start": 186, "tag": "PharmacologicSubstance"}, {"end": 85, "start": 39, "tag": "ClinicalAttribute"}, {"end": 91, "start": 87, "tag": "ClinicalAttribute"}]}{"id": "1487_1", "text": "Methods pNfL was measured before and after ozanimod 0.46 mg or 0.92 mg daily or interferon beta-1a 30 mu g weekly in the randomized, double-blind SUNBEAM and RADIANCE trials.", "tags": [{"end": 51, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 107, "tag": "TemporalConcept"}, {"end": 131, "start": 121, "tag": "ResearchActivity"}, {"end": 131, "start": 121, "tag": "Finding"}, {"end": 173, "start": 167, "tag": "ResearchActivity"}, {"end": 145, "start": 133, "tag": "ResearchActivity"}, {"end": 76, "start": 71, "tag": "TemporalConcept"}, {"end": 25, "start": 17, "tag": "HealthCareActivity"}, {"end": 12, "start": 8, "tag": "ClinicalAttribute"}, {"end": 51, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 172, "start": 167, "tag": "ResearchActivity"}, {"end": 153, "start": 146, "tag": "ResearchActivity"}, {"end": 172, "start": 158, "tag": "ResearchActivity"}, {"end": 98, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 80, "tag": "PharmacologicSubstance"}]}{"id": "1487_2", "text": "In these post hoc analyses, we investigated relationships between pNfL (at baseline and median percentage change from baseline to Month 12 [SUNBEAM] or 24 [RADIANCE]) and clinical and magnetic resonance imaging outcomes.", "tags": [{"end": 135, "start": 130, "tag": "TemporalConcept"}, {"end": 57, "start": 44, "tag": "Finding"}, {"end": 210, "start": 184, "tag": "HealthCareActivity"}, {"end": 210, "start": 203, "tag": "HealthCareActivity"}, {"end": 210, "start": 184, "tag": "ManufacturedObject"}, {"end": 126, "start": 88, "tag": "ResearchActivity"}, {"end": 13, "start": 9, "tag": "TemporalConcept"}, {"end": 70, "start": 66, "tag": "ClinicalAttribute"}, {"end": 26, "start": 9, "tag": "ResearchActivity"}, {"end": 147, "start": 140, "tag": "ResearchActivity"}, {"end": 164, "start": 156, "tag": "ResearchActivity"}]}{"id": "1487_3", "text": "Results Median (Q1, Q3) baseline pNfL, available in 1244 of 1346 SUNBEAM participants, was 14.70 (10.16, 23.26) pg/ml and in 1109 of 1313 RADIANCE participants was 13.35 (9.42, 20.41) pg/ml.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 85, "start": 73, "tag": "PopulationGroup"}, {"end": 159, "start": 147, "tag": "PopulationGroup"}, {"end": 37, "start": 33, "tag": "ClinicalAttribute"}, {"end": 72, "start": 65, "tag": "ResearchActivity"}, {"end": 146, "start": 138, "tag": "ResearchActivity"}]}{"id": "1487_4", "text": "Baseline gadolinium-enhancing (GdE) and T2 lesion counts increased and brain volume decreased with increasing baseline pNfL.", "tags": [{"end": 49, "start": 43, "tag": "Finding"}, {"end": 29, "start": 9, "tag": "Finding"}, {"end": 34, "start": 31, "tag": "Finding"}, {"end": 123, "start": 119, "tag": "ClinicalAttribute"}, {"end": 83, "start": 71, "tag": "ClinicalAttribute"}]}{"id": "1487_5", "text": "Baseline pNfL was higher in those with versus without on-treatment relapse.", "tags": [{"end": 66, "start": 57, "tag": "HealthCareActivity"}, {"end": 66, "start": 57, "tag": "ResearchActivity"}, {"end": 74, "start": 67, "tag": "TemporalConcept"}, {"end": 74, "start": 67, "tag": "Finding"}, {"end": 13, "start": 9, "tag": "ClinicalAttribute"}]}{"id": "1487_6", "text": "Median percentage reduction in pNfL at 12 months in SUNBEAM (n = 1238) and 24 months in RADIANCE (n = 1088) was greater for ozanimod (20%-27%) than interferon beta-1a (13%-16%; p < 0.01).", "tags": [{"end": 132, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 166, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 39, "tag": "TemporalConcept"}, {"end": 27, "start": 18, "tag": "Finding"}, {"end": 27, "start": 18, "tag": "NaturalPhenomenonOrProcess"}, {"end": 48, "start": 42, "tag": "TemporalConcept"}, {"end": 84, "start": 78, "tag": "TemporalConcept"}, {"end": 35, "start": 31, "tag": "ClinicalAttribute"}, {"end": 59, "start": 52, "tag": "ResearchActivity"}, {"end": 96, "start": 88, "tag": "ResearchActivity"}, {"end": 132, "start": 124, "tag": "PharmacologicSubstance"}, {"end": 166, "start": 148, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 148, "tag": "PharmacologicSubstance"}]}{"id": "1487_7", "text": "Greater pNfL reduction was associated with fewer GdE lesions, fewer new/enlarging T2 lesions per scan, less loss of brain volume, lower annualized relapse rate (ARR), and no evidence of disease activity.", "tags": [{"end": 60, "start": 49, "tag": "Finding"}, {"end": 101, "start": 97, "tag": "HealthCareActivity"}, {"end": 101, "start": 97, "tag": "Finding"}, {"end": 182, "start": 174, "tag": "Finding"}, {"end": 22, "start": 13, "tag": "Finding"}, {"end": 22, "start": 13, "tag": "NaturalPhenomenonOrProcess"}, {"end": 202, "start": 186, "tag": "HealthCareActivity"}, {"end": 60, "start": 53, "tag": "InjuryOrPoisoning"}, {"end": 92, "start": 82, "tag": "InjuryOrPoisoning"}, {"end": 12, "start": 8, "tag": "ClinicalAttribute"}, {"end": 128, "start": 116, "tag": "ClinicalAttribute"}, {"end": 159, "start": 136, "tag": "HealthCareActivity"}, {"end": 164, "start": 161, "tag": "HealthCareActivity"}]}{"id": "1487_8", "text": "The following models predicted ARR: 0.5111 + 0.0116 x Delta NfL at 12 months (SUNBEAM) and 0.4079 + 0.0088 x Delta NfL at 24 months (RADIANCE).", "tags": [{"end": 76, "start": 67, "tag": "TemporalConcept"}, {"end": 63, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 131, "start": 125, "tag": "TemporalConcept"}, {"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 34, "start": 31, "tag": "HealthCareActivity"}, {"end": 85, "start": 78, "tag": "ResearchActivity"}, {"end": 141, "start": 133, "tag": "ResearchActivity"}]}{"id": "1487_9", "text": "Conclusions pNfL was associated with clinical and radiologic measures of disease and treatment effects in RMS, supporting its use as a biomarker.", "tags": [{"end": 69, "start": 50, "tag": "ClinicalAttribute"}, {"end": 102, "start": 85, "tag": "Finding"}, {"end": 109, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 135, "tag": "ClinicalAttribute"}, {"end": 94, "start": 85, "tag": "HealthCareActivity"}, {"end": 94, "start": 85, "tag": "ResearchActivity"}, {"end": 16, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1488_0", "text": "The A/T/N research framework has been proposed for the diagnosis and prognosis of Alzheimer's disease (AD).", "tags": [{"end": 78, "start": 69, "tag": "HealthCareActivity"}, {"end": 101, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 4, "tag": "ResearchActivity"}, {"end": 64, "start": 55, "tag": "HealthCareActivity"}]}{"id": "1488_1", "text": "However, the spatial distribution of ATN biomarkers and their relationship with cognitive impairment and neuropsychiatric symptoms (NPS) need further clarification in patients with AD.", "tags": [{"end": 135, "start": 132, "tag": "SignOrSymptom"}, {"end": 130, "start": 105, "tag": "SignOrSymptom"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 167, "tag": "PatientOrDisabledGroup"}, {"end": 100, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 37, "tag": "ClinicalAttribute"}, {"end": 74, "start": 62, "tag": "Finding"}]}{"id": "1488_2", "text": "We scanned 83 AD patients and 38 cognitively normal controls who independently completed the mini-mental state examination and Neuropsychiatric Inventory scales.", "tags": [{"end": 10, "start": 3, "tag": "HealthCareActivity"}, {"end": 122, "start": 93, "tag": "HealthCareActivity"}, {"end": 51, "start": 45, "tag": "Finding"}, {"end": 60, "start": 45, "tag": "PopulationGroup"}, {"end": 16, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 17, "tag": "PatientOrDisabledGroup"}, {"end": 51, "start": 33, "tag": "Finding"}, {"end": 160, "start": 127, "tag": "HealthCareActivity"}]}{"id": "1488_3", "text": "Tau, Ap, and hypometabolism spatial patterns were characterized using Statistical Parametric Mapping together with [18F]flortaucipir, [18F]florbetapir, and [18F]FDG positron emission tomography.", "tags": [{"end": 27, "start": 13, "tag": "Finding"}, {"end": 150, "start": 134, "tag": "Chemical"}, {"end": 132, "start": 115, "tag": "Chemical"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 165, "tag": "HealthCareActivity"}, {"end": 44, "start": 36, "tag": "ResearchActivity"}, {"end": 100, "start": 70, "tag": "HealthCareActivity"}, {"end": 164, "start": 156, "tag": "Chemical"}]}{"id": "1488_4", "text": "Piecewise linear regression, two-sample t-tests, and support vector machine algorithms were used to explore the relationship between tau, A beta, and hypometabolism and cognition, NPS, and AD diagnosis.", "tags": [{"end": 164, "start": 150, "tag": "Finding"}, {"end": 183, "start": 180, "tag": "SignOrSymptom"}, {"end": 27, "start": 0, "tag": "ResearchActivity"}, {"end": 86, "start": 53, "tag": "MachineActivity"}, {"end": 136, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 191, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 192, "tag": "HealthCareActivity"}, {"end": 178, "start": 169, "tag": "BiologicFunction"}, {"end": 124, "start": 112, "tag": "Finding"}, {"end": 47, "start": 29, "tag": "ResearchActivity"}, {"end": 144, "start": 138, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1488_5", "text": "The results showed that regions with tau deposition are region-specific and mainly occurred in inferior temporal lobes in AD, which extensively overlaps with the hypometabolic regions.", "tags": [{"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 37, "tag": "PathologicFunction"}]}{"id": "1488_6", "text": "While the deposition regions of A beta were unique and the regions affected by hypometabolism were widely distributed.", "tags": [{"end": 93, "start": 79, "tag": "Finding"}, {"end": 38, "start": 32, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1488_7", "text": "Unlike A beta, tau and hypometabolism build up monotonically with increasing cognitive impairment in the late stages of AD.", "tags": [{"end": 37, "start": 23, "tag": "Finding"}, {"end": 116, "start": 105, "tag": "TemporalConcept"}, {"end": 116, "start": 110, "tag": "TemporalConcept"}, {"end": 122, "start": 110, "tag": "ClinicalAttribute"}, {"end": 76, "start": 66, "tag": "Finding"}, {"end": 18, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 7, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1488_8", "text": "In addition, NPS in AD were associated with tau deposition closely, followed by hypometabolism, but not with A beta.", "tags": [{"end": 16, "start": 13, "tag": "SignOrSymptom"}, {"end": 94, "start": 80, "tag": "Finding"}, {"end": 47, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 44, "tag": "PathologicFunction"}]}{"id": "1488_9", "text": "Finally, hypometabolism and tau had higher accuracy in differentiating the AD patients from controls (accuracy = 0.88, accuracy = 0.85) than A beta (accuracy = 0.81), and the combined three were the highest (accuracy = 0.95).", "tags": [{"end": 23, "start": 9, "tag": "Finding"}, {"end": 31, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 92, "tag": "PopulationGroup"}, {"end": 86, "start": 78, "tag": "PatientOrDisabledGroup"}, {"end": 51, "start": 43, "tag": "Finding"}, {"end": 110, "start": 102, "tag": "Finding"}, {"end": 127, "start": 119, "tag": "Finding"}, {"end": 157, "start": 149, "tag": "Finding"}, {"end": 216, "start": 208, "tag": "Finding"}, {"end": 147, "start": 141, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1488_10", "text": "These findings suggest tau pathology is superior over A beta and glucose metabolism to identify cognitive impairment and NPS.", "tags": [{"end": 124, "start": 121, "tag": "SignOrSymptom"}, {"end": 83, "start": 65, "tag": "CellFunction"}, {"end": 83, "start": 73, "tag": "BiologicFunction"}, {"end": 83, "start": 73, "tag": "CellFunction"}, {"end": 26, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 23, "tag": "PathologicFunction"}, {"end": 72, "start": 65, "tag": "Chemical"}, {"end": 72, "start": 65, "tag": "PharmacologicSubstance"}, {"end": 72, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 54, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1488_11", "text": "Its results support tau accumulation can be used as a biomarker of clinical impairment in AD.", "tags": [{"end": 23, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 54, "tag": "ClinicalAttribute"}, {"end": 36, "start": 24, "tag": "Finding"}, {"end": 86, "start": 67, "tag": "SignOrSymptom"}]}{"id": "1489_0", "text": "Introduction: Amyloid beta (A beta) oligomers are one of the most toxic structural forms of the A beta protein and are hypothesized to cause synaptotoxicity and memory failure as they build up in Alzheimer's disease (AD) patients' brain tissue.", "tags": [{"end": 71, "start": 66, "tag": "InjuryOrPoisoning"}, {"end": 110, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 215, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 221, "tag": "PatientOrDisabledGroup"}, {"end": 219, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 243, "start": 231, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 167, "start": 161, "tag": "BiologicFunction"}, {"end": 45, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 141, "tag": "InjuryOrPoisoning"}, {"end": 175, "start": 161, "tag": "PathologicFunction"}]}{"id": "1489_1", "text": "We previously demonstrated that antagonists of the sigma-2 receptor complex effectively block A beta oligomer toxicity.", "tags": [{"end": 43, "start": 32, "tag": "Chemical"}, {"end": 75, "start": 32, "tag": "PharmacologicSubstance"}, {"end": 118, "start": 110, "tag": "InjuryOrPoisoning"}, {"end": 75, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 51, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1489_2", "text": "CT1812 is an orally bioavailable, brain penetrant small molecule antagonist of the sigma-2 receptor complex that appears safe and well tolerated in healthy elderly volunteers.", "tags": [{"end": 19, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 50, "tag": "Chemical"}, {"end": 99, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 156, "tag": "PopulationGroup"}, {"end": 155, "start": 148, "tag": "OrganismAttribute"}, {"end": 6, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 6, "start": 0, "tag": "Chemical"}, {"end": 107, "start": 65, "tag": "Chemical"}, {"end": 107, "start": 65, "tag": "PharmacologicSubstance"}, {"end": 174, "start": 164, "tag": "PopulationGroup"}]}{"id": "1489_3", "text": "We tested CT1812's effect on A beta oligomer pathobiology in preclinical AD models and evaluated CT1812's impact on cerebrospinal fluid (CSF) protein biomarkers in mild to moderate AD patients in a clinical trial (ClinicalTrials.gov NCT02907567).", "tags": [{"end": 232, "start": 214, "tag": "HealthCareRelatedOrganization"}, {"end": 212, "start": 198, "tag": "ResearchActivity"}, {"end": 160, "start": 142, "tag": "ClinicalAttribute"}, {"end": 192, "start": 184, "tag": "PatientOrDisabledGroup"}, {"end": 140, "start": 137, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 76, "tag": "ResearchActivity"}, {"end": 75, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 130, "tag": "Substance"}, {"end": 44, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 10, "tag": "Chemical"}, {"end": 16, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 103, "start": 97, "tag": "PharmacologicSubstance"}, {"end": 103, "start": 97, "tag": "Chemical"}, {"end": 57, "start": 45, "tag": "PathologicFunction"}, {"end": 244, "start": 233, "tag": "ResearchActivity"}]}{"id": "1489_4", "text": "Methods: Experiments were performed to measure the impact of CT1812 versus vehicle on A beta oligomer binding to synapses in vitro, to human AD patient post mortem brain tissue ex vivo, and in living APP(S)(we)/PS1dE9 transgenic mice in vivo.", "tags": [{"end": 20, "start": 9, "tag": "ResearchActivity"}, {"end": 121, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 233, "start": 218, "tag": "Eukaryote"}, {"end": 233, "start": 218, "tag": "ResearchActivity"}, {"end": 241, "start": 234, "tag": "ResearchActivity"}, {"end": 203, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 200, "tag": "GeneOrGenome"}, {"end": 203, "start": 200, "tag": "BiologicallyActiveSubstance"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 233, "start": 229, "tag": "Eukaryote"}, {"end": 176, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 102, "tag": "CellFunction"}, {"end": 140, "start": 135, "tag": "Eukaryote"}, {"end": 101, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 122, "tag": "ResearchActivity"}, {"end": 151, "start": 144, "tag": "PatientOrDisabledGroup"}, {"end": 163, "start": 152, "tag": "TemporalConcept"}, {"end": 67, "start": 61, "tag": "Chemical"}, {"end": 67, "start": 61, "tag": "PharmacologicSubstance"}, {"end": 184, "start": 177, "tag": "ResearchActivity"}, {"end": 233, "start": 200, "tag": "ExperimentalModelOfDisease"}]}{"id": "1489_5", "text": "Additional experiments were performed to measure the impact of CT1812 versus vehicle on A beta oligomer-induced deficits in membrane trafficking rate, synapse number, and protein expression in mature hippocampal/cortical neurons in vitro.", "tags": [{"end": 158, "start": 151, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 228, "start": 212, "tag": "Cell"}, {"end": 22, "start": 11, "tag": "ResearchActivity"}, {"end": 132, "start": 124, "tag": "CellComponent"}, {"end": 189, "start": 171, "tag": "CellFunction"}, {"end": 199, "start": 193, "tag": "TemporalConcept"}, {"end": 120, "start": 112, "tag": "Finding"}, {"end": 149, "start": 145, "tag": "TemporalConcept"}, {"end": 103, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 237, "start": 229, "tag": "ResearchActivity"}, {"end": 211, "start": 200, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 200, "tag": "Cell"}, {"end": 69, "start": 63, "tag": "PharmacologicSubstance"}, {"end": 69, "start": 63, "tag": "Chemical"}, {"end": 144, "start": 124, "tag": "CellFunction"}]}{"id": "1489_6", "text": "The impact of CT1812 on cognitive function was measured in transgenic Thy1 huAPP(Swe/Lnd+) and wild-type littermates.", "tags": [{"end": 42, "start": 24, "tag": "BiologicFunction"}, {"end": 69, "start": 59, "tag": "GeneOrGenome"}, {"end": 74, "start": 70, "tag": "GeneOrGenome"}, {"end": 116, "start": 95, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "Chemical"}, {"end": 20, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 90, "start": 59, "tag": "ExperimentalModelOfDisease"}]}{"id": "1489_7", "text": "A multicenter, double-blind, placebo-controlled parallel group trial was performed to evaluate the safety, tolerability, and impact on protein biomarker expression of CT1812 or placebo given once daily for 28 days to AD patients (Mini-Mental State Examination 18-26).", "tags": [{"end": 13, "start": 2, "tag": "ResearchActivity"}, {"end": 27, "start": 15, "tag": "ResearchActivity"}, {"end": 47, "start": 29, "tag": "ResearchActivity"}, {"end": 119, "start": 107, "tag": "ResearchActivity"}, {"end": 36, "start": 29, "tag": "HealthCareActivity"}, {"end": 184, "start": 177, "tag": "HealthCareActivity"}, {"end": 105, "start": 99, "tag": "HealthCareActivity"}, {"end": 213, "start": 209, "tag": "TemporalConcept"}, {"end": 228, "start": 220, "tag": "PatientOrDisabledGroup"}, {"end": 219, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 135, "tag": "ClinicalAttribute"}, {"end": 62, "start": 57, "tag": "PopulationGroup"}, {"end": 201, "start": 196, "tag": "TemporalConcept"}, {"end": 259, "start": 230, "tag": "HealthCareActivity"}, {"end": 173, "start": 167, "tag": "Chemical"}, {"end": 173, "start": 167, "tag": "PharmacologicSubstance"}, {"end": 68, "start": 63, "tag": "ResearchActivity"}]}{"id": "1489_8", "text": "CSF protein expression was measured by liquid chromatography with tandem mass spectrometry or enzyme-linked immunosorbent assay in samples drawn prior to dosing (Day 0) and at end of dosing (Day 28) and compared within each patient and between pooled treated versus placebo-treated dosing groups.", "tags": [{"end": 60, "start": 39, "tag": "ResearchActivity"}, {"end": 90, "start": 66, "tag": "ResearchActivity"}, {"end": 127, "start": 94, "tag": "ResearchActivity"}, {"end": 165, "start": 162, "tag": "TemporalConcept"}, {"end": 194, "start": 191, "tag": "TemporalConcept"}, {"end": 22, "start": 4, "tag": "CellFunction"}, {"end": 273, "start": 266, "tag": "HealthCareActivity"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 295, "start": 289, "tag": "PopulationGroup"}, {"end": 90, "start": 73, "tag": "ResearchActivity"}, {"end": 100, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 231, "start": 224, "tag": "PatientOrDisabledGroup"}]}{"id": "1489_9", "text": "Results: CT1812 significantly and dose-dependently displaced A beta oligomers bound to synaptic receptors in three independent preclinical models of AD, facilitated oligomer clearance into the CSF, increased synaptic number and protein expression in neurons, and improved cognitive performance in transgenic mice.", "tags": [{"end": 105, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 174, "tag": "NaturalPhenomenonOrProcess"}, {"end": 312, "start": 297, "tag": "Eukaryote"}, {"end": 246, "start": 228, "tag": "CellFunction"}, {"end": 312, "start": 297, "tag": "ResearchActivity"}, {"end": 293, "start": 272, "tag": "Finding"}, {"end": 196, "start": 193, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 151, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 127, "tag": "ResearchActivity"}, {"end": 312, "start": 308, "tag": "Eukaryote"}, {"end": 77, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 257, "start": 250, "tag": "Cell"}, {"end": 15, "start": 9, "tag": "Chemical"}, {"end": 15, "start": 9, "tag": "PharmacologicSubstance"}, {"end": 105, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 223, "start": 208, "tag": "CellFunction"}]}{"id": "1489_10", "text": "CT1812 significantly increased CSF concentrations of A beta oligomers in AD patient CSF, reduced concentrations of synaptic proteins and phosphorylated tau fragments, and reversed expression of many AD-related proteins dysregulated in CSF.", "tags": [{"end": 231, "start": 210, "tag": "PathologicFunction"}, {"end": 30, "start": 7, "tag": "Finding"}, {"end": 155, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 235, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 199, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 210, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 76, "tag": "PatientOrDisabledGroup"}, {"end": 6, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 6, "start": 0, "tag": "Chemical"}, {"end": 69, "start": 31, "tag": "ClinicalAttribute"}]}{"id": "1489_11", "text": "Discussion: These preclinical studies demonstrate the novel disease-modifying mechanism of action of CT1812 against AD and A beta oligomers.", "tags": [{"end": 37, "start": 18, "tag": "ResearchActivity"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 101, "tag": "Chemical"}, {"end": 107, "start": 101, "tag": "PharmacologicSubstance"}]}{"id": "1489_12", "text": "The clinical results are consistent with preclinical data and provide evidence of target engagement and impact on fundamental disease-related signaling pathways in AD patients, supporting further development of CT1812.", "tags": [{"end": 160, "start": 142, "tag": "CellFunction"}, {"end": 175, "start": 167, "tag": "PatientOrDisabledGroup"}, {"end": 166, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 41, "tag": "ResearchActivity"}, {"end": 57, "start": 53, "tag": "ResearchActivity"}, {"end": 207, "start": 196, "tag": "BiologicFunction"}, {"end": 207, "start": 196, "tag": "CellFunction"}, {"end": 78, "start": 70, "tag": "Finding"}, {"end": 99, "start": 82, "tag": "Finding"}, {"end": 217, "start": 211, "tag": "PharmacologicSubstance"}, {"end": 217, "start": 211, "tag": "Chemical"}]}{"id": "1490_0", "text": "Introduction: Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined.", "tags": [{"end": 103, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 70, "tag": "ClinicalAttribute"}]}{"id": "1490_1", "text": "Methods: We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples.", "tags": [{"end": 88, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 43, "tag": "ResearchActivity"}, {"end": 33, "start": 25, "tag": "PopulationGroup"}, {"end": 96, "start": 89, "tag": "Substance"}, {"end": 96, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1490_2", "text": "Diagnoses were subjective cognitive decline (n = 75), mild cognitive impairment (n = 128), and AD dementia (n = 110), and a group of cognitively unimpaired subjects (n = 154) were also included.", "tags": [{"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 155, "start": 133, "tag": "Finding"}, {"end": 43, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 124, "tag": "PopulationGroup"}, {"end": 164, "start": 156, "tag": "PopulationGroup"}]}{"id": "1490_3", "text": "We measured baseline and follow-up CSF levels of total tau (t-tau), phosphorylated tau (p-tau), YKL-40, and neurofilament light (NfL).", "tags": [{"end": 127, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 68, "tag": "CellFunction"}, {"end": 11, "start": 3, "tag": "HealthCareActivity"}, {"end": 132, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 25, "tag": "HealthCareActivity"}, {"end": 34, "start": 25, "tag": "TemporalConcept"}, {"end": 93, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 88, "tag": "BiologicallyActiveSubstance"}]}{"id": "1490_4", "text": "Median CSF sampling interval was 2.1 years.", "tags": [{"end": 10, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 37, "tag": "TemporalConcept"}, {"end": 28, "start": 20, "tag": "TemporalConcept"}, {"end": 19, "start": 7, "tag": "HealthCareActivity"}]}{"id": "1490_5", "text": "Results: CSF levels of t-tau, p-tau, NfL, and YKL-40 were 2% higher per each year of baseline age in controls (P <.", "tags": [{"end": 52, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 77, "tag": "TemporalConcept"}, {"end": 40, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 101, "tag": "PopulationGroup"}, {"end": 28, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 97, "start": 94, "tag": "OrganismAttribute"}, {"end": 35, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 9, "tag": "ClinicalAttribute"}]}{"id": "1490_6", "text": "001).", "tags": []}{"id": "1490_7", "text": "In AD, t-tau levels were 1% lower (P <.", "tags": [{"end": 33, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 5, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 7, "tag": "ClinicalAttribute"}]}{"id": "1490_8", "text": "001) and p-tau levels did not change per each year of baseline age.", "tags": [{"end": 50, "start": 46, "tag": "TemporalConcept"}, {"end": 14, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 63, "tag": "OrganismAttribute"}, {"end": 14, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 9, "tag": "ClinicalAttribute"}]}{"id": "1490_9", "text": "Longitudinally, only NfL (P <.", "tags": [{"end": 24, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 21, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1490_10", "text": "001) and YKL-40 (P <.", "tags": [{"end": 15, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 9, "tag": "BiologicallyActiveSubstance"}]}{"id": "1490_11", "text": "02) increased during the study period.", "tags": [{"end": 37, "start": 31, "tag": "TemporalConcept"}, {"end": 30, "start": 25, "tag": "ResearchActivity"}]}{"id": "1490_12", "text": "Discussion: All four CSF biomarkers increase with age, but this effect deviates in AD for t-tau and ptau.", "tags": [{"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 25, "tag": "ClinicalAttribute"}, {"end": 95, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 50, "tag": "OrganismAttribute"}]}{"id": "1490_13", "text": "(C) 2019 the Alzheimer's Association.", "tags": [{"end": 36, "start": 13, "tag": "HealthCareRelatedOrganization"}]}{"id": "1490_14", "text": "Published by Elsevier Inc.", "tags": []}{"id": "1490_15", "text": "All rights reserved.", "tags": []}{"id": "1491_0", "text": "Observational studies suggest that angiotcnsin receptor blockers in hypertensive adults are associated with lower post-mortem indicators of Alzheimer's disease pathology.", "tags": [{"end": 80, "start": 68, "tag": "Finding"}, {"end": 55, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 152, "tag": "PathologicFunction"}, {"end": 159, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 14, "tag": "ResearchActivity"}, {"end": 87, "start": 81, "tag": "PopulationGroup"}, {"end": 118, "start": 114, "tag": "TemporalConcept"}, {"end": 125, "start": 114, "tag": "TemporalConcept"}, {"end": 87, "start": 68, "tag": "PatientOrDisabledGroup"}]}{"id": "1491_1", "text": "Candesartan, an angiotensin receptor blocker, has a positive cognitive effect in mild cognitive impairment with hypertension.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 44, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 124, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 112, "tag": "Finding"}, {"end": 36, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "1491_2", "text": "However, its safety and effects in non, hypertensive individuals with Alzheimer's disease are unclear.", "tags": [{"end": 89, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 35, "tag": "PopulationGroup"}, {"end": 19, "start": 13, "tag": "HealthCareActivity"}, {"end": 31, "start": 24, "tag": "Finding"}]}{"id": "1491_3", "text": "This is the first double-blind randomized placebo-controlled trial aimed to assess safety and effects of 1-year therapy of candesartan on biomarkers and clinical indicators of Alzheimer's disease in non-hypertensive individuals with biomarker-confirmed prodromal Alzheimer's disease, Seventy-seven non-hypertensive participants 50 years or older (mean age: 68.1 years; 62% women; 20% African American) with mild cognitive impairment and biomarker confirmed Alzheimer's disease were randomized to escalating doses of once daily oral candesartan (up to 32 mg) or matched placebo.", "tags": [{"end": 134, "start": 123, "tag": "Chemical"}, {"end": 520, "start": 516, "tag": "TemporalConcept"}, {"end": 543, "start": 532, "tag": "Chemical"}, {"end": 282, "start": 253, "tag": "DiseaseOrSyndrome"}, {"end": 391, "start": 384, "tag": "PopulationGroup"}, {"end": 345, "start": 340, "tag": "TemporalConcept"}, {"end": 17, "start": 12, "tag": "TemporalConcept"}, {"end": 111, "start": 107, "tag": "TemporalConcept"}, {"end": 400, "start": 384, "tag": "PopulationGroup"}, {"end": 195, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 282, "start": 263, "tag": "DiseaseOrSyndrome"}, {"end": 476, "start": 457, "tag": "DiseaseOrSyndrome"}, {"end": 242, "start": 233, "tag": "ClinicalAttribute"}, {"end": 446, "start": 437, "tag": "ClinicalAttribute"}, {"end": 327, "start": 315, "tag": "PopulationGroup"}, {"end": 227, "start": 199, "tag": "PopulationGroup"}, {"end": 148, "start": 138, "tag": "ClinicalAttribute"}, {"end": 378, "start": 373, "tag": "PopulationGroup"}, {"end": 355, "start": 352, "tag": "OrganismAttribute"}, {"end": 89, "start": 83, "tag": "HealthCareActivity"}, {"end": 336, "start": 331, "tag": "TemporalConcept"}, {"end": 367, "start": 362, "tag": "TemporalConcept"}, {"end": 66, "start": 18, "tag": "ResearchActivity"}, {"end": 576, "start": 569, "tag": "HealthCareActivity"}, {"end": 101, "start": 94, "tag": "Finding"}, {"end": 119, "start": 112, "tag": "HealthCareActivity"}, {"end": 432, "start": 407, "tag": "DiseaseOrSyndrome"}, {"end": 526, "start": 521, "tag": "TemporalConcept"}, {"end": 134, "start": 123, "tag": "PharmacologicSubstance"}, {"end": 531, "start": 527, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 543, "start": 532, "tag": "PharmacologicSubstance"}]}{"id": "1491_4", "text": "Main outcomes included safety and tolerability of candesartan, cerebrospinal fluid biomarkers (amyloid-beta 42, amyloid-beta 40, total tau and phospho-tau).", "tags": [{"end": 61, "start": 50, "tag": "Chemical"}, {"end": 46, "start": 34, "tag": "ResearchActivity"}, {"end": 154, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 83, "tag": "ClinicalAttribute"}, {"end": 13, "start": 5, "tag": "Finding"}, {"end": 29, "start": 23, "tag": "HealthCareActivity"}, {"end": 61, "start": 50, "tag": "PharmacologicSubstance"}]}{"id": "1491_5", "text": "Additional exploratory outcomes included PET imaging (Pittsburgh Compound-B (C-11-PiB) and F-18-flortaucipir), brain MRI (structural and connectivity measures) and cognitive functioning.", "tags": [{"end": 185, "start": 164, "tag": "BiologicFunction"}, {"end": 52, "start": 41, "tag": "HealthCareActivity"}, {"end": 120, "start": 111, "tag": "HealthCareActivity"}, {"end": 85, "start": 82, "tag": "Chemical"}, {"end": 52, "start": 45, "tag": "HealthCareActivity"}, {"end": 108, "start": 91, "tag": "Chemical"}, {"end": 31, "start": 23, "tag": "Finding"}, {"end": 44, "start": 41, "tag": "HealthCareActivity"}, {"end": 149, "start": 137, "tag": "BiologicFunction"}, {"end": 75, "start": 54, "tag": "Chemical"}]}{"id": "1491_6", "text": "Analyses used intentionto-treat approach with group comparisons of safety measures using Chi-square test, and repeated measures mixed effects models were used to assess candesartan effects on main and exploratory outcomes (ClinicalTrials.gov , NCT02646982).", "tags": [{"end": 180, "start": 169, "tag": "Chemical"}, {"end": 241, "start": 223, "tag": "HealthCareRelatedOrganization"}, {"end": 221, "start": 213, "tag": "Finding"}, {"end": 82, "start": 67, "tag": "HealthCareActivity"}, {"end": 188, "start": 181, "tag": "Finding"}, {"end": 148, "start": 110, "tag": "ResearchActivity"}, {"end": 51, "start": 46, "tag": "PopulationGroup"}, {"end": 104, "start": 89, "tag": "ResearchActivity"}, {"end": 104, "start": 100, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 56, "start": 55, "tag": "ResearchActivity"}, {"end": 180, "start": 169, "tag": "PharmacologicSubstance"}]}{"id": "1491_7", "text": "Candesartan was found to be safe with no significant difference in safety measures: symptoms of hypotension, renal failure or hyperkalemia.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 107, "start": 96, "tag": "Finding"}, {"end": 122, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 126, "tag": "Finding"}, {"end": 92, "start": 84, "tag": "SignOrSymptom"}, {"end": 63, "start": 38, "tag": "Finding"}, {"end": 82, "start": 67, "tag": "HealthCareActivity"}, {"end": 4, "start": 3, "tag": "PharmacologicSubstance"}]}{"id": "1491_8", "text": "Candesartan was also found to be associated with increases in cerebrospinal fluid A beta 40 (between-group mean difference: 1211.95 pg/ml, 95% confidence interval: 313.27, 2110.63) and A beta 42 (49.51 pg/ml, 95% confidence interval: - 98.05, -0.98) reflecting lower brain amyloid accumulation.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 91, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 194, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 194, "start": 185, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 143, "tag": "ResearchActivity"}, {"end": 232, "start": 213, "tag": "ResearchActivity"}, {"end": 81, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 272, "start": 267, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 280, "start": 273, "tag": "AminoAcidPeptideOrProtein"}, {"end": 280, "start": 273, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 101, "tag": "PopulationGroup"}, {"end": 293, "start": 281, "tag": "Finding"}, {"end": 11, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "1491_9", "text": "Candesartan was associated with decreased 1 C-PiB in the parahippocampal region (-0.1104, 95% confidence interval: -0.19, -0.029) which remained significant after false discovery rate correction, and with an increase in functional network connectivity in the subcortical networks.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 279, "start": 271, "tag": "CellFunction"}, {"end": 41, "start": 32, "tag": "Finding"}, {"end": 49, "start": 44, "tag": "Chemical"}, {"end": 270, "start": 259, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 94, "tag": "ResearchActivity"}, {"end": 194, "start": 163, "tag": "ResearchActivity"}, {"end": 251, "start": 220, "tag": "BiologicFunction"}, {"end": 11, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 79, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1491_10", "text": "Candesartan was further associated with improved executive function (Trail Making Test Part B) performance (-11.41 s, 95% confidence interval: -11.94, -10.89) and trended for an improved global cognitive functioning reflected by a composite cognitive score (0.002, 95% confidence interval: -0.0002, 0.005).", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 67, "start": 49, "tag": "BiologicFunction"}, {"end": 215, "start": 194, "tag": "BiologicFunction"}, {"end": 48, "start": 40, "tag": "Finding"}, {"end": 186, "start": 178, "tag": "Finding"}, {"end": 141, "start": 122, "tag": "ResearchActivity"}, {"end": 288, "start": 269, "tag": "ResearchActivity"}, {"end": 256, "start": 251, "tag": "Finding"}, {"end": 106, "start": 95, "tag": "Finding"}, {"end": 11, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 93, "start": 69, "tag": "HealthCareActivity"}]}{"id": "1491_11", "text": "We did not observe significant effects on tau levels, hippocampal volume or other cognitive measures (memory or clinical dementia rating scale-sum of boxes).", "tags": [{"end": 155, "start": 112, "tag": "HealthCareActivity"}, {"end": 100, "start": 82, "tag": "ClinicalAttribute"}, {"end": 45, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 31, "tag": "Finding"}, {"end": 108, "start": 102, "tag": "BiologicFunction"}, {"end": 72, "start": 54, "tag": "ClinicalAttribute"}, {"end": 52, "start": 42, "tag": "ClinicalAttribute"}]}{"id": "1491_12", "text": "In conclusion, among non-hypertensive prodromal Alzheimer's disease, candesartan is safe and likely decreases brain amyloid biomarkers, enhances subcortical brain connectivity and has favourable cognitive effects.", "tags": [{"end": 80, "start": 69, "tag": "Chemical"}, {"end": 67, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 124, "tag": "ClinicalAttribute"}, {"end": 212, "start": 184, "tag": "Finding"}, {"end": 175, "start": 163, "tag": "BiologicFunction"}, {"end": 80, "start": 69, "tag": "PharmacologicSubstance"}]}{"id": "1491_13", "text": "These findings suggest that candesartan may have an important therapeutic role in Alzheimer's disease, and warrant further investigation given the lack of clear treatment options for this devastating illness.", "tags": [{"end": 39, "start": 28, "tag": "Chemical"}, {"end": 207, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 123, "tag": "ResearchActivity"}, {"end": 101, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 161, "tag": "HealthCareActivity"}, {"end": 170, "start": 161, "tag": "ResearchActivity"}, {"end": 39, "start": 28, "tag": "PharmacologicSubstance"}, {"end": 78, "start": 62, "tag": "Finding"}]}{"id": "1492_0", "text": "IntroductionAlzheimer's disease (AD) is a public health priority.", "tags": [{"end": 31, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 49, "tag": "HealthCareActivity"}, {"end": 55, "start": 42, "tag": "HealthCareActivity"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}]}{"id": "1492_1", "text": "AD biomarkers may vary based on race, but the recruitment of diverse participants has been challenging.", "tags": [{"end": 36, "start": 32, "tag": "PopulationGroup"}, {"end": 13, "start": 3, "tag": "ClinicalAttribute"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 69, "tag": "PopulationGroup"}]}{"id": "1492_2", "text": "MethodsThree groups of Black and White participants with and without prior research advocacy or participation were interviewed individually or in focus groups to better understand perspectives related to AD biomarker research participation.", "tags": [{"end": 51, "start": 39, "tag": "PopulationGroup"}, {"end": 28, "start": 23, "tag": "PopulationGroup"}, {"end": 158, "start": 146, "tag": "PopulationGroup"}, {"end": 92, "start": 75, "tag": "ResearchActivity"}, {"end": 239, "start": 217, "tag": "ResearchActivity"}, {"end": 206, "start": 204, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 207, "tag": "ClinicalAttribute"}, {"end": 51, "start": 39, "tag": "PopulationGroup"}, {"end": 51, "start": 33, "tag": "PopulationGroup"}, {"end": 109, "start": 96, "tag": "ResearchActivity"}, {"end": 83, "start": 75, "tag": "ResearchActivity"}]}{"id": "1492_3", "text": "A rapid qualitative data analytic approach was used to analyze the data.", "tags": [{"end": 42, "start": 8, "tag": "ResearchActivity"}, {"end": 71, "start": 67, "tag": "ResearchActivity"}]}{"id": "1492_4", "text": "ResultsIdentified barriers to AD biomarker research participation included hesitancy due to fear, distrust of research and researchers, lack of relevant knowledge, and lack of research test results disclosure.", "tags": [{"end": 84, "start": 75, "tag": "SignOrSymptom"}, {"end": 162, "start": 136, "tag": "Finding"}, {"end": 134, "start": 123, "tag": "ResearchActivity"}, {"end": 65, "start": 43, "tag": "ResearchActivity"}, {"end": 118, "start": 110, "tag": "ResearchActivity"}, {"end": 197, "start": 176, "tag": "ResearchActivity"}, {"end": 32, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 33, "tag": "ClinicalAttribute"}, {"end": 96, "start": 92, "tag": "BiologicFunction"}, {"end": 118, "start": 98, "tag": "Finding"}, {"end": 208, "start": 168, "tag": "Finding"}]}{"id": "1492_5", "text": "Drivers for engagement in biomarker research procedures included knowledge about research, AD, and related clinical procedures, perceived benefits of participation, and outreach from trusted sources.", "tags": [{"end": 7, "start": 0, "tag": "ManufacturedObject"}, {"end": 7, "start": 0, "tag": "PopulationGroup"}, {"end": 22, "start": 12, "tag": "Finding"}, {"end": 198, "start": 191, "tag": "Finding"}, {"end": 74, "start": 65, "tag": "Finding"}, {"end": 44, "start": 36, "tag": "ResearchActivity"}, {"end": 89, "start": 81, "tag": "ResearchActivity"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 26, "tag": "ClinicalAttribute"}, {"end": 126, "start": 107, "tag": "HealthCareActivity"}, {"end": 177, "start": 169, "tag": "ResearchActivity"}, {"end": 163, "start": 138, "tag": "Finding"}]}{"id": "1492_6", "text": "DiscussionParticipants' comments related to the need for diversity in research and desire for results disclosure suggest opportunities to engage Black individuals.", "tags": [{"end": 89, "start": 83, "tag": "BiologicFunction"}, {"end": 150, "start": 145, "tag": "PopulationGroup"}, {"end": 78, "start": 70, "tag": "ResearchActivity"}, {"end": 112, "start": 94, "tag": "ResearchActivity"}, {"end": 162, "start": 151, "tag": "PopulationGroup"}]}{"id": "1492_7", "text": "HighlightsBlack Americans experience more salient barriers to Alzheimer's disease (AD) biomarker research participation.Concerns about research diversity influence research participation decisions.Research test disclosure may affect research participation and retention.", "tags": [{"end": 25, "start": 10, "tag": "PopulationGroup"}, {"end": 36, "start": 26, "tag": "BiologicFunction"}, {"end": 196, "start": 187, "tag": "BiologicFunction"}, {"end": 221, "start": 197, "tag": "ResearchActivity"}, {"end": 119, "start": 97, "tag": "ResearchActivity"}, {"end": 143, "start": 135, "tag": "ResearchActivity"}, {"end": 186, "start": 164, "tag": "ResearchActivity"}, {"end": 255, "start": 233, "tag": "ResearchActivity"}, {"end": 81, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 87, "tag": "ClinicalAttribute"}, {"end": 269, "start": 260, "tag": "ResearchActivity"}, {"end": 241, "start": 233, "tag": "ResearchActivity"}]}{"id": "1493_0", "text": "Introduction Batch differences in cerebrospinal fluid (CSF) biomarker measurement can introduce bias into analyses for Alzheimer's disease studies.", "tags": [{"end": 146, "start": 139, "tag": "ResearchActivity"}, {"end": 138, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 60, "tag": "ClinicalAttribute"}, {"end": 58, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 48, "tag": "Substance"}, {"end": 53, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 13, "tag": "Finding"}, {"end": 114, "start": 106, "tag": "ResearchActivity"}]}{"id": "1493_1", "text": "We evaluated and adjusted for batch differences using statistical methods.", "tags": [{"end": 73, "start": 54, "tag": "ResearchActivity"}, {"end": 47, "start": 30, "tag": "Finding"}]}{"id": "1493_2", "text": "Methods A total of 792 CSF samples from 528 participants were assayed in three batches for 12 biomarkers and 3 biomarker ratios.", "tags": [{"end": 104, "start": 94, "tag": "ClinicalAttribute"}, {"end": 120, "start": 111, "tag": "ClinicalAttribute"}, {"end": 26, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 44, "tag": "PopulationGroup"}]}{"id": "1493_3", "text": "Batch differences were assessed using Bland-Altman plot, paired t test, Pitman-Morgan test, and linear regression.", "tags": [{"end": 17, "start": 0, "tag": "Finding"}, {"end": 55, "start": 38, "tag": "ResearchActivity"}, {"end": 70, "start": 57, "tag": "ResearchActivity"}, {"end": 90, "start": 72, "tag": "ResearchActivity"}, {"end": 113, "start": 96, "tag": "ResearchActivity"}]}{"id": "1493_4", "text": "Generalized linear models were applied to convert CSF values between batches.", "tags": [{"end": 53, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 0, "tag": "ResearchActivity"}]}{"id": "1493_5", "text": "Results We found statistically significant batch differences for all biomarkers and ratios, except that neurofilament light was comparable between batches 1 and 2.", "tags": [{"end": 79, "start": 69, "tag": "ClinicalAttribute"}, {"end": 123, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 60, "start": 43, "tag": "Finding"}]}{"id": "1493_6", "text": "The conversion models generally had high R-2 except for converting P-tau between batches 1 and 3.", "tags": [{"end": 72, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 4, "tag": "ResearchActivity"}]}{"id": "1493_7", "text": "Discussion Between-batch conversion allows harmonized CSF values to be used in the same analysis.", "tags": [{"end": 96, "start": 88, "tag": "ResearchActivity"}, {"end": 57, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 11, "tag": "ResearchActivity"}]}{"id": "1493_8", "text": "Such method may be applied to adjust for other sources of variability in measuring CSF or other types of biomarkers.", "tags": [{"end": 69, "start": 47, "tag": "Finding"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 115, "start": 105, "tag": "ClinicalAttribute"}, {"end": 86, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1494_0", "text": "Introduction: We aimed to estimate the frequency of each AT(N) (beta-amyloid deposition [A], pathologic tau [T], and neurodegeneration [N]) profile in different clinical diagnosis groups and to describe the longitudinal change in clinical outcomes of individuals in each group.", "tags": [{"end": 186, "start": 180, "tag": "PopulationGroup"}, {"end": 179, "start": 161, "tag": "HealthCareActivity"}, {"end": 76, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 170, "tag": "HealthCareActivity"}, {"end": 134, "start": 117, "tag": "CellOrMolecularDysfunction"}, {"end": 247, "start": 230, "tag": "ClinicalAttribute"}, {"end": 262, "start": 251, "tag": "PopulationGroup"}, {"end": 276, "start": 271, "tag": "PopulationGroup"}, {"end": 226, "start": 207, "tag": "ResearchActivity"}, {"end": 48, "start": 39, "tag": "TemporalConcept"}, {"end": 76, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 62, "start": 57, "tag": "ResearchActivity"}, {"end": 147, "start": 140, "tag": "ResearchActivity"}, {"end": 87, "start": 64, "tag": "PathologicFunction"}]}{"id": "1494_1", "text": "Methods: Longitudinal change in clinical outcomes and conversion risk of AT(N) profiles are assessed using linear mixed-effects models and multivariate Cox proportional-hazard models, respectively.", "tags": [{"end": 87, "start": 73, "tag": "ResearchActivity"}, {"end": 49, "start": 32, "tag": "ClinicalAttribute"}, {"end": 134, "start": 107, "tag": "ResearchActivity"}, {"end": 182, "start": 139, "tag": "ResearchActivity"}, {"end": 28, "start": 9, "tag": "ResearchActivity"}, {"end": 69, "start": 54, "tag": "ClinicalAttribute"}]}{"id": "1494_2", "text": "Results: Participants with A+T+N+ showed faster clinical progression than those with A-T-N- and A+T +/- N-.", "tags": [{"end": 68, "start": 48, "tag": "TemporalConcept"}, {"end": 68, "start": 57, "tag": "PathologicFunction"}, {"end": 68, "start": 57, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 21, "start": 9, "tag": "PopulationGroup"}]}{"id": "1494_3", "text": "Compared with A-T-N-, participants with A+T+N +/- had an increased risk of conversion from cognitively normal (CN) to incident prodromal stage of Alzheimer's disease (AD), and from MCI to AD dementia.", "tags": [{"end": 184, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 111, "tag": "Finding"}, {"end": 109, "start": 103, "tag": "Finding"}, {"end": 142, "start": 127, "tag": "TemporalConcept"}, {"end": 165, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 199, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 22, "tag": "PopulationGroup"}, {"end": 85, "start": 67, "tag": "ClinicalAttribute"}]}{"id": "1494_4", "text": "A+T +N+ showed an increased conversion risk when compared with A+T +/- N-.", "tags": [{"end": 43, "start": 28, "tag": "ClinicalAttribute"}]}{"id": "1494_5", "text": "Discussion: The 2018 research framework may provide prognostic information of clinical change and progression.", "tags": [{"end": 109, "start": 98, "tag": "PathologicFunction"}, {"end": 109, "start": 98, "tag": "TemporalConcept"}, {"end": 29, "start": 21, "tag": "ResearchActivity"}, {"end": 93, "start": 78, "tag": "ClinicalAttribute"}]}{"id": "1494_6", "text": "It may also be useful for targeted recruitment of participants with AD into clinical trials.", "tags": [{"end": 70, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 76, "tag": "ResearchActivity"}, {"end": 62, "start": 50, "tag": "PopulationGroup"}]}{"id": "1494_7", "text": "(C) 2019 the Alzheimer's Association.", "tags": [{"end": 36, "start": 13, "tag": "HealthCareRelatedOrganization"}]}{"id": "1494_8", "text": "Published by Elsevier Inc.", "tags": []}{"id": "1494_9", "text": "All rights reserved.", "tags": []}{"id": "1495_0", "text": "Introduction: The accumulation of endogenous formaldehyde is considered a pathogenic factor in Alzheimer's disease (AD).", "tags": [{"end": 57, "start": 45, "tag": "Chemical"}, {"end": 91, "start": 74, "tag": "PathologicFunction"}, {"end": 30, "start": 18, "tag": "Finding"}, {"end": 114, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 45, "tag": "PharmacologicSubstance"}, {"end": 57, "start": 45, "tag": "InjuryOrPoisoning"}]}{"id": "1495_1", "text": "The purpose of this study was to investigate the relationship between urinary formic acid and plasma biomarkers in AD.Materials and methods: Five hundred and seventy-four participants were divided into five groups according to their diagnosis: 71 with normal cognitive (NC), 101 with subjective cognitive decline (SCD), 131 with cognitive impairment without mild cognitive impairment (CINM), 158 with mild cognitive impairment (MCI), and 113 with AD.Results: With the progression of the disease, urinary formic acid levels showed an overall upward trend.", "tags": [{"end": 213, "start": 207, "tag": "PopulationGroup"}, {"end": 389, "start": 385, "tag": "DiseaseOrSyndrome"}, {"end": 431, "start": 428, "tag": "DiseaseOrSyndrome"}, {"end": 268, "start": 252, "tag": "Finding"}, {"end": 494, "start": 468, "tag": "PathologicFunction"}, {"end": 494, "start": 468, "tag": "TemporalConcept"}, {"end": 61, "start": 49, "tag": "Finding"}, {"end": 25, "start": 20, "tag": "ResearchActivity"}, {"end": 479, "start": 468, "tag": "PathologicFunction"}, {"end": 479, "start": 468, "tag": "TemporalConcept"}, {"end": 242, "start": 233, "tag": "HealthCareActivity"}, {"end": 111, "start": 101, "tag": "ClinicalAttribute"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 449, "start": 447, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 457, "start": 450, "tag": "ResearchActivity"}, {"end": 183, "start": 171, "tag": "PopulationGroup"}, {"end": 349, "start": 329, "tag": "DiseaseOrSyndrome"}, {"end": 383, "start": 363, "tag": "DiseaseOrSyndrome"}, {"end": 426, "start": 406, "tag": "DiseaseOrSyndrome"}, {"end": 312, "start": 295, "tag": "DiseaseOrSyndrome"}, {"end": 383, "start": 358, "tag": "DiseaseOrSyndrome"}, {"end": 426, "start": 401, "tag": "DiseaseOrSyndrome"}, {"end": 522, "start": 496, "tag": "ClinicalAttribute"}, {"end": 515, "start": 504, "tag": "Chemical"}, {"end": 89, "start": 78, "tag": "Chemical"}, {"end": 77, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 503, "start": 496, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1495_2", "text": "Urinary formic acid was significantly correlated with Mini-Mental State Examination (MMSE) scores, the Chinese version of Addenbrooke's Cognitive Examination III (ACE-III) scores, and Montreal Cognitive Assessment-Basic (MoCA-B) time.", "tags": [{"end": 110, "start": 103, "tag": "PopulationGroup"}, {"end": 83, "start": 54, "tag": "HealthCareActivity"}, {"end": 219, "start": 184, "tag": "HealthCareActivity"}, {"end": 227, "start": 221, "tag": "HealthCareActivity"}, {"end": 233, "start": 229, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 8, "tag": "Chemical"}, {"end": 89, "start": 85, "tag": "HealthCareActivity"}, {"end": 161, "start": 122, "tag": "HealthCareActivity"}, {"end": 170, "start": 163, "tag": "HealthCareActivity"}]}{"id": "1495_3", "text": "The areas under the receiver operating characteristic curves (AUC) of urinary formic acid in distinguishing NC from AD was 0.797, which was similar to that of plasma neurofilament light chain (NfL; AUC = 0.768) and better than other plasma biomarkers (A beta 40, A beta 42, A beta 42/A beta 40, T-tau, P-tau181, and P-tau181/T-tau).", "tags": [{"end": 300, "start": 295, "tag": "AminoAcidPeptideOrProtein"}, {"end": 330, "start": 325, "tag": "AminoAcidPeptideOrProtein"}, {"end": 250, "start": 240, "tag": "ClinicalAttribute"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 239, "start": 233, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 196, "start": 193, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 62, "tag": "ResearchActivity"}, {"end": 201, "start": 198, "tag": "ResearchActivity"}, {"end": 185, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 196, "start": 193, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 300, "start": 295, "tag": "BiologicallyActiveSubstance"}, {"end": 330, "start": 325, "tag": "BiologicallyActiveSubstance"}, {"end": 261, "start": 252, "tag": "AminoAcidPeptideOrProtein"}, {"end": 272, "start": 263, "tag": "AminoAcidPeptideOrProtein"}, {"end": 283, "start": 274, "tag": "AminoAcidPeptideOrProtein"}, {"end": 293, "start": 284, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 4, "tag": "ResearchActivity"}, {"end": 77, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 78, "tag": "Chemical"}, {"end": 261, "start": 252, "tag": "BiologicallyActiveSubstance"}, {"end": 272, "start": 263, "tag": "BiologicallyActiveSubstance"}, {"end": 283, "start": 274, "tag": "BiologicallyActiveSubstance"}, {"end": 293, "start": 284, "tag": "BiologicallyActiveSubstance"}, {"end": 310, "start": 302, "tag": "BiologicallyActiveSubstance"}, {"end": 310, "start": 302, "tag": "AminoAcidPeptideOrProtein"}, {"end": 324, "start": 316, "tag": "BiologicallyActiveSubstance"}, {"end": 324, "start": 316, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1495_4", "text": "We also found that using urinary formic acid and formaldehyde levels could improve the accuracy of using plasma biomarkers to determine AD disease stage.Discussion: Our study revealed the possibility of urinary formic acid as a potential novel biomarker for the early diagnosis of AD.", "tags": [{"end": 61, "start": 49, "tag": "Chemical"}, {"end": 277, "start": 262, "tag": "HealthCareActivity"}, {"end": 174, "start": 169, "tag": "ResearchActivity"}, {"end": 277, "start": 268, "tag": "HealthCareActivity"}, {"end": 122, "start": 112, "tag": "ClinicalAttribute"}, {"end": 138, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 283, "start": 281, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 253, "start": 244, "tag": "ClinicalAttribute"}, {"end": 152, "start": 139, "tag": "ClinicalAttribute"}, {"end": 152, "start": 139, "tag": "TemporalConcept"}, {"end": 253, "start": 238, "tag": "ClinicalAttribute"}, {"end": 32, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 33, "tag": "Chemical"}, {"end": 95, "start": 87, "tag": "Finding"}, {"end": 210, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 222, "start": 211, "tag": "Chemical"}, {"end": 61, "start": 49, "tag": "InjuryOrPoisoning"}, {"end": 61, "start": 49, "tag": "PharmacologicSubstance"}]}{"id": "1496_0", "text": "The identification of biomarkers of Alzheimer's disease (AD) is an important and urgent area of study, not only to aid in the early diagnosis of AD, but also to evaluate potentially new anti-AD drugs.", "tags": [{"end": 141, "start": 126, "tag": "HealthCareActivity"}, {"end": 199, "start": 186, "tag": "PharmacologicSubstance"}, {"end": 101, "start": 96, "tag": "ResearchActivity"}, {"end": 141, "start": 132, "tag": "HealthCareActivity"}, {"end": 55, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 22, "tag": "ClinicalAttribute"}, {"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 191, "tag": "DiseaseOrSyndrome"}]}{"id": "1496_1", "text": "The aim of this study was to explore cofilin 2 in serum as a novel biomarker for AD.", "tags": [{"end": 46, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 37, "tag": "GeneOrGenome"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 67, "tag": "ClinicalAttribute"}, {"end": 55, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 61, "tag": "ClinicalAttribute"}, {"end": 46, "start": 37, "tag": "BiologicallyActiveSubstance"}]}{"id": "1496_2", "text": "The upregulation was observed in AD patients and different AD animal models compared to the controls, as well as in AD cell models.", "tags": [{"end": 16, "start": 4, "tag": "CellFunction"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 36, "tag": "PatientOrDisabledGroup"}, {"end": 100, "start": 92, "tag": "PopulationGroup"}, {"end": 75, "start": 59, "tag": "ExperimentalModelOfDisease"}, {"end": 130, "start": 116, "tag": "ExperimentalModelOfDisease"}, {"end": 68, "start": 62, "tag": "Eukaryote"}]}{"id": "1496_3", "text": "Memantine and donepezil can attenuate the upregulation of cofilin 2 expression in APP/PS1 mice.", "tags": [{"end": 23, "start": 14, "tag": "Chemical"}, {"end": 54, "start": 42, "tag": "CellFunction"}, {"end": 67, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 58, "tag": "GeneOrGenome"}, {"end": 85, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 82, "tag": "GeneOrGenome"}, {"end": 85, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 82, "tag": "ExperimentalModelOfDisease"}, {"end": 94, "start": 90, "tag": "Eukaryote"}, {"end": 9, "start": 0, "tag": "Chemical"}, {"end": 9, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 23, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 58, "tag": "BiologicallyActiveSubstance"}]}{"id": "1496_4", "text": "The serum levels of cofilin 2 in AD or mild cognitive impairment (MCI) patients were significantly higher compared to controls (AD: 167.9 +/- 35.3 pg/mL; MCI: 115.9 +/- 15.4 pg/mL; Control: 90.5 +/- 27.1 pg/mL; p < 0.01).", "tags": [{"end": 29, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 20, "tag": "GeneOrGenome"}, {"end": 69, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 71, "tag": "PatientOrDisabledGroup"}, {"end": 9, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 118, "tag": "PopulationGroup"}, {"end": 64, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 4, "tag": "ClinicalAttribute"}]}{"id": "1496_5", "text": "A significant correlation between cofilin 2 levels and cognitive decline was observed (r = -0.792; p < 0.001).", "tags": [{"end": 43, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 34, "tag": "GeneOrGenome"}, {"end": 72, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 34, "tag": "BiologicallyActiveSubstance"}]}{"id": "1496_6", "text": "The receiver operating characteristic curve (ROC) analysis showed the area under the curve (AUC) of cofilin 2 was 0.957, and the diagnostic accuracy was 80%, with 93% sensitivity and 87% specificity.", "tags": [{"end": 109, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 100, "tag": "GeneOrGenome"}, {"end": 198, "start": 187, "tag": "Finding"}, {"end": 58, "start": 4, "tag": "ResearchActivity"}, {"end": 178, "start": 167, "tag": "Finding"}, {"end": 95, "start": 92, "tag": "ResearchActivity"}, {"end": 148, "start": 129, "tag": "Finding"}, {"end": 90, "start": 70, "tag": "ResearchActivity"}, {"end": 109, "start": 100, "tag": "BiologicallyActiveSubstance"}]}{"id": "1496_7", "text": "The optimal cut-off value was 130.4 pg/ml.", "tags": [{"end": 25, "start": 4, "tag": "Finding"}]}{"id": "1496_8", "text": "Our results indicate the possibility of serum cofilin 2 as a novel and non-invasive biomarker for AD.", "tags": [{"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 84, "tag": "ClinicalAttribute"}, {"end": 45, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 71, "tag": "ClinicalAttribute"}, {"end": 55, "start": 40, "tag": "ClinicalAttribute"}]}{"id": "1496_9", "text": "In addition, the expression of cofilin 2 was found to be significantly increased in AD compared to vascular dementia (VaD), and only an increased trend but not significant was detected in VaD compared to the controls.", "tags": [{"end": 40, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 31, "tag": "GeneOrGenome"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 208, "tag": "PopulationGroup"}, {"end": 121, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 31, "tag": "BiologicallyActiveSubstance"}]}{"id": "1496_10", "text": "ROC analysis between AD and VaD showed that the AUC was 0.824, which could indicate a role of cofilin 2 as a biomarker in the differential diagnosis between AD and VaD.", "tags": [{"end": 103, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 94, "tag": "GeneOrGenome"}, {"end": 148, "start": 139, "tag": "HealthCareActivity"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 109, "tag": "ClinicalAttribute"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 51, "start": 48, "tag": "ResearchActivity"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 148, "start": 126, "tag": "HealthCareActivity"}, {"end": 103, "start": 94, "tag": "BiologicallyActiveSubstance"}]}{"id": "1497_0", "text": "INTRODUCTION: Brain cell-derived small extracellular vesicles (sEVs) in blood offer unique cellular and molecular information related to the onset and progression of Alzheimer's disease (AD).", "tags": [{"end": 67, "start": 63, "tag": "CellComponent"}, {"end": 24, "start": 14, "tag": "Cell"}, {"end": 162, "start": 151, "tag": "PathologicFunction"}, {"end": 162, "start": 151, "tag": "TemporalConcept"}, {"end": 61, "start": 39, "tag": "CellComponent"}, {"end": 185, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 33, "tag": "CellComponent"}, {"end": 146, "start": 141, "tag": "TemporalConcept"}]}{"id": "1497_1", "text": "We simultaneously enriched six specific sEV subtypes from the plasma and analyzed a selected panel of microRNAs (miRNAs) in older adults with/without cognitive impairment.METHODS: Total sEVs were isolated from the plasma of participants with normal cognition (CN; n = 11), mild cognitive impairment (MCI; n = 11), MCI conversion to AD dementia (MCI-AD; n = 6), and AD dementia (n = 11).", "tags": [{"end": 111, "start": 102, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 111, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 186, "tag": "CellComponent"}, {"end": 17, "start": 3, "tag": "TemporalConcept"}, {"end": 136, "start": 124, "tag": "PopulationGroup"}, {"end": 303, "start": 300, "tag": "DiseaseOrSyndrome"}, {"end": 317, "start": 314, "tag": "DiseaseOrSyndrome"}, {"end": 348, "start": 345, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 40, "tag": "CellComponent"}, {"end": 258, "start": 242, "tag": "Finding"}, {"end": 262, "start": 260, "tag": "Finding"}, {"end": 248, "start": 242, "tag": "Finding"}, {"end": 334, "start": 332, "tag": "DiseaseOrSyndrome"}, {"end": 351, "start": 349, "tag": "DiseaseOrSyndrome"}, {"end": 367, "start": 365, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 113, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 119, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 220, "start": 214, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 343, "start": 335, "tag": "DiseaseOrSyndrome"}, {"end": 376, "start": 368, "tag": "DiseaseOrSyndrome"}, {"end": 258, "start": 249, "tag": "BiologicFunction"}, {"end": 129, "start": 124, "tag": "TemporalConcept"}, {"end": 236, "start": 224, "tag": "PopulationGroup"}, {"end": 136, "start": 130, "tag": "PopulationGroup"}, {"end": 170, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 298, "start": 278, "tag": "DiseaseOrSyndrome"}, {"end": 298, "start": 273, "tag": "DiseaseOrSyndrome"}]}{"id": "1497_2", "text": "Various brain cell-derived sEVs (from neurons, astrocytes, microglia, oligodendrocytes, pericytes, and endothelial cells) were enriched and analyzed for specific miRNAs.RESULTS: miRNAs in sEV subtypes differentially expressed in MCI, MCI-AD, and AD dementia compared to the CN group clearly distinguished dementia status, with an area under the curve (AUC) > 0.90 and correlated with the temporal cortical region thickness on magnetic resonance imaging (MRI).DISCUSSION: miRNA analyses in specific sEVs could serve as a novel blood-based molecular biomarker for AD.Highlights", "tags": [{"end": 320, "start": 314, "tag": "Finding"}, {"end": 45, "start": 38, "tag": "Cell"}, {"end": 31, "start": 27, "tag": "CellComponent"}, {"end": 502, "start": 498, "tag": "CellComponent"}, {"end": 232, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 237, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 70, "tag": "Cell"}, {"end": 97, "start": 88, "tag": "Cell"}, {"end": 120, "start": 103, "tag": "Cell"}, {"end": 18, "start": 8, "tag": "Cell"}, {"end": 422, "start": 388, "tag": "ClinicalAttribute"}, {"end": 57, "start": 47, "tag": "Cell"}, {"end": 225, "start": 201, "tag": "Finding"}, {"end": 412, "start": 388, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 557, "start": 538, "tag": "ClinicalAttribute"}, {"end": 191, "start": 188, "tag": "CellComponent"}, {"end": 276, "start": 274, "tag": "Finding"}, {"end": 114, "start": 103, "tag": "Cell"}, {"end": 240, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 246, "tag": "DiseaseOrSyndrome"}, {"end": 564, "start": 562, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 162, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 184, "start": 178, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 168, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 178, "tag": "BiologicallyActiveSubstance"}, {"end": 531, "start": 526, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 476, "start": 471, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 476, "start": 471, "tag": "BiologicallyActiveSubstance"}, {"end": 557, "start": 548, "tag": "ClinicalAttribute"}, {"end": 257, "start": 249, "tag": "DiseaseOrSyndrome"}, {"end": 313, "start": 305, "tag": "DiseaseOrSyndrome"}, {"end": 355, "start": 352, "tag": "ResearchActivity"}, {"end": 225, "start": 216, "tag": "CellFunction"}, {"end": 457, "start": 454, "tag": "HealthCareActivity"}, {"end": 452, "start": 426, "tag": "HealthCareActivity"}, {"end": 452, "start": 445, "tag": "HealthCareActivity"}, {"end": 452, "start": 426, "tag": "ManufacturedObject"}, {"end": 68, "start": 59, "tag": "Cell"}, {"end": 148, "start": 140, "tag": "ResearchActivity"}, {"end": 282, "start": 277, "tag": "PopulationGroup"}, {"end": 350, "start": 330, "tag": "ResearchActivity"}, {"end": 485, "start": 477, "tag": "ResearchActivity"}]}{"id": "1498_0", "text": "IntroductionLoss of entorhinal cortex (EC) layer II neurons represents the earliest Alzheimer's disease (AD) lesion in the brain.", "tags": [{"end": 59, "start": 52, "tag": "Cell"}, {"end": 51, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 75, "tag": "TemporalConcept"}, {"end": 128, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 109, "tag": "InjuryOrPoisoning"}, {"end": 59, "start": 52, "tag": "CellOrMolecularDysfunction"}, {"end": 16, "start": 12, "tag": "CellOrMolecularDysfunction"}, {"end": 41, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1498_1", "text": "Research suggests differing functional roles between two EC subregions, the anterolateral EC (aLEC) and the posteromedial EC (pMEC).", "tags": [{"end": 70, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 92, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1498_2", "text": "MethodsWe use joint label fusion to obtain aLEC and pMEC cortical thickness measurements from serial magnetic resonance imaging scans of 775 ADNI-1 participants (219 healthy; 380 mild cognitive impairment; 176 AD) and use linear mixed-effects models to analyze longitudinal associations among cortical thickness, disease status, and cognitive measures.", "tags": [{"end": 32, "start": 14, "tag": "HealthCareActivity"}, {"end": 88, "start": 76, "tag": "HealthCareActivity"}, {"end": 133, "start": 101, "tag": "HealthCareActivity"}, {"end": 65, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 301, "start": 293, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 57, "tag": "ClinicalAttribute"}, {"end": 311, "start": 293, "tag": "ClinicalAttribute"}, {"end": 212, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 166, "tag": "OrganismAttribute"}, {"end": 127, "start": 101, "tag": "HealthCareActivity"}, {"end": 127, "start": 120, "tag": "HealthCareActivity"}, {"end": 127, "start": 101, "tag": "ManufacturedObject"}, {"end": 160, "start": 148, "tag": "PopulationGroup"}, {"end": 286, "start": 261, "tag": "ResearchActivity"}, {"end": 204, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 222, "tag": "ResearchActivity"}, {"end": 204, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 327, "start": 313, "tag": "ClinicalAttribute"}, {"end": 351, "start": 333, "tag": "ClinicalAttribute"}]}{"id": "1498_3", "text": "ResultsGroup status is reliably predicted by aLEC thickness, which also exhibits greater associations with cognitive outcomes than does pMEC thickness.", "tags": [{"end": 150, "start": 136, "tag": "ClinicalAttribute"}, {"end": 59, "start": 45, "tag": "ClinicalAttribute"}, {"end": 125, "start": 107, "tag": "ClinicalAttribute"}]}{"id": "1498_4", "text": "Change in aLEC thickness is also associated with cerebrospinal fluid amyloid and tau levels.", "tags": [{"end": 6, "start": 0, "tag": "Finding"}, {"end": 24, "start": 10, "tag": "ClinicalAttribute"}, {"end": 84, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 63, "tag": "Substance"}, {"end": 68, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 81, "tag": "ClinicalAttribute"}]}{"id": "1498_5", "text": "DiscussionThinning of aLEC is a sensitive structural biomarker that changes over short durations in the course of AD and tracks disease severity-it is a strong candidate biomarker for detection of early AD.", "tags": [{"end": 41, "start": 32, "tag": "PathologicFunction"}, {"end": 127, "start": 121, "tag": "ManufacturedObject"}, {"end": 96, "start": 87, "tag": "TemporalConcept"}, {"end": 144, "start": 128, "tag": "ClinicalAttribute"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 53, "tag": "ClinicalAttribute"}, {"end": 179, "start": 170, "tag": "ClinicalAttribute"}, {"end": 193, "start": 184, "tag": "HealthCareActivity"}, {"end": 144, "start": 128, "tag": "Finding"}, {"end": 110, "start": 104, "tag": "TemporalConcept"}, {"end": 26, "start": 10, "tag": "Finding"}]}{"id": "1499_0", "text": "Cholecystokinin (CCK) is a satiety hormone that is highly expressed in brain regions like the hippocampus.", "tags": [{"end": 15, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 20, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 17, "tag": "PharmacologicSubstance"}, {"end": 20, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 27, "tag": "BiologicallyActiveSubstance"}]}{"id": "1499_1", "text": "CCK is integral for maintaining or enhancing memory and thus may be a useful marker of cognitive and neural integrity in participants with normal cognition, mild cognitive impairment, and Alzheimer's disease (AD).", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 51, "start": 45, "tag": "BiologicFunction"}, {"end": 117, "start": 108, "tag": "IndividualBehavior"}, {"end": 155, "start": 139, "tag": "Finding"}, {"end": 207, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 146, "tag": "BiologicFunction"}, {"end": 83, "start": 77, "tag": "ClinicalAttribute"}, {"end": 133, "start": 121, "tag": "PopulationGroup"}, {"end": 182, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 101, "tag": "Finding"}]}{"id": "1499_2", "text": "Cerebrospinal fluid (CSF) CCK levels were examined in 287 subjects from the Alzheimer's Disease Neuroimaging Initiative.", "tags": [{"end": 19, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 26, "tag": "PharmacologicSubstance"}, {"end": 29, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 14, "tag": "Substance"}, {"end": 66, "start": 58, "tag": "PopulationGroup"}, {"end": 36, "start": 26, "tag": "ClinicalAttribute"}, {"end": 119, "start": 76, "tag": "HealthCareRelatedOrganization"}]}{"id": "1499_3", "text": "Linear or voxelwise regression was used to examine associations between CCK, regional gray matter, CSF AD biomarkers, and cognitive outcomes.", "tags": [{"end": 75, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 72, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 106, "tag": "ClinicalAttribute"}, {"end": 105, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 10, "tag": "ResearchActivity"}, {"end": 30, "start": 20, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 140, "start": 122, "tag": "ClinicalAttribute"}]}{"id": "1499_4", "text": "Briefly, higher CCK was related to a decreased likelihood of having mild cognitive impairment or AD, better global and memory scores, and more gray matter volume primarily spanning posterior cingulate cortex, parahippocampal gyrus, and medial prefrontal cortex.", "tags": [{"end": 19, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 207, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 230, "start": 209, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 260, "start": 236, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 37, "tag": "Finding"}, {"end": 154, "start": 143, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 143, "tag": "ClinicalAttribute"}, {"end": 125, "start": 119, "tag": "BiologicFunction"}]}{"id": "1499_5", "text": "CSF CCK was also strongly related to higher CSF total tau (R-2 = 0.342) and p-tau-181 (R-2 = 0.256) but not A beta 1-42.", "tags": [{"end": 7, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 4, "tag": "PharmacologicSubstance"}, {"end": 57, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 76, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1499_6", "text": "Tau levels partially mediated CCK and cognition associations.", "tags": [{"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 30, "tag": "PharmacologicSubstance"}, {"end": 47, "start": 38, "tag": "BiologicFunction"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1499_7", "text": "In conclusion, CCK levels may reflect compensatory protection as AD pathology progresses.", "tags": [{"end": 18, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 15, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 68, "tag": "PathologicFunction"}, {"end": 77, "start": 68, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 25, "start": 15, "tag": "ClinicalAttribute"}]}{"id": "1499_8", "text": "(C) 2019 Elsevier Inc.", "tags": []}{"id": "1499_9", "text": "All rights reserved.", "tags": []}{"id": "1500_0", "text": "Objective To determine whether the Alzheimer disease (AD) dementia conversion-related pattern (ADCRP) on [F-18]FDG PET can serve as a valid predictor for the development of AD dementia, the individual expression of the ADCRP (subject score) and its prognostic value were examined in patients with mild cognitive impairment (MCI) and biologically defined AD.", "tags": [{"end": 52, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 356, "start": 354, "tag": "DiseaseOrSyndrome"}, {"end": 291, "start": 283, "tag": "PatientOrDisabledGroup"}, {"end": 169, "start": 158, "tag": "BiologicFunction"}, {"end": 169, "start": 158, "tag": "CellFunction"}, {"end": 66, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 327, "start": 324, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 190, "tag": "PopulationGroup"}, {"end": 200, "start": 190, "tag": "OrganismAttribute"}, {"end": 118, "start": 105, "tag": "HealthCareActivity"}, {"end": 322, "start": 297, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 67, "tag": "Finding"}, {"end": 265, "start": 249, "tag": "Finding"}, {"end": 93, "start": 35, "tag": "ClinicalAttribute"}, {"end": 100, "start": 95, "tag": "ClinicalAttribute"}, {"end": 240, "start": 219, "tag": "ClinicalAttribute"}, {"end": 224, "start": 186, "tag": "ClinicalAttribute"}]}{"id": "1500_1", "text": "Methods A total of 269 patients with available [F-18]FDG PET, [F-18]AV-45 PET, phosphorylated and total tau in CSF, and neurofilament light chain in plasma were included.", "tags": [{"end": 139, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 79, "tag": "CellFunction"}, {"end": 107, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 107, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 47, "tag": "HealthCareActivity"}, {"end": 77, "start": 62, "tag": "HealthCareActivity"}, {"end": 145, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 120, "tag": "BiologicallyActiveSubstance"}]}{"id": "1500_2", "text": "Following the AT(N) classification scheme, where AD is defined biologically by in vivo biomarkers of beta-amyloid (A beta) deposition (A) and pathologic tau (T), patients were categorized to the A-T-, A+T-, A+T+ (AD), and A-T+ groups.", "tags": [{"end": 133, "start": 123, "tag": "CellOrMolecularDysfunction"}, {"end": 113, "start": 101, "tag": "CellOrMolecularDysfunction"}, {"end": 156, "start": 142, "tag": "CellOrMolecularDysfunction"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 162, "tag": "PatientOrDisabledGroup"}, {"end": 113, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 87, "tag": "ClinicalAttribute"}, {"end": 233, "start": 227, "tag": "PopulationGroup"}, {"end": 121, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 79, "tag": "ResearchActivity"}, {"end": 41, "start": 14, "tag": "HealthCareActivity"}]}{"id": "1500_3", "text": "Results The mean subject score of the ADCRP was significantly higher in the A+T+ group compared to each of the other group (all p < 0.05) but was similar among the latter (all p > 0.1).", "tags": [{"end": 30, "start": 12, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 86, "start": 81, "tag": "PopulationGroup"}, {"end": 122, "start": 117, "tag": "PopulationGroup"}, {"end": 43, "start": 38, "tag": "ClinicalAttribute"}]}{"id": "1500_4", "text": "Within the A+T+ group, the subject score of ADCRP was a significant predictor of conversion to dementia (hazard ratio, 2.02 per z score increase; p < 0.001), with higher predictive value than of alternative biomarkers of neurodegeneration (total tau and neurofilament light chain).", "tags": [{"end": 186, "start": 170, "tag": "Finding"}, {"end": 273, "start": 254, "tag": "AminoAcidPeptideOrProtein"}, {"end": 273, "start": 254, "tag": "BiologicallyActiveSubstance"}, {"end": 249, "start": 246, "tag": "AminoAcidPeptideOrProtein"}, {"end": 249, "start": 246, "tag": "BiologicallyActiveSubstance"}, {"end": 249, "start": 240, "tag": "AminoAcidPeptideOrProtein"}, {"end": 249, "start": 240, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 130, "tag": "Finding"}, {"end": 103, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 207, "tag": "ClinicalAttribute"}, {"end": 21, "start": 16, "tag": "PopulationGroup"}, {"end": 238, "start": 221, "tag": "CellOrMolecularDysfunction"}, {"end": 91, "start": 81, "tag": "Finding"}, {"end": 279, "start": 254, "tag": "AminoAcidPeptideOrProtein"}, {"end": 279, "start": 254, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 27, "tag": "ClinicalAttribute"}]}{"id": "1500_5", "text": "Stratification of A+T+ patients by the subject score of ADCRP yielded well-separated groups of high, medium, and low conversion risks.", "tags": [{"end": 14, "start": 0, "tag": "ResearchActivity"}, {"end": 107, "start": 101, "tag": "Substance"}, {"end": 107, "start": 101, "tag": "Finding"}, {"end": 116, "start": 113, "tag": "Finding"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 91, "start": 85, "tag": "PopulationGroup"}, {"end": 133, "start": 117, "tag": "Finding"}, {"end": 99, "start": 95, "tag": "Finding"}, {"end": 61, "start": 39, "tag": "ClinicalAttribute"}]}{"id": "1500_6", "text": "Conclusions The ADCRP is a valuable biomarker of neurodegeneration in patients with MCI and biologically defined AD.", "tags": [{"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 36, "tag": "ClinicalAttribute"}, {"end": 78, "start": 70, "tag": "PatientOrDisabledGroup"}, {"end": 87, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 49, "tag": "CellOrMolecularDysfunction"}, {"end": 21, "start": 16, "tag": "ClinicalAttribute"}]}{"id": "1500_7", "text": "It shows great potential for stratifying the risk and estimating the time to conversion to dementia in patients with MCI and underlying AD (A+T+).", "tags": [{"end": 138, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 103, "tag": "PatientOrDisabledGroup"}, {"end": 99, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 69, "tag": "TemporalConcept"}, {"end": 87, "start": 77, "tag": "Finding"}, {"end": 49, "start": 45, "tag": "Finding"}]}{"id": "1500_8", "text": "Classification of Evidence This study provides Class I evidence that [F-18]FDG PET predicts the development of AD dementia in individuals with MCI and underlying AD as defined by the AT(N) framework.", "tags": [{"end": 54, "start": 47, "tag": "Finding"}, {"end": 54, "start": 47, "tag": "GeneOrGenome"}, {"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 126, "tag": "PopulationGroup"}, {"end": 107, "start": 96, "tag": "BiologicFunction"}, {"end": 107, "start": 96, "tag": "CellFunction"}, {"end": 122, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 32, "tag": "ResearchActivity"}, {"end": 146, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 55, "tag": "Finding"}, {"end": 82, "start": 69, "tag": "HealthCareActivity"}, {"end": 198, "start": 183, "tag": "HealthCareActivity"}, {"end": 26, "start": 18, "tag": "Finding"}]}{"id": "1501_0", "text": "Objective This study was mainly conducted to explore the expression changes of GSDMD and conventional markers (including T-Tau, Tau181p, and A beta(1-42)) in the cerebrospinal fluid among patients with Alzheimer's disease (AD) and vascular dementia (VD), followed by determination of role of GSDMD in diagnosing and identifying AD and VD.", "tags": [{"end": 84, "start": 79, "tag": "GeneOrGenome"}, {"end": 101, "start": 89, "tag": "HealthCareActivity"}, {"end": 297, "start": 292, "tag": "GeneOrGenome"}, {"end": 252, "start": 250, "tag": "DiseaseOrSyndrome"}, {"end": 337, "start": 335, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 231, "tag": "DiseaseOrSyndrome"}, {"end": 311, "start": 301, "tag": "HealthCareActivity"}, {"end": 126, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 221, "start": 202, "tag": "DiseaseOrSyndrome"}, {"end": 225, "start": 223, "tag": "DiseaseOrSyndrome"}, {"end": 330, "start": 328, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 162, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 196, "start": 188, "tag": "PatientOrDisabledGroup"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 153, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 102, "tag": "ClinicalAttribute"}, {"end": 135, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 297, "start": 292, "tag": "BiologicallyActiveSubstance"}, {"end": 297, "start": 292, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1501_1", "text": "Methods In this study, 60 patients with VD, 60 patients with AD, and 50 healthy controls were enrolled.", "tags": [{"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 26, "tag": "PatientOrDisabledGroup"}, {"end": 55, "start": 47, "tag": "PatientOrDisabledGroup"}, {"end": 79, "start": 72, "tag": "OrganismAttribute"}, {"end": 88, "start": 72, "tag": "PopulationGroup"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}]}{"id": "1501_2", "text": "Lumbar puncture was performed to collect cerebrospinal fluid samples.", "tags": [{"end": 15, "start": 0, "tag": "HealthCareActivity"}, {"end": 60, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 61, "tag": "Substance"}]}{"id": "1501_3", "text": "Patients with VD and patients with AD were evaluated using the Mini-Mental State Examination (MMSE) scale, Montreal Cognitive Assessment (MoCA) scale, Clinical Dementia Rating (CDR) scale, Activity of Daily Living (ADL) scale, and Neuropsychiatric Inventory (NPI) questionnaire, aiming to determine the behavioral ability of patients.", "tags": [{"end": 225, "start": 220, "tag": "HealthCareActivity"}, {"end": 213, "start": 189, "tag": "HealthCareActivity"}, {"end": 142, "start": 138, "tag": "HealthCareActivity"}, {"end": 16, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 94, "tag": "HealthCareActivity"}, {"end": 321, "start": 314, "tag": "OrganismAttribute"}, {"end": 149, "start": 144, "tag": "HealthCareActivity"}, {"end": 136, "start": 107, "tag": "HealthCareActivity"}, {"end": 37, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 21, "tag": "PatientOrDisabledGroup"}, {"end": 333, "start": 325, "tag": "PatientOrDisabledGroup"}, {"end": 105, "start": 100, "tag": "HealthCareActivity"}, {"end": 92, "start": 63, "tag": "HealthCareActivity"}, {"end": 187, "start": 182, "tag": "HealthCareActivity"}, {"end": 175, "start": 151, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 180, "start": 177, "tag": "HealthCareActivity"}, {"end": 277, "start": 264, "tag": "HealthCareActivity"}, {"end": 257, "start": 231, "tag": "HealthCareActivity"}]}{"id": "1501_4", "text": "ELISA kit was purchased to determine the levels of GSDMD, T-Tau, Tau181p, and A beta(1-42) in cerebrospinal fluid, and the expression of inflammatory factors, IL-1 beta and IL-6, was also detected.", "tags": [{"end": 56, "start": 51, "tag": "GeneOrGenome"}, {"end": 5, "start": 0, "tag": "ResearchActivity"}, {"end": 177, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 173, "tag": "GeneOrGenome"}, {"end": 177, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 78, "tag": "BiologicallyActiveSubstance"}]}{"id": "1501_5", "text": "Results (1) The levels of GSDMD, T-Tau, and Tau181p in the cerebrospinal fluid were higher in patients with AD than those of patients with VD and healthy controls, while the levels of A beta(1-42) in the cerebrospinal fluid were lower in patients with AD than that in healthy controls and patients with VD.", "tags": [{"end": 31, "start": 26, "tag": "GeneOrGenome"}, {"end": 141, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 305, "start": 303, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 254, "start": 252, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 223, "start": 204, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 94, "tag": "PatientOrDisabledGroup"}, {"end": 133, "start": 125, "tag": "PatientOrDisabledGroup"}, {"end": 246, "start": 238, "tag": "PatientOrDisabledGroup"}, {"end": 297, "start": 289, "tag": "PatientOrDisabledGroup"}, {"end": 162, "start": 146, "tag": "PopulationGroup"}, {"end": 284, "start": 268, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 196, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 196, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 26, "tag": "BiologicallyActiveSubstance"}]}{"id": "1501_6", "text": "(2) GSDMD had good diagnostic accuracy in AD.", "tags": [{"end": 9, "start": 4, "tag": "GeneOrGenome"}, {"end": 38, "start": 19, "tag": "Finding"}, {"end": 44, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 4, "tag": "BiologicallyActiveSubstance"}]}{"id": "1501_7", "text": "Additionally, GSDMD, T-Tau, Tau181p, and A beta(1-42) had good discrimination accuracy in distinguishing AD and VD.", "tags": [{"end": 19, "start": 14, "tag": "GeneOrGenome"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 63, "tag": "Finding"}, {"end": 53, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 41, "tag": "BiologicallyActiveSubstance"}]}{"id": "1501_8", "text": "(3) The expression levels of inflammatory factors (IL-1 beta and IL-6) in cerebrospinal fluid were higher in patients with AD than those of healthy controls and patients with VD, which were positively correlated with GSDMD expression.", "tags": [{"end": 222, "start": 217, "tag": "GeneOrGenome"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 65, "tag": "GeneOrGenome"}, {"end": 69, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 109, "tag": "PatientOrDisabledGroup"}, {"end": 169, "start": 161, "tag": "PatientOrDisabledGroup"}, {"end": 156, "start": 140, "tag": "PopulationGroup"}, {"end": 222, "start": 217, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 217, "tag": "BiologicallyActiveSubstance"}, {"end": 233, "start": 223, "tag": "CellFunction"}, {"end": 18, "start": 8, "tag": "CellFunction"}]}{"id": "1501_9", "text": "Conclusion The expression of GSDMD was increased in patients with AD, which could be used as a biomarker for AD diagnosis and identification from VD.", "tags": [{"end": 34, "start": 29, "tag": "GeneOrGenome"}, {"end": 148, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 95, "tag": "ClinicalAttribute"}, {"end": 60, "start": 52, "tag": "PatientOrDisabledGroup"}, {"end": 121, "start": 112, "tag": "HealthCareActivity"}, {"end": 25, "start": 15, "tag": "CellFunction"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1502_0", "text": "Hippocampal changes are associated with increased age and cognitive decline due to mild cognitive impairment (MCI) and Alzheimer's disease (AD).", "tags": [{"end": 11, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 50, "tag": "OrganismAttribute"}, {"end": 108, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 12, "tag": "Finding"}]}{"id": "1502_1", "text": "These associations are often observed only in the later stages of decline.", "tags": [{"end": 62, "start": 56, "tag": "TemporalConcept"}, {"end": 55, "start": 50, "tag": "TemporalConcept"}]}{"id": "1502_2", "text": "This study examined if hippocampal grading, a method measuring local morphological similarity of the hippocampus to cognitively normal controls (NCs) and AD participants, is associated with cognition in NCs, subjective cognitive decline (SCD), early (eMCI), late (lMCI), and AD.", "tags": [{"end": 134, "start": 128, "tag": "Finding"}, {"end": 236, "start": 208, "tag": "DiseaseOrSyndrome"}, {"end": 241, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 128, "tag": "PopulationGroup"}, {"end": 156, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 277, "start": 275, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 46, "tag": "ResearchActivity"}, {"end": 52, "start": 46, "tag": "HealthCareActivity"}, {"end": 169, "start": 157, "tag": "PopulationGroup"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 134, "start": 116, "tag": "Finding"}, {"end": 249, "start": 244, "tag": "TemporalConcept"}, {"end": 199, "start": 190, "tag": "BiologicFunction"}, {"end": 112, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 23, "tag": "ClinicalAttribute"}, {"end": 93, "start": 69, "tag": "Finding"}]}{"id": "1502_3", "text": "A total of 1620 Alzheimer's Disease Neuroimaging Initiative participants were examined (495 NC, 262 eMCI, 545 lMCI, and 318 AD) because they had baseline MRIs and Alzheimer's disease Assessment Scale (ADAS-13) and Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores.", "tags": [{"end": 199, "start": 163, "tag": "HealthCareActivity"}, {"end": 158, "start": 154, "tag": "HealthCareActivity"}, {"end": 59, "start": 16, "tag": "ResearchActivity"}, {"end": 59, "start": 16, "tag": "HealthCareRelatedOrganization"}, {"end": 267, "start": 261, "tag": "Finding"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 60, "tag": "PopulationGroup"}, {"end": 35, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 251, "start": 214, "tag": "HealthCareActivity"}, {"end": 259, "start": 253, "tag": "HealthCareActivity"}, {"end": 94, "start": 92, "tag": "PopulationGroup"}, {"end": 208, "start": 201, "tag": "HealthCareActivity"}]}{"id": "1502_4", "text": "In a sub-analysis, NCs with episodic memory scores (as measured by Rey Auditory Verbal Learning Test, RAVLT) were divided into those with subjective cognitive decline (SCD+; 103) and those without (SCD-; 390).", "tags": [{"end": 166, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 198, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 67, "tag": "HealthCareActivity"}, {"end": 50, "start": 44, "tag": "Finding"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 43, "start": 37, "tag": "BiologicFunction"}, {"end": 107, "start": 102, "tag": "HealthCareActivity"}]}{"id": "1502_5", "text": "Linear regressions evaluated the influence of hippocampal grading on cognition in preclinical and prodromal AD.", "tags": [{"end": 110, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 69, "tag": "BiologicFunction"}, {"end": 65, "start": 46, "tag": "ClinicalAttribute"}, {"end": 18, "start": 0, "tag": "ResearchActivity"}, {"end": 93, "start": 82, "tag": "TemporalConcept"}]}{"id": "1502_6", "text": "Lower global cognition, as measured by increased ADAS-13, was associated with hippocampal grading: NC (p < .001), eMCI (p < .05), lMCI (p < .05), and AD (p = .01).", "tags": [{"end": 152, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 13, "tag": "BiologicFunction"}, {"end": 101, "start": 99, "tag": "PopulationGroup"}, {"end": 97, "start": 78, "tag": "ClinicalAttribute"}, {"end": 56, "start": 49, "tag": "HealthCareActivity"}]}{"id": "1502_7", "text": "Lower global cognition as measured increased CDR-SB was associated with hippocampal grading in lMCI (p < .05) and AD (p < .001).", "tags": [{"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 13, "tag": "BiologicFunction"}, {"end": 51, "start": 45, "tag": "HealthCareActivity"}, {"end": 91, "start": 72, "tag": "ClinicalAttribute"}]}{"id": "1502_8", "text": "Lower RAVLT performance was associated with hippocampal grading in SCD- (p < .05) and SCD+ (p < .05).", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 12, "tag": "Finding"}, {"end": 11, "start": 6, "tag": "HealthCareActivity"}, {"end": 63, "start": 44, "tag": "ClinicalAttribute"}]}{"id": "1502_9", "text": "These findings suggest that hippocampal grading is associated with global cognition in NC, eMCI, lMCI, and AD.", "tags": [{"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 74, "tag": "BiologicFunction"}, {"end": 89, "start": 87, "tag": "PopulationGroup"}, {"end": 47, "start": 28, "tag": "ClinicalAttribute"}]}{"id": "1502_10", "text": "Early changes in episodic memory during pre-clinical AD are associated with changes in hippocampal grading.", "tags": [{"end": 32, "start": 17, "tag": "BiologicFunction"}, {"end": 52, "start": 40, "tag": "TemporalConcept"}, {"end": 5, "start": 0, "tag": "TemporalConcept"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 6, "tag": "Finding"}, {"end": 106, "start": 87, "tag": "ClinicalAttribute"}]}{"id": "1502_11", "text": "Hippocampal grading may be sensitive to progressive changes early in the disease course.", "tags": [{"end": 36, "start": 27, "tag": "PathologicFunction"}, {"end": 87, "start": 73, "tag": "TemporalConcept"}, {"end": 51, "start": 40, "tag": "TemporalConcept"}, {"end": 65, "start": 60, "tag": "TemporalConcept"}, {"end": 59, "start": 52, "tag": "Finding"}, {"end": 19, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1503_0", "text": "Introduction Synaptic degeneration is a key part of the pathophysiology of neurodegenerative diseases, and biomarkers reflecting the pathological alterations are greatly needed.", "tags": [{"end": 34, "start": 13, "tag": "PathologicFunction"}, {"end": 101, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 107, "tag": "ClinicalAttribute"}, {"end": 71, "start": 56, "tag": "PathologicFunction"}, {"end": 71, "start": 56, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 157, "start": 133, "tag": "PathologicFunction"}]}{"id": "1503_1", "text": "Method Seventeen synaptic proteins were quantified in a pathology-confirmed cerebrospinal fluid cohort of patients with Alzheimer's disease (AD; n = 63), frontotemporal lobar degeneration (FTLD; n = 53), and Lewy body spectrum of disorders (LBD; n = 21), as well as healthy controls (HC; n = 48).", "tags": [{"end": 187, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 244, "start": 241, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 286, "start": 284, "tag": "PopulationGroup"}, {"end": 139, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 106, "tag": "PatientOrDisabledGroup"}, {"end": 282, "start": 266, "tag": "PopulationGroup"}, {"end": 65, "start": 56, "tag": "PathologicFunction"}, {"end": 65, "start": 56, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 102, "start": 96, "tag": "PopulationGroup"}, {"end": 239, "start": 208, "tag": "DiseaseOrSyndrome"}]}{"id": "1503_2", "text": "Results Comparisons revealed four distinct patterns: markers decreased across all neurodegenerative conditions compared to HC (the neuronal pentraxins), markers increased across all neurodegenerative conditions (14-3-3 zeta/delta), markers selectively increased in AD compared to other neurodegenerative conditions (neurogranin and beta-synuclein), and markers selectively decreased in LBD and FTLD compared to HC and AD (AP2B1 and syntaxin-1B).", "tags": [{"end": 389, "start": 386, "tag": "DiseaseOrSyndrome"}, {"end": 398, "start": 394, "tag": "DiseaseOrSyndrome"}, {"end": 427, "start": 422, "tag": "GeneOrGenome"}, {"end": 427, "start": 422, "tag": "AminoAcidPeptideOrProtein"}, {"end": 443, "start": 432, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 314, "start": 286, "tag": "DiseaseOrSyndrome"}, {"end": 346, "start": 332, "tag": "AminoAcidPeptideOrProtein"}, {"end": 327, "start": 316, "tag": "AminoAcidPeptideOrProtein"}, {"end": 327, "start": 316, "tag": "BiologicallyActiveSubstance"}, {"end": 346, "start": 337, "tag": "AminoAcidPeptideOrProtein"}, {"end": 346, "start": 337, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 123, "tag": "PopulationGroup"}, {"end": 413, "start": 411, "tag": "PopulationGroup"}, {"end": 267, "start": 265, "tag": "DiseaseOrSyndrome"}, {"end": 420, "start": 418, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 51, "start": 43, "tag": "ResearchActivity"}, {"end": 60, "start": 53, "tag": "ClinicalAttribute"}, {"end": 160, "start": 153, "tag": "ClinicalAttribute"}, {"end": 239, "start": 232, "tag": "ClinicalAttribute"}, {"end": 360, "start": 353, "tag": "ClinicalAttribute"}, {"end": 19, "start": 8, "tag": "ResearchActivity"}, {"end": 150, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 427, "start": 422, "tag": "BiologicallyActiveSubstance"}, {"end": 443, "start": 432, "tag": "BiologicallyActiveSubstance"}, {"end": 229, "start": 212, "tag": "AminoAcidPeptideOrProtein"}, {"end": 229, "start": 212, "tag": "BiologicallyActiveSubstance"}]}{"id": "1503_3", "text": "Discussion Several of the synaptic proteins may serve as biomarkers for synaptic dysfunction in AD, LBD, and FTLD.", "tags": [{"end": 103, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 72, "tag": "CellOrMolecularDysfunction"}, {"end": 43, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 57, "tag": "ClinicalAttribute"}]}{"id": "1503_4", "text": "Additionally, differential patterns of synaptic protein alterations seem to be present across neurodegenerative diseases.", "tags": [{"end": 120, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 27, "tag": "ResearchActivity"}, {"end": 55, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 56, "tag": "Finding"}]}{"id": "1503_5", "text": "Highlights A panel of synaptic proteins were quantified in the cerebrospinal fluid using mass spectrometry.", "tags": [{"end": 39, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 89, "tag": "ResearchActivity"}, {"end": 82, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1503_6", "text": "We compared Alzheimer's disease, frontotemporal degeneration, and Lewy body spectrum of disorders.", "tags": [{"end": 60, "start": 33, "tag": "PathologicFunction"}, {"end": 60, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 12, "tag": "DiseaseOrSyndrome"}]}{"id": "1503_7", "text": "Pathology was confirmed by autopsy or familial mutations.", "tags": [{"end": 9, "start": 0, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 9, "start": 0, "tag": "PathologicFunction"}, {"end": 34, "start": 27, "tag": "HealthCareActivity"}, {"end": 46, "start": 38, "tag": "PopulationGroup"}, {"end": 56, "start": 47, "tag": "CellFunction"}, {"end": 56, "start": 47, "tag": "CellOrMolecularDysfunction"}]}{"id": "1503_8", "text": "We discovered synaptic biomarkers for synaptic degeneration and cognitive decline.", "tags": [{"end": 59, "start": 38, "tag": "CellOrMolecularDysfunction"}, {"end": 33, "start": 14, "tag": "ClinicalAttribute"}, {"end": 81, "start": 64, "tag": "DiseaseOrSyndrome"}]}{"id": "1503_9", "text": "We found differential patterns of synaptic proteins across neurodegenerative diseases.", "tags": [{"end": 51, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 22, "tag": "ResearchActivity"}]}{"id": "1504_0", "text": "Alzheimer's disease (AD) is a devastating neurodegenerative disorder affecting millions of people worldwide.", "tags": [{"end": 68, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 91, "tag": "PopulationGroup"}]}{"id": "1504_1", "text": "Progressive and relentless efforts are being made for therapeutic development by way of advancing understanding of non-invasive imaging modalities for the causal molecular process of AD.", "tags": [{"end": 77, "start": 54, "tag": "ResearchActivity"}, {"end": 111, "start": 98, "tag": "BiologicFunction"}, {"end": 185, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 115, "tag": "HealthCareActivity"}, {"end": 77, "start": 66, "tag": "BiologicFunction"}, {"end": 77, "start": 66, "tag": "CellFunction"}]}{"id": "1504_2", "text": "We present a Hadoop-based big data framework integrating non-invasive magnetic resonance imaging (MRI), MR spectroscopy (MRS) as well as neuropsychological test outcomes to identify early diagnostic biomarkers of AD.", "tags": [{"end": 119, "start": 104, "tag": "HealthCareActivity"}, {"end": 124, "start": 121, "tag": "HealthCareActivity"}, {"end": 169, "start": 137, "tag": "HealthCareActivity"}, {"end": 209, "start": 188, "tag": "ClinicalAttribute"}, {"end": 215, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 13, "tag": "ResearchActivity"}, {"end": 101, "start": 98, "tag": "HealthCareActivity"}, {"end": 96, "start": 70, "tag": "HealthCareActivity"}, {"end": 96, "start": 89, "tag": "HealthCareActivity"}, {"end": 96, "start": 70, "tag": "ManufacturedObject"}]}{"id": "1504_3", "text": "This big data framework for AD incorporates the three Vs (volume, variety, velocity) with advanced data mining, machine learning, and statistical modeling algorithms.", "tags": [{"end": 165, "start": 134, "tag": "ResearchActivity"}, {"end": 128, "start": 112, "tag": "MachineActivity"}, {"end": 30, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 5, "tag": "ResearchActivity"}, {"end": 110, "start": 90, "tag": "ResearchActivity"}, {"end": 128, "start": 120, "tag": "BiologicFunction"}, {"end": 84, "start": 44, "tag": "ResearchActivity"}]}{"id": "1504_4", "text": "A large volume of longitudinal information from non-invasive imaging modalities with colligated parametric variety and speed for both data acquisition and processing as velocity complete the fundamental requirements of this big data framework for early AD diagnosis.", "tags": [{"end": 265, "start": 256, "tag": "HealthCareActivity"}, {"end": 255, "start": 253, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 134, "tag": "ResearchActivity"}, {"end": 242, "start": 224, "tag": "ResearchActivity"}, {"end": 68, "start": 48, "tag": "HealthCareActivity"}, {"end": 42, "start": 18, "tag": "ResearchActivity"}, {"end": 165, "start": 155, "tag": "ResearchActivity"}, {"end": 138, "start": 134, "tag": "ResearchActivity"}, {"end": 114, "start": 85, "tag": "ResearchActivity"}]}{"id": "1504_5", "text": "Brain structural, neurochemical, and behavioral features are extracted from MRI, MRS, and neuropsychological scores, respectively.", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 76, "tag": "HealthCareActivity"}, {"end": 84, "start": 81, "tag": "HealthCareActivity"}, {"end": 115, "start": 90, "tag": "HealthCareActivity"}]}{"id": "1504_6", "text": "Subsequently, feature selection and ensemble-based classification are proposed and their outputs are fused based on the combination rule for final accurate classification and validation from clinicians.", "tags": [{"end": 185, "start": 175, "tag": "ResearchActivity"}, {"end": 201, "start": 191, "tag": "HealthCareActivity"}, {"end": 65, "start": 36, "tag": "HealthCareActivity"}]}{"id": "1504_7", "text": "A multi-modality-based decision framework (BHARAT) for classification of early AD will be immensely helpful.", "tags": [{"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 2, "tag": "HealthCareActivity"}, {"end": 49, "start": 43, "tag": "HealthCareActivity"}]}{"id": "1505_0", "text": "We aimed to evaluate the value of ATN biomarker classification system (amyloid beta [A], pathologic tau [T], and neurodegeneration [N]) for predicting conversion from mild cognitive impairment (MCI) to dementia.", "tags": [{"end": 99, "start": 89, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 103, "start": 89, "tag": "CellOrMolecularDysfunction"}, {"end": 103, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 202, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 113, "tag": "CellOrMolecularDysfunction"}, {"end": 171, "start": 167, "tag": "Finding"}, {"end": 83, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 151, "tag": "Finding"}, {"end": 69, "start": 34, "tag": "HealthCareActivity"}, {"end": 47, "start": 34, "tag": "ClinicalAttribute"}]}{"id": "1505_1", "text": "In a sample of people with MCI (n = 415) we assessed predictive performance of ATN classification using empirical knowledge-based cut-offs for each component of ATN and compared it to two data-driven approaches, logistic regression and RUSBoost machine learning classifiers, which used continuous clinical or biomarker scores.", "tags": [{"end": 164, "start": 161, "tag": "HealthCareActivity"}, {"end": 231, "start": 212, "tag": "ResearchActivity"}, {"end": 123, "start": 114, "tag": "Finding"}, {"end": 273, "start": 236, "tag": "MachineActivity"}, {"end": 325, "start": 319, "tag": "Finding"}, {"end": 296, "start": 286, "tag": "TemporalConcept"}, {"end": 318, "start": 309, "tag": "ClinicalAttribute"}, {"end": 210, "start": 188, "tag": "ResearchActivity"}, {"end": 30, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 64, "tag": "Finding"}, {"end": 21, "start": 15, "tag": "PopulationGroup"}, {"end": 11, "start": 5, "tag": "Substance"}, {"end": 11, "start": 5, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 97, "start": 79, "tag": "HealthCareActivity"}, {"end": 138, "start": 104, "tag": "ResearchActivity"}]}{"id": "1505_2", "text": "In data-driven approaches, we identified ATN features that distinguish normals from individuals with dementia and used them to classify persons with MCI into dementia-like and normal groups.", "tags": [{"end": 44, "start": 41, "tag": "HealthCareActivity"}, {"end": 143, "start": 136, "tag": "PopulationGroup"}, {"end": 182, "start": 176, "tag": "Finding"}, {"end": 25, "start": 3, "tag": "ResearchActivity"}, {"end": 95, "start": 84, "tag": "PopulationGroup"}, {"end": 109, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 183, "tag": "PopulationGroup"}]}{"id": "1505_3", "text": "Both data-driven classification methods performed better than the empirical cut-offs for ATN biomarkers in predicting conversion to dementia.", "tags": [{"end": 39, "start": 5, "tag": "ResearchActivity"}, {"end": 140, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 89, "tag": "ClinicalAttribute"}, {"end": 128, "start": 118, "tag": "Finding"}, {"end": 84, "start": 66, "tag": "ResearchActivity"}]}{"id": "1505_4", "text": "Classifiers that used clinical features performed as well as classifiers that used ATN biomarkers for prediction of progression to dementia.", "tags": [{"end": 39, "start": 22, "tag": "ClinicalAttribute"}, {"end": 139, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 83, "tag": "ClinicalAttribute"}, {"end": 127, "start": 116, "tag": "PathologicFunction"}, {"end": 127, "start": 116, "tag": "TemporalConcept"}, {"end": 112, "start": 102, "tag": "Finding"}, {"end": 72, "start": 61, "tag": "ResearchActivity"}, {"end": 11, "start": 0, "tag": "ResearchActivity"}]}{"id": "1505_5", "text": "We discuss that data-driven modeling approaches can improve our ability to predict disease progression and might have implications in future clinical trials.", "tags": [{"end": 47, "start": 28, "tag": "ResearchActivity"}, {"end": 156, "start": 141, "tag": "ResearchActivity"}, {"end": 71, "start": 64, "tag": "OrganismAttribute"}, {"end": 20, "start": 16, "tag": "ResearchActivity"}, {"end": 102, "start": 91, "tag": "PathologicFunction"}, {"end": 102, "start": 91, "tag": "TemporalConcept"}, {"end": 102, "start": 83, "tag": "PathologicFunction"}, {"end": 140, "start": 134, "tag": "TemporalConcept"}]}{"id": "1506_0", "text": "Red blood cells (RBCs) are characterized by a remarkable elasticity, which allows them to undergo very large deformation when passing through small vessels and capillaries.", "tags": [{"end": 15, "start": 0, "tag": "Cell"}, {"end": 21, "start": 17, "tag": "Cell"}, {"end": 67, "start": 57, "tag": "NaturalPhenomenonOrProcess"}, {"end": 67, "start": 57, "tag": "ClinicalAttribute"}, {"end": 171, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1506_1", "text": "This extreme deformability is altered in various clinical conditions, suggesting that the analysis of red blood cell (RBC) mechanics has potential applications in the search for non-invasive and cost-effective blood biomarkers.", "tags": [{"end": 26, "start": 13, "tag": "NaturalPhenomenonOrProcess"}, {"end": 116, "start": 102, "tag": "Cell"}, {"end": 121, "start": 118, "tag": "Cell"}, {"end": 132, "start": 123, "tag": "NaturalPhenomenonOrProcess"}, {"end": 132, "start": 123, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 159, "start": 147, "tag": "HealthCareActivity"}, {"end": 173, "start": 167, "tag": "ResearchActivity"}, {"end": 226, "start": 216, "tag": "ClinicalAttribute"}, {"end": 190, "start": 178, "tag": "ClinicalAttribute"}, {"end": 116, "start": 106, "tag": "Cell"}, {"end": 226, "start": 216, "tag": "ClinicalAttribute"}, {"end": 209, "start": 195, "tag": "ClinicalAttribute"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 68, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 226, "start": 216, "tag": "ClinicalAttribute"}, {"end": 215, "start": 210, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 90, "tag": "ResearchActivity"}]}{"id": "1506_2", "text": "Here, we provide a comparative study of the mechanical response of RBCs in patients with Alzheimer's disease (AD) and healthy subjects.", "tags": [{"end": 36, "start": 19, "tag": "ResearchActivity"}, {"end": 71, "start": 67, "tag": "Cell"}, {"end": 134, "start": 118, "tag": "PopulationGroup"}, {"end": 108, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 75, "tag": "PatientOrDisabledGroup"}, {"end": 125, "start": 118, "tag": "OrganismAttribute"}, {"end": 134, "start": 126, "tag": "PopulationGroup"}, {"end": 63, "start": 55, "tag": "OrganismAttribute"}]}{"id": "1506_3", "text": "For this purpose, RBC viscoelastic response was investigated using atomic force microscopy (AFM) in the force spectroscopy mode.", "tags": [{"end": 21, "start": 18, "tag": "Cell"}, {"end": 95, "start": 92, "tag": "ResearchActivity"}, {"end": 95, "start": 92, "tag": "ManufacturedObject"}, {"end": 90, "start": 67, "tag": "ResearchActivity"}, {"end": 43, "start": 22, "tag": "Finding"}, {"end": 127, "start": 104, "tag": "ResearchActivity"}, {"end": 60, "start": 48, "tag": "HealthCareActivity"}, {"end": 43, "start": 35, "tag": "OrganismAttribute"}]}{"id": "1506_4", "text": "Two types of analyses were performed: (i) a conventional analysis of AFM force-distance (FD) curves, which allowed us to retrieve the apparent Young's modulus, E; and (ii) a more in-depth analysis of time-dependent relaxation curves in the framework of the standard linear solid (SLS) model, which allowed us to estimate cell viscosity and elasticity, independently.", "tags": [{"end": 72, "start": 69, "tag": "ResearchActivity"}, {"end": 72, "start": 69, "tag": "ManufacturedObject"}, {"end": 335, "start": 326, "tag": "NaturalPhenomenonOrProcess"}, {"end": 350, "start": 340, "tag": "NaturalPhenomenonOrProcess"}, {"end": 350, "start": 340, "tag": "ClinicalAttribute"}, {"end": 290, "start": 257, "tag": "ResearchActivity"}, {"end": 65, "start": 44, "tag": "ResearchActivity"}, {"end": 99, "start": 73, "tag": "ResearchActivity"}, {"end": 158, "start": 143, "tag": "ResearchActivity"}, {"end": 232, "start": 215, "tag": "ResearchActivity"}, {"end": 325, "start": 321, "tag": "Cell"}, {"end": 214, "start": 205, "tag": "Finding"}, {"end": 204, "start": 200, "tag": "TemporalConcept"}, {"end": 21, "start": 13, "tag": "ResearchActivity"}, {"end": 65, "start": 57, "tag": "ResearchActivity"}, {"end": 196, "start": 188, "tag": "ResearchActivity"}]}{"id": "1506_5", "text": "Our data demonstrate that, while conventional analysis of AFM FD curves fails in distinguishing the two groups, the mechanical parameters obtained with the SLS model show a very good classification ability.", "tags": [{"end": 61, "start": 58, "tag": "ResearchActivity"}, {"end": 61, "start": 58, "tag": "ManufacturedObject"}, {"end": 165, "start": 156, "tag": "ResearchActivity"}, {"end": 54, "start": 33, "tag": "ResearchActivity"}, {"end": 71, "start": 62, "tag": "ResearchActivity"}, {"end": 205, "start": 198, "tag": "OrganismAttribute"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 110, "start": 104, "tag": "PopulationGroup"}, {"end": 54, "start": 46, "tag": "ResearchActivity"}]}{"id": "1506_6", "text": "The diagnostic performance of mechanical parameters was assessed using receiving operator characteristic (ROC) curves, showing very large areas under the curves (AUC) for selected biomarkers (AUC > 0.9).", "tags": [{"end": 117, "start": 72, "tag": "ResearchActivity"}, {"end": 160, "start": 138, "tag": "ResearchActivity"}, {"end": 109, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 180, "tag": "ClinicalAttribute"}, {"end": 26, "start": 15, "tag": "Finding"}, {"end": 14, "start": 4, "tag": "HealthCareActivity"}, {"end": 165, "start": 162, "tag": "ResearchActivity"}, {"end": 195, "start": 192, "tag": "ResearchActivity"}]}{"id": "1506_7", "text": "Taken all together, the data presented here demonstrate that RBC mechanics are significantly altered in AD, also highlighting the key role played by viscous forces.", "tags": [{"end": 64, "start": 61, "tag": "Cell"}, {"end": 74, "start": 65, "tag": "NaturalPhenomenonOrProcess"}, {"end": 74, "start": 65, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 24, "tag": "ResearchActivity"}]}{"id": "1506_8", "text": "These RBC abnormalities in AD, which include both a modified elasticity and viscosity, could be considered a potential source of plasmatic biomarkers in the field of liquid biopsy to be used in combination with more established indicators of the pathology.", "tags": [{"end": 9, "start": 6, "tag": "Cell"}, {"end": 71, "start": 61, "tag": "NaturalPhenomenonOrProcess"}, {"end": 71, "start": 61, "tag": "ClinicalAttribute"}, {"end": 85, "start": 76, "tag": "NaturalPhenomenonOrProcess"}, {"end": 149, "start": 129, "tag": "ClinicalAttribute"}, {"end": 179, "start": 166, "tag": "HealthCareActivity"}, {"end": 23, "start": 6, "tag": "CellOrMolecularDysfunction"}, {"end": 238, "start": 228, "tag": "Chemical"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 139, "tag": "ClinicalAttribute"}, {"end": 255, "start": 246, "tag": "PathologicFunction"}, {"end": 255, "start": 246, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1507_0", "text": "Introduction: We examined factors related to willingness to enroll in hypothetical Alzheimer disease (AD) biomarker studies.", "tags": [{"end": 100, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 45, "tag": "BiologicFunction"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 106, "tag": "ClinicalAttribute"}, {"end": 123, "start": 116, "tag": "ResearchActivity"}]}{"id": "1507_1", "text": "Methods: Using linear regression, we assessed the relationship among enrollment willingness and demographics, family dementia history, research attitudes, concern about AD, experiences of discrimination, and belief in AD risk modifiability.", "tags": [{"end": 91, "start": 69, "tag": "Finding"}, {"end": 133, "start": 110, "tag": "Finding"}, {"end": 184, "start": 173, "tag": "BiologicFunction"}, {"end": 202, "start": 188, "tag": "BiologicFunction"}, {"end": 214, "start": 208, "tag": "BiologicFunction"}, {"end": 153, "start": 135, "tag": "ResearchActivity"}, {"end": 239, "start": 221, "tag": "Finding"}, {"end": 32, "start": 15, "tag": "ResearchActivity"}, {"end": 91, "start": 80, "tag": "BiologicFunction"}, {"end": 133, "start": 126, "tag": "Finding"}, {"end": 171, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 220, "start": 218, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 135, "tag": "ResearchActivity"}, {"end": 125, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 69, "tag": "HealthCareActivity"}, {"end": 62, "start": 50, "tag": "Finding"}]}{"id": "1507_2", "text": "Inductive coding was used to assess qualitative data.", "tags": [{"end": 52, "start": 36, "tag": "ResearchActivity"}, {"end": 16, "start": 0, "tag": "ResearchActivity"}, {"end": 52, "start": 48, "tag": "ResearchActivity"}]}{"id": "1507_3", "text": "Results: In middle-aged and older adult AD research participants ( n = 334), willingness to enroll in biomarker studies was driven by biomarker collection method, research attitudes, and disclosure of personal results.", "tags": [{"end": 23, "start": 12, "tag": "PopulationGroup"}, {"end": 39, "start": 28, "tag": "PopulationGroup"}, {"end": 39, "start": 34, "tag": "PopulationGroup"}, {"end": 181, "start": 163, "tag": "ResearchActivity"}, {"end": 98, "start": 77, "tag": "Finding"}, {"end": 197, "start": 187, "tag": "IndividualBehavior"}, {"end": 33, "start": 28, "tag": "TemporalConcept"}, {"end": 209, "start": 201, "tag": "OrganismAttribute"}, {"end": 88, "start": 77, "tag": "BiologicFunction"}, {"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 102, "tag": "ClinicalAttribute"}, {"end": 143, "start": 134, "tag": "ClinicalAttribute"}, {"end": 161, "start": 155, "tag": "ResearchActivity"}, {"end": 161, "start": 155, "tag": "HealthCareActivity"}, {"end": 64, "start": 52, "tag": "PopulationGroup"}, {"end": 51, "start": 43, "tag": "ResearchActivity"}, {"end": 171, "start": 163, "tag": "ResearchActivity"}, {"end": 119, "start": 112, "tag": "ResearchActivity"}, {"end": 23, "start": 19, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}{"id": "1507_4", "text": "Predictors of willingness were similar for Black and White participants.", "tags": [{"end": 71, "start": 53, "tag": "PopulationGroup"}, {"end": 48, "start": 43, "tag": "PopulationGroup"}, {"end": 25, "start": 14, "tag": "BiologicFunction"}, {"end": 71, "start": 59, "tag": "PopulationGroup"}]}{"id": "1507_5", "text": "Themes associated with increased willingness included a desire to learn biomarker results and support research.", "tags": [{"end": 62, "start": 56, "tag": "BiologicFunction"}, {"end": 44, "start": 33, "tag": "BiologicFunction"}, {"end": 81, "start": 72, "tag": "ClinicalAttribute"}, {"end": 110, "start": 102, "tag": "ResearchActivity"}]}{"id": "1507_6", "text": "Discussion: Research attitudes were an important predictor of biomarker study willingness regardless of race.", "tags": [{"end": 108, "start": 104, "tag": "PopulationGroup"}, {"end": 30, "start": 12, "tag": "ResearchActivity"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 89, "start": 78, "tag": "BiologicFunction"}, {"end": 71, "start": 62, "tag": "ClinicalAttribute"}, {"end": 77, "start": 72, "tag": "ResearchActivity"}]}{"id": "1507_7", "text": "As seen elsewhere, Black participants were more hesitant to participate in biomarker research.", "tags": [{"end": 37, "start": 19, "tag": "PopulationGroup"}, {"end": 24, "start": 19, "tag": "PopulationGroup"}, {"end": 84, "start": 75, "tag": "ClinicalAttribute"}, {"end": 37, "start": 25, "tag": "PopulationGroup"}, {"end": 93, "start": 85, "tag": "ResearchActivity"}]}{"id": "1507_8", "text": "Disclosure of biomarker results/risk can bolster willingness to enroll in biomarker studies, particularly for Black participants.", "tags": [{"end": 128, "start": 110, "tag": "PopulationGroup"}, {"end": 70, "start": 49, "tag": "Finding"}, {"end": 10, "start": 0, "tag": "IndividualBehavior"}, {"end": 115, "start": 110, "tag": "PopulationGroup"}, {"end": 60, "start": 49, "tag": "BiologicFunction"}, {"end": 23, "start": 14, "tag": "ClinicalAttribute"}, {"end": 83, "start": 74, "tag": "ClinicalAttribute"}, {"end": 128, "start": 116, "tag": "PopulationGroup"}, {"end": 91, "start": 84, "tag": "ResearchActivity"}]}{"id": "1508_0", "text": "Background Synaptic dysfunction is an early core feature of Alzheimer's disease (AD), closely associated with cognitive symptoms.", "tags": [{"end": 79, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 110, "tag": "SignOrSymptom"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 11, "tag": "CellOrMolecularDysfunction"}, {"end": 31, "start": 20, "tag": "PathologicFunction"}]}{"id": "1508_1", "text": "Neuregulin 1 (NRG1) is a growth and differentiation factor with a key role in the development and maintenance of synaptic transmission.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 0, "tag": "GeneOrGenome"}, {"end": 18, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 14, "tag": "GeneOrGenome"}, {"end": 58, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 113, "tag": "CellFunction"}, {"end": 134, "start": 113, "tag": "BiologicFunction"}, {"end": 31, "start": 25, "tag": "BiologicFunction"}, {"end": 109, "start": 98, "tag": "BiologicFunction"}, {"end": 51, "start": 36, "tag": "CellFunction"}, {"end": 93, "start": 82, "tag": "BiologicFunction"}, {"end": 93, "start": 82, "tag": "CellFunction"}, {"end": 12, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 36, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1508_2", "text": "Previous reports have shown that changes in cerebrospinal fluid (CSF) NRG1 concentration are associated with cognitive status and biomarker evidence of AD pathology.", "tags": [{"end": 74, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 70, "tag": "GeneOrGenome"}, {"end": 16, "start": 9, "tag": "HealthCareActivity"}, {"end": 16, "start": 9, "tag": "ResearchActivity"}, {"end": 125, "start": 109, "tag": "BiologicFunction"}, {"end": 68, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 155, "tag": "PathologicFunction"}, {"end": 164, "start": 155, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 154, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 130, "tag": "ClinicalAttribute"}, {"end": 63, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 148, "start": 140, "tag": "Finding"}, {"end": 88, "start": 70, "tag": "ClinicalAttribute"}, {"end": 63, "start": 44, "tag": "ClinicalAttribute"}]}{"id": "1508_3", "text": "Plasma biomarkers reflecting synaptic impairment would be of great clinical interest.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 7, "tag": "ClinicalAttribute"}, {"end": 48, "start": 29, "tag": "CellOrMolecularDysfunction"}, {"end": 84, "start": 61, "tag": "Finding"}]}{"id": "1508_4", "text": "Objective To measure plasma NRG1 concentration in AD patients in comparison with other neurodegenerative disorders and neurological controls (NC) and to study its association with cerebrospinal fluid (CSF) core AD and synaptic biomarkers.", "tags": [{"end": 32, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 28, "tag": "GeneOrGenome"}, {"end": 237, "start": 218, "tag": "ClinicalAttribute"}, {"end": 27, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 53, "tag": "PatientOrDisabledGroup"}, {"end": 204, "start": 201, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 213, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 153, "tag": "ResearchActivity"}, {"end": 199, "start": 180, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 132, "tag": "PopulationGroup"}, {"end": 114, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 65, "tag": "ResearchActivity"}, {"end": 144, "start": 142, "tag": "PopulationGroup"}, {"end": 32, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 21, "tag": "ClinicalAttribute"}]}{"id": "1508_5", "text": "Methods This retrospective study enrolled 127 participants including patients with AD at mild cognitive impairment stage (AD-MCI, n = 27) and at dementia stage (n = 35), non-AD dementia (n = 26, A beta-negative), non-AD MCI (n = 19), and neurological controls (n=20).", "tags": [{"end": 32, "start": 13, "tag": "ResearchActivity"}, {"end": 77, "start": 69, "tag": "PatientOrDisabledGroup"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 176, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 46, "tag": "PopulationGroup"}, {"end": 259, "start": 251, "tag": "PopulationGroup"}, {"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 159, "start": 154, "tag": "TemporalConcept"}, {"end": 120, "start": 115, "tag": "ClinicalAttribute"}, {"end": 128, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 154, "tag": "ClinicalAttribute"}]}{"id": "1508_6", "text": "Plasma and CSF NRG1, as well as CSF core AD biomarkers (A beta 42/A beta 40 ratio, phospho-tau, and total tau), were measured using ELISA.", "tags": [{"end": 19, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 15, "tag": "GeneOrGenome"}, {"end": 137, "start": 132, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 44, "tag": "ClinicalAttribute"}, {"end": 14, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 15, "tag": "BiologicallyActiveSubstance"}]}{"id": "1508_7", "text": "CSF synaptic markers were measured using ELISA for GAP-43 and neurogranin and through immunoprecipitation mass spectrometry for SNAP-25.", "tags": [{"end": 57, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 128, "tag": "GeneOrGenome"}, {"end": 135, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 41, "tag": "ResearchActivity"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 106, "tag": "ResearchActivity"}, {"end": 105, "start": 86, "tag": "ResearchActivity"}, {"end": 135, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 4, "tag": "ClinicalAttribute"}, {"end": 57, "start": 51, "tag": "BiologicallyActiveSubstance"}]}{"id": "1508_8", "text": "Results Plasma NRG1 concentration was higher in AD-MCI and AD dementia patients compared with neurological controls (respectively P = 0.005 and P < 0.001).", "tags": [{"end": 19, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 15, "tag": "GeneOrGenome"}, {"end": 14, "start": 8, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 71, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 107, "tag": "PopulationGroup"}, {"end": 54, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 8, "tag": "ClinicalAttribute"}]}{"id": "1508_9", "text": "Plasma NRG1 differentiated AD MCI patients from neurological controls with an area under the curve of 88.3%, and AD dementia patients from NC with an area under the curve of 87.3%.", "tags": [{"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 34, "tag": "PatientOrDisabledGroup"}, {"end": 133, "start": 125, "tag": "PatientOrDisabledGroup"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 61, "tag": "PopulationGroup"}, {"end": 98, "start": 78, "tag": "ResearchActivity"}, {"end": 170, "start": 150, "tag": "ResearchActivity"}, {"end": 33, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 139, "tag": "PopulationGroup"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1508_10", "text": "Plasma NRG1 correlated with CSF NRG1 (beta = 0.372, P = 0.0056, adjusted on age and sex).", "tags": [{"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 36, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 32, "tag": "GeneOrGenome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 76, "tag": "OrganismAttribute"}, {"end": 87, "start": 84, "tag": "OrganismAttribute"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 0, "tag": "ClinicalAttribute"}, {"end": 36, "start": 28, "tag": "ClinicalAttribute"}, {"end": 36, "start": 32, "tag": "BiologicallyActiveSubstance"}]}{"id": "1508_11", "text": "Plasma NRG1 was associated with AD CSF core biomarkers in the whole cohort and in A beta-positive patients (beta = -0.197-0.423).", "tags": [{"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 44, "tag": "ClinicalAttribute"}, {"end": 106, "start": 98, "tag": "PatientOrDisabledGroup"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 68, "tag": "PopulationGroup"}, {"end": 34, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1508_12", "text": "Plasma NRG1 correlated with CSF GAP-43, neurogranin, and SNAP-25 (beta = 0.278-0.355).", "tags": [{"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 38, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 57, "tag": "GeneOrGenome"}, {"end": 64, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 0, "tag": "ClinicalAttribute"}, {"end": 38, "start": 32, "tag": "BiologicallyActiveSubstance"}]}{"id": "1508_13", "text": "Plasma NRG1 concentration correlated inversely with MMSE in the whole cohort and in A beta-positive patients (all, beta = -0.188, P = 0.038; A beta+: beta = -0.255, P = 0.038).", "tags": [{"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 100, "tag": "PatientOrDisabledGroup"}, {"end": 76, "start": 70, "tag": "PopulationGroup"}, {"end": 90, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 52, "tag": "HealthCareActivity"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1508_14", "text": "Conclusion Plasma NRG1 concentration is increased in AD patients and correlates with CSF core AD and synaptic biomarkers and cognitive status.", "tags": [{"end": 22, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 18, "tag": "GeneOrGenome"}, {"end": 141, "start": 125, "tag": "BiologicFunction"}, {"end": 17, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 101, "tag": "ClinicalAttribute"}, {"end": 64, "start": 56, "tag": "PatientOrDisabledGroup"}, {"end": 88, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 11, "tag": "ClinicalAttribute"}]}{"id": "1508_15", "text": "Thus, plasma NRG1 is a promising non-invasive biomarker to monitor synaptic impairment in AD.", "tags": [{"end": 17, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 13, "tag": "GeneOrGenome"}, {"end": 12, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 59, "tag": "HealthCareActivity"}, {"end": 66, "start": 59, "tag": "ManufacturedObject"}, {"end": 55, "start": 33, "tag": "ClinicalAttribute"}, {"end": 17, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 67, "tag": "CellOrMolecularDysfunction"}, {"end": 17, "start": 6, "tag": "ClinicalAttribute"}]}{"id": "1509_0", "text": "Background: Oligomeric amyloid-beta (A beta) is one of the major contributors to the pathomechanism of Alzheimer's disease (AD); A beta oligomerization in plasma can be measured using a Multimer Detection System-Oligomeric A beta (MDS-OA beta) after incubation with spiked synthetic A beta.", "tags": [{"end": 260, "start": 250, "tag": "IndividualBehavior"}, {"end": 260, "start": 250, "tag": "ResearchActivity"}, {"end": 122, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 289, "start": 266, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 129, "tag": "CellFunction"}, {"end": 229, "start": 186, "tag": "HealthCareActivity"}, {"end": 242, "start": 231, "tag": "HealthCareActivity"}, {"end": 99, "start": 85, "tag": "PathologicFunction"}]}{"id": "1509_1", "text": "Objective: We evaluated the clinical sensitivity and specificity of the MDS-OA beta values for prediction of AD.", "tags": [{"end": 48, "start": 28, "tag": "Finding"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 53, "tag": "Finding"}, {"end": 83, "start": 72, "tag": "HealthCareActivity"}, {"end": 105, "start": 95, "tag": "Finding"}]}{"id": "1509_2", "text": "Methods: The MDS-OA beta values measured using in Blood (TM) OA beta test in heparin-treated plasma samples from 52ADpatients in comparison with 52 community-based subjects with normal cognition (NC).", "tags": [{"end": 157, "start": 148, "tag": "HealthCareRelatedOrganization"}, {"end": 59, "start": 57, "tag": "CellComponent"}, {"end": 99, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 178, "tag": "Finding"}, {"end": 194, "start": 178, "tag": "Finding"}, {"end": 194, "start": 185, "tag": "BiologicFunction"}, {"end": 172, "start": 164, "tag": "PopulationGroup"}, {"end": 139, "start": 129, "tag": "ResearchActivity"}, {"end": 55, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 198, "start": 196, "tag": "PopulationGroup"}, {"end": 40, "start": 32, "tag": "HealthCareActivity"}, {"end": 24, "start": 13, "tag": "HealthCareActivity"}]}{"id": "1509_3", "text": "The inclusion criterion was proposed by the NINCDS-ADRDA and additionally required at least 6 months of follow-up from the initial clinical diagnosis in the course of AD.", "tags": [{"end": 130, "start": 123, "tag": "TemporalConcept"}, {"end": 169, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 140, "tag": "HealthCareActivity"}, {"end": 113, "start": 104, "tag": "HealthCareActivity"}, {"end": 113, "start": 104, "tag": "TemporalConcept"}, {"end": 163, "start": 157, "tag": "TemporalConcept"}, {"end": 100, "start": 94, "tag": "TemporalConcept"}, {"end": 149, "start": 131, "tag": "HealthCareActivity"}, {"end": 23, "start": 4, "tag": "ResearchActivity"}, {"end": 56, "start": 44, "tag": "HealthCareActivity"}]}{"id": "1509_4", "text": "Results: The MDS-OA beta values were 1.43 +/- 0.30 ng/ml in AD and 0.45 +/- 0.19 (p < 0.001) in NC, respectively.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 62, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 96, "tag": "PopulationGroup"}, {"end": 24, "start": 13, "tag": "HealthCareActivity"}]}{"id": "1509_5", "text": "Using a cut-off value of 0.78 ng/ml, the results revealed 100% sensitivity and 92.31% specificity.", "tags": [{"end": 74, "start": 63, "tag": "Finding"}, {"end": 97, "start": 86, "tag": "Finding"}]}{"id": "1509_6", "text": "Conclusion: MDS-OA beta to measure plasma A beta oligomerization is a valuable blood-based biomarker for clinical diagnosis of AD, with high sensitivity and specificity.", "tags": [{"end": 152, "start": 136, "tag": "Finding"}, {"end": 168, "start": 136, "tag": "Finding"}, {"end": 41, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 91, "tag": "ClinicalAttribute"}, {"end": 84, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 141, "tag": "Finding"}, {"end": 123, "start": 105, "tag": "HealthCareActivity"}, {"end": 168, "start": 157, "tag": "Finding"}, {"end": 23, "start": 12, "tag": "HealthCareActivity"}, {"end": 64, "start": 35, "tag": "ClinicalAttribute"}]}{"id": "1510_0", "text": "Introduction There has been significant development in blood-based biomarkers targeting amyloidopathy of Alzheimer's disease (AD).", "tags": [{"end": 124, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 67, "tag": "ClinicalAttribute"}, {"end": 128, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 40, "tag": "BiologicFunction"}, {"end": 51, "start": 40, "tag": "CellFunction"}, {"end": 101, "start": 88, "tag": "PathologicFunction"}]}{"id": "1510_1", "text": "However, the guidelines for integrating such biomarkers into AD diagnosis are still inadequate.", "tags": [{"end": 55, "start": 45, "tag": "ClinicalAttribute"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 64, "tag": "HealthCareActivity"}]}{"id": "1510_2", "text": "Multimer Detection System-Oligomeric Amyloid-beta (MDS-OA beta) as a plasma biomarker detecting oligomerization tendency is available in the clinical practice.Main text We suggest how to interpret the results of plasma biomarker for amyloidopathy using MDS-OA beta with neuropsychological test, brain magnetic resonance imaging (MRI), and amyloid PET for AD diagnosis.", "tags": [{"end": 111, "start": 96, "tag": "CellFunction"}, {"end": 293, "start": 270, "tag": "HealthCareActivity"}, {"end": 158, "start": 141, "tag": "HealthCareActivity"}, {"end": 75, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 218, "start": 212, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 346, "start": 339, "tag": "AminoAcidPeptideOrProtein"}, {"end": 346, "start": 339, "tag": "BiologicallyActiveSubstance"}, {"end": 357, "start": 355, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 76, "tag": "ClinicalAttribute"}, {"end": 228, "start": 219, "tag": "ClinicalAttribute"}, {"end": 300, "start": 295, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 332, "start": 329, "tag": "HealthCareActivity"}, {"end": 350, "start": 347, "tag": "HealthCareActivity"}, {"end": 367, "start": 358, "tag": "HealthCareActivity"}, {"end": 327, "start": 301, "tag": "HealthCareActivity"}, {"end": 49, "start": 0, "tag": "HealthCareActivity"}, {"end": 62, "start": 51, "tag": "HealthCareActivity"}, {"end": 264, "start": 253, "tag": "HealthCareActivity"}, {"end": 246, "start": 233, "tag": "PathologicFunction"}, {"end": 120, "start": 112, "tag": "Finding"}]}{"id": "1510_3", "text": "Combination of each test result differentiates various stages of AD, other neurodegenerative diseases, or cognitive impairment due to the causes other than neurodegeneration.Discussion A systematic interpretation strategy could support accurate diagnosis and staging of AD.", "tags": [{"end": 24, "start": 20, "tag": "ResearchActivity"}, {"end": 24, "start": 20, "tag": "HealthCareActivity"}, {"end": 101, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 156, "tag": "CellOrMolecularDysfunction"}, {"end": 31, "start": 25, "tag": "Finding"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 272, "start": 270, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 55, "tag": "TemporalConcept"}, {"end": 254, "start": 245, "tag": "HealthCareActivity"}, {"end": 266, "start": 259, "tag": "TemporalConcept"}, {"end": 126, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 55, "tag": "ClinicalAttribute"}]}{"id": "1510_4", "text": "Moreover, comprehensive use of biomarkers that target amyloidopathy such as amyloid PET on brain amyloid plaque and MDS-OA beta on amyloid-beta oligomerization tendency can complement to gain advanced insights on amyloid-beta dynamics in AD.", "tags": [{"end": 111, "start": 97, "tag": "AnatomicalAbnormality"}, {"end": 234, "start": 226, "tag": "NaturalPhenomenonOrProcess"}, {"end": 41, "start": 31, "tag": "ClinicalAttribute"}, {"end": 225, "start": 213, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 240, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 84, "tag": "HealthCareActivity"}, {"end": 127, "start": 116, "tag": "HealthCareActivity"}, {"end": 67, "start": 54, "tag": "PathologicFunction"}, {"end": 159, "start": 131, "tag": "CellFunction"}, {"end": 168, "start": 160, "tag": "Finding"}, {"end": 209, "start": 192, "tag": "Finding"}]}{"id": "1511_0", "text": "Background: While cutoffs for abnormal levels of the cerebrospinal fluid (CSF) biomarkers amyloid-beta 1-42 (A beta(1-42)), total tau (t-tau), phosphorylated tau (p-tau), and the ratios of t-tau/A beta(1-42) and p-tau/A beta(1-42), have been established in Alzheimer's disease (AD), biologically relevant cutoffs have not been studied extensively in Parkinson's disease (PD).", "tags": [{"end": 45, "start": 30, "tag": "Finding"}, {"end": 140, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 194, "start": 189, "tag": "AminoAcidPeptideOrProtein"}, {"end": 276, "start": 257, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 79, "tag": "ClinicalAttribute"}, {"end": 77, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 194, "start": 189, "tag": "BiologicallyActiveSubstance"}, {"end": 280, "start": 278, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 161, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 369, "start": 350, "tag": "DiseaseOrSyndrome"}, {"end": 373, "start": 371, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 207, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 230, "start": 218, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 217, "start": 212, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 217, "start": 212, "tag": "BiologicallyActiveSubstance"}, {"end": 207, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 207, "start": 179, "tag": "ClinicalAttribute"}, {"end": 230, "start": 218, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 18, "tag": "ResearchActivity"}, {"end": 312, "start": 305, "tag": "ResearchActivity"}]}{"id": "1511_1", "text": "Objective: Assess the suitability and diagnostic accuracy of established AD-derived CSF biomarker cutoffs in the PD population.", "tags": [{"end": 87, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 88, "tag": "ClinicalAttribute"}, {"end": 126, "start": 116, "tag": "PopulationGroup"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 38, "tag": "Finding"}, {"end": 33, "start": 22, "tag": "Finding"}, {"end": 105, "start": 98, "tag": "ResearchActivity"}]}{"id": "1511_2", "text": "Methods: Baseline and longitudinal data on CSF biomarkers, cognitive diagnoses, and PET amyloid imaging in 423 newly diagnosed patients with PD from the Parkinson's Progression Markers Initiative (PPMI) cohort were used to evaluate established AD biomarker cutoffs compared with optimal cutoffs derived from the PPMI cohort.", "tags": [{"end": 57, "start": 47, "tag": "ClinicalAttribute"}, {"end": 135, "start": 127, "tag": "PatientOrDisabledGroup"}, {"end": 46, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 203, "tag": "PopulationGroup"}, {"end": 323, "start": 317, "tag": "PopulationGroup"}, {"end": 95, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 246, "start": 244, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 247, "tag": "ClinicalAttribute"}, {"end": 103, "start": 96, "tag": "HealthCareActivity"}, {"end": 39, "start": 22, "tag": "ResearchActivity"}, {"end": 87, "start": 84, "tag": "HealthCareActivity"}, {"end": 126, "start": 117, "tag": "HealthCareActivity"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 59, "tag": "HealthCareActivity"}, {"end": 195, "start": 153, "tag": "HealthCareRelatedOrganization"}, {"end": 201, "start": 197, "tag": "HealthCareRelatedOrganization"}, {"end": 316, "start": 312, "tag": "HealthCareRelatedOrganization"}, {"end": 294, "start": 279, "tag": "ResearchActivity"}, {"end": 39, "start": 35, "tag": "ResearchActivity"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 264, "start": 257, "tag": "ResearchActivity"}]}{"id": "1511_3", "text": "Results: Using PET amyloid imaging as the gold standard for AD pathology, the optimal cutoff of A beta(1-42) was higher than the AD cutoff, the optimal cutoffs of t-tau/A beta(1-42) and p-tau/A beta(1-42) were lower than the AD cutoffs, and their confidence intervals (CIs) did not overlap with the AD cutoffs.", "tags": [{"end": 55, "start": 42, "tag": "ResearchActivity"}, {"end": 289, "start": 282, "tag": "TemporalConcept"}, {"end": 168, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 63, "tag": "PathologicFunction"}, {"end": 72, "start": 63, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 26, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 227, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 301, "start": 299, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 27, "tag": "HealthCareActivity"}, {"end": 18, "start": 15, "tag": "HealthCareActivity"}, {"end": 108, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 204, "start": 192, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 132, "tag": "ResearchActivity"}, {"end": 92, "start": 78, "tag": "ResearchActivity"}, {"end": 108, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 144, "tag": "ResearchActivity"}, {"end": 181, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 204, "start": 192, "tag": "BiologicallyActiveSubstance"}, {"end": 267, "start": 247, "tag": "ResearchActivity"}, {"end": 272, "start": 269, "tag": "ResearchActivity"}, {"end": 309, "start": 302, "tag": "ResearchActivity"}, {"end": 235, "start": 228, "tag": "ResearchActivity"}]}{"id": "1511_4", "text": "Optimal cutoffs for t-tau and p-tau to predict cognitive impairment were significantly lower than the AD cutoffs, and their CIs did not overlap with the AD cutoffs.", "tags": [{"end": 25, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 136, "tag": "TemporalConcept"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 105, "tag": "ResearchActivity"}, {"end": 15, "start": 0, "tag": "ResearchActivity"}, {"end": 127, "start": 124, "tag": "ResearchActivity"}, {"end": 163, "start": 156, "tag": "ResearchActivity"}]}{"id": "1511_5", "text": "Conclusion: Optimal cutoffs for the PPMI cohort for A beta(1-42), t-tau/A beta(1-42), and p-tau/A beta(1-42) to predict amyloid-PET positivity and for t-tau and p-tau to predict cognitive impairment differ significantly from cutoffs derived from AD populations.", "tags": [{"end": 142, "start": 132, "tag": "ResearchActivity"}, {"end": 156, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 151, "tag": "BiologicallyActiveSubstance"}, {"end": 260, "start": 249, "tag": "PopulationGroup"}, {"end": 71, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 41, "tag": "PopulationGroup"}, {"end": 127, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 248, "start": 246, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 128, "tag": "HealthCareActivity"}, {"end": 198, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 166, "start": 161, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 161, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 12, "tag": "ResearchActivity"}, {"end": 40, "start": 36, "tag": "HealthCareRelatedOrganization"}, {"end": 64, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 225, "tag": "ResearchActivity"}, {"end": 84, "start": 72, "tag": "BiologicallyActiveSubstance"}]}{"id": "1511_6", "text": "The presence of additional pathologies such as alpha-synuclein in PD may lead to disease-specific CSF biomarker characteristics.", "tags": [{"end": 12, "start": 4, "tag": "Finding"}, {"end": 38, "start": 27, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 62, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 102, "tag": "ClinicalAttribute"}, {"end": 62, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}]}{"id": "1512_0", "text": "Background Alzheimer's disease (AD) is a neurodegenerative disorder associated with extracellular amyloid-beta peptide deposition and progressive neuron loss.", "tags": [{"end": 145, "start": 134, "tag": "TemporalConcept"}, {"end": 30, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 146, "tag": "Cell"}, {"end": 67, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 84, "tag": "CellOrMolecularDysfunction"}, {"end": 157, "start": 146, "tag": "CellOrMolecularDysfunction"}]}{"id": "1512_1", "text": "Strong evidence supports that neuroinflammatory changes such as the activation of astrocytes and microglia cells are important in the disease process.", "tags": [{"end": 112, "start": 97, "tag": "Cell"}, {"end": 47, "start": 30, "tag": "PathologicFunction"}, {"end": 15, "start": 7, "tag": "Finding"}, {"end": 92, "start": 82, "tag": "Cell"}, {"end": 106, "start": 97, "tag": "Cell"}]}{"id": "1512_2", "text": "Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a transmembrane glycoprotein that has recently been associated with an emerging role in neuroinflammation, which has been reported to be increased in post-mortem brain samples from AD and Parkinson's disease patients.", "tags": [{"end": 45, "start": 0, "tag": "GeneOrGenome"}, {"end": 45, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 47, "tag": "GeneOrGenome"}, {"end": 52, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 52, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 207, "tag": "TemporalConcept"}, {"end": 103, "start": 95, "tag": "TemporalConcept"}, {"end": 273, "start": 265, "tag": "PatientOrDisabledGroup"}, {"end": 240, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 224, "start": 219, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 145, "tag": "PathologicFunction"}, {"end": 264, "start": 245, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 207, "tag": "TemporalConcept"}]}{"id": "1512_3", "text": "Methods The present study describes the partial fit for purpose validation of a commercially available immunoassay for the determination of GPNMB levels in the cerebrospinal fluid (CSF).", "tags": [{"end": 114, "start": 103, "tag": "ResearchActivity"}, {"end": 74, "start": 64, "tag": "ResearchActivity"}, {"end": 184, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 20, "tag": "ResearchActivity"}, {"end": 179, "start": 140, "tag": "ClinicalAttribute"}]}{"id": "1512_4", "text": "We further assessed the applicability of GPNMB as a potential biomarker for AD in two different cohorts that were defined by biomarker-supported clinical diagnosis or by neuroimaging with amyloid positron emission tomography, respectively.", "tags": [{"end": 46, "start": 41, "tag": "GeneOrGenome"}, {"end": 46, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 52, "tag": "ClinicalAttribute"}, {"end": 195, "start": 188, "tag": "AminoAcidPeptideOrProtein"}, {"end": 195, "start": 188, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 62, "tag": "ClinicalAttribute"}, {"end": 134, "start": 125, "tag": "ClinicalAttribute"}, {"end": 163, "start": 154, "tag": "HealthCareActivity"}, {"end": 182, "start": 170, "tag": "HealthCareActivity"}, {"end": 103, "start": 96, "tag": "PopulationGroup"}, {"end": 224, "start": 196, "tag": "HealthCareActivity"}, {"end": 163, "start": 145, "tag": "HealthCareActivity"}]}{"id": "1512_5", "text": "Results The results indicated that CSF GPNMB levels could not distinguish between AD or controls with other neurological diseases but correlated with other parameters such as aging and CSF pTau levels.", "tags": [{"end": 44, "start": 39, "tag": "GeneOrGenome"}, {"end": 44, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 188, "start": 185, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 88, "tag": "PopulationGroup"}, {"end": 193, "start": 189, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 189, "tag": "BiologicallyActiveSubstance"}, {"end": 180, "start": 175, "tag": "BiologicFunction"}, {"end": 180, "start": 175, "tag": "CellFunction"}, {"end": 51, "start": 35, "tag": "ClinicalAttribute"}, {"end": 200, "start": 185, "tag": "ClinicalAttribute"}]}{"id": "1512_6", "text": "Conclusions The findings of this study do not support GPNMB in CSF as a valuable neurochemical diagnostic biomarker of AD but warrant further studies employing healthy control individuals.", "tags": [{"end": 59, "start": 54, "tag": "GeneOrGenome"}, {"end": 59, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 142, "tag": "ResearchActivity"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 106, "tag": "ClinicalAttribute"}, {"end": 38, "start": 33, "tag": "ResearchActivity"}, {"end": 187, "start": 168, "tag": "PopulationGroup"}, {"end": 105, "start": 95, "tag": "HealthCareActivity"}, {"end": 167, "start": 160, "tag": "OrganismAttribute"}]}{"id": "1513_0", "text": "Background: Elevated blood pressure is linked to cognitive impairment and Alzheimer's disease (AD) biomarker abnormality.", "tags": [{"end": 35, "start": 12, "tag": "Finding"}, {"end": 93, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 99, "tag": "ClinicalAttribute"}, {"end": 69, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 21, "tag": "BiologicFunction"}, {"end": 120, "start": 109, "tag": "Finding"}]}{"id": "1513_1", "text": "However, blood pressure levels vary over time.", "tags": [{"end": 45, "start": 41, "tag": "TemporalConcept"}, {"end": 30, "start": 9, "tag": "ClinicalAttribute"}]}{"id": "1513_2", "text": "Less is known about the role of long-term blood pressure variability in cognitive impairment and AD pathophysiology.", "tags": [{"end": 56, "start": 42, "tag": "BiologicFunction"}, {"end": 41, "start": 32, "tag": "TemporalConcept"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 100, "tag": "PathologicFunction"}, {"end": 115, "start": 100, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 68, "start": 57, "tag": "Finding"}]}{"id": "1513_3", "text": "Objective: Determine whether long-term blood pressure variability is elevated across the clinical and biomarker spectrum of AD.", "tags": [{"end": 53, "start": 39, "tag": "BiologicFunction"}, {"end": 120, "start": 102, "tag": "ResearchActivity"}, {"end": 38, "start": 29, "tag": "TemporalConcept"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 102, "tag": "ClinicalAttribute"}, {"end": 65, "start": 54, "tag": "Finding"}]}{"id": "1513_4", "text": "Methods: Alzheimer's Disease Neuroimaging Initiative participants (cognitively normal, mild cognitive impairment, AD [n = 1,421]) underwent baseline exam, including blood pressure measurement at 0, 6, and 12 months.", "tags": [{"end": 153, "start": 149, "tag": "HealthCareActivity"}, {"end": 179, "start": 165, "tag": "BiologicFunction"}, {"end": 191, "start": 180, "tag": "ResearchActivity"}, {"end": 191, "start": 180, "tag": "HealthCareActivity"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 53, "tag": "PopulationGroup"}, {"end": 85, "start": 67, "tag": "Finding"}, {"end": 112, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 9, "tag": "ResearchActivity"}, {"end": 214, "start": 208, "tag": "TemporalConcept"}, {"end": 52, "start": 9, "tag": "HealthCareRelatedOrganization"}]}{"id": "1513_5", "text": "A subset (n = 318) underwent baseline lumbar puncture to determine cerebrospinal fluid amyloid-beta and phosphorylated tau levels.", "tags": [{"end": 99, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 38, "tag": "HealthCareActivity"}, {"end": 122, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 104, "tag": "ClinicalAttribute"}]}{"id": "1513_6", "text": "Clinical groups and biomarker-confirmed AD groups were compared on blood pressure variability over 12 months.", "tags": [{"end": 81, "start": 67, "tag": "BiologicFunction"}, {"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 20, "tag": "ClinicalAttribute"}, {"end": 15, "start": 9, "tag": "PopulationGroup"}, {"end": 49, "start": 43, "tag": "PopulationGroup"}, {"end": 108, "start": 102, "tag": "TemporalConcept"}, {"end": 93, "start": 82, "tag": "Finding"}]}{"id": "1513_7", "text": "Results: Systolic blood pressure variability was elevated in clinically diagnosed AD dementia (VIM: F-2,F-1195 = 6.657, p = 0.001, eta(2) = 0.01) compared to cognitively normal participants (p = 0.001), and in mild cognitive impairment relative to cognitively normal participants (p = 0.01).", "tags": [{"end": 32, "start": 9, "tag": "ClinicalAttribute"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 177, "tag": "PopulationGroup"}, {"end": 279, "start": 267, "tag": "PopulationGroup"}, {"end": 176, "start": 158, "tag": "Finding"}, {"end": 266, "start": 248, "tag": "Finding"}, {"end": 81, "start": 72, "tag": "HealthCareActivity"}, {"end": 235, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 33, "tag": "Finding"}]}{"id": "1513_8", "text": "Findings were maintained in biomarker-confirmed AD (VIM: F-2,F-850 = 5.216, p = 0.006, eta(2) = 0.01), such that systolic blood pressure variability was elevated in biomarker-confirmed dementia due to AD relative to cognitively normal participants (p = 0.005) and in biomarker-confirmed mild cognitive impairment due to AD compared to cognitively normal participants (p = 0.04).", "tags": [{"end": 136, "start": 113, "tag": "ClinicalAttribute"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 203, "start": 201, "tag": "DiseaseOrSyndrome"}, {"end": 322, "start": 320, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 28, "tag": "ClinicalAttribute"}, {"end": 174, "start": 165, "tag": "ClinicalAttribute"}, {"end": 276, "start": 267, "tag": "ClinicalAttribute"}, {"end": 193, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 247, "start": 235, "tag": "PopulationGroup"}, {"end": 366, "start": 354, "tag": "PopulationGroup"}, {"end": 234, "start": 216, "tag": "Finding"}, {"end": 353, "start": 335, "tag": "Finding"}, {"end": 312, "start": 287, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 137, "tag": "Finding"}]}{"id": "1513_9", "text": "Conclusion: Long-term systolic blood pressure variability is elevated in cognitive impairment due to AD.", "tags": [{"end": 21, "start": 12, "tag": "TemporalConcept"}, {"end": 21, "start": 12, "tag": "HealthCareActivity"}, {"end": 45, "start": 22, "tag": "ClinicalAttribute"}, {"end": 103, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 46, "tag": "Finding"}]}{"id": "1513_10", "text": "Blood pressure variability may represent an understudied aspect of vascular dysfunction in AD with potential clinical implications.", "tags": [{"end": 14, "start": 0, "tag": "BiologicFunction"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 76, "tag": "PathologicFunction"}, {"end": 26, "start": 15, "tag": "Finding"}]}{"id": "1514_0", "text": "T The blood-brain barrier (BBB) regulates cerebrovascular permeability and leakage of blood-derived fibrinogen.", "tags": [{"end": 57, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 75, "tag": "Finding"}, {"end": 30, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 58, "tag": "BiologicFunction"}, {"end": 110, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 100, "tag": "PharmacologicSubstance"}]}{"id": "1514_1", "text": "Dysfunction of the BBB has been associated with cerebral arteriolosclerosis small vessel disease (SVD) and white matter lesions (WML).", "tags": [{"end": 11, "start": 0, "tag": "PathologicFunction"}, {"end": 127, "start": 107, "tag": "Finding"}, {"end": 132, "start": 129, "tag": "Finding"}, {"end": 119, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 120, "tag": "InjuryOrPoisoning"}, {"end": 96, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 98, "tag": "DiseaseOrSyndrome"}]}{"id": "1514_2", "text": "Furthermore, BBB dysfunction is associated with the pathogenesis of Alzheimer's disease (AD) with the presence of CSF plasma proteins suggested to be a potential biomarker of AD.", "tags": [{"end": 110, "start": 102, "tag": "Finding"}, {"end": 64, "start": 52, "tag": "PathologicFunction"}, {"end": 171, "start": 152, "tag": "ClinicalAttribute"}, {"end": 87, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 162, "tag": "ClinicalAttribute"}, {"end": 16, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 17, "tag": "PathologicFunction"}, {"end": 133, "start": 125, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1514_3", "text": "We aimed to determine if extravascular fibrinogen in the white matter was associated with the development of AD hallmark pathologies, i.e., hyperphosphorylated tau (HP tau) and amyloid-beta (A beta), as well as SVD, cerebral amyloid angiopathy (CAA) and measures of white matter damage.", "tags": [{"end": 132, "start": 121, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 243, "start": 216, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 245, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 112, "tag": "Finding"}, {"end": 69, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 278, "start": 266, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 94, "tag": "BiologicFunction"}, {"end": 105, "start": 94, "tag": "CellFunction"}, {"end": 197, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 214, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 25, "tag": "ClinicalAttribute"}]}{"id": "1514_4", "text": "Using human post-mortem brains, parietal tissue from 20 AD and 22 non-demented controls was quantitatively assessed for HP tau, A beta, white matter damage severity, axonal density, demyelination and the burden of extravascular fibrinogen in both WML and normal appearing white matter (NAWM).", "tags": [{"end": 23, "start": 12, "tag": "TemporalConcept"}, {"end": 250, "start": 247, "tag": "Finding"}, {"end": 210, "start": 204, "tag": "ResearchActivity"}, {"end": 195, "start": 182, "tag": "PathologicFunction"}, {"end": 148, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 284, "start": 272, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 290, "start": 286, "tag": "ClinicalAttribute"}, {"end": 126, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 271, "start": 255, "tag": "Finding"}, {"end": 87, "start": 66, "tag": "PopulationGroup"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 156, "tag": "ClinicalAttribute"}, {"end": 164, "start": 156, "tag": "Finding"}, {"end": 47, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 6, "tag": "Eukaryote"}, {"end": 134, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 12, "tag": "TemporalConcept"}, {"end": 180, "start": 166, "tag": "ClinicalAttribute"}, {"end": 238, "start": 214, "tag": "ClinicalAttribute"}]}{"id": "1514_5", "text": "SVD severity was determined by calculating sclerotic indices.", "tags": [{"end": 52, "start": 43, "tag": "PathologicFunction"}, {"end": 12, "start": 4, "tag": "ClinicalAttribute"}, {"end": 12, "start": 4, "tag": "Finding"}, {"end": 3, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "1514_6", "text": "WML- and NAWM fibrinogen burden was not significantly different between AD and controls nor was it associated with the burden of HP tau or A beta pathology, or any measures of white matter damage.", "tags": [{"end": 31, "start": 25, "tag": "ResearchActivity"}, {"end": 125, "start": 119, "tag": "ResearchActivity"}, {"end": 188, "start": 176, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 9, "tag": "ClinicalAttribute"}, {"end": 135, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 146, "tag": "PathologicFunction"}, {"end": 155, "start": 146, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 135, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 79, "tag": "PopulationGroup"}, {"end": 145, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "Finding"}, {"end": 24, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 24, "start": 14, "tag": "BiologicallyActiveSubstance"}]}{"id": "1514_7", "text": "Increasing severity of SVD was associated with and a predictor of both higher WML- and NAWM fibrinogen burden (all P < 0.05) in controls only.", "tags": [{"end": 109, "start": 103, "tag": "ResearchActivity"}, {"end": 91, "start": 87, "tag": "ClinicalAttribute"}, {"end": 136, "start": 128, "tag": "PopulationGroup"}, {"end": 19, "start": 11, "tag": "ClinicalAttribute"}, {"end": 19, "start": 11, "tag": "Finding"}, {"end": 26, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 92, "tag": "PharmacologicSubstance"}, {"end": 102, "start": 92, "tag": "BiologicallyActiveSubstance"}]}{"id": "1514_8", "text": "In cases with minimal SVD NAWM fibrinogen burden was significantly higher in the AD cases (P < 0.05).", "tags": [{"end": 48, "start": 42, "tag": "ResearchActivity"}, {"end": 30, "start": 26, "tag": "ClinicalAttribute"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 31, "tag": "PharmacologicSubstance"}]}{"id": "1514_9", "text": "BBB dysfunction was present in both non-demented and AD brains and was not associated with the burden of AD-associated cortical pathologies.", "tags": [{"end": 101, "start": 95, "tag": "ResearchActivity"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 4, "tag": "PathologicFunction"}, {"end": 48, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1514_10", "text": "BBB dysfunction was strongly associated with SVD but only in the non-demented controls.", "tags": [{"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 78, "tag": "PopulationGroup"}, {"end": 15, "start": 4, "tag": "PathologicFunction"}, {"end": 77, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 45, "tag": "DiseaseOrSyndrome"}]}{"id": "1514_11", "text": "In cases with minimal SVD, BBB dysfunction was significantly worse in AD cases possibly indicating the influence of CAA.", "tags": [{"end": 119, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 31, "tag": "PathologicFunction"}, {"end": 78, "start": 70, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 22, "tag": "DiseaseOrSyndrome"}]}{"id": "1514_12", "text": "In conclusion, extravascular fibrinogen is not associated with AD hallmark pathologies but indicates SVD, suggesting that the presence of fibrinogen in the CSF is not a surrogate marker for AD pathology.", "tags": [{"end": 86, "start": 75, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 134, "start": 126, "tag": "Finding"}, {"end": 148, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 66, "tag": "Finding"}, {"end": 159, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 202, "start": 193, "tag": "PathologicFunction"}, {"end": 202, "start": 193, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 169, "tag": "ClinicalAttribute"}, {"end": 104, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 15, "tag": "ClinicalAttribute"}, {"end": 148, "start": 138, "tag": "PharmacologicSubstance"}]}{"id": "1515_0", "text": "Background: A clinical diagnosis of cognitive impairment is traditionally based on a single cognitive exam, but serial cognitive testing can be sensitive to subtle cognitive changes in asymptomatic individuals and inform cognitive trajectory.", "tags": [{"end": 197, "start": 185, "tag": "Finding"}, {"end": 136, "start": 129, "tag": "HealthCareActivity"}, {"end": 209, "start": 198, "tag": "PopulationGroup"}, {"end": 181, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 14, "tag": "HealthCareActivity"}, {"end": 153, "start": 144, "tag": "PathologicFunction"}]}{"id": "1515_1", "text": "Objective: We evaluated the prognostic utility of identifying longitudinal neuropsychological decline along with single cognitive exam and Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers in predicting dementia.", "tags": [{"end": 158, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 190, "tag": "ClinicalAttribute"}, {"end": 188, "start": 185, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 28, "tag": "Finding"}, {"end": 101, "start": 62, "tag": "PathologicFunction"}, {"end": 134, "start": 120, "tag": "HealthCareActivity"}]}{"id": "1515_2", "text": "We also examined brain volumetric differences based on decline trajectories.", "tags": [{"end": 33, "start": 23, "tag": "HealthCareActivity"}, {"end": 45, "start": 34, "tag": "Finding"}, {"end": 22, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1515_3", "text": "Method: Regression models quantified 12-month neuropsychological decline relative to normative expectations among nondemented older adults (N = 1,074).", "tags": [{"end": 94, "start": 85, "tag": "ResearchActivity"}, {"end": 138, "start": 132, "tag": "PopulationGroup"}, {"end": 25, "start": 8, "tag": "ResearchActivity"}, {"end": 131, "start": 126, "tag": "TemporalConcept"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 138, "start": 126, "tag": "PopulationGroup"}, {"end": 72, "start": 46, "tag": "PathologicFunction"}]}{"id": "1515_4", "text": "Progression to dementia over follow-up (18-120 months) was diagnosed using independent modes of assessment.", "tags": [{"end": 11, "start": 0, "tag": "PathologicFunction"}, {"end": 23, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 29, "tag": "HealthCareActivity"}, {"end": 38, "start": 29, "tag": "TemporalConcept"}, {"end": 68, "start": 59, "tag": "HealthCareActivity"}, {"end": 106, "start": 96, "tag": "HealthCareActivity"}, {"end": 106, "start": 96, "tag": "ResearchActivity"}, {"end": 53, "start": 47, "tag": "TemporalConcept"}]}{"id": "1515_5", "text": "Results: In Cox regression models controlling for age, sex, education, apolipoprotein E4, and baseline cognitive diagnosis, neuropsychological decline predicted increased dementia risk, chi(2) = 69.861, p < 0.001, odds ratio = 2.841, even after correction for CSF biomarkers (amyloid-beta, phosphorylated tau, total tau), chi(2) = 26.365, p < 0.001, odds ratio = 2.283.", "tags": [{"end": 88, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 71, "tag": "GeneOrGenome"}, {"end": 274, "start": 264, "tag": "ClinicalAttribute"}, {"end": 288, "start": 276, "tag": "AminoAcidPeptideOrProtein"}, {"end": 263, "start": 260, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 53, "start": 50, "tag": "OrganismAttribute"}, {"end": 179, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 12, "tag": "ResearchActivity"}, {"end": 308, "start": 290, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 94, "tag": "HealthCareActivity"}, {"end": 308, "start": 290, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 60, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 58, "start": 55, "tag": "OrganismAttribute"}, {"end": 319, "start": 310, "tag": "AminoAcidPeptideOrProtein"}, {"end": 319, "start": 310, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 124, "tag": "PathologicFunction"}]}{"id": "1515_6", "text": "Voxel-based morphometry analysis indicated smaller hippocampal and medial temporal volume in participants with neuropsychological decline.", "tags": [{"end": 105, "start": 93, "tag": "PopulationGroup"}, {"end": 32, "start": 0, "tag": "ResearchActivity"}, {"end": 89, "start": 83, "tag": "ClinicalAttribute"}, {"end": 62, "start": 51, "tag": "ClinicalAttribute"}, {"end": 89, "start": 67, "tag": "ClinicalAttribute"}, {"end": 137, "start": 111, "tag": "PathologicFunction"}]}{"id": "1515_7", "text": "Conclusions: Longitudinal diagnosis of neuropsychological decline improved prognostic accuracy beyond single cognitive exam diagnoses and AD CSF biomarkers, even in asymptomatic older adults.", "tags": [{"end": 133, "start": 124, "tag": "HealthCareActivity"}, {"end": 177, "start": 165, "tag": "Finding"}, {"end": 155, "start": 145, "tag": "ClinicalAttribute"}, {"end": 144, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 184, "tag": "PopulationGroup"}, {"end": 183, "start": 178, "tag": "TemporalConcept"}, {"end": 35, "start": 13, "tag": "HealthCareActivity"}, {"end": 94, "start": 86, "tag": "Finding"}, {"end": 190, "start": 178, "tag": "PopulationGroup"}, {"end": 65, "start": 39, "tag": "PathologicFunction"}, {"end": 123, "start": 102, "tag": "HealthCareActivity"}]}{"id": "1515_8", "text": "Older adults with a trajectory of neuropsychological decline exhibit smaller medial temporal and hippocampal brain volume.", "tags": [{"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 12, "start": 6, "tag": "PopulationGroup"}, {"end": 121, "start": 97, "tag": "ClinicalAttribute"}, {"end": 121, "start": 109, "tag": "ClinicalAttribute"}, {"end": 60, "start": 34, "tag": "PathologicFunction"}, {"end": 121, "start": 109, "tag": "ClinicalAttribute"}, {"end": 92, "start": 77, "tag": "ClinicalAttribute"}]}{"id": "1515_9", "text": "Longitudinal diagnostic approaches may benefit selection and randomization procedures for AD clinical trials in asymptomatic individuals.", "tags": [{"end": 124, "start": 112, "tag": "Finding"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 125, "tag": "PopulationGroup"}, {"end": 108, "start": 93, "tag": "ResearchActivity"}, {"end": 34, "start": 0, "tag": "HealthCareActivity"}]}{"id": "1516_0", "text": "BackgroundElectroencephalogram (EEG) has emerged as a non-invasive tool to detect the aberrant neuronal activity related to different stages of Alzheimer's disease (AD).", "tags": [{"end": 35, "start": 32, "tag": "HealthCareActivity"}, {"end": 163, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 134, "tag": "TemporalConcept"}, {"end": 30, "start": 10, "tag": "HealthCareActivity"}, {"end": 112, "start": 86, "tag": "CellOrMolecularDysfunction"}]}{"id": "1516_1", "text": "However, the effectiveness of EEG in the precise diagnosis and assessment of AD and its preclinical stage, amnestic mild cognitive impairment (MCI), has yet to be fully elucidated.", "tags": [{"end": 33, "start": 30, "tag": "HealthCareActivity"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 88, "tag": "TemporalConcept"}, {"end": 105, "start": 100, "tag": "TemporalConcept"}, {"end": 105, "start": 100, "tag": "ClinicalAttribute"}, {"end": 58, "start": 49, "tag": "HealthCareActivity"}, {"end": 146, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 13, "tag": "Finding"}, {"end": 141, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 63, "tag": "HealthCareActivity"}, {"end": 73, "start": 63, "tag": "ResearchActivity"}]}{"id": "1516_2", "text": "In this study, we aimed to identify key EEG biomarkers that are effective in distinguishing patients at the early stage of AD and monitoring the progression of AD.MethodsA total of 890 participants, including 189 patients with MCI, 330 patients with AD, 125 patients with other dementias (frontotemporal dementia, dementia with Lewy bodies, and vascular cognitive impairment), and 246 healthy controls (HC) were enrolled.", "tags": [{"end": 43, "start": 40, "tag": "HealthCareActivity"}, {"end": 119, "start": 108, "tag": "TemporalConcept"}, {"end": 374, "start": 345, "tag": "DiseaseOrSyndrome"}, {"end": 312, "start": 289, "tag": "DiseaseOrSyndrome"}, {"end": 339, "start": 328, "tag": "CellComponent"}, {"end": 401, "start": 385, "tag": "PopulationGroup"}, {"end": 54, "start": 44, "tag": "ClinicalAttribute"}, {"end": 100, "start": 92, "tag": "PatientOrDisabledGroup"}, {"end": 221, "start": 213, "tag": "PatientOrDisabledGroup"}, {"end": 244, "start": 236, "tag": "PatientOrDisabledGroup"}, {"end": 266, "start": 258, "tag": "PatientOrDisabledGroup"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 252, "start": 250, "tag": "DiseaseOrSyndrome"}, {"end": 322, "start": 314, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 185, "tag": "PopulationGroup"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 353, "start": 345, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 114, "tag": "TemporalConcept"}, {"end": 119, "start": 114, "tag": "ClinicalAttribute"}, {"end": 156, "start": 145, "tag": "PathologicFunction"}, {"end": 156, "start": 145, "tag": "TemporalConcept"}, {"end": 230, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 374, "start": 354, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 130, "tag": "HealthCareActivity"}, {"end": 287, "start": 278, "tag": "DiseaseOrSyndrome"}, {"end": 392, "start": 385, "tag": "OrganismAttribute"}]}{"id": "1516_3", "text": "Biomarkers were extracted from resting-state EEG recordings for a three-level classification of HC, MCI, and AD.", "tags": [{"end": 48, "start": 45, "tag": "HealthCareActivity"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 59, "start": 31, "tag": "ResearchActivity"}, {"end": 92, "start": 66, "tag": "HealthCareActivity"}]}{"id": "1516_4", "text": "The optimal EEG biomarkers were then identified based on the classification performance.", "tags": [{"end": 15, "start": 12, "tag": "HealthCareActivity"}, {"end": 87, "start": 76, "tag": "Finding"}, {"end": 26, "start": 16, "tag": "ClinicalAttribute"}]}{"id": "1516_5", "text": "Random forest regression was used to train a series of models by combining participants' EEG biomarkers, demographic information (i.e., sex, age), CSF biomarkers, and APOE phenotype for assessing the disease progression and individual's cognitive function.ResultsThe identified EEG biomarkers achieved over 70% accuracy in the three-level classification of HC, MCI, and AD.", "tags": [{"end": 24, "start": 0, "tag": "ResearchActivity"}, {"end": 92, "start": 89, "tag": "HealthCareActivity"}, {"end": 255, "start": 237, "tag": "BiologicFunction"}, {"end": 281, "start": 278, "tag": "HealthCareActivity"}, {"end": 181, "start": 172, "tag": "OrganismAttribute"}, {"end": 42, "start": 37, "tag": "BiologicFunction"}, {"end": 103, "start": 93, "tag": "ClinicalAttribute"}, {"end": 161, "start": 151, "tag": "ClinicalAttribute"}, {"end": 292, "start": 282, "tag": "ClinicalAttribute"}, {"end": 150, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 141, "tag": "OrganismAttribute"}, {"end": 372, "start": 370, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 75, "tag": "PopulationGroup"}, {"end": 61, "start": 55, "tag": "ResearchActivity"}, {"end": 219, "start": 208, "tag": "PathologicFunction"}, {"end": 219, "start": 208, "tag": "TemporalConcept"}, {"end": 139, "start": 136, "tag": "OrganismAttribute"}, {"end": 319, "start": 311, "tag": "Finding"}, {"end": 364, "start": 361, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 219, "start": 200, "tag": "PathologicFunction"}, {"end": 353, "start": 327, "tag": "HealthCareActivity"}]}{"id": "1516_6", "text": "Among all six groups, the most prominent effects of AD-linked neurodegeneration on EEG metrics were localized at parieto-occipital regions.", "tags": [{"end": 48, "start": 41, "tag": "PathologicFunction"}, {"end": 86, "start": 83, "tag": "HealthCareActivity"}, {"end": 94, "start": 87, "tag": "Chemical"}, {"end": 79, "start": 62, "tag": "CellOrMolecularDysfunction"}, {"end": 54, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 14, "tag": "PopulationGroup"}]}{"id": "1516_7", "text": "In the cross-validation predictive analyses, the optimal EEG features were more effective than the CSF + APOE biomarkers in predicting the age of onset and disease course, whereas the combination of EEG + CSF + APOE measures achieved the best performance for all targets of prediction.ConclusionsOur study indicates that EEG can be used as a useful screening tool for the diagnosis and disease progression evaluation of MCI and AD.", "tags": [{"end": 60, "start": 57, "tag": "HealthCareActivity"}, {"end": 202, "start": 199, "tag": "HealthCareActivity"}, {"end": 324, "start": 321, "tag": "HealthCareActivity"}, {"end": 151, "start": 139, "tag": "TemporalConcept"}, {"end": 170, "start": 156, "tag": "TemporalConcept"}, {"end": 254, "start": 243, "tag": "Finding"}, {"end": 120, "start": 110, "tag": "ClinicalAttribute"}, {"end": 102, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 430, "start": 428, "tag": "DiseaseOrSyndrome"}, {"end": 305, "start": 300, "tag": "ResearchActivity"}, {"end": 405, "start": 394, "tag": "PathologicFunction"}, {"end": 405, "start": 394, "tag": "TemporalConcept"}, {"end": 381, "start": 372, "tag": "HealthCareActivity"}, {"end": 423, "start": 420, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 215, "start": 211, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 215, "start": 211, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 164, "tag": "TemporalConcept"}, {"end": 416, "start": 406, "tag": "HealthCareActivity"}, {"end": 416, "start": 406, "tag": "ResearchActivity"}, {"end": 405, "start": 386, "tag": "PathologicFunction"}, {"end": 43, "start": 7, "tag": "ResearchActivity"}, {"end": 284, "start": 274, "tag": "Finding"}]}{"id": "1517_0", "text": "This study characterizes individuals in the Alzheimer's Disease Neuroimaging Initiative (ADNI) data set with tau abnormality indicated by cerebrospinal fluid assay or positron emission tomography.", "tags": [{"end": 87, "start": 44, "tag": "ResearchActivity"}, {"end": 87, "start": 44, "tag": "HealthCareRelatedOrganization"}, {"end": 93, "start": 89, "tag": "HealthCareRelatedOrganization"}, {"end": 93, "start": 89, "tag": "ResearchActivity"}, {"end": 112, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 95, "tag": "ResearchActivity"}, {"end": 36, "start": 25, "tag": "PopulationGroup"}, {"end": 157, "start": 152, "tag": "Substance"}, {"end": 63, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 195, "start": 167, "tag": "HealthCareActivity"}, {"end": 124, "start": 113, "tag": "Finding"}, {"end": 195, "start": 167, "tag": "ManufacturedObject"}]}{"id": "1517_1", "text": "Question Do cerebrospinal fluid (CSF) and positron emission tomography (PET) measures provide different information about Alzheimer disease-related tau pathology? Findings In this cohort study using the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset, one-third of participants had abnormal CSF tau or were tau positive on both CSF assay and PET, while tau-PET positivity alone was relatively rare.", "tags": [{"end": 348, "start": 343, "tag": "ResearchActivity"}, {"end": 246, "start": 203, "tag": "ResearchActivity"}, {"end": 246, "start": 203, "tag": "HealthCareRelatedOrganization"}, {"end": 301, "start": 293, "tag": "Finding"}, {"end": 382, "start": 372, "tag": "ResearchActivity"}, {"end": 309, "start": 302, "tag": "ClinicalAttribute"}, {"end": 252, "start": 248, "tag": "HealthCareRelatedOrganization"}, {"end": 252, "start": 248, "tag": "ResearchActivity"}, {"end": 139, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 309, "start": 306, "tag": "AminoAcidPeptideOrProtein"}, {"end": 321, "start": 318, "tag": "AminoAcidPeptideOrProtein"}, {"end": 367, "start": 364, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 305, "start": 302, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 342, "start": 339, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 148, "tag": "BiologicallyActiveSubstance"}, {"end": 309, "start": 306, "tag": "BiologicallyActiveSubstance"}, {"end": 321, "start": 318, "tag": "BiologicallyActiveSubstance"}, {"end": 367, "start": 364, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 161, "start": 148, "tag": "PathologicFunction"}, {"end": 288, "start": 276, "tag": "PopulationGroup"}, {"end": 31, "start": 26, "tag": "Substance"}, {"end": 222, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 187, "tag": "ResearchActivity"}, {"end": 261, "start": 254, "tag": "ResearchActivity"}, {"end": 75, "start": 72, "tag": "HealthCareActivity"}, {"end": 356, "start": 353, "tag": "HealthCareActivity"}, {"end": 371, "start": 368, "tag": "HealthCareActivity"}, {"end": 70, "start": 42, "tag": "HealthCareActivity"}, {"end": 186, "start": 180, "tag": "PopulationGroup"}, {"end": 408, "start": 404, "tag": "TemporalConcept"}, {"end": 70, "start": 42, "tag": "ManufacturedObject"}]}{"id": "1517_2", "text": "Individuals whose CSF was tau positive had a history of accelerated CSF tau accrual, but only persons with tau-PET abnormality showed a similar significant decline in cognition.", "tags": [{"end": 101, "start": 94, "tag": "PopulationGroup"}, {"end": 126, "start": 111, "tag": "ClinicalAttribute"}, {"end": 11, "start": 0, "tag": "PopulationGroup"}, {"end": 75, "start": 68, "tag": "ClinicalAttribute"}, {"end": 52, "start": 45, "tag": "Finding"}, {"end": 29, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 167, "tag": "BiologicFunction"}, {"end": 114, "start": 111, "tag": "HealthCareActivity"}, {"end": 126, "start": 115, "tag": "Finding"}]}{"id": "1517_3", "text": "Meaning Cerebrospinal fluid tau abnormality may be detected earlier in the AD pathogenetic process than flortaucipir-PET positivity and may occur before measurable cognitive decline.", "tags": [{"end": 27, "start": 8, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 104, "tag": "Chemical"}, {"end": 131, "start": 121, "tag": "ResearchActivity"}, {"end": 67, "start": 60, "tag": "TemporalConcept"}, {"end": 31, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 22, "tag": "Substance"}, {"end": 152, "start": 146, "tag": "TemporalConcept"}, {"end": 181, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 117, "tag": "HealthCareActivity"}, {"end": 43, "start": 32, "tag": "Finding"}]}{"id": "1517_4", "text": "Importance Fluid and imaging biomarkers of Alzheimer disease (AD) are often used interchangeably, but some biomarkers may reveal earlier stages of disease.", "tags": [{"end": 16, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 11, "tag": "Substance"}, {"end": 28, "start": 21, "tag": "HealthCareActivity"}, {"end": 143, "start": 137, "tag": "TemporalConcept"}, {"end": 60, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 129, "tag": "TemporalConcept"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 29, "tag": "ClinicalAttribute"}, {"end": 117, "start": 107, "tag": "ClinicalAttribute"}]}{"id": "1517_5", "text": "Objective To characterize individuals with tau abnormality indicated by cerebrospinal fluid (CSF) assay or positron emission tomography (PET).", "tags": [{"end": 103, "start": 98, "tag": "ResearchActivity"}, {"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 26, "tag": "PopulationGroup"}, {"end": 91, "start": 86, "tag": "Substance"}, {"end": 140, "start": 137, "tag": "HealthCareActivity"}, {"end": 135, "start": 107, "tag": "HealthCareActivity"}, {"end": 58, "start": 47, "tag": "Finding"}, {"end": 135, "start": 107, "tag": "ManufacturedObject"}]}{"id": "1517_6", "text": "Design, Setting, and Participants Between 2010 and 2019, 322 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent CSF and PET assessments of tau pathology.", "tags": [{"end": 165, "start": 154, "tag": "HealthCareActivity"}, {"end": 124, "start": 81, "tag": "ResearchActivity"}, {"end": 124, "start": 81, "tag": "HealthCareRelatedOrganization"}, {"end": 130, "start": 126, "tag": "HealthCareRelatedOrganization"}, {"end": 130, "start": 126, "tag": "ResearchActivity"}, {"end": 172, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 142, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 182, "start": 169, "tag": "PathologicFunction"}, {"end": 73, "start": 61, "tag": "PopulationGroup"}, {"end": 100, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 8, "tag": "BiologicFunction"}, {"end": 33, "start": 21, "tag": "PopulationGroup"}, {"end": 153, "start": 150, "tag": "HealthCareActivity"}]}{"id": "1517_7", "text": "Data-driven, clinically relevant thresholds for CSF phosphorylated tau (P-tau) (>= 26.64 pg/mL) and flortaucipir-PET meta-regions of interest (ROI) (standard uptake value ratio >= 1.37) indicated participants' tau status as CSF-/PET-, CSF+/PET-, CSF-/PET+, and CSF+/PET+.", "tags": [{"end": 66, "start": 52, "tag": "CellFunction"}, {"end": 112, "start": 100, "tag": "Chemical"}, {"end": 141, "start": 122, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 213, "start": 210, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 227, "start": 224, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 235, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 249, "start": 246, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 264, "start": 261, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 213, "start": 210, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 208, "start": 196, "tag": "PopulationGroup"}, {"end": 116, "start": 113, "tag": "HealthCareActivity"}, {"end": 232, "start": 229, "tag": "HealthCareActivity"}, {"end": 243, "start": 240, "tag": "HealthCareActivity"}, {"end": 254, "start": 251, "tag": "HealthCareActivity"}, {"end": 269, "start": 266, "tag": "HealthCareActivity"}, {"end": 43, "start": 33, "tag": "Finding"}, {"end": 220, "start": 214, "tag": "Finding"}, {"end": 4, "start": 0, "tag": "ResearchActivity"}, {"end": 164, "start": 158, "tag": "BiologicFunction"}, {"end": 164, "start": 158, "tag": "CellFunction"}]}{"id": "1517_8", "text": "Of 1659 ADNI participants with a CSF or flortaucipir assessment, 588 had both measures (1071 were excluded).", "tags": [{"end": 52, "start": 40, "tag": "Chemical"}, {"end": 12, "start": 8, "tag": "HealthCareRelatedOrganization"}, {"end": 12, "start": 8, "tag": "ResearchActivity"}, {"end": 36, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 13, "tag": "PopulationGroup"}, {"end": 63, "start": 53, "tag": "HealthCareActivity"}, {"end": 63, "start": 53, "tag": "ResearchActivity"}]}{"id": "1517_9", "text": "Among these, 266 were further excluded because they did not have flortaucipir and CSF testing within less than 25 months, leaving 322 for analysis.", "tags": [{"end": 77, "start": 65, "tag": "Chemical"}, {"end": 85, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 86, "tag": "HealthCareActivity"}, {"end": 120, "start": 114, "tag": "TemporalConcept"}, {"end": 146, "start": 138, "tag": "ResearchActivity"}]}{"id": "1517_10", "text": "Of these, 213 were cognitively unimpaired (CU); 98 had mild cognitive impairment (MCI); and 11 had AD dementia.", "tags": [{"end": 41, "start": 19, "tag": "Finding"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 55, "tag": "Finding"}]}{"id": "1517_11", "text": "Main Outcomes and Measures We compared tau-positive vs tau-negative groups as indicated by either modality or demographic and clinical variables, amyloid beta-PET burden, and flortaucipir-PET binding across Braak stage-related ROIs.", "tags": [{"end": 106, "start": 98, "tag": "HealthCareActivity"}, {"end": 231, "start": 227, "tag": "ResearchActivity"}, {"end": 187, "start": 175, "tag": "Chemical"}, {"end": 199, "start": 192, "tag": "CellFunction"}, {"end": 42, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 218, "start": 207, "tag": "HealthCareActivity"}, {"end": 153, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 146, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 5, "tag": "HealthCareActivity"}, {"end": 74, "start": 68, "tag": "PopulationGroup"}, {"end": 162, "start": 159, "tag": "HealthCareActivity"}, {"end": 191, "start": 188, "tag": "HealthCareActivity"}, {"end": 158, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 163, "tag": "ResearchActivity"}, {"end": 218, "start": 213, "tag": "TemporalConcept"}, {"end": 218, "start": 213, "tag": "ClinicalAttribute"}]}{"id": "1517_12", "text": "We also compared 5-year rates of CSF P-tau accumulation and cognitive decline prior to flortaucipir-PET scanning.", "tags": [{"end": 99, "start": 87, "tag": "Chemical"}, {"end": 23, "start": 19, "tag": "TemporalConcept"}, {"end": 42, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 100, "tag": "HealthCareActivity"}, {"end": 55, "start": 43, "tag": "Finding"}, {"end": 42, "start": 33, "tag": "ClinicalAttribute"}]}{"id": "1517_13", "text": "Results Among the 322 study participants, 180 were women (56%), and the mean (SD) age was 73.08 (7.37) years.", "tags": [{"end": 40, "start": 28, "tag": "PopulationGroup"}, {"end": 27, "start": 22, "tag": "ResearchActivity"}, {"end": 56, "start": 51, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 85, "start": 82, "tag": "OrganismAttribute"}, {"end": 108, "start": 103, "tag": "TemporalConcept"}, {"end": 80, "start": 78, "tag": "ResearchActivity"}]}{"id": "1517_14", "text": "Two hundred ten participants were CSF-/PET- (65%); 63 were CSF+/PET- (19.5%); 15 were CSF-/PET+ (4.6%); and 34 were CSF+/PET+ (10.5%).", "tags": [{"end": 37, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 16, "tag": "PopulationGroup"}, {"end": 42, "start": 39, "tag": "HealthCareActivity"}, {"end": 67, "start": 64, "tag": "HealthCareActivity"}, {"end": 94, "start": 91, "tag": "HealthCareActivity"}, {"end": 124, "start": 121, "tag": "HealthCareActivity"}]}{"id": "1517_15", "text": "Most CSF-/PET+ participants had measures near CSF or PET tau thresholds.", "tags": [{"end": 60, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 5, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 15, "tag": "PopulationGroup"}, {"end": 13, "start": 10, "tag": "HealthCareActivity"}, {"end": 56, "start": 53, "tag": "HealthCareActivity"}, {"end": 71, "start": 61, "tag": "Finding"}]}{"id": "1517_16", "text": "The CSF+/PET- participants showed faster 5-year accrual of P-tau and increased flortaucipir-PET binding in early Braak ROIs but similar memory decline compared with CSF-/PET- participants.", "tags": [{"end": 123, "start": 119, "tag": "ResearchActivity"}, {"end": 123, "start": 113, "tag": "ResearchActivity"}, {"end": 91, "start": 79, "tag": "Chemical"}, {"end": 103, "start": 96, "tag": "CellFunction"}, {"end": 47, "start": 43, "tag": "TemporalConcept"}, {"end": 64, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 14, "tag": "PopulationGroup"}, {"end": 187, "start": 175, "tag": "PopulationGroup"}, {"end": 112, "start": 107, "tag": "TemporalConcept"}, {"end": 12, "start": 9, "tag": "HealthCareActivity"}, {"end": 95, "start": 92, "tag": "HealthCareActivity"}, {"end": 173, "start": 170, "tag": "HealthCareActivity"}, {"end": 142, "start": 136, "tag": "BiologicFunction"}, {"end": 150, "start": 136, "tag": "DiseaseOrSyndrome"}]}{"id": "1517_17", "text": "Tau-positive individuals by either measure showed increased amyloid beta-PET burden.", "tags": [{"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 13, "tag": "PopulationGroup"}, {"end": 67, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 73, "tag": "HealthCareActivity"}, {"end": 72, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 77, "tag": "ResearchActivity"}]}{"id": "1517_18", "text": "All CSF+/PET+ individuals were amyloid-positive, and 26 had MCI or AD dementia (76%).", "tags": [{"end": 7, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 14, "tag": "PopulationGroup"}, {"end": 38, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 9, "tag": "HealthCareActivity"}]}{"id": "1517_19", "text": "Compared with the CSF-/PET- group, CSF+/PET+ individuals had experienced faster 5-year accrual of CSF P-tau and decline in memory and executive function, resulting in reduced cognitive abilities at the time of flortaucipir-PET assessment.", "tags": [{"end": 152, "start": 134, "tag": "BiologicFunction"}, {"end": 152, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 175, "tag": "BiologicFunction"}, {"end": 222, "start": 210, "tag": "Chemical"}, {"end": 86, "start": 82, "tag": "TemporalConcept"}, {"end": 107, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 45, "tag": "PopulationGroup"}, {"end": 237, "start": 227, "tag": "HealthCareActivity"}, {"end": 237, "start": 227, "tag": "ResearchActivity"}, {"end": 206, "start": 202, "tag": "TemporalConcept"}, {"end": 26, "start": 23, "tag": "HealthCareActivity"}, {"end": 43, "start": 40, "tag": "HealthCareActivity"}, {"end": 226, "start": 223, "tag": "HealthCareActivity"}, {"end": 33, "start": 28, "tag": "PopulationGroup"}, {"end": 129, "start": 123, "tag": "BiologicFunction"}, {"end": 107, "start": 98, "tag": "ClinicalAttribute"}, {"end": 119, "start": 112, "tag": "Finding"}]}{"id": "1517_20", "text": "Conclusions and Relevance Suprathreshold CSF P-tau without flortaucipir-PET abnormality may indicate a stage of AD development characterized by early tau abnormality without measurable loss in cognitive performance.", "tags": [{"end": 71, "start": 59, "tag": "Chemical"}, {"end": 87, "start": 72, "tag": "ClinicalAttribute"}, {"end": 50, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 150, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 115, "tag": "BiologicFunction"}, {"end": 126, "start": 115, "tag": "CellFunction"}, {"end": 149, "start": 144, "tag": "TemporalConcept"}, {"end": 75, "start": 72, "tag": "HealthCareActivity"}, {"end": 214, "start": 185, "tag": "Finding"}, {"end": 108, "start": 103, "tag": "TemporalConcept"}, {"end": 108, "start": 103, "tag": "ClinicalAttribute"}, {"end": 87, "start": 76, "tag": "Finding"}, {"end": 165, "start": 154, "tag": "Finding"}, {"end": 50, "start": 41, "tag": "ClinicalAttribute"}, {"end": 126, "start": 112, "tag": "PathologicFunction"}]}{"id": "1517_21", "text": "Persons with both tau CSF and PET abnormality appear to have reduced cognitive capacities resulting from faster antecedent cognitive decline.", "tags": [{"end": 7, "start": 0, "tag": "PopulationGroup"}, {"end": 89, "start": 61, "tag": "Finding"}, {"end": 45, "start": 30, "tag": "ClinicalAttribute"}, {"end": 21, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 30, "tag": "HealthCareActivity"}, {"end": 45, "start": 34, "tag": "Finding"}]}{"id": "1517_22", "text": "Elevation of CSF P-tau appears to precede flortaucipir-PET positivity in the progression of AD pathogenesis and related cognitive decline.", "tags": [{"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "Finding"}, {"end": 9, "start": 0, "tag": "CellFunction"}, {"end": 88, "start": 77, "tag": "TemporalConcept"}, {"end": 54, "start": 42, "tag": "Chemical"}, {"end": 69, "start": 59, "tag": "ResearchActivity"}, {"end": 22, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 77, "tag": "PathologicFunction"}, {"end": 88, "start": 77, "tag": "TemporalConcept"}, {"end": 137, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 95, "tag": "PathologicFunction"}, {"end": 58, "start": 55, "tag": "HealthCareActivity"}, {"end": 22, "start": 13, "tag": "ClinicalAttribute"}]}{"id": "1518_0", "text": "Introduction The aim of this study was to investigate retinal thickness as a biomarker for identifying patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD).", "tags": [{"end": 172, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 103, "tag": "PatientOrDisabledGroup"}, {"end": 176, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 77, "tag": "ClinicalAttribute"}, {"end": 34, "start": 29, "tag": "ResearchActivity"}, {"end": 147, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 54, "tag": "ClinicalAttribute"}]}{"id": "1518_1", "text": "Methods The retinal thickness, utilizing the spectral domain optical coherence tomography, was compared among 73 patients with AD, 51 patients with MCI, 67 cognitive normal control (NC) subjects.", "tags": [{"end": 89, "start": 45, "tag": "HealthCareActivity"}, {"end": 89, "start": 61, "tag": "HealthCareActivity"}, {"end": 121, "start": 113, "tag": "PatientOrDisabledGroup"}, {"end": 142, "start": 134, "tag": "PatientOrDisabledGroup"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 166, "tag": "Finding"}, {"end": 194, "start": 186, "tag": "PopulationGroup"}, {"end": 151, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 182, "tag": "PopulationGroup"}, {"end": 29, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1518_2", "text": "Results The retinal thickness of ganglion cell complex and peripapillary retinal nerve fiber layer decreased in both AD and MCI patients, in comparison with NC subjects (AD vs.", "tags": [{"end": 98, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 33, "tag": "Cell"}, {"end": 136, "start": 128, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 119, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 160, "tag": "PopulationGroup"}, {"end": 127, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 141, "tag": "ResearchActivity"}, {"end": 46, "start": 42, "tag": "Cell"}, {"end": 159, "start": 157, "tag": "PopulationGroup"}, {"end": 29, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1518_3", "text": "NC, P < .01; MCI vs.", "tags": [{"end": 16, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 2, "start": 0, "tag": "PopulationGroup"}]}{"id": "1518_4", "text": "NC, P < .01).", "tags": [{"end": 2, "start": 0, "tag": "PopulationGroup"}]}{"id": "1518_5", "text": "The inner retinal layers in macular area in MCI exhibited significant thinning compared with NC (P < .001).", "tags": [{"end": 24, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 93, "tag": "PopulationGroup"}, {"end": 40, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 58, "tag": "Finding"}]}{"id": "1518_6", "text": "Remarkable association was found between the retinal thickness and brain volume (P < .05).", "tags": [{"end": 79, "start": 67, "tag": "ClinicalAttribute"}, {"end": 62, "start": 45, "tag": "ClinicalAttribute"}, {"end": 22, "start": 0, "tag": "Finding"}]}{"id": "1518_7", "text": "Better correlation was seen between the inner perifovea retinal thickness and the hippocampal and entorhinal cortex volume (r: 0.427-0.644, P < .01).", "tags": [{"end": 73, "start": 40, "tag": "ClinicalAttribute"}, {"end": 122, "start": 98, "tag": "ClinicalAttribute"}, {"end": 122, "start": 116, "tag": "ClinicalAttribute"}, {"end": 93, "start": 82, "tag": "ClinicalAttribute"}, {"end": 18, "start": 0, "tag": "Finding"}]}{"id": "1518_8", "text": "Discussion The retinal thickness, especially the inner retinal layer thickness, is a potentially early AD marker indicating neurodegeneration.", "tags": [{"end": 141, "start": 124, "tag": "CellOrMolecularDysfunction"}, {"end": 105, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 106, "tag": "ClinicalAttribute"}, {"end": 32, "start": 15, "tag": "ClinicalAttribute"}, {"end": 78, "start": 49, "tag": "ClinicalAttribute"}]}{"id": "1519_0", "text": "Abnormal tau inclusions are hallmarks of Alzheimer's disease and predictors of clinical decline.", "tags": [{"end": 23, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 60, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 65, "tag": "Finding"}, {"end": 37, "start": 28, "tag": "Finding"}, {"end": 95, "start": 79, "tag": "Finding"}]}{"id": "1519_1", "text": "Several tau PET tracers are available for neurodegenerative disease research, opening avenues for molecular diagnosis in vivo.", "tags": [{"end": 117, "start": 98, "tag": "ResearchActivity"}, {"end": 67, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 118, "tag": "ResearchActivity"}, {"end": 11, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 68, "tag": "ResearchActivity"}, {"end": 15, "start": 12, "tag": "HealthCareActivity"}, {"end": 23, "start": 16, "tag": "Chemical"}]}{"id": "1519_2", "text": "However, few have been approved for clinical use.", "tags": [{"end": 48, "start": 36, "tag": "HealthCareActivity"}]}{"id": "1519_3", "text": "Understanding the neurobiological basis of PET signal validation remains problematic because it requires a large-scale, voxel-to-voxel correlation between PET and (immuno) histological signals.", "tags": [{"end": 192, "start": 185, "tag": "CellFunction"}, {"end": 64, "start": 54, "tag": "ResearchActivity"}, {"end": 46, "start": 43, "tag": "HealthCareActivity"}, {"end": 158, "start": 155, "tag": "HealthCareActivity"}, {"end": 146, "start": 120, "tag": "ResearchActivity"}, {"end": 192, "start": 163, "tag": "HealthCareActivity"}, {"end": 192, "start": 163, "tag": "ResearchActivity"}]}{"id": "1519_4", "text": "Large dimensionality of whole human brains, tissue deformation impacting co-registration, and computing requirements to process terabytes of information preclude proper validation.", "tags": [{"end": 179, "start": 169, "tag": "ResearchActivity"}, {"end": 42, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 30, "tag": "Eukaryote"}, {"end": 88, "start": 73, "tag": "ResearchActivity"}, {"end": 116, "start": 94, "tag": "MachineActivity"}, {"end": 62, "start": 44, "tag": "Finding"}]}{"id": "1519_5", "text": "We developed a computational pipeline to identify and segment particles of interest in billion-pixel digital pathology images to generate quantitative, 3D density maps.", "tags": [{"end": 71, "start": 62, "tag": "Chemical"}, {"end": 118, "start": 109, "tag": "PathologicFunction"}, {"end": 118, "start": 109, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 167, "start": 152, "tag": "ResearchActivity"}, {"end": 37, "start": 15, "tag": "MachineActivity"}, {"end": 125, "start": 87, "tag": "ResearchActivity"}]}{"id": "1519_6", "text": "The proposed convolutional neural network for immunohistochemistry samples, IHCNet, is at the pipeline's core.", "tags": [{"end": 66, "start": 46, "tag": "ResearchActivity"}, {"end": 41, "start": 13, "tag": "MachineActivity"}, {"end": 82, "start": 76, "tag": "ResearchActivity"}]}{"id": "1519_7", "text": "We have successfully processed and immunostained over 500 slides from two whole human brains with three phospho-tau antibodies (AT100, AT8, and MC1), spanning several terabytes of images.", "tags": [{"end": 92, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 80, "tag": "Eukaryote"}, {"end": 126, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 58, "tag": "ManufacturedObject"}]}{"id": "1519_8", "text": "Our artificial neural network estimated tau inclusion from brain images, which performs with ROC AUC of 0.87, 0.85, and 0.91 for AT100, AT8, and MC1, respectively.", "tags": [{"end": 96, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 97, "tag": "ResearchActivity"}, {"end": 29, "start": 4, "tag": "MachineActivity"}, {"end": 134, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 40, "tag": "CellOrMolecularDysfunction"}, {"end": 71, "start": 59, "tag": "ResearchActivity"}]}{"id": "1519_9", "text": "Introspection studies further assessed the ability of our trained model to learn tau-related features.", "tags": [{"end": 84, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 0, "tag": "ResearchActivity"}, {"end": 71, "start": 66, "tag": "ResearchActivity"}, {"end": 50, "start": 43, "tag": "OrganismAttribute"}]}{"id": "1519_10", "text": "We present an end-to-end pipeline to create terabytes-large 3D tau inclusion density maps co-registered to MRI as a means to facilitate validation of PET tracers.", "tags": [{"end": 146, "start": 136, "tag": "ResearchActivity"}, {"end": 66, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 107, "tag": "HealthCareActivity"}, {"end": 153, "start": 150, "tag": "HealthCareActivity"}, {"end": 161, "start": 154, "tag": "Chemical"}, {"end": 89, "start": 60, "tag": "ResearchActivity"}, {"end": 33, "start": 14, "tag": "ResearchActivity"}, {"end": 76, "start": 63, "tag": "CellOrMolecularDysfunction"}]}{"id": "1520_0", "text": "Background The progression rates of Alzheimer's disease (AD) are variable and dynamic, yet the mechanisms that contribute to heterogeneity in progression rates remain ill-understood.", "tags": [{"end": 138, "start": 125, "tag": "Finding"}, {"end": 55, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 15, "tag": "PathologicFunction"}, {"end": 153, "start": 142, "tag": "PathologicFunction"}, {"end": 26, "start": 15, "tag": "TemporalConcept"}, {"end": 153, "start": 142, "tag": "TemporalConcept"}, {"end": 32, "start": 27, "tag": "TemporalConcept"}, {"end": 159, "start": 154, "tag": "TemporalConcept"}]}{"id": "1520_1", "text": "Particularly, the role of synergies in pathological processes reflected by biomarkers for amyloid-beta ('A'), tau ('T'), and neurodegeneration ('N') in progression along the AD continuum is not fully understood.", "tags": [{"end": 186, "start": 177, "tag": "TemporalConcept"}, {"end": 61, "start": 39, "tag": "PathologicFunction"}, {"end": 113, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 75, "tag": "ClinicalAttribute"}, {"end": 102, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 152, "tag": "PathologicFunction"}, {"end": 163, "start": 152, "tag": "TemporalConcept"}, {"end": 142, "start": 125, "tag": "CellOrMolecularDysfunction"}]}{"id": "1520_2", "text": "Methods Here, we used a combination of model and data-driven approaches to address this question.", "tags": [{"end": 53, "start": 49, "tag": "ResearchActivity"}, {"end": 44, "start": 39, "tag": "ResearchActivity"}]}{"id": "1520_3", "text": "Working with a large dataset (N = 321 across the training and testing cohorts), we first applied unsupervised clustering on longitudinal cognitive assessments to divide individuals on the AD continuum into those showing fast vs.", "tags": [{"end": 200, "start": 191, "tag": "HealthCareActivity"}, {"end": 88, "start": 83, "tag": "TemporalConcept"}, {"end": 190, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 70, "tag": "PopulationGroup"}, {"end": 180, "start": 169, "tag": "PopulationGroup"}, {"end": 69, "start": 62, "tag": "HealthCareActivity"}, {"end": 28, "start": 21, "tag": "ResearchActivity"}, {"end": 120, "start": 97, "tag": "ResearchActivity"}, {"end": 158, "start": 124, "tag": "HealthCareActivity"}, {"end": 224, "start": 220, "tag": "Finding"}]}{"id": "1520_4", "text": "moderate decline.", "tags": [{"end": 16, "start": 0, "tag": "Finding"}, {"end": 16, "start": 9, "tag": "Finding"}]}{"id": "1520_5", "text": "Next, we developed a deep learning model that differentiated fast vs.", "tags": [{"end": 65, "start": 61, "tag": "Finding"}, {"end": 34, "start": 21, "tag": "MachineActivity"}, {"end": 34, "start": 26, "tag": "BiologicFunction"}, {"end": 40, "start": 35, "tag": "ResearchActivity"}]}{"id": "1520_6", "text": "moderate decline using baseline AT(N) biomarkers.", "tags": [{"end": 16, "start": 9, "tag": "Finding"}, {"end": 16, "start": 0, "tag": "Finding"}, {"end": 48, "start": 32, "tag": "ClinicalAttribute"}]}{"id": "1520_7", "text": "Results Training the model with AT(N) biomarker combination revealed more prognostic utility than any individual biomarkers alone.", "tags": [{"end": 92, "start": 74, "tag": "Finding"}, {"end": 47, "start": 32, "tag": "ClinicalAttribute"}, {"end": 123, "start": 113, "tag": "ClinicalAttribute"}, {"end": 112, "start": 102, "tag": "PopulationGroup"}, {"end": 112, "start": 102, "tag": "OrganismAttribute"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 26, "start": 21, "tag": "ResearchActivity"}, {"end": 16, "start": 8, "tag": "BiologicFunction"}]}{"id": "1520_8", "text": "We additionally found little overlap between the model-driven progression phenotypes and established atrophy-based AD subtypes.", "tags": [{"end": 36, "start": 29, "tag": "TemporalConcept"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 74, "tag": "OrganismAttribute"}, {"end": 73, "start": 62, "tag": "PathologicFunction"}, {"end": 73, "start": 62, "tag": "TemporalConcept"}, {"end": 54, "start": 49, "tag": "ResearchActivity"}, {"end": 108, "start": 101, "tag": "PathologicFunction"}, {"end": 108, "start": 101, "tag": "DiseaseOrSyndrome"}]}{"id": "1520_9", "text": "Our model showed that the combination of all AT(N) biomarkers had the most prognostic utility in predicting progression along the AD continuum.", "tags": [{"end": 142, "start": 133, "tag": "TemporalConcept"}, {"end": 93, "start": 75, "tag": "Finding"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 45, "tag": "ClinicalAttribute"}, {"end": 119, "start": 108, "tag": "PathologicFunction"}, {"end": 119, "start": 108, "tag": "TemporalConcept"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}]}{"id": "1520_10", "text": "A comprehensive AT(N) model showed better predictive performance than biomarker pairs (A(N) and T(N)) and individual biomarkers (A, T, or N).", "tags": [{"end": 79, "start": 70, "tag": "ClinicalAttribute"}, {"end": 127, "start": 117, "tag": "ClinicalAttribute"}, {"end": 64, "start": 42, "tag": "Finding"}, {"end": 116, "start": 106, "tag": "PopulationGroup"}, {"end": 116, "start": 106, "tag": "OrganismAttribute"}, {"end": 27, "start": 16, "tag": "ResearchActivity"}]}{"id": "1520_11", "text": "Conclusions This study combined data and model-driven methods to uncover the role of AT(N) biomarker synergies in the progression of cognitive decline along the AD continuum.", "tags": [{"end": 173, "start": 164, "tag": "TemporalConcept"}, {"end": 163, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 85, "tag": "ClinicalAttribute"}, {"end": 36, "start": 32, "tag": "ResearchActivity"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}, {"end": 129, "start": 118, "tag": "PathologicFunction"}, {"end": 129, "start": 118, "tag": "TemporalConcept"}, {"end": 150, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 41, "tag": "ResearchActivity"}]}{"id": "1520_12", "text": "The results suggest a synergistic relationship between AT(N) biomarkers in determining this progression, extending previous evidence of A-T synergistic mechanisms.", "tags": [{"end": 71, "start": 55, "tag": "ClinicalAttribute"}, {"end": 103, "start": 92, "tag": "PathologicFunction"}, {"end": 103, "start": 92, "tag": "TemporalConcept"}, {"end": 132, "start": 124, "tag": "Finding"}, {"end": 46, "start": 34, "tag": "Finding"}]}{"id": "1521_0", "text": "Mitochondrial dysfunction plays a key role in the pathogenesis of Alzheimer's disease (AD).", "tags": [{"end": 25, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 62, "start": 50, "tag": "PathologicFunction"}, {"end": 85, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}]}{"id": "1521_1", "text": "The translocase of the outer membrane (TOM) complex controls the input of mitochondrial precursor proteins to maintain mitochondrial function under pathophysiological conditions.", "tags": [{"end": 51, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 74, "tag": "CellComponent"}, {"end": 141, "start": 119, "tag": "CellFunction"}, {"end": 177, "start": 148, "tag": "PathologicFunction"}, {"end": 60, "start": 52, "tag": "PopulationGroup"}, {"end": 106, "start": 88, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1521_2", "text": "However, its role in AD development remains unclear.", "tags": [{"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 24, "tag": "BiologicFunction"}, {"end": 35, "start": 24, "tag": "CellFunction"}]}{"id": "1521_3", "text": "TOM70 is an important translocase present in the TOM complex.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 33, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 49, "tag": "BiologicallyActiveSubstance"}]}{"id": "1521_4", "text": "In the current study, we found that TOM70 levels were reduced in the peripheral blood and hippocampus of the APP/PS1 mice.", "tags": [{"end": 41, "start": 36, "tag": "GeneOrGenome"}, {"end": 85, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 14, "start": 7, "tag": "TemporalConcept"}, {"end": 101, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 109, "tag": "ExperimentalModelOfDisease"}, {"end": 41, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 36, "tag": "BiologicallyActiveSubstance"}]}{"id": "1521_5", "text": "In addition, we examined the whole-blood mRNA levels of TOM70 in patients with AD, dementia with Lewy bodies (DLB), and post-stroke dementia (PSD).", "tags": [{"end": 61, "start": 56, "tag": "GeneOrGenome"}, {"end": 113, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 41, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 108, "start": 97, "tag": "CellComponent"}, {"end": 73, "start": 65, "tag": "PatientOrDisabledGroup"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 120, "tag": "TemporalConcept"}, {"end": 61, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 142, "tag": "DiseaseOrSyndrome"}]}{"id": "1521_6", "text": "Our study revealed that the mRNA level of TOM70 was decreased in the blood samples of patients with AD, which was also correlated with the progression of clinical stages.", "tags": [{"end": 47, "start": 42, "tag": "GeneOrGenome"}, {"end": 169, "start": 154, "tag": "TemporalConcept"}, {"end": 32, "start": 28, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 94, "start": 86, "tag": "PatientOrDisabledGroup"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 82, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 139, "tag": "PathologicFunction"}, {"end": 150, "start": 139, "tag": "TemporalConcept"}]}{"id": "1521_7", "text": "Therefore, we proposed that the expression of TOM70 could be a promising biomarker for AD diagnosis and monitoring of disease progression.", "tags": [{"end": 51, "start": 46, "tag": "GeneOrGenome"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 73, "tag": "ClinicalAttribute"}, {"end": 137, "start": 126, "tag": "PathologicFunction"}, {"end": 137, "start": 126, "tag": "TemporalConcept"}, {"end": 99, "start": 90, "tag": "HealthCareActivity"}, {"end": 114, "start": 104, "tag": "HealthCareActivity"}, {"end": 137, "start": 118, "tag": "PathologicFunction"}, {"end": 51, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 46, "tag": "BiologicallyActiveSubstance"}]}{"id": "1522_0", "text": "Alzheimer's disease (AD) is an accelerating neurodegenerative disorder.", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 44, "tag": "DiseaseOrSyndrome"}]}{"id": "1522_1", "text": "Dysfunction of mitochondria and oxidative stress contributes to the pathogenesis of AD.", "tags": [{"end": 11, "start": 0, "tag": "PathologicFunction"}, {"end": 48, "start": 32, "tag": "CellOrMolecularDysfunction"}, {"end": 27, "start": 15, "tag": "CellComponent"}, {"end": 80, "start": 68, "tag": "PathologicFunction"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}]}{"id": "1522_2", "text": "Sirtuins play a role in this pathway and can be a potential marker to study neurodegenerative changes.", "tags": [{"end": 8, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 29, "tag": "CellFunction"}, {"end": 101, "start": 76, "tag": "PathologicFunction"}, {"end": 75, "start": 70, "tag": "ResearchActivity"}, {"end": 66, "start": 60, "tag": "ClinicalAttribute"}]}{"id": "1522_3", "text": "This study evaluated serum levels of all seven sirtuin (SIRT1-SIRT7) proteins in three study groups: AD, mild cognitive impairment (MCI) and geriatric control (GC) by surface plasmon resonance (SPR) technique.", "tags": [{"end": 33, "start": 21, "tag": "ResearchActivity"}, {"end": 54, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 167, "tag": "ResearchActivity"}, {"end": 208, "start": 199, "tag": "ResearchActivity"}, {"end": 103, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 92, "start": 87, "tag": "ResearchActivity"}, {"end": 77, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 93, "tag": "PopulationGroup"}, {"end": 26, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 56, "tag": "GeneOrGenome"}, {"end": 67, "start": 62, "tag": "GeneOrGenome"}, {"end": 67, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 141, "tag": "PopulationGroup"}, {"end": 197, "start": 194, "tag": "ResearchActivity"}]}{"id": "1522_4", "text": "Further, it was validated by the Western blot experiment.", "tags": [{"end": 56, "start": 33, "tag": "ResearchActivity"}]}{"id": "1522_5", "text": "ROC analysis was performed to differentiate the study group based on the concentration of serum SIRT proteins.", "tags": [{"end": 53, "start": 48, "tag": "ResearchActivity"}, {"end": 59, "start": 54, "tag": "PopulationGroup"}, {"end": 95, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 109, "start": 73, "tag": "ClinicalAttribute"}, {"end": 109, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 96, "tag": "BiologicallyActiveSubstance"}]}{"id": "1522_6", "text": "Out of seven sirtuins, serum SIRT1, SIRT3 and SIRT6 levels (mean +/- SD) were significantly decreased in AD (1.65 +/- 0.56, 3.15 +/- 0.28, 3.36 +/- 0.32 ng/mu l), compared to MCI (2.17 +/- 0.39, 3.60 +/- 0.51, 3.73 +/- 0.48 ng/mu l) and GC (2.84 +/- 0.47, 4.55 +/- 0.48, 4.65 +/- 0.55 ng/mu l).", "tags": [{"end": 21, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 29, "tag": "GeneOrGenome"}, {"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 36, "tag": "GeneOrGenome"}, {"end": 41, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 46, "tag": "GeneOrGenome"}, {"end": 71, "start": 69, "tag": "ResearchActivity"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 239, "start": 237, "tag": "PopulationGroup"}]}{"id": "1522_7", "text": "ROC analysis showed the cut-off value with high sensitivity and specificity for cognitive impairment (AD and MCI).", "tags": [{"end": 75, "start": 43, "tag": "Finding"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 31, "start": 24, "tag": "ResearchActivity"}]}{"id": "1522_8", "text": "The concentration declined significantly with the disease progression.", "tags": [{"end": 69, "start": 58, "tag": "PathologicFunction"}, {"end": 69, "start": 58, "tag": "TemporalConcept"}, {"end": 69, "start": 50, "tag": "PathologicFunction"}]}{"id": "1522_9", "text": "No specific difference was observed in the case of other SIRTs between the study groups.", "tags": [{"end": 62, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 43, "tag": "ManufacturedObject"}, {"end": 80, "start": 75, "tag": "ResearchActivity"}, {"end": 87, "start": 81, "tag": "PopulationGroup"}, {"end": 22, "start": 0, "tag": "Finding"}, {"end": 62, "start": 57, "tag": "BiologicallyActiveSubstance"}]}{"id": "1522_10", "text": "This study reveals an inverse relation of serum SIRT1, SIRT3 and SIRT6 concentration with AD.", "tags": [{"end": 53, "start": 48, "tag": "GeneOrGenome"}, {"end": 53, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 55, "tag": "GeneOrGenome"}, {"end": 60, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 65, "tag": "GeneOrGenome"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 47, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 22, "tag": "ResearchActivity"}, {"end": 53, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 65, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1522_11", "text": "ROC analysis showed that these serum proteins have greater accuracy in diagnosing of AD.", "tags": [{"end": 81, "start": 71, "tag": "HealthCareActivity"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 59, "tag": "Finding"}, {"end": 36, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}]}{"id": "1522_12", "text": "This is the first report of estimation of all seven serum sirtuins and the clinical relevance of SIRT3 and SIRT6 as serum protein markers for AD.", "tags": [{"end": 102, "start": 97, "tag": "GeneOrGenome"}, {"end": 102, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 107, "tag": "GeneOrGenome"}, {"end": 24, "start": 18, "tag": "HealthCareActivity"}, {"end": 24, "start": 18, "tag": "ResearchActivity"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 12, "tag": "TemporalConcept"}, {"end": 57, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 75, "tag": "Finding"}, {"end": 102, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 116, "tag": "ClinicalAttribute"}]}{"id": "1523_0", "text": "Huntington's disease (HD) is an autosomal-dominant neurodegenerative movement disorder that presents with prominent cognitive and psychiatric dysfunction.", "tags": [{"end": 86, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 116, "tag": "PathologicFunction"}]}{"id": "1523_1", "text": "Brain-derived neurotrophic factor (BDNF) plays an important role in the pathophysiology of HD, as well as other neurodegenerative and psychiatric disorders, and epigenetic alterations in the complex BDNF promoter have been associated with its deregulation in pathological conditions.", "tags": [{"end": 33, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 204, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 282, "start": 259, "tag": "PathologicFunction"}, {"end": 255, "start": 243, "tag": "CellOrMolecularDysfunction"}, {"end": 39, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 199, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 199, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 72, "tag": "PathologicFunction"}, {"end": 87, "start": 72, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 33, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 161, "tag": "Finding"}, {"end": 212, "start": 204, "tag": "BiologicallyActiveSubstance"}]}{"id": "1523_2", "text": "BDNF has gained increased attention as a potential biomarker of disease; but currently, the conflicting results from measurements of BDNF in different biofluids difficult the assessment of its utility as a biomarker for HD.", "tags": [{"end": 35, "start": 26, "tag": "BiologicFunction"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 222, "start": 220, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 41, "tag": "ClinicalAttribute"}, {"end": 86, "start": 77, "tag": "TemporalConcept"}, {"end": 215, "start": 206, "tag": "ClinicalAttribute"}, {"end": 160, "start": 151, "tag": "Substance"}, {"end": 185, "start": 175, "tag": "HealthCareActivity"}, {"end": 185, "start": 175, "tag": "ResearchActivity"}, {"end": 129, "start": 117, "tag": "HealthCareActivity"}]}{"id": "1523_3", "text": "Here, we measured BDNF protein levels in plasma (n = 85) and saliva (n = 81) samples from premanifest and manifest HD patients and normal controls using ELISA assays.", "tags": [{"end": 30, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 153, "tag": "ResearchActivity"}, {"end": 126, "start": 115, "tag": "PatientOrDisabledGroup"}, {"end": 114, "start": 106, "tag": "SignOrSymptom"}, {"end": 47, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 131, "tag": "Finding"}, {"end": 146, "start": 138, "tag": "PopulationGroup"}, {"end": 67, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 18, "tag": "ClinicalAttribute"}]}{"id": "1523_4", "text": "We further examined DNA methylation levels of BDNF promoter IV using DNA derived from whole blood of HD patients and healthy controls (n = 40) using pyrosequencing.", "tags": [{"end": 97, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 149, "tag": "ResearchActivity"}, {"end": 35, "start": 20, "tag": "CellFunction"}, {"end": 50, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 117, "tag": "PopulationGroup"}, {"end": 112, "start": 101, "tag": "PatientOrDisabledGroup"}, {"end": 97, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 20, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 72, "start": 69, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 124, "start": 117, "tag": "OrganismAttribute"}, {"end": 62, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 51, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1523_5", "text": "BDNF protein levels were not significantly different in plasma samples across diagnostic groups.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 89, "tag": "PopulationGroup"}, {"end": 88, "start": 78, "tag": "HealthCareActivity"}, {"end": 19, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1523_6", "text": "Plasma BDNF was significantly correlated with age in control subjects but not in HD patients, nor were significant gender effects observed.", "tags": [{"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 121, "start": 115, "tag": "OrganismAttribute"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 46, "tag": "OrganismAttribute"}, {"end": 69, "start": 53, "tag": "PopulationGroup"}, {"end": 69, "start": 61, "tag": "PopulationGroup"}, {"end": 11, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1523_7", "text": "Similar to plasma, salivary BDNF was correlated with age only in control subjects, with no gender effects observed.", "tags": [{"end": 32, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 91, "tag": "OrganismAttribute"}, {"end": 17, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 53, "tag": "OrganismAttribute"}, {"end": 81, "start": 65, "tag": "PopulationGroup"}, {"end": 27, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 19, "tag": "ClinicalAttribute"}]}{"id": "1523_8", "text": "Importantly, we detected significantly lower levels of salivary BDNF in premanifest and manifest HD patients compared to control subjects, with lower BDNF levels being observed in premanifest patients within a predicted 10 years to disease onset.", "tags": [{"end": 245, "start": 232, "tag": "TemporalConcept"}, {"end": 68, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 150, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 97, "tag": "PatientOrDisabledGroup"}, {"end": 96, "start": 88, "tag": "SignOrSymptom"}, {"end": 228, "start": 223, "tag": "TemporalConcept"}, {"end": 200, "start": 192, "tag": "PatientOrDisabledGroup"}, {"end": 137, "start": 121, "tag": "PopulationGroup"}, {"end": 63, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 55, "tag": "ClinicalAttribute"}]}{"id": "1523_9", "text": "Salivary and plasma BDNF levels were not significantly correlated with one another, suggesting different origins.", "tags": [{"end": 112, "start": 105, "tag": "TemporalConcept"}, {"end": 24, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 13, "tag": "ClinicalAttribute"}]}{"id": "1523_10", "text": "DNA methylation at four out of the 12 CpG sites studied in promoter IV were significantly altered in HD patients in comparison to controls.", "tags": [{"end": 15, "start": 0, "tag": "CellFunction"}, {"end": 112, "start": 101, "tag": "PatientOrDisabledGroup"}, {"end": 138, "start": 130, "tag": "PopulationGroup"}, {"end": 126, "start": 116, "tag": "ResearchActivity"}, {"end": 3, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 47, "start": 38, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 47, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 59, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1523_11", "text": "Interestingly, methylation at three of these CpG sites was inversely correlated to the Hospital Anxiety and Depression Scale (HADS) scores.", "tags": [{"end": 26, "start": 15, "tag": "CellFunction"}, {"end": 124, "start": 87, "tag": "HealthCareActivity"}, {"end": 54, "start": 45, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 54, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "HealthCareActivity"}]}{"id": "1523_12", "text": "BDNF promoter methylation was not correlated with motor or cognitive scores in HD patients, and was not associated with sex or age in neither disease nor control groups.", "tags": [{"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 154, "tag": "PopulationGroup"}, {"end": 90, "start": 79, "tag": "PatientOrDisabledGroup"}, {"end": 130, "start": 127, "tag": "OrganismAttribute"}, {"end": 123, "start": 120, "tag": "OrganismAttribute"}, {"end": 168, "start": 162, "tag": "PopulationGroup"}, {"end": 25, "start": 5, "tag": "CellFunction"}]}{"id": "1523_13", "text": "Conclusion: Our studies show that BDNF protein levels are decreased in saliva; and BDNF promoter methylation increased in blood in HD subjects when compared to controls.", "tags": [{"end": 142, "start": 131, "tag": "PatientOrDisabledGroup"}, {"end": 46, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 16, "tag": "ResearchActivity"}, {"end": 127, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 160, "tag": "PopulationGroup"}, {"end": 77, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 88, "tag": "CellFunction"}]}{"id": "1523_14", "text": "These findings suggest that salivary BDNF measures may represent an early marker of disease onset and DNA methylation at the BDNF promoter IV, could represent a biomarker of psychiatric symptoms in HD patients.", "tags": [{"end": 97, "start": 84, "tag": "TemporalConcept"}, {"end": 194, "start": 174, "tag": "SignOrSymptom"}, {"end": 117, "start": 102, "tag": "CellFunction"}, {"end": 41, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 209, "start": 198, "tag": "PatientOrDisabledGroup"}, {"end": 170, "start": 161, "tag": "ClinicalAttribute"}, {"end": 36, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 74, "tag": "ClinicalAttribute"}, {"end": 105, "start": 102, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 50, "start": 28, "tag": "ClinicalAttribute"}, {"end": 73, "start": 68, "tag": "TemporalConcept"}, {"end": 141, "start": 130, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 141, "start": 130, "tag": "BiologicallyActiveSubstance"}]}{"id": "1524_0", "text": "Objective: To test the feasibility of conducting a full-scale project evaluating the potential value of the phosphorylated neurofilament H (pNF-H) and several cytokines as disability markers in relapsing-remitting multiple sclerosis (RRMS).", "tags": [{"end": 34, "start": 23, "tag": "ResearchActivity"}, {"end": 69, "start": 62, "tag": "ResearchActivity"}, {"end": 232, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 238, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 182, "start": 172, "tag": "Finding"}, {"end": 138, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 183, "tag": "ClinicalAttribute"}, {"end": 145, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 140, "tag": "BiologicallyActiveSubstance"}]}{"id": "1524_1", "text": "Methods: Twenty-four patients with 5-year RRMS evolution and eleven healthy control subjects entered the study.", "tags": [{"end": 46, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 47, "tag": "TemporalConcept"}, {"end": 56, "start": 47, "tag": "BiologicFunction"}, {"end": 29, "start": 21, "tag": "PatientOrDisabledGroup"}, {"end": 110, "start": 105, "tag": "ResearchActivity"}, {"end": 41, "start": 37, "tag": "TemporalConcept"}, {"end": 92, "start": 76, "tag": "PopulationGroup"}, {"end": 75, "start": 68, "tag": "OrganismAttribute"}]}{"id": "1524_2", "text": "None of the participants had an inflammatory systemic or metabolic disease.", "tags": [{"end": 74, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 12, "tag": "PopulationGroup"}, {"end": 74, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 32, "tag": "DiseaseOrSyndrome"}]}{"id": "1524_3", "text": "Disability progression was evaluated using the Expanded Disability Status Scale.", "tags": [{"end": 79, "start": 47, "tag": "HealthCareActivity"}, {"end": 22, "start": 11, "tag": "PathologicFunction"}, {"end": 22, "start": 11, "tag": "TemporalConcept"}, {"end": 10, "start": 0, "tag": "Finding"}]}{"id": "1524_4", "text": "Serum level of pNF-H, the anti-inflammatory cytokine transforming growth factor-beta 1 (TGF-beta 1), and the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-17A (IL-17A), monocyte chemotactic protein-1 (MCP-1), and soluble intercellular cell-adhesion molecule 1 (sICAM-1) were quantified using enzyme-linked immunosorbent assay (ELISA).", "tags": [{"end": 98, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 88, "tag": "GeneOrGenome"}, {"end": 98, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 136, "tag": "GeneOrGenome"}, {"end": 195, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 209, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 209, "tag": "BiologicallyActiveSubstance"}, {"end": 228, "start": 224, "tag": "AminoAcidPeptideOrProtein"}, {"end": 228, "start": 224, "tag": "GeneOrGenome"}, {"end": 228, "start": 224, "tag": "BiologicallyActiveSubstance"}, {"end": 244, "start": 231, "tag": "AminoAcidPeptideOrProtein"}, {"end": 244, "start": 231, "tag": "BiologicallyActiveSubstance"}, {"end": 250, "start": 246, "tag": "AminoAcidPeptideOrProtein"}, {"end": 250, "start": 246, "tag": "BiologicallyActiveSubstance"}, {"end": 250, "start": 246, "tag": "GeneOrGenome"}, {"end": 268, "start": 253, "tag": "AminoAcidPeptideOrProtein"}, {"end": 268, "start": 253, "tag": "BiologicallyActiveSubstance"}, {"end": 276, "start": 270, "tag": "AminoAcidPeptideOrProtein"}, {"end": 276, "start": 270, "tag": "BiologicallyActiveSubstance"}, {"end": 309, "start": 279, "tag": "AminoAcidPeptideOrProtein"}, {"end": 309, "start": 279, "tag": "BiologicallyActiveSubstance"}, {"end": 316, "start": 311, "tag": "AminoAcidPeptideOrProtein"}, {"end": 316, "start": 311, "tag": "BiologicallyActiveSubstance"}, {"end": 316, "start": 311, "tag": "GeneOrGenome"}, {"end": 330, "start": 323, "tag": "CellComponent"}, {"end": 369, "start": 331, "tag": "AminoAcidPeptideOrProtein"}, {"end": 369, "start": 331, "tag": "BiologicallyActiveSubstance"}, {"end": 435, "start": 402, "tag": "ResearchActivity"}, {"end": 43, "start": 26, "tag": "BiologicFunction"}, {"end": 43, "start": 26, "tag": "PharmacologicSubstance"}, {"end": 206, "start": 197, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 206, "start": 197, "tag": "BiologicallyActiveSubstance"}, {"end": 206, "start": 197, "tag": "PharmacologicSubstance"}, {"end": 125, "start": 109, "tag": "PathologicFunction"}, {"end": 442, "start": 437, "tag": "ResearchActivity"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 0, "tag": "ClinicalAttribute"}, {"end": 86, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 44, "tag": "PharmacologicSubstance"}, {"end": 195, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 276, "start": 270, "tag": "GeneOrGenome"}, {"end": 378, "start": 371, "tag": "ClinicalAttribute"}, {"end": 369, "start": 323, "tag": "ClinicalAttribute"}]}{"id": "1524_5", "text": "Results: The patients had higher serum level of TGF-beta 1, IL-6, sICAM-1, and pNF-H.", "tags": [{"end": 58, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 48, "tag": "GeneOrGenome"}, {"end": 58, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 13, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 38, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 66, "tag": "ClinicalAttribute"}, {"end": 84, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 79, "tag": "BiologicallyActiveSubstance"}]}{"id": "1524_6", "text": "Based on these findings, a sample of at least 49 controls and 89 recent-onset RRMS patients is required to find an at least 1-point between-group difference in pNF-H with a power of 80% and an alpha error = 0.05.", "tags": [{"end": 33, "start": 27, "tag": "Substance"}, {"end": 33, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 65, "tag": "TemporalConcept"}, {"end": 82, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 83, "tag": "PatientOrDisabledGroup"}, {"end": 77, "start": 72, "tag": "TemporalConcept"}, {"end": 57, "start": 49, "tag": "PopulationGroup"}, {"end": 145, "start": 140, "tag": "PopulationGroup"}, {"end": 165, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 165, "start": 160, "tag": "BiologicallyActiveSubstance"}]}{"id": "1524_7", "text": "The progression of the disease was correlated with the level of pNF-H (Spearman rho = 0.624, p = 0.006), but not with the cytokines'.", "tags": [{"end": 131, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 4, "tag": "PathologicFunction"}, {"end": 15, "start": 4, "tag": "TemporalConcept"}, {"end": 30, "start": 4, "tag": "PathologicFunction"}, {"end": 30, "start": 4, "tag": "TemporalConcept"}, {"end": 69, "start": 55, "tag": "ClinicalAttribute"}, {"end": 83, "start": 71, "tag": "ResearchActivity"}]}{"id": "1524_8", "text": "Conclusions: The serum level of pNF-H, EDSS score-correlated, might stand for a potential biomarker of disability in RRMS reflecting progressive axonal damage and cumulative neurological deterioration.", "tags": [{"end": 151, "start": 145, "tag": "CellComponent"}, {"end": 200, "start": 174, "tag": "Finding"}, {"end": 144, "start": 133, "tag": "TemporalConcept"}, {"end": 121, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 80, "tag": "ClinicalAttribute"}, {"end": 121, "start": 117, "tag": "HealthCareActivity"}, {"end": 99, "start": 90, "tag": "ClinicalAttribute"}, {"end": 22, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 103, "tag": "Finding"}, {"end": 43, "start": 39, "tag": "HealthCareActivity"}, {"end": 49, "start": 39, "tag": "HealthCareActivity"}, {"end": 158, "start": 145, "tag": "CellOrMolecularDysfunction"}, {"end": 37, "start": 17, "tag": "ClinicalAttribute"}]}{"id": "1524_9", "text": "The novelty of these results warrants conducting a larger confirmatory trial.", "tags": [{"end": 76, "start": 58, "tag": "ResearchActivity"}]}{"id": "1525_0", "text": "Background: Myeloperoxidase (MPO), a neutrophil-derived pro-inflammatory protein, co-localizes with amyloid-beta (A beta) plaques in Alzheimer's disease (AD).", "tags": [{"end": 27, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 12, "tag": "Chemical"}, {"end": 27, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 29, "tag": "Chemical"}, {"end": 32, "start": 29, "tag": "GeneOrGenome"}, {"end": 32, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 122, "tag": "AnatomicalAbnormality"}, {"end": 112, "start": 100, "tag": "AnatomicalAbnormality"}, {"end": 72, "start": 56, "tag": "PathologicFunction"}, {"end": 152, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 37, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1525_1", "text": "Anti-dementia treatment may facilitate efflux of A beta and associated plaque proteins from the brain to the peripheral circulation, therefore providing potential biomarkers for the monitoring of donor response to drug treatment.", "tags": [{"end": 131, "start": 109, "tag": "BiologicFunction"}, {"end": 201, "start": 196, "tag": "PopulationGroup"}, {"end": 45, "start": 39, "tag": "CellFunction"}, {"end": 228, "start": 214, "tag": "HealthCareActivity"}, {"end": 228, "start": 214, "tag": "ResearchActivity"}, {"end": 77, "start": 71, "tag": "AnatomicalAbnormality"}, {"end": 192, "start": 182, "tag": "HealthCareActivity"}, {"end": 218, "start": 214, "tag": "PharmacologicSubstance"}, {"end": 101, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 0, "tag": "HealthCareActivity"}, {"end": 228, "start": 219, "tag": "HealthCareActivity"}, {"end": 228, "start": 219, "tag": "ResearchActivity"}, {"end": 13, "start": 5, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 153, "tag": "ClinicalAttribute"}, {"end": 210, "start": 202, "tag": "OrganismAttribute"}, {"end": 55, "start": 49, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1525_2", "text": "Objective: We investigated the diagnostic utility of MPO as a biomarker of AD, and how anti-dementia treatment alters plasma MPO concentration.", "tags": [{"end": 56, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 53, "tag": "Chemical"}, {"end": 56, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 125, "tag": "Chemical"}, {"end": 128, "start": 125, "tag": "GeneOrGenome"}, {"end": 128, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 62, "tag": "ClinicalAttribute"}, {"end": 110, "start": 87, "tag": "HealthCareActivity"}, {"end": 100, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 14, "tag": "ResearchActivity"}, {"end": 49, "start": 31, "tag": "Finding"}, {"end": 142, "start": 118, "tag": "ClinicalAttribute"}, {"end": 56, "start": 53, "tag": "GeneOrGenome"}]}{"id": "1525_3", "text": "Methods: Thirty-two AD patients were recruited, and plasma collected pre-drug administration (baseline), and 1- and 6-months post-treatment.", "tags": [{"end": 92, "start": 73, "tag": "ResearchActivity"}, {"end": 92, "start": 73, "tag": "HealthCareActivity"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 77, "start": 73, "tag": "PharmacologicSubstance"}, {"end": 139, "start": 130, "tag": "HealthCareActivity"}, {"end": 139, "start": 130, "tag": "ResearchActivity"}, {"end": 58, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 118, "tag": "TemporalConcept"}, {"end": 129, "start": 125, "tag": "TemporalConcept"}]}{"id": "1525_4", "text": "All patients received cholinesterase inhibitors (ChEIs).", "tags": [{"end": 47, "start": 22, "tag": "Chemical"}, {"end": 47, "start": 22, "tag": "PharmacologicSubstance"}, {"end": 54, "start": 49, "tag": "Chemical"}, {"end": 54, "start": 49, "tag": "PharmacologicSubstance"}, {"end": 12, "start": 4, "tag": "PatientOrDisabledGroup"}]}{"id": "1525_5", "text": "At baseline and 6 months, patients underwent neuropsychological assessment.", "tags": [{"end": 74, "start": 45, "tag": "HealthCareActivity"}, {"end": 34, "start": 26, "tag": "PatientOrDisabledGroup"}, {"end": 24, "start": 18, "tag": "TemporalConcept"}]}{"id": "1525_6", "text": "Forty-nine elderly healthy individuals with normal cognitive status served as controls.", "tags": [{"end": 67, "start": 44, "tag": "Finding"}, {"end": 38, "start": 19, "tag": "PopulationGroup"}, {"end": 86, "start": 78, "tag": "PopulationGroup"}, {"end": 18, "start": 11, "tag": "PopulationGroup"}]}{"id": "1525_7", "text": "Plasma MPO concentration was measured by ELISA.", "tags": [{"end": 10, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 7, "tag": "Chemical"}, {"end": 10, "start": 7, "tag": "GeneOrGenome"}, {"end": 10, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 41, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1525_8", "text": "Results: AD drug naive patients had similar plasma MPO concentration to their control counterparts (p > 0.05).", "tags": [{"end": 11, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 16, "start": 12, "tag": "PharmacologicSubstance"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 78, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 68, "start": 44, "tag": "ClinicalAttribute"}]}{"id": "1525_9", "text": "Baseline MPO levels positively correlated with Neuropsychiatric Inventory score (r = 0.5080; p = 0.011) and carer distress (r = 0.5022; p = 0.012).", "tags": [{"end": 12, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 9, "tag": "Chemical"}, {"end": 12, "start": 9, "tag": "GeneOrGenome"}, {"end": 12, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 114, "tag": "BiologicFunction"}, {"end": 79, "start": 74, "tag": "Finding"}, {"end": 79, "start": 47, "tag": "HealthCareActivity"}, {"end": 113, "start": 108, "tag": "PopulationGroup"}]}{"id": "1525_10", "text": "Following 1-month ChEI treatment, 84.4% of AD patients exhibited increased plasma MPO levels (p < 0.001), which decreased at 6 months (p < 0.001).", "tags": [{"end": 85, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 82, "tag": "Chemical"}, {"end": 85, "start": 82, "tag": "GeneOrGenome"}, {"end": 85, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 46, "tag": "PatientOrDisabledGroup"}, {"end": 32, "start": 23, "tag": "HealthCareActivity"}, {"end": 32, "start": 23, "tag": "ResearchActivity"}, {"end": 81, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 12, "tag": "TemporalConcept"}, {"end": 133, "start": 127, "tag": "TemporalConcept"}, {"end": 22, "start": 18, "tag": "PharmacologicSubstance"}, {"end": 22, "start": 18, "tag": "Chemical"}, {"end": 92, "start": 75, "tag": "ClinicalAttribute"}]}{"id": "1525_11", "text": "MPO concentration at 1 month was greatest in AD patients whose memory deteriorated during the study period (p = 0.028), and for AD patients with deterioration in Cornell assessment score (p = 0.044).", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "Chemical"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 70, "tag": "Finding"}, {"end": 158, "start": 145, "tag": "Finding"}, {"end": 47, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 48, "tag": "PatientOrDisabledGroup"}, {"end": 139, "start": 131, "tag": "PatientOrDisabledGroup"}, {"end": 186, "start": 181, "tag": "Finding"}, {"end": 106, "start": 100, "tag": "TemporalConcept"}, {"end": 99, "start": 94, "tag": "ResearchActivity"}, {"end": 186, "start": 162, "tag": "HealthCareActivity"}, {"end": 180, "start": 170, "tag": "ResearchActivity"}, {"end": 28, "start": 23, "tag": "TemporalConcept"}, {"end": 69, "start": 63, "tag": "BiologicFunction"}, {"end": 17, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1525_12", "text": "Conclusion: Whereas baseline MPO levels did not differentiate between healthy and AD populations, baseline MPO positively correlated with initial Neuropsychiatric Inventory evaluation.", "tags": [{"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 29, "tag": "Chemical"}, {"end": 32, "start": 29, "tag": "GeneOrGenome"}, {"end": 32, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 107, "tag": "Chemical"}, {"end": 110, "start": 107, "tag": "GeneOrGenome"}, {"end": 110, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 48, "tag": "CellFunction"}, {"end": 96, "start": 85, "tag": "PopulationGroup"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 70, "tag": "OrganismAttribute"}, {"end": 145, "start": 138, "tag": "TemporalConcept"}, {"end": 39, "start": 29, "tag": "ClinicalAttribute"}, {"end": 183, "start": 146, "tag": "HealthCareActivity"}]}{"id": "1525_13", "text": "Post-treatment, transient MPO upregulation in ChEI-treated patients may reflect worse therapeutic outcome.", "tags": [{"end": 29, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 26, "tag": "Chemical"}, {"end": 29, "start": 26, "tag": "GeneOrGenome"}, {"end": 29, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 16, "tag": "TemporalConcept"}, {"end": 42, "start": 30, "tag": "CellFunction"}, {"end": 105, "start": 80, "tag": "Finding"}, {"end": 67, "start": 59, "tag": "PatientOrDisabledGroup"}, {"end": 14, "start": 5, "tag": "HealthCareActivity"}, {"end": 14, "start": 5, "tag": "ResearchActivity"}, {"end": 14, "start": 0, "tag": "TemporalConcept"}, {"end": 50, "start": 46, "tag": "PharmacologicSubstance"}, {"end": 50, "start": 46, "tag": "Chemical"}]}{"id": "1525_14", "text": "Further studies are required to assess the potential of plasma MPO as an AD therapeutic biomarker.", "tags": [{"end": 66, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 63, "tag": "Chemical"}, {"end": 66, "start": 63, "tag": "GeneOrGenome"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 73, "tag": "HealthCareActivity"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 88, "tag": "ClinicalAttribute"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 62, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 56, "tag": "ClinicalAttribute"}]}{"id": "1526_0", "text": "Background Plasma biomarkers showed a promising value in the disease diagnosis and management of Alzheimer's disease (AD).", "tags": [{"end": 93, "start": 83, "tag": "HealthCareActivity"}, {"end": 17, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 61, "tag": "HealthCareActivity"}, {"end": 116, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 18, "tag": "ClinicalAttribute"}]}{"id": "1526_1", "text": "However, profiles of the biomarkers and the associations with cognition across a spectrum of cognitive stages have seldom been reported.", "tags": [{"end": 89, "start": 81, "tag": "ResearchActivity"}, {"end": 109, "start": 103, "tag": "TemporalConcept"}, {"end": 35, "start": 25, "tag": "ClinicalAttribute"}, {"end": 71, "start": 62, "tag": "BiologicFunction"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}]}{"id": "1526_2", "text": "Methods We recruited 320 individuals with cognitive impairment and 131 cognitively normal participants from a memory clinic and a community cohort.", "tags": [{"end": 139, "start": 130, "tag": "HealthCareRelatedOrganization"}, {"end": 102, "start": 90, "tag": "PopulationGroup"}, {"end": 36, "start": 25, "tag": "PopulationGroup"}, {"end": 62, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 71, "tag": "Finding"}, {"end": 146, "start": 140, "tag": "PopulationGroup"}, {"end": 116, "start": 110, "tag": "BiologicFunction"}]}{"id": "1526_3", "text": "Participants were classified into 6 groups based on their Clinical Dementia Rating (CDR) scores and clinical diagnosis, including AD, amnestic mild cognitive impairment (aMCI), and normal cognition (NC).", "tags": [{"end": 197, "start": 181, "tag": "Finding"}, {"end": 95, "start": 89, "tag": "Finding"}, {"end": 174, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 36, "tag": "PopulationGroup"}, {"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 82, "start": 58, "tag": "HealthCareActivity"}, {"end": 168, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 84, "tag": "HealthCareActivity"}, {"end": 118, "start": 100, "tag": "HealthCareActivity"}]}{"id": "1526_4", "text": "A battery of neuropsychological tests was used to assess the global and domain-specific cognition.", "tags": [{"end": 9, "start": 2, "tag": "ManufacturedObject"}, {"end": 37, "start": 13, "tag": "HealthCareActivity"}, {"end": 97, "start": 88, "tag": "BiologicFunction"}]}{"id": "1526_5", "text": "Plasma A beta(1-40), A beta(1-42), A beta(1-42)/A beta(1-40), total tau (t-tau), neurofilament protein light chain (NfL), and phosphorylated tau at threonine 181 (p-tau181) were quantified using the single-molecule array (Simoa) platform.", "tags": [{"end": 114, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 237, "start": 229, "tag": "ResearchActivity"}, {"end": 220, "start": 199, "tag": "ResearchActivity"}, {"end": 140, "start": 126, "tag": "CellFunction"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 0, "tag": "ClinicalAttribute"}, {"end": 33, "start": 21, "tag": "ClinicalAttribute"}, {"end": 6, "start": 0, "tag": "ClinicalAttribute"}, {"end": 60, "start": 35, "tag": "ClinicalAttribute"}, {"end": 6, "start": 0, "tag": "ClinicalAttribute"}, {"end": 161, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 228, "start": 222, "tag": "ResearchActivity"}]}{"id": "1526_6", "text": "Results All the plasma markers (A beta(1-40), A beta(1-42), A beta(1-42)/A beta(1-40), t-tau, NfL, p-tau181) showed certain discrepancies among NC, aMCI, and AD groups.", "tags": [{"end": 137, "start": 124, "tag": "Finding"}, {"end": 97, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 167, "start": 161, "tag": "PopulationGroup"}, {"end": 44, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 144, "tag": "PopulationGroup"}, {"end": 30, "start": 23, "tag": "ClinicalAttribute"}, {"end": 44, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 60, "tag": "ClinicalAttribute"}, {"end": 58, "start": 46, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1526_7", "text": "The p-tau181 level showed a continuous escalating trend as the CDR scores increased from 0 (NC group) to 3 (severe AD).", "tags": [{"end": 73, "start": 67, "tag": "Finding"}, {"end": 38, "start": 28, "tag": "TemporalConcept"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 95, "tag": "PopulationGroup"}, {"end": 66, "start": 63, "tag": "HealthCareActivity"}, {"end": 114, "start": 108, "tag": "Finding"}, {"end": 94, "start": 92, "tag": "PopulationGroup"}]}{"id": "1526_8", "text": "Compared with other biomarkers, p-tau181 had correlations with broader cognitive domains, covering global cognition (r = -0.536, P < 0.0001), memory (r = -0.481, P < 0.0001), attention (r = -0.437, P < 0.0001), visuospatial function (r = -0.385, P < 0.0001), and language (r = -0.177, P = 0.0003).", "tags": [{"end": 271, "start": 263, "tag": "BiologicFunction"}, {"end": 184, "start": 175, "tag": "BiologicFunction"}, {"end": 30, "start": 20, "tag": "ClinicalAttribute"}, {"end": 40, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 106, "tag": "BiologicFunction"}, {"end": 148, "start": 142, "tag": "BiologicFunction"}, {"end": 57, "start": 45, "tag": "ResearchActivity"}, {"end": 232, "start": 211, "tag": "BiologicFunction"}, {"end": 88, "start": 71, "tag": "Finding"}]}{"id": "1526_9", "text": "Among participants with CDR >= 1, higher p-tau181 was correlated with worse global cognition (r = -0.301, P < 0.001).", "tags": [{"end": 75, "start": 70, "tag": "Finding"}, {"end": 18, "start": 6, "tag": "PopulationGroup"}, {"end": 49, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 83, "tag": "BiologicFunction"}, {"end": 27, "start": 24, "tag": "HealthCareActivity"}]}{"id": "1526_10", "text": "Conclusions Plasma p-tau181 had correlations with broader cognitive domains, suggesting its potential as a promising clinical-relevant blood-based biomarker.", "tags": [{"end": 18, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 147, "tag": "ClinicalAttribute"}, {"end": 27, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 12, "tag": "ClinicalAttribute"}, {"end": 75, "start": 58, "tag": "Finding"}]}{"id": "1527_0", "text": "Background: Cerebrospinal Fluid (CSF) biomarkers are associated with conversion from mild cognitive impairment to Alzheimer's Disease (AD), but their predictive value for later end-points has been less evaluated with inconsistent results.", "tags": [{"end": 31, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 150, "tag": "Finding"}, {"end": 176, "start": 171, "tag": "TemporalConcept"}, {"end": 36, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 38, "tag": "ClinicalAttribute"}, {"end": 110, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 85, "tag": "Finding"}, {"end": 79, "start": 69, "tag": "Finding"}]}{"id": "1527_1", "text": "Objective: We investigated potential relationships between CSF amyloid-beta(1-42) (A beta(42)), Phosphorylated tau (P-tau), and Total tau (T-tau) with time to Nursing Home Placement (NHP) and life expectancy after diagnosis.", "tags": [{"end": 110, "start": 96, "tag": "CellFunction"}, {"end": 186, "start": 183, "tag": "HealthCareActivity"}, {"end": 196, "start": 192, "tag": "TemporalConcept"}, {"end": 144, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 207, "start": 192, "tag": "TemporalConcept"}, {"end": 81, "start": 59, "tag": "ClinicalAttribute"}, {"end": 121, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 37, "tag": "Finding"}, {"end": 70, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 223, "start": 214, "tag": "HealthCareActivity"}, {"end": 75, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 151, "tag": "TemporalConcept"}, {"end": 26, "start": 14, "tag": "HealthCareActivity"}, {"end": 93, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 159, "tag": "HealthCareActivity"}, {"end": 93, "start": 83, "tag": "BiologicallyActiveSubstance"}]}{"id": "1527_2", "text": "Methods: This prospective observational study included 129 outpatients clinically diagnosed with mild-to-moderate AD who underwent a lumbar puncture.", "tags": [{"end": 70, "start": 59, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 14, "tag": "BiologicFunction"}, {"end": 45, "start": 26, "tag": "ResearchActivity"}, {"end": 113, "start": 105, "tag": "Finding"}, {"end": 148, "start": 133, "tag": "HealthCareActivity"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 82, "tag": "HealthCareActivity"}, {"end": 101, "start": 97, "tag": "Finding"}]}{"id": "1527_3", "text": "The CSF biomarkers were analysed with xMAP technology.", "tags": [{"end": 7, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 8, "tag": "ClinicalAttribute"}, {"end": 53, "start": 38, "tag": "ResearchActivity"}]}{"id": "1527_4", "text": "Dates of institutionalisation and death were recorded.", "tags": [{"end": 5, "start": 0, "tag": "TemporalConcept"}, {"end": 39, "start": 34, "tag": "BiologicFunction"}, {"end": 39, "start": 34, "tag": "PathologicFunction"}, {"end": 39, "start": 34, "tag": "CellFunction"}, {"end": 29, "start": 9, "tag": "HealthCareActivity"}]}{"id": "1527_5", "text": "Results: After 20 years of follow-up, 123 patients (95%) were deceased.", "tags": [{"end": 70, "start": 62, "tag": "BiologicFunction"}, {"end": 50, "start": 42, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 36, "start": 27, "tag": "HealthCareActivity"}, {"end": 36, "start": 27, "tag": "TemporalConcept"}, {"end": 23, "start": 18, "tag": "TemporalConcept"}]}{"id": "1527_6", "text": "The participants with abnormal P-tau and T-tau (A+ T+ (N)+) died earlier than those with normal P-tau/abnormal T-tau (A+ T-(N)+) (mean, 80.5 vs.", "tags": [{"end": 46, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 89, "tag": "Finding"}, {"end": 30, "start": 22, "tag": "Finding"}, {"end": 110, "start": 102, "tag": "Finding"}, {"end": 72, "start": 65, "tag": "TemporalConcept"}, {"end": 36, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 4, "tag": "PopulationGroup"}]}{"id": "1527_7", "text": "85.4 years).", "tags": [{"end": 10, "start": 5, "tag": "TemporalConcept"}]}{"id": "1527_8", "text": "Linear associations were demonstrated between lower A beta(42) and shorter time to NHP (p = 0.017), and higher P-tau and younger age at death (p = 0.016).", "tags": [{"end": 51, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 83, "tag": "Eukaryote"}, {"end": 141, "start": 136, "tag": "BiologicFunction"}, {"end": 141, "start": 136, "tag": "PathologicFunction"}, {"end": 141, "start": 136, "tag": "CellFunction"}, {"end": 116, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 75, "tag": "TemporalConcept"}, {"end": 132, "start": 129, "tag": "OrganismAttribute"}, {"end": 62, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 121, "tag": "TemporalConcept"}, {"end": 62, "start": 52, "tag": "BiologicallyActiveSubstance"}]}{"id": "1527_9", "text": "No correlations were detected between survival after AD diagnosis and CSF biomarkers.", "tags": [{"end": 73, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 56, "tag": "HealthCareActivity"}, {"end": 84, "start": 74, "tag": "ClinicalAttribute"}, {"end": 46, "start": 38, "tag": "CellFunction"}, {"end": 15, "start": 3, "tag": "ResearchActivity"}]}{"id": "1527_10", "text": "In sex and-age-adjusted Cox regression models, higher P-tau and T-tau were independent predictors of shorter lifespan after diagnosis.", "tags": [{"end": 117, "start": 109, "tag": "TemporalConcept"}, {"end": 69, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 3, "tag": "OrganismAttribute"}, {"end": 45, "start": 24, "tag": "ResearchActivity"}, {"end": 97, "start": 87, "tag": "Finding"}, {"end": 45, "start": 28, "tag": "ResearchActivity"}, {"end": 59, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 124, "tag": "HealthCareActivity"}, {"end": 14, "start": 11, "tag": "OrganismAttribute"}]}{"id": "1527_11", "text": "In multivariate Cox models, older age and lower baseline cognitive status, but not elevated tau, significantly precipitated both institutionalisation and death.", "tags": [{"end": 73, "start": 57, "tag": "BiologicFunction"}, {"end": 33, "start": 28, "tag": "TemporalConcept"}, {"end": 159, "start": 154, "tag": "BiologicFunction"}, {"end": 159, "start": 154, "tag": "PathologicFunction"}, {"end": 159, "start": 154, "tag": "CellFunction"}, {"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 48, "tag": "Finding"}, {"end": 37, "start": 34, "tag": "OrganismAttribute"}, {"end": 25, "start": 3, "tag": "ResearchActivity"}, {"end": 73, "start": 67, "tag": "Finding"}, {"end": 149, "start": 129, "tag": "HealthCareActivity"}]}{"id": "1527_12", "text": "Conclusion: These findings suggest that CSF biomarker levels plateau in the dementia phase of AD, which may limit their possible relationships with clinical end-points, such as NHP and survival time.", "tags": [{"end": 198, "start": 185, "tag": "ClinicalAttribute"}, {"end": 198, "start": 185, "tag": "TemporalConcept"}, {"end": 180, "start": 177, "tag": "HealthCareActivity"}, {"end": 43, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 44, "tag": "ClinicalAttribute"}, {"end": 142, "start": 129, "tag": "Finding"}, {"end": 84, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 85, "tag": "TemporalConcept"}, {"end": 167, "start": 148, "tag": "ClinicalAttribute"}]}{"id": "1527_13", "text": "However, the biomarkers reflect the central pathophysiologies of AD.", "tags": [{"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 13, "tag": "ClinicalAttribute"}, {"end": 61, "start": 44, "tag": "PathologicFunction"}]}{"id": "1527_14", "text": "In particular, pathologic tau is associated with more advanced disease, younger age at onset, and earlier death.", "tags": [{"end": 25, "start": 15, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 29, "start": 15, "tag": "CellOrMolecularDysfunction"}, {"end": 111, "start": 106, "tag": "BiologicFunction"}, {"end": 111, "start": 106, "tag": "PathologicFunction"}, {"end": 111, "start": 106, "tag": "CellFunction"}, {"end": 105, "start": 98, "tag": "TemporalConcept"}, {"end": 29, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 80, "tag": "OrganismAttribute"}, {"end": 92, "start": 87, "tag": "TemporalConcept"}, {"end": 79, "start": 72, "tag": "TemporalConcept"}]}{"id": "1528_0", "text": "Background: Because dementia is an emerging problem in the world, biochemical markers of cerebrospinal fluid (CSF) and radio-isotopic analyses are helpful for diagnosing Alzheimer's disease (AD).", "tags": [{"end": 51, "start": 44, "tag": "Finding"}, {"end": 169, "start": 159, "tag": "HealthCareActivity"}, {"end": 189, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 59, "tag": "PopulationGroup"}, {"end": 28, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 119, "tag": "ResearchActivity"}, {"end": 85, "start": 66, "tag": "ClinicalAttribute"}]}{"id": "1528_1", "text": "Although blood sample is more feasible and plausible than CSF or radiological biomarkers for screening potential AD, measurements of serum amyloid-beta(A beta), plasma tau, and serum antibodies for A beta(1-42 )are not yet well established.", "tags": [{"end": 21, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 177, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 171, "start": 168, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 171, "start": 168, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 93, "tag": "HealthCareActivity"}, {"end": 102, "start": 93, "tag": "ResearchActivity"}, {"end": 146, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 65, "tag": "ClinicalAttribute"}, {"end": 167, "start": 161, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 117, "tag": "HealthCareActivity"}, {"end": 158, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 204, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 133, "tag": "ClinicalAttribute"}, {"end": 171, "start": 161, "tag": "ClinicalAttribute"}, {"end": 211, "start": 177, "tag": "ClinicalAttribute"}]}{"id": "1528_2", "text": "Objective: We aimed to identify a new serum biomarker to detect mild cognitive impairment (MCI) and AD in comparison to cognitively healthy control by a new peptidome technology.", "tags": [{"end": 116, "start": 106, "tag": "ResearchActivity"}, {"end": 43, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 44, "tag": "ClinicalAttribute"}, {"end": 139, "start": 132, "tag": "OrganismAttribute"}, {"end": 89, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 140, "tag": "PopulationGroup"}, {"end": 89, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 120, "tag": "OrganismAttribute"}, {"end": 68, "start": 64, "tag": "Finding"}, {"end": 177, "start": 157, "tag": "ResearchActivity"}]}{"id": "1528_3", "text": "Methods: With only 1.5 mu l of serum, we examined a new target plate BLOTCHIP (R) plus a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS) to discriminate control (n = 100), MCI (n = 60), and AD (n = 99).", "tags": [{"end": 165, "start": 89, "tag": "ResearchActivity"}, {"end": 179, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 148, "tag": "ResearchActivity"}, {"end": 36, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 236, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 216, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 63, "tag": "ManufacturedObject"}, {"end": 137, "start": 133, "tag": "TemporalConcept"}, {"end": 204, "start": 197, "tag": "PopulationGroup"}, {"end": 179, "start": 167, "tag": "ResearchActivity"}, {"end": 77, "start": 69, "tag": "ResearchActivity"}]}{"id": "1528_4", "text": "In some subjects, cognitive Mini-Mental State Examination (MMSE) were compared to positron emission tomography (PET) with Pittsburgh compound B (PiB) and the serum probability of dementia (SPD).", "tags": [{"end": 143, "start": 122, "tag": "Chemical"}, {"end": 148, "start": 145, "tag": "Chemical"}, {"end": 63, "start": 59, "tag": "HealthCareActivity"}, {"end": 163, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 28, "tag": "HealthCareActivity"}, {"end": 187, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 112, "tag": "HealthCareActivity"}, {"end": 16, "start": 8, "tag": "PopulationGroup"}, {"end": 110, "start": 82, "tag": "HealthCareActivity"}]}{"id": "1528_5", "text": "The mother proteins of candidate serum peptides were examined in autopsied AD brains.", "tags": [{"end": 10, "start": 4, "tag": "PopulationGroup"}, {"end": 47, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1528_6", "text": "Results: Apart from A beta or tau, the present study discovered a new diagnostic 4-peptides-set biomarker for discriminating control, MCI, and AD with 87% of sensitivity and 65% of specificity between control and AD (***p < 0.001).", "tags": [{"end": 91, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 96, "tag": "ClinicalAttribute"}, {"end": 52, "start": 47, "tag": "ResearchActivity"}, {"end": 137, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 158, "tag": "Finding"}, {"end": 192, "start": 181, "tag": "Finding"}, {"end": 132, "start": 125, "tag": "PopulationGroup"}, {"end": 208, "start": 201, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 26, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 70, "tag": "HealthCareActivity"}]}{"id": "1528_7", "text": "MMSE score was well correlated to brain A beta deposition and to SPD of AD.", "tags": [{"end": 4, "start": 0, "tag": "HealthCareActivity"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "Finding"}, {"end": 39, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 40, "tag": "PathologicFunction"}]}{"id": "1528_8", "text": "The mother proteins of the four peptides were upregulated for coagulation, complement, and plasticity (three proteins), and was downregulated for anti-inflammation (one protein) in AD brains.", "tags": [{"end": 10, "start": 4, "tag": "PopulationGroup"}, {"end": 73, "start": 62, "tag": "BiologicFunction"}, {"end": 85, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 91, "tag": "NaturalPhenomenonOrProcess"}, {"end": 101, "start": 91, "tag": "CellFunction"}, {"end": 163, "start": 146, "tag": "PharmacologicSubstance"}, {"end": 141, "start": 128, "tag": "CellFunction"}, {"end": 40, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 151, "tag": "PathologicFunction"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 184, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1528_9", "text": "Conclusion: The present serum biomarker set provides a new, rapid, non-invasive, highly quantitative and low-cost clinical application for dementia screening, and also suggests an alternative pathomechanism of AD for neuroinflammation and neurovascular unit damage.", "tags": [{"end": 134, "start": 114, "tag": "HealthCareActivity"}, {"end": 257, "start": 239, "tag": "Cell"}, {"end": 79, "start": 67, "tag": "ClinicalAttribute"}, {"end": 79, "start": 71, "tag": "Finding"}, {"end": 206, "start": 192, "tag": "PathologicFunction"}, {"end": 29, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 105, "tag": "Finding"}, {"end": 212, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 30, "tag": "ClinicalAttribute"}, {"end": 234, "start": 217, "tag": "PathologicFunction"}, {"end": 157, "start": 148, "tag": "HealthCareActivity"}, {"end": 157, "start": 148, "tag": "ResearchActivity"}, {"end": 147, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 264, "start": 258, "tag": "InjuryOrPoisoning"}]}{"id": "1529_0", "text": "Background: Progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia can be predicted by clinical features and a combination of biomarkers may increase the predictive power.", "tags": [{"end": 133, "start": 116, "tag": "ClinicalAttribute"}, {"end": 23, "start": 12, "tag": "PathologicFunction"}, {"end": 81, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 155, "tag": "ClinicalAttribute"}, {"end": 57, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 27, "tag": "Finding"}, {"end": 199, "start": 183, "tag": "Finding"}]}{"id": "1529_1", "text": "In the present study, we investigated whether the combination of olfactory function and plasma neuronal-derived exosome (NDE) A beta(1-42) can best predict progression to AD dementia.", "tags": [{"end": 119, "start": 112, "tag": "CellComponent"}, {"end": 173, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 95, "tag": "Cell"}, {"end": 182, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 94, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 156, "tag": "PathologicFunction"}, {"end": 167, "start": 156, "tag": "TemporalConcept"}, {"end": 37, "start": 25, "tag": "ResearchActivity"}, {"end": 138, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 65, "tag": "BiologicFunction"}, {"end": 138, "start": 126, "tag": "ClinicalAttribute"}, {"end": 119, "start": 88, "tag": "ClinicalAttribute"}, {"end": 124, "start": 121, "tag": "CellComponent"}]}{"id": "1529_2", "text": "Methods: 87 MCI patients were enrolled and received the cognitive assessment at 2-year and 3-year follow-up to reevaluate cognition.", "tags": [{"end": 86, "start": 82, "tag": "TemporalConcept"}, {"end": 97, "start": 93, "tag": "TemporalConcept"}, {"end": 24, "start": 16, "tag": "PatientOrDisabledGroup"}, {"end": 15, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 66, "tag": "HealthCareActivity"}, {"end": 76, "start": 66, "tag": "ResearchActivity"}, {"end": 76, "start": 56, "tag": "HealthCareActivity"}, {"end": 107, "start": 98, "tag": "HealthCareActivity"}, {"end": 107, "start": 98, "tag": "TemporalConcept"}, {"end": 131, "start": 122, "tag": "BiologicFunction"}]}{"id": "1529_3", "text": "In the meanwhile, 80 healthy controls and 88 AD dementia patients were enrolled at baseline as well to evaluate the diagnose value in cross-section.", "tags": [{"end": 124, "start": 116, "tag": "HealthCareActivity"}, {"end": 47, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 57, "tag": "PatientOrDisabledGroup"}, {"end": 28, "start": 21, "tag": "OrganismAttribute"}, {"end": 37, "start": 21, "tag": "PopulationGroup"}, {"end": 56, "start": 48, "tag": "DiseaseOrSyndrome"}]}{"id": "1529_4", "text": "Olfactory function was evaluated with the sniffin sticks (SS-16) and A beta(1-42) levels in NDEs were determined by ELISA.", "tags": [{"end": 121, "start": 116, "tag": "ResearchActivity"}, {"end": 81, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 0, "tag": "BiologicFunction"}, {"end": 56, "start": 42, "tag": "ManufacturedObject"}, {"end": 56, "start": 42, "tag": "HealthCareActivity"}, {"end": 96, "start": 69, "tag": "ClinicalAttribute"}]}{"id": "1529_5", "text": "Logistic regression was performed to evaluate the risk factors for cognitive decline in MCI at 2-year and 3-year revisits.", "tags": [{"end": 19, "start": 0, "tag": "ResearchActivity"}, {"end": 101, "start": 97, "tag": "TemporalConcept"}, {"end": 112, "start": 108, "tag": "TemporalConcept"}, {"end": 91, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 50, "tag": "Finding"}]}{"id": "1529_6", "text": "Results: In the cross cohort, lower SS-16 scores and higher A beta(1-42) levels in NDEs were found in MCI and AD dementia compared to healthy controls.", "tags": [{"end": 48, "start": 42, "tag": "Finding"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 134, "tag": "OrganismAttribute"}, {"end": 150, "start": 134, "tag": "PopulationGroup"}, {"end": 121, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 72, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 22, "tag": "PopulationGroup"}, {"end": 87, "start": 60, "tag": "ClinicalAttribute"}, {"end": 72, "start": 60, "tag": "BiologicallyActiveSubstance"}]}{"id": "1529_7", "text": "For the longitudinal set, 8 MCI individuals developed AD dementia within 2 years, and 16 MCI individuals developed AD dementia within 3 years.", "tags": [{"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 32, "tag": "PopulationGroup"}, {"end": 104, "start": 93, "tag": "PopulationGroup"}, {"end": 65, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 75, "tag": "TemporalConcept"}, {"end": 141, "start": 136, "tag": "TemporalConcept"}, {"end": 20, "start": 8, "tag": "ResearchActivity"}]}{"id": "1529_8", "text": "The two parameter-combination of SS-16 scores and A beta(1-42) level in NDEs showed better prediction in the conversion of MCI to AD dementia at 2-year and 3-year revisit.", "tags": [{"end": 151, "start": 147, "tag": "TemporalConcept"}, {"end": 162, "start": 158, "tag": "TemporalConcept"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 91, "tag": "Finding"}, {"end": 56, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 109, "tag": "Finding"}, {"end": 45, "start": 33, "tag": "HealthCareActivity"}, {"end": 76, "start": 50, "tag": "ClinicalAttribute"}]}{"id": "1529_9", "text": "Moreover, after a 3-year follow-up, SS-16 scores also significantly predicted the conversion to AD dementia, where lower scores were associated with a 10-fold increased risk of developing AD dementia (p = 0.006).", "tags": [{"end": 24, "start": 20, "tag": "TemporalConcept"}, {"end": 127, "start": 121, "tag": "Finding"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 199, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 25, "tag": "HealthCareActivity"}, {"end": 34, "start": 25, "tag": "TemporalConcept"}, {"end": 173, "start": 159, "tag": "Finding"}, {"end": 92, "start": 82, "tag": "Finding"}, {"end": 48, "start": 36, "tag": "HealthCareActivity"}]}{"id": "1529_10", "text": "Similarly, higher A beta(1-42) levels in NDEs in patients with MCI increased the risk of developing AD dementia by 8.5-fold (p = 0.002).", "tags": [{"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 49, "tag": "PatientOrDisabledGroup"}, {"end": 111, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 18, "tag": "ClinicalAttribute"}]}{"id": "1529_11", "text": "Conclusion: A combination of two biomarkers of NDEs (A beta(1-42)) and SS-16 predicted the conversion of MCI to AD dementia more accurately in combination.", "tags": [{"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 33, "tag": "ClinicalAttribute"}, {"end": 108, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 91, "tag": "Finding"}, {"end": 76, "start": 71, "tag": "HealthCareActivity"}]}{"id": "1529_12", "text": "These findings have critical implications for understanding the pathophysiology of AD dementia and for developing preventative treatments for cognitive decline.", "tags": [{"end": 137, "start": 114, "tag": "HealthCareActivity"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 64, "tag": "PathologicFunction"}, {"end": 79, "start": 64, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 159, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 46, "tag": "BiologicFunction"}, {"end": 41, "start": 20, "tag": "Finding"}]}{"id": "1530_0", "text": "Objective: To investigate variation in the characteristics of regional cerebral blood flow (rCBF), brain activity, and intrinsic functional connectivity (FC) across the Alzheimer's disease spectrum (ADS).", "tags": [{"end": 58, "start": 43, "tag": "OrganismAttribute"}, {"end": 113, "start": 99, "tag": "BiologicFunction"}, {"end": 156, "start": 154, "tag": "BiologicFunction"}, {"end": 197, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 199, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 62, "tag": "BiologicFunction"}, {"end": 96, "start": 92, "tag": "BiologicFunction"}, {"end": 152, "start": 129, "tag": "BiologicFunction"}]}{"id": "1530_1", "text": "Methods: The study recruited 20 individuals in each of the following categories: Alzheimer's disease (AD), mild cognitive impairment (MCI), subjective cognitive decline (SCD), and healthy control (HC).", "tags": [{"end": 100, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 13, "tag": "ResearchActivity"}, {"end": 43, "start": 32, "tag": "PopulationGroup"}, {"end": 168, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 180, "tag": "OrganismAttribute"}, {"end": 173, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 188, "tag": "PopulationGroup"}, {"end": 199, "start": 197, "tag": "PopulationGroup"}]}{"id": "1530_2", "text": "All participants completed the 3.0T resting-state functional MRI (rs-fMRI) and arterial spin labeling scans in addition to neuropsychological tests.", "tags": [{"end": 147, "start": 123, "tag": "HealthCareActivity"}, {"end": 16, "start": 4, "tag": "PopulationGroup"}, {"end": 64, "start": 31, "tag": "HealthCareActivity"}, {"end": 147, "start": 142, "tag": "ResearchActivity"}, {"end": 147, "start": 142, "tag": "HealthCareActivity"}, {"end": 73, "start": 66, "tag": "HealthCareActivity"}, {"end": 107, "start": 79, "tag": "HealthCareActivity"}]}{"id": "1530_3", "text": "Additionally, the normalized CBF, regional homogeneity (ReHo), and amplitude of low-frequency fluctuation (ALFF) of individual subjects were compared in the ADS.", "tags": [{"end": 32, "start": 29, "tag": "BiologicFunction"}, {"end": 160, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 127, "tag": "PopulationGroup"}, {"end": 54, "start": 34, "tag": "ResearchActivity"}, {"end": 105, "start": 67, "tag": "ResearchActivity"}, {"end": 111, "start": 107, "tag": "ResearchActivity"}, {"end": 60, "start": 56, "tag": "ResearchActivity"}]}{"id": "1530_4", "text": "Moreover, the changes in intrinsic FC were investigated across the ADS using the abnormal rCBF regions as seeds and behavioral correlations.", "tags": [{"end": 70, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "Finding"}, {"end": 94, "start": 90, "tag": "BiologicFunction"}, {"end": 139, "start": 127, "tag": "ResearchActivity"}]}{"id": "1530_5", "text": "Finally, a support-vector classifier model of machine learning was used to distinguish individuals with ADS from HC.", "tags": [{"end": 107, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 46, "tag": "MachineActivity"}, {"end": 42, "start": 11, "tag": "ResearchActivity"}, {"end": 98, "start": 87, "tag": "PopulationGroup"}, {"end": 115, "start": 113, "tag": "PopulationGroup"}]}{"id": "1530_6", "text": "Results: Compared to the HC subjects, patients with AD showed the poorest level of rCBF in the left precuneus (LPCUN) and right middle frontal gyrus (RMFG) among all participants.", "tags": [{"end": 109, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 38, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 54, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 166, "tag": "PopulationGroup"}, {"end": 87, "start": 83, "tag": "HealthCareActivity"}, {"end": 36, "start": 28, "tag": "PopulationGroup"}]}{"id": "1530_7", "text": "In addition, there was a significant decrease in the ALFF in the bilateral posterior cingulate cortex (PCC) and ReHo in the right PCC.", "tags": [{"end": 101, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 25, "tag": "Finding"}, {"end": 101, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 53, "tag": "ResearchActivity"}, {"end": 116, "start": 112, "tag": "ResearchActivity"}]}{"id": "1530_8", "text": "Moreover, RMFG- and LPCUN-based FC analysis revealed that the altered FCs were primarily located in the posterior brain regions.", "tags": [{"end": 43, "start": 35, "tag": "ResearchActivity"}, {"end": 127, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 70, "tag": "BiologicFunction"}, {"end": 34, "start": 32, "tag": "BiologicFunction"}]}{"id": "1530_9", "text": "Finally, a combination of altered rCBF, ALFF, and ReHo in posterior cingulate cortex/precuneus (PCC/PCUN) showed a better ability to differentiate ADS from HC, AD from SCD and MCI, but not MCI from SCD.", "tags": [{"end": 150, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 122, "tag": "OrganismAttribute"}, {"end": 38, "start": 34, "tag": "BiologicFunction"}, {"end": 179, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 40, "tag": "ResearchActivity"}, {"end": 54, "start": 50, "tag": "ResearchActivity"}, {"end": 94, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 156, "tag": "PopulationGroup"}, {"end": 171, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 198, "tag": "DiseaseOrSyndrome"}]}{"id": "1530_10", "text": "Conclusions: The study demonstrated the significance of an altered rCBF and brain activity in the early stages of ADS.", "tags": [{"end": 90, "start": 76, "tag": "BiologicFunction"}, {"end": 117, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}, {"end": 71, "start": 67, "tag": "HealthCareActivity"}, {"end": 110, "start": 104, "tag": "TemporalConcept"}, {"end": 110, "start": 98, "tag": "TemporalConcept"}]}{"id": "1530_11", "text": "These findings, therefore, present a potential diagnostic neuroimaging-based biomarker in ADS.", "tags": [{"end": 93, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 77, "tag": "ClinicalAttribute"}, {"end": 70, "start": 58, "tag": "HealthCareActivity"}, {"end": 57, "start": 47, "tag": "HealthCareActivity"}]}{"id": "1530_12", "text": "Additionally, the study provides a better understanding of the pathophysiology of AD.", "tags": [{"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 18, "tag": "ResearchActivity"}, {"end": 78, "start": 63, "tag": "PathologicFunction"}, {"end": 78, "start": 63, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 55, "start": 42, "tag": "BiologicFunction"}]}{"id": "1531_0", "text": "Introduction: Previous in vivo optical coherence tomography studies have proposed the retinal choroid as a potential oculovascular biomarker for Alzheimer's disease (AD).", "tags": [{"end": 101, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 31, "tag": "HealthCareActivity"}, {"end": 93, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 14, "tag": "TemporalConcept"}, {"end": 164, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 117, "tag": "ClinicalAttribute"}, {"end": 67, "start": 60, "tag": "ResearchActivity"}, {"end": 30, "start": 23, "tag": "ResearchActivity"}]}{"id": "1531_1", "text": "However, the clinical use of the choroid as a purported surrogate marker remains poorly understood.", "tags": [{"end": 40, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 56, "tag": "PopulationGroup"}, {"end": 72, "start": 56, "tag": "ClinicalAttribute"}, {"end": 72, "start": 66, "tag": "ClinicalAttribute"}, {"end": 25, "start": 13, "tag": "Finding"}]}{"id": "1531_2", "text": "We pursued a histopathological approach to assess choroidal thickness and vascular morphology in severe disease.", "tags": [{"end": 69, "start": 50, "tag": "ClinicalAttribute"}, {"end": 82, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 97, "tag": "Finding"}, {"end": 39, "start": 13, "tag": "ResearchActivity"}, {"end": 39, "start": 13, "tag": "HealthCareActivity"}, {"end": 93, "start": 74, "tag": "OrganismAttribute"}]}{"id": "1531_3", "text": "Methods: Human postmortem tissues from 8 patients with AD (mean age: 80.1 +/- 12.7 years) and from 11 age-matched controls (mean age: 78.4 +/- 16.57 years) were analyzed.", "tags": [{"end": 33, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 114, "tag": "PopulationGroup"}, {"end": 49, "start": 41, "tag": "PatientOrDisabledGroup"}, {"end": 67, "start": 64, "tag": "OrganismAttribute"}, {"end": 105, "start": 102, "tag": "OrganismAttribute"}, {"end": 132, "start": 129, "tag": "OrganismAttribute"}, {"end": 88, "start": 83, "tag": "TemporalConcept"}, {"end": 154, "start": 149, "tag": "TemporalConcept"}, {"end": 25, "start": 15, "tag": "TemporalConcept"}, {"end": 169, "start": 161, "tag": "ResearchActivity"}, {"end": 14, "start": 9, "tag": "Eukaryote"}]}{"id": "1531_4", "text": "Thickness, area, and vascularity of the retinal choroid and its sublayers were measured from the nasal and temporal quadrants of the superior retina.", "tags": [{"end": 55, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 33, "tag": "ClinicalAttribute"}, {"end": 9, "start": 0, "tag": "ClinicalAttribute"}, {"end": 55, "start": 33, "tag": "ClinicalAttribute"}, {"end": 15, "start": 11, "tag": "ClinicalAttribute"}, {"end": 55, "start": 21, "tag": "ClinicalAttribute"}]}{"id": "1531_5", "text": "Results: Nasally, the choroid was thinner in the patients with AD than in the controls (22% thickness reduction; P < .001), but to our surprise, the choroid was thicker in the patients with AD than in the controls (similar to 60% increase; P < .03) within the macula, temporally.", "tags": [{"end": 29, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 266, "start": 260, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 92, "tag": "Finding"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 78, "tag": "PopulationGroup"}, {"end": 213, "start": 205, "tag": "PopulationGroup"}, {"end": 57, "start": 49, "tag": "PatientOrDisabledGroup"}, {"end": 184, "start": 176, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 16, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1531_6", "text": "The choroidal area was also significantly greater in the patients with AD than in the controls (similar to 60% increase; P < .03).", "tags": [{"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 86, "tag": "PopulationGroup"}, {"end": 65, "start": 57, "tag": "PatientOrDisabledGroup"}, {"end": 18, "start": 4, "tag": "ClinicalAttribute"}]}{"id": "1531_7", "text": "Choroidal thickening in AD was strongly correlated with the stromal vessel number (R-2 = 0.96, P < .001).", "tags": [{"end": 74, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "Finding"}, {"end": 81, "start": 60, "tag": "ClinicalAttribute"}]}{"id": "1531_8", "text": "Discussion: We found significant differences in the retinal choroid by layer and by region, nasally and temporally with respect to the optic nerve.", "tags": [{"end": 67, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 33, "tag": "Finding"}, {"end": 99, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1531_9", "text": "Intriguingly, the choroid was markedly thicker in the central macular region and was strongly associated with vessel number in the stromal vascular layer.", "tags": [{"end": 25, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 110, "tag": "ClinicalAttribute"}]}{"id": "1531_10", "text": "These quantified histological findings in severe disease expand our understanding of vascular pathology in AD and suggest vascularity as a potential biomarker supplementary to thickness when evaluating the retinal choroid in AD.", "tags": [{"end": 221, "start": 214, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 213, "start": 206, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 227, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 149, "tag": "ClinicalAttribute"}, {"end": 103, "start": 94, "tag": "PathologicFunction"}, {"end": 103, "start": 94, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 81, "start": 68, "tag": "BiologicFunction"}, {"end": 158, "start": 139, "tag": "ClinicalAttribute"}, {"end": 56, "start": 42, "tag": "Finding"}, {"end": 133, "start": 122, "tag": "ClinicalAttribute"}]}{"id": "1531_11", "text": "(C) 2019 The Authors.", "tags": []}{"id": "1531_12", "text": "Published by Elsevier Inc.", "tags": []}{"id": "1531_13", "text": "on behalf of the Alzheimer's Association.", "tags": [{"end": 40, "start": 17, "tag": "HealthCareRelatedOrganization"}]}{"id": "1532_0", "text": "Background: Alzheimer's disease (AD) is associated with EEG changes across the sleep-wake cycle.", "tags": [{"end": 59, "start": 56, "tag": "HealthCareActivity"}, {"end": 95, "start": 79, "tag": "BiologicFunction"}, {"end": 31, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}]}{"id": "1532_1", "text": "As the brain is a non-linear system, non-linear EEG features across behavioral states may provide an informative physiologic biomarker of AD.", "tags": [{"end": 51, "start": 48, "tag": "HealthCareActivity"}, {"end": 85, "start": 79, "tag": "TemporalConcept"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 113, "tag": "ClinicalAttribute"}, {"end": 12, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1532_2", "text": "Multiscale fluctuation dispersion entropy (MFDE) provides a sensitive non-linear measure of EEG information content across a range of biologically relevant time-scales.", "tags": [{"end": 95, "start": 92, "tag": "HealthCareActivity"}, {"end": 160, "start": 156, "tag": "TemporalConcept"}, {"end": 41, "start": 0, "tag": "ClinicalAttribute"}, {"end": 47, "start": 43, "tag": "HealthCareActivity"}, {"end": 88, "start": 60, "tag": "ResearchActivity"}]}{"id": "1532_3", "text": "Objective: To evaluate MFDE in awake and sleep EEGs as a potential biomarker for AD.", "tags": [{"end": 36, "start": 31, "tag": "Finding"}, {"end": 46, "start": 41, "tag": "BiologicFunction"}, {"end": 76, "start": 57, "tag": "ClinicalAttribute"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 47, "tag": "HealthCareActivity"}, {"end": 27, "start": 23, "tag": "ClinicalAttribute"}]}{"id": "1532_4", "text": "Methods: We analyzed overnight scalp EEGs from 35 cognitively normal healthy controls, 23 participants with mild cognitive impairment (MCI), and 19 participants with mild dementia due to AD.", "tags": [{"end": 36, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 69, "tag": "PopulationGroup"}, {"end": 189, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 90, "tag": "PopulationGroup"}, {"end": 160, "start": 148, "tag": "PopulationGroup"}, {"end": 68, "start": 50, "tag": "Finding"}, {"end": 138, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 166, "tag": "Finding"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 41, "start": 37, "tag": "HealthCareActivity"}, {"end": 30, "start": 21, "tag": "TemporalConcept"}]}{"id": "1532_5", "text": "We examined measures of entropy in wake and sleep states, including a slow-to-fast-activity ratio of entropy (SFAR-entropy).", "tags": [{"end": 39, "start": 35, "tag": "BiologicFunction"}, {"end": 39, "start": 35, "tag": "TemporalConcept"}, {"end": 56, "start": 50, "tag": "TemporalConcept"}, {"end": 49, "start": 44, "tag": "BiologicFunction"}, {"end": 31, "start": 24, "tag": "NaturalPhenomenonOrProcess"}, {"end": 108, "start": 70, "tag": "ClinicalAttribute"}, {"end": 122, "start": 110, "tag": "ClinicalAttribute"}]}{"id": "1532_6", "text": "We compared SFAR-entropy to linear EEG measures including a slow-to-fast-activity ratio of power spectral density (SFAR-PSD) and relative alpha power, as well as to cognitive function.", "tags": [{"end": 38, "start": 35, "tag": "HealthCareActivity"}, {"end": 183, "start": 165, "tag": "BiologicFunction"}, {"end": 113, "start": 60, "tag": "ClinicalAttribute"}, {"end": 149, "start": 129, "tag": "ClinicalAttribute"}, {"end": 123, "start": 115, "tag": "ClinicalAttribute"}, {"end": 24, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1532_7", "text": "Results: SFAR-entropy differentiated dementia from MCI and controls.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 45, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 59, "tag": "PopulationGroup"}, {"end": 54, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 9, "tag": "ClinicalAttribute"}]}{"id": "1532_8", "text": "This effect was greatest in REM sleep, a state associated with high cholinergic activity.", "tags": [{"end": 37, "start": 28, "tag": "BiologicFunction"}, {"end": 88, "start": 68, "tag": "BiologicFunction"}]}{"id": "1532_9", "text": "Differentiation was evident in the whole brain EEG and was most prominent in temporal and occipital regions.", "tags": [{"end": 50, "start": 47, "tag": "HealthCareActivity"}, {"end": 107, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 0, "tag": "CellFunction"}, {"end": 46, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1532_10", "text": "Five minutes of REM sleep was sufficient to distinguish dementia from MCI and controls.", "tags": [{"end": 25, "start": 16, "tag": "BiologicFunction"}, {"end": 64, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 78, "tag": "PopulationGroup"}, {"end": 73, "start": 70, "tag": "DiseaseOrSyndrome"}]}{"id": "1532_11", "text": "Higher SFAR-entropy during REM sleep was associated with worse performance on the Montreal Cognitive Assessment.", "tags": [{"end": 36, "start": 27, "tag": "BiologicFunction"}, {"end": 62, "start": 57, "tag": "Finding"}, {"end": 111, "start": 82, "tag": "HealthCareActivity"}, {"end": 74, "start": 63, "tag": "Finding"}, {"end": 19, "start": 7, "tag": "ClinicalAttribute"}]}{"id": "1532_12", "text": "Classifiers based on REM sleep SFAR-entropy distinguished dementia from MCI and controls with high accuracy, and outperformed classifiers based on SFAR-PSD and relative alpha power.", "tags": [{"end": 30, "start": 21, "tag": "BiologicFunction"}, {"end": 66, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 80, "tag": "PopulationGroup"}, {"end": 107, "start": 99, "tag": "Finding"}, {"end": 75, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 31, "tag": "ClinicalAttribute"}, {"end": 155, "start": 147, "tag": "ClinicalAttribute"}, {"end": 180, "start": 160, "tag": "ClinicalAttribute"}]}{"id": "1532_13", "text": "Conclusion: SFAR-entropy measured in REM sleep robustly discriminates dementia in AD from MCI and healthy controls.", "tags": [{"end": 46, "start": 37, "tag": "BiologicFunction"}, {"end": 114, "start": 98, "tag": "PopulationGroup"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 25, "tag": "HealthCareActivity"}, {"end": 24, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1533_0", "text": "Microglia, the major immune cells in the brain, mediate neuroinflammation, increased oxidative stress, and impaired neurotransmission in Alzheimer's disease (AD), in which most AD risk genes are highly expressed.", "tags": [{"end": 133, "start": 116, "tag": "CellFunction"}, {"end": 33, "start": 21, "tag": "Cell"}, {"end": 9, "start": 0, "tag": "Cell"}, {"end": 211, "start": 202, "tag": "CellFunction"}, {"end": 156, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 56, "tag": "PathologicFunction"}, {"end": 101, "start": 85, "tag": "CellOrMolecularDysfunction"}, {"end": 190, "start": 180, "tag": "GeneOrGenome"}]}{"id": "1533_1", "text": "In microglia, due to the limitations of current single-omics data analysis, risk genes, the regulatory mechanisms, the mechanisms of action of immune responses and the exploration of drug targets for AD immunotherapy are still unclear.", "tags": [{"end": 102, "start": 92, "tag": "GeneOrGenome"}, {"end": 179, "start": 168, "tag": "HealthCareActivity"}, {"end": 216, "start": 203, "tag": "PharmacologicSubstance"}, {"end": 216, "start": 203, "tag": "HealthCareActivity"}, {"end": 159, "start": 143, "tag": "BiologicFunction"}, {"end": 187, "start": 183, "tag": "PharmacologicSubstance"}, {"end": 202, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 3, "tag": "Cell"}, {"end": 74, "start": 48, "tag": "ResearchActivity"}, {"end": 47, "start": 40, "tag": "TemporalConcept"}, {"end": 86, "start": 76, "tag": "GeneOrGenome"}]}{"id": "1533_2", "text": "Therefore, we proposed a method to integrate multi-omics data based on the construction of gene regulatory networks (GRN), by combining weighted gene co-expression network analysis (WGCNA) with single-cell regulatory network inference and clustering (SCENIC).", "tags": [{"end": 115, "start": 91, "tag": "ResearchActivity"}, {"end": 120, "start": 117, "tag": "ResearchActivity"}, {"end": 249, "start": 194, "tag": "ResearchActivity"}, {"end": 61, "start": 45, "tag": "ResearchActivity"}, {"end": 61, "start": 57, "tag": "ResearchActivity"}, {"end": 180, "start": 136, "tag": "ResearchActivity"}, {"end": 31, "start": 25, "tag": "ResearchActivity"}, {"end": 31, "start": 25, "tag": "HealthCareActivity"}, {"end": 187, "start": 182, "tag": "ResearchActivity"}, {"end": 257, "start": 251, "tag": "ResearchActivity"}]}{"id": "1533_3", "text": "This enables snRNA-seq data and bulkRNA-seq data to obtain data on the deeper intermolecular regulatory relationships, related genes, and the molecular mechanisms of immune-cell action.", "tags": [{"end": 132, "start": 127, "tag": "GeneOrGenome"}, {"end": 162, "start": 142, "tag": "CellFunction"}, {"end": 27, "start": 13, "tag": "ResearchActivity"}, {"end": 48, "start": 32, "tag": "ResearchActivity"}, {"end": 63, "start": 59, "tag": "ResearchActivity"}, {"end": 177, "start": 166, "tag": "Cell"}, {"end": 117, "start": 104, "tag": "Finding"}]}{"id": "1533_4", "text": "In our approach, not only were central transcription factors (TF) STAT3, CEBPB, SPI1, and regulatory mechanisms identified more accurately than with single-omics but also immunotherapy targeting central TFs to drugs was found to be significantly different between patients.", "tags": [{"end": 64, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 73, "tag": "GeneOrGenome"}, {"end": 84, "start": 80, "tag": "GeneOrGenome"}, {"end": 84, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 171, "tag": "HealthCareActivity"}, {"end": 215, "start": 210, "tag": "PharmacologicSubstance"}, {"end": 60, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 66, "tag": "GeneOrGenome"}, {"end": 71, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 272, "start": 264, "tag": "PatientOrDisabledGroup"}, {"end": 161, "start": 149, "tag": "ResearchActivity"}, {"end": 78, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 206, "start": 203, "tag": "AminoAcidPeptideOrProtein"}, {"end": 206, "start": 203, "tag": "BiologicallyActiveSubstance"}]}{"id": "1533_5", "text": "Thus, in addition to providing new insights into the potential regulatory mechanisms and pathogenic genes of AD microglia, this approach can assist clinicians in making the most rational treatment plans for patients with different risks; it also has significant implications for identifying AD immunotherapy targets and targeting microglia-associated immune drugs.", "tags": [{"end": 307, "start": 294, "tag": "HealthCareActivity"}, {"end": 99, "start": 89, "tag": "PathologicFunction"}, {"end": 363, "start": 351, "tag": "PharmacologicSubstance"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 293, "start": 291, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 207, "tag": "PatientOrDisabledGroup"}, {"end": 121, "start": 112, "tag": "Cell"}, {"end": 339, "start": 330, "tag": "Cell"}, {"end": 196, "start": 187, "tag": "HealthCareActivity"}, {"end": 196, "start": 187, "tag": "ResearchActivity"}, {"end": 158, "start": 148, "tag": "HealthCareActivity"}, {"end": 105, "start": 100, "tag": "GeneOrGenome"}]}{"id": "1534_0", "text": "Objective: Increased life expectancy and exponential growth of adults suffering from Alzheimer's disease (AD) worldwide, has led to biomarkers incorporation for diagnosis in early stages.", "tags": [{"end": 25, "start": 21, "tag": "TemporalConcept"}, {"end": 186, "start": 180, "tag": "TemporalConcept"}, {"end": 59, "start": 53, "tag": "BiologicFunction"}, {"end": 186, "start": 174, "tag": "TemporalConcept"}, {"end": 36, "start": 21, "tag": "TemporalConcept"}, {"end": 104, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 161, "tag": "HealthCareActivity"}, {"end": 142, "start": 132, "tag": "ClinicalAttribute"}, {"end": 179, "start": 174, "tag": "TemporalConcept"}, {"end": 69, "start": 63, "tag": "PopulationGroup"}]}{"id": "1534_1", "text": "Use of neuropsychological testing remains limited.", "tags": [{"end": 33, "start": 7, "tag": "HealthCareActivity"}]}{"id": "1534_2", "text": "This study aimed to identify which neuropsychological tests best indicated underlying AD pathophysiology.", "tags": [{"end": 59, "start": 35, "tag": "HealthCareActivity"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 104, "start": 89, "tag": "PathologicFunction"}, {"end": 104, "start": 89, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1534_3", "text": "Methods: One hundred and forty-one patients with MCI (Mild Cognitive Impairment) were studied.", "tags": [{"end": 79, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 35, "tag": "PatientOrDisabledGroup"}, {"end": 52, "start": 49, "tag": "DiseaseOrSyndrome"}]}{"id": "1534_4", "text": "A neuropsychological test battery based on the Uniform Data Set (UDS) from the Alzheimer's Disease Centers program of the National Institute on Aging (NIA) was performed and amyloid markers recorded; according to presence or absence of amyloid identified by positive PIB-PET findings, or low CSF A beta 42 levels, patients were separated into MCI amyloid-(n:58) and MCI amyloid + (n = 83) cases.", "tags": [{"end": 33, "start": 2, "tag": "HealthCareActivity"}, {"end": 149, "start": 122, "tag": "HealthCareRelatedOrganization"}, {"end": 154, "start": 151, "tag": "HealthCareRelatedOrganization"}, {"end": 305, "start": 296, "tag": "AminoAcidPeptideOrProtein"}, {"end": 305, "start": 296, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 2, "tag": "HealthCareActivity"}, {"end": 291, "start": 288, "tag": "Finding"}, {"end": 295, "start": 292, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 322, "start": 314, "tag": "PatientOrDisabledGroup"}, {"end": 181, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 243, "start": 236, "tag": "AminoAcidPeptideOrProtein"}, {"end": 354, "start": 347, "tag": "AminoAcidPeptideOrProtein"}, {"end": 377, "start": 370, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 243, "start": 236, "tag": "BiologicallyActiveSubstance"}, {"end": 354, "start": 347, "tag": "BiologicallyActiveSubstance"}, {"end": 377, "start": 370, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 346, "start": 343, "tag": "DiseaseOrSyndrome"}, {"end": 369, "start": 366, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 213, "tag": "Finding"}, {"end": 274, "start": 267, "tag": "HealthCareActivity"}, {"end": 302, "start": 296, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 47, "tag": "ResearchActivity"}, {"end": 20, "start": 2, "tag": "HealthCareActivity"}, {"end": 25, "start": 21, "tag": "ResearchActivity"}, {"end": 25, "start": 21, "tag": "HealthCareActivity"}, {"end": 189, "start": 182, "tag": "ClinicalAttribute"}, {"end": 114, "start": 79, "tag": "ResearchActivity"}, {"end": 232, "start": 225, "tag": "Finding"}, {"end": 312, "start": 292, "tag": "ClinicalAttribute"}, {"end": 68, "start": 65, "tag": "ResearchActivity"}]}{"id": "1534_5", "text": "Results: Statistical differences were found in all memory tests between groups.", "tags": [{"end": 32, "start": 9, "tag": "Finding"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 78, "start": 72, "tag": "PopulationGroup"}, {"end": 63, "start": 51, "tag": "ResearchActivity"}, {"end": 63, "start": 51, "tag": "HealthCareActivity"}, {"end": 57, "start": 51, "tag": "BiologicFunction"}]}{"id": "1534_6", "text": "Delayed recall score at thirty minutes on the Rey Auditory Verbal Learning Test (AVLT) was the best predictor of amyloid pathology presence (AUC 0.68), followed by AVLT total learning (AUC 0.66) and AVLT Recognition (AUC 0.59) scores, providing useful cut off values in the clinical setting.", "tags": [{"end": 38, "start": 31, "tag": "TemporalConcept"}, {"end": 14, "start": 8, "tag": "BiologicFunction"}, {"end": 130, "start": 113, "tag": "PathologicFunction"}, {"end": 290, "start": 274, "tag": "HealthCareActivity"}, {"end": 183, "start": 175, "tag": "BiologicFunction"}, {"end": 215, "start": 204, "tag": "BiologicFunction"}, {"end": 79, "start": 46, "tag": "HealthCareActivity"}, {"end": 233, "start": 227, "tag": "Finding"}, {"end": 20, "start": 15, "tag": "Finding"}, {"end": 120, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 131, "tag": "Finding"}, {"end": 144, "start": 141, "tag": "ResearchActivity"}, {"end": 188, "start": 185, "tag": "ResearchActivity"}, {"end": 220, "start": 217, "tag": "ResearchActivity"}, {"end": 85, "start": 81, "tag": "HealthCareActivity"}, {"end": 168, "start": 164, "tag": "HealthCareActivity"}, {"end": 203, "start": 199, "tag": "HealthCareActivity"}, {"end": 266, "start": 252, "tag": "ResearchActivity"}]}{"id": "1534_7", "text": "Conclusions: Use of neuropsychological testing, specifically AVLT scores with cutoff values, contributed to the correct diagnosis of MCI due to AD in this SouthAmerican cohort.", "tags": [{"end": 91, "start": 78, "tag": "ResearchActivity"}, {"end": 46, "start": 20, "tag": "HealthCareActivity"}, {"end": 72, "start": 66, "tag": "Finding"}, {"end": 146, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 120, "tag": "HealthCareActivity"}, {"end": 136, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 169, "tag": "PopulationGroup"}, {"end": 65, "start": 61, "tag": "ResearchActivity"}, {"end": 168, "start": 155, "tag": "PopulationGroup"}]}{"id": "1535_0", "text": "Objectives: Cognitive impairment and apathy are well-documented features of idiopathic normal pressure hydrocephalus (iNPH).", "tags": [{"end": 43, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 118, "tag": "DiseaseOrSyndrome"}]}{"id": "1535_1", "text": "However, research examining other neuropsychiatric manifestations of iNPH is scant, and it is unknown whether the neuropsychiatric presentation differs for iNPH patients with comorbid Alzheimer's disease (AD)versusiNPH without AD.", "tags": [{"end": 143, "start": 131, "tag": "Finding"}, {"end": 65, "start": 34, "tag": "SignOrSymptom"}, {"end": 203, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 161, "tag": "PatientOrDisabledGroup"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 73, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 218, "start": 214, "tag": "DiseaseOrSyndrome"}]}{"id": "1535_2", "text": "This study aims to advance our understanding of neuropsychiatric syndromes associated with iNPH.", "tags": [{"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 44, "start": 31, "tag": "BiologicFunction"}, {"end": 74, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 91, "tag": "DiseaseOrSyndrome"}]}{"id": "1535_3", "text": "Methods: Fifty patients from Butler Hospital's Normal Pressure Hydrocephalus Clinic met inclusion criteria.", "tags": [{"end": 76, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 15, "tag": "PatientOrDisabledGroup"}, {"end": 46, "start": 29, "tag": "HealthCareRelatedOrganization"}, {"end": 83, "start": 47, "tag": "HealthCareRelatedOrganization"}, {"end": 106, "start": 88, "tag": "HealthCareActivity"}]}{"id": "1535_4", "text": "Caregiver ratings on the Frontal Systems Behavior Scale (FrSBe) were examined to appraise changes in apathy, executive dysfunction, and disinhibition.", "tags": [{"end": 149, "start": 136, "tag": "BiologicFunction"}, {"end": 149, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 62, "start": 57, "tag": "HealthCareActivity"}, {"end": 130, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 119, "tag": "PathologicFunction"}, {"end": 55, "start": 25, "tag": "HealthCareActivity"}]}{"id": "1535_5", "text": "Patients also completed cognitive tests of global cognition, psychomotor speed, and executive functioning.", "tags": [{"end": 105, "start": 84, "tag": "BiologicFunction"}, {"end": 59, "start": 50, "tag": "BiologicFunction"}, {"end": 39, "start": 24, "tag": "HealthCareActivity"}, {"end": 39, "start": 24, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 78, "start": 61, "tag": "BiologicFunction"}]}{"id": "1535_6", "text": "AD biomarker status was determined by either amyloid-beta (A beta) positron emission tomography (PET) imaging or cerebrospinal fluid (CSF) total tau to A beta-42 ratio.", "tags": [{"end": 109, "start": 102, "tag": "HealthCareActivity"}, {"end": 148, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 3, "tag": "ClinicalAttribute"}, {"end": 132, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 52, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 97, "tag": "HealthCareActivity"}, {"end": 19, "start": 13, "tag": "Finding"}, {"end": 65, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 67, "tag": "HealthCareActivity"}, {"end": 167, "start": 139, "tag": "ClinicalAttribute"}, {"end": 132, "start": 113, "tag": "ClinicalAttribute"}]}{"id": "1535_7", "text": "Results: Results revealed clinically significant elevations on the FrSBe's apathy and executive dysfunction scales and modest correlations among these scales and cognitive measures.", "tags": [{"end": 48, "start": 26, "tag": "Finding"}, {"end": 59, "start": 49, "tag": "Finding"}, {"end": 72, "start": 67, "tag": "HealthCareActivity"}, {"end": 107, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 162, "tag": "ClinicalAttribute"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 16, "start": 9, "tag": "ResearchActivity"}, {"end": 138, "start": 126, "tag": "ResearchActivity"}]}{"id": "1535_8", "text": "Of the 44 patients with available neuroimaging or CSF draw data, 14 presented with comorbid AD.", "tags": [{"end": 46, "start": 34, "tag": "HealthCareActivity"}, {"end": 53, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 10, "tag": "PatientOrDisabledGroup"}, {"end": 63, "start": 59, "tag": "ResearchActivity"}]}{"id": "1535_9", "text": "Relative to the iNPH-only group, the iNPH + AD group showed a larger increase from pre-illness to current informant ratings on the executive dysfunction scale, but not the apathy or disinhibition scales.", "tags": [{"end": 152, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 98, "tag": "TemporalConcept"}, {"end": 31, "start": 26, "tag": "PopulationGroup"}, {"end": 52, "start": 47, "tag": "PopulationGroup"}, {"end": 20, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 83, "tag": "TemporalConcept"}]}{"id": "1535_10", "text": "Conclusions: These results replicate and extend prior research by identifying apathy and executive dysfunction as prominent neuropsychiatric symptoms of iNPH and suggest comorbid AD exacerbates dysexecutive behaviors.", "tags": [{"end": 149, "start": 124, "tag": "SignOrSymptom"}, {"end": 110, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 54, "tag": "ResearchActivity"}, {"end": 157, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 194, "tag": "DiseaseOrSyndrome"}]}{"id": "1535_11", "text": "Future research is warranted to examine the effects of comorbid AD pathology in response to shunt surgery for iNPH, neuropsychiatric symptom changes, and resultant caregiver burden.", "tags": [{"end": 180, "start": 164, "tag": "BiologicFunction"}, {"end": 66, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 7, "tag": "ResearchActivity"}, {"end": 76, "start": 67, "tag": "PathologicFunction"}, {"end": 76, "start": 67, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 51, "start": 44, "tag": "Finding"}, {"end": 88, "start": 80, "tag": "OrganismAttribute"}, {"end": 140, "start": 116, "tag": "SignOrSymptom"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 113, "start": 112, "tag": "DiseaseOrSyndrome"}]}{"id": "1536_0", "text": "Background: Wide-ranging functional defects in eye movements have been reported in Alzheimer's disease (AD) dementia.", "tags": [{"end": 60, "start": 47, "tag": "BiologicFunction"}, {"end": 102, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 12, "tag": "PathologicFunction"}]}{"id": "1536_1", "text": "The detection of abnormal eye movements and reading problems may identify persons at risk of AD when clear clinical symptoms are lacking.", "tags": [{"end": 60, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 17, "tag": "PathologicFunction"}, {"end": 81, "start": 74, "tag": "PopulationGroup"}, {"end": 25, "start": 17, "tag": "Finding"}, {"end": 124, "start": 107, "tag": "SignOrSymptom"}, {"end": 95, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 4, "tag": "HealthCareActivity"}, {"end": 89, "start": 85, "tag": "Finding"}]}{"id": "1536_2", "text": "Objective: To examine whether computer-based eye-tracking (ET) analysis of King-Devick (KD) test results differentiates cognitively healthy persons from persons with minor problems in cognitive testing or diagnosed mild AD.", "tags": [{"end": 147, "start": 140, "tag": "PopulationGroup"}, {"end": 160, "start": 153, "tag": "PopulationGroup"}, {"end": 222, "start": 220, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 132, "tag": "OrganismAttribute"}, {"end": 214, "start": 205, "tag": "HealthCareActivity"}, {"end": 201, "start": 194, "tag": "HealthCareActivity"}, {"end": 201, "start": 184, "tag": "HealthCareActivity"}, {"end": 71, "start": 63, "tag": "HealthCareActivity"}, {"end": 57, "start": 30, "tag": "HealthCareActivity"}, {"end": 139, "start": 120, "tag": "OrganismAttribute"}, {"end": 219, "start": 215, "tag": "Finding"}, {"end": 96, "start": 92, "tag": "ResearchActivity"}, {"end": 96, "start": 92, "tag": "HealthCareActivity"}, {"end": 86, "start": 75, "tag": "HealthCareActivity"}]}{"id": "1536_3", "text": "Methods: We recruited 78 participants (57 non-demented, 21 with mild AD) who underwent neurological examination, the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological test battery (CERAD-NB), and a Clinical Dementia Rating (CDR) interview.", "tags": [{"end": 111, "start": 87, "tag": "HealthCareActivity"}, {"end": 54, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 199, "start": 176, "tag": "HealthCareActivity"}, {"end": 217, "start": 209, "tag": "HealthCareActivity"}, {"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 25, "tag": "PopulationGroup"}, {"end": 175, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 250, "start": 226, "tag": "HealthCareActivity"}, {"end": 255, "start": 252, "tag": "HealthCareActivity"}, {"end": 68, "start": 64, "tag": "Finding"}, {"end": 199, "start": 195, "tag": "ResearchActivity"}, {"end": 199, "start": 195, "tag": "HealthCareActivity"}, {"end": 207, "start": 117, "tag": "HealthCareActivity"}]}{"id": "1536_4", "text": "The non-demented participants were further divided into control (normal CERAD subtests, mean MMSE= 28) and objective mild cognitive impairment (MCI; decline in at least one CERAD memory score, mean MMSE= 27) groups.", "tags": [{"end": 71, "start": 65, "tag": "Finding"}, {"end": 16, "start": 8, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 93, "tag": "HealthCareActivity"}, {"end": 202, "start": 198, "tag": "HealthCareActivity"}, {"end": 77, "start": 72, "tag": "HealthCareActivity"}, {"end": 178, "start": 173, "tag": "HealthCareActivity"}, {"end": 191, "start": 186, "tag": "Finding"}, {"end": 29, "start": 17, "tag": "PopulationGroup"}, {"end": 142, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 56, "tag": "PopulationGroup"}, {"end": 214, "start": 208, "tag": "PopulationGroup"}, {"end": 142, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 117, "tag": "Finding"}, {"end": 185, "start": 179, "tag": "BiologicFunction"}]}{"id": "1536_5", "text": "The KD reading test was performed using computer-based ET.", "tags": [{"end": 19, "start": 4, "tag": "HealthCareActivity"}, {"end": 57, "start": 40, "tag": "HealthCareActivity"}]}{"id": "1536_6", "text": "The total time used for the reading test, errors made, fixation and saccade durations, and saccade amplitudes were analyzed.", "tags": [{"end": 48, "start": 42, "tag": "Finding"}, {"end": 63, "start": 55, "tag": "HealthCareActivity"}, {"end": 63, "start": 55, "tag": "BiologicFunction"}, {"end": 63, "start": 55, "tag": "ResearchActivity"}, {"end": 75, "start": 68, "tag": "Finding"}, {"end": 98, "start": 91, "tag": "Finding"}, {"end": 14, "start": 10, "tag": "TemporalConcept"}, {"end": 123, "start": 115, "tag": "ResearchActivity"}, {"end": 40, "start": 28, "tag": "HealthCareActivity"}, {"end": 85, "start": 76, "tag": "TemporalConcept"}]}{"id": "1536_7", "text": "Results: We found significant differences between the control, objective MCI, and AD groups in regard to the mean saccade amplitude (3.58, 3.33, and 3.21 ms, respectively, p < 0.03) and duration (27.1, 25.3, and 24.8 ms, respectively, p < 0.05).", "tags": [{"end": 194, "start": 186, "tag": "TemporalConcept"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 54, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 91, "start": 85, "tag": "PopulationGroup"}, {"end": 41, "start": 18, "tag": "Finding"}, {"end": 121, "start": 114, "tag": "Finding"}]}{"id": "1536_8", "text": "The KD error scores in the AD group differed significantly (p < 0.01) from the other groups.", "tags": [{"end": 19, "start": 7, "tag": "Finding"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 85, "tag": "PopulationGroup"}, {"end": 35, "start": 30, "tag": "PopulationGroup"}, {"end": 6, "start": 4, "tag": "HealthCareActivity"}]}{"id": "1536_9", "text": "Conclusion: Computed ET analysis of the KD test may help detect persons with objective MCI early when clear clinical symptoms are lacking.", "tags": [{"end": 71, "start": 64, "tag": "PopulationGroup"}, {"end": 125, "start": 108, "tag": "SignOrSymptom"}, {"end": 90, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 91, "tag": "TemporalConcept"}, {"end": 32, "start": 24, "tag": "ResearchActivity"}, {"end": 47, "start": 43, "tag": "ResearchActivity"}, {"end": 47, "start": 43, "tag": "HealthCareActivity"}, {"end": 23, "start": 12, "tag": "HealthCareActivity"}, {"end": 42, "start": 40, "tag": "HealthCareActivity"}]}{"id": "1536_10", "text": "The portable device for ET is easy to use in primary health care memory clinics.", "tags": [{"end": 26, "start": 24, "tag": "HealthCareActivity"}, {"end": 79, "start": 45, "tag": "HealthCareRelatedOrganization"}]}{"id": "1537_0", "text": "Introduction: Machine learning (ML) may harbor the potential to capture the metabolic complexity in Alzheimer Disease (AD).", "tags": [{"end": 30, "start": 14, "tag": "MachineActivity"}, {"end": 85, "start": 76, "tag": "CellFunction"}, {"end": 117, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 32, "tag": "MachineActivity"}]}{"id": "1537_1", "text": "Here we set out to test the performance of metabolites in blood to categorize AD when compared to CSF biomarkers.", "tags": [{"end": 101, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 102, "tag": "ClinicalAttribute"}, {"end": 63, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 28, "tag": "Finding"}, {"end": 54, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 19, "tag": "ResearchActivity"}, {"end": 23, "start": 19, "tag": "HealthCareActivity"}]}{"id": "1537_2", "text": "Methods: This study analyzed samples from 242 cognitively normal (CN) people and 115 with AD-type dementia utilizing plasma metabolites (n=883).", "tags": [{"end": 68, "start": 66, "tag": "Finding"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 14, "tag": "ResearchActivity"}, {"end": 123, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 46, "tag": "Finding"}, {"end": 76, "start": 70, "tag": "PopulationGroup"}, {"end": 135, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 29, "tag": "Substance"}]}{"id": "1537_3", "text": "Deep Learning (DL), Extreme Gradient Boosting (XGBoost) and Random Forest (RF) were used to differentiate AD from CN.", "tags": [{"end": 13, "start": 0, "tag": "MachineActivity"}, {"end": 17, "start": 15, "tag": "MachineActivity"}, {"end": 105, "start": 92, "tag": "CellFunction"}, {"end": 116, "start": 114, "tag": "Finding"}, {"end": 73, "start": 60, "tag": "MachineActivity"}, {"end": 77, "start": 75, "tag": "MachineActivity"}, {"end": 108, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 20, "tag": "MachineActivity"}, {"end": 54, "start": 47, "tag": "MachineActivity"}]}{"id": "1537_4", "text": "These models were internally validated using Nested Cross Validation (NCV).", "tags": [{"end": 68, "start": 45, "tag": "ResearchActivity"}, {"end": 73, "start": 70, "tag": "ResearchActivity"}, {"end": 12, "start": 6, "tag": "ResearchActivity"}]}{"id": "1537_5", "text": "Results: On the test data, DL produced the AUC of 0.85 (0.80-0.89), XGBoost produced 0.88 (0.86-0.89) and RF produced 0.85 (0.83-0.87).", "tags": [{"end": 29, "start": 27, "tag": "MachineActivity"}, {"end": 108, "start": 106, "tag": "MachineActivity"}, {"end": 25, "start": 21, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 46, "start": 43, "tag": "ResearchActivity"}, {"end": 20, "start": 16, "tag": "ResearchActivity"}, {"end": 20, "start": 16, "tag": "HealthCareActivity"}, {"end": 75, "start": 68, "tag": "MachineActivity"}]}{"id": "1537_6", "text": "By comparison, CSF measures of amyloid, p-tau and t-tau (together with age and gender) produced with XGBoost the AUC values of 0.78, 0.83 and 0.87, respectively.", "tags": [{"end": 13, "start": 3, "tag": "ResearchActivity"}, {"end": 45, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 71, "tag": "OrganismAttribute"}, {"end": 45, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 113, "tag": "ResearchActivity"}, {"end": 85, "start": 79, "tag": "OrganismAttribute"}, {"end": 108, "start": 101, "tag": "MachineActivity"}]}{"id": "1537_7", "text": "Discussion: This study showed that plasma metabolites have the potential to match the AUC of well-established AD CSF biomarkers in a relatively small cohort.", "tags": [{"end": 81, "start": 76, "tag": "ResearchActivity"}, {"end": 116, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 117, "tag": "ClinicalAttribute"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}, {"end": 41, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 150, "tag": "PopulationGroup"}, {"end": 89, "start": 86, "tag": "ResearchActivity"}, {"end": 53, "start": 42, "tag": "BiologicallyActiveSubstance"}]}{"id": "1537_8", "text": "Further studies in independent cohorts are needed to validate whether this specific panel of blood metabolites can separate AD from controls, and how specific it is for AD as compared with other neurodegenerative disorders.", "tags": [{"end": 222, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 132, "tag": "PopulationGroup"}, {"end": 38, "start": 31, "tag": "PopulationGroup"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 98, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 99, "tag": "BiologicallyActiveSubstance"}]}{"id": "1537_9", "text": "(C) 2019 The Authors.", "tags": []}{"id": "1537_10", "text": "Published by Elsevier Inc.", "tags": []}{"id": "1537_11", "text": "on behalf of the Alzheimer's Association.", "tags": [{"end": 40, "start": 17, "tag": "HealthCareRelatedOrganization"}]}{"id": "1538_0", "text": "Background: Growing evidence suggests that there may be a sex-specific biological risk for Alzheimer's disease (AD).", "tags": [{"end": 110, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 58, "tag": "OrganismAttribute"}, {"end": 28, "start": 20, "tag": "Finding"}]}{"id": "1538_1", "text": "Individuals with autosomal dominant AD due to a mutation (E280A) in Presenilin-1 (PSEN1) are genetically determined to develop early-onset dementia and thus, have few age-related risk factors for AD that are known to vary by sex (i.e., cardiovascular disease, menopause, life expectancy).", "tags": [{"end": 11, "start": 0, "tag": "PopulationGroup"}, {"end": 258, "start": 236, "tag": "DiseaseOrSyndrome"}, {"end": 258, "start": 236, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 269, "start": 260, "tag": "BiologicFunction"}, {"end": 191, "start": 179, "tag": "Finding"}, {"end": 286, "start": 271, "tag": "TemporalConcept"}, {"end": 80, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 68, "tag": "GeneOrGenome"}, {"end": 80, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 82, "tag": "GeneOrGenome"}, {"end": 87, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 133, "tag": "TemporalConcept"}, {"end": 56, "start": 48, "tag": "CellOrMolecularDysfunction"}, {"end": 170, "start": 167, "tag": "OrganismAttribute"}, {"end": 198, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 225, "tag": "OrganismAttribute"}, {"end": 63, "start": 58, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1538_2", "text": "Objective: Investigate sex differences in markers of cognition and neurodegeneration in autosomal dominant AD.", "tags": [{"end": 38, "start": 27, "tag": "Finding"}, {"end": 109, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 67, "tag": "CellOrMolecularDysfunction"}, {"end": 62, "start": 53, "tag": "BiologicFunction"}, {"end": 26, "start": 23, "tag": "OrganismAttribute"}]}{"id": "1538_3", "text": "Methods: We conducted a retrospective study in 19 cognitively-unimpaired PSEN1 mutation carriers (age range 20-44; 11 females), 11 symptomatic carriers (age range 42-56; 8 females), and 23 matched non-carriers family members (age range 20-50; 13 females).", "tags": [{"end": 43, "start": 24, "tag": "ResearchActivity"}, {"end": 125, "start": 118, "tag": "OrganismAttribute"}, {"end": 179, "start": 172, "tag": "OrganismAttribute"}, {"end": 224, "start": 210, "tag": "PopulationGroup"}, {"end": 224, "start": 210, "tag": "Finding"}, {"end": 253, "start": 246, "tag": "OrganismAttribute"}, {"end": 142, "start": 131, "tag": "SignOrSymptom"}, {"end": 96, "start": 88, "tag": "PopulationGroup"}, {"end": 151, "start": 143, "tag": "PopulationGroup"}, {"end": 209, "start": 201, "tag": "PopulationGroup"}, {"end": 78, "start": 73, "tag": "GeneOrGenome"}, {"end": 78, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 79, "tag": "CellOrMolecularDysfunction"}, {"end": 209, "start": 197, "tag": "PopulationGroup"}, {"end": 101, "start": 98, "tag": "OrganismAttribute"}, {"end": 156, "start": 153, "tag": "OrganismAttribute"}, {"end": 229, "start": 226, "tag": "OrganismAttribute"}, {"end": 96, "start": 79, "tag": "PopulationGroup"}]}{"id": "1538_4", "text": "We examined hippocampal volume ratio, CERAD Total Score, and CERAD Word List (i.e., Learning, Delayed Recall, and Recognition).", "tags": [{"end": 92, "start": 84, "tag": "BiologicFunction"}, {"end": 125, "start": 114, "tag": "BiologicFunction"}, {"end": 30, "start": 12, "tag": "ClinicalAttribute"}, {"end": 55, "start": 38, "tag": "HealthCareActivity"}, {"end": 76, "start": 61, "tag": "HealthCareActivity"}, {"end": 108, "start": 94, "tag": "BiologicFunction"}]}{"id": "1538_5", "text": "Mann-Whitney U tests, Spearman correlations and regression models were conducted.", "tags": [{"end": 65, "start": 48, "tag": "ResearchActivity"}, {"end": 43, "start": 22, "tag": "ResearchActivity"}, {"end": 20, "start": 0, "tag": "ResearchActivity"}]}{"id": "1538_6", "text": "Results: There were no differential associations between age, CERAD Total Score, CERAD Word List-Learning, Delayed Recall, Recognition, and hippocampal volume ratio in male and female carriers and non-carriers.", "tags": [{"end": 134, "start": 123, "tag": "BiologicFunction"}, {"end": 183, "start": 177, "tag": "OrganismAttribute"}, {"end": 172, "start": 168, "tag": "OrganismAttribute"}, {"end": 192, "start": 184, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 209, "start": 197, "tag": "PopulationGroup"}, {"end": 60, "start": 57, "tag": "OrganismAttribute"}, {"end": 158, "start": 140, "tag": "ClinicalAttribute"}, {"end": 67, "start": 62, "tag": "HealthCareActivity"}, {"end": 105, "start": 81, "tag": "HealthCareActivity"}, {"end": 121, "start": 107, "tag": "BiologicFunction"}, {"end": 121, "start": 107, "tag": "HealthCareActivity"}, {"end": 79, "start": 68, "tag": "Finding"}]}{"id": "1538_7", "text": "Cognitively-unimpaired female carriers showed better CERAD Total scores and CERAD Word List-Learning than cognitively-unimpaired male carriers, despite having similar hippocampal volume ratios.", "tags": [{"end": 71, "start": 59, "tag": "Finding"}, {"end": 29, "start": 23, "tag": "OrganismAttribute"}, {"end": 133, "start": 129, "tag": "OrganismAttribute"}, {"end": 38, "start": 30, "tag": "PopulationGroup"}, {"end": 142, "start": 134, "tag": "PopulationGroup"}, {"end": 185, "start": 167, "tag": "ClinicalAttribute"}, {"end": 22, "start": 0, "tag": "Finding"}, {"end": 58, "start": 53, "tag": "HealthCareActivity"}, {"end": 100, "start": 76, "tag": "HealthCareActivity"}, {"end": 128, "start": 106, "tag": "Finding"}]}{"id": "1538_8", "text": "The interaction of sex and hippocampal volume ratio did not predict cognitive performance across groups.", "tags": [{"end": 89, "start": 78, "tag": "Finding"}, {"end": 22, "start": 19, "tag": "OrganismAttribute"}, {"end": 103, "start": 97, "tag": "PopulationGroup"}, {"end": 45, "start": 27, "tag": "ClinicalAttribute"}]}{"id": "1538_9", "text": "Conclusion: Our preliminary findings suggest that cognitively-unimpaired female carriers showed a verbal memory reserve, and as disease progresses, female carriers did not exhibit a cognitive susceptibility to AD-related neurodegeneration.", "tags": [{"end": 27, "start": 16, "tag": "TemporalConcept"}, {"end": 79, "start": 73, "tag": "OrganismAttribute"}, {"end": 154, "start": 148, "tag": "OrganismAttribute"}, {"end": 88, "start": 80, "tag": "PopulationGroup"}, {"end": 163, "start": 155, "tag": "PopulationGroup"}, {"end": 238, "start": 221, "tag": "CellOrMolecularDysfunction"}, {"end": 212, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 98, "tag": "BiologicFunction"}, {"end": 72, "start": 50, "tag": "Finding"}]}{"id": "1538_10", "text": "Future studies with larger samples of autosomal dominant AD are warranted to further understand sex differences in AD-related clinical and pathological markers.", "tags": [{"end": 111, "start": 100, "tag": "Finding"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 59, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 96, "tag": "OrganismAttribute"}]}{"id": "1539_0", "text": "The biological definition of Alzheimer's disease using CSF biomarkers requires abnormal levels of both amyloid (A) and tau (T).", "tags": [{"end": 87, "start": 79, "tag": "Finding"}, {"end": 94, "start": 79, "tag": "Finding"}, {"end": 122, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 59, "tag": "ClinicalAttribute"}]}{"id": "1539_1", "text": "However, biomarkers and corresponding cutoffs may not always reflect the presence or absence of pathology.", "tags": [{"end": 45, "start": 38, "tag": "ResearchActivity"}, {"end": 19, "start": 9, "tag": "ClinicalAttribute"}, {"end": 105, "start": 96, "tag": "PathologicFunction"}, {"end": 105, "start": 96, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 81, "start": 73, "tag": "Finding"}, {"end": 92, "start": 85, "tag": "Finding"}]}{"id": "1539_2", "text": "Previous studies suggest that up to 32% of individuals with autopsy-confirmed Alzheimer's disease show normal CSF p-tau levels in vivo, but these studies are sparse and had small sample sizes.", "tags": [{"end": 109, "start": 103, "tag": "Finding"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 119, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 43, "tag": "PopulationGroup"}, {"end": 16, "start": 9, "tag": "ResearchActivity"}, {"end": 153, "start": 146, "tag": "ResearchActivity"}, {"end": 119, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 127, "tag": "ResearchActivity"}, {"end": 185, "start": 179, "tag": "Substance"}, {"end": 185, "start": 179, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 110, "tag": "ClinicalAttribute"}, {"end": 67, "start": 60, "tag": "HealthCareActivity"}]}{"id": "1539_3", "text": "Therefore, in three independent autopsy cohorts, we studied whether or not CSF A+T- excluded Alzheimer's disease based on autopsy.", "tags": [{"end": 39, "start": 32, "tag": "HealthCareActivity"}, {"end": 129, "start": 122, "tag": "HealthCareActivity"}, {"end": 112, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 40, "tag": "PopulationGroup"}]}{"id": "1539_4", "text": "We included 215 individuals, for whom ante-mortem CSF collection and autopsy had been performed, from three cohorts: (i) the Amsterdam Dementia Cohort (ADC) [n = 80, 37 (46%) Alzheimer's disease at autopsy, time between CSF collection and death 4.5 +/- 2.9 years]; (ii) the Antwerp Dementia Cohort (DEM) [n = 92, 84 (91%) Alzheimer's disease at autopsy, time CSF collection to death 1.7 +/- 2.3 years]; and (iii) the Alzheimer's Disease Neuroimaging Initiative (ADNI) [n = 43, 31 (72%) Alzheimer's disease at autopsy, time CSF collection to death 5.1 +/- 2.5 years].", "tags": [{"end": 64, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 69, "tag": "HealthCareActivity"}, {"end": 205, "start": 198, "tag": "HealthCareActivity"}, {"end": 352, "start": 345, "tag": "HealthCareActivity"}, {"end": 373, "start": 363, "tag": "AminoAcidPeptideOrProtein"}, {"end": 516, "start": 509, "tag": "HealthCareActivity"}, {"end": 460, "start": 417, "tag": "ResearchActivity"}, {"end": 460, "start": 417, "tag": "HealthCareRelatedOrganization"}, {"end": 143, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 290, "start": 282, "tag": "DiseaseOrSyndrome"}, {"end": 466, "start": 462, "tag": "HealthCareRelatedOrganization"}, {"end": 466, "start": 462, "tag": "ResearchActivity"}, {"end": 244, "start": 239, "tag": "BiologicFunction"}, {"end": 382, "start": 377, "tag": "BiologicFunction"}, {"end": 546, "start": 541, "tag": "BiologicFunction"}, {"end": 244, "start": 239, "tag": "PathologicFunction"}, {"end": 382, "start": 377, "tag": "PathologicFunction"}, {"end": 546, "start": 541, "tag": "PathologicFunction"}, {"end": 244, "start": 239, "tag": "CellFunction"}, {"end": 382, "start": 377, "tag": "CellFunction"}, {"end": 546, "start": 541, "tag": "CellFunction"}, {"end": 194, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 341, "start": 322, "tag": "DiseaseOrSyndrome"}, {"end": 505, "start": 486, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 223, "start": 220, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 362, "start": 359, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 526, "start": 523, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 108, "tag": "PopulationGroup"}, {"end": 27, "start": 16, "tag": "PopulationGroup"}, {"end": 436, "start": 417, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 207, "tag": "TemporalConcept"}, {"end": 358, "start": 354, "tag": "TemporalConcept"}, {"end": 522, "start": 518, "tag": "TemporalConcept"}, {"end": 262, "start": 257, "tag": "TemporalConcept"}, {"end": 400, "start": 395, "tag": "TemporalConcept"}, {"end": 564, "start": 559, "tag": "TemporalConcept"}, {"end": 150, "start": 125, "tag": "PatientOrDisabledGroup"}, {"end": 297, "start": 274, "tag": "PatientOrDisabledGroup"}]}{"id": "1539_5", "text": "Biomarker profiles were based on dichotomized CSF A beta(1-42) and p-tau levels.", "tags": [{"end": 72, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 10, "tag": "ResearchActivity"}, {"end": 9, "start": 0, "tag": "ClinicalAttribute"}, {"end": 79, "start": 69, "tag": "ClinicalAttribute"}]}{"id": "1539_6", "text": "The accuracy of CSF AT profiles to detect autopsy-confirmed Alzheimer's disease was assessed.", "tags": [{"end": 79, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 4, "tag": "Finding"}, {"end": 31, "start": 23, "tag": "ResearchActivity"}, {"end": 49, "start": 42, "tag": "HealthCareActivity"}]}{"id": "1539_7", "text": "Lastly, we investigated whether the concordance of AT profiles with autopsy diagnosis improved when CSF was collected closer to death in 9 (10%) DEM and 30 (70%) ADNI individuals with repeated CSF measurements available.", "tags": [{"end": 75, "start": 68, "tag": "HealthCareActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 166, "start": 162, "tag": "HealthCareRelatedOrganization"}, {"end": 166, "start": 162, "tag": "ResearchActivity"}, {"end": 133, "start": 128, "tag": "BiologicFunction"}, {"end": 133, "start": 128, "tag": "PathologicFunction"}, {"end": 133, "start": 128, "tag": "CellFunction"}, {"end": 103, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 196, "start": 193, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 167, "tag": "PopulationGroup"}, {"end": 85, "start": 76, "tag": "HealthCareActivity"}, {"end": 209, "start": 197, "tag": "HealthCareActivity"}, {"end": 62, "start": 54, "tag": "ResearchActivity"}, {"end": 209, "start": 197, "tag": "ResearchActivity"}]}{"id": "1539_8", "text": "In total, 50-73% of A+T- individuals and 100% of A+T+ individuals had Alzheimer's disease at autopsy.", "tags": [{"end": 100, "start": 93, "tag": "HealthCareActivity"}, {"end": 89, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 25, "tag": "PopulationGroup"}, {"end": 65, "start": 54, "tag": "PopulationGroup"}]}{"id": "1539_9", "text": "Amyloid status showed the highest accuracy to detect autopsy-confirmed Alzheimer's disease (accuracy, sensitivity and specificity in the ADC: 88%, 92% and 84%; in the DEM: 87%, 94% and 12%; and in the ADNI cohort: 86%, 90% and 75%, respectively).", "tags": [{"end": 205, "start": 201, "tag": "HealthCareRelatedOrganization"}, {"end": 205, "start": 201, "tag": "ResearchActivity"}, {"end": 90, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 102, "tag": "Finding"}, {"end": 129, "start": 118, "tag": "Finding"}, {"end": 42, "start": 34, "tag": "Finding"}, {"end": 100, "start": 92, "tag": "Finding"}, {"end": 14, "start": 8, "tag": "Finding"}, {"end": 212, "start": 206, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 53, "tag": "HealthCareActivity"}]}{"id": "1539_10", "text": "The addition of CSF p-tau did not further improve these estimates.", "tags": [{"end": 25, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 16, "tag": "ClinicalAttribute"}]}{"id": "1539_11", "text": "We observed no differences in demographics or degree of Alzheimer's disease neuropathology between A+T- and A+T+ individuals with autopsy-confirmed Alzheimer's disease.", "tags": [{"end": 26, "start": 12, "tag": "Finding"}, {"end": 75, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 76, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 90, "start": 76, "tag": "PathologicFunction"}, {"end": 124, "start": 113, "tag": "PopulationGroup"}, {"end": 137, "start": 130, "tag": "HealthCareActivity"}]}{"id": "1539_12", "text": "All individuals with repeated CSF measurements remained stable in A beta(1-42) status during follow-up.", "tags": [{"end": 33, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 4, "tag": "PopulationGroup"}, {"end": 102, "start": 93, "tag": "HealthCareActivity"}, {"end": 102, "start": 93, "tag": "TemporalConcept"}, {"end": 46, "start": 34, "tag": "HealthCareActivity"}, {"end": 85, "start": 79, "tag": "Finding"}, {"end": 78, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 34, "tag": "ResearchActivity"}, {"end": 78, "start": 66, "tag": "BiologicallyActiveSubstance"}]}{"id": "1539_13", "text": "None of the Alzheimer's disease individuals with a normal p-tau status changed to abnormal; however, four (44%) DEM individuals and two (7%) ADNI individuals changed from abnormal to normal p-tau status over time, and all had Alzheimer's disease at autopsy.", "tags": [{"end": 256, "start": 249, "tag": "HealthCareActivity"}, {"end": 57, "start": 51, "tag": "Finding"}, {"end": 189, "start": 183, "tag": "Finding"}, {"end": 90, "start": 82, "tag": "Finding"}, {"end": 179, "start": 171, "tag": "Finding"}, {"end": 145, "start": 141, "tag": "HealthCareRelatedOrganization"}, {"end": 145, "start": 141, "tag": "ResearchActivity"}, {"end": 63, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 195, "start": 192, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 245, "start": 226, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 192, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 32, "tag": "PopulationGroup"}, {"end": 127, "start": 116, "tag": "PopulationGroup"}, {"end": 157, "start": 146, "tag": "PopulationGroup"}, {"end": 212, "start": 208, "tag": "TemporalConcept"}, {"end": 63, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 195, "start": 190, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 190, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 64, "tag": "Finding"}, {"end": 202, "start": 196, "tag": "Finding"}]}{"id": "1539_14", "text": "In summary, we found that up to 73% of A+T- individuals had Alzheimer's disease at autopsy.", "tags": [{"end": 90, "start": 83, "tag": "HealthCareActivity"}, {"end": 79, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 44, "tag": "PopulationGroup"}]}{"id": "1539_15", "text": "This should be taken into account in both research and clinical settings.", "tags": [{"end": 72, "start": 55, "tag": "ResearchActivity"}, {"end": 50, "start": 42, "tag": "ResearchActivity"}]}{"id": "1539_16", "text": "The biological definition of Alzheimer's disease using CSF biomarkers requires both abnormal amyloid (A) and tau (T) levels.", "tags": [{"end": 92, "start": 84, "tag": "Finding"}, {"end": 112, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 59, "tag": "ClinicalAttribute"}]}{"id": "1539_17", "text": "However, in a large multicentre cohort, Vromen et al.", "tags": [{"end": 38, "start": 32, "tag": "PopulationGroup"}]}{"id": "1539_18", "text": "found that up to 73% of A+T- individuals had Alzheimer's disease at autopsy, with implications for both research and clinical settings.", "tags": [{"end": 75, "start": 68, "tag": "HealthCareActivity"}, {"end": 134, "start": 117, "tag": "ResearchActivity"}, {"end": 64, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 29, "tag": "PopulationGroup"}, {"end": 112, "start": 104, "tag": "ResearchActivity"}]}{"id": "1540_0", "text": "Background: Obesity is related to quantitative neuroimaging abnormalities including reduced gray matter volumes and impaired white matter microstructural integrity, although the underlying mechanisms are not well understood.", "tags": [{"end": 19, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 154, "tag": "IndividualBehavior"}, {"end": 59, "start": 47, "tag": "HealthCareActivity"}, {"end": 103, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 34, "tag": "Finding"}, {"end": 163, "start": 125, "tag": "ClinicalAttribute"}, {"end": 111, "start": 92, "tag": "ClinicalAttribute"}]}{"id": "1540_1", "text": "Objective: We assessed influence of obesity on neuroinflammation imaging that may mediate brain morphometric changes.", "tags": [{"end": 43, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 65, "tag": "HealthCareActivity"}, {"end": 95, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 47, "tag": "PathologicFunction"}]}{"id": "1540_2", "text": "Establishing the role of neuroinflammation in obesity will enhance understanding of this modifiable disorder as a risk factor for Alzheimer's disease (AD) dementia.", "tags": [{"end": 53, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 114, "tag": "Finding"}, {"end": 149, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 25, "tag": "PathologicFunction"}, {"end": 163, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 67, "tag": "BiologicFunction"}]}{"id": "1540_3", "text": "Methods: We analyzed brain MRIs from 104 cognitively normal participants (CDR = 0) and biomarker negativity for CSF amyloid or tau.", "tags": [{"end": 31, "start": 27, "tag": "HealthCareActivity"}, {"end": 123, "start": 112, "tag": "ClinicalAttribute"}, {"end": 130, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 87, "tag": "ClinicalAttribute"}, {"end": 26, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 60, "tag": "PopulationGroup"}, {"end": 123, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 41, "tag": "Finding"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 130, "start": 127, "tag": "ClinicalAttribute"}, {"end": 115, "start": 112, "tag": "ClinicalAttribute"}]}{"id": "1540_4", "text": "We classified body mass index (BMI) as normal (BMI <25, N = 62) or overweight and obese (BMI = 25, N = 42).", "tags": [{"end": 77, "start": 67, "tag": "Finding"}, {"end": 87, "start": 82, "tag": "Finding"}, {"end": 45, "start": 39, "tag": "Finding"}, {"end": 34, "start": 31, "tag": "ClinicalAttribute"}, {"end": 50, "start": 47, "tag": "ClinicalAttribute"}, {"end": 92, "start": 89, "tag": "ClinicalAttribute"}, {"end": 29, "start": 14, "tag": "ClinicalAttribute"}, {"end": 18, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1540_5", "text": "Blood pressure was measured.", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 0, "tag": "BiologicFunction"}]}{"id": "1540_6", "text": "BMI and blood pressure classifications were related to neuroinflammation imaging (NII) derived edema fraction in 17 white matter tracts.", "tags": [{"end": 100, "start": 95, "tag": "PathologicFunction"}, {"end": 135, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 73, "tag": "HealthCareActivity"}, {"end": 22, "start": 8, "tag": "BiologicFunction"}, {"end": 3, "start": 0, "tag": "ClinicalAttribute"}, {"end": 72, "start": 55, "tag": "PathologicFunction"}, {"end": 109, "start": 95, "tag": "ClinicalAttribute"}]}{"id": "1540_7", "text": "This metric was also correlated to hippocampal volumes and CSF biomarkers of inflammation and neurodegeneration: YKL-40, SNAP25, VILIP, tau, and NFL.", "tags": [{"end": 127, "start": 121, "tag": "GeneOrGenome"}, {"end": 127, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 77, "tag": "PathologicFunction"}, {"end": 139, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 63, "tag": "ClinicalAttribute"}, {"end": 111, "start": 94, "tag": "CellOrMolecularDysfunction"}, {"end": 54, "start": 35, "tag": "ClinicalAttribute"}, {"end": 127, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 129, "tag": "BiologicallyActiveSubstance"}]}{"id": "1540_8", "text": "Results: Participants with BMI <25 had lower NII-derived edema fraction, with protective effects of normal blood pressure.", "tags": [{"end": 62, "start": 57, "tag": "PathologicFunction"}, {"end": 106, "start": 100, "tag": "Finding"}, {"end": 121, "start": 107, "tag": "BiologicFunction"}, {"end": 30, "start": 27, "tag": "ClinicalAttribute"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 21, "start": 9, "tag": "PopulationGroup"}, {"end": 96, "start": 78, "tag": "Finding"}, {"end": 71, "start": 57, "tag": "ClinicalAttribute"}]}{"id": "1540_9", "text": "Statistically significant white matter tracts included the internal capsule, external capsule, and corona radiata, FDR corrected for multiple comparisons to alpha = 0.05.", "tags": [{"end": 75, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1540_10", "text": "Higher NII-derived edema fractions in the internal capsule, corpus callosum, gyrus, and superior fronto-occipital fasciculus were related with smaller hippocampal volumes only in individuals with BMI >= 25.", "tags": [{"end": 24, "start": 19, "tag": "PathologicFunction"}, {"end": 58, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 199, "start": 196, "tag": "ClinicalAttribute"}, {"end": 190, "start": 179, "tag": "PopulationGroup"}, {"end": 82, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 170, "start": 151, "tag": "ClinicalAttribute"}]}{"id": "1540_11", "text": "There were no statistically significant correlations between NII-derived edema fraction and CSF biomarkers.", "tags": [{"end": 78, "start": 73, "tag": "PathologicFunction"}, {"end": 52, "start": 28, "tag": "Finding"}, {"end": 95, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 96, "tag": "ClinicalAttribute"}, {"end": 87, "start": 73, "tag": "ClinicalAttribute"}]}{"id": "1540_12", "text": "Conclusion: We demonstrate statistically significant relationships between neuroinflammation, elevated BMI, and hippocampal volume, raising implications for neuroinflammation mechanisms of obesity-related brain dysfunction in cognitively normal elderly.", "tags": [{"end": 66, "start": 41, "tag": "Finding"}, {"end": 222, "start": 211, "tag": "PathologicFunction"}, {"end": 106, "start": 103, "tag": "ClinicalAttribute"}, {"end": 210, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 75, "tag": "PathologicFunction"}, {"end": 174, "start": 157, "tag": "PathologicFunction"}, {"end": 244, "start": 226, "tag": "Finding"}, {"end": 252, "start": 245, "tag": "PopulationGroup"}, {"end": 130, "start": 112, "tag": "ClinicalAttribute"}, {"end": 196, "start": 189, "tag": "DiseaseOrSyndrome"}]}{"id": "1541_0", "text": "Background: Psychotic symptoms are common in Alzheimer's disease (AD) and related neurodegenerative disorders and are associated with more rapid disease progression and increased mortality.", "tags": [{"end": 30, "start": 12, "tag": "SignOrSymptom"}, {"end": 188, "start": 179, "tag": "Finding"}, {"end": 109, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 153, "tag": "PathologicFunction"}, {"end": 164, "start": 153, "tag": "TemporalConcept"}, {"end": 164, "start": 145, "tag": "PathologicFunction"}]}{"id": "1541_1", "text": "It is unclear to what degree existing criteria are utilized in clinical research and practice.", "tags": [{"end": 80, "start": 63, "tag": "ResearchActivity"}, {"end": 93, "start": 85, "tag": "BiologicFunction"}, {"end": 93, "start": 85, "tag": "HealthCareActivity"}, {"end": 71, "start": 63, "tag": "HealthCareActivity"}]}{"id": "1541_2", "text": "Objective: To establish research criteria for the diagnosis of psychosis in AD.", "tags": [{"end": 72, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 24, "tag": "ResearchActivity"}, {"end": 59, "start": 50, "tag": "HealthCareActivity"}]}{"id": "1541_3", "text": "Methods: The International Society to Advance Alzheimer's Research and Treatment (ISTAART) Neuropsychiatric Symptoms (NPS) Professional Interest Area (PIA) psychosis subgroup reviewed existing criteria for psychosis in AD and related dementias.", "tags": [{"end": 121, "start": 118, "tag": "SignOrSymptom"}, {"end": 165, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 243, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 219, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 13, "tag": "HealthCareRelatedOrganization"}, {"end": 89, "start": 82, "tag": "HealthCareRelatedOrganization"}, {"end": 116, "start": 91, "tag": "SignOrSymptom"}]}{"id": "1541_4", "text": "Through a series of in person and on-line meetings, a priority checklist was devised to capture features necessary for current research and clinical needs.", "tags": [{"end": 29, "start": 23, "tag": "PopulationGroup"}, {"end": 50, "start": 34, "tag": "ResearchActivity"}, {"end": 126, "start": 119, "tag": "TemporalConcept"}, {"end": 135, "start": 127, "tag": "ResearchActivity"}, {"end": 62, "start": 54, "tag": "Finding"}]}{"id": "1541_5", "text": "PubMed, Medline and other relevant databases were searched for relevant criteria.", "tags": [{"end": 44, "start": 35, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "HealthCareRelatedOrganization"}, {"end": 15, "start": 8, "tag": "HealthCareRelatedOrganization"}]}{"id": "1541_6", "text": "Results: Consensus identified three sets of criteria suitable for review including those of Jeste and Finkel, Lyketsos, and the Diagnostic and Statistical Manual for Mental Disorders, 5th edition.", "tags": [{"end": 72, "start": 66, "tag": "ResearchActivity"}, {"end": 72, "start": 66, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 182, "start": 128, "tag": "HealthCareActivity"}]}{"id": "1541_7", "text": "It was concluded that existing criteria could be augmented by including a more specific differentiation between delusions and hallucinations, address overlap with related conditions (agitation in particular), adding the possibility of symptoms emerging in the preclinical and prodromal phases, and building on developing research in disease biomarkers.", "tags": [{"end": 121, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 183, "tag": "SignOrSymptom"}, {"end": 103, "start": 88, "tag": "CellFunction"}, {"end": 157, "start": 150, "tag": "TemporalConcept"}, {"end": 243, "start": 235, "tag": "SignOrSymptom"}, {"end": 181, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 329, "start": 321, "tag": "ResearchActivity"}, {"end": 351, "start": 341, "tag": "ClinicalAttribute"}, {"end": 292, "start": 286, "tag": "TemporalConcept"}, {"end": 271, "start": 260, "tag": "TemporalConcept"}, {"end": 292, "start": 276, "tag": "TemporalConcept"}]}{"id": "1541_8", "text": "Conclusion: We propose criteria, developed to improve phenotypic classification of psychosis in AD, and advance the research agenda in the field to improve epidemiological, biomarker, and genetics research in the field.", "tags": [{"end": 131, "start": 116, "tag": "ResearchActivity"}, {"end": 171, "start": 156, "tag": "ResearchActivity"}, {"end": 196, "start": 188, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 196, "start": 188, "tag": "CellFunction"}, {"end": 92, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 173, "tag": "ClinicalAttribute"}, {"end": 205, "start": 197, "tag": "ResearchActivity"}, {"end": 64, "start": 54, "tag": "OrganismAttribute"}, {"end": 79, "start": 65, "tag": "ResearchActivity"}]}{"id": "1541_9", "text": "These criteria serve as a complement to the International Psychogeriatric Association criteria for psychosis in neurocognitive disorders.", "tags": [{"end": 136, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 44, "tag": "HealthCareRelatedOrganization"}]}{"id": "1542_0", "text": "The identification of reliable biomarkers in biological fluids is paramount to optimizing the diagnosis of Alzheimer's disease (AD).", "tags": [{"end": 126, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 94, "tag": "HealthCareActivity"}, {"end": 41, "start": 31, "tag": "ClinicalAttribute"}, {"end": 62, "start": 45, "tag": "Substance"}]}{"id": "1542_1", "text": "Measurement of A beta 42, t-tau, and p-tau in cerebrospinal fluid (CSF) is the most accepted method to support the diagnosis of AD.", "tags": [{"end": 11, "start": 0, "tag": "ResearchActivity"}, {"end": 11, "start": 0, "tag": "HealthCareActivity"}, {"end": 24, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 93, "tag": "ResearchActivity"}, {"end": 99, "start": 93, "tag": "HealthCareActivity"}, {"end": 124, "start": 115, "tag": "HealthCareActivity"}, {"end": 31, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 15, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1542_2", "text": "However, lumbar puncture represents an invasive investigation, whereas saliva is one of the most accessible body fluids.", "tags": [{"end": 119, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 108, "tag": "Substance"}, {"end": 47, "start": 39, "tag": "Finding"}, {"end": 61, "start": 48, "tag": "ResearchActivity"}, {"end": 24, "start": 9, "tag": "HealthCareActivity"}, {"end": 77, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1542_3", "text": "The aim of our study was to investigate salivary concentrations in AD and evaluate the correlation between salivary and CSF A beta 42 concentrations in AD patients, patients with non-AD dementias, and controls.", "tags": [{"end": 63, "start": 49, "tag": "BiologicFunction"}, {"end": 148, "start": 120, "tag": "ClinicalAttribute"}, {"end": 133, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 209, "start": 201, "tag": "PopulationGroup"}, {"end": 163, "start": 155, "tag": "PatientOrDisabledGroup"}, {"end": 173, "start": 165, "tag": "PatientOrDisabledGroup"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 130, "start": 124, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1542_4", "text": "We recruited 100 subjects: 18 AD patients, 64 patients with non-AD dementias, and 18 controls.", "tags": [{"end": 76, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 85, "tag": "PopulationGroup"}, {"end": 41, "start": 33, "tag": "PatientOrDisabledGroup"}, {"end": 54, "start": 46, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 17, "tag": "PopulationGroup"}]}{"id": "1542_5", "text": "The mean saliva A beta 42 concentrations in AD patients were higher than in controls (p < 0.001), and to patients with non-AD dementias (p = 0.001).", "tags": [{"end": 40, "start": 9, "tag": "ClinicalAttribute"}, {"end": 25, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 76, "tag": "PopulationGroup"}, {"end": 55, "start": 47, "tag": "PatientOrDisabledGroup"}, {"end": 113, "start": 105, "tag": "PatientOrDisabledGroup"}, {"end": 22, "start": 16, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1542_6", "text": "A significant negative correlation between salivary and CSF A beta 42 concentrations was found in the overall group (r = -0.562, p < 0.001) and in non-AD patients (r = -0.443, p < 0.001).", "tags": [{"end": 84, "start": 56, "tag": "ClinicalAttribute"}, {"end": 69, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 154, "tag": "PatientOrDisabledGroup"}, {"end": 115, "start": 110, "tag": "PopulationGroup"}, {"end": 66, "start": 60, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1542_7", "text": "Salivary A beta 42 concentrations positively correlated with CSF t-tau (r = 0.321, p = 0.001) and p-tau (r = 0.297, p = 0.001).", "tags": [{"end": 33, "start": 0, "tag": "ClinicalAttribute"}, {"end": 18, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 61, "tag": "ClinicalAttribute"}, {"end": 103, "start": 98, "tag": "ClinicalAttribute"}, {"end": 64, "start": 61, "tag": "ClinicalAttribute"}]}{"id": "1542_8", "text": "Our study showed that in AD patients' saliva, A beta 42 concentrations are specifically increased, and we found an interesting negative correlation between CSF and salivary A beta 42 concentrations that warrants further investigation.", "tags": [{"end": 70, "start": 56, "tag": "BiologicFunction"}, {"end": 197, "start": 164, "tag": "ClinicalAttribute"}, {"end": 233, "start": 220, "tag": "ResearchActivity"}, {"end": 55, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 182, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 182, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 28, "tag": "PatientOrDisabledGroup"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 52, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 127, "tag": "ResearchActivity"}]}{"id": "1543_0", "text": "Author Summary Functional network disruption is a well-established finding in Alzheimer's disease.", "tags": [{"end": 74, "start": 67, "tag": "Finding"}, {"end": 97, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 15, "tag": "PathologicFunction"}]}{"id": "1543_1", "text": "Sensitive network-based biomarkers are however not available.", "tags": [{"end": 9, "start": 0, "tag": "PathologicFunction"}, {"end": 34, "start": 24, "tag": "ClinicalAttribute"}, {"end": 17, "start": 10, "tag": "PopulationGroup"}, {"end": 17, "start": 10, "tag": "CellFunction"}]}{"id": "1543_2", "text": "We aimed to detect neuronal dysfunction at a predementia (mild cognitive impairment, MCI) stage of Alzheimer's disease, by applying a network-level neural variability measure to magnetoencephalography data: the inverted joint permutation entropy (JPE(inv)).", "tags": [{"end": 18, "start": 12, "tag": "Finding"}, {"end": 39, "start": 19, "tag": "CellOrMolecularDysfunction"}, {"end": 200, "start": 178, "tag": "HealthCareActivity"}, {"end": 118, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 201, "tag": "ResearchActivity"}, {"end": 83, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 155, "tag": "Finding"}, {"end": 141, "start": 134, "tag": "PopulationGroup"}, {"end": 141, "start": 134, "tag": "CellFunction"}, {"end": 83, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 58, "tag": "Finding"}, {"end": 95, "start": 90, "tag": "TemporalConcept"}, {"end": 95, "start": 90, "tag": "ClinicalAttribute"}, {"end": 245, "start": 211, "tag": "ClinicalAttribute"}, {"end": 56, "start": 45, "tag": "TemporalConcept"}, {"end": 174, "start": 167, "tag": "ResearchActivity"}, {"end": 174, "start": 167, "tag": "HealthCareActivity"}, {"end": 255, "start": 247, "tag": "ClinicalAttribute"}]}{"id": "1543_3", "text": "This measure integrates information on local signal variability/complexity and nonlinear coupling.", "tags": [{"end": 97, "start": 89, "tag": "Finding"}, {"end": 63, "start": 52, "tag": "Finding"}]}{"id": "1543_4", "text": "We found significant differences in JPE(inv) between subjects with subjective cognitive decline and MCI, primarily in the theta band.", "tags": [{"end": 132, "start": 122, "tag": "ResearchActivity"}, {"end": 95, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 9, "tag": "Finding"}, {"end": 95, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 53, "tag": "PopulationGroup"}, {"end": 44, "start": 36, "tag": "ClinicalAttribute"}]}{"id": "1543_5", "text": "The diagnostic ability of the JPE(inv) was reported to be similar to that of relative theta power, the most potent neurophysiological biomarker of predementia Alzheimer's disease to date.", "tags": [{"end": 186, "start": 179, "tag": "TemporalConcept"}, {"end": 186, "start": 182, "tag": "TemporalConcept"}, {"end": 22, "start": 15, "tag": "OrganismAttribute"}, {"end": 178, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 115, "tag": "ClinicalAttribute"}, {"end": 14, "start": 4, "tag": "HealthCareActivity"}, {"end": 38, "start": 30, "tag": "ClinicalAttribute"}, {"end": 97, "start": 86, "tag": "ClinicalAttribute"}, {"end": 158, "start": 147, "tag": "TemporalConcept"}]}{"id": "1543_6", "text": "Increasing evidence suggests that measures of signal variability and complexity could present promising biomarkers for Alzheimer's disease (AD).", "tags": [{"end": 138, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 94, "tag": "ClinicalAttribute"}, {"end": 64, "start": 46, "tag": "Finding"}, {"end": 19, "start": 11, "tag": "Finding"}]}{"id": "1543_7", "text": "Earlier studies have however been limited to the characterization of local activity.", "tags": [{"end": 65, "start": 49, "tag": "ResearchActivity"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}]}{"id": "1543_8", "text": "Here, we investigate whether a network version of permutation entropy could serve as a novel biomarker for early-stage AD.", "tags": [{"end": 102, "start": 87, "tag": "ClinicalAttribute"}, {"end": 69, "start": 62, "tag": "NaturalPhenomenonOrProcess"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 93, "tag": "ClinicalAttribute"}, {"end": 112, "start": 107, "tag": "TemporalConcept"}, {"end": 38, "start": 31, "tag": "PopulationGroup"}, {"end": 38, "start": 31, "tag": "CellFunction"}, {"end": 118, "start": 113, "tag": "TemporalConcept"}, {"end": 118, "start": 113, "tag": "ClinicalAttribute"}, {"end": 69, "start": 31, "tag": "ClinicalAttribute"}]}{"id": "1543_9", "text": "Resting-state source-space magnetoencephalography was recorded in 18 subjects with subjective cognitive decline (SCD) and 18 subjects with mild cognitive impairment (MCI).", "tags": [{"end": 49, "start": 0, "tag": "HealthCareActivity"}, {"end": 111, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 69, "tag": "PopulationGroup"}, {"end": 133, "start": 125, "tag": "PopulationGroup"}, {"end": 143, "start": 139, "tag": "Finding"}]}{"id": "1543_10", "text": "Local activity was characterized by permutation entropy (PE).", "tags": [{"end": 55, "start": 48, "tag": "NaturalPhenomenonOrProcess"}, {"end": 55, "start": 36, "tag": "ResearchActivity"}]}{"id": "1543_11", "text": "Network-level interactions were studied using the inverted joint permutation entropy (JPE(inv)), corrected for volume conduction.", "tags": [{"end": 128, "start": 118, "tag": "BiologicFunction"}, {"end": 128, "start": 118, "tag": "NaturalPhenomenonOrProcess"}, {"end": 84, "start": 77, "tag": "NaturalPhenomenonOrProcess"}, {"end": 64, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 14, "tag": "Finding"}, {"end": 84, "start": 50, "tag": "ClinicalAttribute"}, {"end": 94, "start": 86, "tag": "ClinicalAttribute"}]}{"id": "1543_12", "text": "The JPE(inv) showed a reduction of nonlinear connectivity in MCI subjects in the theta and alpha band.", "tags": [{"end": 31, "start": 22, "tag": "Finding"}, {"end": 31, "start": 22, "tag": "NaturalPhenomenonOrProcess"}, {"end": 64, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 65, "tag": "PopulationGroup"}, {"end": 57, "start": 45, "tag": "BiologicFunction"}, {"end": 12, "start": 4, "tag": "ClinicalAttribute"}, {"end": 101, "start": 81, "tag": "ResearchActivity"}]}{"id": "1543_13", "text": "Local PE showed increased theta band entropy.", "tags": [{"end": 36, "start": 26, "tag": "ResearchActivity"}, {"end": 44, "start": 37, "tag": "NaturalPhenomenonOrProcess"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}]}{"id": "1543_14", "text": "Between-group differences were widespread across brain regions.", "tags": [{"end": 25, "start": 8, "tag": "Finding"}, {"end": 62, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 14, "tag": "Finding"}, {"end": 13, "start": 8, "tag": "PopulationGroup"}]}{"id": "1543_15", "text": "Receiver operating characteristic (ROC) analysis of classification of MCI versus SCD subjects revealed that a logistic regression model trained on JPE(inv) features (78.4% [62.5-93.3%]) slightly outperformed PE (76.9% [60.3-93.4%]) and relative theta power-based models (76.9% [60.4-93.3%]).", "tags": [{"end": 135, "start": 110, "tag": "ResearchActivity"}, {"end": 38, "start": 35, "tag": "ResearchActivity"}, {"end": 84, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 33, "start": 0, "tag": "ResearchActivity"}, {"end": 269, "start": 263, "tag": "ResearchActivity"}, {"end": 93, "start": 85, "tag": "PopulationGroup"}, {"end": 155, "start": 147, "tag": "ClinicalAttribute"}, {"end": 256, "start": 245, "tag": "ClinicalAttribute"}]}{"id": "1543_16", "text": "Classification performance of theta JPE(inv) was at least as good as the relative theta power benchmark.", "tags": [{"end": 26, "start": 15, "tag": "Finding"}, {"end": 93, "start": 82, "tag": "ClinicalAttribute"}, {"end": 44, "start": 30, "tag": "ClinicalAttribute"}]}{"id": "1543_17", "text": "The JPE(inv) is therefore a potential biomarker for early-stage AD that should be explored in larger studies.", "tags": [{"end": 66, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 38, "tag": "ClinicalAttribute"}, {"end": 108, "start": 101, "tag": "ResearchActivity"}, {"end": 57, "start": 52, "tag": "TemporalConcept"}, {"end": 47, "start": 28, "tag": "ClinicalAttribute"}, {"end": 63, "start": 58, "tag": "TemporalConcept"}, {"end": 63, "start": 58, "tag": "ClinicalAttribute"}, {"end": 12, "start": 4, "tag": "ClinicalAttribute"}]}{"id": "1544_0", "text": "The coronavirus disease 2019 (COVID-19) pandemic led to an abrupt halt of many Alzheimer's disease (AD) research studies at sites spanning the world.", "tags": [{"end": 120, "start": 104, "tag": "ResearchActivity"}, {"end": 148, "start": 143, "tag": "PopulationGroup"}, {"end": 98, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 4, "tag": "Virus"}, {"end": 28, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 30, "tag": "DiseaseOrSyndrome"}]}{"id": "1544_1", "text": "This is especially true for studies requiring in-person contact, such as studies collecting biofluids.", "tags": [{"end": 35, "start": 28, "tag": "ResearchActivity"}, {"end": 80, "start": 73, "tag": "ResearchActivity"}, {"end": 101, "start": 92, "tag": "Substance"}]}{"id": "1544_2", "text": "Since COVID-19 is likely to remain a threat for an extended period, the resumption of fluid biomarker studies requires the development and implementation of procedures that minimize the risk of in-person visits to participants, staff, and individuals handling the biofluid samples.", "tags": [{"end": 167, "start": 157, "tag": "HealthCareActivity"}, {"end": 233, "start": 228, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 101, "start": 92, "tag": "ClinicalAttribute"}, {"end": 226, "start": 214, "tag": "PopulationGroup"}, {"end": 250, "start": 239, "tag": "PopulationGroup"}, {"end": 91, "start": 86, "tag": "Substance"}, {"end": 134, "start": 123, "tag": "BiologicFunction"}, {"end": 134, "start": 123, "tag": "CellFunction"}, {"end": 109, "start": 102, "tag": "ResearchActivity"}, {"end": 66, "start": 60, "tag": "TemporalConcept"}, {"end": 14, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 194, "tag": "HealthCareActivity"}, {"end": 280, "start": 264, "tag": "Substance"}]}{"id": "1544_3", "text": "Some issues to consider include structuring the visit workflow to minimize contacts and promote social distancing; screening and/or testing participants and staff for COVID-19; wearing masks and performing hand hygiene; and precautions for handling, storing, and analyzing biofluids.", "tags": [{"end": 124, "start": 115, "tag": "HealthCareActivity"}, {"end": 124, "start": 115, "tag": "ResearchActivity"}, {"end": 162, "start": 157, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 218, "start": 206, "tag": "IndividualBehavior"}, {"end": 218, "start": 206, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 53, "start": 48, "tag": "HealthCareActivity"}, {"end": 152, "start": 140, "tag": "PopulationGroup"}, {"end": 139, "start": 132, "tag": "HealthCareActivity"}, {"end": 282, "start": 273, "tag": "Substance"}, {"end": 113, "start": 96, "tag": "Finding"}, {"end": 175, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 177, "tag": "Finding"}]}{"id": "1544_4", "text": "AD fluid biomarker research remains a vitally important public health priority and resuming studies requires appropriate safety procedures to protect research participants and staff.", "tags": [{"end": 138, "start": 121, "tag": "HealthCareActivity"}, {"end": 181, "start": 176, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 69, "start": 56, "tag": "HealthCareActivity"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 9, "tag": "ClinicalAttribute"}, {"end": 171, "start": 159, "tag": "PopulationGroup"}, {"end": 8, "start": 3, "tag": "Substance"}, {"end": 27, "start": 19, "tag": "ResearchActivity"}, {"end": 158, "start": 150, "tag": "ResearchActivity"}, {"end": 99, "start": 92, "tag": "ResearchActivity"}, {"end": 78, "start": 70, "tag": "Finding"}]}{"id": "1545_0", "text": "Cerebrospinal fluid neurofilament light and plasma neurofilament light concentrations are elevated in patients with mild cognitive im-pairment and Alzheimer's disease.", "tags": [{"end": 142, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 102, "tag": "PatientOrDisabledGroup"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 44, "tag": "ClinicalAttribute"}]}{"id": "1545_1", "text": "We investigated the clinical rele-vance of increased neurofilament light concentrations in mild cog-nitive impairment and Alzheimer's disease patients.", "tags": [{"end": 117, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 73, "tag": "BiologicFunction"}, {"end": 141, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 142, "tag": "PatientOrDisabledGroup"}, {"end": 15, "start": 3, "tag": "ResearchActivity"}, {"end": 95, "start": 91, "tag": "Finding"}]}{"id": "1545_2", "text": "In this study, 244 subjects were divided into cognitively normal control (n = 67), stable mild cognitive impairment (n = 52), progressive mild cogni-tive impairment (n = 68), and Alzheimer's disease (n = 57).", "tags": [{"end": 198, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 126, "tag": "TemporalConcept"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 72, "start": 65, "tag": "PopulationGroup"}, {"end": 64, "start": 46, "tag": "Finding"}, {"end": 115, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 19, "tag": "PopulationGroup"}, {"end": 142, "start": 138, "tag": "Finding"}]}{"id": "1545_3", "text": "Linear regression examined the relationships between neurofilament light levels in cerebrospinal fluid or plasma and the diagnostic group.", "tags": [{"end": 72, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 0, "tag": "ResearchActivity"}, {"end": 102, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 31, "tag": "Finding"}, {"end": 112, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 121, "tag": "PopulationGroup"}]}{"id": "1545_4", "text": "The relationships between neurofilament light and other biomark-ers were assessed by Spearman correlation.", "tags": [{"end": 45, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 4, "tag": "Finding"}, {"end": 105, "start": 85, "tag": "ResearchActivity"}]}{"id": "1545_5", "text": "Linear mixed-effects models were used to test cerebrospinal fluid and plasma neurofil-ament light as predictors of Alzheimer's disease characteristics, in-cluding cognition, cortical glucose metabolism, and brain structure.", "tags": [{"end": 222, "start": 207, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 183, "tag": "CellFunction"}, {"end": 150, "start": 127, "tag": "ClinicalAttribute"}, {"end": 182, "start": 174, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 101, "tag": "Finding"}, {"end": 150, "start": 135, "tag": "OrganismAttribute"}, {"end": 201, "start": 191, "tag": "BiologicFunction"}, {"end": 201, "start": 191, "tag": "CellFunction"}, {"end": 134, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 183, "tag": "Chemical"}, {"end": 190, "start": 183, "tag": "PharmacologicSubstance"}, {"end": 190, "start": 183, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 163, "tag": "BiologicFunction"}, {"end": 27, "start": 0, "tag": "ResearchActivity"}, {"end": 45, "start": 41, "tag": "ResearchActivity"}, {"end": 45, "start": 41, "tag": "HealthCareActivity"}, {"end": 97, "start": 70, "tag": "ClinicalAttribute"}]}{"id": "1545_6", "text": "Cerebrospinal fluid and plasma neurofilament light levels were sig-nificantly elevated in Alzheimer's disease.", "tags": [{"end": 50, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 24, "tag": "ClinicalAttribute"}]}{"id": "1545_7", "text": "Still, the correlations be-tween neurofilament light and other cerebrospinal fluid biomark-ers within the diagnostic groups were often not statistically signif-icant.", "tags": [{"end": 52, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 117, "tag": "PopulationGroup"}, {"end": 116, "start": 106, "tag": "HealthCareActivity"}, {"end": 23, "start": 11, "tag": "ResearchActivity"}, {"end": 94, "start": 83, "tag": "ClinicalAttribute"}]}{"id": "1545_8", "text": "In addition, the diagnostic accuracy of cerebrospinal fluid and plasma neurofilament light for progressive mild cognitive im-pairment and Alzheimer's disease was almost the same as that of cerebrospinal fluid total tau (T-tau).", "tags": [{"end": 90, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 225, "start": 220, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 220, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 17, "tag": "Finding"}, {"end": 218, "start": 215, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 222, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 218, "start": 215, "tag": "BiologicallyActiveSubstance"}, {"end": 225, "start": 222, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 189, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 95, "tag": "TemporalConcept"}, {"end": 218, "start": 209, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 209, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 107, "tag": "Finding"}, {"end": 218, "start": 189, "tag": "ClinicalAttribute"}, {"end": 90, "start": 64, "tag": "ClinicalAttribute"}]}{"id": "1545_9", "text": "It is phosphorylated tau (P-tau) and high cerebrospinal fluid.", "tags": [{"end": 20, "start": 6, "tag": "CellFunction"}, {"end": 31, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 37, "tag": "Finding"}]}{"id": "1545_10", "text": "Neurofilament light predicted conversion from mild cognitive impairment to Alzheimer's disease.", "tags": [{"end": 19, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 46, "tag": "Finding"}, {"end": 40, "start": 30, "tag": "Finding"}]}{"id": "1545_11", "text": "A high neurofilament light is related to poor cognition, low cere-bral metabolism, hippocampal atrophy, and ventricular enlarge-ment caused by Alzheimer's disease.", "tags": [{"end": 55, "start": 41, "tag": "Finding"}, {"end": 102, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 71, "tag": "BiologicFunction"}, {"end": 81, "start": 71, "tag": "CellFunction"}, {"end": 60, "start": 57, "tag": "Finding"}, {"end": 162, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 46, "tag": "BiologicFunction"}, {"end": 94, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 83, "tag": "Cell"}, {"end": 6, "start": 2, "tag": "Finding"}]}{"id": "1545_12", "text": "Our work further identifies cerebrospinal fluid neurofilament light and plasma neurofilament light as biomarkers of axonal degeneration in patients with mild cog-nitive impairment and Alzheimer's disease.", "tags": [{"end": 135, "start": 116, "tag": "CellOrMolecularDysfunction"}, {"end": 67, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 123, "tag": "PathologicFunction"}, {"end": 203, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 139, "tag": "PatientOrDisabledGroup"}, {"end": 112, "start": 102, "tag": "ClinicalAttribute"}, {"end": 78, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 116, "tag": "CellComponent"}, {"end": 179, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 28, "tag": "ClinicalAttribute"}, {"end": 98, "start": 72, "tag": "ClinicalAttribute"}]}{"id": "1546_0", "text": "Introduction: Retinal thickness measured with optical coherence tomography has been proposed as a noninvasive biomarker for Alzheimer's disease (AD).", "tags": [{"end": 21, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 46, "tag": "HealthCareActivity"}, {"end": 143, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 98, "tag": "ClinicalAttribute"}, {"end": 31, "start": 14, "tag": "ClinicalAttribute"}]}{"id": "1546_1", "text": "We therefore measured retinal thickness in well-characterized AD and control participants, considering ophthalmological confounders.", "tags": [{"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 77, "tag": "PopulationGroup"}, {"end": 131, "start": 103, "tag": "Finding"}, {"end": 39, "start": 22, "tag": "ClinicalAttribute"}]}{"id": "1546_2", "text": "Methods: We included 57 amyloid-proven AD cases and 85 cognitively normal, amyloid-negative controls.", "tags": [{"end": 31, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 92, "tag": "PopulationGroup"}, {"end": 73, "start": 55, "tag": "Finding"}, {"end": 47, "start": 39, "tag": "PatientOrDisabledGroup"}]}{"id": "1546_3", "text": "All subjects underwent retinal thickness measurements with spectral domain optical coherence tomography and an ophthalmological assessment to exclude ocular disease.", "tags": [{"end": 103, "start": 59, "tag": "HealthCareActivity"}, {"end": 12, "start": 4, "tag": "PopulationGroup"}, {"end": 164, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 111, "tag": "HealthCareActivity"}, {"end": 40, "start": 23, "tag": "ClinicalAttribute"}]}{"id": "1546_4", "text": "Results: Retinal thickness did not discriminate cases from controls, including stratified analyses for early- versus late-onset AD.", "tags": [{"end": 127, "start": 117, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 59, "tag": "PopulationGroup"}, {"end": 98, "start": 90, "tag": "ResearchActivity"}, {"end": 26, "start": 9, "tag": "ClinicalAttribute"}, {"end": 108, "start": 103, "tag": "TemporalConcept"}]}{"id": "1546_5", "text": "We found significant associations between macular thickness and global cortical atrophy [beta -0.358; P = .01] and parietal cortical atrophy on magnetic resonance imaging [beta -0.371; P < .01] in AD cases.", "tags": [{"end": 140, "start": 115, "tag": "AnatomicalAbnormality"}, {"end": 59, "start": 42, "tag": "ClinicalAttribute"}, {"end": 199, "start": 197, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 197, "tag": "PatientOrDisabledGroup"}, {"end": 87, "start": 80, "tag": "PathologicFunction"}, {"end": 87, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 144, "tag": "HealthCareActivity"}, {"end": 79, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1546_6", "text": "Discussion: In this study, representing the largest optical coherence tomography cohort with amyloid-proven AD cases, we show that retinal thickness does not discriminate AD from controls, despite evident changes on clinical, neuroimaging, and CSF measures, querying the use of retinal thickness measurements as an AD biomarker.", "tags": [{"end": 80, "start": 52, "tag": "HealthCareActivity"}, {"end": 247, "start": 244, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 81, "tag": "PopulationGroup"}, {"end": 100, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 317, "start": 315, "tag": "DiseaseOrSyndrome"}, {"end": 327, "start": 318, "tag": "ClinicalAttribute"}, {"end": 25, "start": 20, "tag": "ResearchActivity"}, {"end": 187, "start": 179, "tag": "PopulationGroup"}, {"end": 238, "start": 226, "tag": "HealthCareActivity"}, {"end": 116, "start": 108, "tag": "PatientOrDisabledGroup"}, {"end": 308, "start": 296, "tag": "HealthCareActivity"}, {"end": 148, "start": 131, "tag": "ClinicalAttribute"}, {"end": 295, "start": 278, "tag": "ClinicalAttribute"}]}{"id": "1547_0", "text": "Introduction Blood proteins are emerging as candidate biomarkers for Alzheimer's disease (AD).", "tags": [{"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 54, "tag": "ClinicalAttribute"}, {"end": 27, "start": 19, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1547_1", "text": "We systematically profiled the plasma proteome to identify novel AD blood biomarkers and develop a high-performance, blood-based test for AD.", "tags": [{"end": 46, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 74, "tag": "ClinicalAttribute"}, {"end": 37, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 104, "tag": "Finding"}, {"end": 133, "start": 129, "tag": "ResearchActivity"}, {"end": 133, "start": 129, "tag": "HealthCareActivity"}, {"end": 103, "start": 99, "tag": "Finding"}]}{"id": "1547_2", "text": "Methods We quantified 1160 plasma proteins in a Hong Kong Chinese cohort by high-throughput proximity extension assay and validated the results in an independent cohort.", "tags": [{"end": 161, "start": 150, "tag": "Finding"}, {"end": 65, "start": 48, "tag": "PopulationGroup"}, {"end": 33, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 66, "tag": "PopulationGroup"}, {"end": 168, "start": 162, "tag": "PopulationGroup"}, {"end": 117, "start": 76, "tag": "ResearchActivity"}]}{"id": "1547_3", "text": "In subgroup analyses, plasma biomarkers for amyloid, tau, phosphorylated tau, and neurodegeneration were used as endophenotypes of AD.", "tags": [{"end": 72, "start": 58, "tag": "CellFunction"}, {"end": 56, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 29, "tag": "ClinicalAttribute"}, {"end": 28, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 99, "start": 82, "tag": "CellOrMolecularDysfunction"}, {"end": 127, "start": 113, "tag": "ClinicalAttribute"}]}{"id": "1547_4", "text": "Results We identified 429 proteins that were dysregulated in AD plasma.", "tags": [{"end": 57, "start": 45, "tag": "PathologicFunction"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}{"id": "1547_5", "text": "We selected 19 hub proteins representative of the AD plasma protein profile, which formed the basis of a scoring system that accurately classified clinical AD (area under the curve = 0.9690-0.9816) and associated endophenotypes.", "tags": [{"end": 27, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 160, "tag": "ResearchActivity"}, {"end": 59, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 60, "tag": "ResearchActivity"}, {"end": 227, "start": 213, "tag": "ClinicalAttribute"}]}{"id": "1547_6", "text": "Moreover, specific hub proteins exhibit disease stage-dependent dysregulation, which can delineate AD stages.", "tags": [{"end": 31, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 40, "tag": "ClinicalAttribute"}, {"end": 53, "start": 40, "tag": "TemporalConcept"}, {"end": 108, "start": 102, "tag": "TemporalConcept"}, {"end": 77, "start": 64, "tag": "Finding"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}]}{"id": "1547_7", "text": "Discussion This study comprehensively profiled the AD plasma proteome and serves as a foundation for a high-performance, blood-based test for clinical AD screening and staging.", "tags": [{"end": 69, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 175, "start": 168, "tag": "TemporalConcept"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 142, "tag": "HealthCareActivity"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 60, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 108, "tag": "Finding"}, {"end": 137, "start": 133, "tag": "ResearchActivity"}, {"end": 137, "start": 133, "tag": "HealthCareActivity"}, {"end": 107, "start": 103, "tag": "Finding"}]}{"id": "1548_0", "text": "Background CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture.", "tags": [{"end": 58, "start": 51, "tag": "TemporalConcept"}, {"end": 175, "start": 160, "tag": "HealthCareActivity"}, {"end": 14, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 15, "tag": "ClinicalAttribute"}, {"end": 112, "start": 102, "tag": "HealthCareActivity"}, {"end": 112, "start": 102, "tag": "ResearchActivity"}, {"end": 71, "start": 59, "tag": "Finding"}, {"end": 152, "start": 130, "tag": "ResearchActivity"}]}{"id": "1548_1", "text": "Here, we compare in detail biomarker profiles in CSF extracted using either gravity drip or aspiration.", "tags": [{"end": 102, "start": 92, "tag": "ResearchActivity"}, {"end": 52, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 27, "tag": "ClinicalAttribute"}, {"end": 45, "start": 37, "tag": "ResearchActivity"}, {"end": 88, "start": 76, "tag": "ResearchActivity"}]}{"id": "1548_2", "text": "Methods Biomarkers for beta-amyloidopathy (A beta 1-42, A beta 1-40), tauopathy (total tau), or synapse pathology (BACE1, Neurogranin Trunc-p75, alpha-synuclein) were assessed between gravity or aspiration extraction methods in a sub-population of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (cognitively normal, N = 36; mild cognitive impairment, N = 8; Alzheimer's disease, N = 6).", "tags": [{"end": 79, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 191, "start": 184, "tag": "NaturalPhenomenonOrProcess"}, {"end": 224, "start": 195, "tag": "ResearchActivity"}, {"end": 120, "start": 115, "tag": "GeneOrGenome"}, {"end": 120, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 23, "tag": "PathologicFunction"}, {"end": 160, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 151, "tag": "BiologicallyActiveSubstance"}, {"end": 244, "start": 234, "tag": "PopulationGroup"}, {"end": 18, "start": 8, "tag": "ClinicalAttribute"}, {"end": 54, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 392, "start": 373, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 309, "start": 304, "tag": "ResearchActivity"}, {"end": 113, "start": 104, "tag": "PathologicFunction"}, {"end": 113, "start": 104, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 329, "start": 311, "tag": "Finding"}, {"end": 364, "start": 339, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 296, "start": 252, "tag": "ResearchActivity"}, {"end": 302, "start": 298, "tag": "ResearchActivity"}]}{"id": "1548_3", "text": "Results High biomarker concordance between extraction methods was seen (concordance correlation > 0.85).", "tags": [{"end": 22, "start": 13, "tag": "ClinicalAttribute"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 61, "start": 43, "tag": "ResearchActivity"}, {"end": 95, "start": 72, "tag": "ResearchActivity"}]}{"id": "1548_4", "text": "Passing Bablock regression defined low beta coefficients indicating high scalability.", "tags": [{"end": 38, "start": 35, "tag": "Finding"}, {"end": 72, "start": 68, "tag": "Finding"}, {"end": 56, "start": 39, "tag": "ResearchActivity"}, {"end": 26, "start": 0, "tag": "ResearchActivity"}, {"end": 84, "start": 73, "tag": "ResearchActivity"}]}{"id": "1548_5", "text": "Conclusions Levels of these commonly assessed CSF biomarkers are not influenced by extraction method.", "tags": [{"end": 49, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 83, "tag": "ResearchActivity"}, {"end": 60, "start": 50, "tag": "ClinicalAttribute"}]}{"id": "1548_6", "text": "Results of this study should be incorporated into new consensus guidelines for CSF collection, storage, and analysis of biomarkers.", "tags": [{"end": 93, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 95, "tag": "CellComponent"}, {"end": 102, "start": 95, "tag": "BiologicFunction"}, {"end": 82, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 120, "tag": "ClinicalAttribute"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 116, "start": 108, "tag": "ResearchActivity"}]}{"id": "1549_0", "text": "Alzheimer's disease (AD) is the most frequent neurodegenerative disease with an increasing prevalence in industrialized, aging populations.", "tags": [{"end": 101, "start": 80, "tag": "Finding"}, {"end": 133, "start": 132, "tag": "PopulationGroup"}, {"end": 119, "start": 105, "tag": "PopulationGroup"}, {"end": 126, "start": 121, "tag": "BiologicFunction"}, {"end": 126, "start": 121, "tag": "CellFunction"}, {"end": 71, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 37, "tag": "TemporalConcept"}, {"end": 138, "start": 121, "tag": "PopulationGroup"}]}{"id": "1549_1", "text": "AD susceptibility has an established genetic basis which has been the focus of a large number of genome-wide association studies (GWAS) published over the last decade.", "tags": [{"end": 17, "start": 3, "tag": "Finding"}, {"end": 44, "start": 37, "tag": "HealthCareActivity"}, {"end": 166, "start": 155, "tag": "TemporalConcept"}, {"end": 50, "start": 37, "tag": "CellFunction"}, {"end": 128, "start": 97, "tag": "ResearchActivity"}, {"end": 134, "start": 130, "tag": "ResearchActivity"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "1549_2", "text": "Most of these GWAS used dichotomized clinical diagnostic status, i.e., case vs.", "tags": [{"end": 18, "start": 14, "tag": "ResearchActivity"}, {"end": 63, "start": 24, "tag": "ResearchActivity"}]}{"id": "1549_3", "text": "control classification, as outcome phenotypes, without the use of biomarkers.", "tags": [{"end": 34, "start": 27, "tag": "Finding"}, {"end": 45, "start": 35, "tag": "OrganismAttribute"}, {"end": 76, "start": 66, "tag": "ClinicalAttribute"}]}{"id": "1549_4", "text": "An alternative and potentially more powerful study design is afforded by using quantitative AD-related phenotypes as GWAS outcome traits, an analysis paradigm that we followed in this work.", "tags": [{"end": 129, "start": 122, "tag": "Finding"}, {"end": 158, "start": 150, "tag": "ResearchActivity"}, {"end": 121, "start": 117, "tag": "ResearchActivity"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 103, "tag": "OrganismAttribute"}, {"end": 50, "start": 45, "tag": "ResearchActivity"}, {"end": 149, "start": 141, "tag": "ResearchActivity"}, {"end": 57, "start": 51, "tag": "ResearchActivity"}, {"end": 57, "start": 51, "tag": "HealthCareActivity"}]}{"id": "1549_5", "text": "Specifically, we utilized genotype and phenotype data from n = 931 individuals collected under the auspices of the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study to perform a total of 19 separate GWAS analyses.", "tags": [{"end": 267, "start": 263, "tag": "ResearchActivity"}, {"end": 48, "start": 39, "tag": "OrganismAttribute"}, {"end": 217, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 49, "tag": "ResearchActivity"}, {"end": 78, "start": 67, "tag": "PopulationGroup"}, {"end": 177, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 223, "tag": "ResearchActivity"}, {"end": 208, "start": 115, "tag": "ResearchActivity"}, {"end": 276, "start": 268, "tag": "ResearchActivity"}, {"end": 34, "start": 26, "tag": "OrganismAttribute"}, {"end": 198, "start": 189, "tag": "ClinicalAttribute"}, {"end": 123, "start": 115, "tag": "PopulationGroup"}, {"end": 153, "start": 115, "tag": "HealthCareRelatedOrganization"}, {"end": 221, "start": 210, "tag": "ResearchActivity"}]}{"id": "1549_6", "text": "As outcomes we used five magnetic resonance imaging (MRI) traits and seven cognitive performance traits.", "tags": [{"end": 64, "start": 58, "tag": "OrganismAttribute"}, {"end": 103, "start": 97, "tag": "OrganismAttribute"}, {"end": 11, "start": 3, "tag": "Finding"}, {"end": 56, "start": 53, "tag": "HealthCareActivity"}, {"end": 96, "start": 75, "tag": "Finding"}, {"end": 51, "start": 25, "tag": "HealthCareActivity"}]}{"id": "1549_7", "text": "For the latter, longitudinal data from at least two timepoints were available in addition to cross-sectional assessments at baseline.", "tags": [{"end": 62, "start": 52, "tag": "TemporalConcept"}, {"end": 33, "start": 16, "tag": "ResearchActivity"}, {"end": 120, "start": 93, "tag": "ResearchActivity"}]}{"id": "1549_8", "text": "Our GWAS analyses revealed several genome-wide significant associations for the neuropsychological performance measures, in particular those assayed longitudinally.", "tags": [{"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 110, "start": 99, "tag": "Finding"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 98, "start": 80, "tag": "HealthCareActivity"}, {"end": 71, "start": 35, "tag": "Finding"}]}{"id": "1549_9", "text": "Among the most noteworthy signals were associations in or near EHBP1 (EH domain binding protein 1; on chromosome 2p15) and CEP112 (centrosomal protein 112; 17q24.1) with delayed recall as well as SMOC2 (SPARC related modular calcium binding 2; 6p27) with immediate recall in a memory performance test.", "tags": [{"end": 68, "start": 63, "tag": "GeneOrGenome"}, {"end": 97, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 242, "start": 203, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 178, "tag": "BiologicFunction"}, {"end": 271, "start": 265, "tag": "BiologicFunction"}, {"end": 264, "start": 255, "tag": "TemporalConcept"}, {"end": 177, "start": 170, "tag": "TemporalConcept"}, {"end": 295, "start": 284, "tag": "Finding"}, {"end": 283, "start": 277, "tag": "BiologicFunction"}, {"end": 300, "start": 296, "tag": "ResearchActivity"}, {"end": 300, "start": 296, "tag": "HealthCareActivity"}, {"end": 33, "start": 26, "tag": "CellFunction"}, {"end": 68, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 102, "tag": "CellComponent"}, {"end": 129, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 242, "start": 203, "tag": "BiologicallyActiveSubstance"}, {"end": 201, "start": 196, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 196, "tag": "GeneOrGenome"}]}{"id": "1549_10", "text": "On the X chromosome, which is often excluded in other GWAS, we identified a genome-wide significant signal near IL1RAPL1 (interleukin 1 receptor accessory protein like 1; Xp21.3).", "tags": [{"end": 19, "start": 7, "tag": "CellComponent"}, {"end": 19, "start": 7, "tag": "GeneOrGenome"}, {"end": 58, "start": 54, "tag": "ResearchActivity"}, {"end": 82, "start": 76, "tag": "GeneOrGenome"}, {"end": 120, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 112, "tag": "GeneOrGenome"}]}{"id": "1549_11", "text": "While polygenic score (PGS) analyses showed the expected strong associations with SNPs highlighted in relevant previous GWAS on hippocampal volume and cognitive function, they did not show noteworthy associations with recent AD risk GWAS findings.", "tags": [{"end": 86, "start": 82, "tag": "MolecularSequence"}, {"end": 124, "start": 120, "tag": "ResearchActivity"}, {"end": 237, "start": 233, "tag": "ResearchActivity"}, {"end": 224, "start": 218, "tag": "TemporalConcept"}, {"end": 227, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 6, "tag": "ResearchActivity"}, {"end": 169, "start": 151, "tag": "BiologicFunction"}, {"end": 146, "start": 128, "tag": "ClinicalAttribute"}, {"end": 232, "start": 228, "tag": "Finding"}]}{"id": "1549_12", "text": "In summary, our study highlights the power of using quantitative endophenotypes as outcome traits in AD-related GWAS analyses and nominates several new loci not previously implicated in cognitive decline.", "tags": [{"end": 90, "start": 83, "tag": "PathologicFunction"}, {"end": 97, "start": 91, "tag": "OrganismAttribute"}, {"end": 116, "start": 112, "tag": "ResearchActivity"}, {"end": 103, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 203, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 117, "tag": "ResearchActivity"}, {"end": 79, "start": 52, "tag": "ClinicalAttribute"}, {"end": 156, "start": 152, "tag": "GeneOrGenome"}]}{"id": "1550_0", "text": "BACKGROUND: Preclinical Alzheimer's disease clinical trials test candidate treatments in individuals with biomarker evidence but no cognitive impairment.", "tags": [{"end": 85, "start": 75, "tag": "HealthCareActivity"}, {"end": 85, "start": 75, "tag": "ResearchActivity"}, {"end": 59, "start": 44, "tag": "ResearchActivity"}, {"end": 43, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 106, "tag": "ClinicalAttribute"}, {"end": 100, "start": 89, "tag": "PopulationGroup"}, {"end": 152, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 116, "tag": "Finding"}, {"end": 64, "start": 60, "tag": "ResearchActivity"}, {"end": 64, "start": 60, "tag": "HealthCareActivity"}, {"end": 23, "start": 12, "tag": "TemporalConcept"}]}{"id": "1550_1", "text": "Participants are required to co-enroll with a knowledgeable study partner, to whom biomarker information is disclosed.", "tags": [{"end": 92, "start": 83, "tag": "ClinicalAttribute"}, {"end": 65, "start": 60, "tag": "ResearchActivity"}, {"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 73, "start": 66, "tag": "PopulationGroup"}]}{"id": "1550_2", "text": "OBJECTIVE: We investigated whether reluctance to share biomarker results is associated with viewing the study partner requirement as a barrier to preclinical trial enrollment.", "tags": [{"end": 45, "start": 35, "tag": "BiologicFunction"}, {"end": 142, "start": 135, "tag": "ManufacturedObject"}, {"end": 163, "start": 146, "tag": "ResearchActivity"}, {"end": 64, "start": 55, "tag": "ClinicalAttribute"}, {"end": 109, "start": 104, "tag": "ResearchActivity"}, {"end": 174, "start": 164, "tag": "HealthCareActivity"}, {"end": 117, "start": 110, "tag": "PopulationGroup"}]}{"id": "1550_3", "text": "DESIGN: We developed a nine-item assessment on views toward the study partner requirement and performed in-person interviews based on a hypothetical clinical trial requiring biomarker testing and disclosure.", "tags": [{"end": 206, "start": 196, "tag": "IndividualBehavior"}, {"end": 163, "start": 149, "tag": "ResearchActivity"}, {"end": 183, "start": 174, "tag": "ClinicalAttribute"}, {"end": 191, "start": 184, "tag": "HealthCareActivity"}, {"end": 69, "start": 64, "tag": "ResearchActivity"}, {"end": 43, "start": 33, "tag": "HealthCareActivity"}, {"end": 43, "start": 33, "tag": "ResearchActivity"}, {"end": 77, "start": 70, "tag": "PopulationGroup"}, {"end": 89, "start": 78, "tag": "Finding"}, {"end": 124, "start": 104, "tag": "HealthCareActivity"}]}{"id": "1550_4", "text": "SETTING: We conducted interviews on campus at the University of California, Irvine.", "tags": [{"end": 7, "start": 0, "tag": "BiologicFunction"}, {"end": 82, "start": 50, "tag": "HealthCareRelatedOrganization"}, {"end": 32, "start": 22, "tag": "HealthCareActivity"}]}{"id": "1550_5", "text": "PARTICIPANTS: Two hundred cognitively unimpaired older adults recruited from the University of California, Irvine Consent-to-Contact Registry participated in the study.", "tags": [{"end": 48, "start": 26, "tag": "Finding"}, {"end": 54, "start": 49, "tag": "TemporalConcept"}, {"end": 61, "start": 49, "tag": "PopulationGroup"}, {"end": 167, "start": 162, "tag": "ResearchActivity"}, {"end": 113, "start": 81, "tag": "HealthCareRelatedOrganization"}, {"end": 61, "start": 55, "tag": "PopulationGroup"}]}{"id": "1550_6", "text": "MEASUREMENTS: We used logistic regression models, adjusting for potential confounders, to examine potential associations with viewing the study partner requirement as a barrier to preclinical trial enrollment.", "tags": [{"end": 176, "start": 169, "tag": "ManufacturedObject"}, {"end": 197, "start": 180, "tag": "ResearchActivity"}, {"end": 85, "start": 74, "tag": "Finding"}, {"end": 48, "start": 22, "tag": "ResearchActivity"}, {"end": 143, "start": 138, "tag": "ResearchActivity"}, {"end": 208, "start": 198, "tag": "HealthCareActivity"}, {"end": 151, "start": 144, "tag": "PopulationGroup"}, {"end": 163, "start": 152, "tag": "Finding"}]}{"id": "1550_7", "text": "RESULTS: Eighteen percent of participants reported strong agreement that the study partner requirement was a barrier to enrollment.", "tags": [{"end": 116, "start": 109, "tag": "ManufacturedObject"}, {"end": 41, "start": 29, "tag": "PopulationGroup"}, {"end": 82, "start": 77, "tag": "ResearchActivity"}, {"end": 130, "start": 120, "tag": "HealthCareActivity"}, {"end": 90, "start": 83, "tag": "PopulationGroup"}, {"end": 102, "start": 91, "tag": "Finding"}]}{"id": "1550_8", "text": "Ten participants (5%) agreed at any level that they would be reluctant to share their biomarker result with a study partner.", "tags": [{"end": 95, "start": 86, "tag": "ClinicalAttribute"}, {"end": 16, "start": 4, "tag": "PopulationGroup"}, {"end": 115, "start": 110, "tag": "ResearchActivity"}, {"end": 102, "start": 96, "tag": "Finding"}, {"end": 123, "start": 116, "tag": "PopulationGroup"}]}{"id": "1550_9", "text": "The estimated odds of viewing the study partner requirement as a barrier to enrollment were 26 times higher for these participants (OR=26.3, 95% CI 4.0, 172.3), compared to those who strongly disagreed that they would be reluctant to share their biomarker result.", "tags": [{"end": 72, "start": 65, "tag": "ManufacturedObject"}, {"end": 255, "start": 246, "tag": "ClinicalAttribute"}, {"end": 130, "start": 118, "tag": "PopulationGroup"}, {"end": 39, "start": 34, "tag": "ResearchActivity"}, {"end": 262, "start": 256, "tag": "Finding"}, {"end": 147, "start": 145, "tag": "ResearchActivity"}, {"end": 86, "start": 76, "tag": "HealthCareActivity"}, {"end": 47, "start": 40, "tag": "PopulationGroup"}, {"end": 59, "start": 48, "tag": "Finding"}]}{"id": "1550_10", "text": "Overall, participants more frequently agreed with positive statements than negative statements about the study partner requirement, including 76% indicating they would want their study partner with them when they learned biomarker results.", "tags": [{"end": 37, "start": 27, "tag": "TemporalConcept"}, {"end": 230, "start": 221, "tag": "ClinicalAttribute"}, {"end": 21, "start": 9, "tag": "PopulationGroup"}, {"end": 110, "start": 105, "tag": "ResearchActivity"}, {"end": 184, "start": 179, "tag": "ResearchActivity"}, {"end": 192, "start": 185, "tag": "PopulationGroup"}, {"end": 118, "start": 111, "tag": "PopulationGroup"}]}{"id": "1550_11", "text": "CONCLUSIONS: This is one of the first studies to explore how potential preclinical Alzheimer's disease trial participants feel about sharing their personal biomarker information with a study partner.", "tags": [{"end": 37, "start": 32, "tag": "TemporalConcept"}, {"end": 155, "start": 147, "tag": "OrganismAttribute"}, {"end": 102, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 156, "tag": "ClinicalAttribute"}, {"end": 121, "start": 109, "tag": "PopulationGroup"}, {"end": 45, "start": 38, "tag": "ResearchActivity"}, {"end": 190, "start": 185, "tag": "ResearchActivity"}, {"end": 108, "start": 103, "tag": "ResearchActivity"}, {"end": 82, "start": 71, "tag": "TemporalConcept"}, {"end": 198, "start": 191, "tag": "PopulationGroup"}]}{"id": "1550_12", "text": "Most participants viewed the study partner as an asset to trial enrollment, including having a partner present during biomarker disclosure.", "tags": [{"end": 138, "start": 128, "tag": "IndividualBehavior"}, {"end": 127, "start": 118, "tag": "ClinicalAttribute"}, {"end": 17, "start": 5, "tag": "PopulationGroup"}, {"end": 34, "start": 29, "tag": "ResearchActivity"}, {"end": 63, "start": 58, "tag": "ResearchActivity"}, {"end": 74, "start": 64, "tag": "HealthCareActivity"}, {"end": 42, "start": 35, "tag": "PopulationGroup"}, {"end": 102, "start": 95, "tag": "PopulationGroup"}]}{"id": "1551_0", "text": "Background: Neuroimaging studies of autosomal dominant Alzheimer's disease (ADAD) enable characterization of the trajectories of cerebral amyloid-beta (A beta) and tau accumulation in the decades prior to clinical symptom onset.", "tags": [{"end": 105, "start": 89, "tag": "ResearchActivity"}, {"end": 195, "start": 188, "tag": "TemporalConcept"}, {"end": 74, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 164, "tag": "AminoAcidPeptideOrProtein"}, {"end": 167, "start": 164, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 25, "tag": "ResearchActivity"}, {"end": 145, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 168, "tag": "Finding"}, {"end": 227, "start": 214, "tag": "TemporalConcept"}, {"end": 221, "start": 214, "tag": "SignOrSymptom"}, {"end": 80, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 12, "tag": "HealthCareActivity"}]}{"id": "1551_1", "text": "Longitudinal rates of regional tau accumulation measured with positron emission tomography (PET) and their relationship with other biomarker and cognitive changes remain to be fully characterized in ADAD.", "tags": [{"end": 162, "start": 145, "tag": "Finding"}, {"end": 34, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 131, "tag": "ClinicalAttribute"}, {"end": 119, "start": 107, "tag": "Finding"}, {"end": 95, "start": 92, "tag": "HealthCareActivity"}, {"end": 47, "start": 35, "tag": "Finding"}, {"end": 90, "start": 62, "tag": "HealthCareActivity"}, {"end": 203, "start": 199, "tag": "DiseaseOrSyndrome"}]}{"id": "1551_2", "text": "Methods: Fourteen ADAD mutation carriers (Presenilin-1 E280A) and 15 age-matched non-carriers from the Colombian kindred underwent 2-3 sessions of A beta (11C-Pittsburgh compound B) and tau (18F-flortaucipir) PET, structural magnetic resonance imaging, and neuropsychological evaluation over a 2-4-year follow-up period.", "tags": [{"end": 112, "start": 103, "tag": "PopulationGroup"}, {"end": 180, "start": 155, "tag": "Chemical"}, {"end": 251, "start": 214, "tag": "HealthCareActivity"}, {"end": 207, "start": 191, "tag": "Chemical"}, {"end": 302, "start": 298, "tag": "TemporalConcept"}, {"end": 54, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 42, "tag": "GeneOrGenome"}, {"end": 54, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 23, "tag": "CellOrMolecularDysfunction"}, {"end": 93, "start": 81, "tag": "PopulationGroup"}, {"end": 60, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 319, "start": 313, "tag": "TemporalConcept"}, {"end": 72, "start": 69, "tag": "OrganismAttribute"}, {"end": 312, "start": 303, "tag": "HealthCareActivity"}, {"end": 312, "start": 303, "tag": "TemporalConcept"}, {"end": 212, "start": 209, "tag": "HealthCareActivity"}, {"end": 40, "start": 32, "tag": "PopulationGroup"}, {"end": 153, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 286, "start": 257, "tag": "HealthCareActivity"}, {"end": 22, "start": 18, "tag": "DiseaseOrSyndrome"}]}{"id": "1551_3", "text": "Annualized rates of change for imaging and cognitive variables were compared between carriers and non-carriers, and relationships among baseline measurements and rates of change were assessed within carriers.", "tags": [{"end": 38, "start": 31, "tag": "HealthCareActivity"}, {"end": 110, "start": 98, "tag": "PopulationGroup"}, {"end": 129, "start": 116, "tag": "Finding"}, {"end": 157, "start": 145, "tag": "HealthCareActivity"}, {"end": 93, "start": 85, "tag": "PopulationGroup"}, {"end": 207, "start": 199, "tag": "PopulationGroup"}, {"end": 16, "start": 11, "tag": "TemporalConcept"}, {"end": 167, "start": 162, "tag": "TemporalConcept"}]}{"id": "1551_4", "text": "Results: Longitudinal measurements were consistent with a sequence of ADAD-related changes beginning with A beta accumulation (16 years prior to expected symptom onset, EYO), followed by entorhinal cortex (EC) tau (9 EYO), neocortical tau (6 EYO), hippocampal atrophy (6 EYO), and cognitive decline (4 EYO).", "tags": [{"end": 267, "start": 248, "tag": "DiseaseOrSyndrome"}, {"end": 204, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 169, "tag": "TemporalConcept"}, {"end": 220, "start": 217, "tag": "TemporalConcept"}, {"end": 245, "start": 242, "tag": "TemporalConcept"}, {"end": 274, "start": 271, "tag": "TemporalConcept"}, {"end": 305, "start": 302, "tag": "TemporalConcept"}, {"end": 208, "start": 206, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 213, "start": 210, "tag": "AminoAcidPeptideOrProtein"}, {"end": 238, "start": 235, "tag": "AminoAcidPeptideOrProtein"}, {"end": 213, "start": 210, "tag": "BiologicallyActiveSubstance"}, {"end": 238, "start": 235, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 298, "start": 281, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 130, "tag": "TemporalConcept"}, {"end": 34, "start": 9, "tag": "HealthCareActivity"}, {"end": 112, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 113, "tag": "Finding"}, {"end": 167, "start": 145, "tag": "TemporalConcept"}, {"end": 74, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 83, "tag": "Finding"}, {"end": 234, "start": 223, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1551_5", "text": "Rates of tau accumulation among carriers were most rapid in parietal neocortex (similar to 9%/year).", "tags": [{"end": 98, "start": 94, "tag": "TemporalConcept"}, {"end": 12, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 40, "start": 32, "tag": "PopulationGroup"}, {"end": 25, "start": 13, "tag": "Finding"}, {"end": 78, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1551_6", "text": "EC tau PET signal at baseline was a significant predictor of subsequent neocortical tau accumulation and cognitive decline within carriers.", "tags": [{"end": 2, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 6, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 3, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 7, "tag": "HealthCareActivity"}, {"end": 138, "start": 130, "tag": "PopulationGroup"}, {"end": 100, "start": 88, "tag": "Finding"}, {"end": 83, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1551_7", "text": "Conclusions: Our results are consistent with the sequence of biological changes in ADAD implied by cross-sectional studies and highlight the importance of EC tau as an early biomarker and a potential link between A beta burden and neocortical tau accumulation in ADAD.", "tags": [{"end": 122, "start": 99, "tag": "ResearchActivity"}, {"end": 157, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 161, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 246, "start": 243, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 246, "start": 243, "tag": "BiologicallyActiveSubstance"}, {"end": 183, "start": 174, "tag": "ClinicalAttribute"}, {"end": 173, "start": 168, "tag": "TemporalConcept"}, {"end": 219, "start": 213, "tag": "AminoAcidPeptideOrProtein"}, {"end": 259, "start": 247, "tag": "Finding"}, {"end": 226, "start": 220, "tag": "ResearchActivity"}, {"end": 87, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 267, "start": 263, "tag": "DiseaseOrSyndrome"}, {"end": 242, "start": 231, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1552_0", "text": "Background: Assessment of human brain atrophy in temporal regions using magnetic resonance imaging (MRI), resting state functional MRI connectivity in the left parietal cortex, and limbic electroencephalographic (rsEEG) rhythms as well as plasma amyloid peptide 42 (A beta(42)) has shown that each is a promising biomarker of disease progression in amnestic mild cognitive impairment (aMCI) patients with prodromal Alzheimer's disease (AD).", "tags": [{"end": 22, "start": 12, "tag": "HealthCareActivity"}, {"end": 22, "start": 12, "tag": "ResearchActivity"}, {"end": 175, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 188, "tag": "HealthCareActivity"}, {"end": 227, "start": 220, "tag": "Finding"}, {"end": 227, "start": 220, "tag": "BiologicFunction"}, {"end": 434, "start": 405, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 389, "start": 385, "tag": "DiseaseOrSyndrome"}, {"end": 438, "start": 436, "tag": "DiseaseOrSyndrome"}, {"end": 322, "start": 313, "tag": "ClinicalAttribute"}, {"end": 399, "start": 391, "tag": "PatientOrDisabledGroup"}, {"end": 345, "start": 326, "tag": "PathologicFunction"}, {"end": 103, "start": 100, "tag": "HealthCareActivity"}, {"end": 134, "start": 106, "tag": "HealthCareActivity"}, {"end": 383, "start": 349, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 26, "tag": "Eukaryote"}, {"end": 147, "start": 135, "tag": "BiologicFunction"}, {"end": 98, "start": 72, "tag": "HealthCareActivity"}, {"end": 187, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 264, "start": 239, "tag": "ClinicalAttribute"}]}{"id": "1552_1", "text": "However, the value of their combined use is unknown.", "tags": []}{"id": "1552_2", "text": "Objective: To evaluate the association with cognitive decline and the effect on sample size calculation when using a biomarker composite matrix in prodromal AD clinical trials.", "tags": [{"end": 175, "start": 160, "tag": "ResearchActivity"}, {"end": 159, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 117, "tag": "ClinicalAttribute"}, {"end": 91, "start": 87, "tag": "OrganismAttribute"}, {"end": 61, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 80, "tag": "Substance"}, {"end": 86, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1552_3", "text": "Methods: Multicenter longitudinal study with follow-up of 2 years or until development of incident dementia.", "tags": [{"end": 39, "start": 9, "tag": "ResearchActivity"}, {"end": 86, "start": 75, "tag": "BiologicFunction"}, {"end": 86, "start": 75, "tag": "CellFunction"}, {"end": 107, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 45, "tag": "HealthCareActivity"}, {"end": 54, "start": 45, "tag": "TemporalConcept"}, {"end": 65, "start": 60, "tag": "TemporalConcept"}]}{"id": "1552_4", "text": "APOE epsilon 4-specific cerebrospinal fluid (CSF) A beta(42)/P-tau cut-offs were used to identify aMCI with prodromal AD.", "tags": [{"end": 120, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 0, "tag": "GeneOrGenome"}, {"end": 75, "start": 67, "tag": "ResearchActivity"}, {"end": 66, "start": 24, "tag": "ClinicalAttribute"}]}{"id": "1552_5", "text": "Linear mixed models were performed 1) with repeated matrix values and time as factors to explain the longitudinal changes in ADAS-cog13, 2) with CSF A beta(42)/P-tau status, time, and CSF A beta(42)/P-tau status x time interaction as factors to explain the longitudinal changes in matrix measures, and 3) to compute sample size estimation for a trial implemented with the selected matrices.", "tags": [{"end": 338, "start": 328, "tag": "BiologicFunction"}, {"end": 121, "start": 101, "tag": "ResearchActivity"}, {"end": 277, "start": 257, "tag": "ResearchActivity"}, {"end": 74, "start": 70, "tag": "TemporalConcept"}, {"end": 178, "start": 174, "tag": "TemporalConcept"}, {"end": 218, "start": 214, "tag": "TemporalConcept"}, {"end": 327, "start": 323, "tag": "OrganismAttribute"}, {"end": 350, "start": 345, "tag": "ResearchActivity"}, {"end": 19, "start": 0, "tag": "ResearchActivity"}, {"end": 172, "start": 166, "tag": "Finding"}, {"end": 211, "start": 205, "tag": "Finding"}, {"end": 322, "start": 316, "tag": "Substance"}, {"end": 322, "start": 316, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 125, "tag": "HealthCareActivity"}, {"end": 165, "start": 145, "tag": "ClinicalAttribute"}, {"end": 204, "start": 184, "tag": "ClinicalAttribute"}, {"end": 65, "start": 43, "tag": "ResearchActivity"}, {"end": 296, "start": 281, "tag": "ResearchActivity"}]}{"id": "1552_6", "text": "Results: The best composite matrix included the MRI volumes of hippocampal dentate gyrus and lateral ventricle.", "tags": [{"end": 110, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 51, "start": 48, "tag": "HealthCareActivity"}, {"end": 88, "start": 52, "tag": "ClinicalAttribute"}, {"end": 34, "start": 18, "tag": "ResearchActivity"}]}{"id": "1552_7", "text": "This matrix showed the best sensitivity to track disease progression and required a sample size 31% lower than that of the best individual biomarker (i.e., volume of hippocampal dentate gyrus).", "tags": [{"end": 191, "start": 166, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 139, "tag": "ClinicalAttribute"}, {"end": 39, "start": 28, "tag": "Finding"}, {"end": 68, "start": 49, "tag": "PathologicFunction"}, {"end": 138, "start": 128, "tag": "PopulationGroup"}, {"end": 138, "start": 128, "tag": "OrganismAttribute"}, {"end": 95, "start": 91, "tag": "OrganismAttribute"}, {"end": 90, "start": 84, "tag": "Substance"}, {"end": 90, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 191, "start": 156, "tag": "ClinicalAttribute"}]}{"id": "1552_8", "text": "Conclusion: Optimal matrices improved the statistical power to track disease development and to measure clinical progression in the short-term period.", "tags": [{"end": 59, "start": 42, "tag": "ResearchActivity"}, {"end": 88, "start": 69, "tag": "PathologicFunction"}, {"end": 37, "start": 29, "tag": "Finding"}, {"end": 124, "start": 104, "tag": "TemporalConcept"}, {"end": 149, "start": 143, "tag": "TemporalConcept"}, {"end": 142, "start": 132, "tag": "TemporalConcept"}]}{"id": "1552_9", "text": "This might contribute to optimize the design of future clinical trials in MCI.", "tags": [{"end": 70, "start": 55, "tag": "ResearchActivity"}, {"end": 77, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 48, "tag": "TemporalConcept"}, {"end": 44, "start": 38, "tag": "ResearchActivity"}, {"end": 44, "start": 38, "tag": "HealthCareActivity"}]}{"id": "1553_0", "text": "Neuroimaging-based brain-age estimation via machine learning has emerged as an important new approach for studying brain aging.", "tags": [{"end": 39, "start": 29, "tag": "BiologicFunction"}, {"end": 126, "start": 121, "tag": "BiologicFunction"}, {"end": 126, "start": 121, "tag": "CellFunction"}, {"end": 60, "start": 44, "tag": "MachineActivity"}, {"end": 24, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 25, "tag": "OrganismAttribute"}]}{"id": "1553_1", "text": "The difference between one's estimated brain age and chronological age, the brain age gap (BAG), has been proposed as an Alzheimer's Disease (AD) biomarker.", "tags": [{"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 146, "tag": "ClinicalAttribute"}, {"end": 44, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 45, "tag": "OrganismAttribute"}, {"end": 85, "start": 82, "tag": "OrganismAttribute"}, {"end": 70, "start": 53, "tag": "OrganismAttribute"}, {"end": 89, "start": 76, "tag": "ClinicalAttribute"}, {"end": 94, "start": 91, "tag": "ClinicalAttribute"}]}{"id": "1553_2", "text": "However, most past studies on the BAG have been cross-sectional.", "tags": [{"end": 63, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 14, "tag": "TemporalConcept"}, {"end": 26, "start": 19, "tag": "ResearchActivity"}, {"end": 37, "start": 34, "tag": "ClinicalAttribute"}]}{"id": "1553_3", "text": "Quantifying longitudinal changes in an individual's BAG temporal pattern would likely improve prediction of AD progression and clinical outcome based on neurophysiological changes.", "tags": [{"end": 32, "start": 12, "tag": "ResearchActivity"}, {"end": 143, "start": 127, "tag": "ClinicalAttribute"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 111, "tag": "PathologicFunction"}, {"end": 122, "start": 111, "tag": "TemporalConcept"}, {"end": 49, "start": 39, "tag": "PopulationGroup"}, {"end": 49, "start": 39, "tag": "OrganismAttribute"}, {"end": 64, "start": 56, "tag": "TemporalConcept"}, {"end": 104, "start": 94, "tag": "Finding"}, {"end": 24, "start": 12, "tag": "ResearchActivity"}, {"end": 179, "start": 153, "tag": "Finding"}, {"end": 55, "start": 52, "tag": "ClinicalAttribute"}]}{"id": "1553_4", "text": "To fill this gap, our study conducted predictive modeling using a large neuroimaging dataset with up to 8 years of follow-up to examine the temporal patterns of the BAG's trajectory and how it varies by subject-level characteristics (sex, APOE e 4 carriership) and disease status.", "tags": [{"end": 57, "start": 49, "tag": "ResearchActivity"}, {"end": 279, "start": 265, "tag": "ClinicalAttribute"}, {"end": 237, "start": 234, "tag": "OrganismAttribute"}, {"end": 84, "start": 72, "tag": "HealthCareActivity"}, {"end": 232, "start": 217, "tag": "OrganismAttribute"}, {"end": 27, "start": 22, "tag": "ResearchActivity"}, {"end": 124, "start": 115, "tag": "HealthCareActivity"}, {"end": 124, "start": 115, "tag": "TemporalConcept"}, {"end": 111, "start": 106, "tag": "TemporalConcept"}, {"end": 92, "start": 85, "tag": "ResearchActivity"}, {"end": 148, "start": 140, "tag": "TemporalConcept"}, {"end": 243, "start": 239, "tag": "AminoAcidPeptideOrProtein"}, {"end": 243, "start": 239, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 149, "tag": "ResearchActivity"}, {"end": 247, "start": 239, "tag": "GeneOrGenome"}, {"end": 259, "start": 248, "tag": "Finding"}, {"end": 168, "start": 165, "tag": "ClinicalAttribute"}]}{"id": "1553_5", "text": "Specifically, we explored the pattern and rate of change in BAG over time in individuals who remain stable with normal cognition or mild cognitive impairment (MCI), as well as individuals who progress to clinical AD.", "tags": [{"end": 200, "start": 192, "tag": "TemporalConcept"}, {"end": 118, "start": 112, "tag": "Finding"}, {"end": 46, "start": 42, "tag": "TemporalConcept"}, {"end": 215, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 77, "tag": "PopulationGroup"}, {"end": 187, "start": 176, "tag": "PopulationGroup"}, {"end": 162, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 69, "tag": "TemporalConcept"}, {"end": 128, "start": 119, "tag": "BiologicFunction"}, {"end": 157, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 50, "tag": "Finding"}, {"end": 63, "start": 60, "tag": "ClinicalAttribute"}]}{"id": "1553_6", "text": "Combining multimodal imaging data in a support vector regression model to estimate brain age yielded improved performance over single modality.", "tags": [{"end": 28, "start": 10, "tag": "HealthCareActivity"}, {"end": 142, "start": 134, "tag": "HealthCareActivity"}, {"end": 70, "start": 39, "tag": "ResearchActivity"}, {"end": 88, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 29, "tag": "ResearchActivity"}, {"end": 121, "start": 110, "tag": "Finding"}, {"end": 92, "start": 89, "tag": "OrganismAttribute"}]}{"id": "1553_7", "text": "Multilevel modeling results showed the BAG followed a linear increasing trajectory with a significantly faster rate in individuals with MCI who progressed to AD compared to cognitively normal or MCI individuals who did not progress.", "tags": [{"end": 19, "start": 0, "tag": "ResearchActivity"}, {"end": 231, "start": 223, "tag": "TemporalConcept"}, {"end": 115, "start": 111, "tag": "TemporalConcept"}, {"end": 71, "start": 61, "tag": "Finding"}, {"end": 160, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 119, "tag": "PopulationGroup"}, {"end": 210, "start": 199, "tag": "PopulationGroup"}, {"end": 139, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 173, "tag": "Finding"}, {"end": 42, "start": 39, "tag": "ClinicalAttribute"}]}{"id": "1553_8", "text": "The dynamic changes in the BAG during AD progression were further moderated by sex and APOE e 4 carriership.", "tags": [{"end": 82, "start": 79, "tag": "OrganismAttribute"}, {"end": 40, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 41, "tag": "PathologicFunction"}, {"end": 52, "start": 41, "tag": "TemporalConcept"}, {"end": 91, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 4, "tag": "Finding"}, {"end": 95, "start": 87, "tag": "GeneOrGenome"}, {"end": 107, "start": 96, "tag": "Finding"}, {"end": 30, "start": 27, "tag": "ClinicalAttribute"}]}{"id": "1553_9", "text": "Our findings demonstrate the BAG as a potential biomarker for understanding individual specific temporal patterns related to AD progression.", "tags": [{"end": 127, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 128, "tag": "PathologicFunction"}, {"end": 139, "start": 128, "tag": "TemporalConcept"}, {"end": 86, "start": 76, "tag": "PopulationGroup"}, {"end": 86, "start": 76, "tag": "OrganismAttribute"}, {"end": 104, "start": 96, "tag": "TemporalConcept"}, {"end": 75, "start": 62, "tag": "BiologicFunction"}, {"end": 57, "start": 38, "tag": "ClinicalAttribute"}, {"end": 113, "start": 105, "tag": "ResearchActivity"}, {"end": 32, "start": 29, "tag": "ClinicalAttribute"}]}{"id": "1554_0", "text": "Background: The REFLECT trials were conducted to examine the treatment of mild-to-moderate Alzheimer's disease utilizing a peroxisome proliferator-activated receptor gamma agonist.", "tags": [{"end": 171, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 172, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 82, "tag": "Finding"}, {"end": 171, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 61, "tag": "HealthCareActivity"}, {"end": 70, "start": 61, "tag": "ResearchActivity"}, {"end": 78, "start": 74, "tag": "Finding"}, {"end": 30, "start": 16, "tag": "ResearchActivity"}]}{"id": "1554_1", "text": "Objective: To generate a predictive biomarker indicative of positive treatment response using samples from the previously conducted REFLECT trials.", "tags": [{"end": 146, "start": 132, "tag": "ResearchActivity"}, {"end": 87, "start": 69, "tag": "ClinicalAttribute"}, {"end": 45, "start": 25, "tag": "ClinicalAttribute"}]}{"id": "1554_2", "text": "Methods: Data were analyzed on 360 participants spanning multiple negative REFLECT trials, which included treatment with rosiglitazone and rosiglitazone XR.", "tags": [{"end": 134, "start": 121, "tag": "Chemical"}, {"end": 155, "start": 139, "tag": "Chemical"}, {"end": 115, "start": 106, "tag": "HealthCareActivity"}, {"end": 115, "start": 106, "tag": "ResearchActivity"}, {"end": 47, "start": 35, "tag": "PopulationGroup"}, {"end": 13, "start": 9, "tag": "ResearchActivity"}, {"end": 134, "start": 121, "tag": "PharmacologicSubstance"}, {"end": 155, "start": 139, "tag": "PharmacologicSubstance"}, {"end": 89, "start": 75, "tag": "ResearchActivity"}]}{"id": "1554_3", "text": "Support vector machine analyses were conducted to generate a predictive biomarker profile.", "tags": [{"end": 81, "start": 61, "tag": "ClinicalAttribute"}, {"end": 22, "start": 0, "tag": "MachineActivity"}, {"end": 31, "start": 23, "tag": "ResearchActivity"}]}{"id": "1554_4", "text": "Results: A pre-defined 6-protein predictive biomarker (IL6, IL10, CRP, TNF alpha, FABP-3, and PPY) correctly classified treatment response with 100%accuracy across study arms for REFLECT Phase II trial (AVA100193) and multiple Phase III trials (AVA105640, AV102672, and AVA102670).", "tags": [{"end": 58, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "GeneOrGenome"}, {"end": 69, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 66, "tag": "GeneOrGenome"}, {"end": 69, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 94, "tag": "GeneOrGenome"}, {"end": 201, "start": 187, "tag": "ResearchActivity"}, {"end": 138, "start": 120, "tag": "ClinicalAttribute"}, {"end": 53, "start": 33, "tag": "ClinicalAttribute"}, {"end": 169, "start": 164, "tag": "ResearchActivity"}, {"end": 156, "start": 148, "tag": "Finding"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 201, "start": 179, "tag": "ResearchActivity"}, {"end": 64, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 60, "tag": "GeneOrGenome"}, {"end": 80, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 82, "tag": "GeneOrGenome"}, {"end": 97, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 243, "start": 227, "tag": "ResearchActivity"}, {"end": 254, "start": 245, "tag": "ResearchActivity"}, {"end": 264, "start": 256, "tag": "ResearchActivity"}, {"end": 279, "start": 270, "tag": "ResearchActivity"}, {"end": 212, "start": 203, "tag": "ResearchActivity"}]}{"id": "1554_5", "text": "When the data was combined across all rosiglitazone trial arms, a global RSG-predictive biomarker with the same 6-protein predictive biomarker was able to accurately classify 98%of treatment responders.", "tags": [{"end": 51, "start": 38, "tag": "Chemical"}, {"end": 97, "start": 77, "tag": "ClinicalAttribute"}, {"end": 142, "start": 122, "tag": "ClinicalAttribute"}, {"end": 13, "start": 9, "tag": "ResearchActivity"}, {"end": 190, "start": 181, "tag": "HealthCareActivity"}, {"end": 190, "start": 181, "tag": "ResearchActivity"}, {"end": 57, "start": 52, "tag": "ResearchActivity"}, {"end": 51, "start": 38, "tag": "PharmacologicSubstance"}, {"end": 201, "start": 191, "tag": "PopulationGroup"}]}{"id": "1554_6", "text": "Conclusion: A predictive biomarker comprising of metabolic and inflammatory markers was highly accurate in identifying those patients most likely to experience positive treatment response across the REFLECT trials.", "tags": [{"end": 58, "start": 49, "tag": "CellFunction"}, {"end": 187, "start": 169, "tag": "ClinicalAttribute"}, {"end": 34, "start": 14, "tag": "ClinicalAttribute"}, {"end": 159, "start": 149, "tag": "BiologicFunction"}, {"end": 133, "start": 125, "tag": "PatientOrDisabledGroup"}, {"end": 83, "start": 63, "tag": "ClinicalAttribute"}, {"end": 213, "start": 199, "tag": "ResearchActivity"}]}{"id": "1554_7", "text": "This study provides additional proof-of-concept that a predictive biomarker can be utilized to help with screening and predicting treatment response, which holds tremendous benefit for clinical trials.", "tags": [{"end": 148, "start": 130, "tag": "ClinicalAttribute"}, {"end": 75, "start": 55, "tag": "ClinicalAttribute"}, {"end": 200, "start": 185, "tag": "ResearchActivity"}, {"end": 114, "start": 105, "tag": "HealthCareActivity"}, {"end": 114, "start": 105, "tag": "ResearchActivity"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 175, "start": 174, "tag": "Finding"}]}{"id": "1555_0", "text": "The apolipoprotein E epsilon 4 allele (APOE4) is the major genetic risk factor for sporadic Alzheimer's disease (AD).", "tags": [{"end": 78, "start": 59, "tag": "Finding"}, {"end": 111, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 83, "tag": "TemporalConcept"}, {"end": 111, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 31, "tag": "GeneOrGenome"}, {"end": 37, "start": 4, "tag": "GeneOrGenome"}, {"end": 44, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 39, "tag": "BiologicallyActiveSubstance"}]}{"id": "1555_1", "text": "APOE4 may have effects on cognition and brain atrophy years before the onset of symptomatic AD.", "tags": [{"end": 53, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 60, "tag": "TemporalConcept"}, {"end": 59, "start": 54, "tag": "TemporalConcept"}, {"end": 35, "start": 26, "tag": "BiologicFunction"}, {"end": 22, "start": 15, "tag": "Finding"}, {"end": 76, "start": 71, "tag": "TemporalConcept"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 80, "tag": "SignOrSymptom"}]}{"id": "1555_2", "text": "We analyzed the effects of APOE4 in a unique cohort of young adults who had undergone comprehensive assessments as part of the Dominantly Inherited Alzheimer Network (DIAN), an international longitudinal study of individuals from families with autosomal dominant AD.", "tags": [{"end": 67, "start": 55, "tag": "PopulationGroup"}, {"end": 111, "start": 100, "tag": "HealthCareActivity"}, {"end": 238, "start": 230, "tag": "PopulationGroup"}, {"end": 265, "start": 244, "tag": "DiseaseOrSyndrome"}, {"end": 209, "start": 191, "tag": "ResearchActivity"}, {"end": 224, "start": 213, "tag": "PopulationGroup"}, {"end": 23, "start": 16, "tag": "Finding"}, {"end": 32, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 45, "tag": "PopulationGroup"}, {"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 165, "start": 127, "tag": "HealthCareRelatedOrganization"}, {"end": 171, "start": 167, "tag": "HealthCareRelatedOrganization"}]}{"id": "1555_3", "text": "We analyzed the effect of an APOE4 allele on cognitive measures, volumetric MRI, amyloid deposition, glucose metabolism, and on cerebrospinal fluid levels of AD biomarkers in 162 participants that did not carry the mutant gene (noncarriers).", "tags": [{"end": 226, "start": 215, "tag": "GeneOrGenome"}, {"end": 221, "start": 215, "tag": "CellOrMolecularDysfunction"}, {"end": 119, "start": 101, "tag": "CellFunction"}, {"end": 63, "start": 45, "tag": "ClinicalAttribute"}, {"end": 79, "start": 65, "tag": "HealthCareActivity"}, {"end": 239, "start": 228, "tag": "PopulationGroup"}, {"end": 160, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 191, "start": 179, "tag": "PopulationGroup"}, {"end": 88, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 161, "tag": "ClinicalAttribute"}, {"end": 41, "start": 35, "tag": "GeneOrGenome"}, {"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 99, "start": 81, "tag": "PathologicFunction"}]}{"id": "1555_4", "text": "APOE4+ and APOE4- mutation noncarriers had similar performance on cognitive measures.", "tags": [{"end": 84, "start": 66, "tag": "ClinicalAttribute"}, {"end": 26, "start": 18, "tag": "CellOrMolecularDysfunction"}, {"end": 38, "start": 27, "tag": "PopulationGroup"}, {"end": 62, "start": 51, "tag": "Finding"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 11, "tag": "BiologicallyActiveSubstance"}]}{"id": "1555_5", "text": "Amyloid deposition began at an earlier age in APOE4+ participants, whereas hippocampal volume was similar between the groups.", "tags": [{"end": 38, "start": 31, "tag": "TemporalConcept"}, {"end": 65, "start": 53, "tag": "PopulationGroup"}, {"end": 124, "start": 118, "tag": "PopulationGroup"}, {"end": 42, "start": 39, "tag": "OrganismAttribute"}, {"end": 51, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 75, "tag": "ClinicalAttribute"}, {"end": 18, "start": 0, "tag": "PathologicFunction"}]}{"id": "1555_6", "text": "These preliminary findings are consistent with growing evidence that the APOE4 allele may exert effects in midlife years before symptom onset, promoting amyloid deposition before altering cognitive performance or brain structure.", "tags": [{"end": 228, "start": 213, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 107, "tag": "TemporalConcept"}, {"end": 63, "start": 47, "tag": "Finding"}, {"end": 17, "start": 6, "tag": "TemporalConcept"}, {"end": 160, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 153, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 121, "tag": "TemporalConcept"}, {"end": 178, "start": 172, "tag": "TemporalConcept"}, {"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 103, "start": 96, "tag": "Finding"}, {"end": 209, "start": 188, "tag": "Finding"}, {"end": 85, "start": 79, "tag": "GeneOrGenome"}, {"end": 78, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 136, "tag": "TemporalConcept"}, {"end": 135, "start": 128, "tag": "SignOrSymptom"}, {"end": 171, "start": 153, "tag": "PathologicFunction"}]}{"id": "1555_7", "text": "(C) 2019 Elsevier Inc.", "tags": []}{"id": "1555_8", "text": "All rights reserved.", "tags": []}{"id": "1556_0", "text": "Introduction Neurofilament light chain (NfL) is becoming increasingly notable in neurological diseases including AD, and it has been suggested as a new peripherical biomarker of neurodegeneration.", "tags": [{"end": 102, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 178, "tag": "CellOrMolecularDysfunction"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 152, "tag": "ClinicalAttribute"}, {"end": 38, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 13, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1556_1", "text": "We aimed to compare plasma NfL levels among Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), and AD patients and to evaluate relationships between NfL and CSF biomarkers and neuropsychological scores.", "tags": [{"end": 105, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 179, "tag": "ClinicalAttribute"}, {"end": 26, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 120, "tag": "PatientOrDisabledGroup"}, {"end": 178, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 145, "tag": "Finding"}, {"end": 219, "start": 194, "tag": "HealthCareActivity"}, {"end": 37, "start": 20, "tag": "ClinicalAttribute"}, {"end": 72, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 74, "tag": "DiseaseOrSyndrome"}]}{"id": "1556_2", "text": "Materials and methods We enrolled 110 patients (34 SCD, 53 MCI, and 23 AD), who underwent clinical and neuropsychological evaluation, APOE genotyping, and plasma NfL analysis.", "tags": [{"end": 149, "start": 139, "tag": "ResearchActivity"}, {"end": 161, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 38, "tag": "PatientOrDisabledGroup"}, {"end": 165, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 162, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 90, "tag": "HealthCareActivity"}, {"end": 174, "start": 166, "tag": "ResearchActivity"}, {"end": 21, "start": 0, "tag": "ResearchActivity"}, {"end": 54, "start": 51, "tag": "DiseaseOrSyndrome"}]}{"id": "1556_3", "text": "Ninety-one patients underwent at least one amyloid burden biomarker (CSF and/or amyloid PET); 86 patients also underwent CSF phosphorylated-tau (p-tau) and total-tau (t-tau) measurement.", "tags": [{"end": 57, "start": 51, "tag": "ResearchActivity"}, {"end": 139, "start": 125, "tag": "CellFunction"}, {"end": 143, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 165, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 11, "tag": "PatientOrDisabledGroup"}, {"end": 105, "start": 97, "tag": "PatientOrDisabledGroup"}, {"end": 72, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 143, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 156, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 185, "start": 174, "tag": "ResearchActivity"}, {"end": 185, "start": 174, "tag": "HealthCareActivity"}, {"end": 67, "start": 58, "tag": "ClinicalAttribute"}, {"end": 91, "start": 88, "tag": "HealthCareActivity"}, {"end": 150, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 145, "tag": "BiologicallyActiveSubstance"}]}{"id": "1556_4", "text": "Patients were classified as A + if they presented at least one positive amyloid biomarker or A- if not.", "tags": [{"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 79, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 80, "tag": "ClinicalAttribute"}]}{"id": "1556_5", "text": "Results NfL levels were significantly increased in AD and MCI compared to SCD patients.", "tags": [{"end": 47, "start": 24, "tag": "Finding"}, {"end": 86, "start": 78, "tag": "PatientOrDisabledGroup"}, {"end": 11, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 8, "tag": "ClinicalAttribute"}, {"end": 77, "start": 74, "tag": "DiseaseOrSyndrome"}]}{"id": "1556_6", "text": "These differences depend on A status, e.g., SCD A + had lower NfLs than MCI A + but comparable with MCI A-.", "tags": [{"end": 66, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 6, "tag": "Finding"}, {"end": 36, "start": 30, "tag": "Finding"}, {"end": 75, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 44, "tag": "DiseaseOrSyndrome"}]}{"id": "1556_7", "text": "Similarly, MCI A + had higher NfL levels than MCI A-, but comparable with AD.", "tags": [{"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 30, "tag": "ClinicalAttribute"}]}{"id": "1556_8", "text": "NfL levels correlated with p-tau in SCD, with all CSF biomarkers in MCI patients.", "tags": [{"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 54, "tag": "ClinicalAttribute"}, {"end": 80, "start": 72, "tag": "PatientOrDisabledGroup"}, {"end": 53, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 39, "start": 36, "tag": "DiseaseOrSyndrome"}]}{"id": "1556_9", "text": "No correlations were found in AD subgroup.", "tags": [{"end": 32, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 3, "tag": "ResearchActivity"}]}{"id": "1556_10", "text": "In SCD, NfL levels were negatively correlated with memory test scores.", "tags": [{"end": 11, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 51, "tag": "BiologicFunction"}, {"end": 6, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 8, "tag": "ClinicalAttribute"}, {"end": 69, "start": 51, "tag": "HealthCareActivity"}]}{"id": "1556_11", "text": "Conclusions Plasma NfL levels might be a promising biomarker for neurodegeneration to discriminate cognitive decline due to AD from other conditions causing cognitive impairment in prodromal stages.", "tags": [{"end": 148, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 181, "tag": "SignOrSymptom"}, {"end": 18, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 65, "tag": "CellOrMolecularDysfunction"}, {"end": 22, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 51, "tag": "ClinicalAttribute"}, {"end": 197, "start": 191, "tag": "TemporalConcept"}, {"end": 116, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1556_12", "text": "Considering correlations with CSF p-tau and memory tests in SCD, NfL might be a useful peripheral biomarker also in preclinical phases of AD.", "tags": [{"end": 39, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 98, "tag": "ClinicalAttribute"}, {"end": 97, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 12, "tag": "ResearchActivity"}, {"end": 56, "start": 51, "tag": "ResearchActivity"}, {"end": 56, "start": 51, "tag": "HealthCareActivity"}, {"end": 39, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 44, "tag": "BiologicFunction"}, {"end": 63, "start": 60, "tag": "DiseaseOrSyndrome"}]}{"id": "1557_0", "text": "Background: Alzheimer's disease (AD)-related tauopathy can be measured with CSF phosphorylated tau (pTau) and tau PET.", "tags": [{"end": 54, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 114, "tag": "HealthCareActivity"}]}{"id": "1557_1", "text": "We aim to investigate the associations between these measurements and their relative ability to predict subsequent disease progression.", "tags": [{"end": 92, "start": 85, "tag": "OrganismAttribute"}, {"end": 134, "start": 115, "tag": "PathologicFunction"}, {"end": 65, "start": 53, "tag": "HealthCareActivity"}]}{"id": "1557_2", "text": "Methods: In 219 cognitively unimpaired and 122 impaired Alzheimer's Disease Neuroimaging Initiative participants with concurrent amyloid-beta (A beta) PET (F-18-florbetapir or(18)F-florbetaben),F-18-flortaucipir (FTP) PET, CSF measurements, structural MRI, and cognition, we examined inter-relationships between these biomarkers and their predictions of subsequent FTP and cognition changes.", "tags": [{"end": 390, "start": 373, "tag": "Finding"}, {"end": 128, "start": 118, "tag": "TemporalConcept"}, {"end": 99, "start": 56, "tag": "ResearchActivity"}, {"end": 99, "start": 56, "tag": "HealthCareRelatedOrganization"}, {"end": 211, "start": 199, "tag": "Chemical"}, {"end": 38, "start": 16, "tag": "Finding"}, {"end": 211, "start": 194, "tag": "Chemical"}, {"end": 255, "start": 241, "tag": "HealthCareActivity"}, {"end": 226, "start": 223, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 303, "start": 290, "tag": "Finding"}, {"end": 112, "start": 100, "tag": "PopulationGroup"}, {"end": 75, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 328, "start": 318, "tag": "ClinicalAttribute"}, {"end": 141, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 270, "start": 261, "tag": "BiologicFunction"}, {"end": 239, "start": 227, "tag": "HealthCareActivity"}, {"end": 154, "start": 151, "tag": "HealthCareActivity"}, {"end": 221, "start": 218, "tag": "HealthCareActivity"}, {"end": 149, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 156, "tag": "Chemical"}, {"end": 192, "start": 175, "tag": "Chemical"}]}{"id": "1557_3", "text": "Results: The use of a CSF pTau/A beta(40) ratio eliminated positive associations we observed between CSF pTau alone and CSF A beta(42) in the normal A beta range likely reflecting individual differences in CSF production rather than pathology.", "tags": [{"end": 148, "start": 142, "tag": "Finding"}, {"end": 109, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 206, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 242, "start": 233, "tag": "PathologicFunction"}, {"end": 242, "start": 233, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 202, "start": 191, "tag": "Finding"}, {"end": 190, "start": 180, "tag": "PopulationGroup"}, {"end": 190, "start": 180, "tag": "OrganismAttribute"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 134, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 22, "tag": "ClinicalAttribute"}, {"end": 134, "start": 124, "tag": "BiologicallyActiveSubstance"}]}{"id": "1557_4", "text": "Use of the CSF pTau/A beta(40) ratio also increased expected associations with A beta PET, FTP PET, hippocampal volume, and cognitive decline compared to pTau alone.", "tags": [{"end": 158, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 86, "tag": "HealthCareActivity"}, {"end": 98, "start": 95, "tag": "HealthCareActivity"}, {"end": 85, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 100, "tag": "ClinicalAttribute"}, {"end": 36, "start": 11, "tag": "ClinicalAttribute"}, {"end": 94, "start": 91, "tag": "Chemical"}]}{"id": "1557_5", "text": "In A beta+ individuals, abnormal CSF pTau/A beta(40) only individuals (26.7%) were 4 times more prevalent (p < 0.001) than abnormal FTP only individuals (6.8%).", "tags": [{"end": 32, "start": 24, "tag": "Finding"}, {"end": 131, "start": 123, "tag": "Finding"}, {"end": 22, "start": 11, "tag": "PopulationGroup"}, {"end": 69, "start": 58, "tag": "PopulationGroup"}, {"end": 152, "start": 141, "tag": "PopulationGroup"}, {"end": 9, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 33, "tag": "ClinicalAttribute"}, {"end": 135, "start": 132, "tag": "Chemical"}]}{"id": "1557_6", "text": "Furthermore, among individuals on the AD pathway, CSF pTau/A beta(40) mediates the association between A beta PET and FTP PET accumulation, but FTP PET is more closely linked to subsequent cognitive decline than CSF pTau/A beta(40).", "tags": [{"end": 40, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 19, "tag": "PopulationGroup"}, {"end": 206, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 41, "tag": "CellFunction"}, {"end": 113, "start": 110, "tag": "HealthCareActivity"}, {"end": 125, "start": 122, "tag": "HealthCareActivity"}, {"end": 151, "start": 148, "tag": "HealthCareActivity"}, {"end": 109, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 126, "tag": "Finding"}, {"end": 69, "start": 50, "tag": "ClinicalAttribute"}, {"end": 121, "start": 118, "tag": "Chemical"}, {"end": 147, "start": 144, "tag": "Chemical"}, {"end": 231, "start": 212, "tag": "ClinicalAttribute"}]}{"id": "1557_7", "text": "Conclusions: Together, these findings suggest that CSF pTau/A beta(40) may be a superior measure of tauopathy compared to CSF pTau alone, and CSF pTau/A beta(40) enables detection of tau accumulation at an earlier stage than FTP among A beta+ individuals.", "tags": [{"end": 109, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 213, "start": 206, "tag": "TemporalConcept"}, {"end": 186, "start": 183, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 183, "tag": "BiologicallyActiveSubstance"}, {"end": 254, "start": 243, "tag": "PopulationGroup"}, {"end": 179, "start": 170, "tag": "HealthCareActivity"}, {"end": 241, "start": 235, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 187, "tag": "Finding"}, {"end": 219, "start": 214, "tag": "TemporalConcept"}, {"end": 219, "start": 214, "tag": "ClinicalAttribute"}, {"end": 70, "start": 51, "tag": "ClinicalAttribute"}, {"end": 161, "start": 142, "tag": "ClinicalAttribute"}, {"end": 228, "start": 225, "tag": "Chemical"}]}{"id": "1558_0", "text": "Background Previous models of Alzheimer's disease (AD) progression were primarily hypothetical or based on data originating from single cohort studies.", "tags": [{"end": 19, "start": 11, "tag": "TemporalConcept"}, {"end": 49, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 107, "tag": "ResearchActivity"}, {"end": 150, "start": 129, "tag": "ResearchActivity"}, {"end": 66, "start": 55, "tag": "PathologicFunction"}, {"end": 66, "start": 55, "tag": "TemporalConcept"}, {"end": 26, "start": 20, "tag": "ResearchActivity"}, {"end": 142, "start": 136, "tag": "PopulationGroup"}]}{"id": "1558_1", "text": "However, cohort datasets are subject to specific inclusion and exclusion criteria that influence the signals observed in their collected data.", "tags": [{"end": 141, "start": 137, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "PopulationGroup"}, {"end": 24, "start": 16, "tag": "ResearchActivity"}, {"end": 108, "start": 101, "tag": "CellFunction"}, {"end": 81, "start": 63, "tag": "ResearchActivity"}, {"end": 81, "start": 73, "tag": "ResearchActivity"}, {"end": 58, "start": 49, "tag": "ResearchActivity"}]}{"id": "1558_2", "text": "Furthermore, each study measures only a subset of AD-relevant variables.", "tags": [{"end": 52, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 18, "tag": "ResearchActivity"}]}{"id": "1558_3", "text": "To gain a comprehensive understanding of AD progression, the heterogeneity and robustness of estimated progression patterns must be understood, and complementary information contained in cohort datasets be leveraged.", "tags": [{"end": 37, "start": 10, "tag": "ResearchActivity"}, {"end": 74, "start": 61, "tag": "Finding"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 44, "tag": "PathologicFunction"}, {"end": 114, "start": 103, "tag": "PathologicFunction"}, {"end": 55, "start": 44, "tag": "TemporalConcept"}, {"end": 114, "start": 103, "tag": "TemporalConcept"}, {"end": 193, "start": 187, "tag": "PopulationGroup"}, {"end": 123, "start": 115, "tag": "ResearchActivity"}, {"end": 202, "start": 194, "tag": "ResearchActivity"}, {"end": 89, "start": 79, "tag": "ResearchActivity"}]}{"id": "1558_4", "text": "Methods We compared ten event-based models that we fit to ten independent AD cohort datasets.", "tags": [{"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 36, "tag": "ResearchActivity"}, {"end": 83, "start": 77, "tag": "PopulationGroup"}, {"end": 92, "start": 84, "tag": "ResearchActivity"}]}{"id": "1558_5", "text": "Additionally, we designed and applied a novel rank aggregation algorithm that combines partially overlapping, individual event sequences into a meta-sequence containing the complementary information from each cohort.", "tags": [{"end": 72, "start": 40, "tag": "MachineActivity"}, {"end": 120, "start": 110, "tag": "PopulationGroup"}, {"end": 120, "start": 110, "tag": "OrganismAttribute"}, {"end": 215, "start": 209, "tag": "PopulationGroup"}, {"end": 157, "start": 144, "tag": "MachineActivity"}]}{"id": "1558_6", "text": "Results We observed overall consistency across the ten event-based model sequences (average pairwise Kendall's tau correlation coefficient of 0.69 +/- 0.28), despite variance in the positioning of mainly imaging variables.", "tags": [{"end": 193, "start": 182, "tag": "HealthCareActivity"}, {"end": 211, "start": 204, "tag": "HealthCareActivity"}, {"end": 114, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 72, "start": 55, "tag": "ResearchActivity"}, {"end": 138, "start": 101, "tag": "ResearchActivity"}]}{"id": "1558_7", "text": "The changes described in the aggregated meta-sequence are broadly consistent with the current understanding of AD progression, starting with cerebrospinal fluid amyloid beta, followed by tauopathy, memory impairment, FDG-PET, and ultimately brain deterioration and impairment of visual memory.", "tags": [{"end": 196, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 275, "start": 265, "tag": "Finding"}, {"end": 292, "start": 279, "tag": "BiologicFunction"}, {"end": 215, "start": 198, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 246, "start": 241, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 86, "tag": "TemporalConcept"}, {"end": 224, "start": 217, "tag": "HealthCareActivity"}, {"end": 125, "start": 114, "tag": "PathologicFunction"}, {"end": 125, "start": 114, "tag": "TemporalConcept"}, {"end": 107, "start": 94, "tag": "BiologicFunction"}, {"end": 173, "start": 161, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 4, "tag": "Finding"}, {"end": 260, "start": 247, "tag": "Finding"}, {"end": 53, "start": 40, "tag": "MachineActivity"}]}{"id": "1558_8", "text": "Conclusion Overall, the event-based models demonstrated similar and robust disease cascades across independent AD cohorts.", "tags": [{"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 114, "tag": "PopulationGroup"}, {"end": 42, "start": 24, "tag": "ResearchActivity"}]}{"id": "1558_9", "text": "Aggregation of data-driven results can combine complementary strengths and information of patient-level datasets.", "tags": [{"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 11, "start": 0, "tag": "ResearchActivity"}, {"end": 97, "start": 90, "tag": "PatientOrDisabledGroup"}, {"end": 34, "start": 15, "tag": "ResearchActivity"}, {"end": 112, "start": 104, "tag": "ResearchActivity"}]}{"id": "1558_10", "text": "Accordingly, the derived meta-sequence draws a more complete picture of AD pathology compared to models relying on single cohorts.", "tags": [{"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 122, "tag": "PopulationGroup"}, {"end": 84, "start": 75, "tag": "PathologicFunction"}, {"end": 84, "start": 75, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 103, "start": 97, "tag": "ResearchActivity"}, {"end": 38, "start": 25, "tag": "MachineActivity"}]}{"id": "1559_0", "text": "IntroductionPreviously generated serum and plasma proteomic profiles were examined among adults with Down syndrome (DS) to determine whether these profiles could discriminate those with mild cognitive impairment (MCI-DS) and Alzheimer's disease (DS-AD) from those cognitively stable (CS).", "tags": [{"end": 68, "start": 50, "tag": "ResearchActivity"}, {"end": 38, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 244, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 251, "start": 249, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 246, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 89, "tag": "PopulationGroup"}, {"end": 155, "start": 147, "tag": "ResearchActivity"}, {"end": 282, "start": 264, "tag": "Finding"}]}{"id": "1559_1", "text": "MethodsData were analyzed on n = 305 (n = 225 CS; n = 44 MCI-DS; n = 36 DS-AD) enrolled in the Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS).", "tags": [{"end": 149, "start": 143, "tag": "HealthCareRelatedOrganization"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 95, "tag": "HealthCareRelatedOrganization"}]}{"id": "1559_2", "text": "ResultsDistinguishing MCI-DS from CS, the serum profile produced an area under the curve (AUC) = 0.95 (sensitivity [SN] = 0.91; specificity [SP] = 0.99) and an AUC = 0.98 (SN = 0.96; SP = 0.97) for plasma when using an optimized cut-off score.", "tags": [{"end": 47, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 236, "start": 229, "tag": "ResearchActivity"}, {"end": 88, "start": 68, "tag": "ResearchActivity"}, {"end": 242, "start": 237, "tag": "Finding"}, {"end": 25, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 103, "tag": "Finding"}, {"end": 139, "start": 128, "tag": "Finding"}, {"end": 204, "start": 198, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 90, "tag": "ResearchActivity"}, {"end": 163, "start": 160, "tag": "ResearchActivity"}, {"end": 55, "start": 48, "tag": "ResearchActivity"}]}{"id": "1559_3", "text": "Distinguishing DS-AD from CS, the serum profile produced an AUC = 0.93 (SN = 0.81; SP = 0.99) and an AUC = 0.95 (SN = 0.86; SP = 1.0) for plasma when using an optimized cut-off score.", "tags": [{"end": 39, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 169, "tag": "ResearchActivity"}, {"end": 20, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 177, "tag": "Finding"}, {"end": 144, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 60, "tag": "ResearchActivity"}, {"end": 104, "start": 101, "tag": "ResearchActivity"}]}{"id": "1559_4", "text": "AUC remained unchanged to slightly improved when age and sex were included.", "tags": [{"end": 60, "start": 57, "tag": "OrganismAttribute"}, {"end": 52, "start": 49, "tag": "OrganismAttribute"}, {"end": 3, "start": 0, "tag": "ResearchActivity"}]}{"id": "1559_5", "text": "Eotaxin3, interleukin (IL)-10, C-reactive protein, IL-18, serum amyloid A , and FABP3 correlated fractions at r(2) > = 0.90.", "tags": [{"end": 8, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 51, "tag": "GeneOrGenome"}, {"end": 73, "start": 58, "tag": "ClinicalAttribute"}, {"end": 85, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 80, "tag": "GeneOrGenome"}, {"end": 85, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 8, "start": 0, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1559_6", "text": "DiscussionProteomic profiles showed excellent detection accuracy for MCI-DS and DS-AD.", "tags": [{"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 56, "tag": "Finding"}, {"end": 55, "start": 46, "tag": "HealthCareActivity"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 10, "tag": "ResearchActivity"}]}{"id": "1560_0", "text": "We have previously investigated, discovered, and replicated plasma protein biomarkers for use to triage potential trials participants for PET or cerebrospinal fluid measures of Alzheimer's disease (AD) pathology.", "tags": [{"end": 103, "start": 97, "tag": "HealthCareActivity"}, {"end": 85, "start": 67, "tag": "ClinicalAttribute"}, {"end": 196, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 198, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 121, "tag": "PopulationGroup"}, {"end": 66, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 202, "tag": "PathologicFunction"}, {"end": 211, "start": 202, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 141, "start": 138, "tag": "HealthCareActivity"}, {"end": 120, "start": 114, "tag": "ResearchActivity"}]}{"id": "1560_1", "text": "This study sought to undertake validation of these candidate plasma biomarkers in a large, multi-center sample collection.", "tags": [{"end": 41, "start": 31, "tag": "ResearchActivity"}, {"end": 78, "start": 68, "tag": "ClinicalAttribute"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 67, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 104, "tag": "HealthCareActivity"}]}{"id": "1560_2", "text": "Targeted plasma analyses of 34 proteins with prior evidence for prediction of in vivo pathology were conducted in up to 1,000 samples from cognitively healthy elderly individuals, people with mild cognitive impairment, and in patients with AD-type dementia, selected from the EMIF-AD catalogue.", "tags": [{"end": 242, "start": 240, "tag": "DiseaseOrSyndrome"}, {"end": 283, "start": 281, "tag": "DiseaseOrSyndrome"}, {"end": 234, "start": 226, "tag": "PatientOrDisabledGroup"}, {"end": 178, "start": 167, "tag": "PopulationGroup"}, {"end": 256, "start": 248, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 86, "tag": "PathologicFunction"}, {"end": 95, "start": 86, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 39, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 51, "tag": "Finding"}, {"end": 24, "start": 16, "tag": "ResearchActivity"}, {"end": 166, "start": 159, "tag": "PopulationGroup"}, {"end": 74, "start": 64, "tag": "Finding"}, {"end": 217, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 139, "tag": "OrganismAttribute"}, {"end": 85, "start": 78, "tag": "ResearchActivity"}, {"end": 186, "start": 180, "tag": "PopulationGroup"}, {"end": 256, "start": 240, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 126, "tag": "Substance"}, {"end": 133, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 293, "start": 276, "tag": "ResearchActivity"}]}{"id": "1560_3", "text": "Proteins were measured using Luminex xMAP, ELISA, and Meso Scale Discovery assays.", "tags": [{"end": 8, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 29, "tag": "ResearchActivity"}, {"end": 48, "start": 43, "tag": "ResearchActivity"}, {"end": 81, "start": 54, "tag": "ResearchActivity"}]}{"id": "1560_4", "text": "Seven proteins replicated in their ability to predict in vivo amyloid pathology.", "tags": [{"end": 79, "start": 62, "tag": "PathologicFunction"}, {"end": 42, "start": 35, "tag": "OrganismAttribute"}, {"end": 14, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 54, "tag": "ResearchActivity"}]}{"id": "1560_5", "text": "These proteins form a biomarker panel that, along with age, could significantly discriminate between individuals with high and low amyloid pathology with an area under the curve of 0.74.", "tags": [{"end": 148, "start": 131, "tag": "PathologicFunction"}, {"end": 130, "start": 127, "tag": "Finding"}, {"end": 31, "start": 22, "tag": "ClinicalAttribute"}, {"end": 177, "start": 157, "tag": "ResearchActivity"}, {"end": 112, "start": 101, "tag": "PopulationGroup"}, {"end": 14, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "OrganismAttribute"}, {"end": 122, "start": 118, "tag": "Finding"}, {"end": 37, "start": 22, "tag": "ResearchActivity"}]}{"id": "1560_6", "text": "The performance of this biomarker panel remained consistent when tested in apolipoprotein E epsilon 4 non-carrier individuals only.", "tags": [{"end": 33, "start": 24, "tag": "ClinicalAttribute"}, {"end": 125, "start": 114, "tag": "PopulationGroup"}, {"end": 15, "start": 4, "tag": "Finding"}, {"end": 39, "start": 24, "tag": "ResearchActivity"}, {"end": 101, "start": 75, "tag": "GeneOrGenome"}, {"end": 113, "start": 102, "tag": "PopulationGroup"}]}{"id": "1560_7", "text": "This blood-based panel is biologically relevant, measurable using practical immunocapture arrays, and could significantly reduce the cost incurred to clinical trials through screen failure.", "tags": [{"end": 188, "start": 181, "tag": "IndividualBehavior"}, {"end": 188, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 150, "tag": "ResearchActivity"}, {"end": 10, "start": 5, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 180, "start": 174, "tag": "HealthCareActivity"}, {"end": 180, "start": 174, "tag": "ResearchActivity"}, {"end": 96, "start": 76, "tag": "ResearchActivity"}]}{"id": "1561_0", "text": "Background: Aberrant amyloid-beta (A beta) deposition in the brain occurs two decades prior to the manifestation of Alzheimer's disease (AD) clinical symptoms and therefore brain A beta load measured using PET serves as a gold standard biomarker for the early diagnosis of AD.", "tags": [{"end": 112, "start": 99, "tag": "SignOrSymptom"}, {"end": 85, "start": 78, "tag": "TemporalConcept"}, {"end": 158, "start": 141, "tag": "SignOrSymptom"}, {"end": 135, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 275, "start": 273, "tag": "DiseaseOrSyndrome"}, {"end": 245, "start": 236, "tag": "ClinicalAttribute"}, {"end": 66, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 269, "start": 260, "tag": "HealthCareActivity"}, {"end": 33, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 259, "start": 254, "tag": "TemporalConcept"}, {"end": 209, "start": 206, "tag": "HealthCareActivity"}, {"end": 41, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 179, "tag": "AminoAcidPeptideOrProtein"}, {"end": 269, "start": 254, "tag": "HealthCareActivity"}, {"end": 53, "start": 43, "tag": "PathologicFunction"}, {"end": 33, "start": 12, "tag": "PathologicFunction"}, {"end": 190, "start": 173, "tag": "ClinicalAttribute"}]}{"id": "1561_1", "text": "However, the uneconomical nature of PET makes blood markers, that reflect brain A beta deposition, attractive candidates for investigation as surrogate markers.", "tags": [{"end": 138, "start": 125, "tag": "ResearchActivity"}, {"end": 79, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 36, "tag": "HealthCareActivity"}, {"end": 86, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 52, "tag": "ClinicalAttribute"}, {"end": 159, "start": 142, "tag": "ClinicalAttribute"}, {"end": 97, "start": 80, "tag": "PathologicFunction"}]}{"id": "1561_2", "text": "Objective: Investigation of plasma A beta as a surrogate marker for brain A beta deposition in cognitively normal elderly individuals.", "tags": [{"end": 24, "start": 11, "tag": "ResearchActivity"}, {"end": 63, "start": 47, "tag": "ClinicalAttribute"}, {"end": 73, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 122, "tag": "PopulationGroup"}, {"end": 34, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 95, "tag": "Finding"}, {"end": 121, "start": 114, "tag": "PopulationGroup"}, {"end": 41, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 74, "tag": "PathologicFunction"}]}{"id": "1561_3", "text": "Methods: Plasma A beta(40) and A beta(42) concentrations were measured using the ultrasensitive Single Molecule Array (Simoa) assay in 95 cognitively normal elderly individuals, who have all undergone PET to assess brain A beta deposition.", "tags": [{"end": 131, "start": 126, "tag": "ResearchActivity"}, {"end": 222, "start": 215, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 42, "tag": "BiologicFunction"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 165, "tag": "PopulationGroup"}, {"end": 156, "start": 138, "tag": "Finding"}, {"end": 164, "start": 157, "tag": "PopulationGroup"}, {"end": 204, "start": 201, "tag": "HealthCareActivity"}, {"end": 26, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 227, "start": 221, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 96, "tag": "ResearchActivity"}, {"end": 124, "start": 119, "tag": "ResearchActivity"}, {"end": 238, "start": 221, "tag": "PathologicFunction"}]}{"id": "1561_4", "text": "Based on the standard uptake value ratios (SUVR) obtained from PET imaging, using the tracer F-18-Florbetaben, plasma A beta was compared between 32 participants assessed to have low brain A beta load (A beta-, SUVR <1.35) and 63 assessed to have high brain A beta load (A beta+, SUVR >= 1.35).", "tags": [{"end": 92, "start": 86, "tag": "Chemical"}, {"end": 74, "start": 63, "tag": "HealthCareActivity"}, {"end": 182, "start": 179, "tag": "Finding"}, {"end": 161, "start": 149, "tag": "PopulationGroup"}, {"end": 117, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 208, "start": 202, "tag": "AminoAcidPeptideOrProtein"}, {"end": 277, "start": 271, "tag": "AminoAcidPeptideOrProtein"}, {"end": 251, "start": 247, "tag": "Finding"}, {"end": 109, "start": 93, "tag": "Chemical"}, {"end": 41, "start": 13, "tag": "ResearchActivity"}, {"end": 47, "start": 43, "tag": "ResearchActivity"}, {"end": 200, "start": 183, "tag": "ClinicalAttribute"}, {"end": 269, "start": 252, "tag": "ClinicalAttribute"}, {"end": 215, "start": 211, "tag": "ResearchActivity"}, {"end": 284, "start": 280, "tag": "ResearchActivity"}]}{"id": "1561_5", "text": "Results: Plasma A beta(42)/A beta(40) ratios were lower in the A beta+ group compared to the A beta- group.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 76, "start": 71, "tag": "PopulationGroup"}, {"end": 106, "start": 101, "tag": "PopulationGroup"}, {"end": 69, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 9, "tag": "ClinicalAttribute"}]}{"id": "1561_6", "text": "Plasma A beta(40) and A beta(42) levels were not significantly different between A beta- and A beta+ groups, although a trend of higher plasma A beta(40) was observed in the A beta+ group.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 101, "tag": "PopulationGroup"}, {"end": 187, "start": 182, "tag": "PopulationGroup"}, {"end": 17, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 22, "tag": "BiologicallyActiveSubstance"}]}{"id": "1561_7", "text": "Additionally, plasma A beta(42)/A beta(40) ratios along with the known AD risk factors, age and APOE epsilon 4 status, resulted in A beta+ participants being distinguished from A beta- participants based on an area under the receiver operating characteristic curve shown to be 78%.", "tags": [{"end": 264, "start": 210, "tag": "ResearchActivity"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 139, "tag": "PopulationGroup"}, {"end": 197, "start": 185, "tag": "PopulationGroup"}, {"end": 91, "start": 88, "tag": "OrganismAttribute"}, {"end": 117, "start": 111, "tag": "Finding"}, {"end": 137, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 74, "tag": "Finding"}, {"end": 110, "start": 96, "tag": "GeneOrGenome"}, {"end": 49, "start": 14, "tag": "ClinicalAttribute"}]}{"id": "1561_8", "text": "Conclusion: Plasma A beta ratios in this study are a potential biomarker for brain A beta deposition and therefore, for preclinical AD.", "tags": [{"end": 18, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 41, "tag": "ResearchActivity"}, {"end": 134, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 53, "tag": "ClinicalAttribute"}, {"end": 100, "start": 83, "tag": "PathologicFunction"}]}{"id": "1561_9", "text": "However, this method to measure plasma A beta needs further development to increase the accuracy of this promising AD blood biomarker.", "tags": [{"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 124, "tag": "ClinicalAttribute"}, {"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 71, "start": 60, "tag": "BiologicFunction"}, {"end": 71, "start": 60, "tag": "CellFunction"}, {"end": 96, "start": 88, "tag": "Finding"}, {"end": 38, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 39, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1562_0", "text": "Introduction: Plasma markers have been reported to be associated with brain amyloid burden, tau pathology, or neurodegeneration.", "tags": [{"end": 20, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 92, "tag": "PathologicFunction"}, {"end": 75, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 110, "tag": "CellOrMolecularDysfunction"}, {"end": 90, "start": 84, "tag": "ResearchActivity"}, {"end": 28, "start": 21, "tag": "ClinicalAttribute"}]}{"id": "1562_1", "text": "We aimed to evaluate whether plasma biomarker profiles could predict Alzheimer's disease (AD) pathology and clinical progression in older adults without dementia.", "tags": [{"end": 128, "start": 108, "tag": "TemporalConcept"}, {"end": 144, "start": 132, "tag": "PopulationGroup"}, {"end": 88, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 36, "tag": "ClinicalAttribute"}, {"end": 161, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 94, "tag": "PathologicFunction"}, {"end": 103, "start": 94, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 128, "start": 117, "tag": "PathologicFunction"}, {"end": 128, "start": 117, "tag": "TemporalConcept"}, {"end": 54, "start": 46, "tag": "ResearchActivity"}]}{"id": "1562_2", "text": "Methods: Cross-sectional and longitudinal data of participants enrolled in this study were from the Alzheimer's Disease Neuroimaging Initiative (ADNI).", "tags": [{"end": 46, "start": 42, "tag": "ResearchActivity"}, {"end": 24, "start": 9, "tag": "ResearchActivity"}, {"end": 143, "start": 100, "tag": "ResearchActivity"}, {"end": 143, "start": 100, "tag": "HealthCareRelatedOrganization"}, {"end": 46, "start": 29, "tag": "ResearchActivity"}, {"end": 149, "start": 145, "tag": "HealthCareRelatedOrganization"}, {"end": 149, "start": 145, "tag": "ResearchActivity"}, {"end": 46, "start": 42, "tag": "ResearchActivity"}, {"end": 62, "start": 50, "tag": "PopulationGroup"}, {"end": 119, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 80, "tag": "ResearchActivity"}]}{"id": "1562_3", "text": "Plasma amyloid beta (A beta)(1-42)/A beta(1-40) ratio was selected as the marker for amyloid pathology, p-tau181 for tau pathology, and neurofilament light for neurodegeneration.", "tags": [{"end": 102, "start": 85, "tag": "PathologicFunction"}, {"end": 155, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 117, "tag": "PathologicFunction"}, {"end": 14, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 74, "tag": "ClinicalAttribute"}, {"end": 112, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 160, "tag": "CellOrMolecularDysfunction"}, {"end": 19, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 20, "tag": "ClinicalAttribute"}, {"end": 6, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1562_4", "text": "Cut-offs for these plasma markers were calculated with well-established positron emission tomography and structural imaging biomarkers as reference.", "tags": [{"end": 123, "start": 105, "tag": "HealthCareActivity"}, {"end": 134, "start": 124, "tag": "ClinicalAttribute"}, {"end": 25, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 72, "tag": "HealthCareActivity"}, {"end": 33, "start": 26, "tag": "ClinicalAttribute"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}]}{"id": "1562_5", "text": "Older adults without dementia were categorized into eight groups at baseline by plasma amyloid/tau/neurodegeneration (A/T/N) cut-offs.", "tags": [{"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 98, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 58, "tag": "PopulationGroup"}, {"end": 116, "start": 99, "tag": "CellOrMolecularDysfunction"}, {"end": 133, "start": 125, "tag": "ResearchActivity"}]}{"id": "1562_6", "text": "Clinical progression was analyzed using linear mixed-effects models and Cox proportional hazard models.", "tags": [{"end": 67, "start": 40, "tag": "ResearchActivity"}, {"end": 20, "start": 0, "tag": "TemporalConcept"}, {"end": 102, "start": 72, "tag": "ResearchActivity"}]}{"id": "1562_7", "text": "Results: A total of 183 participants (97 cognitively normal [CN] subjects and 86 patients with mild cognitive impairment [MCI]; mean age 72.6 years, and 48.1% men) were included.", "tags": [{"end": 63, "start": 61, "tag": "Finding"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 36, "start": 24, "tag": "PopulationGroup"}, {"end": 125, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 136, "start": 133, "tag": "OrganismAttribute"}, {"end": 147, "start": 142, "tag": "TemporalConcept"}, {"end": 59, "start": 41, "tag": "Finding"}, {"end": 120, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 65, "tag": "PopulationGroup"}, {"end": 162, "start": 159, "tag": "PopulationGroup"}]}{"id": "1562_8", "text": "Participants with A+ had significantly higher proportions of apolipoprotein E (APOE) gene 4 carriers than those with A-.", "tags": [{"end": 91, "start": 85, "tag": "GeneOrGenome"}, {"end": 77, "start": 61, "tag": "GeneOrGenome"}, {"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 83, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 92, "tag": "PopulationGroup"}]}{"id": "1562_9", "text": "Brain atrophy was observed in all groups of CN, whereas cognition decline was obvious in the A+T+N+ group.", "tags": [{"end": 13, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 44, "tag": "Finding"}, {"end": 40, "start": 34, "tag": "PopulationGroup"}, {"end": 65, "start": 56, "tag": "BiologicFunction"}, {"end": 105, "start": 100, "tag": "PopulationGroup"}, {"end": 73, "start": 66, "tag": "Finding"}]}{"id": "1562_10", "text": "Compared to A-T-N-, MCI patients with A+T+N+ had faster cognition worsening and faster brain atrophy.", "tags": [{"end": 75, "start": 66, "tag": "Finding"}, {"end": 100, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 24, "tag": "PatientOrDisabledGroup"}, {"end": 23, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 56, "tag": "BiologicFunction"}]}{"id": "1562_11", "text": "In the whole cohort, A+T+N+ and A+T+N- participants were at higher risk of clinical progression.", "tags": [{"end": 95, "start": 75, "tag": "TemporalConcept"}, {"end": 51, "start": 39, "tag": "PopulationGroup"}, {"end": 19, "start": 13, "tag": "PopulationGroup"}, {"end": 71, "start": 67, "tag": "Finding"}]}{"id": "1562_12", "text": "Discussion: Plasma A/T/N biomarker profiles may predict AD pathology and clinical progression, indicating a potential role for plasma biomarkers in clinical trials.", "tags": [{"end": 93, "start": 73, "tag": "TemporalConcept"}, {"end": 18, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 148, "tag": "ResearchActivity"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 12, "tag": "ClinicalAttribute"}, {"end": 144, "start": 134, "tag": "ClinicalAttribute"}, {"end": 133, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 59, "tag": "PathologicFunction"}, {"end": 68, "start": 59, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 43, "start": 35, "tag": "ResearchActivity"}]}{"id": "1562_13", "text": "More research is warranted to develop a robust plasma AD framework.", "tags": [{"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 5, "tag": "ResearchActivity"}, {"end": 53, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1563_0", "text": "Background: Biomarkers may soon be used to predict decline in older individuals.", "tags": [{"end": 67, "start": 62, "tag": "TemporalConcept"}, {"end": 79, "start": 68, "tag": "PopulationGroup"}, {"end": 22, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1563_1", "text": "Extended follow-up studies are needed to determine the stability of such biomarker-based predictions.", "tags": [{"end": 26, "start": 9, "tag": "ResearchActivity"}, {"end": 82, "start": 73, "tag": "ClinicalAttribute"}]}{"id": "1563_2", "text": "Objective: To examine the long-term performance of baseline cognitive, neuroimaging, and cerebrospinal fluid (CSF) biomarker-assisted prognosis in patients with mild cognitive impairment.", "tags": [{"end": 143, "start": 134, "tag": "HealthCareActivity"}, {"end": 35, "start": 26, "tag": "TemporalConcept"}, {"end": 47, "start": 36, "tag": "Finding"}, {"end": 155, "start": 147, "tag": "PatientOrDisabledGroup"}, {"end": 113, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 115, "tag": "ClinicalAttribute"}, {"end": 108, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 71, "tag": "HealthCareActivity"}, {"end": 186, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 161, "tag": "Finding"}]}{"id": "1563_3", "text": "Methods: Established, biomarker-defined, cohorts of subjects with mild cognitive impairment were examined for progression to dementia.", "tags": [{"end": 31, "start": 22, "tag": "ClinicalAttribute"}, {"end": 133, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 110, "tag": "PathologicFunction"}, {"end": 121, "start": 110, "tag": "TemporalConcept"}, {"end": 60, "start": 52, "tag": "PopulationGroup"}, {"end": 91, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 41, "tag": "PopulationGroup"}, {"end": 70, "start": 66, "tag": "Finding"}]}{"id": "1563_4", "text": "Subjects with a baseline volumetric MRI, lumbar puncture, and Rey Auditory Verbal Learning Test were included.", "tags": [{"end": 56, "start": 41, "tag": "HealthCareActivity"}, {"end": 39, "start": 25, "tag": "HealthCareActivity"}, {"end": 95, "start": 62, "tag": "HealthCareActivity"}]}{"id": "1563_5", "text": "Dementia-free survival time in each biomarker-defined risk group was determined with Kaplan-Meier survival curves.", "tags": [{"end": 45, "start": 36, "tag": "ClinicalAttribute"}, {"end": 22, "start": 14, "tag": "CellFunction"}, {"end": 106, "start": 98, "tag": "CellFunction"}, {"end": 64, "start": 59, "tag": "PopulationGroup"}, {"end": 27, "start": 23, "tag": "TemporalConcept"}, {"end": 8, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 85, "tag": "ResearchActivity"}]}{"id": "1563_6", "text": "The influence of each risk factor or combination of factors on dementia-free survival was examined with Cox proportional hazard analyses.", "tags": [{"end": 33, "start": 22, "tag": "Finding"}, {"end": 71, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 77, "tag": "CellFunction"}, {"end": 136, "start": 104, "tag": "ResearchActivity"}]}{"id": "1563_7", "text": "Results: 185 subjects were followed longitudinally for a mean (SD) 4.3 (2.8) years.", "tags": [{"end": 82, "start": 77, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 21, "start": 13, "tag": "PopulationGroup"}]}{"id": "1563_8", "text": "59% of participants converted within the follow-up period and the median dementia-free survival time was 2.8 years.", "tags": [{"end": 72, "start": 66, "tag": "ResearchActivity"}, {"end": 114, "start": 109, "tag": "TemporalConcept"}, {"end": 81, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 7, "tag": "PopulationGroup"}, {"end": 57, "start": 51, "tag": "TemporalConcept"}, {"end": 95, "start": 87, "tag": "CellFunction"}, {"end": 50, "start": 41, "tag": "HealthCareActivity"}, {"end": 50, "start": 41, "tag": "TemporalConcept"}, {"end": 100, "start": 96, "tag": "TemporalConcept"}]}{"id": "1563_9", "text": "Each individual risk factor predicted conversion to dementia (HR 1.9-3.7).", "tags": [{"end": 15, "start": 5, "tag": "PopulationGroup"}, {"end": 15, "start": 5, "tag": "OrganismAttribute"}, {"end": 48, "start": 38, "tag": "Finding"}, {"end": 27, "start": 16, "tag": "Finding"}, {"end": 60, "start": 52, "tag": "DiseaseOrSyndrome"}]}{"id": "1563_10", "text": "The joint presence of any two risk factors increased risk for conversion (HR 7.1-11.0), with the presence of medial temporal atrophy and memory impairment showing the greatest risk for decline.", "tags": [{"end": 9, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 10, "tag": "Finding"}, {"end": 72, "start": 62, "tag": "CellFunction"}, {"end": 105, "start": 97, "tag": "Finding"}, {"end": 42, "start": 30, "tag": "Finding"}, {"end": 154, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 125, "tag": "PathologicFunction"}, {"end": 132, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 137, "tag": "BiologicFunction"}, {"end": 124, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1563_11", "text": "Concordant atrophy, memory impairment, and abnormal CSF amyloid and tau was associated with the highest risk for conversion (HR 15.1).", "tags": [{"end": 71, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 11, "tag": "PathologicFunction"}, {"end": 18, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 52, "tag": "ClinicalAttribute"}, {"end": 123, "start": 104, "tag": "Finding"}, {"end": 71, "start": 68, "tag": "ClinicalAttribute"}, {"end": 55, "start": 52, "tag": "ClinicalAttribute"}]}{"id": "1563_12", "text": "The presence of medial temporal atrophy was associated with the shortest dementia-free survival time, both alone and in combination with memory impairment, abnormal CSF amyloid and tau, or both.", "tags": [{"end": 12, "start": 4, "tag": "Finding"}, {"end": 164, "start": 156, "tag": "Finding"}, {"end": 184, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 181, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 87, "tag": "CellFunction"}, {"end": 154, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 32, "tag": "PathologicFunction"}, {"end": 39, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 96, "tag": "TemporalConcept"}, {"end": 31, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1563_13", "text": "Conclusion: These results suggest that baseline biomarker-assisted predictions of decline to dementia are stable over the long term, and that combinations of complementary biomarkers can improve the accuracy of these predictions.", "tags": [{"end": 131, "start": 122, "tag": "TemporalConcept"}, {"end": 182, "start": 172, "tag": "ClinicalAttribute"}, {"end": 57, "start": 48, "tag": "ClinicalAttribute"}, {"end": 101, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 199, "tag": "Finding"}]}{"id": "1564_0", "text": "PurposeThis study aimed to investigate the influence of 24-h ambulatory blood pressure (BP) on cognitive function and neuropathological biomarkers in patients with Alzheimer's disease (AD) at the stages of mild cognitive impairment (MCI) and dementia.", "tags": [{"end": 86, "start": 61, "tag": "Finding"}, {"end": 90, "start": 88, "tag": "BiologicFunction"}, {"end": 202, "start": 196, "tag": "TemporalConcept"}, {"end": 86, "start": 72, "tag": "BiologicFunction"}, {"end": 183, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 150, "tag": "PatientOrDisabledGroup"}, {"end": 250, "start": 242, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 118, "tag": "ClinicalAttribute"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 236, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 95, "tag": "BiologicFunction"}, {"end": 60, "start": 56, "tag": "TemporalConcept"}]}{"id": "1564_1", "text": "MethodsThe patients with AD were divided into the MCI (AD-MCI) group and the dementia (AD-D) group.", "tags": [{"end": 27, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 11, "tag": "PatientOrDisabledGroup"}, {"end": 85, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 63, "tag": "PopulationGroup"}, {"end": 98, "start": 93, "tag": "PopulationGroup"}]}{"id": "1564_2", "text": "Notably, 24-h BP variables, including BP level, coefficient of variation (CV) of BP, and pulse pressure, were collected and compared between the two groups.", "tags": [{"end": 16, "start": 14, "tag": "BiologicFunction"}, {"end": 40, "start": 38, "tag": "BiologicFunction"}, {"end": 83, "start": 81, "tag": "BiologicFunction"}, {"end": 103, "start": 89, "tag": "BiologicFunction"}, {"end": 155, "start": 149, "tag": "PopulationGroup"}, {"end": 72, "start": 48, "tag": "ResearchActivity"}, {"end": 13, "start": 9, "tag": "TemporalConcept"}]}{"id": "1564_3", "text": "The correlations between 24-h BP variables and the scores of cognitive domains were analyzed.", "tags": [{"end": 32, "start": 30, "tag": "BiologicFunction"}, {"end": 57, "start": 51, "tag": "Finding"}, {"end": 16, "start": 4, "tag": "ResearchActivity"}, {"end": 92, "start": 84, "tag": "ResearchActivity"}, {"end": 29, "start": 25, "tag": "TemporalConcept"}, {"end": 78, "start": 61, "tag": "Finding"}]}{"id": "1564_4", "text": "The independent influencing factors of cognitive domains of patients with AD were investigated.", "tags": [{"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 60, "tag": "PatientOrDisabledGroup"}, {"end": 56, "start": 39, "tag": "Finding"}, {"end": 35, "start": 4, "tag": "Finding"}]}{"id": "1564_5", "text": "The levels of neuropathological biomarkers of AD, including beta amyloid (A beta)(1-42), phosphorylated tau (P-tau), and total tau (T-tau), in cerebrospinal fluid (CSF) were measured and compared between the two groups, and the correlations between 24-h BP variables and the levels of neuropathological biomarkers of AD were analyzed.", "tags": [{"end": 72, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 256, "start": 254, "tag": "BiologicFunction"}, {"end": 137, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 167, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 319, "start": 317, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 143, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 14, "tag": "ClinicalAttribute"}, {"end": 313, "start": 285, "tag": "ClinicalAttribute"}, {"end": 218, "start": 212, "tag": "PopulationGroup"}, {"end": 80, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 240, "start": 228, "tag": "ResearchActivity"}, {"end": 253, "start": 249, "tag": "TemporalConcept"}]}{"id": "1564_6", "text": "ResultsDaytime CV of systolic BP (SBP) was significantly increased in the AD-D group compared to that in the AD-MCI group.", "tags": [{"end": 32, "start": 21, "tag": "ClinicalAttribute"}, {"end": 37, "start": 34, "tag": "ClinicalAttribute"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 43, "tag": "Finding"}, {"end": 115, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 79, "tag": "PopulationGroup"}, {"end": 121, "start": 116, "tag": "PopulationGroup"}, {"end": 14, "start": 7, "tag": "TemporalConcept"}]}{"id": "1564_7", "text": "The 24-h and daytime CV of SBP and ambulatory pulse pressure were significantly and negatively correlated with memory score.", "tags": [{"end": 20, "start": 13, "tag": "TemporalConcept"}, {"end": 30, "start": 27, "tag": "ClinicalAttribute"}, {"end": 123, "start": 118, "tag": "Finding"}, {"end": 117, "start": 111, "tag": "BiologicFunction"}, {"end": 60, "start": 35, "tag": "BiologicFunction"}, {"end": 8, "start": 4, "tag": "TemporalConcept"}]}{"id": "1564_8", "text": "The average 24-h and average daytime SBP level and CV of SBP, daytime CV of diastolic BP (DBP), and 24-h, daytime, and night-time ambulatory pulse pressure were significantly and negatively correlated with language score.", "tags": [{"end": 40, "start": 37, "tag": "ClinicalAttribute"}, {"end": 60, "start": 57, "tag": "ClinicalAttribute"}, {"end": 93, "start": 90, "tag": "ClinicalAttribute"}, {"end": 113, "start": 106, "tag": "TemporalConcept"}, {"end": 220, "start": 215, "tag": "Finding"}, {"end": 129, "start": 125, "tag": "TemporalConcept"}, {"end": 16, "start": 12, "tag": "TemporalConcept"}, {"end": 104, "start": 100, "tag": "TemporalConcept"}, {"end": 36, "start": 29, "tag": "TemporalConcept"}, {"end": 65, "start": 64, "tag": "TemporalConcept"}, {"end": 88, "start": 76, "tag": "ClinicalAttribute"}, {"end": 155, "start": 130, "tag": "BiologicFunction"}, {"end": 214, "start": 206, "tag": "BiologicFunction"}]}{"id": "1564_9", "text": "The average 24-h SBP level, daytime CV of SBP, and 24-h, daytime, and night-time ambulatory pulse pressure were significantly and negatively correlated with attention score.", "tags": [{"end": 20, "start": 17, "tag": "ClinicalAttribute"}, {"end": 45, "start": 42, "tag": "ClinicalAttribute"}, {"end": 64, "start": 57, "tag": "TemporalConcept"}, {"end": 166, "start": 157, "tag": "BiologicFunction"}, {"end": 172, "start": 167, "tag": "Finding"}, {"end": 80, "start": 76, "tag": "TemporalConcept"}, {"end": 106, "start": 81, "tag": "BiologicFunction"}, {"end": 16, "start": 12, "tag": "TemporalConcept"}, {"end": 55, "start": 51, "tag": "TemporalConcept"}, {"end": 35, "start": 28, "tag": "TemporalConcept"}, {"end": 75, "start": 70, "tag": "TemporalConcept"}]}{"id": "1564_10", "text": "Further analysis indicated that daytime CV of SBP as well as age and course of disease were the independent influencing factors of language.", "tags": [{"end": 39, "start": 32, "tag": "TemporalConcept"}, {"end": 49, "start": 46, "tag": "ClinicalAttribute"}, {"end": 64, "start": 61, "tag": "OrganismAttribute"}, {"end": 16, "start": 8, "tag": "ResearchActivity"}, {"end": 75, "start": 69, "tag": "TemporalConcept"}, {"end": 127, "start": 96, "tag": "Finding"}, {"end": 139, "start": 131, "tag": "BiologicFunction"}]}{"id": "1564_11", "text": "Age was also the independent influencing factor of memory and attention of patients with AD.", "tags": [{"end": 71, "start": 62, "tag": "BiologicFunction"}, {"end": 3, "start": 0, "tag": "OrganismAttribute"}, {"end": 91, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 75, "tag": "PatientOrDisabledGroup"}, {"end": 57, "start": 51, "tag": "BiologicFunction"}, {"end": 47, "start": 17, "tag": "Finding"}]}{"id": "1564_12", "text": "T-tau level in CSF in the AD-D group was significantly higher than that in the AD-MCI group, but the levels of A beta(1-42), P-tau, and T-tau in CSF were not correlated with 24-h ambulatory BP variables.", "tags": [{"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 31, "tag": "PopulationGroup"}, {"end": 91, "start": 86, "tag": "PopulationGroup"}, {"end": 123, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 179, "tag": "BiologicFunction"}, {"end": 178, "start": 174, "tag": "TemporalConcept"}, {"end": 123, "start": 111, "tag": "BiologicallyActiveSubstance"}]}{"id": "1564_13", "text": "ConclusionDaytime CV of SBP was the independent influencing factor of language in patients with AD.", "tags": [{"end": 27, "start": 24, "tag": "ClinicalAttribute"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 82, "tag": "PatientOrDisabledGroup"}, {"end": 17, "start": 10, "tag": "TemporalConcept"}, {"end": 66, "start": 36, "tag": "Finding"}, {"end": 78, "start": 70, "tag": "BiologicFunction"}]}{"id": "1564_14", "text": "The AD-D patients had significantly severe neurodegeneration than AD-MCI patients, which was, however, not through the influence of 24-h ambulatory BP variables on neuropathological biomarkers of AD.", "tags": [{"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 9, "tag": "PatientOrDisabledGroup"}, {"end": 81, "start": 73, "tag": "PatientOrDisabledGroup"}, {"end": 192, "start": 164, "tag": "ClinicalAttribute"}, {"end": 60, "start": 43, "tag": "CellOrMolecularDysfunction"}, {"end": 42, "start": 36, "tag": "Finding"}, {"end": 150, "start": 137, "tag": "BiologicFunction"}, {"end": 136, "start": 132, "tag": "TemporalConcept"}, {"end": 72, "start": 69, "tag": "DiseaseOrSyndrome"}]}{"id": "1565_0", "text": "The aim of our study was to establish empirically to what extent reduced glucose uptake in the precuneus, posterior cingulate and/or temporo-parietal cortex (PCTP), which is thought to indicate brain amyloidosis in patients with dementia or MCI due to Alzheimer's Disease (AD), permits to distinguish amyloid-positive from amyloid-negative patients with non-classical AD phenotypes at the single-case level.", "tags": [{"end": 87, "start": 73, "tag": "CellFunction"}, {"end": 125, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 400, "start": 389, "tag": "ResearchActivity"}, {"end": 80, "start": 73, "tag": "Chemical"}, {"end": 80, "start": 73, "tag": "PharmacologicSubstance"}, {"end": 80, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 381, "start": 371, "tag": "OrganismAttribute"}, {"end": 87, "start": 73, "tag": "BiologicFunction"}, {"end": 308, "start": 301, "tag": "AminoAcidPeptideOrProtein"}, {"end": 330, "start": 323, "tag": "AminoAcidPeptideOrProtein"}, {"end": 308, "start": 301, "tag": "BiologicallyActiveSubstance"}, {"end": 330, "start": 323, "tag": "BiologicallyActiveSubstance"}, {"end": 275, "start": 273, "tag": "DiseaseOrSyndrome"}, {"end": 370, "start": 368, "tag": "DiseaseOrSyndrome"}, {"end": 271, "start": 252, "tag": "DiseaseOrSyndrome"}, {"end": 237, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 215, "tag": "PatientOrDisabledGroup"}, {"end": 348, "start": 340, "tag": "PatientOrDisabledGroup"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 244, "start": 241, "tag": "DiseaseOrSyndrome"}, {"end": 400, "start": 396, "tag": "ManufacturedObject"}, {"end": 104, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1565_1", "text": "We enrolled 127 neurodegenerative patients with cognitive impairment and a positive (n.", "tags": [{"end": 68, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 16, "tag": "PatientOrDisabledGroup"}]}{"id": "1565_2", "text": "63) or negative (n.", "tags": []}{"id": "1565_3", "text": "64) amyloid marker (cerebrospinal fluid or amy-PET).", "tags": [{"end": 11, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 43, "tag": "HealthCareActivity"}, {"end": 18, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1565_4", "text": "Three rating methods of FDG-PET scan were applied: purely qualitative visual interpretation of uptake images (VIUI), and visual reading assisted by a semi-automated and semi-quantitative tool: INLAB, provided by the Italian National Research Council, or Cortex ID Suite, marketed by GE Healthcare.", "tags": [{"end": 31, "start": 24, "tag": "HealthCareActivity"}, {"end": 296, "start": 283, "tag": "HealthCareActivity"}, {"end": 36, "start": 32, "tag": "HealthCareActivity"}, {"end": 249, "start": 216, "tag": "HealthCareRelatedOrganization"}, {"end": 108, "start": 70, "tag": "HealthCareActivity"}, {"end": 114, "start": 110, "tag": "HealthCareActivity"}, {"end": 191, "start": 150, "tag": "ResearchActivity"}, {"end": 198, "start": 193, "tag": "ResearchActivity"}, {"end": 269, "start": 254, "tag": "ResearchActivity"}]}{"id": "1565_5", "text": "Fourteen scans (11.0%) patients remained unclassified by VIUI or INLAB procedures, therefore, validity values were computed on the remaining 113 cases.", "tags": [{"end": 14, "start": 9, "tag": "HealthCareActivity"}, {"end": 102, "start": 94, "tag": "Finding"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 61, "start": 57, "tag": "ResearchActivity"}, {"end": 70, "start": 65, "tag": "ResearchActivity"}]}{"id": "1565_6", "text": "The three rating approaches showed good total accuracy (77-78%), good to optimal sensitivity (81-93%), but poorer specificity (62-75%).", "tags": [{"end": 92, "start": 81, "tag": "Finding"}, {"end": 125, "start": 114, "tag": "Finding"}, {"end": 54, "start": 46, "tag": "Finding"}]}{"id": "1565_7", "text": "VIUI showed the highest sensitivity and the lowest specificity, and also the highest proportion of unclassified cases.", "tags": [{"end": 35, "start": 24, "tag": "Finding"}, {"end": 62, "start": 51, "tag": "Finding"}]}{"id": "1565_8", "text": "Cases with asymmetric temporo-parietal hypometabolism and a progressive aphasia or corticobasal clinical profile, in particular, tended to be rated as AD-like, even if biomarkers indicated non-amyloid pathology.", "tags": [{"end": 79, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 189, "tag": "PathologicFunction"}, {"end": 112, "start": 96, "tag": "ClinicalAttribute"}, {"end": 200, "start": 193, "tag": "AminoAcidPeptideOrProtein"}, {"end": 200, "start": 193, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 168, "tag": "ClinicalAttribute"}, {"end": 95, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 11, "tag": "Finding"}]}{"id": "1565_9", "text": "Our findings provide formal support to the value of PCTP hypometabolism for single-level diagnosis of amyloid pathophysiology in atypical AD, but also highlight the risk of qualitative assessment to misclassify patients with non-AD PPA or CBS underpinned by asymmetric temporo-parietal hypometabolism.", "tags": [{"end": 71, "start": 52, "tag": "Finding"}, {"end": 242, "start": 239, "tag": "GeneOrGenome"}, {"end": 109, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 89, "tag": "HealthCareActivity"}, {"end": 137, "start": 129, "tag": "Finding"}, {"end": 219, "start": 211, "tag": "PatientOrDisabledGroup"}, {"end": 125, "start": 110, "tag": "PathologicFunction"}, {"end": 125, "start": 110, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 195, "start": 185, "tag": "HealthCareActivity"}, {"end": 195, "start": 185, "tag": "ResearchActivity"}, {"end": 300, "start": 258, "tag": "Finding"}]}{"id": "1566_0", "text": "Background: Vascular risk factors promote cerebral small vessel disease and neuropathological changes, particularly in white matter where large-caliber axons are located.", "tags": [{"end": 71, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 138, "tag": "CellComponent"}, {"end": 33, "start": 21, "tag": "Finding"}, {"end": 131, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 76, "tag": "Finding"}, {"end": 20, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1566_1", "text": "How Alzheimer's disease pathology influences the brain's vulnerability in this regard is not well understood.", "tags": [{"end": 70, "start": 57, "tag": "ClinicalAttribute"}, {"end": 33, "start": 16, "tag": "PathologicFunction"}, {"end": 23, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1566_2", "text": "Objective: Systemic vascular risk was assessed in relation to cerebrospinal fluid concentrations of neurofilament light, a biomarker of large-caliber axonal injury, evaluating for interactions by clinical and protein markers of Alzheimer's disease.", "tags": [{"end": 119, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 82, "tag": "BiologicFunction"}, {"end": 163, "start": 157, "tag": "InjuryOrPoisoning"}, {"end": 28, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 180, "tag": "Finding"}, {"end": 247, "start": 228, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 123, "tag": "ClinicalAttribute"}, {"end": 81, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 224, "start": 217, "tag": "ClinicalAttribute"}, {"end": 156, "start": 136, "tag": "CellComponent"}, {"end": 33, "start": 29, "tag": "Finding"}]}{"id": "1566_3", "text": "Methods: Among Alzheimer's Disease Neuroimaging Initiative participants with normal cognition (n = 117), mild cognitive impairment (n = 190), and Alzheimer's disease (n = 95), linear regression related vascular risk (as measured by the modified Framingham Stroke Risk Profile) to neurofilament light, adjusting for age, sex, education, and cognitive diagnosis.", "tags": [{"end": 299, "start": 280, "tag": "AminoAcidPeptideOrProtein"}, {"end": 299, "start": 280, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 77, "tag": "Finding"}, {"end": 58, "start": 15, "tag": "ResearchActivity"}, {"end": 58, "start": 15, "tag": "HealthCareRelatedOrganization"}, {"end": 210, "start": 202, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 323, "start": 320, "tag": "OrganismAttribute"}, {"end": 93, "start": 77, "tag": "Finding"}, {"end": 193, "start": 176, "tag": "ResearchActivity"}, {"end": 165, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 59, "tag": "PopulationGroup"}, {"end": 130, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 359, "start": 340, "tag": "HealthCareActivity"}, {"end": 318, "start": 315, "tag": "OrganismAttribute"}, {"end": 93, "start": 84, "tag": "BiologicFunction"}, {"end": 130, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 334, "start": 325, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 109, "start": 105, "tag": "Finding"}, {"end": 215, "start": 211, "tag": "Finding"}, {"end": 275, "start": 236, "tag": "HealthCareActivity"}]}{"id": "1566_4", "text": "Interactions were assessed by cognitive diagnosis, and by cerebrospinal fluid markers of A beta(42), hyperphosphorylated tau, and total tau.", "tags": [{"end": 124, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 130, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 30, "tag": "HealthCareActivity"}, {"end": 99, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 78, "tag": "ClinicalAttribute"}, {"end": 99, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 0, "tag": "Finding"}]}{"id": "1566_5", "text": "Results: Vascular risk and neurofilament light were not related in the main effect model (p = 0.08).", "tags": [{"end": 46, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 88, "start": 71, "tag": "ResearchActivity"}, {"end": 17, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 18, "tag": "Finding"}]}{"id": "1566_6", "text": "However, interactions emerged for total tau (p = 0.01) and hyperphosphorylated tau (p = 0.002) reflecting vascular risk becoming more associated with cerebrospinal fluid neurofilament light in the context of greater concentrations of tau biomarkers.", "tags": [{"end": 189, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 230, "start": 216, "tag": "BiologicFunction"}, {"end": 114, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 9, "tag": "Finding"}, {"end": 237, "start": 234, "tag": "AminoAcidPeptideOrProtein"}, {"end": 237, "start": 234, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 248, "start": 238, "tag": "ClinicalAttribute"}, {"end": 119, "start": 115, "tag": "Finding"}]}{"id": "1566_7", "text": "An interaction also emerged for the Alzheimer's disease biomarker profiles (p = 0.046) where in comparison to the referent 'normal' biomarker group, individuals with abnormal levels of both A beta(42) and total tau showed stronger associations between vascular risk and neurofilament light.", "tags": [{"end": 289, "start": 270, "tag": "AminoAcidPeptideOrProtein"}, {"end": 289, "start": 270, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 124, "tag": "Finding"}, {"end": 260, "start": 252, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 166, "tag": "Finding"}, {"end": 106, "start": 96, "tag": "ResearchActivity"}, {"end": 181, "start": 166, "tag": "Finding"}, {"end": 55, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 56, "tag": "ClinicalAttribute"}, {"end": 141, "start": 132, "tag": "ClinicalAttribute"}, {"end": 214, "start": 205, "tag": "AminoAcidPeptideOrProtein"}, {"end": 214, "start": 205, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 149, "tag": "PopulationGroup"}, {"end": 147, "start": 142, "tag": "PopulationGroup"}, {"end": 200, "start": 190, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 66, "tag": "ResearchActivity"}, {"end": 200, "start": 190, "tag": "BiologicallyActiveSubstance"}, {"end": 265, "start": 261, "tag": "Finding"}]}{"id": "1566_8", "text": "Conclusion: Older adults may be more vulnerable to axonal injury in response to higher vascular risk burdens in the context of concomitant Alzheimer's disease pathology.", "tags": [{"end": 138, "start": 127, "tag": "TemporalConcept"}, {"end": 64, "start": 58, "tag": "InjuryOrPoisoning"}, {"end": 95, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 12, "tag": "PopulationGroup"}, {"end": 168, "start": 151, "tag": "PathologicFunction"}, {"end": 158, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 51, "tag": "CellComponent"}, {"end": 100, "start": 96, "tag": "Finding"}]}{"id": "1567_0", "text": "The core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers; amyloid-beta (Ass), total tau (t-tau), and phosphorylated tau (p-tau181), are strong indicators of the presence of AD pathology, but do not correlate well with disease progression, and can be difficult to implement in longitudinal studies where repeat biofluid sampling is required.", "tags": [{"end": 310, "start": 290, "tag": "ResearchActivity"}, {"end": 28, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 199, "start": 190, "tag": "PathologicFunction"}, {"end": 199, "start": 190, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 32, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 251, "start": 240, "tag": "PathologicFunction"}, {"end": 251, "start": 240, "tag": "TemporalConcept"}, {"end": 143, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 60, "tag": "ClinicalAttribute"}, {"end": 101, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 175, "tag": "Finding"}, {"end": 251, "start": 232, "tag": "PathologicFunction"}, {"end": 341, "start": 333, "tag": "HealthCareActivity"}, {"end": 332, "start": 324, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1567_1", "text": "As a result, blood-based biomarkers are increasingly being sought as alternatives.", "tags": [{"end": 35, "start": 25, "tag": "ClinicalAttribute"}, {"end": 11, "start": 5, "tag": "Finding"}, {"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1567_2", "text": "In this study, we aimed to evaluate a promising blood biomarker discovery technology, Olink Proximity Extension Assays for technical reproducibility characteristics in order to highlight the advantages and disadvantages of using this technology in biomarker discovery in AD.", "tags": [{"end": 73, "start": 64, "tag": "ResearchActivity"}, {"end": 267, "start": 258, "tag": "ResearchActivity"}, {"end": 273, "start": 271, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 54, "tag": "ClinicalAttribute"}, {"end": 257, "start": 248, "tag": "ClinicalAttribute"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 53, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 86, "tag": "ResearchActivity"}]}{"id": "1567_3", "text": "We evaluated the performance of five Olink Proteomic multiplex proximity extension assays (PEA) in plasma samples.", "tags": [{"end": 105, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 17, "tag": "Finding"}, {"end": 89, "start": 37, "tag": "ResearchActivity"}]}{"id": "1567_4", "text": "Three technical control samples included on each plate allowed calculation of technical variability.", "tags": [{"end": 54, "start": 49, "tag": "ManufacturedObject"}, {"end": 99, "start": 88, "tag": "Finding"}, {"end": 23, "start": 16, "tag": "PopulationGroup"}]}{"id": "1567_5", "text": "Biotemporal stability was measured in three sequential annual samples from 54 individuals with and without AD.", "tags": [{"end": 61, "start": 55, "tag": "TemporalConcept"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 78, "tag": "PopulationGroup"}]}{"id": "1567_6", "text": "Coefficients of variation (CVs), analysis of variance (ANOVA), and variance component analyses were used to quantify technical and individual variation over time.", "tags": [{"end": 30, "start": 27, "tag": "ResearchActivity"}, {"end": 60, "start": 55, "tag": "ResearchActivity"}, {"end": 53, "start": 33, "tag": "ResearchActivity"}, {"end": 161, "start": 157, "tag": "TemporalConcept"}, {"end": 94, "start": 67, "tag": "ResearchActivity"}, {"end": 141, "start": 131, "tag": "PopulationGroup"}, {"end": 141, "start": 131, "tag": "OrganismAttribute"}, {"end": 25, "start": 0, "tag": "ResearchActivity"}]}{"id": "1567_7", "text": "We show that overall, Olink assays are technically robust, with the largest experimental variation stemming from biological differences between individuals for most analytes.", "tags": [{"end": 173, "start": 165, "tag": "Substance"}, {"end": 155, "start": 144, "tag": "PopulationGroup"}, {"end": 135, "start": 124, "tag": "Finding"}, {"end": 34, "start": 22, "tag": "ResearchActivity"}, {"end": 98, "start": 76, "tag": "ResearchActivity"}]}{"id": "1567_8", "text": "As a powerful illustration of one of the potential pitfalls of using a multi-plexed technology for discovery, we performed power calculations using the baseline samples to demonstrate the size of study required to overcome the need for multiple test correction with this technology.", "tags": [{"end": 108, "start": 71, "tag": "ResearchActivity"}, {"end": 201, "start": 196, "tag": "ResearchActivity"}, {"end": 260, "start": 245, "tag": "ResearchActivity"}, {"end": 192, "start": 188, "tag": "OrganismAttribute"}]}{"id": "1567_9", "text": "We show that the power of moderate effect size proteins was strongly reduced, and as a result investigators should strongly consider pooling resources to perform larger studies using this multiplexed technique where possible.", "tags": [{"end": 93, "start": 87, "tag": "Finding"}, {"end": 55, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 169, "tag": "ResearchActivity"}, {"end": 209, "start": 188, "tag": "ResearchActivity"}, {"end": 46, "start": 35, "tag": "ResearchActivity"}]}{"id": "1568_0", "text": "Intraindividual variability (IIV) across neuropsychological measures within a single testing session is a promising marker predictive of cognitive decline and development of Alzheimer's disease (AD).", "tags": [{"end": 100, "start": 85, "tag": "HealthCareActivity"}, {"end": 193, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 159, "tag": "BiologicFunction"}, {"end": 170, "start": 159, "tag": "CellFunction"}, {"end": 154, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 116, "tag": "ClinicalAttribute"}, {"end": 68, "start": 41, "tag": "HealthCareActivity"}, {"end": 27, "start": 0, "tag": "ClinicalAttribute"}, {"end": 32, "start": 29, "tag": "ClinicalAttribute"}]}{"id": "1568_1", "text": "We have previously shown that greater IIV is cross-sectionally associated with reduced cerebral blood flow (CBF), but not with cortical thickness or brain volume, in older adults without dementia who were amyloid beta (A beta) positive.", "tags": [{"end": 111, "start": 108, "tag": "BiologicFunction"}, {"end": 217, "start": 205, "tag": "AminoAcidPeptideOrProtein"}, {"end": 212, "start": 205, "tag": "AminoAcidPeptideOrProtein"}, {"end": 212, "start": 205, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 172, "tag": "PopulationGroup"}, {"end": 171, "start": 166, "tag": "TemporalConcept"}, {"end": 106, "start": 87, "tag": "BiologicFunction"}, {"end": 101, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 225, "start": 219, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 166, "tag": "PopulationGroup"}, {"end": 135, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 127, "tag": "ClinicalAttribute"}, {"end": 161, "start": 149, "tag": "ClinicalAttribute"}, {"end": 41, "start": 38, "tag": "ClinicalAttribute"}]}{"id": "1568_2", "text": "However, there is little known about the association between change in IIV and CBF over time.", "tags": [{"end": 82, "start": 79, "tag": "BiologicFunction"}, {"end": 92, "start": 88, "tag": "TemporalConcept"}, {"end": 74, "start": 71, "tag": "ClinicalAttribute"}]}{"id": "1568_3", "text": "Therefore, we examined 12-month longitudinal change in IIV and interactions of IIV and AD biomarker status on changes in regional CBF.", "tags": [{"end": 133, "start": 130, "tag": "BiologicFunction"}, {"end": 75, "start": 63, "tag": "Finding"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 90, "tag": "ClinicalAttribute"}, {"end": 106, "start": 100, "tag": "Finding"}, {"end": 51, "start": 32, "tag": "ResearchActivity"}, {"end": 58, "start": 55, "tag": "ClinicalAttribute"}, {"end": 82, "start": 79, "tag": "ClinicalAttribute"}]}{"id": "1568_4", "text": "Fifty-three non-demented Alzheimer's Disease Neuroimaging Initiative (ADNI) participants underwent lumbar puncture to obtain cerebrospinal fluid (CSF) at baseline and neuropsychological testing and magnetic resonance imaging (MRI) exams at baseline and 12-month follow-up evaluation.", "tags": [{"end": 193, "start": 167, "tag": "HealthCareActivity"}, {"end": 149, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 76, "tag": "PopulationGroup"}, {"end": 114, "start": 99, "tag": "HealthCareActivity"}, {"end": 224, "start": 217, "tag": "HealthCareActivity"}, {"end": 144, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 229, "start": 226, "tag": "HealthCareActivity"}, {"end": 271, "start": 262, "tag": "HealthCareActivity"}, {"end": 271, "start": 262, "tag": "TemporalConcept"}, {"end": 144, "start": 139, "tag": "Substance"}, {"end": 44, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 25, "tag": "ResearchActivity"}, {"end": 282, "start": 272, "tag": "HealthCareActivity"}, {"end": 282, "start": 272, "tag": "ResearchActivity"}, {"end": 24, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 224, "start": 198, "tag": "HealthCareActivity"}, {"end": 224, "start": 198, "tag": "ManufacturedObject"}, {"end": 68, "start": 25, "tag": "HealthCareRelatedOrganization"}, {"end": 74, "start": 70, "tag": "HealthCareRelatedOrganization"}, {"end": 74, "start": 70, "tag": "ResearchActivity"}]}{"id": "1568_5", "text": "IIV was calculated as the intraindividual standard deviation across 6 demographically-corrected neuropsychological measures.", "tags": [{"end": 41, "start": 26, "tag": "PopulationGroup"}, {"end": 60, "start": 42, "tag": "ResearchActivity"}, {"end": 3, "start": 0, "tag": "ClinicalAttribute"}, {"end": 123, "start": 96, "tag": "HealthCareActivity"}]}{"id": "1568_6", "text": "Pulsed arterial spin labeling (ASL) MRI was acquired to quantify CBF and FreeSurfer-derived a priori CBF regions of interest (ROIs) were examined.", "tags": [{"end": 68, "start": 65, "tag": "BiologicFunction"}, {"end": 104, "start": 101, "tag": "BiologicFunction"}, {"end": 39, "start": 0, "tag": "HealthCareActivity"}, {"end": 130, "start": 126, "tag": "ResearchActivity"}, {"end": 124, "start": 105, "tag": "ResearchActivity"}]}{"id": "1568_7", "text": "AD biomarker positivity was determined using a published CSF p-tau/A beta ratio cut-score.", "tags": [{"end": 23, "start": 13, "tag": "ResearchActivity"}, {"end": 66, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 3, "tag": "ClinicalAttribute"}, {"end": 73, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 57, "tag": "ClinicalAttribute"}, {"end": 89, "start": 80, "tag": "ResearchActivity"}]}{"id": "1568_8", "text": "Change scores were calculated for IIV, CBF, and mean neuropsychological performance from baseline to 12 months.", "tags": [{"end": 42, "start": 39, "tag": "BiologicFunction"}, {"end": 83, "start": 72, "tag": "Finding"}, {"end": 110, "start": 104, "tag": "TemporalConcept"}, {"end": 6, "start": 0, "tag": "Finding"}, {"end": 37, "start": 34, "tag": "ClinicalAttribute"}]}{"id": "1568_9", "text": "Hierarchical linear regression models showed that after adjusting for age and gender, there was a significant interaction between IIV change and biomarker-positivity (p-tau/A beta+) for change in entorhinal and hippocampal CBF but not for the other ROIs.", "tags": [{"end": 226, "start": 223, "tag": "BiologicFunction"}, {"end": 84, "start": 78, "tag": "OrganismAttribute"}, {"end": 172, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 70, "tag": "OrganismAttribute"}, {"end": 154, "start": 145, "tag": "ClinicalAttribute"}, {"end": 179, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 253, "start": 249, "tag": "ResearchActivity"}, {"end": 222, "start": 211, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 222, "start": 211, "tag": "Cell"}, {"end": 172, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 13, "tag": "ResearchActivity"}, {"end": 30, "start": 13, "tag": "ResearchActivity"}, {"end": 133, "start": 130, "tag": "ClinicalAttribute"}, {"end": 121, "start": 98, "tag": "Finding"}, {"end": 165, "start": 155, "tag": "ResearchActivity"}, {"end": 206, "start": 196, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1568_10", "text": "Specifically, increases in IIV were associated with reductions in entorhinal and hippocampal CBF among individuals who were biomarker-positive (n = 21).", "tags": [{"end": 62, "start": 52, "tag": "NaturalPhenomenonOrProcess"}, {"end": 62, "start": 52, "tag": "HealthCareActivity"}, {"end": 96, "start": 93, "tag": "BiologicFunction"}, {"end": 133, "start": 124, "tag": "ClinicalAttribute"}, {"end": 114, "start": 103, "tag": "PopulationGroup"}, {"end": 92, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 81, "tag": "Cell"}, {"end": 30, "start": 27, "tag": "ClinicalAttribute"}, {"end": 76, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1568_11", "text": "In contrast, there were no significant associations between change in IIV and CBF among those who were biomarker-negative (n = 32).", "tags": [{"end": 81, "start": 78, "tag": "BiologicFunction"}, {"end": 112, "start": 103, "tag": "ClinicalAttribute"}, {"end": 51, "start": 24, "tag": "Finding"}, {"end": 73, "start": 70, "tag": "ClinicalAttribute"}]}{"id": "1568_12", "text": "Findings remained similar when analyses were performed adjusting for change in mean level of neuropsychological performance.", "tags": [{"end": 111, "start": 93, "tag": "HealthCareActivity"}, {"end": 123, "start": 112, "tag": "Finding"}, {"end": 39, "start": 31, "tag": "ResearchActivity"}]}{"id": "1568_13", "text": "Changes in IIV may be sensitive to changes in regional hypoperfusion in AD-vulnerable regions among AD biomarker-positive individuals, above and beyond demographics and mean neuropsychological performance.", "tags": [{"end": 192, "start": 174, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "Finding"}, {"end": 204, "start": 193, "tag": "Finding"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 103, "tag": "ClinicalAttribute"}, {"end": 133, "start": 122, "tag": "PopulationGroup"}, {"end": 31, "start": 22, "tag": "PathologicFunction"}, {"end": 14, "start": 11, "tag": "ClinicalAttribute"}, {"end": 68, "start": 55, "tag": "PathologicFunction"}]}{"id": "1568_14", "text": "These findings provide further evidence supporting IIV as a potential marker of cerebrovascular brain changes in individuals at risk for dementia.", "tags": [{"end": 95, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 113, "tag": "PopulationGroup"}, {"end": 109, "start": 96, "tag": "Finding"}, {"end": 76, "start": 70, "tag": "ClinicalAttribute"}, {"end": 39, "start": 31, "tag": "Finding"}, {"end": 54, "start": 51, "tag": "ClinicalAttribute"}]}{"id": "1569_0", "text": "This randomized clinical trial evaluates the short-term effects of atabecestat in preclinical Alzheimer disease.", "tags": [{"end": 30, "start": 5, "tag": "ResearchActivity"}, {"end": 55, "start": 45, "tag": "TemporalConcept"}, {"end": 78, "start": 67, "tag": "Chemical"}, {"end": 111, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 67, "tag": "PharmacologicSubstance"}, {"end": 63, "start": 56, "tag": "Finding"}]}{"id": "1569_1", "text": "Question What are the short-term effects of atabecestat in preclinical Alzheimer disease (AD), and are adverse effects reversible after stopping treatment? Findings In this truncated randomized clinical trial of 557 participants with preclinical AD, atabecestat treatment was associated with statistically significant greater, dose-related cognitive worsening and neuropsychiatric adverse events (AEs) vs placebo.", "tags": [{"end": 32, "start": 22, "tag": "TemporalConcept"}, {"end": 55, "start": 44, "tag": "Chemical"}, {"end": 118, "start": 103, "tag": "PathologicFunction"}, {"end": 144, "start": 136, "tag": "PharmacologicSubstance"}, {"end": 208, "start": 183, "tag": "ResearchActivity"}, {"end": 261, "start": 250, "tag": "Chemical"}, {"end": 400, "start": 397, "tag": "PathologicFunction"}, {"end": 359, "start": 340, "tag": "Finding"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 216, "tag": "PopulationGroup"}, {"end": 248, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 412, "start": 405, "tag": "HealthCareActivity"}, {"end": 40, "start": 33, "tag": "Finding"}, {"end": 88, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 145, "tag": "HealthCareActivity"}, {"end": 271, "start": 262, "tag": "HealthCareActivity"}, {"end": 154, "start": 145, "tag": "ResearchActivity"}, {"end": 271, "start": 262, "tag": "ResearchActivity"}, {"end": 55, "start": 44, "tag": "PharmacologicSubstance"}, {"end": 261, "start": 250, "tag": "PharmacologicSubstance"}, {"end": 395, "start": 364, "tag": "PathologicFunction"}]}{"id": "1569_2", "text": "Baseline to last off-treatment cognitive assessment suggested return to baseline cognitive status, and frequency of neuropsychiatric AEs returned to placebo levels after stopping atabecestat.", "tags": [{"end": 178, "start": 170, "tag": "PharmacologicSubstance"}, {"end": 190, "start": 179, "tag": "Chemical"}, {"end": 51, "start": 31, "tag": "HealthCareActivity"}, {"end": 97, "start": 72, "tag": "Finding"}, {"end": 112, "start": 103, "tag": "TemporalConcept"}, {"end": 156, "start": 149, "tag": "HealthCareActivity"}, {"end": 30, "start": 21, "tag": "HealthCareActivity"}, {"end": 30, "start": 21, "tag": "ResearchActivity"}, {"end": 190, "start": 179, "tag": "PharmacologicSubstance"}, {"end": 136, "start": 116, "tag": "PathologicFunction"}]}{"id": "1569_3", "text": "Meaning This study's findings confirm dose-related worsening of cognition and neuropsychiatric AEs in atabecestat-treated participants, with recovery after up to 6 months off treatment.", "tags": [{"end": 60, "start": 38, "tag": "Finding"}, {"end": 149, "start": 141, "tag": "BiologicFunction"}, {"end": 149, "start": 141, "tag": "HealthCareActivity"}, {"end": 149, "start": 141, "tag": "TemporalConcept"}, {"end": 134, "start": 122, "tag": "PopulationGroup"}, {"end": 18, "start": 13, "tag": "ResearchActivity"}, {"end": 73, "start": 64, "tag": "BiologicFunction"}, {"end": 170, "start": 164, "tag": "TemporalConcept"}, {"end": 184, "start": 171, "tag": "HealthCareActivity"}, {"end": 98, "start": 78, "tag": "PathologicFunction"}, {"end": 113, "start": 102, "tag": "PharmacologicSubstance"}, {"end": 113, "start": 102, "tag": "Chemical"}]}{"id": "1569_4", "text": "Importance Atabecestat, a nonselective oral beta-secretase inhibitor, was evaluated in the EARLY trial for slowing cognitive decline in participants with preclinical Alzheimer disease.", "tags": [{"end": 22, "start": 11, "tag": "Chemical"}, {"end": 68, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 59, "tag": "PharmacologicSubstance"}, {"end": 68, "start": 59, "tag": "Chemical"}, {"end": 148, "start": 136, "tag": "PopulationGroup"}, {"end": 132, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 91, "tag": "ResearchActivity"}, {"end": 184, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 11, "tag": "PharmacologicSubstance"}, {"end": 58, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 44, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1569_5", "text": "Preliminary analyses suggested dose-related cognitive worsening and neuropsychiatric adverse events (AEs).", "tags": [{"end": 104, "start": 101, "tag": "PathologicFunction"}, {"end": 63, "start": 44, "tag": "Finding"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 99, "start": 68, "tag": "PathologicFunction"}]}{"id": "1569_6", "text": "Objective To report efficacy, safety, and biomarker findings in the EARLY trial, both on and off atabecestat treatment, with focus on potential recovery of effects on cognition and behavior.", "tags": [{"end": 108, "start": 97, "tag": "Chemical"}, {"end": 152, "start": 144, "tag": "BiologicFunction"}, {"end": 152, "start": 144, "tag": "HealthCareActivity"}, {"end": 152, "start": 144, "tag": "TemporalConcept"}, {"end": 189, "start": 181, "tag": "BiologicFunction"}, {"end": 189, "start": 181, "tag": "IndividualBehavior"}, {"end": 189, "start": 181, "tag": "ResearchActivity"}, {"end": 51, "start": 42, "tag": "ClinicalAttribute"}, {"end": 36, "start": 30, "tag": "HealthCareActivity"}, {"end": 79, "start": 68, "tag": "ResearchActivity"}, {"end": 176, "start": 167, "tag": "BiologicFunction"}, {"end": 19, "start": 13, "tag": "HealthCareActivity"}, {"end": 19, "start": 13, "tag": "ResearchActivity"}, {"end": 118, "start": 109, "tag": "HealthCareActivity"}, {"end": 118, "start": 109, "tag": "ResearchActivity"}, {"end": 108, "start": 97, "tag": "PharmacologicSubstance"}, {"end": 28, "start": 20, "tag": "Finding"}]}{"id": "1569_7", "text": "Design, Setting, and Participants Randomized, double-blind, placebo-controlled, phase 2b/3 study conducted from November 2015 to December 2018 after being stopped prematurely.", "tags": [{"end": 15, "start": 8, "tag": "BiologicFunction"}, {"end": 44, "start": 34, "tag": "ResearchActivity"}, {"end": 44, "start": 34, "tag": "Finding"}, {"end": 85, "start": 80, "tag": "TemporalConcept"}, {"end": 33, "start": 21, "tag": "PopulationGroup"}, {"end": 96, "start": 91, "tag": "ResearchActivity"}, {"end": 58, "start": 46, "tag": "ResearchActivity"}, {"end": 78, "start": 60, "tag": "ResearchActivity"}, {"end": 67, "start": 60, "tag": "HealthCareActivity"}, {"end": 125, "start": 112, "tag": "TemporalConcept"}, {"end": 142, "start": 129, "tag": "TemporalConcept"}, {"end": 174, "start": 163, "tag": "TemporalConcept"}]}{"id": "1569_8", "text": "The study was conducted at 143 centers across 14 countries.", "tags": [{"end": 9, "start": 4, "tag": "ResearchActivity"}]}{"id": "1569_9", "text": "Participants were permitted to be followed off-treatment by the original protocol, collecting safety and efficacy data.", "tags": [{"end": 81, "start": 73, "tag": "HealthCareActivity"}, {"end": 100, "start": 94, "tag": "HealthCareActivity"}, {"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 118, "start": 114, "tag": "ResearchActivity"}, {"end": 56, "start": 47, "tag": "HealthCareActivity"}, {"end": 56, "start": 47, "tag": "ResearchActivity"}, {"end": 113, "start": 105, "tag": "Finding"}]}{"id": "1569_10", "text": "From 4464 screened participants, 557 amyloid-positive, cognitively normal (Clinical Dementia Rating of 0; aged 60-85 years) participants (approximately 34% of originally planned 1650) were randomized before the trial sponsor stopped enrollment.", "tags": [{"end": 18, "start": 10, "tag": "HealthCareActivity"}, {"end": 18, "start": 10, "tag": "ResearchActivity"}, {"end": 110, "start": 106, "tag": "TemporalConcept"}, {"end": 206, "start": 200, "tag": "TemporalConcept"}, {"end": 44, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 19, "tag": "PopulationGroup"}, {"end": 136, "start": 124, "tag": "PopulationGroup"}, {"end": 122, "start": 117, "tag": "TemporalConcept"}, {"end": 73, "start": 55, "tag": "Finding"}, {"end": 216, "start": 211, "tag": "ResearchActivity"}, {"end": 243, "start": 233, "tag": "HealthCareActivity"}, {"end": 99, "start": 75, "tag": "HealthCareActivity"}]}{"id": "1569_11", "text": "Interventions Participants were randomized (1:1:1) to atabecestat, 5 mg (n = 189), 25 mg (n = 183), or placebo (n = 185).", "tags": [{"end": 13, "start": 0, "tag": "HealthCareActivity"}, {"end": 65, "start": 54, "tag": "Chemical"}, {"end": 26, "start": 14, "tag": "PopulationGroup"}, {"end": 110, "start": 103, "tag": "HealthCareActivity"}, {"end": 65, "start": 54, "tag": "PharmacologicSubstance"}]}{"id": "1569_12", "text": "Main Outcomes and Measures Primary outcome: change from baseline in Preclinical Alzheimer Cognitive Composite score.", "tags": [{"end": 13, "start": 5, "tag": "HealthCareActivity"}, {"end": 115, "start": 110, "tag": "Finding"}, {"end": 109, "start": 68, "tag": "HealthCareActivity"}]}{"id": "1569_13", "text": "Secondary outcomes: change from baseline in the Cognitive Function Index and the Repeatable Battery for the Assessment of Neuropsychological Status total scale score.", "tags": [{"end": 72, "start": 48, "tag": "HealthCareActivity"}, {"end": 18, "start": 10, "tag": "Finding"}, {"end": 165, "start": 160, "tag": "Finding"}, {"end": 159, "start": 81, "tag": "HealthCareActivity"}]}{"id": "1569_14", "text": "Safety was monitored throughout the study.", "tags": [{"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 41, "start": 36, "tag": "ResearchActivity"}]}{"id": "1569_15", "text": "Results Of 557 participants, 341 were women (61.2%); mean (SD) age was 70.4 (5.56) years.", "tags": [{"end": 43, "start": 38, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 27, "start": 15, "tag": "PopulationGroup"}, {"end": 66, "start": 63, "tag": "OrganismAttribute"}, {"end": 88, "start": 83, "tag": "TemporalConcept"}, {"end": 61, "start": 59, "tag": "ResearchActivity"}]}{"id": "1569_16", "text": "In May 2018, study medication was stopped early owing to hepatic-related AEs; participants were followed up off-treatment for 6 months.", "tags": [{"end": 76, "start": 57, "tag": "PathologicFunction"}, {"end": 90, "start": 78, "tag": "PopulationGroup"}, {"end": 18, "start": 13, "tag": "ResearchActivity"}, {"end": 47, "start": 42, "tag": "TemporalConcept"}, {"end": 134, "start": 128, "tag": "TemporalConcept"}, {"end": 121, "start": 112, "tag": "HealthCareActivity"}, {"end": 121, "start": 112, "tag": "ResearchActivity"}, {"end": 11, "start": 3, "tag": "TemporalConcept"}]}{"id": "1569_17", "text": "Atabecestat, 25 mg, showed significant cognitive worsening vs placebo for Preclinical Alzheimer Cognitive Composite at month 6 (least-square mean difference, -1.09; 95% CI, -1.66 to -0.53; P < .001) and month 12 (least-square mean, -1.62; 95% CI, -2.49 to -0.76; P < .001), and at month 3 for Repeatable Battery for the Assessment of Neuropsychological Status (least-square mean, -3.70; 95% CI, -5.76 to -1.63; P < .001).", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 124, "start": 119, "tag": "TemporalConcept"}, {"end": 208, "start": 203, "tag": "TemporalConcept"}, {"end": 286, "start": 281, "tag": "TemporalConcept"}, {"end": 58, "start": 39, "tag": "Finding"}, {"end": 171, "start": 169, "tag": "ResearchActivity"}, {"end": 245, "start": 243, "tag": "ResearchActivity"}, {"end": 393, "start": 391, "tag": "ResearchActivity"}, {"end": 69, "start": 62, "tag": "HealthCareActivity"}, {"end": 11, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 115, "start": 74, "tag": "HealthCareActivity"}, {"end": 359, "start": 293, "tag": "HealthCareActivity"}]}{"id": "1569_18", "text": "Cognitive Function Index participant report showed nonsignificant worsening at month 12.", "tags": [{"end": 24, "start": 0, "tag": "HealthCareActivity"}, {"end": 84, "start": 79, "tag": "TemporalConcept"}, {"end": 75, "start": 51, "tag": "Finding"}, {"end": 36, "start": 25, "tag": "PopulationGroup"}, {"end": 43, "start": 37, "tag": "HealthCareActivity"}, {"end": 43, "start": 37, "tag": "ResearchActivity"}]}{"id": "1569_19", "text": "Systemic and neuropsychiatric-related treatment-emergent AEs were greater in atabecestat groups vs placebo.", "tags": [{"end": 60, "start": 57, "tag": "PathologicFunction"}, {"end": 88, "start": 77, "tag": "Chemical"}, {"end": 95, "start": 89, "tag": "PopulationGroup"}, {"end": 106, "start": 99, "tag": "HealthCareActivity"}, {"end": 47, "start": 38, "tag": "HealthCareActivity"}, {"end": 47, "start": 38, "tag": "ResearchActivity"}, {"end": 88, "start": 77, "tag": "PharmacologicSubstance"}]}{"id": "1569_20", "text": "After stopping treatment, follow-up cognitive testing and AE assessment provided evidence of reversibility of drug-induced cognitive worsening and AEs in atabecestat groups.", "tags": [{"end": 60, "start": 58, "tag": "PathologicFunction"}, {"end": 106, "start": 93, "tag": "TemporalConcept"}, {"end": 150, "start": 147, "tag": "PathologicFunction"}, {"end": 165, "start": 154, "tag": "Chemical"}, {"end": 142, "start": 123, "tag": "Finding"}, {"end": 114, "start": 110, "tag": "PharmacologicSubstance"}, {"end": 172, "start": 166, "tag": "PopulationGroup"}, {"end": 53, "start": 36, "tag": "HealthCareActivity"}, {"end": 35, "start": 26, "tag": "HealthCareActivity"}, {"end": 35, "start": 26, "tag": "TemporalConcept"}, {"end": 89, "start": 81, "tag": "Finding"}, {"end": 71, "start": 61, "tag": "HealthCareActivity"}, {"end": 71, "start": 61, "tag": "ResearchActivity"}, {"end": 24, "start": 15, "tag": "HealthCareActivity"}, {"end": 24, "start": 15, "tag": "ResearchActivity"}, {"end": 165, "start": 154, "tag": "PharmacologicSubstance"}]}{"id": "1569_21", "text": "Conclusions and Relevance Atabecestat treatment was associated with dose-related cognitive worsening as early as 3 months and presence of neuropsychiatric treatment-emergent AEs, with evidence of reversibility after 6 months off treatment.", "tags": [{"end": 37, "start": 26, "tag": "Chemical"}, {"end": 209, "start": 196, "tag": "TemporalConcept"}, {"end": 100, "start": 81, "tag": "Finding"}, {"end": 192, "start": 184, "tag": "Finding"}, {"end": 109, "start": 104, "tag": "TemporalConcept"}, {"end": 121, "start": 115, "tag": "TemporalConcept"}, {"end": 224, "start": 218, "tag": "TemporalConcept"}, {"end": 134, "start": 126, "tag": "Finding"}, {"end": 47, "start": 38, "tag": "HealthCareActivity"}, {"end": 164, "start": 138, "tag": "HealthCareActivity"}, {"end": 238, "start": 225, "tag": "HealthCareActivity"}, {"end": 47, "start": 38, "tag": "ResearchActivity"}, {"end": 37, "start": 26, "tag": "PharmacologicSubstance"}, {"end": 177, "start": 174, "tag": "PathologicFunction"}]}{"id": "1570_0", "text": "Background: We investigated a sample of cognitively healthy subjects with normal Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarker levels to identify the earliest variables related to longitudinal memory changes.", "tags": [{"end": 36, "start": 30, "tag": "Substance"}, {"end": 36, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 132, "tag": "ClinicalAttribute"}, {"end": 80, "start": 74, "tag": "Finding"}, {"end": 125, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 173, "start": 165, "tag": "TemporalConcept"}, {"end": 68, "start": 60, "tag": "PopulationGroup"}, {"end": 59, "start": 40, "tag": "OrganismAttribute"}, {"end": 214, "start": 208, "tag": "BiologicFunction"}, {"end": 222, "start": 195, "tag": "Finding"}]}{"id": "1570_1", "text": "Objective: Employing a new highly demanding learning and memory test (the Ancient Farming Equipment Test; AFE-T), we aimed to investigate whether a biomarker related to neurodegeneration (i.e., CSF tau) was associated with longitudinal memory decline.", "tags": [{"end": 63, "start": 44, "tag": "BiologicFunction"}, {"end": 250, "start": 223, "tag": "Finding"}, {"end": 201, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 186, "start": 169, "tag": "CellOrMolecularDysfunction"}, {"end": 197, "start": 194, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 198, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 148, "tag": "ClinicalAttribute"}, {"end": 52, "start": 44, "tag": "BiologicFunction"}, {"end": 63, "start": 57, "tag": "BiologicFunction"}, {"end": 242, "start": 236, "tag": "BiologicFunction"}, {"end": 68, "start": 44, "tag": "HealthCareActivity"}, {"end": 104, "start": 74, "tag": "HealthCareActivity"}, {"end": 111, "start": 106, "tag": "HealthCareActivity"}]}{"id": "1570_2", "text": "Methods: Thirty-two cognitively and biologically normal (CBN) subjects underwent MRI, neuropsychological assessment, and the AFE-T at baseline and 18 months later.", "tags": [{"end": 55, "start": 49, "tag": "Finding"}, {"end": 84, "start": 81, "tag": "HealthCareActivity"}, {"end": 70, "start": 62, "tag": "PopulationGroup"}, {"end": 115, "start": 86, "tag": "HealthCareActivity"}, {"end": 115, "start": 105, "tag": "HealthCareActivity"}, {"end": 115, "start": 105, "tag": "ResearchActivity"}, {"end": 156, "start": 150, "tag": "TemporalConcept"}, {"end": 130, "start": 125, "tag": "HealthCareActivity"}, {"end": 162, "start": 157, "tag": "TemporalConcept"}]}{"id": "1570_3", "text": "To explore the relationship between cognitive performance and relevant factors, a linear model was set up.", "tags": [{"end": 57, "start": 46, "tag": "Finding"}, {"end": 94, "start": 82, "tag": "ResearchActivity"}, {"end": 27, "start": 15, "tag": "Finding"}]}{"id": "1570_4", "text": "For a secondary analysis that further explore the effect of tau, the subjects were divided into CBN-Tau(down arrow) (tau < 228.64 pg/ml; n= 16) and CBN-Tau(up arrow) (tau (>)228.64 pg/ml; n= 16).", "tags": [{"end": 63, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 117, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 69, "tag": "PopulationGroup"}, {"end": 24, "start": 16, "tag": "ResearchActivity"}, {"end": 103, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 152, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1570_5", "text": "We also performed voxel-based morphometry (VBM) to identify regions of grey matter volume that would predict both baseline and longitudinal cognitive performance.", "tags": [{"end": 82, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 161, "start": 127, "tag": "Finding"}, {"end": 89, "start": 71, "tag": "ClinicalAttribute"}, {"end": 41, "start": 18, "tag": "HealthCareActivity"}, {"end": 46, "start": 43, "tag": "HealthCareActivity"}]}{"id": "1570_6", "text": "Results: Our main finding was an association between CSF tau and longitudinal memory decline measured with AFE-T (B = -0.17, p < 0.05; r= -0.414; p <0.01), and further analyses showed different evolvement between subgroups, with an accelerated decline in individuals with higher tau (F(1,31) = 8.37; p < 0.01).", "tags": [{"end": 25, "start": 18, "tag": "Finding"}, {"end": 60, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 282, "start": 279, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 282, "start": 279, "tag": "BiologicallyActiveSubstance"}, {"end": 266, "start": 255, "tag": "PopulationGroup"}, {"end": 176, "start": 168, "tag": "ResearchActivity"}, {"end": 92, "start": 65, "tag": "Finding"}, {"end": 112, "start": 107, "tag": "HealthCareActivity"}]}{"id": "1570_7", "text": "VBM results suggested that AFE-T performance is related to grey matter volume in a medial temporal, middle frontal, and posterior cerebellar network at baseline, and that there are strategic brain areas driving the longitudinal cognitive changes.", "tags": [{"end": 70, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 90, "tag": "TemporalConcept"}, {"end": 148, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 245, "start": 215, "tag": "Finding"}, {"end": 44, "start": 33, "tag": "Finding"}, {"end": 196, "start": 191, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 210, "start": 203, "tag": "IndividualBehavior"}, {"end": 3, "start": 0, "tag": "HealthCareActivity"}, {"end": 32, "start": 27, "tag": "HealthCareActivity"}, {"end": 77, "start": 59, "tag": "ClinicalAttribute"}, {"end": 148, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1570_8", "text": "Conclusions: The present findings provide evidence for structural and biological markers linked to cognitive aging by highlighting the role of tau, a marker of neurodegeneration, which can be related with the earliest memory changes in healthy subjects.", "tags": [{"end": 252, "start": 236, "tag": "PopulationGroup"}, {"end": 146, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 160, "tag": "CellOrMolecularDysfunction"}, {"end": 146, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 217, "start": 209, "tag": "TemporalConcept"}, {"end": 252, "start": 244, "tag": "PopulationGroup"}, {"end": 114, "start": 99, "tag": "BiologicFunction"}, {"end": 114, "start": 109, "tag": "CellFunction"}, {"end": 156, "start": 150, "tag": "ClinicalAttribute"}, {"end": 50, "start": 42, "tag": "Finding"}, {"end": 243, "start": 236, "tag": "OrganismAttribute"}, {"end": 224, "start": 218, "tag": "BiologicFunction"}, {"end": 88, "start": 70, "tag": "ClinicalAttribute"}, {"end": 232, "start": 218, "tag": "Finding"}]}{"id": "1571_0", "text": "The parahippocampal gyrus-orbitofrontal cortex (PHG-OFC) circuit in humans is homologous to the postrhinal cortex (POR)-ventral lateral orbitofrontal cortex (vlOFC) circuit in rodents.", "tags": [{"end": 25, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 183, "start": 176, "tag": "Eukaryote"}, {"end": 74, "start": 68, "tag": "Eukaryote"}, {"end": 46, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1571_1", "text": "Both are associated with visuospatial malfunctions in Alzheimer's disease (AD).", "tags": [{"end": 73, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 25, "tag": "PathologicFunction"}]}{"id": "1571_2", "text": "However, the underlying mechanisms remain to be elucidated.", "tags": []}{"id": "1571_3", "text": "In this study, we explored the relationship between an impaired POR-vlOFC circuit and visuospatial memory deficits through retrograde tracing and in vivo local field potential recordings in 5XFAD mice, and investigated alterations of the PHG-OFC circuit by multi-domain magnetic resonance imaging (MRI) in patients on the AD spectrum.", "tags": [{"end": 200, "start": 190, "tag": "ExperimentalModelOfDisease"}, {"end": 333, "start": 322, "tag": "DiseaseOrSyndrome"}, {"end": 301, "start": 298, "tag": "HealthCareActivity"}, {"end": 43, "start": 31, "tag": "Finding"}, {"end": 314, "start": 306, "tag": "PatientOrDisabledGroup"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 186, "start": 146, "tag": "ResearchActivity"}, {"end": 296, "start": 257, "tag": "HealthCareActivity"}, {"end": 81, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 86, "tag": "PathologicFunction"}, {"end": 141, "start": 123, "tag": "ResearchActivity"}, {"end": 253, "start": 238, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1571_4", "text": "We demonstrated that an impaired glutamatergic POR-vlOFC circuit resulted in deficient visuospatial memory in 5XFAD mice.", "tags": [{"end": 120, "start": 110, "tag": "ExperimentalModelOfDisease"}, {"end": 64, "start": 24, "tag": "PathologicFunction"}, {"end": 106, "start": 77, "tag": "PathologicFunction"}]}{"id": "1571_5", "text": "Moreover, MRI measurements of the PHG-OFC circuit had an accuracy of 77.33% for the classification of amnestic mild cognitive impairment converters versus non-converters.", "tags": [{"end": 13, "start": 10, "tag": "HealthCareActivity"}, {"end": 26, "start": 14, "tag": "HealthCareActivity"}, {"end": 65, "start": 57, "tag": "Finding"}, {"end": 136, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1571_6", "text": "Thus, the PHG-OFC circuit explains the neuroanatomical basis of visuospatial memory deficits in AD, thereby providing a potential predictor for AD progression and a promising interventional approach for AD.", "tags": [{"end": 54, "start": 39, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 147, "tag": "PathologicFunction"}, {"end": 158, "start": 147, "tag": "TemporalConcept"}, {"end": 25, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 64, "tag": "PathologicFunction"}, {"end": 198, "start": 175, "tag": "HealthCareActivity"}]}{"id": "1572_0", "text": "BACKGROUND AND PURPOSE: Cell loss within the nucleus basalis of Meynert is an early event in Alzheimer disease.", "tags": [{"end": 71, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 78, "tag": "TemporalConcept"}, {"end": 33, "start": 24, "tag": "CellOrMolecularDysfunction"}]}{"id": "1572_1", "text": "The thickness of the nucleus basalis of Meynert (NBM) can be measured on structural MR imaging.", "tags": [{"end": 47, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 73, "tag": "HealthCareActivity"}]}{"id": "1572_2", "text": "We investigated NBM thickness in relation to cognitive state and biochemical markers.", "tags": [{"end": 19, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 65, "tag": "ClinicalAttribute"}, {"end": 29, "start": 16, "tag": "ClinicalAttribute"}]}{"id": "1572_3", "text": "MATERIALS AND METHODS: Mean bilateral nucleus basalis of Meynert thickness was measured on coronal T1-weighted MR imaging scans from the Alzheimer?s Disease Neuroimaging Initiative dataset.", "tags": [{"end": 127, "start": 91, "tag": "HealthCareActivity"}, {"end": 188, "start": 137, "tag": "ResearchActivity"}, {"end": 64, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 38, "tag": "ClinicalAttribute"}, {"end": 180, "start": 137, "tag": "HealthCareRelatedOrganization"}]}{"id": "1572_4", "text": "Three hundred and fifteen scans (80 controls, 79 cases of early mild cognitive impairment, 77 cases of late mild cognitive impairment and 79 cases of Alzheimer disease) were assessed.", "tags": [{"end": 167, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 36, "tag": "PopulationGroup"}, {"end": 31, "start": 26, "tag": "HealthCareActivity"}, {"end": 63, "start": 58, "tag": "TemporalConcept"}, {"end": 89, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 108, "tag": "DiseaseOrSyndrome"}]}